0001125376-23-000018.txt : 20230202 0001125376-23-000018.hdr.sgml : 20230202 20230202160105 ACCESSION NUMBER: 0001125376-23-000018 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 129 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230202 DATE AS OF CHANGE: 20230202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENSIGN GROUP, INC CENTRAL INDEX KEY: 0001125376 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 330861263 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33757 FILM NUMBER: 23580761 BUSINESS ADDRESS: STREET 1: 29222 RANCHO VIEJO RD. STREET 2: SUITE 127 CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 BUSINESS PHONE: (949) 487-9500 MAIL ADDRESS: STREET 1: 29222 RANCHO VIEJO RD. STREET 2: SUITE 127 CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 FORMER COMPANY: FORMER CONFORMED NAME: ENSIGN GROUP INC DATE OF NAME CHANGE: 20000930 10-K 1 ensg-20221231.htm 10-K ensg-20221231
00011253762022FYfalseP3Y0M0DP10YP4M0DP5Y0MP10Y0MP10Y0MP5Y0MP3Y0M00011253762022-01-012022-12-3100011253762022-06-30iso4217:USD00011253762023-01-30xbrli:shares00011253762022-12-3100011253762021-12-31iso4217:USDxbrli:shares00011253762021-01-012021-12-3100011253762020-01-012020-12-310001125376us-gaap:CommonStockMember2019-12-310001125376us-gaap:AdditionalPaidInCapitalMember2019-12-310001125376us-gaap:RetainedEarningsMember2019-12-310001125376us-gaap:TreasuryStockCommonMember2019-12-310001125376us-gaap:NoncontrollingInterestMember2019-12-3100011253762019-12-310001125376us-gaap:CommonStockMember2020-01-012020-12-310001125376us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001125376us-gaap:TreasuryStockCommonMember2020-01-012020-12-310001125376us-gaap:RetainedEarningsMember2020-01-012020-12-310001125376us-gaap:NoncontrollingInterestMember2020-01-012020-12-310001125376us-gaap:CommonStockMember2020-12-310001125376us-gaap:AdditionalPaidInCapitalMember2020-12-310001125376us-gaap:RetainedEarningsMember2020-12-310001125376us-gaap:TreasuryStockCommonMember2020-12-310001125376us-gaap:NoncontrollingInterestMember2020-12-3100011253762020-12-310001125376us-gaap:CommonStockMember2021-01-012021-12-310001125376us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001125376us-gaap:TreasuryStockCommonMember2021-01-012021-12-310001125376us-gaap:RetainedEarningsMember2021-01-012021-12-310001125376us-gaap:NoncontrollingInterestMember2021-01-012021-12-310001125376us-gaap:CommonStockMember2021-12-310001125376us-gaap:AdditionalPaidInCapitalMember2021-12-310001125376us-gaap:RetainedEarningsMember2021-12-310001125376us-gaap:TreasuryStockCommonMember2021-12-310001125376us-gaap:NoncontrollingInterestMember2021-12-310001125376us-gaap:CommonStockMember2022-01-012022-12-310001125376us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001125376us-gaap:TreasuryStockCommonMember2022-01-012022-12-310001125376us-gaap:RetainedEarningsMember2022-01-012022-12-310001125376us-gaap:NoncontrollingInterestMember2022-01-012022-12-310001125376us-gaap:CommonStockMember2022-12-310001125376us-gaap:AdditionalPaidInCapitalMember2022-12-310001125376us-gaap:RetainedEarningsMember2022-12-310001125376us-gaap:TreasuryStockCommonMember2022-12-310001125376us-gaap:NoncontrollingInterestMember2022-12-31ensg:facilityensg:bedensg:senior_living_unit0001125376us-gaap:WhollyOwnedPropertiesMember2022-12-310001125376us-gaap:SpinoffMemberensg:ThePennantGroupInc.Memberensg:SeniorLivingFacilitiesMember2022-12-31ensg:senior_living_community0001125376us-gaap:SpinoffMemberensg:RemainingCompanyMemberensg:SkilledNursingOperationsMemberensg:StandardBearerHealthcareREITIncMember2022-12-31ensg:operation0001125376srt:MinimumMember2022-01-012022-12-310001125376srt:MaximumMember2022-01-012022-12-31ensg:renewal_option0001125376srt:MinimumMember2022-12-310001125376srt:MaximumMember2022-12-310001125376ensg:AssembledOccupancyAcquiredMembersrt:MinimumMember2022-01-012022-12-310001125376srt:MaximumMemberensg:AssembledOccupancyAcquiredMember2022-01-012022-12-310001125376us-gaap:TradeNamesMember2022-01-012022-12-310001125376us-gaap:CustomerRelationshipsMember2022-01-012022-12-310001125376srt:ParentCompanyMemberensg:SelfInsuranceRetentionPerClaimMemberus-gaap:GeneralLiabilityMember2022-12-310001125376srt:ParentCompanyMemberstpr:CAensg:AggregateDeductibleMemberus-gaap:GeneralLiabilityMember2022-12-310001125376srt:ParentCompanyMemberensg:AggregateDeductibleMemberus-gaap:GeneralLiabilityMemberensg:NonCaliforniaMember2022-12-310001125376ensg:PerOccurenceMembernaics:ZZ524292us-gaap:GeneralLiabilityMemberensg:AllStatesExceptColoradoMember2022-12-310001125376naics:ZZ524292us-gaap:GeneralLiabilityMemberensg:AllStatesExceptColoradoMemberensg:PerFacilityMember2022-12-310001125376ensg:BlanketAggregateMembernaics:ZZ524292us-gaap:GeneralLiabilityMemberensg:AllStatesExceptColoradoMember2022-12-310001125376ensg:PerOccurenceMembernaics:ZZ524292us-gaap:GeneralLiabilityMemberstpr:CO2022-12-310001125376naics:ZZ524292us-gaap:GeneralLiabilityMemberstpr:COensg:PerFacilityMember2022-12-310001125376us-gaap:WorkersCompensationInsuranceMember2022-12-310001125376us-gaap:WorkersCompensationInsuranceMemberstpr:TX2022-12-310001125376ensg:OtherStatesExceptCaliforniaTexasAndWashingtonMemberensg:LossSensitivelimitperclaimMemberMemberus-gaap:WorkersCompensationInsuranceMember2022-12-310001125376ensg:SelfInsuranceRetentionPerClaimMemberus-gaap:GeneralLiabilityMember2022-12-310001125376ensg:HealthLiabilityInsuranceMemberensg:StopLossInsuranceLimitPerClaimMember2022-12-310001125376ensg:HealthLiabilityInsuranceMemberensg:StopLossInsuranceLimitPerClaimMember2021-12-310001125376ensg:HealthLiabilityInsuranceMemberensg:StopLossInsuranceLimitPerClaimMember2020-12-310001125376us-gaap:RevolvingCreditFacilityMemberensg:TruistBankMember2022-01-012022-12-310001125376us-gaap:RevolvingCreditFacilityMemberensg:TruistBankMember2022-12-3100011253762021-03-012021-03-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicaidAndMedicareMember2022-01-012022-12-31xbrli:pure0001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicaidAndMedicareMember2021-01-012021-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicaidAndMedicareMember2020-01-012020-12-310001125376ensg:MedicaidMember2022-01-012022-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicaidMember2022-01-012022-12-310001125376ensg:MedicaidMember2021-01-012021-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicaidMember2021-01-012021-12-310001125376ensg:MedicaidMember2020-01-012020-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicaidMember2020-01-012020-12-310001125376ensg:MedicareMember2022-01-012022-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicareMember2022-01-012022-12-310001125376ensg:MedicareMember2021-01-012021-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicareMember2021-01-012021-12-310001125376ensg:MedicareMember2020-01-012020-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:MedicareMember2020-01-012020-12-310001125376ensg:MedicaidSkilledMember2022-01-012022-12-310001125376ensg:MedicaidSkilledMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001125376ensg:MedicaidSkilledMember2021-01-012021-12-310001125376ensg:MedicaidSkilledMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001125376ensg:MedicaidSkilledMember2020-01-012020-12-310001125376ensg:MedicaidSkilledMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-12-310001125376ensg:MedicaidAndMedicareMember2022-01-012022-12-310001125376ensg:MedicaidAndMedicareMember2021-01-012021-12-310001125376ensg:MedicaidAndMedicareMember2020-01-012020-12-310001125376ensg:ManagedCareMember2022-01-012022-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:ManagedCareMember2022-01-012022-12-310001125376ensg:ManagedCareMember2021-01-012021-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:ManagedCareMember2021-01-012021-12-310001125376ensg:ManagedCareMember2020-01-012020-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:ManagedCareMember2020-01-012020-12-310001125376ensg:PrivatePayAndOtherMember2022-01-012022-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001125376ensg:PrivatePayAndOtherMember2021-01-012021-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001125376ensg:PrivatePayAndOtherMember2020-01-012020-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001125376us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-12-310001125376ensg:MedicaidMember2022-12-310001125376ensg:MedicaidMember2021-12-310001125376ensg:ManagedCareMember2022-12-310001125376ensg:ManagedCareMember2021-12-310001125376ensg:MedicareMember2022-12-310001125376ensg:MedicareMember2021-12-310001125376ensg:PrivatePayAndOtherMember2022-12-310001125376ensg:PrivatePayAndOtherMember2021-12-310001125376us-gaap:FairValueInputsLevel1Member2022-12-310001125376us-gaap:FairValueInputsLevel1Member2021-12-310001125376srt:SubsidiariesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001125376srt:SubsidiariesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001125376us-gaap:FairValueInputsLevel2Member2022-12-310001125376us-gaap:FairValueInputsLevel2Member2021-12-310001125376ensg:StandardBearerHealthcareREITIncMember2022-12-310001125376us-gaap:WhollyOwnedPropertiesMemberensg:StandardBearerHealthcareREITIncMember2022-12-310001125376ensg:ThirdPartiesMemberensg:StandardBearerHealthcareREITIncMember2022-12-310001125376ensg:SkilledNursingOperationsMemberensg:StandardBearerHealthcareREITIncMember2022-01-012022-12-31ensg:skilled_nursing_property00011253762022-01-012022-01-31ensg:lease0001125376ensg:StandardBearerMasterLeasesMembersrt:MinimumMember2022-01-310001125376ensg:StandardBearerMasterLeasesMembersrt:MaximumMember2022-01-310001125376ensg:StandardBearerMasterLeasesMember2022-01-31ensg:renewal0001125376ensg:StandardBearerSegmentMember2022-01-012022-12-310001125376ensg:StandardBearerSegmentMember2021-01-012021-12-310001125376ensg:StandardBearerSegmentMember2020-01-012020-12-310001125376ensg:StandardBearerMasterLeasesMember2022-01-012022-12-310001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceBaseMember2022-01-012022-01-310001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceIncentiveMember2022-01-012022-01-310001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceBaseMember2022-01-012022-12-310001125376ensg:StandardBearerMasterLeasesMemberensg:ManagementServiceTotalMember2022-01-012022-12-310001125376ensg:StandardBearerMasterLeasesMemberensg:ManagementServiceTotalMember2022-10-012022-12-310001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceBaseMember2021-01-012021-12-310001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceBaseMember2020-01-012020-12-310001125376us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberensg:TruistBankMember2022-04-082022-04-080001125376us-gaap:BaseRateMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberensg:TruistBankMember2022-04-082022-04-080001125376us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberensg:TruistBankMember2022-04-082022-04-080001125376srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberensg:TruistBankMember2022-04-082022-04-080001125376ensg:StandardBearerEquityPlanMember2022-01-012022-01-310001125376ensg:StandardBearerEquityPlanMember2022-01-012022-12-310001125376us-gaap:RestrictedStockMemberensg:StandardBearerEquityPlanMember2022-01-012022-12-310001125376us-gaap:RestrictedStockMemberensg:StandardBearerEquityPlanMember2022-10-012022-12-310001125376ensg:StandardBearerEquityPlanMember2022-10-012022-12-310001125376ensg:StandardBearerHealthcareREITIncMember2022-01-012022-12-3100011253762022-01-012022-03-31ensg:segment0001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:RealEstateSegmentMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2022-01-012022-12-310001125376srt:ConsolidationEliminationsMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:RealEstateSegmentMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2021-01-012021-12-310001125376srt:ConsolidationEliminationsMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2020-01-012020-12-310001125376us-gaap:OperatingSegmentsMemberensg:RealEstateSegmentMember2020-01-012020-12-310001125376us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2020-01-012020-12-310001125376srt:ConsolidationEliminationsMember2020-01-012020-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMemberensg:MedicaidMember2022-01-012022-12-310001125376us-gaap:CorporateNonSegmentMemberensg:MedicaidMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMemberensg:MedicareMember2022-01-012022-12-310001125376ensg:MedicareMemberus-gaap:CorporateNonSegmentMember2022-01-012022-12-310001125376ensg:MedicaidSkilledMemberus-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2022-01-012022-12-310001125376ensg:MedicaidSkilledMemberus-gaap:CorporateNonSegmentMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMemberensg:MedicaidAndMedicareMember2022-01-012022-12-310001125376ensg:MedicaidAndMedicareMemberus-gaap:CorporateNonSegmentMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:ManagedCareMemberensg:SkilledServicesSegmentMember2022-01-012022-12-310001125376ensg:ManagedCareMemberus-gaap:CorporateNonSegmentMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:PrivatePayAndOtherMemberensg:SkilledServicesSegmentMember2022-01-012022-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:CorporateNonSegmentMember2022-01-012022-12-310001125376us-gaap:CorporateNonSegmentMember2022-01-012022-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMemberensg:MedicaidMember2021-01-012021-12-310001125376us-gaap:CorporateNonSegmentMemberensg:MedicaidMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMemberensg:MedicareMember2021-01-012021-12-310001125376ensg:MedicareMemberus-gaap:CorporateNonSegmentMember2021-01-012021-12-310001125376ensg:MedicaidSkilledMemberus-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2021-01-012021-12-310001125376ensg:MedicaidSkilledMemberus-gaap:CorporateNonSegmentMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMemberensg:MedicaidAndMedicareMember2021-01-012021-12-310001125376ensg:MedicaidAndMedicareMemberus-gaap:CorporateNonSegmentMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:ManagedCareMemberensg:SkilledServicesSegmentMember2021-01-012021-12-310001125376ensg:ManagedCareMemberus-gaap:CorporateNonSegmentMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:PrivatePayAndOtherMemberensg:SkilledServicesSegmentMember2021-01-012021-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:CorporateNonSegmentMember2021-01-012021-12-310001125376us-gaap:CorporateNonSegmentMember2021-01-012021-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMemberensg:MedicaidMember2020-01-012020-12-310001125376us-gaap:CorporateNonSegmentMemberensg:MedicaidMember2020-01-012020-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMemberensg:MedicareMember2020-01-012020-12-310001125376ensg:MedicareMemberus-gaap:CorporateNonSegmentMember2020-01-012020-12-310001125376ensg:MedicaidSkilledMemberus-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2020-01-012020-12-310001125376ensg:MedicaidSkilledMemberus-gaap:CorporateNonSegmentMember2020-01-012020-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMemberensg:MedicaidAndMedicareMember2020-01-012020-12-310001125376ensg:MedicaidAndMedicareMemberus-gaap:CorporateNonSegmentMember2020-01-012020-12-310001125376us-gaap:OperatingSegmentsMemberensg:ManagedCareMemberensg:SkilledServicesSegmentMember2020-01-012020-12-310001125376ensg:ManagedCareMemberus-gaap:CorporateNonSegmentMember2020-01-012020-12-310001125376us-gaap:OperatingSegmentsMemberensg:PrivatePayAndOtherMemberensg:SkilledServicesSegmentMember2020-01-012020-12-310001125376ensg:PrivatePayAndOtherMemberus-gaap:CorporateNonSegmentMember2020-01-012020-12-310001125376us-gaap:CorporateNonSegmentMember2020-01-012020-12-310001125376ensg:SkilledNursingOperationsMember2022-01-012022-12-310001125376ensg:CampusOperationMember2022-01-012022-12-31ensg:asset_acquisition0001125376ensg:SeniorLivingFacilitiesMember2022-01-012022-12-310001125376ensg:SkilledNursingOperationsMember2022-12-310001125376ensg:SeniorLivingFacilitiesMember2022-12-310001125376us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember2022-01-012022-12-310001125376us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-12-310001125376us-gaap:SubsequentEventMemberensg:SkilledNursingOperationsMember2023-01-012023-02-020001125376us-gaap:SubsequentEventMemberensg:SkilledNursingOperationsMember2023-02-020001125376ensg:SkilledNursingOperationsMember2021-01-012021-12-310001125376ensg:RealEstatePurchasesMember2021-01-012021-12-31ensg:business0001125376ensg:RealEstatePurchasesOfPreviousOperationsMember2021-01-012021-12-310001125376ensg:SkilledNursingOperationsMember2021-12-310001125376us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember2021-01-012021-12-310001125376us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-01-012021-12-310001125376ensg:SkilledNursingOperationsMember2020-01-012020-12-310001125376ensg:SeniorLivingFacilitiesMember2020-01-012020-12-310001125376ensg:SkilledServicesAndSeniorLivingCampusesMember2020-01-012020-12-310001125376ensg:OwnedPropertiesMember2020-01-012020-12-310001125376ensg:SkilledNursingOperationsMember2020-12-310001125376ensg:SeniorLivingFacilitiesMember2020-12-310001125376ensg:AssetAcquisitionMember2020-01-012020-12-310001125376ensg:ThePennantGroupInc.Memberensg:SeniorLivingFacilitiesMember2020-03-310001125376us-gaap:LandMemberensg:AssetAcquisitionMember2022-01-012022-12-310001125376us-gaap:LandMemberensg:AssetAcquisitionMember2021-01-012021-12-310001125376us-gaap:LandMemberensg:AssetAcquisitionMember2020-01-012020-12-310001125376us-gaap:BuildingAndBuildingImprovementsMemberensg:AssetAcquisitionMember2022-01-012022-12-310001125376us-gaap:BuildingAndBuildingImprovementsMemberensg:AssetAcquisitionMember2021-01-012021-12-310001125376us-gaap:BuildingAndBuildingImprovementsMemberensg:AssetAcquisitionMember2020-01-012020-12-310001125376us-gaap:FurnitureAndFixturesMemberensg:AssetAcquisitionMember2022-01-012022-12-310001125376us-gaap:FurnitureAndFixturesMemberensg:AssetAcquisitionMember2021-01-012021-12-310001125376us-gaap:FurnitureAndFixturesMemberensg:AssetAcquisitionMember2020-01-012020-12-310001125376ensg:AssembledOccupancyAcquiredMemberensg:AssetAcquisitionMember2022-01-012022-12-310001125376ensg:AssembledOccupancyAcquiredMemberensg:AssetAcquisitionMember2021-01-012021-12-310001125376ensg:AssembledOccupancyAcquiredMemberensg:AssetAcquisitionMember2020-01-012020-12-310001125376ensg:AssetAcquisitionMember2022-01-012022-12-310001125376ensg:AssetAcquisitionMember2021-01-012021-12-310001125376us-gaap:LandMember2022-12-310001125376us-gaap:LandMember2021-12-310001125376us-gaap:BuildingAndBuildingImprovementsMember2022-12-310001125376us-gaap:BuildingAndBuildingImprovementsMember2021-12-310001125376us-gaap:LeaseholdImprovementsMember2022-12-310001125376us-gaap:LeaseholdImprovementsMember2021-12-310001125376us-gaap:EquipmentMember2022-12-310001125376us-gaap:EquipmentMember2021-12-310001125376us-gaap:FurnitureAndFixturesMember2022-12-310001125376us-gaap:FurnitureAndFixturesMember2021-12-310001125376us-gaap:ConstructionInProgressMember2022-12-310001125376us-gaap:ConstructionInProgressMember2021-12-310001125376ensg:SeniorLivingOperationsMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-12-310001125376ensg:AssembledOccupancyAcquiredMember2022-01-012022-12-310001125376ensg:AssembledOccupancyAcquiredMember2022-12-310001125376ensg:AssembledOccupancyAcquiredMember2021-12-310001125376us-gaap:TradeNamesMember2022-12-310001125376us-gaap:TradeNamesMember2021-12-310001125376us-gaap:CustomerRelationshipsMember2022-12-310001125376us-gaap:CustomerRelationshipsMember2021-12-310001125376ensg:DepreciationAndAmortizationMember2022-01-012022-12-310001125376ensg:DepreciationAndAmortizationMember2021-01-012021-12-310001125376ensg:DepreciationAndAmortizationMember2020-01-012020-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2019-12-310001125376us-gaap:CorporateNonSegmentMember2019-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2020-12-310001125376us-gaap:CorporateNonSegmentMember2020-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2021-12-310001125376us-gaap:CorporateNonSegmentMember2021-12-310001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2022-12-310001125376us-gaap:CorporateNonSegmentMember2022-12-310001125376ensg:MedicareandMedicaidLicensesMember2022-01-012022-12-310001125376ensg:MedicareandMedicaidLicensesMember2021-01-012021-12-310001125376ensg:MedicareandMedicaidLicensesMember2020-01-012020-12-310001125376us-gaap:TradeNamesMember2022-12-310001125376us-gaap:TradeNamesMember2021-12-310001125376ensg:MedicareandMedicaidLicensesMember2022-12-310001125376ensg:MedicareandMedicaidLicensesMember2021-12-310001125376us-gaap:CollateralizedDebtObligationsMemberus-gaap:NotesPayableOtherPayablesMember2022-12-310001125376us-gaap:CollateralizedDebtObligationsMemberus-gaap:NotesPayableOtherPayablesMember2021-12-310001125376us-gaap:RevolvingCreditFacilityMemberensg:TruistBankMember2022-04-070001125376us-gaap:RevolvingCreditFacilityMemberensg:TruistBankMember2022-04-080001125376us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberensg:TruistBankMember2022-04-082022-04-080001125376srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberensg:TruistBankMember2022-04-082022-04-080001125376us-gaap:SubsequentEventMemberus-gaap:RevolvingCreditFacilityMemberensg:TruistBankMember2023-01-300001125376ensg:TwentyThreeSubsidiariesMemberus-gaap:CollateralizedDebtObligationsMemberus-gaap:MortgagesMember2022-12-31ensg:subsidiary0001125376us-gaap:CollateralizedDebtObligationsMemberus-gaap:NotesPayableToBanksMembersrt:MinimumMember2022-12-310001125376srt:MaximumMemberus-gaap:CollateralizedDebtObligationsMemberus-gaap:NotesPayableToBanksMember2022-12-310001125376us-gaap:CollateralizedDebtObligationsMemberus-gaap:MortgagesMember2022-12-310001125376us-gaap:CollateralizedDebtObligationsMembersrt:MinimumMemberus-gaap:MortgagesMember2022-01-012022-12-310001125376srt:MaximumMemberus-gaap:CollateralizedDebtObligationsMemberus-gaap:MortgagesMember2022-01-012022-12-310001125376us-gaap:CollateralizedDebtObligationsMember2022-01-012022-12-31ensg:promissory_note0001125376us-gaap:CollateralizedDebtObligationsMemberensg:PromissoryNote50Member2022-12-310001125376ensg:PromissoryNote53Memberus-gaap:CollateralizedDebtObligationsMember2022-12-310001125376us-gaap:CollateralizedDebtObligationsMemberensg:PromissoryNote50Member2022-01-012022-12-310001125376ensg:PromissoryNote53Memberus-gaap:CollateralizedDebtObligationsMember2022-01-012022-12-31ensg:repurchase_program0001125376ensg:A2022PlanMember2022-06-300001125376ensg:A2022PlanMember2022-04-012022-06-300001125376us-gaap:ShareBasedPaymentArrangementNonemployeeMemberensg:A2022PlanMember2022-04-012022-06-30ensg:installment0001125376ensg:A2022PlanMember2022-12-310001125376ensg:A2017PlanMember2017-12-310001125376us-gaap:SpinoffMemberensg:A2017PlanMember2019-10-310001125376ensg:A2017PlanMember2022-01-012022-12-310001125376ensg:A2017PlanMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-01-012022-12-310001125376us-gaap:RestrictedStockMemberensg:A2017PlanMember2022-01-012022-12-310001125376ensg:ExercisePriceRangeOneMember2022-01-012022-12-310001125376ensg:ExercisePriceRangeOneMember2022-12-310001125376ensg:ExercisePriceRangeTwoMember2022-01-012022-12-310001125376ensg:ExercisePriceRangeTwoMember2022-12-310001125376ensg:ExercisePriceRangeThreeMember2022-01-012022-12-310001125376ensg:ExercisePriceRangeThreeMember2022-12-310001125376ensg:ExercisePriceRangeFourMember2022-01-012022-12-310001125376ensg:ExercisePriceRangeFourMember2022-12-310001125376ensg:ExercisePriceRangeFiveMember2022-01-012022-12-310001125376ensg:ExercisePriceRangeFiveMember2022-12-310001125376ensg:ExercisePriceRangeSixMember2022-01-012022-12-310001125376ensg:ExercisePriceRangeSixMember2022-12-310001125376ensg:ExercisePriceRangeSevenMember2022-01-012022-12-310001125376ensg:ExercisePriceRangeSevenMember2022-12-310001125376ensg:ExercisePriceRangeEightMember2022-01-012022-12-310001125376ensg:ExercisePriceRangeEightMember2022-12-310001125376ensg:ExercisePriceRangeNineMember2022-01-012022-12-310001125376ensg:ExercisePriceRangeNineMember2022-12-310001125376ensg:ExercisePriceRangeTenMember2022-01-012022-12-310001125376ensg:ExercisePriceRangeTenMember2022-12-310001125376us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001125376us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001125376us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001125376us-gaap:RestrictedStockMember2022-01-012022-12-310001125376us-gaap:RestrictedStockMember2021-01-012021-12-310001125376us-gaap:RestrictedStockMember2020-01-012020-12-310001125376us-gaap:RestrictedStockMembersrt:MinimumMember2022-01-012022-12-310001125376srt:MaximumMemberus-gaap:RestrictedStockMember2022-01-012022-12-310001125376us-gaap:RestrictedStockMembersrt:MinimumMember2021-01-012021-12-310001125376srt:MaximumMemberus-gaap:RestrictedStockMember2021-01-012021-12-310001125376us-gaap:RestrictedStockMembersrt:MinimumMember2020-01-012020-12-310001125376srt:MaximumMemberus-gaap:RestrictedStockMember2020-01-012020-12-310001125376us-gaap:RestrictedStockMember2019-12-310001125376us-gaap:RestrictedStockMember2020-12-310001125376us-gaap:RestrictedStockMember2021-12-310001125376us-gaap:RestrictedStockMember2022-12-310001125376us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-01-012022-12-310001125376us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMembersrt:MinimumMember2022-01-012022-12-310001125376srt:MaximumMemberus-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-01-012022-12-310001125376us-gaap:SpinoffMemberensg:A2019LTIPlanMember2019-08-270001125376us-gaap:SpinoffMemberensg:A2019LTIPlanMember2019-08-272019-08-270001125376us-gaap:SpinoffMemberensg:A2019LTIPlanMember2022-01-012022-12-310001125376us-gaap:SpinoffMemberensg:A2019LTIPlanMember2021-01-012021-12-310001125376us-gaap:SpinoffMemberensg:A2019LTIPlanMember2020-01-012020-12-310001125376ensg:StockAwardsMember2022-01-012022-12-310001125376ensg:StockAwardsMember2021-01-012021-12-310001125376ensg:StockAwardsMember2020-01-012020-12-310001125376us-gaap:EmployeeStockOptionMember2022-12-310001125376ensg:CareTrustREITMember2022-12-310001125376ensg:ThirdPartyTenantsUnderTripleNetLeaseArrangementsMemberensg:CareTrustREITMember2022-12-31ensg:agreement0001125376ensg:CareTrustREITMembersrt:MinimumMember2022-12-310001125376srt:MaximumMemberensg:CareTrustREITMember2022-12-310001125376ensg:PurchaseOptionMemberensg:CareTrustREITMember2022-12-310001125376ensg:CareTrustREITMember2022-01-012022-12-310001125376ensg:CareTrustREITMember2021-01-012021-12-310001125376ensg:CareTrustREITMember2020-01-012020-12-310001125376ensg:VariousLandlordsMembersrt:MinimumMember2022-12-310001125376srt:MaximumMemberensg:VariousLandlordsMember2022-12-310001125376ensg:VariousLandlordsMembersrt:MinimumMemberus-gaap:EquipmentMember2022-12-310001125376srt:MaximumMemberensg:VariousLandlordsMemberus-gaap:EquipmentMember2022-12-310001125376ensg:CostofSalesandGeneralandAdministrativeExpenseMember2022-01-012022-12-310001125376ensg:CostofSalesandGeneralandAdministrativeExpenseMember2021-01-012021-12-310001125376ensg:CostofSalesandGeneralandAdministrativeExpenseMember2020-01-012020-12-310001125376ensg:VariousLandlordsMember2022-12-310001125376ensg:AmendedMasterLeaseAgreementMember2022-12-310001125376ensg:AmendedMasterLeaseAgreementMember2022-01-012022-12-310001125376ensg:NewMasterLeaseAgreeementMember2022-01-012022-12-310001125376ensg:NewMasterLeaseAgreeementMemberensg:VariousLandlordsMember2022-01-012022-12-310001125376us-gaap:CostOfSalesMember2022-01-012022-12-310001125376us-gaap:CostOfSalesMember2021-01-012021-12-310001125376us-gaap:CostOfSalesMember2020-01-012020-12-310001125376us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001125376us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001125376us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-310001125376us-gaap:SubsequentEventMemberensg:NewMasterLeaseAgreementMemberensg:SkilledNursingOperationsMember2023-02-020001125376us-gaap:SubsequentEventMemberensg:NewMasterLeaseAgreementMemberensg:SkilledNursingOperationsMember2023-01-012023-02-020001125376us-gaap:SubsequentEventMemberensg:AmendedMasterLeaseMemberensg:SkilledNursingOperationsMember2023-01-012023-02-020001125376us-gaap:SubsequentEventMemberensg:SubleasedToThirdPartyMemberensg:SkilledNursingOperationsMember2023-01-012023-02-020001125376us-gaap:SubsequentEventMemberensg:AmendedMasterLeaseMember2023-02-020001125376us-gaap:SubsequentEventMemberensg:AmendedMasterLeaseMember2023-01-012023-02-020001125376us-gaap:SpinoffMemberensg:ThePennantGroupInc.Memberensg:SeniorLivingFacilitiesMember2019-10-310001125376us-gaap:SpinoffMembersrt:MinimumMember2022-12-310001125376srt:MaximumMemberus-gaap:SpinoffMember2022-12-310001125376ensg:ThePennantGroupInc.Member2022-01-012022-12-310001125376ensg:ThePennantGroupInc.Member2021-01-012021-12-310001125376ensg:ThePennantGroupInc.Member2020-01-012020-12-310001125376ensg:ThirdPartyTenantsMember2022-01-012022-12-310001125376ensg:ThirdPartyTenantsMember2021-01-012021-12-310001125376ensg:ThirdPartyTenantsMember2020-01-012020-12-310001125376ensg:ThePennantGroupInc.Member2022-01-012022-12-310001125376ensg:ThePennantGroupInc.Member2021-01-012021-12-310001125376ensg:ThePennantGroupInc.Member2020-01-012020-12-310001125376us-gaap:ProfessionalMalpracticeLiabilityMember2022-12-310001125376us-gaap:ProfessionalMalpracticeLiabilityMember2021-12-310001125376us-gaap:QualifiedPlanMember2022-01-012022-12-310001125376us-gaap:NonqualifiedPlanMember2022-01-012022-12-3100011253762018-05-312018-05-31ensg:operating_entity0001125376us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberensg:MedicaidAndMedicareMember2022-01-012022-12-310001125376us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberensg:MedicaidAndMedicareMember2021-01-012021-12-310001125376us-gaap:SubsequentEventMember2023-01-300001125376ensg:July2022RepurchaseProgramMember2022-07-280001125376ensg:July2022RepurchaseProgramMember2022-07-282022-07-280001125376ensg:February92022RepurchaseProgramMember2022-02-090001125376ensg:February92022RepurchaseProgramMember2022-02-092022-02-090001125376ensg:February92022RepurchaseProgramMember2022-04-012022-06-300001125376ensg:October212021RepurchaseProgramMember2021-10-210001125376ensg:October212021RepurchaseProgramMember2021-10-212021-10-210001125376ensg:October212021RepurchaseProgramMember2022-01-012022-12-310001125376ensg:October212021RepurchaseProgramMember2021-01-012021-12-3100011253762020-03-130001125376ensg:March42020RepurchaseProgramMember2020-03-040001125376ensg:March132020RepurchaseProgramMember2020-03-130001125376ensg:March42020RepurchaseProgramMember2020-03-042020-03-040001125376ensg:March42020RepurchaseProgramMember2020-01-012020-03-310001125376ensg:March132020RepurchaseProgramMember2020-01-012020-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the fiscal year ended December 31, 2022.
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the transition period from                      to                     .
Commission file number: 001-33757
_____________________________
ensg-20221231_g1.jpg
THE ENSIGN GROUP, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware33-0861263
(State or Other Jurisdiction of(I.R.S. Employer
Incorporation or Organization)Identification No.)

29222 Rancho Viejo Road, Suite 127
San Juan Capistrano, CA 92675
(Address of Principal Executive Offices and Zip Code)
(949487-9500
(Registrant’s Telephone Number, Including Area Code)
_____________________________
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareENSGNASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark:
if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.þYesNo
if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.YesþNo
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.þYesNo
whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).þYesNo
whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act:
Large accelerated filerþAccelerated filerNon-accelerated filerSmaller reporting companyEmerging growth company
If an emerging growth company, indicate if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.YesNo
whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section-404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.YesNo
If securities are registered pursuant to Section 12(b) of the Act, whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. YesþNo
whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).YesþNo
whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YesþNo
As of June 30, 2022, the aggregate market value of the Registrant's Common Stock held by non-affiliates was:
Common Stock$2,400,450,000
The aggregate market value of Common Stock was computed by reference to the closing price as of the last business day of the registrant's most recently completed second fiscal quarter. Shares of Common Stock held by each executive officer, director and each person owning more than 10% of the outstanding Common Stock of the registrant have been excluded (in the amount of $1,511,035,000) in that such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
As of January 30, 2023, 55,732,114 shares of the registrant’s common stock, $0.001 par value, were outstanding.



THE ENSIGN GROUP, INC.
INDEX TO ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022
TABLE OF CONTENTS
PART I
PART II.
PART III.
PART IV.



CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 
This Annual Report on Form 10-K contains forward-looking statements, which include, but are not limited to our expected future financial position, results of operations, cash flows, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities and plans and objectives of management. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. These statements are subject to the safe harbors under Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Additionally, many of these risks and uncertainties are currently, and in the future may continue to be, amplified by the impacts of the coronavirus (COVID-19) pandemic, including the response efforts of federal, state and local government authorities, businesses, individuals and us. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, some of which are listed under the section “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K. Accordingly, you should not rely upon forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this Annual Report, and are based on our current expectations, estimates and projections about our industry and business, management's beliefs, and certain assumptions made by us, all of which are subject to change. We undertake no obligation to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law.

As used in this Annual Report on Form 10-K, the words, "Ensign," "Company," “we,” “our” and “us” refer to The Ensign Group, Inc. and its consolidated subsidiaries. All of our operating subsidiaries, the Service Center (defined below) and our wholly-owned captive insurance subsidiary (the Captive Insurance) and captive real estate investment trust called Standard Bearer Healthcare REIT, Inc. (Standard Bearer) are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “our” and similar terms in this Annual Report on Form 10-K is not meant to imply, nor should it be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Ensign Group.

 
The Ensign Group, Inc. is a holding company with no direct operating assets, employees or revenues. In addition, certain of our wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide centralized accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Captive Insurance provides some claims-made coverage to our operating subsidiaries for general and professional liability, as well as for certain workers' compensation insurance liabilities. Standard Bearer owns and manages our real estate business.

The Service Center address is 29222 Rancho Viejo Rd Suite 127, San Juan Capistrano, CA 92675, and our telephone number is (949) 487-9500. Our corporate website is located at www.ensigngroup.net. The information contained in, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 10-K.

EnsignTM is our United States trademark. All other trademarks and trade names appearing in this annual report are the property of their respective owners.




PART I.
ITEM 1. BUSINESS
Founded in 1999, The Ensign Group, Inc. ("Ensign") is a holding company with subsidiaries that provide skilled nursing, senior living and rehabilitative services, as well as other ancillary businesses (including mobile diagnostics and medical transportation), in 13 states. As part of our investment strategy, we also acquire, lease and own healthcare real estate to service the post-acute care continuum through acquisition and investment opportunities in healthcare properties. For the year ended December 31, 2022, we generated approximately 96.1% of our revenue from our skilled nursing facilities. The remainder of our revenue is primarily generated from our real estate properties, senior living services and other ancillary services.
OPERATIONS
Overview
As of December 31, 2022, we offered skilled nursing, senior living and rehabilitative care services through 271 skilled nursing and senior living facilities. Of the 271 facilities, we operated 192 facilities under long-term lease arrangements and have options to purchase 11 of those 192 facilities. Our real estate portfolio includes 108 owned real estate properties, which included 79 facilities operated and managed by us, 29 senior living operations leased to and operated by The Pennant Group, Inc., or Pennant, as part of the spin-off transaction that occurred in October 2019, and the Service Center location. Of the 29 real estate operations leased to Pennant, one senior living operation is located on the same real estate property as a skilled nursing facility that we own and operate.
Our Unique Approach and Structure
The name "Ensign" is synonymous with a "flag" or a "standard" and refers to our goal of setting the standard by which all others in our industry are measured. We believe that through our efforts and leadership, we can foster a new level of patient care and professional competence at our affiliated operating subsidiaries, and set a new industry standard for each patient we service. We view healthcare services primarily as a local business. We believe our success is largely driven by our proven ability to build strong relationships with key stakeholders in local healthcare communities, in part, by leveraging our reputation for providing superior care. Accordingly, our brand strategy and organizational structure promotes the empowerment of local leadership and staff to make their facility the “operation of choice” in their community. This is accomplished by allowing local leadership to discern and address the unique needs and priorities of healthcare professionals, customers and other stakeholders in the local community or market, and then work to create a superior service offering for, and reputation in, their particular community. This local empowerment is unique within the healthcare services industry.
We believe that our localized approach encourages prospective patients and referral sources to choose or recommend our local operations. In addition, our leaders are enabled and motivated to share real-time operating data and otherwise benchmark clinical and operational performance against their peers in order to improve clinical care, enhance patient satisfaction and augment operational efficiencies, promoting the sharing of best practices.
We organize our operating subsidiaries into portfolio companies, which we believe has enabled us to maintain a local, field-driven organizational structure, attract additional qualified leadership talent, and to identify, acquire, and improve operations at a generally faster rate. Each of our portfolio companies has its own leader. These leaders, who are generally taken from the ranks of operational CEOs, serve as leadership resources within their own portfolio companies, and have the primary responsibility for recruiting qualified talent, finding potential acquisition targets, and identifying other internal and external growth opportunities. We believe this organizational structure has improved the quality of our recruiting and will continue to facilitate successful acquisitions.
Since we spun-off our owned real estate properties into a public real estate investment trust (REIT) in 2014, we have continued to expand our real estate portfolio. Following the real estate spin-off, we have acquired and currently own 108 real estate properties, including 29 real estate properties that are leased to a third party under triple-net long-term leases. We manage and operate the remaining real estate properties, including the Service Center location. We are committed to growing our real estate portfolio, which we believe will further enhance our earnings and maximize long-term shareholder value.

1

To continue with our growth strategy on our real estate portfolio, in January 2022, we formed Standard Bearer. Standard Bearer owns and manages our real estate business. We believe the REIT structure allows us to better demonstrate the growing value of our owned real estate and provide us with an efficient vehicle for future acquisitions of properties that could be operated by Ensign affiliates or other third parties. We believe this structure gives us new pathways to growth with transactions we would not have considered in the past. Standard Bearer intends to qualify and elect to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. The real estate portfolio in Standard Bearer consists of 103 of our 108 owned real estate properties. For further details on the Standard Bearer REIT, refer to Note 7, Standard Bearer, in Notes to the Consolidated Financial Statements of this Annual Report on Form 10-K.
SEGMENTS
We have two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of select properties owned by us through our captive REIT and leased to skilled nursing and senior living operations, including our own operating subsidiaries and third party operators.
We also report an “all other” category that includes operating results from our senior living operations, mobile diagnostics, transportation, other real estate and other ancillary operations. These businesses are neither significant individually, nor in aggregate and therefore do not constitute a reportable segment. Our Chief Executive Officer, who is our chief operating decision maker, or CODM, reviews financial information at the operating segment level. We have presented our segment results in this Annual Report on Form 10-K on a comparative basis to conform to the segment structure. For more information about our operating segments, as well as financial information, see Part II Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations and Note 8, Business Segments of the Notes to the Consolidated Financial Statements.
Skilled Services
As of December 31, 2022, our skilled nursing companies provided skilled nursing care at 260 operations, with 28,130 operational beds, in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. We provide short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly. Our residents are often high-acuity patients that come to our facilities to recover from strokes, cardiovascular and respiratory conditions, neurological conditions, joint replacements, and other muscular or skeletal disorders. We use interdisciplinary teams of experienced medical professionals to provide services prescribed by physicians. These medical professionals provide individualized comprehensive nursing care to our short-stay and long-stay patients. Many of our skilled nursing facilities are equipped to provide specialty care, such as on-site dialysis, ventilator care, cardiac and pulmonary management. We also provide standard services such as room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. We are dedicated to ensuring our residents are happy, comfortable, and motivated to achieve their health goals through the provision of quality care. We generate our skilled services revenue from Medicaid, Medicare, managed care, commercial insurance, and private pay. During the year ended December 31, 2022, approximately 46.8% and 28.6% of our skilled services revenue was derived from Medicaid and Medicare programs, respectively.
Standard Bearer
We engage in the acquisition and leasing of skilled nursing and senior living properties. We generate rental revenue primarily by leasing post-acute care properties we acquired to healthcare operators under triple-net lease arrangements, whereby the tenant is solely responsible for the costs related to the property, including property taxes, insurance and maintenance and repair costs, subject to certain exceptions. As of December 31, 2022, our real estate portfolio within Standard Bearer is comprised of 103 real estate properties located in Arizona, California, Colorado, Idaho, Kansas, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Of these properties, 75 are leased to affiliated skilled nursing facilities wholly-owned and managed by us and 29 are leased to senior living operations wholly-owned and managed by Pennant. Of the 29 real estate operations leased to Pennant, one senior living operation is located on the same real estate property as a skilled nursing facility that we own and operate. During the year ended December 31, 2022, we generated rental revenues of $72.9 million, of which $58.0 million was derived from affiliated wholly-owned healthcare operators, and therefore eliminated in consolidation.

2

Other
Revenue from our senior living operations, other real estate, mobile diagnostics and other ancillary operations comprise approximately 4.1% of our annual revenue.

Senior Living — As of December 31, 2022, we had an aggregate of 3,021 senior living units across 37 operations, of which 26 are located on the same site location as our skilled nursing care operations. Our senior living communities located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Texas, Utah and Washington, provide residential accommodations, activities, meals, housekeeping and assistance in the activities of daily living to seniors who are independent or who require some support, but not the level of nursing care provided in a skilled nursing operation. Our independent living units are non-licensed independent living apartments in which residents are independent and require no support with the activities of daily living.
Our senior living operations comprise approximately 2.2% of our annual revenue. We generate revenue at these units primarily from private pay sources, with a small portion derived from Medicaid or other state-specific programs. Specifically, during the year ended December 31, 2022, approximately 63.1% of our senior living revenue was derived from private pay sources.
Ancillary — As of December 31, 2022, we held a majority membership interest of ancillary operations located in Arizona, California, Colorado, Idaho, Texas, Utah and Washington. We have invested in and are exploring new business lines that are complementary to our existing skilled services and senior living services. These new business lines consist of mobile ancillary services, including digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory and patient transportation to people in their homes or at long-term care facilities. To date these businesses were not meaningful contributors to our operating results.
GROWTH

We have an established track record of successful acquisitions. Much of our historical growth can be attributed to implementing our expertise in acquiring real estate or leasing both under-performing and performing post-acute care operations and transforming them into market leaders in clinical quality, staff competency, employee loyalty and financial performance. With each acquisition, we apply our core operating expertise to improve these operations, both clinically and financially. In years where pricing has been high, we have focused on the integration and improvement of our existing operating subsidiaries while limiting our acquisitions to strategically situated properties.

From January 1, 2012 through December 31, 2022, we acquired 223 facilities, which added 18,443 operational skilled nursing beds and 5,000 senior living units to our operating subsidiaries, which included the operations that were contributed to Pennant. The following table summarizes cumulative skilled nursing and senior living operation, operational skilled nursing bed and senior living unit counts at the end of 2012 and each of the last five years to reflect our growth over a ten-year period and five-year period as a result of the acquisition of these facilities:
 December 31,
 
2012(2)
2018(2)
2019(1)(2)
202020212022
Cumulative number of skilled nursing and senior living operations108 244 223 228 245 271 
Cumulative number of operational skilled nursing beds10,215 19,615 22,625 23,172 25,032 28,130 
Cumulative number of senior living units1,677 5,664 2,154 2,254 2,237 3,021 
(1) Number of operational beds and number of operations for 2018 and 2019 include operational beds and operations that we no longer operated. The number of operations and operational beds do not include the closed facilities beginning in the year of their closures.
(2) Included in the 2012 and 2018-2019 number of operational units and number of operations are the operational units and operations of senior living facilities that we transferred to Pennant in 2019. In 2019, the number of operations and operational units do not include operations transferred to Pennant.
We have also invested in new business lines that are complementary to our existing businesses, such as ancillary services. We plan to continue to grow our revenue and earnings by:

continuing to grow our talent base and develop future leaders;

increasing the overall percentage or “mix” of higher-acuity patients;

focusing on organic growth and internal operating efficiencies;

continuing to acquire additional operations in existing and new markets;

3

expanding and renovating our existing operations, and

strategically investing in and integrating other post-acute care healthcare businesses.

New Market CEO and New Ventures Programs.  In order to broaden our reach into new markets, and in an effort to provide existing leaders in our company with the entrepreneurial opportunity and challenge of entering a new market and starting a new business, we established our New Market CEO program in 2006. Supported by our Service Center and other resources, a New Market CEO evaluates a target market, develops a comprehensive business plan, and relocates to the target market to find talent and connect with other providers, regulators and the healthcare community in that market, with the goal of ultimately acquiring businesses and establishing an operating platform for future growth. In addition, this program includes other lines of business that are closely related to the skilled nursing industry. The New Ventures program encourages our local leaders to evaluate service offerings with the goal of establishing an operating platform in new markets and new businesses. We believe that this program will not only continue to drive growth, but will also provide a valuable training ground for our next generation of leaders, who will have experienced the challenges of growing and operating a new business.
EXPANSIONS
During the year ended December 31, 2022, we expanded our operations and real estate portfolio through a combination of long-term leases and real estate purchases, with the addition of 23 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of seven of the stand-alone skilled nursing operations, which were leased back to Ensign affiliated entities. In addition, we purchased the real estate of three skilled nursing properties which our affiliated operating subsidiaries already operated, further expanding our real estate portfolio. We also added five senior living operations that were transferred from Pennant, three of which are part of campuses operated by our affiliated operating subsidiaries. These new operations added a total of 3,058 operational skilled nursing beds and 674 operational senior living units to be operated by our affiliated operating subsidiaries. Additionally, we invested in new ancillary services that are complementary to our existing businesses.
Subsequent to December 31, 2022, we expanded our operations through long-term leases, with the addition of seventeen stand-alone skilled nursing operations. These new operations added 1,462 operational skilled nursing beds to be operated by our affiliated operating subsidiaries.
For further discussion of our acquisitions, see Note 9, Operation Expansions in the Notes to the Consolidated Financial Statements.
QUALITY OF CARE MEASURES
Improvement in Acquired Facilities. In December 2008, the Centers for Medicare and Medicaid Services (CMS) introduced the Five-Star Quality Rating System to help consumers, their families and caregivers compare nursing homes more easily. The Five-Star Quality Rating System gives each skilled nursing operation a rating between one and five stars in various categories. We have a strong history of quickly improving the quality of care in the facilities we acquire. Thus, as new assessments are conducted post-acquisition, the star ratings see consistent improvement. At the time of acquisition, the majority of our facilities have 1 and 2-Star ratings.
Over the last few years, CMS had modified the Star rating requirements. These changes have been significant and made it more difficult to achieve a 4 or 5-Star rating. The 2019 changes resulted in nursing centers losing stars in their "Quality" and "Staffing" ratings, which negatively impacted the "Overall" ratings. Nevertheless, we continue to demonstrate strong performance in the Five-Star Quality Rating System. We believe compliance and quality outcomes are precursors to outstanding financial performance. Thus, we strive to aggressively increase quality and compliance in every facility we acquire, and to adjust our overall policies to adapt to CMS’s changing criteria for the Five-Star Quality Rating System. As a result of the COVID-19 pandemic, CMS temporarily waived certain reporting timeframes and suspended certain inspections that impacted the underlying data used for calculating star-ratings. This resulted in CMS freezing affected quality measures by only using data collected for periods not impacted by the COVID-19 waivers. CMS continues to change the way the star-rating is calculated, both through ongoing regulation changes and CMS's enactment or expiration of waivers regarding reporting and calculation requirements for five-star ratings. Therefore, depending on the changes, we may experience periods of time where the number of facilities with 4 or 5-Star ratings decline. The star-rating calculations resumed on January 27, 2021.
4

The table below summarizes the number of our facilities with 4 and 5-Star ratings since 2018:
 As of December 31,
 20182019202020212022
4 and 5-Star Quality Rated skilled nursing facilities91 102 116 114 113 

Above-Average Ratings. Additionally, despite the fact that Ensign’s acquisition of facilities with 1 or 2-Star ratings skews our company-wide ratings, our mean score on the Five-Star Quality Rating System is 64.8%, which exceeds the national average score of 58.0%.

INDUSTRY TRENDS
The post-acute care industry has evolved to meet the growing demand for post-acute and custodial healthcare services generated by an aging population, increasing life expectancies and the trend toward shifting patient care to lower cost settings. The industry has evolved in recent years, which we believe has led to a number of favorable improvements in the industry, as described below:
Shift of Patient Care to Lower Cost Alternatives The growth of the senior population in the U.S. continues to increase healthcare costs, often faster than the available funding from government-sponsored healthcare programs. In response, federal and state governments have adopted cost-containment measures that encourage the treatment of patients in more cost-effective settings such as skilled nursing facilities, for which the staffing requirements and associated costs are often significantly lower than acute care hospitals and other post-acute care settings. As a result, skilled nursing facilities are generally serving a larger population of higher-acuity patients than in the past.
Significant Acquisition and Consolidation Opportunities The skilled nursing industry is large and highly fragmented, characterized predominantly by numerous local and regional providers. Due to the increasing demands from hospitals and insurance carriers to implement sophisticated and expensive reporting systems, we believe this fragmentation provides us with significant acquisition and consolidation opportunities.
Improving Supply and Demand Balance The number of skilled nursing facilities has declined modestly over the past several years. We expect that the supply and demand balance in the skilled nursing industry will continue to improve due to the shift of patient care to lower cost settings, an aging population and increasing life expectancies.
Increased Demand Driven by Aging Populations As seniors account for an increasing percentage of the total U.S. population, we believe the demand for skilled nursing and senior living services will continue to increase. According to the census projection released by the U.S. Census Bureau in early 2020, between 2016 and 2030, the number of individuals over 65 years old is projected to be one of the fastest growing segments of the United States population, growing from 16% to 21%. The Bureau expects this segment to increase nearly 50% to 73 million, as compared to the total U.S. population which is projected to increase by 10% over that time period. Furthermore, the generation currently retiring has accumulated less savings than prior generations, creating demand for more affordable senior housing and skilled nursing services. As a high-quality provider in lower cost settings, we believe we are well-positioned to benefit from this trend.
Transition to Value-Based Payment Models In response to rising healthcare spending in the United States, commercial, government and other payors are generally shifting away from fee-for-service (FFS) payment models towards value-based models, including risk-based payment models that tie financial incentives to quality, efficiency and coordination of care. We believe that patient-centered outcomes driven reimbursement models will continue to grow in prominence. Many of our operations already receive value-based payments, and as valued-based payment systems continue to increase in prominence, it is our view that our strong clinical outcomes will be increasingly rewarded.

5

Accountable Care Organizations and Reimbursement Reform A significant goal of U.S. federal health care reform is to transform the delivery of health care by changing reimbursement to reflect and support the quality and safety of care that providers deliver, increase efficiency, and reduce growth in spending. Reimbursement models that provide financial incentives to encourage efficiency, affordability, and high-quality care have been developed and implemented by government and commercial third-party payers. The most prolific of these models, the Accountable Care Organization (ACO) model, incentivizes groups of providers to share in savings that are achieved through the coordination of care and chronic disease management of an assigned patient population. Reimbursement methodology reform includes Value-Based Purchasing (VBP), in which a portion of provider reimbursement is redistributed based on relative performance, or improvement on designated economic, clinical quality, and patient satisfaction metrics. In addition, the Centers for Medicare and Medicaid Services (CMS) has implemented Episode-based demonstration, voluntary and mandatory payment initiatives that bundle acute care and post-acute care reimbursement. These bundled payment models incentivize cross-continuum care coordination and include financial and performance accountability for episodes of care. These reimbursement methodologies and similar programs are likely to continue and expand, both in government and commercial health plans. Many of our operations already participate in ACOs. With our focus on quality care and strong clinical outcomes, Ensign is well-positioned to benefit from these outcome-based payment models.
We believe the post-acute industry has been and will continue to be impacted by several other trends. The use of long-term care (LTC) insurance is increasing among seniors as a means of planning for the costs of skilled nursing services. In addition, as a result of increased mobility in society, reduction of average family size, and the increased number of two-wage earner couples, more residents are looking for alternatives outside the family for their care.
Our business is affected by seasonal fluctuations in occupancy and acuity which are most prominent when comparing the summer and winter months of the calendar year (including volatility arising from COVID-19).
REVENUE SOURCES

 
We derive revenue primarily from the Medicaid and Medicare programs, managed care and commercial insurance payors, and private pay patients. The majority of our revenue is derived from skilled nursing, which is highly dependent upon the Medicaid and Medicare programs. Thus, any changes to payment models, reimbursements and budgets impact our revenue, some positively and some negatively. A detailed discussion of the regulatory framework impacting our business is found in the Government Regulation section below. See also, Item 1A., Risk Factors.
A brief overview of each of our revenue sources is as follows:
Medicaid   Medicaid is a program financed by state funds and matching federal funds administered by the states and their political subdivisions, and often go by state-specific names, such as Medi-Cal in California and the Arizona Healthcare Cost Containment System in Arizona. Medicaid programs generally provide health benefits for qualifying individuals, and may supplement Medicare benefits for the disabled and for persons aged 65 and older meeting financial eligibility requirements. Medicaid reimbursement formulas are established by each state with the approval of the federal government in accordance with federal guidelines. Seniors who enter skilled nursing facilities as private pay clients can become eligible for Medicaid once they have substantially depleted their assets. Medicaid is generally the largest source of funding for most skilled nursing facilities.
Medicaid reimbursement varies from state to state and is based upon a number of different systems, including cost-based, prospective payment; case mixed adjusted payments and negotiated rate systems. Rates are subject to a state’s annual budgetary requirements and funding, statutory and regulatory changes and interpretations and rulings by individual state agencies and State Plan Amendments approved by CMS.

Medicaid typically covers patients that require standard room and board services and provides reimbursement rates that are generally lower than rates earned from other sources. We monitor our payor mix to measure the level received from each payor across each of our business units. We intend to continue to focus on enhancing our care offerings to accommodate more high acuity patients.


6

Approximately 81.9% of our Medicaid revenue comes from Arizona, California, Colorado, Texas, and Utah. In California, the state enacted legislation expanding their Medicaid program, which in recent years has continued to see budget increases, but may see Medicaid spending decrease in the 2022-2023 period. It is projected that California General Fund spending on California Medicaid will be $35.5 billion for the 2022-2023 budget year, which is a decrease of approximately $900 million from its 2022-2023 budget estimate. California also estimates that the 2023-2024 budget year's Medicaid spending will decrease by $1.3 billion to $34.2 billion. Over the longer term, however, California expects its Medicaid spending to increase, reaching more than $38 billiion by the 2026-2027 budget year. Texas is one of the remaining states that has not expanded Medicaid under the Affordable Care Act. Texas lawmakers have, in the past, underfunded Medicaid, requiring an infusion of state and federal funds. Funding for the 2022-2023 Texas biennium includes $25.1 billion in general revenue funds, which is a decrease of $400 million in general funds from the 2020-2021 biennium amounts. In Arizona, the state enacted legislation expanding their Medicaid program in 2013 but has seen decreased Medicaid enrollments in recent years. Their 2021 budget for the state Medicaid program included $1.9 billion from the general fund and the 2022 budget increased to over $1.92 billion. In Utah, a public referendum to expand the state’s Medicaid program succeeded in 2018, and in 2020 the Utah legislature fully implemented this Medicaid program expansion. Utah’s fiscal year 2021 Medicaid spending was $3.9 billion, and the state’s budget for 2022 fiscal year Medicaid spending, which will continue into 2023, is expected to be similar.

Medicare   Medicare is a federal program that provides healthcare benefits to individuals who are 65 years of age or older or are disabled. To achieve and maintain Medicare certification, a skilled nursing facility must sign a Medicare provider agreement and meet the CMS “Conditions of Participation” on an ongoing basis, as determined in periodic facility inspections or “surveys” conducted primarily by the state licensing agency in the state where the facility is located. Medicare pays for inpatient skilled nursing facility services under the prospective payment system (PPS). Under PPS, facilities are paid a predetermined amount per patient, per day, for certain services. Medicare Part A skilled nursing facility coverage is limited to 100 days per episode of illness for those beneficiaries who require daily care following discharge from an acute care hospital.
For Medicare beneficiaries who qualify for the Medicare Part A coverage, rehabilitation services are included in the per diem payment. For beneficiaries who do not meet the coverage criteria for Part A services, rehabilitation services may qualify for the services to be provided under Medicare Part B.
Managed Care and Private Insurance   Managed care patients consist of individuals who are insured by certain third-party entities, or who are Medicare beneficiaries who have assigned their Medicare benefits to a senior managed care organization plan. Another type of insurance, long-term care insurance, is also becoming more available to consumers, but is not expected to contribute significantly to industry revenues in the near term.
Private and Other Payors   Private and other payors consist primarily of individuals, family members or other third parties who directly pay for the services we provide.
Rental Revenue Real estate rental revenue is generated by leasing post-acute care properties that we acquired to healthcare operators under triple-net lease arrangements, whereby the tenant is solely responsible for the costs related to the property, including property taxes, insurance and maintenance and repair costs, subject to certain exceptions.
The following charts sets forth our total service revenue by payor source generated by our consolidated operations and skilled services segment as a percentage of total revenue for the years ended December 31, 2022 and 2021, respectively:


7

CONSOLIDATED SERVICE REVENUE BY PAYOR
ensg-20221231_g2.jpgensg-20221231_g3.jpg
SKILLED SERVICES REVENUE BY PAYOR
ensg-20221231_g4.jpgensg-20221231_g5.jpg
Payor Sources as a Percentage of Skilled Nursing Services The following table sets forth our percentage of skilled nursing patient days by payor source:
 Year Ended December 31,
 20222021
Percentage of Skilled Nursing Days:
Medicare13.5 %13.5 %
Managed care13.1 13.0 
Other skilled5.2 5.2 
SKILLED MIX31.8 31.7 
Private and other payors10.3 10.2 
Medicaid57.9 58.1 
TOTAL SKILLED NURSING100.0 %100.0 %

8

REIMBURSEMENT FOR SPECIFIC SERVICES

Reimbursement for Skilled Nursing Services   Skilled nursing facility revenue is primarily derived from Medicaid, Medicare, managed care and private payors. Our skilled nursing operations provide Medicaid-covered services to eligible individuals consisting of nursing care, room and board and social services. In addition, states may, at their option, cover other services such as physical, occupational and speech therapies.

Historically, adjustments to reimbursement under Medicare and Medicaid have had a significant effect on our revenue and results of operations. Recently enacted, pending and proposed legislation and administrative rulemaking at the federal and state levels could have similar effects on our business. Efforts to impose reduced reimbursement rates, greater discounts and more stringent cost controls by government and other payors are expected to continue for the foreseeable future and could adversely affect our business, financial condition and results of operations. Additionally, any delay or default by the federal or state governments in making Medicare and/or Medicaid reimbursement payments could materially and adversely affect our business, financial condition and results of operations.

Reimbursement for Rehabilitation Therapy Services   Rehabilitation therapy revenue is primarily received from private pay, managed care and Medicare for services provided at skilled nursing operations and senior living operations. The payments are based on negotiated patient per diem rates or a negotiated fee schedule based on the type of service rendered.

Reimbursement for Senior Living   Senior living facility revenue is primarily derived from private pay patients at rates we established, with only a small portion of such revenue derived from state-specific programs such as Medicaid.

Reimbursement for Other Ancillary Services  Other ancillary revenue, such as mobile diagnostics and medical transportation, is primarily derived from Medicare Part B, Medicaid, managed care and private payors at rates we establish based upon the services we provide and market conditions in the area of operation.
RENTAL REVENUE

Rental revenue from third party rental property tenants Standard Bearer's owned properties are leased pursuant to non-cancelable operating leases, generally with an initial term of 10 to 15 years. All of the post-acute care healthcare properties leased contain renewal options. The leases provide for fixed minimum base rent during the initial and renewal periods. Standard Bearer's leases contain provisions for specified annual increases over the rents of the prior year and those increases are generally computed on a calculation based on the Consumer Price Index.

Each lease is a triple net lease which requires the lessee to pay all taxes, insurance, maintenance and repairs, capital and non-capital expenditures and other costs necessary in the operations of the facilities. In addition, Standard Bearer's leases with third-parties are typically structured as master leases. The master leases consist of multiple leases, each with its own pool of properties, that have varying maturities and diversity in property geography.

If a lessee makes payments for taxes and insurance directly to a third-party on our behalf, we are required to exclude these payments from variable payments and from revenue recognition in our consolidated statements of income. Otherwise, tenant reimbursements paid to us for taxes and insurance are classified as additional rental revenue recognized by us on a gross basis.

Rental revenue from Ensign-affiliated tenants Rental revenue from Ensign-affiliated operations is based on mutually agreed-upon base rents that are subject to change from time to time. Intercompany revenue is eliminated in consolidation, along with the corresponding intercompany rent expenses of the related healthcare facilities.
COMPETITION

 
The post-acute care industry is highly competitive, and we expect that the industry will become increasingly competitive in the future. The industry is highly fragmented and characterized by numerous local and regional providers, in addition to large national providers that have achieved geographic diversity and economies of scale. Our operating subsidiaries also compete with inpatient rehabilitation facilities and long-term acute care hospitals.  Increasingly, we are competing with home health and community-based providers who have developed programs designed to provide services to seniors outside a facility-based setting, potentially decreasing the time they need the higher level of care provided in a skilled nursing facility. Competitiveness may vary significantly from location to location, depending upon factors such as the number of competing facilities, availability of services, expertise of staff, and the physical appearance and amenities of each location. We believe that the primary competitive factors in the post-acute care industry are:
9


ability to attract and to retain qualified management and caregivers;

reputation and achievements of quality healthcare outcomes;

attractiveness and location of facilities;

the expertise and commitment of the management team and employees; and

community value, including amenities and ancillary services.

 
 
We seek to compete effectively in each market by establishing a reputation within the local community as the “operation of choice.” This means that the operation leaders are generally free to discern and address the unique needs and priorities of healthcare professionals, customers and other stakeholders in the local community or market, and then create a superior service offering and reputation for that particular community or market that is calculated to encourage prospective customers and referral sources to choose or recommend the operation.

Increased competition could limit our ability to attract and retain patients, maintain or increase rates or to expand our business. Some of our competitors have greater financial and other resources than we have, may have greater brand recognition and may be more established in their respective communities than we are. Competing companies may also offer newer facilities or different programs or services than we offer, and may therefore attract individuals who are currently patients of our facilities, potential patients of our facilities, or who are otherwise receiving our healthcare services. Other competitors may have lower expenses or other competitive advantages than us and, therefore, provide services at lower prices than we offer.

Our other services, such as senior living facilities and other ancillary services, also compete with local, regional, and national companies. The primary competitive factors in these businesses are similar to those for our skilled nursing facilities and include reputation, cost of services, quality of clinical services, responsiveness to patient/resident needs, location and the ability to provide support in other areas such as third-party reimbursement, information management and patient recordkeeping.

Our Standard Bearer segment competes for real property investments with healthcare providers, healthcare-related REITs, real estate partnerships, banks, private equity funds, venture capital funds and other investors. Some of these competitors are significantly larger and have greater financial resources and lower costs of capital than us. Our ability to compete successfully for real property investments will be determined by numerous factors, including our ability to identify suitable acquisition targets, our ability to negotiate acceptable terms for any such acquisition and our cost of capital in the event an acquisition requires debt or equity financing.
OUR COMPETITIVE STRENGTHS

 
We believe that we are well positioned to benefit from the ongoing changes within our industry. We believe that our ability to acquire, integrate and improve our facilities is a direct result of the following key competitive strengths:

 Experienced and Dedicated Employees   We believe that our operating subsidiaries' employees are among the best in their respective industries. We believe each of our operating subsidiaries is led by an experienced and caring leadership team, including dedicated front-line care staff, who participates daily in the clinical and operational improvement of their individual operations. We have been successful in attracting, training, incentivizing and retaining a core group of outstanding business and clinical leaders to spearhead our operating subsidiaries. These leaders operate as separate local businesses. With broad local control, these talented leaders and their care staffs are able to quickly meet the needs of their patients and residents, employees and local communities, without waiting for permission to act or being bound to a “one-size-fits-all” corporate strategy.

 Unique Incentive Programs   We believe that our employee compensation programs are unique within the industry. Employee stock options and performance bonuses, based on achieving target clinical quality, cultural, compliance and financial benchmarks, represent a significant component of total compensation for our operational leaders. We believe that these compensation programs assist us in encouraging our leaders and key employees to act with a shared ownership mentality. Furthermore, our leaders are motivated to help local operations within a defined “cluster” and "market," which is a group of geographically proximate operations that share clinical best practices, real-time financial data and other resources and information.

10

 Staff and Leadership Development  We have a company-wide commitment to ongoing education, training and professional development. Accordingly, our operational leaders participate in regular training. Most participate in training sessions at Ensign University, our in-house educational system. Other training opportunities are generally offered via on-demand training tools, including podcasts. In addition, we offer weekly cultural and interactive educational topics including leadership development, our values, updates on Medicaid and Medicare billing requirements, updates on new regulations or legislation, infection control, COVID-19 clinical and regulations, emerging healthcare service alternatives and other relevant clinical, business and industry specific coursework. Additionally, we encourage and provide ongoing education classes for our clinical staff to maintain licensing and increase the breadth of their knowledge and expertise. We believe that our commitment to, and substantial investment in, ongoing education will further strengthen the quality of our operational leaders and staff, and the quality of the care they provide to our patients and residents.

 Innovative Service Center Approach   We do not maintain a corporate headquarters; rather, we operate a Service Center to support the efforts of each operation. Our Service Center is a dedicated service organization that acts as a resource and provides centralized information technology, human resources, accounting, payroll, legal, risk management, educational and other back office support services, so that local leaders can focus on delivering top-quality care and efficient business operations. Our Service Center approach allows individual operations to function with the strength, synergies and economies of scale found in larger organizations, but without what we believe are the disadvantages of a top-down management structure or corporate hierarchy. We believe our Service Center approach is unique within the industry, and allows us to preserve the “one-operation-at-a-time” focus and culture that has contributed to our success.

Proven Track Record of Successful Acquisitions   We have established a disciplined acquisition strategy that is focused on selectively acquiring operations within our target markets. Our acquisition strategy is driven by our operations team. Prospective leaders are included in the decision-making process and compensated as these acquired operations reach pre-established clinical quality and financial benchmarks, helping to ensure that we only undertake acquisitions that key leaders believe can become clinically sound and contribute to our financial performance.

As of December 31, 2022, we have expanded to 271 facilities with an aggregate of 28,130 operational skilled nursing beds and 3,021 senior living units, through both long-term leases and purchases. We believe our experience in acquiring these operations and our demonstrated success in significantly improving their operations enables us to consider a broad range of acquisition targets. In addition, we believe we have developed expertise in transitioning newly acquired operations to our unique organizational culture and systems, which enables us to acquire operations with limited disruption to patients, residents and operating staff, while significantly improving quality of care. We have also constructed new facilities to target demand, which exists for high-end healthcare facilities when we determine that market conditions justify the cost of new construction in some of our markets.

Successful Real Estate Investment Strategy As part of our Standard Bearer segment, we maintain a real estate portfolio of long-term healthcare facilities diversified by geographic location and operated by a diverse group of established healthcare providers. We are focused on selectively acquiring real estate properties based on our industry experience and opportunistic strategy, which we believe provides us with greater investment and purchasing opportunities. Due to our credit strength, we have the ability to acquire large portfolios of real estate properties; a portion of which can be managed and operated by our Ensign affiliated established healthcare leaders and a portion of which can be leased to third parties.

As of December 31, 2022, our real estate portfolio consists of 108 owned facilities, which include properties leased to and operated by third parties and properties we managed and operated. We believe our real estate investment strategy has allowed us to accumulate a portfolio that aids our healthcare operators in improving performance and generating additional returns through leases with third parties.

 
Reputation for Quality Care  We believe that we have achieved a reputation for high-quality and cost-effective care and services to our patients and residents within the communities we serve. We believe that our achievement of quality outcomes enhances our reputation for quality, that when coupled with the integrated services that we offer, allows us to attract patients that require more intensive and medically complex care and generally result in higher reimbursement rates than lower acuity patients.
11

Community Focused Approach  We view our services primarily as a local, community-based business. Our local leadership-centered management culture enables each operation's nursing support staff and leaders to meet the unique needs of their patients and local communities. We believe that our commitment to this “one-operation-at-a-time” philosophy helps to ensure that each operation, its patients, their family members and the community will receive the individualized attention they need. By serving our patients, their families, the community and our fellow healthcare professionals, we strive to make each individual business the operation of choice in its local community.

 
We further believe that when choosing a healthcare provider, consumers usually choose a person or people they know and trust, rather than a corporation or business. Therefore, rather than pursuing a traditional organization-wide branding strategy, we actively seek to develop the operations brand at the local level, serving and marketing one-on-one to caregivers, our patients, their families, the community and our fellow healthcare professionals in the local market.

Investment in Information Technology  We utilize information technology that enables our operational leaders to access, and to share with their peers, both clinical and financial performance data in real time. Armed with relevant and current information, our operation leaders and their management teams are able to share best practices and the latest information, adjust to challenges and opportunities on a timely basis, improve quality of care, mitigate risk and improve both clinical outcomes and financial performance. We have also invested in specialized healthcare technology systems to assist our nursing and support staff. We have installed software and touch-screen interface systems in each operation to enable our clinical staff to more efficiently monitor and deliver patient care and record patient information. We believe these systems have improved the quality of our medical and billing records, while improving the productivity of our staff.
OUR GROWTH STRATEGY

We believe that the following strategies are primarily responsible for our growth to date, and will continue to drive the growth of our business:

 
Grow Talent Base and Develop Future Leaders   Our primary growth strategy is to expand our talent base and develop future leaders. A key component of our organizational culture is our belief that strong local leadership is a primary key to the success of each operation. While we believe that significant acquisition opportunities exist, we have generally followed a disciplined approach to growth that permits us to acquire an operation only when we believe, among other things, that we will have qualified leadership for that operation. To develop these leaders, we have a rigorous “CEO-in-Training Program” that attracts proven business leaders from various industries and backgrounds, and provides them the knowledge and hands-on training they need to successfully lead one of our operating subsidiaries. We generally have between 25 and 30 prospective administrators progressing through the various stages of this training program, which is generally much more rigorous, hands-on and intensive than the minimum 1,000 hours of training mandated by the licensing requirements of most states where we do business. Once administrators are licensed and assigned to an operation, they continue to learn and develop in our operational Chief Executive Officer Program (CEO Program), which facilitates the continued development of these talented business leaders into outstanding operational chief executive officers, through regular peer review, our Ensign University and on-the-job training.

 
In addition, our Chief Operating Officer Program (COO Program) recruits and trains highly qualified Directors of Nursing to lead the clinical programs in our operations. Working together with their operational CEO and/or administrator, other key operational leaders and front-line staff, these experienced nurses manage delivery of care and other clinical personnel and programs to optimize both clinical outcomes and employee and patient satisfaction.

 
Increase Mix of High Acuity Patients   Many skilled nursing facilities are serving an increasingly larger population of patients who require a high level of skilled nursing and rehabilitative care, whom we refer to as high acuity patients, as a result of government and other payors seeking lower-cost alternatives to traditional acute-care hospitals. We generally receive higher reimbursement rates for providing care for these medically complex patients. In addition, many of these patients require therapy and other rehabilitative services, which we are able to provide as part of our integrated service offerings. Where higher complex services are medically necessary and prescribed by a patient's physician or other appropriate healthcare professional, we generally receive additional revenue in connection with the provision of those services. By making these integrated services available to such patients, and maintaining established clinical standards in the delivery of those services, we are able to increase our overall revenues. We believe that we can continue to attract high acuity patients to our operations by maintaining and enhancing our reputation for quality care and continuing our community focused approach.

 

12

Focus on Organic Growth and Internal Operating Efficiencies   We plan to continue to grow organically by focusing on increasing patient occupancy within our existing operations. Although some of the facilities we have acquired were in good physical and operating condition, the majority have been clinically and financially troubled, with some facilities having had occupancy rates as low as 30% at the time of acquisition. Additionally, we believe that incremental operating margins on the last 20% of our beds/units are significantly higher than on the first 80%, offering opportunities to improve financial performance within our existing facilities. Our overall occupancy is impacted significantly by the number of facilities acquired and the operational occupancy on the acquisition date. Therefore, consolidated occupancy will vary significantly based on these factors. Our average occupancy rates for our skilled nursing facilities was 75.3% and 72.8% for the years ended December 31, 2022 and 2021, respectively. Our average occupancy rates in 2022 continue to improve as we recover from the COVID-19 pandemic.
We also believe we can generate organic growth by improving operating efficiencies and the quality of care at the patient level. By focusing on staff development, clinical systems and the efficient delivery of quality patient care, we believe we are able to deliver higher quality care at lower costs than many of our competitors.

Historically, we have achieved incremental occupancy and revenue growth by creating or expanding clinical service offerings in existing operations. For example, by expanding clinical programs to provide outpatient therapy services in many markets, we are able to increase revenue while spreading the fixed costs of maintaining these programs over a larger patient base. Outpatient therapy has also proven to be an effective marketing tool, raising the visibility of our facilities in their local communities and enhancing the reputation of our facilities with short-stay rehabilitation patients.

Add New Facilities and Expand Existing Facilities   One of our growth strategies includes the acquisition of new and existing facilities from third parties and the expansion and upgrades to current facilities. In the near term, we plan to take advantage of the fragmented skilled nursing industry by acquiring operations within select geographic markets and may consider the construction of new facilities. In addition, we have targeted facilities that we believed were performing and operations that were underperforming, where we believed we could improve service delivery, occupancy rates and cash flow. With experienced leaders in place at the community level and demonstrated success in significantly improving operating conditions at acquired facilities, we believe that we are well positioned for continued growth. While the integration of underperforming facilities generally has a negative short-term effect on overall operating margins, these facilities are typically accretive to earnings within 12 to 18 months following their acquisition. For the facilities that we acquired from 2001 through 2022, the aggregate EBITDAR as a percentage of revenue improved from 15.8% during the first full three months of operations to 17.2% during the thirteenth through fifteenth months of operation and to 18.8% during the 45th quarter of operation.
Standard Bearer Portfolio Growth An important part of our business strategy is to continue to expand and diversify our real estate portfolio through accretive acquisition and investment opportunities in healthcare properties. Our execution of this strategy hinges on our ability to successfully identify, secure and consummate beneficial transactions. We have a proven track record of acquiring properties that we have determined are investment opportunities and develop these into thriving properties that are well-suited for operational purposes. We then use these properties for our skilled nursing or senior living operations, or we lease the properties to other long-term care facility operators. We expect that our newly formed REIT structure will allow us to expand our real estate footprint while bringing the best operational practices to our own and other operators in the industry.
HUMAN CAPITAL

At December 31, 2022, we had approximately 29,900 full-time equivalent employees who were employed by our Service Center and our operating subsidiaries. For the year ended December 31, 2022, approximately 60.0% of our total expenses were payroll related. Periodically, market forces, which vary by region, require that we increase wages in excess of general inflation or in excess of increases in reimbursement rates we receive. We believe that we staff appropriately, focusing primarily on the acuity level and day-to-day needs of our patients and residents. In most of the states where we operate, our skilled nursing facilities are subject to state mandated minimum staffing ratios, so our ability to reduce costs by decreasing staff, notwithstanding decreases in acuity or need, is limited and subject to government audits and penalties in some states. We seek to manage our labor costs by improving staff retention, improving operating efficiencies, maintaining competitive wage rates and benefits and reducing reliance on overtime compensation and temporary nursing agency services. Our Chief Human Capital Officer reports to our Board of Directors and oversees the following human capital initiatives:


13

Our Culture The operation of our skilled nursing and senior living facilities requires a large number of highly skilled healthcare professionals and support staff. Our employees are at the heart of our Company and we are committed to their health, professional development and workplace satisfaction. Our core values, which focuses on developing our employees, fostering an ownership mentality and allowing for intelligent risk taking, guide us in our decision making and inspire us to be better people, both professionally and personally.

 
Compensation and Benefits The healthcare industry as a whole has been experiencing shortages of qualified professional clinical staff. We believe that our ability to attract and retain qualified professional clinical staff stems from our ability to offer attractive wage and benefits packages, a high level of employee training, an empowered culture that provides incentives for individual efforts and a quality work environment.

Diversity and Inclusion We value diversity in our recruiting, hiring and career development practices. Our commitment is to provide equal opportunity and fair treatment to all individuals based on merit and without discriminations. In 2022, we formed our Diversity, Equity and Inclusion (DEI) Committee, a multidisciplinary group led by our Chief Executive Officer, to advance our DEI initiatives throughout the organization

Training and Development We provide training and development to all employees. We have many training programs at all levels such as our CEO in Training, Director of Nursing in Training, Director of Rehab in Training, nursing certified assistant schools, weekly culture trainings, boot camps and annual meetings, where we focus on both career and professional development.

Social Sustainability We continuously work towards bridging the gap between what the healthcare system currently provides and the basic needs of individuals. We aim to have an enduring impact on the communities in which we live and work. Elevate Charities is a non-profit organization that is dedicated to elevating the condition and quality of life for members of the senior healthcare community - employees, caregivers, family members, patients and residents. Elevate Charities has three unique funds: Heritage Fund, Heritage Scholarship Fund and the Emergency Fund.

The Heritage Fund and the Heritage Scholarship Fund engage in a mission to enhance the quality of life for seniors in our communities through caring service, fulfilling essential needs and providing education to caregivers. The Heritage Fund helps the caregiver identify specific and practical ways to meet the needs of those under their care. This can help provide a better life, improved experience and greater satisfaction for our aging population. The financial support provided by the Heritage Fund benefits seniors directly. In addition, the Heritage Scholarship Fund helps qualified clinical professionals who may not be able to afford to advance in the field of long-term care. Through grants and scholarships, the fund helps these qualified professionals gain the education needed to advance in the field of senior-focused healthcare. Since 2019, we awarded 150 scholarships to employees in our workforce.

Lastly, the Emergency Fund is a way of passing the hat to help our co-workers whose lives are affected by tragedy. This program is funded for Company team members by the Company team members. All Company team members can contribute to the fund either through a one-time donation or by recurring payroll deduction. In 2022, approximately 80% of those employed by our operating subsidiaries contributed to the Emergency Fund. In 2022, we distributed approximately $2.5 million in grants to members of our Ensign-affiliated family. To date, the Emergency Fund has distributed over 10,900 grants totaling almost $12.5 million to members of our Ensign-affiliated family in their time of need.

COVID-19 Our teams have been on the front lines in the battle against COVID-19. When it would have been easier to simply hunker down and wait for the challenges to pass, the heroes in our operations continued to provide selfless service to all their patients, including COVID patients. To recognize these front-line workers, our company, along with each individual operating subsidiary, provided financial awards to our employees for their tirelessly daily efforts to provide outstanding care to each resident they serve. We are beyond grateful for their enormous efforts and will continue to recognize the sacrifices of these employees as we navigate through the pandemic.

For additional information on human capital matters, please see our most recent proxy statement or Environmental, Social and Governance (ESG) report, each of which is available on our website at www.ensigngroup.net. For additional information on Elevate Charities, please visit www.elevatecharities.org. The information contained in, or that can be accessed through, either of the foregoing websites does not constitute a part of this Annual Report on Form 10-K.


14

GOVERNMENT REGULATION
General
Healthcare is an area of extensive and frequent regulatory change. Changes in the law or new interpretations of existing laws may have a significant impact on revenue, costs and business operations. Our independent operating subsidiaries that provide healthcare services are subject to federal, state and local laws relating to, among other things, licensure, quality and adequacy of care, physical plant requirements, life safety, personnel and operating policies. In addition, these same subsidiaries are subject to federal and state laws that govern billing and reimbursement, relationships with vendors, business relationships with physicians and workplace protection for healthcare staff. Such laws include the Anti-Kickback Statute (AKS), the federal False Claims Act (FCA), the Stark Law, the Health Care Emergency Temporary Standard and state corporate practice of medicine statutes.
Governmental and other authorities periodically inspect the skilled nursing facilities (SNFs), senior living facilities and outpatient rehabilitation agencies of our independent operating subsidiaries to verify continued compliance with applicable regulations and standards. The operations must pass these inspections to remain licensed under state laws and to comply with Medicare and Medicaid provider agreements. The operations can only participate in these third-party payment programs if inspections by regulatory authorities reveal that the operations are in substantial compliance with applicable state and federal requirements. In the ordinary course of business, federal or state regulatory authorities may issue notices to the operations alleging deficiencies in certain regulatory practices. These statements of deficiency may require corrective action to regain and maintain compliance. In some cases, federal or state regulators may impose other remedies including imposition of civil monetary penalties, temporary payment bans, loss of certification as a provider in the Medicare or Medicaid program, or revocation of a state operating license.
We believe that the regulatory environment surrounding the healthcare industry subjects providers to intense scrutiny. In the ordinary course of business, providers are subject to inquiries, investigations and audits by federal and state agencies related to compliance with participation and payment rules under government payment programs. These inquiries may originate from the United States Department of Health and Human Services (HHS) Office of the Inspector General (OIG), state Medicaid agencies, state Attorney Generals, local and state ombudsman offices and CMS Recovery Audit Contractors, among other agencies. In response to the inquiries, investigations and audits, federal and state agencies continue to impose citations for regulatory deficiencies and other regulatory penalties, including demands for refund of overpayments, expanded civil monetary penalties that extend over long periods of time and date back to incidents prior to surveyor visits, Medicare and Medicaid payment bans and terminations from the Medicare and Medicaid programs, which may be temporary or permanent in nature. We vigorously contest each such regulatory outcome when appropriate; however, there are significant legal and other expenses involved that consume our financial and personnel resources. Expansion of enforcement activity could adversely affect our business, financial condition or the results of operations.
Coronavirus
In an effort to promote efficient care delivery and to decrease the spread of COVID-19, federal, state and local regulators have implemented new regulations and waived (in some cases, temporarily) certain existing regulations, including those set forth below, which may expire in 2023.
Temporary suspension of certain patient coverage criteria and documentation and care requirements The Coronavirus Aid, Relief and Economic Security Act of 2020 (the CARES Act) and a series of temporary waivers and guidance issued by CMS suspended various Medicare patient coverage criteria to ensure patients continue to have adequate access to care, notwithstanding the burdens placed on healthcare providers as related to the COVID-19 pandemic. Many of these regulatory waivers were issued pursuant to Section 1135 of the Social Security Act, which authorizes the HHS Secretary to temporarily waive or modify Medicare and Medicaid requirements for affected health care providers and facilities following the declaration of a Public Health Emergency (PHE). HHS also waived requirements specific to SNFs.

Pursuant to the Emergency Waivers, CMS also authorized temporary waivers on medical review requirements, effective March 1, 2020. In addition, CMS also downgraded the priority for scheduled program audits and contract-level Risk Adjustment Data Validation audits for Medicare Advantage organizations, Part D sponsors, Medicare-Medicaid Plans and Programs of All-Inclusive Care for the Elderly organizations. Reducing the priority of those standard or scheduled audit activities allows providers, CMS and other organizations to focus on patient care, including directing audit activities toward infection control. The reprioritization of its audit activities was time-limited and normal activities resumed in 2022, including the expiration of certain Emergency Waivers.
15

Beginning on May 7, 2021, CMS started to end certain Emergency Waivers related to the COVID-19 pandemic, beginning with waivers regarding data reporting and resident grouping, transfer and discharge. The expiration of additional Emergency Waivers in place for SNF and long-term care (LTC) facilities, along with the expiration of other Emergency Waivers for other residential facilities other than hospitals and critical access hospitals occurred on June 6, 2022.
The first group of seven Emergency Waivers that expired on May 7, 2022 were: (1) waiver of the requirement that residents participate in-person during resident groups; (2) physicians’ ability to delegate tasks that otherwise would need to be personally performed by a physician within a SNF; (3) waiver of the requirement for physicians to make personal visits to patients, which the Emergency Waivers allow physicians to delegate to other clinicians; (4) waiver of the requirement for physicians and non-physician providers to conduct in-person visits to nursing home residents (and allowing those visits to be made via telemedicine as appropriate); (5) reducing LTC facilities’ requirements to develop, implement and maintain a Quality Assurance and Performance Improvement (QAPI) program that satisfies federal standards; (6) waiver of LTC facilities’ obligation to participate in discharge planning for residents ending their care at the facility; and (7) waiver of the requirement for LTC facilities to provide residents with a copy of their records within two working days of a resident’s request for those records.
The Emergency Waivers that expired on June 6, 2022 were: (1) waivers of SNF physical environment conditions for temporary use facilities (including COVID-19 treatment locations) and use of interior or non-residential space within a SNF to accommodate residents; (2) waivers of requirements for timely preventative maintenance for certain equipment, including dialysis equipment; (3) the waiver of inspection, testing and maintenance for the facilities and medical equipment used within ICFs and SNFs; (4) the waiver of inspection, testing and maintenance for compliance with applicable life safety codes and health care facility codes for intermediate care facilities (ICFs) and SNFs; (5) the waiver of CMS’s requirement for ICFs and SNFs to have an exterior door or window in every room used for sleeping; (6) life safety code waivers of quarterly fire drills and allowing SNFs to erect temporary walls and barriers between patients; (7) waiving CMS’s minimum training requirements for paid feeding assistants in LTC facilities; (8) CMS’s waiver of its requirement for nurse aides within SNFs to receive at least 12 hours of annual in-service training; and (9) the waiver of an SNF’s normal obligation not to employ any nursing aid longer than 4 months if he or she does not satisfy federal training and certification requirements.
CMS may terminate other Emergency Waivers affecting SNF and other LTC facilities in the future and these terminations may occur quickly and with little public notice. Due to the prevalence of waves of COVID-19 variants, it is uncertain when the remaining Emergency Waivers will expire.
Examples of the Emergency Waivers still in effect as of December 31, 2022 include, but are not limited to, the following: (1) approving temporary transfer, discharge and cohorting of patients to ensure that facilities can separate COVID-19 negative patients from those that are positive for or have been exposed to the virus; (2) allowing SNFs to provide a skill-in-place program for Medicare beneficiaries who are residents of the SNF that meet the skill-in-place criteria, foregoing the usual three-day qualifying hospital stay; and (3) temporarily waiving certain documentation and reporting requirements regarding patient admission, transfer and discharge. Some States have also waived regulations to ease regulatory burdens on the healthcare industry. It remains uncertain when federal and state regulators will resume enforcement of those regulations, which remain waived or are otherwise not being enforced during the PHE. We believe these regulatory actions could contribute to changes in skilled mix, which may have been different without the existence of the Emergency Waivers.
Resuming visitation and resident rights — CMS has issued guidance to facilities throughout the PHE regarding patients’ rights to visitation. While the CMS guidance issued in March 2020 directed facilities to severely restrict visitation, CMS subsequently provided and updated guidance through the course of the pandemic that broadens visitation and provides guidance on visitation procedures. On September 23, 2022, CMS updated their visitation guidance to recommend the use of masks or face coverings when the county where the facility is located has a high rate of COVID-19 transmission, encouraged the use of masks or face coverings regardless of COVID-19 transmission status and allows residents and visitors to choose not to wear masks or face coverings when alone in the resident's room or in a dedicated visitation area. This most recent CMS guidance also included updated advice related to isolation of known or suspected positive COVID-19 cases or those exposed to positive COVID-19 cases. The guidance also encouraged distancing during large group gatherings within the facility.

16

Testing requirements — Beginning in April 2020, authorities in several states in which our independent operating subsidiaries are located began to mandate widespread COVID-19 testing at all nursing home and LTC facilities. This came after the Centers for Disease Control and Prevention (CDC) stated that older adults are at a higher risk for serious illness from the coronavirus and issued updated testing guidelines for nursing homes. Some of these states were also publicly reporting COVID-19 outbreaks in facilities. On April 27, 2021, CMS issued revised parameters for testing, specifying that the requirement for routine testing of staff applies only to those staff members that are unvaccinated - fully vaccinated staff do not have to be routinely tested. Thereafter, CMS's interim final rule (IFR) regarding COVID-19 testing of staff, released on September 23, 2022 stated that routine testing of staff for COVID-19 is no longer generally recommended without exposure to COVID-19. This guidance clarified that individuals who show symptoms of COVID-19, regardless of vaccination status, should be tested for COVID-19 as soon as possible. Additionally, this IFR called for testing of residents and staff and investigation of an outbreak when there is a single positive COVID-19 case among residents or staff of the LTC facility.
Federal and state COVID-19 vaccination requirements — As the Pfizer, Moderna, Johnson & Johnson and Novavax vaccines received FDA approval, CMS developed an IFR requiring all workers within Medicare and Medicaid-participating nursing homes to be vaccinated against COVID-19 as a condition of participation in the Medicare and Medicaid programs. In addition, OSHA introduced an emergency temporary standard (ETS) requiring employers with more than 100 employees to mandate that its employees be fully vaccinated against COVID-19 or submit to weekly testing for the virus. Both CMS’s IFR and OSHA’s emergency temporary standard (ETS) for vaccination were challenged in court and halted from enforcement in certain states, but the United States Supreme Court allowed CMS to enforce its vaccine mandate nationwide.
In addition to the IFR mandating vaccinations for health facility workers, several states where our independent operating facilities are located have issued vaccine mandates that apply to facility staff. These vaccine mandates are largely aligned with CMS's requirements. For example, California issued an order requiring adult care facilities and direct care workers to be vaccinated as well, and for all affected workers to be fully vaccinated by November 30, 2021. The order was expanded to allow workers who had completed their primary vaccination series and contracted COVID-19 since becoming fully vaccinated to defer the receipt of a vaccine booster dose by up to 90 days after infection with COVID-19; otherwise, booster vaccine doses were required to be completed by March 1, 2022. On October 23, 2022, CMS issued further guidance unifying its recommendations for all facilities under its oversight, including SNFs and LTC facilities, reaffirming CMS's activities to verify vaccination of all SNF and LTC facility staff, and where necessary, to pursue corrective action for facilities found deficient in this requirement.
Reporting requirements In accordance with CMS reporting guidance, SNFs are required to report to the CDC National Health Safety Network certain information related to COVID-19 cases on a weekly basis. Facilities are also required to provide residents and staff with vaccine education and offer vaccines, when available, to residents and staff. The IFR published on August 23, 2021 requires facilities to develop policies and procedures to ensure the availability of the COVID-19 vaccine to residents and staff and to educate them concerning the benefits, risks and potential side effects associated with the vaccine. CMS may initiate enforcement activities and assess civil monetary penalties for not meeting any of these COVID-19 related reporting requirements under this IFR and reaffirmed its intent to seek corrective action against SNFs and LTC facilities that do not satisfy these requirements. We do not believe these COVID-19 related requirements will have a material impact on our consolidated financial statements.
Survey Activity and Enforcement — In response to the COVID-19 pandemic environment, CMS included infection controls as part of its survey process along with updating its patients' and residents' rights to receive visitor guidance. The spectrum of remedies available to CMS for imposition includes increased monetary fines, shortened time periods to return to compliance and other administrative penalties for deficiencies.
Changes to Medicaid Reimbursement In March of 2020, the Families First Coronavirus Relief Act (FFCRA) provided a 6.2% increase to the Federal Medicaid Assistance Percentage (FMAP) during the PHE. In addition to this funding increase, the FFCRA imposed conditions restricting the disenrollment and standards for re-enrolling Medicaid beneficiaries to promote continuous care of beneficiaries during the PHE. The bipartisan omnibus spending plan passed by Congress and signed into law by the President on December 29, 2022, amended these Medicaid enrollment protections and increased FMAP funding provided in the FFCRA. In the first quarter of 2023 the FMAP increase CMS provides to the States will remain elevated by 6.2%, but will decline for the remaining quarters in 2023, subject to further reductions noted below: for the second quarter, April through June 2023, this increase will be reduced to 5%; in the third quarter, from July through September, the FMAP increase will be reduced to 2.5%, and in October through December, the FMAP increase will be reduced to 1.5%. Previously, the FMAP funding was dependent on the termination of the PHE. The ultimate amount of funding from each state will vary substantially based on that states’ policies.

17

CMS’s provision of these increased FMAP funds to states is conditioned upon states reporting to CMS certain Medicaid-related information, including data pertaining to Medicaid renewals, termination of Medicaid coverage, beneficiary customer service information, and other eligibility and renewal information that may be identified in regulations or by the HHS Secretary. States that do not report required data to CMS beginning in July of 2023 will be penalized .25 percentage points, up to a total of one percentage point, for each quarter the state does not report data to CMS. The omnibus spending plan also grants CMS authority to impose fines, penalties, and other sanctions upon states that do not comply with this law’s requirements for the unwinding of increased FMAP payments.
Under the omnibus spending bill adopted in December of 2022, states may begin disenrolling Medicaid beneficiaries beginning on April 1, 2023. The FFCRA contemplated continuous Medicaid enrollment until the end of the PHE and provided funding for enrollment during that duration. The omnibus spending plan winds down this Medicaid spending for continuous enrollment in phases, ultimately reducing CMS’s contribution to state-administered Medicaid programs. CMS guidance permits states up to 14 months to initiate and process traditional Medicaid renewals, including the eligibility and enrollment process.
Medicare
Medicare presently accounts for approximately 28.6% of our skilled nursing services revenue year-to-date, being our second-largest payor. The Medicare program and its reimbursement rates and rules are subject to frequent change. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past, and could in the future, result in substantial reductions in our revenue and operating margins.
Patient-Driven Payment Model (PDPM)
The Skilled Nursing Facility Prospective Payment System (SNF PPS) Rule became effective October 1, 2019. The SNF PPS Rule includes a new case-mix model that focuses on the patient’s condition (clinically relevant factors) and resulting care needs, rather than on the volume of care provided, to determine Medicare reimbursement. The case mix-model is called the Patient-Driven Payment Model (PDPM), which utilizes clinically relevant factors for determining Medicare payment by using International Classification of Diseases, Tenth Revision diagnosis codes and other patient characteristics as the basis for patient classification. PDPM utilizes five case-mix adjusted payment components: physician therapy, occupational therapy, speech language pathology, nursing and social services and non-therapy ancillary services. It also uses a sixth non-case mix component to cover utilization of SNFs' resources that do not vary depending on resident characteristics.
PDPM replaces the existing case-mix classification methodology, Resource Utilization Groups, Version IV. The structure of PDPM moves Medicare towards a more value-based, unified post-acute care payment system. For example, PDPM adjusts Medicare payments based on each aspect of a resident’s care, thereby more accurately addressing costs associated with medically complex patients. PDPM also removes therapy minutes as the basis for therapy payment. Finally, PDPM adjusts the SNFs' per diem payments to reflect varying costs throughout the stay, through the physician therapy, occupational therapy and non-therapy ancillary services components.
In addition, PDPM is intended to reduce paperwork requirements for performing patient assessments. Under the SNF PPS PDPM system, the payment to SNFs and nursing homes is based heavily on the patient’s condition rather than the specific services provided by each SNF.
Skilled Nursing Facility - Quality Reporting Program (SNF QRP)
The Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT Act) provided data reporting requirements for certain Post-Acute-Care (PAC) providers. The IMPACT Act requires that each SNF submit their quality measures data. If a SNF does not submit required quality data, their payment rates are reduced by 2.0% for each such fiscal year. Application of the 2.0% reduction may result in payment rates for a fiscal year being less than the preceding fiscal year. In addition, reporting-based reductions to the market basket increase factor will not be cumulative; they will only apply for the fiscal year involved. A SNF's Medicare Administrative Contractor will issue the facility a notice of non-compliance if it does not satisfy its Quality Reporting Program (QPR) reporting requirements.
The SNF QRP standardized a number of standardized patient assessment data elements. The SNF QRP applies to freestanding SNFs, SNFs affiliated with acute care facilities and all non-critical access hospital swing-bed rural hospitals.
18

On July 29, 2021, two new reporting measures were required under the SNF QRP. Starting with the FY 2023 SNF QRP, SNFs are required for the first time to report the SNF Healthcare-Associated Infections (HAI) measure, which tracks the number of infections requiring hospitalization following a medical intervention, and the COVID-19 Vaccination Coverage among Healthcare Personnel (HCP) measure, which tracks COVID-19 vaccination of staff in order to assess whether SNFs are taking steps to limit the spread of COVID-19. The Transfer of Healthcare (TOH) information data SNFs must report, which is included in the Patient-Post-Acute Care measurement, will be changed to exclude SNF patients discharged to their homes under the care of either a home health service or hospice. The elimination of this information will change how the TOH is used in calculating Patient-Post-Acute Care measurement, and may have an impact on our quality ratings and reimbursement from Medicare and Medicaid on a prospective basis.
Beginning in March 2020, due to the COVID-19 pandemic, CMS issued a temporary suspension of SNF QRP reporting requirements effective until June 30, 2020. This effectively gave SNFs discretion as to whether to report data from the fourth quarter (October 1, 2019 – December 31, 2019), and removed reporting requirements entirely for the first and second quarters of 2020 (January 1, 2020 – June 30, 2020). SNFs were required to resume timely quality data collection and submission of measure and patient assessment data effective June 30, 2020. In January 2022, SNF ratings based on the resumed data reporting were recalculated for publication.
In July of 2022, CMS announced revisions to calculating its five-star ratings for the Nursing Home Compare website. Under this new calculation, points are assigned to a SNF based on its performance across six measures: (1) case-mix adjusted total nurse staffing levels (including registered nurses, licensed practical nurses, and nursing aides), measured by hours per resident per day; (2) case-mix adjusted registered nurse staffing levels, measured by hours per resident per day; (3) case-mix adjusted total nurse staffing levels (including registered nurses, licensed practical nurses, and nursing aides), measured by hours per resident day on the weekend; (4) total nurse turnover, defined as the percentage of nursing staff that left the nursing home over a 12-month period; (5) registered nurse turnover, defined as the percentage of registered nursing staff that left the nursing home over a 12-month period; and (6) administrator turnover, defined as the percentage of administrators that left the nursing home over a 12-month period. These six measures will be measured on a quarterly basis.
Staff measurements are scored based on the points assigned to these six measures. For case-mix adjusted total nurse staffing and case-mix adjusted registered nurse staffing, each measure is scored on a 100-point scale in 10-point increments. For case-mix adjusted total nurse staffing on weekends, total nurse turnover, and total registered nurse turnover, each measure is scored on a 50-point scale in five-point increments. The measure of administrator turnover is measured on a 30-point scale, with points assigned based on the number of administrator departures during the measurement period. The result of these staffing measures will affect a SNF’s total five-star score reported on the Nursing Home Compare website.
These six new measures were included in the five-star rating in October 2022 in addition to other changes. In addition, CMS also implemented a planned increase to the quality measure reporting thresholds, increasing each threshold by one-half of the average improvement of quality measure scores since CMS last set quality measure thresholds. Going forward, CMS plans to implement similar rating threshold increases every six months.
On July 29, 2022, CMS announced the adoption of a process measure for influenza vaccination coverage among healthcare personnel within SNFs. This measure will be determined by the percentage of SNF healthcare personnel who receive an influenza vaccine any time from when it first becomes available through March 31 of the following year. SNFs began submitting this data on October 1, 2022 through March 31, 2023.
Additionally, CMS revised certain SNF data reporting requirements, including the transfer of health information measures and certain patient assessment data elements, including ethnicity, preferred language, health literacy, and social isolation, until October 1, 2023.
Medicare Annual Payment Rule
CMS is required to calculate an annual Medicare market-basket update to the payment rates. On July 29, 2022, CMS issued a final rule for fiscal year 2023 that updates the Medicare payment rates to aggregate net market basket increased by 2.7%. The increase is resulted from the 5.1% update to the market basket, which is based on a 3.9% current year market basket increase plus a 1.5% market basket error adjustment, less a 0.3% productivity adjustment and a negative 2.3% adjustment as a result of the recalibrated parity adjustment. The recalibrated parity adjustment is being phased in at a rate of 2.3% per year over two years.

19

On July 29, 2021, CMS issued a final rule for fiscal year 2022 that updates the Medicare payment rates and the quality programs for SNFs. Under the final rule, effective October 1, 2021, the aggregate net market basket rate increased by 1.2% for fiscal year 2022, compared to fiscal year 2021. This increase is attributable to a 2.7% market basket increase factor with a 0.8% reduction for forecast error adjustment and a 0.7% reduction for multifactor productivity adjustment.
Sequestration of Medicare Rates

The Budget Control Act of 2011 requires a mandatory, across the board reduction in federal spending, called a sequestration. Medicare FFS claims with dates of service or dates of discharge on or after April 1, 2013 incur a 2.0% reduction in Medicare payments. All Medicare rate payments and settlements have incurred this mandatory reduction and will continue to be in place through at least 2023, unless Congress takes further action. In response to COVID-19, the CARES Act temporarily suspended the automatic 2.0% reduction of Medicare claim reimbursements for the period of May 1, 2020 through December 31, 2020. On December 27, 2020, the Consolidated Appropriations Act further suspended the 2.0% payment adjustment through March 31, 2021. On April 14, 2021, Congress extended the suspension of the 2.0% payment adjustment through December 31, 2021. On December 10, 2021, President Biden signed into law a bill to postpone the 2.0% payment adjustment through April 1, 2022; from April 1, 2022 through June 30, 2022, the 2.0% payment adjustment is reduced from 2.0% to 1.0%. To pay for the change, Congress would increase the sequester cuts by one year to fiscal year 2030. As of July 1, 2022, Medicare's sequestration cuts have reverted to 2%, which was the sequestration rate in effect before the COVID-19 PHE commenced.
Skilled Nursing Facility Value-Based Purchasing (SNF-VBP) Program

The SNF-VBP Program rewards SNFs with incentive payments based on the quality of care they provide to Medicare beneficiaries, as measured by a hospital readmissions measure. CMS annually adjusts its payment rules for SNFs using the SNF-VBP Program. To fund the SNF-VBP Program incentive payment pool, CMS withheld 2% of Medicare payments and will redistribute 60% of the withheld payments back to SNFs through the program. The program also introduced quality measures to assess how health information is shared and adopted a number of standardized patient assessment data elements that assess factors such as cognitive function and mental status, special services and social determinants of health. On July 29, 2021, CMS finalized its changes for measuring the performance period and amending the data to be reported to CMS, which impacted the SNF-VBP Program rate adjustment to account for COVID-19 impacting readmission rates and SNF admissions during the performance periods of fiscal year 2020. The deadlines for baseline period quality measure quarterly reporting and performance periods and standards will start in the 2023 program year.

On July 29, 2022, CMS released the final rule electing to not apply the SNF 30-Day All-Cause Readmission Measure (SNFRM) as part of performance scoring for fiscal year 2023. CMS will still publicly report the SNFRM, but it will not affect SNF payments. The final rule for the fiscal year 2023 SNF PPS also provided for SNF-VBP program expansion beyond the use of its single, all-cause hospital readmission measure to determine payment, with the inclusion of measures in fiscal year 2026 for SNF healthcare associated infections requiring hospitalization (SNF HAI) and total nursing hours per resident day measures, and in fiscal year 2027, the discharge to community post acute care measure for SNFs, which assesses the rate of successful discharges to the community from a SNF setting.

On February 28, 2022, the Administration published a fact sheet stating its priorities for making changes to senior care, including potential changes to regulations affecting LTCs and SNFs. The SNF-VBP Program was identified as an area for change, with staffing levels, retention and resident experience affecting reimbursement. Following studies by CMS, proposed rules that may affect the SNF-VBP Program are expected by early 2023, with final rules to follow after a notice-and-comment period.

20

Part B Rehabilitation Requirements

Some of our revenue is paid by the Medicare Part B program under a fee schedule. Part B services are limited with a payment cap by combined speech-language pathology services (SLP), physical therapy (PT) services and a separate annual cap for occupational therapy (OT) services. These caps were implemented under the authority of the Balanced Budget Amendments of 1997. These amounts were previously associated with the financial limitation amounts. The Bipartisan Budget Act of 2018 (BBA) repealed those caps while retaining and adding additional limitations to ensure appropriate therapy services. This policy does not limit the amount of medically necessary Medicare Part B therapy services a beneficiary may receive. The BBA establishes coding modifier requirements to obtain payments beyond the updated KX modifier thresholds, discussed below, and reaffirms the specific $3,000 claim audit threshold requirements for the Medicare Administrative Contractors. For PT and SLP combined the threshold for coding modifier requirements was $2,110 for 2021. The KX Modifier threshold was set at $2,150 for CY 2022 with the same threshold for OT services. For CY 2023, the KX modifier threshold has been increased by 3.8%, to $2,230 for PT and SLP, with the same threshold for OT services as well. The KX modifier is a modifier added to medical claims to indicate the providing clinician attests that the services corresponding to that claim were medically necessary and that the justification for those services is contained within the patient’s medical records. This modifier is intended for use where the services will exceed the threshold for those services set by the BBA and updated by annual fee schedule rules, yet are still appropriate and medically necessary, and thus should be compensated by Medicare.
Consistent with CMS’s “Patients over Paperwork” initiative, the agency has also been moving toward eliminating burdensome claims-based functional reporting requirements. Beginning in 2021, CMS rescinded 21 problematic National Correct Coding Initiative edits impacting outpatient therapy services, including services furnished under Medicare Part B primarily related to PT and OT services, removing a coding burden caused by requirements for additional documentation and claim modifier coding.
The calendar year 2021 Physician Fee Schedule (PFS) Final Rule reduced the conversion factor (i.e. the number by which CMS determine all current procedural terminology code payments) by 10.2%. These changes lowered the reimbursement rate for therapy Medicare Part B specialty providers by 9% for PT and OT and by 6% for SLP codes. These reductions were mitigated by the Consolidated Appropriations Act of 2021 (CAA, also referred to as The Omnibus Appropriations Law). The CAA includes three components relevant to the Medicare Part B PFS. First, the CAA incorporated a rate relief of approximately 3.75% for fiscal year 2021. Additionally, the CAA incorporated a freeze to the payment for the physician add-on code for three years which would effectively create relief on the initial cuts through 2023. Finally, the relief called for the 2% sequester to not be applied to the Medicare Part B program for the first quarter of 2021. In addition, the 2% sequester was suspended.
The calendar year 2022 PFS (2022 PFS) required the use of new modifiers to identify and make payments at 85% of the otherwise applicable Part B payment amount for PT and OT services furnished in whole, or in part by PT and OT assistants. The 2022 PFS resulted in FFS Medicare payments adjusted by a sequester of 1% from April 1, 2022 through June 30, 2022, and further adjusted by a total of 2% from July 1, 2022 through December 31, 2022.
On November 1, 2022, CMS issued the calendar year 2023 PFS that would result in a PFS conversion factor of $33.06, a decrease of $1.55 from the calendar year 2022 PFS conversion factor of $34.61. This is a 4.47% cut to the conversion factor for calendar year 2023.
The Multiple Procedure Payment Reduction (MPPR) continues at a 50% reduction, which is applied to therapy procedures by reducing payments for practice expense of the second and subsequent procedures when services provided beyond one unit of one procedure are provided on the same day. The implementation of MPPR includes (1) facilities that provide Medicare Part B speech-language pathology, occupational therapy and physical therapy services and bill under the same provider number; and (2) providers in private practice, including speech-language pathologists, who perform and bill for multiple services in a single day.

21

On May 27, 2020, pursuant to its authority under the Emergency Waivers, CMS added physical therapy, occupational therapy and speech-language pathology to the list of approved telehealth Providers for the Medicare Part B programs provided by a SNF. Subsequently, the calendar year 2021 and 2022 PFS Final Rules added certain of these PT and OT services to the list of Medicare telehealth services on a temporary basis through at least the end of calendar year 2023. On December 31, 2020, CMS announced its 2021 update to the list of codes that describe Medicare Part B outpatient therapy services, making permanent existing and new codes introduced during the COVID-19 PHE for use under PT, OT, or SLP, including several telehealth codes as “sometimes therapy,” to permit physicians and certain non-physician practitioners to render these services outside a therapy plan of care when appropriate. “Sometimes therapy” codes will not have the MPPR applied. On November 19, 2021, CMS expanded these “sometimes therapy” codes further for the 2022 PFS, including five new codes for remote therapeutic monitoring treatment, which are broader than pre-existing monitoring codes and include measuring and evaluating adherence and response to medication and therapy. The Emergency Waivers allow therapists to bill Telehealth therapy services up to 151 days after the end of the PHE.
Pursuant to the Emergency Waivers, CMS allowed for the facility to bill an originating site fee to CMS for telehealth services provided to Medicare Part B beneficiary residents of the facility when the services were provided by a physician from an alternate location, effective March 6, 2020 and ending on May 7, 2022. Our Facilities have thus ceased using these telemedicine Emergency Waivers upon their termination.
Programs of All-Inclusive Care for the Elderly
The requirements under the Programs of All-Inclusive Care for the Elderly (PACE) provide greater operational flexibility and update information under the Medicare and Medicaid programs. Such flexibility includes: (i) more lenient standards applicable to the current requirement that the PACE organization be monitored for compliance with the PACE program requirements during and after a 3-year trial period and (ii) relieving certain restrictions placed upon the interdisciplinary team that comprehensively assesses and provides for the individual needs of each PACE participant by allowing one person to fill two roles and permitting secondary participation in the PACE program. Further, non-physician primary care providers can provide certain services in place of primary care physicians. On October 21, 2021, CMS published an extension of the timeline to complete further final rulemaking for the PACE program until November 1, 2022, which focuses on policy and technical changes to Medicare Advantage, Medicare Prescription Drug Benefit, PACE, Medicaid FFS and Medicaid managed care programs. On November 2, 2022, CMS further extended the timeline for issuing its final rule for the PACE program by three months, until February 1, 2023.
Decisions Regarding Skilled Nursing Facility Payment
Medicare reimbursement rates and rules are subject to frequent change. Historically, adjustments to reimbursement under Medicare have had a significant effect on our revenue. The federal government and state governments continue to focus on efforts to curb spending on healthcare programs such as Medicare and Medicaid. We are not able to predict the outcome of the legislative process. We also cannot predict the extent to which proposals will be adopted or, if adopted and implemented, what effect, if any, such proposals and existing new legislation will have on us. Efforts to impose reduced allowances, greater discounts and more stringent cost controls by government and other payors are expected to continue and could adversely affect our business, financial condition and results of operations.
These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past, and could in the future, result in substantial reductions in our revenue and operating margins. For a discussion of historic adjustments and recent changes to the Medicare program and related reimbursement rates, see Part I, Item 1A Risk Factors under the headings Risks Related to Our Business and Industry.

22

Patient Protection and Affordable Care Act
Various healthcare reform provisions became law upon enactment of the Patient Protection and Affordable Care Act and the Healthcare Education and Reconciliation Act (collectively, the ACA). The reforms contained in the ACA have affected our operating subsidiaries in some manner and are directed in large part at increased quality and cost reductions. Several of the reforms are very significant and could ultimately change the nature of our services, the methods of payment for our services and the underlying regulatory environment. These reforms include modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. The upcoming Congressional elections in the United States and policies implemented by the current and former Presidential administration have resulted in significant changes in legislation, regulation, implementation of Medicare, Medicaid and government policy. In August of 2022, Congress passed and the Biden-Harris Administration signed into law the Inflation Reduction Act of 2022 (IRA), which continued and expanded certain provisions of the ACA. Among other things, the IRA extended premium subsidies paid by the federal government, which were scheduled to expire at the end of 2022, until the end of 2024, resulting in subsidies being available to offset or reduce the costs of private health insurance policies for older persons on fixed incomes or with limited savings. This may aid older patients in obtaining or keeping their health insurance in order to pay for long-term care services. Other healthcare-related provisions of the IRA include phased-in provisions for Medicare to negotiate the prices of certain prescription drugs, limiting the out-of-pocket cost of prescribed drugs to Medicare Part D recipients to $2,000 per year (in addition to a monthly cap on out-of-pocket prescription drug expenses) and limiting the monthly cost of insulin to $35.
The outcomes of the 2022 midterm elections may significantly alter the current regulatory framework and impact our business and the health care industry, including any further extensions or expansions of certain ACA provisions, namely recent rulemaking activity regarding ACA Section 1557's anti-discrimination provisions. We continually monitor these developments so we can respond to the changing regulatory environment impacting our business.
Requirements of Participation
CMS has requirements that providers, including SNFs and other LTC facilities must meet in order to participate in the Medicare and Medicaid Programs. Some of these requirements can be burdensome and costly.
One such requirement of participation in the Medicare and Medicaid programs involves limitations around the use of pre-dispute, binding arbitration agreements by LTC facilities. CMS has issued guidance and direction around arbitration, to include: the facility must not require signing of an arbitration agreement as a condition of admission or a requirement to continue to receive care at the facility, and the agreement must expressly contain language to this effect; the facility must inform the resident or the resident's representative of the right not to sign the agreement; the facility must confirm that the agreement is explained in a manner that can be understood and that the resident or their representative acknowledges their understanding of the agreement; the agreement must provide for the right to rescind the agreement within 30 calendar days of signing; and the agreement may not contain language that prohibits or discourages communications with federal, state, or local officials, including federal and state surveyors, other federal or state health department employees, and representatives of the Office of the State Long-Term Care Ombudsperson. Congress has routinely introduced, but not passed, legislation addressing the issue of arbitration agreements used by LTC facilities. While legislative action is possible in the future, federal regulations and state/federal laws remain our primary source of authority over the use of pre-dispute binding arbitration agreements.
On June 29, 2022, CMS announced updated guidance for Phase 2 and 3 of the Requirements of Participation. CMS distributed these updates to surveyors and state agencies in order to, among other things, enhance responses to resident complaints and reported incidents. This updated guidance arises directly from President Biden’s March 2022 State of the Union Address and accompanying fact sheet regarding nursing home areas of study and potential change. The guidance focuses on the following topics: (1) resident abuse and neglect (including reporting of abuse); (2) admission, transfer and discharge; (3) mental health and substance abuse disorders; (4) nurse staffing and reporting of payroll to evaluate staffing sufficiency; (5) residents’ rights (including visitation); (6) potential inaccurate diagnoses or assessments; (7) prescription and use of pharmaceuticals, including psychotropics and drugs that act like psychotropics; (8) infection prevention and control; (9) arbitration of disputes between facilities and residents; (10) psychosocial outcomes and related severity; and (11) the timeliness and completion of state investigations to improve consistency in the application of standards among various states.
23

On July 29, 2022, CMS updated the Medicare Requirements of Participation for LTC facilities, which includes the modification of requirements associated with a facility's physical environment to minimize unnecessary renovation expenses that could result in the closure of LTC facilities because of the related expense. Specifically, CMS is "grandfathering" certain facilities and will allow LTC facilities that were participating in Medicare before July 5, 2016 and that previously used the Fire Safety Evaluation System (FSES) to continue using the 2001 FSES mandatory values when determining compliance with applicable standards. In addition, CMS updated the Requirements of Participation to include revising existing qualification requirements for directors of food and nutrition services in LTC facilities while "grandfathering" in directors with two or more years of experience and certain minimum training in food safety so that they may continue in that role without obtaining more specific educational and certification requirements.
In October of 2022, CMS published the survey resources CMS and state surveyors would be using to evaluate LTC facilities' compliance with vaccination and reporting requirements, which CMS updated in November of 2022. These updates provided more information for state surveyors to utilize when evaluating LTC facilities’ compliance with the Medicare Requirements of Participation, as well as included guidance for facilities on operationalizing compliance with these requirements based on how surveyors would measure and evaluate facility performance. On September 27, 2022, CMS also provided a summary of its major software enhancements, describing the tools updated and used by CMS to measure and evaluate LTC facility compliance with the Medicare Requirements of Participation.
Civil and Criminal Fraud and Abuse Laws and Enforcement
Various complex federal and state laws exist which govern a wide array of referrals, relationships and arrangements, and prohibit fraud by healthcare providers. Governmental agencies are devoting increasing attention and resources to such anti-fraud efforts. The Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the Balanced Budget Act of 1997 expanded the penalties for healthcare fraud. Additionally, in connection with our involvement with federal healthcare reimbursement programs, the government or those acting on its behalf may bring an action under the FCA, alleging that a healthcare provider has defrauded the government by submitting a claim for items or services not rendered as claimed, which may include coding errors, billing for services not provided and submitting false or erroneous cost reports. The Fraud Enforcement and Recovery Act of 2009 (FERA) expanded the scope of the FCA by, among other things, creating liability for knowingly and improperly avoiding repayment of an overpayment received from the government and broadening protections for whistleblowers. The FCA clarifies that if an item or service is provided in violation of the AKS, the claim submitted for those items or services is a false claim that may be prosecuted under the FCA as a false claim. Civil monetary penalties under the FCA range from approximately $0.012 to $0.025 million per violation and are adjusted annually for inflation. Under the qui tam or “whistleblower” provisions of the FCA, a private individual with knowledge of fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government’s recovery. Due to these whistleblower incentives, lawsuits have become more frequent. Many states also have a false claim prohibition that mirrors or closely tracks the federal FCA.
Federal law also provides that the OIG has the authority to exclude individuals and entities from federally funded health care programs on a number of grounds, including, but not limited to, certain types of criminal offenses, licensure revocations or suspensions and exclusion from state or other federal healthcare programs. CMS can recover overpayments from health care providers up to five years following the year in which payment was made. On February 28, 2022, the Administration published a fact sheet regarding nursing home care, which identified the Administration’s priorities of further funding for SNF and LTC facility inspections, enhancing civil penalties on poor-performing facilities and increasing the scrutiny of companies that operate more than one facility. Proposed rules based on these directives and studies are expected by early 2023, with final rules to follow after a notice-and-comment period.
In November 2019, the OIG released a report of its investigation into overpayments to hospitals that did not comply with Medicare’s post-acute-care transfer policy. Hospitals violating this policy transferred patients to certain post-acute-care settings, such as SNFs, but claimed the higher reimbursements associated with discharges to homes. A similar OIG audit report, released in February 2019, focused on improper payments for SNF services when the Medicare three-day inpatient hospital stay requirement was not met. In 2021, the OIG released the result of an audit finding that Medicare overpaid millions of dollars of chronic care management (CCM) services. The OIG's 2021 report found that in calendar years 2017 and 2018, Medicare overpaid millions of dollars in CCM claims. In 2022, the OIG released an audit revealing that CMS had not collected $226 million, or 45%, of identified overpayments within that period, potentially affecting SNFs. These investigatory actions by OIG demonstrate its increased scrutiny into post-hospital SNF care provided to beneficiaries and may encourage additional oversight or stricter compliance standards.
24

On numerous occasions, CMS has indicated its intent to vigilantly monitor overall payments to SNFs, paying particular attention to facilities that have high reimbursements for ultra-high therapy, therapy resource utilization groups with higher activities of daily living scores and long average lengths of stay. The OIG recognizes that there is a strong financial incentive for facilities to bill for higher levels of therapies, even when not needed by patients. We cannot predict the extent to which the OIG's recommendations to CMS will be implemented and, what effect, if any, such proposals would have on us. Our business model, like those of some other for-profit operators, is based in part on seeking out higher-acuity patients whom we believe are generally more profitable and over time our overall patient mix has consistently shifted to higher-acuity in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording services in order to, among other things, increase reimbursement to levels appropriate for the care actually delivered. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others.
Federal Healthcare Reform
Five-Star Quality Reporting Metrics The Quality Payment Program (QPP) was created under the Medicare Access and Children's Health Insurance Program (CHIP) Reauthorization Act of 2015. This program was based on the Merit-based Incentive Payment System (MIPS) or the use of Alternative Payment Models (APM), which relied on quality data CMS gathered and evaluated using the Five-Star Quality Rating system, which includes a rating of one to five in various categories. These categories include (but are not limited to) the results of surveys conducted by state inspectors, other health inspection outcomes, staffing, spending, readmissions and stay durations; the data collected and its weighting in determining a rating on a scale of one to five stars is subject to periodic and ongoing revision, re-balancing and adjustment by CMS to reflect market conditions and CMS’s priorities in patient care. Since 2020, CMS’s measurement of the data reported by providers, including SNFs, has become more competitive and resulted in a reduction of four- and five-star rankings available under CMS’s Five-Star Quality Rating system.
The Five-Star Quality reporting system for nursing homes is displayed on CMS's consumer-based Nursing Home Compare website. CMS also displays a consumer alert icon next to nursing homes that have been cited for incidents of abuse, neglect, or exploitation on the Nursing Home Compare website, which is updated monthly with CMS’s refresh of survey inspection results on that website.
In 2020, in response to the COVID-19 pandemic, CMS temporarily froze SNF Quality Reporting Program data, including data in the staffing and health inspection domains, on the Nursing Home Compare website to account for the then-suspended reporting and inspection obligations. After suspending inspections in early 2020, CMS announced a new and targeted inspection plan in August 2020 to focus on urgent patient safety threats and infection control, which affected the number of nursing homes inspected and the substance of those inspections. These safety inspections collected different information than traditional surveys and as a result these survey results were not incorporated in CMS’s Five-Star Quality ratings for SNFs from March through December 2020. CMS resumed calculating nursing homes’ health inspection ratings on January 27, 2021 and has continued to include this measure in subsequent updates.
Similarly, although staff reporting requirements were waived for the first six months of 2020, this waiver ended on June 25, 2020. Thereafter, SNFs were required to report staffing data to CMS, which was incorporated into CMS’s Five-Star Quality rating beginning in January 2021. The January 2021 Five-Star Quality rating calculation reflected SNF-provided quarterly updates of most quality measures for the period between June 2019 and June 2020, reflecting the time period in which the normal reporting and inspection obligations were frozen due to COVID-19. CMS’s refreshes of the Nursing Home Compare website since January of 2021 have included these quality measures and other new measures as discussed within this Government Regulation heading.
In January of 2022, CMS issued a bulletin stating that as of the same month, the Nursing Home Compare website would begin reporting SNF weekend staffing as well as staff tenure and other collected staffing data. Beginning in July of 2022, CMS began disclosing weekend staffing of all nurses, as well as staff turnover data for all nurses and administrators, on the Nursing Home Compare website. CMS also now incorporates this data into its Five-Star Quality ratings for SNFs and LTC facilities. This data is adjusted based on a facility's case mixture and evaluated on a quarterly basis. This data was included in the October 2022 refresh of the Nursing Home Care Compare website as well, in addition to increasing the thresholds for quality measures reported on the Nursing Home Care Compare website based on average improvement over prior quality measures.

25

Proposed Federal Legislation Concerning Nursing Home Supervision — On August 10, 2021, the Nursing Home Improvement and Accountability Act of 2021 (Nursing Home Improvement Act) was introduced in the U.S. Senate and was intended to update federal nursing home policy to improve quality of care and oversight. The proposed legislation would reduce SNF payments for inaccurate submission of certain data and provide federal funding to carry out SNF data validation and ensure accuracy of cost report information. The Nursing Home Improvement Act also proposed staffing requirements for SNFs and other measures intended to improve transparency, accountability and quality of care within nursing homes. If passed in its current form the bill would provide participating states with funds for up to six years in order to fund demonstrated improvements in nursing home workforce and care delivery. As of December 31, 2022, no action has been taken on this bill since its introduction to the Senate on August 10, 2021 and referral to the Senate Finance Committee that same day. A similar bill introduced in the United States House of Representatives in January of 2021 was introduced and referred to the Ways and Means Committee’s Healthcare Subcommittee on February 2, 2021.
Proposed State Legislation Concerning Nursing Home Supervision California passed into law AB 35, which changes the limitations, or “caps,” on non-economic damages that can be awarded in medical negligence cases filed against healthcare providers (including skilled nursing and long-term care facilities). Beginning on January 1, 2023, non-economic damages (i.e. pain and suffering) available to plaintiffs suing healthcare providers in medical malpractice and professional negligence cases will be increased from $0.25 million to $0.35 million, and will then increase by $0.04 million per year over the following ten years up to a $0.75 million cap. Once the limit reaches $0.75 million, a 2% annual inflationary adjustment will attach beginning on January 1, 2034. In wrongful death cases that arise from claims of medical malpractice and professional negligence, the cap on non-economic damages will increase from $0.25 million to $0.50 million on January 1, 2023, and increase every year thereafter for ten years until the cap on non-economic damages in such cases is $1.0 million; thereafter, this cap will also be subject to an annual 2% increase to reflect changes in the cost of living. The caps are separate as to each claim, meaning that there is one cap for negligence and one cap for wrongful death. The new limits on non-economic damages apply prospectively to lawsuits filed on and after January 1, 2023.
On September 27, 2022, California’s Governor signed into law AB 1502, also known as the Skilled Nursing Facility Ownership and Management Reform Act of 2022. Expected to take effect on July 1, 2023, this law will affect new license applications for SNFs. AB 1502 increases the oversight authority of the California Department of Public Health, and changes several provisions regarding SNF licensing in the State of California. First, the law eliminates previous regulatory provisions that permitted SNFs to operate in advance of receiving their formal license from the State. AB 1502 also requires SNF license applicants to disclose additional information to the Department of Public Health in connection with a license application and requires the Department of Public Health to consider more data regarding the applicant’s prior operations before issuing it a license. This data includes, but is not limited to: prior citations; sanctions imposed by CMS; legal proceedings commenced by other State or Federal authorities; findings made regarding the applicant by agencies or courts; and actions taken against other facilities owned, operated, or managed by the applicant. The same analysis described above is intended to apply to applications for a change in ownership or a change in management of a skilled nursing facility. AB 1502 authorizes the Department of Public Health to impose civil penalties of up to $0.01 million, and other enforcement action as appropriate, upon applicants that fail to comply with the law’s requirements.
Proposed and Anticipated Administrative Action On February 28, 2022, the Administration published a fact sheet stating its priorities for making changes to senior care, including potential changes to regulations affecting LTC and SNF facilities. The Administration’s priorities, which are to be studied throughout 2022, include transparency and public disclosure for nursing home owners and operators and an examination of the role of private equity investment, real estate investment trusts (REITs) and other investment interests in this sector. The SNF-VBP Program was also identified as an area for change, with staffing levels, retention and resident experience affecting reimbursement. Additional enforcement authority and resources, including enhanced scrutiny of poorly performing facilities and tools for improving their performance, is another Administration priority. The Administration also seeks to improve accessibility to nurse aide training, tie Medicaid payments to staff wages and benefits and enhance the recruitment and career paths for care workers. Finally, the Administration wishes to incorporate the lessons learned from the COVID-19 pandemic to impose new requirements for infection control, emergency preparedness and safety.

On April 11, 2022, CMS issued a proposed rule that could potentially lead to changes in the SNF-VBP Program, and setting SNF and LTC facility staffing levels. On June 29, 2022, CMS published guidance to surveyors for consistently evaluating Phase 2 and 3 Requirements of Participation for LTC facilities, addressing topics including infection control, resident safety, arbitration of disputes, nurse staffing and mental health disorders.


26

On September 22, 2022, CMS issued an IFR addressing nursing home visitation, including recommending the use of masks and face coverings to combat the transmission of COVID-19 and testing of symptomatic nursing home staff and residents regardless of COVID-19 vaccination status. On October 23, 2022, CMS issued further guidance unifying its recommendations for all facilities under its oversight, including SNFs and LTC facilities, reaffirming CMS's activities to verify COVID-19 vaccination of all SNF and LTC facility staff, and to pursue corrective action for facilities found deficient in this requirement.
Monitoring Compliance in Our Facilities 

Governmental agencies and other authorities periodically inspect our independent operating facilities to assess compliance with various standards, rules and regulations. The robust regulatory and enforcement environment continues to impact healthcare providers, especially in connection with responses to any alleged noncompliance identified in periodic surveys and other inspections by governmental authorities. Unannounced surveys or inspections generally occur at least annually and may also follow a government agency's receipt of a complaint about a facility. Facilities must pass these inspections to maintain licensure under state law, to obtain or maintain certification under the Medicare and Medicaid programs, to continue participation in the Veterans Administration program at some facilities, and to comply with provider contracts with managed care clients at many facilities. From time to time, our independent operating subsidiaries, like others in the healthcare industry, may receive notices from federal and state regulatory agencies of an alleged failure to substantially comply with applicable standards, rules or regulations. These notices may require corrective action, may impose civil monetary penalties for noncompliance, and may threaten or impose other operating restrictions on SNFs such as admission holds, provisional skilled nursing license, or increased staffing requirements. If our independent operating subsidiaries fail to comply with these directives or otherwise fail to comply substantially with licensure and certification laws, rules and regulations, the facility could lose its certification as a Medicare or Medicaid provider, or lose its license permitting operation in the State.

Facilities with otherwise acceptable regulatory histories generally are normally given an opportunity to correct deficiencies and continue their participation in the Medicare and Medicaid programs by a certain date, usually within six months; however, although where denial of payment remedies are asserted, such interim remedies go into effect much sooner. Facilities with deficiencies that immediately jeopardize patient health and safety and those that are classified as poor performing facilities, however, may not be given an opportunity to correct their deficiencies prior to the imposition of remedies and other enforcement actions. Moreover, facilities with poor regulatory histories continue to be classified by CMS as poor performing facilities notwithstanding any intervening change in ownership, unless the new owner obtains a new Medicare provider agreement instead of assuming the facility's existing agreement. However, new owners nearly always assume the existing Medicare provider agreement due to the difficulty and time delays generally associated with obtaining new Medicare certifications, especially in previously certified locations with sub-par operating histories. Accordingly, facilities that have poor regulatory histories before acquisition by our independent operating subsidiaries and that develop new deficiencies after acquisition are more likely to have sanctions imposed upon them by CMS or state regulators.
In addition, CMS has increased its focus on facilities with a history of serious or sustained quality of care problems through the special focus facility (SFF) initiative. A facility's administrators and owners are notified when it is identified as a SFF. This information is also provided to the general public. Local state survey agencies recommend to CMS that facilities be placed on special focus status. SFFs receive heightened scrutiny and more frequent regulatory surveys. Failure to improve the quality of care can result in fines and termination from participation in Medicare and Medicaid. A facility “graduates” from the program once it demonstrates significant improvements in quality of care that are continued over a defined period of time.
On October 21, 2022, CMS issued a Memorandum identifying the changes it intends to make in connection with the oversight of those facilities that fall under the SFF Program. These proposed measures included increased penalties for SFFs that fail to improve their performance upon further inspection by CMS, increasing the standards SFFs must meet to graduate from the SFF program, maintaining heightened oversight of any SFF for a period of three years after it graduates and increasing the technical assistance CMS provides to SFFs. The CMS Memorandum also identifies grants that will be available to aid in the hiring, training and education of personnel involved in resident care, including licensed practical nurses and registered nurses. In addition to the communication from CMS, the White House also issued a fact sheet covering these same issues on October 21, 2022. The fact sheet further identified measures the Administration is taking to increase staffing requirements, halt illegal or improper debt collection activities, increase transparency in facility ownership and operation (including SNF performance), and tie reimbursement to the quality of performance.

27

Sanctions such as denial of payment for new admissions often are scheduled to go into effect before surveyors return to verify compliance. Generally, if the surveyors confirm that the facility is in compliance upon their return, the sanctions never take effect. However, if they determine that the facility is not in compliance, the denial of payment goes into effect retroactive to the date given in the original notice. This possibility sometimes leaves affected operators, including our independent subsidiaries, with the difficult task of deciding whether to continue accepting patients after the potential denial of payment date, thus risking the retroactive denial of revenue associated with those patients' care if the operators are later found to be out of compliance, or simply refusing admissions from the potential denial of payment date until the facility is actually found to be in compliance. In the past and from time to time, some of our independent operating subsidiaries have been or will be in denial of payment status due to findings of continued regulatory deficiencies, resulting in an actual loss of revenue associated with Medicare and Medicaid patients admitted after the denial of payment date. Additional sanctions could ensue and, if imposed, could include various remedies up to and including decertification.
CMS has undertaken several initiatives to increase or intensify Medicaid and Medicare survey and enforcement activities, including federal oversight of state actions. CMS is taking steps to focus more survey and enforcement efforts on facilities with findings of substandard care or repeat violations of Medicaid and Medicare standards and to identify multi-facility providers with patterns of noncompliance. CMS is also increasing its oversight of state survey agencies and requiring state agencies to use enforcement sanctions and remedies more promptly when substandard care or repeat violations are identified, to investigate complaints more promptly, and to survey facilities more consistently. On February 28, 2022, the Administration published a fact sheet regarding nursing home care, which identified the Administration’s priorities of further funding for SNF and LTC facility inspections, as well as enhanced penalties and other tools to use against non-compliant facilities. Proposed rules based on these directives and studies are expected in approximately one year, with final rules to follow a notice-and-comment period required by law.
Regulations Regarding Financial Arrangements  
We are also subject to federal and state laws that regulate financial arrangement by and between healthcare providers, such as the federal and state anti-kickback laws, the Stark laws, and various state anti-referral laws.
The Social Security Act prohibits the knowing and willful offer, payment, solicitation, or receipt of any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce the referral of an individual, in return for recommending, or to arrange for, the referral of an individual for any item or service payable under any federal healthcare program, including Medicare or Medicaid. The OIG has issued regulations that create “safe harbors” for certain conduct and business relationships that are deemed protected under the Social Security Act. In order to receive safe harbor protection, all of the requirements of a safe harbor must be met. The fact that a given business arrangement does not fall within one of these safe harbors, however, does not render the arrangement per se illegal. Business arrangements of healthcare service providers that fail to satisfy the applicable safe harbor criteria, if investigated, will be evaluated based upon all facts and circumstances and risk increased scrutiny and possible sanctions by enforcement authorities.
Violations of the Social Security Act can result in inflation-adjusted criminal penalties of more than $0.1 million and ten years imprisonment. It can also result in inflation-adjusted civil monetary penalties of more than $0.1 million per violation and an assessment of up to three times the total amount of remuneration offered, paid, solicited, or received. It may also result in an individual's or organization's exclusion from future participation in federal healthcare programs. State Medicaid programs are required to enact an anti-kickback statute. Many states in which our independent operating subsidiaries operate have adopted or are considering similar legislative proposals, some of which extend beyond the Medicaid program, to prohibit the payment or receipt of remuneration for the referral of patients regardless of the source of payment for the care. We believe that business practices of providers and financial relationships between providers have become subject to increased scrutiny as healthcare reform efforts continue on the federal and state levels.

28

Additionally, the "Stark Law" of the Social Security Act provides that a physician may not refer a Medicare or Medicaid patient for a “designated health service” to an entity with which the physician or an immediate family member has a financial relationship unless the financial arrangement meets an exception under the Stark Law or its regulations. Designated health services include inpatient and outpatient hospital services, PT, OT, SLP, durable medical equipment, prosthetics, orthotics and supplies, diagnostic imaging, enteral and parenteral feeding and supplies and home health services. Under the Stark Law, a “financial relationship” is defined as an ownership or investment interest or a compensation arrangement. If such a financial relationship exists and does not meet a Stark Law exception, the entity is prohibited from submitting or claiming payment under the Medicare or Medicaid programs or from collecting from the patient or other payor. Many of the compensation arrangements exceptions permit referrals if, among other things, the arrangement is set forth in a written agreement signed by the parties, the compensation to be paid is set in advance, is consistent with fair market value and is not determined in a manner that takes into account the volume or value of any referrals or other business generated between the parties. Exceptions may have other requirements. Any funds collected for an item or service resulting from a referral that violates the Stark Law are not eligible for payment by federal healthcare programs and must be repaid to Medicare or Medicaid, any other third-party payor, and the patient. Violations of the Stark Law may result in the imposition of civil monetary penalties, including, treble damages. Individuals and organizations may also be excluded from participation in federal healthcare programs for Stark Law violations. Many states have enacted healthcare provider referral laws that go beyond physician self-referrals or apply to a greater range of services than just the designated health services under the Stark Law.
Regulations Regarding Patient Record Confidentiality
Health care providers are also subject to laws and regulations enacted to protect the confidentiality of patient health information. For example, HHS has issued rules pursuant to HIPAA, including the Health Information Technology for Economic and Clinical Health (HITECH) Act which governs our use and disclosure of protected health information of patients. We have established policies and procedures to comply with HIPAA privacy and security requirements at our independent operating subsidiaries. Our independent operating subsidiaries have adopted and implemented HIPAA compliance plans, which we believe comply with the HIPAA privacy and security regulations. The HIPAA privacy and security regulations have and will continue to impose significant costs on our independent operating subsidiaries in order to comply with these standards. There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. Our independent operating subsidiaries are also subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties for privacy and security breaches. Healthcare entities are also required to afford patients with certain rights of access to their health information under HIPAA and the 21st Century Cures Act (Cures Act). The Office of Civil Rights, the agency responsible for HIPAA enforcement, has targeted investigative and enforcement efforts on violations of patients’ rights of access, including denial of access to medical records, imposing significant fines for violations largely initiated from patient complaints. The Office of the National Coordinator for Health Information Technology can also investigate and impose separate penalties for information blocking violations under the Cures Act.
Antitrust Laws 
We are also subject to federal and state antitrust laws. Enforcement of the antitrust laws against healthcare providers is common, and antitrust liability may arise in a wide variety of circumstances, including third party contracting, physician relations, joint venture, merger, affiliation and acquisition activities. In some respects, the application of federal and state antitrust laws to healthcare is still evolving, and enforcement activity by federal and state agencies appears to be increasing. At various times, healthcare providers and insurance and managed care organizations may be subject to an investigation by a governmental agency charged with the enforcement of antitrust laws, or may be subject to administrative or judicial action by a federal or state agency or a private party. Violators of the antitrust laws could be subject to criminal and civil enforcement by federal and state agencies, as well as by private litigants.
Americans with Disabilities Act
Our independent operating subsidiaries must also comply with the ADA, and similar state and local laws to the extent that the facilities are "public accommodations" as defined in those laws. The obligation to comply with the ADA and other similar laws is an ongoing obligation, and the independent operating subsidiaries continue to assess their facilities relative to ADA compliance and make appropriate modifications as needed.

29

Real Estate Investment Trust (REIT) Qualification

We are electing for Standard Bearer to be taxed as a REIT for U.S. federal income tax purposes beginning with its taxable year ended December 31, 2022. Standard Bearer's qualification as a REIT will depend upon its ability to meet, on a continuing basis, various complex requirements under the Internal Revenue Code, relating to, among other things, the sources of its gross income, the composition and value of its assets, distribution levels to its shareholders and the concentration of ownership of its capital stock. We believe that Standard Bearer is organized in conformity with the requirements for qualification and taxation as a REIT under the Code and that its manner of operation has and will enable it to continue to meet the requirements for qualification and taxation as a REIT.

REGULATIONS SPECIFIC TO SENIOR LIVING COMMUNITIES

As previously mentioned, senior living services revenue (approximately 2.2% of total revenue) is primarily derived from private pay residents, with a small portion of senior living revenue derived from Medicaid funds. Thus, some of the regulations discussed above applicable to Medicaid providers, also apply to senior living. However, the following provides a brief overview of the regulatory framework applicable specifically to senior living.

A majority of states provide, or are approved to provide, Medicaid payments for personal care and medical services to some residents in licensed senior living communities under waivers granted by or under Medicaid state plans approved by CMS. State Medicaid programs control costs for senior living and other home and community-based services by various means such as restrictive financial and functional eligibility standards, enrollment limits and waiting lists. Because rates paid to senior living community operators are generally lower than rates paid to SNF operators, some states use Medicaid funding of senior living services as a means of lowering the cost of services for residents who may not need the higher level of health services provided in SNFs. States that administer Medicaid programs for services in senior living communities are responsible for monitoring the services at, and physical conditions of, the participating communities. As a result of the growth of senior living in recent years, states have adopted licensing standards applicable to senior living communities. Most state licensing standards apply to senior living communities regardless of whether they accept Medicaid funding.

CMS has continued to commence a series of actions to increase its oversight of state quality assurance programs for senior living communities and has provided guidance and technical assistance to states to improve their ability to monitor and improve the quality of services paid through Medicaid waiver programs. CMS is encouraging state Medicaid programs to expand their use of home and community-based services as alternatives to facility-based services, pursuant to provisions of the ACA, and other authorities, through the use of several programs. As noted above, the Administration issued a fact sheet regarding nursing home care priorities and reforms that it intends to seek in the coming year. The Administration’s desired changes are multi-faceted, concerning payment to facilities, staffing level requirements, training and retention of staff, standards of care offered to residents, increased transparency and public disclosure of ownership, and enhanced civil remedies and other authority to exercise upon facilities that do not satisfy CMS’s standards. Proposed rules based on these directives are expected by early 2023, with final rules to follow a notice-and-comment period required by law. In 2022, CMS issued a proposed rule that requested information to be used for study and potential rulemaking consistent with the Administration’s February 28, 2022 fact sheet. CMS also published guidance to surveyors for consistently evaluating the requirements of participation for LTC facilities, specifically infection control, resident safety, arbitration of disputes, nurse staffing and mental health disorders.
The types of laws and statutes affecting the regulatory landscape of the post-acute industry continue to expand. In addition to this changing regulatory environment, federal, state and local officials are increasingly focusing their efforts on the enforcement of these laws. In order to operate our businesses, we must comply with federal, state and local laws relating to licensure, delivery and adequacy of medical care, distribution of pharmaceuticals, equipment, personnel, operating policies, fire prevention, rate-setting, billing and reimbursement, building codes and environmental protection. Additionally, we must also adhere to anti-kickback statues, physician referral laws, the ADA and safety and health standards set by the OSHA Administration. Changes in the law or new interpretations of existing laws may have an adverse impact on our methods and costs of doing business.

Our independent operating subsidiaries are also subject to various regulations and licensing requirements promulgated by state and local health and social service agencies and other regulatory authorities. Requirements vary from state to state and these requirements can affect, among other things, personnel education and training, patient and personnel records, services, staffing levels, monitoring of patient wellness, patient furnishings, housekeeping services, dietary requirements, emergency plans and procedures, certification and licensing of staff prior to beginning employment and patient rights. These laws and regulations could limit our ability to expand into new markets and to expand the services provided by independent operating subsidiaries in existing markets.
30


ENVIRONMENTAL MATTERS

 We strive to reduce our environmental impact through initiatives to modernize our facilities, conserve water, optimize waste, work towards a paperless office and partner with green vendors. Our ongoing and planned facility modernization initiatives include solar projects, heating, ventilation and air condition (HVAC) upgrades, water systems updates, lighting retrofits and utility upgrades. Additionally, we track and evaluate the utilities used by our facilities to drive our initiatives. For the year ended December 31, 2022, we spent $87.5 million on purchases of property improvements and equipment which included facility modernization initiatives.

Our business is subject to a variety of federal, state and local environmental laws and regulations. As a healthcare provider, we face regulatory requirements in areas of air and water quality control, medical and low-level radioactive waste management and disposal, asbestos management, response to mold and lead-based paint in our facilities and employee safety.

 As an owner or operator of our facilities, we also may be required to investigate and remediate hazardous substances that are located on and/or under the property, including any such substances that may have migrated off, or may have been discharged or transported from the property. Part of our operations involves the handling, use, storage, transportation, disposal and discharge of medical, biological, infectious, toxic, flammable and other hazardous materials, wastes, pollutants or contaminants. In addition, we are sometimes unable to determine with certainty whether prior uses of our facilities and properties or surrounding properties may have produced continuing environmental contamination or noncompliance, particularly where the timing or cost of making such determinations is not deemed cost-effective. These activities, as well as the possible presence of such materials in, on and under our properties, may result in damage to individuals, property or the environment; may interrupt operations or increase costs; may result in legal liability, damages, injunctions or fines; may result in investigations, administrative proceedings, penalties or other governmental agency actions; and may not be covered by insurance.

We believe that we are in material compliance with applicable environmental and occupational health and safety requirements. However, we cannot assure you that we will not encounter liabilities with respect to these regulations in the future, and such liabilities may result in material adverse consequences to our operations or financial condition.
AVAILABLE INFORMATION

We are subject to the reporting requirements under the Securities Exchange Act of 1934, as amended (the Exchange Act). Consequently, we are required to file reports and information with the Securities and Exchange Commission (SEC), including reports on the following forms: annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. These reports, proxy and information statements and other information concerning our company may be accessed through the SEC's website at http://www.sec.gov.

You may also find on our website at www.ensigngroup.net, electronic copies of our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. Such filings are placed on our website as soon as reasonably possible after they are filed with the SEC. All such filings are available free of charge. The information contained in, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 10-K.
31

Item 1A. RISK FACTORS
We are providing the following summary of the risk factors contained in our Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the risk factors contained in this Form 10-K in their entirety for additional information regarding the risks and uncertainties that could cause our actual results to vary materially from recent results or from our anticipated future results.

Risks Related to our Business and Industry

We face numerous risks related to the COVID-19 PHE and its expiration in 2023, which could individually or in the aggregate have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects.
Changes to reimbursement rates, rules and other aspects of Medicare and Medicaid, including reductions of the FMAP, could have a material, adverse effect on our revenues, financial condition and results of operations, including the reductions to reimbursement in the 2023 calendar year physician fee schedule and changes to data reporting, measurement and evaluation standards.
Our revenue could be impacted by changes to existing reimbursement models.
Reforms to the U.S. healthcare system, including new regulations under the ACA and its expansion under new laws such as the Inflation Reduction Act of 2022 (IRA) and future legislation, continue to impose new requirements upon us and may increase our costs or lower our reimbursements, which could materially impact our business.
Changes to the U.S. healthcare system, including the Medicare program, may have unforeseen consequences for our business, including, but not limited to a loss of revenue, reduction of services covered by Medicare, limits on out-of-pocket expenses we may charge and other spending cuts that affect us in order to offset limitations on patient expenses for other medical services, such as the limitation on out-of-pocket expenses for prescription drugs.
The recent midterm elections in 2022, may result in significant changes to the regulatory framework, enforcements, and reimbursements in our industry.
We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs.
Public and government calls for increased survey and enforcement efforts toward LTC facilities, potential rulemaking that may result in enhanced enforcement and penalties, and new guidance for surveyors regarding the review of LTC facilities and enforcement of their Requirements of Participation, could result in increased scrutiny by state and federal survey agencies. Potential sanctions and remedies based upon alleged regulatory deficiencies could negatively affect our financial condition and results of operations.
Future cost containment initiatives undertaken by third-party payors may limit our revenue and profitability.
Changes in Medicare reimbursements for physician and non-physician services could impact reimbursement for medical professionals, which could have a negative effect on our business, financial condition or results of operations.
We may be subject to increased investigation and enforcement activities related to HIPAA violations if we fail to adopt and maintain business procedures and systems designed to protect the privacy, security and integrity of patients’ individual health information.
Security breaches and other cyber-security incidents could violate security laws and subject us to significant liability.
If our independent operating subsidiaries are not fully reimbursed for all services for which each facility bills through consolidated billing, our revenue, financial condition and results of operations could be adversely affected.
Increased competition for, or a shortage of, nurses and other skilled personnel could increase our staffing and labor costs and subject us to monetary fines resulting from a failure to maintain minimum staffing requirements, or may affect reimbursement.
Annual caps and other cost-reductions for outpatient therapy services may reduce our future revenue and profitability or cause us to incur losses.
Increased scrutiny of our billing practices by the Office of the Inspector General or other regulatory authorities may result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.
State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.
Newly enacted legislation in the States where our independently operating entities are located may impact the volume of cases filed and the overall cost of those cases from a defense and indemnity standpoint.
Changes to federal and state employment-related laws and regulations could increase our cost of doing business.
Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.
Compliance with federal and state fair housing, fire, safety, staffing, and other regulations may require us to incur unexpected expenses, which could be costly to us.
We depend largely upon reimbursement from third-party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our affiliated facilities as well as payor mix and payment methodologies.
32

We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards. Similarly, a change in the enforceability of arbitration provisions between LTC facilities and SNFs with residents or patients may affect the risks we face from claims and potential litigation.
If our regular internal investigations into the care delivery, recordkeeping and billing processes of our operating subsidiaries detect instances of noncompliance, efforts to correct such non-compliance could materially decrease our revenue.
We may be unable to complete future facility or business acquisitions at attractive prices or at all, or may elect to dispose of underperforming or non-strategic operating subsidiaries, either of which could decrease our revenue.
We may not be able to successfully integrate acquired facilities and businesses into our operations, or we may be exposed to costs, liabilities and regulatory issues that may adversely affect our operations.
If we do not achieve or maintain competitive quality of care ratings from CMS or private organizations engaged in similar monitoring activities, our business may be negatively affected.
If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected, and our self-insurance programs may expose us to significant and unexpected costs and losses.
The geographic concentration of our affiliated facilities could leave us vulnerable to economic downturn, regulatory changes or acts of nature in those areas.
The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability.
The risks associated with leased property that our operators operate in could adversely affect our business, financial position or results of operations.
Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our operating subsidiaries and cause us to lose facilities or experience foreclosures.
Move-in and occupancy rates may remain unpredictable even after the COVID-19 pandemic is over.
A continued housing slowdown or housing downturn could decrease demand for senior living services.
As we continue to acquire and lease real estate assets, we may not be successful in identifying and consummating these transactions.
As we expand our presence in other relevant healthcare industries, we would become subject to risks in a market in which we have limited experience.
If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease.
We may need additional capital to fund our operating subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow.
The condition of the financial markets, including recent and expected future increases to the federal funds rate, inflation and the consumer price index, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our current portfolio of cash, cash equivalents and investments.
Delays in reimbursement may cause liquidity problems.
The continued use and growth of Medicaid managed care organizations may contribute to delays or reductions in our Medicaid reimbursement.
Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.
Failure to safeguard our patient trust funds may subject us to citations, fines and penalties.
We are a holding company with no operations and rely upon our multiple independent operating subsidiaries to provide us with the funds necessary to meet our financial obligations. Liabilities of any one or more of our subsidiaries could be imposed upon us or our other subsidiaries.
We may be exposed to liabilities as a result of the separation of Pennant, including if the spin-off is not tax-free for U.S. federal income tax purposes.
Certain directors who serve on our Board of Directors also serve as directors of Pennant, and ownership of shares of Pennant common stock by our directors and executive officers may create, or appear to create, conflicts of interest.
Standard Bearer's failure to qualify as a REIT may cause it to be subject to U.S. federal income tax. Additionally, legislative or other actions affecting REITs could have a negative effect on Standard Bearer.

Risks Related to Ownership of our Common Stock
We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price.
Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.
33

You should carefully consider each of the following risk factors and all other information set forth in this information statement. The risk factors generally have been separated into two categories: risks relating to our business and our industry and risks relating to our common stock. Based on the information currently known to us, we believe that the following information identifies the most significant risk factors affecting our company in each of these categories of risks. However, the risks and uncertainties we face are not limited to those set forth in the risk factors described below. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. In addition, past financial performance may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods.
 If any of the following risks and uncertainties develops into actual events, these events could have a material adverse effect on our business, financial condition or results of operations. In such case, the trading price of our common stock could decline. You should carefully read the following risk factors, together with the financial statements, related notes and other information contained in this Annual Report on Form 10-K. This Annual Report on Form 10-K contains forward-looking statements that contain risks and uncertainties. Please refer to the section entitled "Cautionary Note Regarding Forward-Looking Statements" on page 1 of this Annual Report on Form 10-K in connection with your consideration of the risk factors and other important factors that may affect future results described below.
Risks Related to Our Business and Industry
We face numerous risks related to the COVID-19 PHE, which could have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects.

The extent to which the COVID-19 PHE will continue impacting our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including future waves of COVID-19 variants and their severity, ongoing federal and state vaccination programs and requirements and the efficacy of vaccinations and the ongoing actions to contain the virus or treat its impact, among others. Some of the risks of COVID-19 are being mitigated as a result of the federal vaccination program, including vaccinations and vaccine booster requirements of nursing facility staff and residents, but there remains uncertainty as to what changes will be made to HHS’s emergency response to reflect the evolving and endemic nature of COVID-19, analogous to seasonal spikes in influenza cases and the final details for unwinding the PHE's Emergency Waivers and other administrative flexibilities at the federal and state levels.

As discussed in Item 1., under Government Regulation, federal, state and local regulators have implemented new regulations and waived existing regulations to promote care delivery during the COVID-19 PHE. While the majority of these changes are beneficial by reducing regulatory burdens, these accommodations may also have an adverse effect through increased legal and operational costs related to compliance and monitoring. Additionally, most of the accommodations are limited in duration and tied to the PHE declaration, thus there may be significant operational change requirements on short notice. As of December 31, 2022, sixteen of the Emergency Waivers relevant to SNFs and LTC facilities expired. Also, the reinstatement of waived state and federal regulations may not occur simultaneously, requiring heightened monitoring to ensure compliance.

Other factors from the continuation of the COVID-19 pandemic that could have an adverse effect on our business, financial condition, liquidity, results of operations and prospects, include:

potential for permanent government regulations and restrictions to combat COVID-19;
increased strain on employees and resources caused by different waves of COVID-19 variants with different infection and effects, affecting employee availability and capacity to work;
reduced occupancy as a result of concerns of residents and their families related to COVID-19 transmissibility within LTC settings, as well as due to government-imposed orders;
increased costs related to additional and changing CDC protocols, federal and state workforce protection and related isolation procedures, including obligations to test patients and staff for COVID-19 vaccination mandates;
limitations on availability of staff due to COVID-19 related illness or exposure, or due to unwillingness to comply with vaccine mandates;
increased scrutiny by regulators of infection control and prevention measures, including increased reporting requirements related to suspected and confirmed COVID-19 diagnoses of residents and staff, which may result in fines or other sanctions related to non-compliance;
increased risk of litigation and related liabilities arising in connection with patient or staff illness, hospitalization and/or death;
34

negative impacts on our patients' ability or willingness to pay for healthcare services and our third parties' ability or willingness to pay rents; and
regulations that require all of our workers to be fully vaccinated, including receiving vaccination boosters, against COVID-19 as a condition of participating in the Medicare and Medicaid programs.
complexity, uncertainty and potential state-by-state rulemaking arising from the expiration of the COVID-19 PHE and expiration of Emergency Waivers.

The extent and duration of the impact of the COVID-19 pandemic on our stock price is uncertain, our stock price may be more volatile, and our ability to raise capital could be impaired.
Our revenue could be impacted by federal and state changes to reimbursement and other aspects of Medicare.

We derived 27.7% and 27.8% of our service revenue from the Medicare programs for the years ended December 31, 2022 and 2021, respectively. In addition, many other payors may use published Medicare rates as a basis for reimbursements. Accordingly, if Medicare reimbursement rates are reduced or fail to increase as quickly as our costs, if there are changes in the rules governing the Medicare program that are disadvantageous to our business or industry, or if there are delays in Medicare payments, our business and results of operations will be adversely affected.

The Medicare program and its reimbursement rates and rules are subject to frequent change. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), annual caps that limit the amount that can be paid (including deductible and coinsurance amounts) administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past and could in the future result in substantial reductions in our revenue and operating margins. For example, see Item 1., under Government Regulation, Sequestration of Medicare Rates.

Additionally, Medicare payments can be delayed or declined due to determinations that certain costs are not reimbursable or reasonable because either adequate or additional documentation was not provided or because certain services were not covered or considered medically necessary. Additionally, revenue from these payors can be retroactively adjusted after a new examination during the claims settlement process or as a result of post-payment audits. New legislation and regulatory proposals could impose further limitations on government payments to healthcare providers.

In addition, CMS often changes the rules governing the Medicare program, including those governing reimbursement. Changes to the Medicare program that could adversely affect our business include:
administrative or legislative changes to base rates or the bases of payment;
limits on the services or types of providers for which Medicare will provide reimbursement;
changes in methodology for patient assessment and/or determination of payment levels;
changes in staff requirements (i.e., requiring all workers to be vaccinated against COVID-19 and receive booster injections for those vaccinations) as a condition of payment or eligibility for Medicare reimbursement (See also, Item 1., under Government Regulation);
the reduction or elimination of annual rate increases, or the end of the reduced payments deferment (See also, Item 1., under Government Regulation); or
an increase in co-payments or deductibles payable by beneficiaries.
Among the important statutory changes that are being implemented by CMS are provisions of the IMPACT Act. This law imposes a stringent timeline for implementing benchmark quality measures and data metrics across post-acute care providers (long stay hospitals, inpatient rehabilitation facilities, skilled nursing facilities (SNFs), and home health agencies). The enactment also mandates specific actions to design a unified payment methodology for post-acute providers. CMS continues to promulgate regulations to implement provisions of this enactment. Depending on the final details, the costs of implementation could be significant. The failure to meet implementation requirements could expose providers to fines and payment reductions. 


35

Reductions in reimbursement rates or the scope of services being reimbursed could have a material, adverse effect on our revenue, financial condition and results of operations or even result in reimbursement rates that are insufficient to cover our operating costs. Loss of Medicare reimbursement entirely would also have a material adverse effect on our revenue. Medicare may rescind our certification and terminate its payor agreements if not all of our employees are fully vaccinated consistent with CMS's IFR requiring vaccination of SNF employees, which has applied to all states since March 21, 2022. In addition, within certain states such as California and Washington, if our employees are not fully vaccinated as required by those states’ vaccination mandates, we could incur a deficiency that could endanger our Medicaid certification and participation status for certain locations within those states where employees have not been vaccinated. In addition, California required employees to receive at least one booster dose of the COVID-19 vaccine by March 1, 2022 in order to comply with its State Public Health Officer Order requiring vaccination of SNF employees. Other states where we operate, such as Colorado, have allowed their COVID-19 vaccinations to expire, or did not impose such mandates for the state’s healthcare workers. Any penalty, suspension, termination, or other sanction under any state’s Medicaid program could lead to reciprocal and commensurate penalties being imposed under the Medicare program, up to termination or rescission of our Medicare participation and payor agreements as noted above. Additionally, any delay or default by the government in making Medicare reimbursement payments could materially and adversely affect our business, financial condition and results of operations.
Reductions in Medicaid reimbursement rates or changes in the rules governing the Medicaid program could have a material, adverse effect on our revenue, financial condition and results of operations.
A significant portion of reimbursement for skilled nursing services comes from Medicaid. In fact, Medicaid is our largest source of revenue, accounting for 46.0% and 45.8% of our revenue for the years ended December 31, 2022 and 2021, respectively. Medicaid is a state-administered program financed by both state funds and matching federal funds. Medicaid spending has increased rapidly in recent years, becoming a significant component of state budgets, which has led both the federal government and many states to institute measures aimed at controlling the growth of Medicaid spending, and in some instances reducing aggregate Medicaid spending. Since a significant portion of our revenue is generated from our skilled nursing operating subsidiaries in California, Texas and Arizona, any budget reductions or delays in these states could adversely affect our net patient service revenue and profitability. Despite present state budget surpluses in many of the states in which we operate, we can expect continuing cost containment pressures on Medicaid outlays for SNFs, and any such decline could adversely affect our financial condition and results of operations.
The Medicaid program and its reimbursement rates and rules are subject to frequent change at both the federal and state level. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which our services are reimbursed by state Medicaid plans. To generate funds to pay for the increasing costs of the Medicaid program, many states utilize financial arrangements commonly referred to as provider taxes. Under provider tax arrangements, states collect taxes from healthcare providers and then use the revenue to pay the providers as a Medicaid expenditure, which allows the states to then claim additional federal matching funds on the additional reimbursements. Current federal law provides for a cap on the maximum allowable provider tax as a percentage of the providers' total revenue. There can be no assurance that federal law will continue to provide matching federal funds on state Medicaid expenditures funded through provider taxes, or that the current caps on provider taxes will not be reduced. Any discontinuance or reduction in federal matching of provider tax-related Medicaid expenditures could have a significant and adverse effect on states' Medicaid expenditures, and as a result could have a material and adverse effect on our business, financial condition or results of operations.
Upcoming changes to Medicaid reimbursement and FMAP may affect our revenues.
The bipartisan omnibus spending plan passed by Congress and signed into law by the President on December 29, 2022, contains provisions that will wind down and end increased FMAP payments provided for by FFCRA, as well as provide for the disenrollment of Medicaid beneficiaries who have participated in the program since early in the COVID-19 pandemic. In the first quarter of 2023, the FMAP increase CMS provides to the States will remain elevated by 6.2%, but will decline for the remaining quarters in 2023, at 5% in the second quarter, 2.5% in the third quarter, and 1.5% in the fourth quarter before increased FMAP spending ends entirely. Previously, the FMAP funding was dependent on the termination of the PHE. The ultimate amount of funding from each state will vary substantially based on that states’ policies. This may result in reductions in Medicaid spending by states where we operate, causing reductions in rates, and delays or withholding of payment for our operating subsidiaries’ services and effect our operating subsidiaries’ ability to profitably perform their services.

36

CMS’s ability to further reduce these declining amounts of increased FMAP payments to states may create further pressure on Medicaid reimbursement in states where we operate. The omnibus spending plan also grants CMS the authority to impose fines, penalties, and other sanctions upon states that do not comply with this law’s requirements for the unwinding of increased FMAP payments. As a result, these reductions may impose further burdens on the Medicaid programs in states where we operate, which may result in reduced payments.
Additionally, beginning on April 1, 2023, states may begin disenrolling Medicaid beneficiaries. CMS guidance regarding disenrollment of beneficiaries and a return to historical renewal, enrollment, and eligibility determination practices permits states up to 14 months to initiate and process traditional Medicaid renewals, including the eligibility and enrollment process. The allowance of disenrollment and return to traditional Medicaid renewal processes, which will include pre-COVID eligibility determinations, may result in a reduction of the number of Medicaid beneficiaries and may result in a reduction of our current and potential patient population. As a result, there may be fewer current or potential patients able to pay for our operating subsidiaries’ services, and increased competition for Medicaid beneficiaries able to provide reimbursement for those services.
Our revenue could be impacted by changes to existing reimbursement models.
As discussed in more detail in Item 1., under Government Regulation, CMS implemented a final rule in October 2019 to replace the existing case-mix classification system, Resource Utilization Groups, Version IV, with a new case-mix classification system, PDPM, that focuses more on the clinical condition of the patient and less on the volume of services provided. CMS may make future adjustments to reimbursement levels as it continues to monitor the impact of PDPM on patient outcomes and budget neutrality. CMS could remove the entire parity calculated adjustment and this would cause a drastic reduction in payments. In addition, the Administration continues to study the nursing home industry and for HHS to issue proposed rules based on those studies, including changes to SNF-VBP Program, may also adversely affect our reimbursement. The Administration continues to act on the issues identified in its February 28, 2022 fact sheet and further regulation is expected regarding LTC and SNF reimbursement. CMS elected to defer the SNF 30-Day All-Cause Readmission Measure (SNFRM) as part of performance scoring for fiscal year 2023, although the SNFRM will still be reported without affecting SNF payment. This final rule also provided for the SNF-VBP program expansion beyond the use of its single, all-cause hospital readmission measure to determine payment, with the inclusion of measures beginning in fiscal year 2026 for SNF healthcare associated infections requiring hospitalization (SNF HAI) and total nursing hours per resident day measures. Beginning in fiscal year 2027, the SNF-VBP program will also consider the discharge to community - post acute care measure for SNFs, which assesses the rate of successful discharges to the community from a SNF setting.
Reforms to the U.S. healthcare system continue to impose new requirements upon us and may increase our costs or lower our reimbursements.

The ACA included sweeping changes to how healthcare is paid for and furnished in the U.S. Applicable to our business, as discussed in greater detail in Item 1., under Government Regulation, the ACA has resulted in significant changes to our operations and reimbursement models for services we provide. CMS continues to issue rules to implement the ACA, including most recently new rules regarding the implementation of the anti-discrimination provisions. Courts continue to interpret and apply the ACA’s provisions. With the passage of the IRA in August of 2022, Congress continues to expand and supplement the ACA, including through the continuation of federally funded insurance premium subsidies for health insurance coverage purchased on the ACA-created marketplace for individual health insurance. This modification of the ACA by the IRA indicates that Congress may continue to change and expand the ACA in the future.

The efficacy of the ACA is the subject of much debate among members of Congress and the public. Additionally, a number of lawsuits have been filed challenging various aspects of the ACA and related regulations with inconsistent outcomes - some expand the ACA while others limit the ACA. In the event that the ACA is repealed or materially amended as a result of future challenges, particularly any elements of the ACA that are beneficial to our business or that cause changes in the health insurance industry, including reimbursement and coverage by private, Medicare or Medicaid payers, our business, operating results and financial condition could be harmed. Thus, the future impact of the ACA on our business is difficult to predict and its continued uncertain future may negatively impact our business. However, any material changes to the ACA or its implementing regulations may negatively impact our operations.


37

Similarly, the proposed Nursing Home Improvement Act may have an impact on our business due to the proposed two percent decrease in payments to SNFs, as well as the staffing and reporting requirements contained within the bill. This bill primarily creates penalties such as reduced reimbursement and monetary penalties for submitting inaccurate cost reports or staffing data. If passed in its current form, however, this bill would provide participating states with a temporary enhanced federal Medicaid match to fund improvements in nursing home workforce and care. This match would last six years, and states would be responsible for showing CMS that Medicaid reimbursement increases were used to increase worker wages and yield new training resources and opportunities for nursing home staff. While it is difficult to determine whether the Nursing Home Improvement Act will be amended prior to adoption, or even passed into law, if passed, this bill may negatively impact our business, with the scope and nature of its consequences unknown. As of December 31, 2022, however, the Nursing Home Improvement Act has not advanced out of the committee where it was introduced, and the same is true for a companion bill introduced in the House of Representatives.

Statements that the Administration made earlier this year indicate that HHS and CMS are being instructed to study the nursing home industry, specifically with regard to staffing levels, and the Administration has called for greater oversight of LTC and SNF facilities—including greater penalties for non-compliance with federal laws and regulations. On April 11, 2022, CMS issued a proposed rule that requested information to be used for study and potential rulemaking. Based upon this information-gathering and subsequent study, HHS and CMS are expected to issue new rules that may subject our business to greater oversight, increase penalties that the Government may seek to impose upon us, and impose additional conditions and measurements upon the reimbursement we receive from Medicare and Medicaid. In addition, CMS has published guidance to surveyors for consistently evaluating requirements of participation for LTC facilities, addressing topics including infection control, resident safety, arbitration of disputes, nurse staffing and mental health disorders. Surveyors' use of these additional Requirements of Participation to evaluate our affiliated facilities may increase our costs of compliance and subject us to additional fines and penalties for alleged non-compliance. CMS has also requested additional information from the public and industry participants that is expected to be used by HHS and CMS in creating additional regulations regarding staffing and operations of SNFs and LTC facilities in the future. These anticipated regulations, consistent with the Administration’s prior statements, may adversely affect our business, its operations, and its profitability.

We cannot predict what effect future reforms to the U.S. healthcare system will have on our business, including the demand for our services or the amount of reimbursement available for those services. However, it is possible these new laws may lower reimbursement or increase the cost of doing business and adversely affect our business.
The results of recent U.S. midterm elections in 2022 may result in significant changes to regulatory framework, enforcements and reimbursements.

The most recent midterm elections in 2022 could result in significant changes in, and uncertainty with respect to, legislation, regulation, implementation or repeal of laws and rules related to government health programs, including Medicare and Medicaid. Democratic proposals for Medicare for All or significant expansion of Medicare, could significantly impact our business and the healthcare industry if implemented. Additionally, Congress’s passage of the IRA in August of 2022, which expanded upon and continued certain provisions of the ACA through administrative rule-making, indicates that additional legislative changes to the ACA may be forthcoming based on the limited changes in the political composition of the House of Representatives and Senate following the November 2022 mid-term elections. If proposed policies specific to nursing facilities are implemented, these may result in significant regulatory changes, increased survey frequency and scope, and increased penalties for non-compliance.

We continually monitor these developments in order to respond to the changing regulatory environment impacting our business. While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the election, including a repeal or material amendment of the ACA (whether to increase or decrease its scope), could harm our business, operating results and financial condition. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.
Our business may be materially impacted if certain aspects of the ACA are amended, repealed, or successfully challenged.

A number of lawsuits have been filed challenging various aspects of the ACA and related regulations. In addition, the ACA may be affected by both the recently completed midterm elections and forthcoming Presidential and Congressional elections in 2024. Cases challenging the ACA or related rules have had inconsistent outcomes - some expand the ACA while others limit the ACA. Thus, the future impact of the ACA on our business is difficult to predict. The uncertainty as to the future of the ACA may negatively impact our business, as will any material changes to the ACA.

38

In the event that legal challenges are successful or the ACA is repealed or materially amended, particularly any elements of the ACA that are beneficial to our business or that cause changes in the health insurance industry, including reimbursement and coverage by private, Medicare or Medicaid payers, our business, operating results and financial condition could be harmed. While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the election, including a repeal or material amendment of the ACA, could harm our business, operating results and financial condition. In addition, even if the ACA is not amended or repealed, the President and the executive branch of the federal government, as well as CMS and HHS have a significant impact on the implementation of the provisions of the ACA, and a new administration could make changes impacting the implementation and enforcement of the ACA, which could harm our business, operating results and financial condition. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.
We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs.

As a result of our participation in the Medicaid and Medicare programs, we are subject to various governmental reviews, audits and investigations to verify our compliance with the rules associated with these programs and related applicable laws and regulations. We are subject to regulatory reviews relating to Medicare services, billings and potential overpayments resulting from the actions of Recovery Audit Contractors, Zone Program Integrity Contractors, Program Safeguard Contractors, Unified Program Integrity Contractors, Supplemental Medical Review Contractors and Medicaid Integrity Contractors programs, (collectively referred to as Reviews), in which third party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Federal and State programs. As discussed above, the Administration has called for HHS and CMS to increase the level of scrutiny in these audits and has requested those agencies to adopt rules that would impose greater penalties upon non-compliant LTC and SNF operators.

On June 29, 2022, CMS announced updated guidance for Phase 2 and 3 of the requirements of participation. The guidance updates the following topics: (1) resident abuse and neglect (including reporting of abuse); (2) admission, transfer and discharge; (3) mental health and substance abuse disorders; (4) nurse staffing and reporting of payroll to evaluate staffing sufficiency; (5) residents’ rights (including visitation); (6) potential inaccurate diagnoses or assessments; (7) prescription and use of pharmaceuticals, including psychotropics and drugs that act like psychotropics; (8) infection prevention and control; (9) arbitration of disputes between facilities and residents; (10) psychosocial outcomes and related severity; and (11) the timeliness and completion of state investigations to improve consistency in the application of standards among various states. The application of CMS’s new guidance could result in more aggressive and stringent surveys, and potential fines, penalties, sanctions, or administrative actions taken against our independent operating subsidiaries.

Private pay sources also reserve the right to conduct audits. We believe that billing and reimbursement errors and disagreements are common in our industry. We are regularly engaged in reviews, audits and appeals of our claims for reimbursement due to the subjectivities inherent in the process related to patient diagnosis and care, record keeping, claims processing and other aspects of the patient service and reimbursement processes, and the errors and disagreements those subjectivities can produce. An adverse review, audit or investigation could result in:

an obligation to refund amounts previously paid to us pursuant to the Medicare or Medicaid programs or from private payors, in amounts that could be material to our business;
state or federal agencies imposing fines, penalties or other sanctions on us;
temporary or permanent loss of our right to participate in the Medicare or Medicaid programs or one or more private payor networks;
an increase in private litigation against us; and
damage to our reputation in the geographies served by our independent operating subsidiaries.
Medicare administrative contractors conduct selected reviews of claims previously submitted by and paid to some of our independent operating entities. Although we have always been subject to post-payment audits and reviews, more intensive “probe reviews” performed in recent years appear to be a regular procedure with our fiscal intermediaries. All findings of overpayment from CMS contractors are eligible for appeal through the CMS defined processes and procedures. With the exception of rare findings of overpayment related to objective errors in Medicare payment methodology or claims processing, we utilize all defenses reasonably available to us to demonstrate that the services provided meet all clinical and regulatory requirements for reimbursement.

39

In cases where claim and documentation review by any CMS contractor results in repeated unsatisfactory results, an operation can be subjected to protracted regulatory oversight. This oversight may include repeat education and re-probe, extended pre-payment review, referral to recovery audit or integrity contractors, or extrapolation of an error rate to other reimbursement outside of specifically reviewed claims. Sustained failure to demonstrate improvement towards meeting all claim filing and documentation requirements could ultimately lead to Medicare decertification. As of December 31, 2022 and since, 34 of our independent operating subsidiaries had reviews scheduled, on appeal, or in a dispute resolution process, either pre- or post-payment. We anticipate that these reviews could increase in frequency in the future.

Additionally, both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and, in particular, SNFs. The focus of these investigations includes, among other things:
cost reporting and billing practices;
quality of care;
financial relationships with referral sources; and
medical necessity of services provided.
On May 31, 2018, we received a Civil Investigative Demand (CID) from the DOJ stating that it is investigating our company to determine whether we have violated the FCA or the Anti-Kickback Statute with respect to the relationships between certain of our SNFs and persons who served as medical directors, advisory board participants or other referral sources. The CID covered the period from October 3, 2013 through 2018 and was limited in scope to ten of our Southern California SNFs. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, our operating entities maintain policies and procedures to promote compliance with the FCA, the Anti-Kickback Statute, and other applicable regulatory requirements. We are fully cooperating with the U.S. Department of Justice. In April 2020, the Company was advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.

If we should agree to a settlement of, claims or obligations under federal Medicare statutes, the federal FCA, or similar State and Federal statutes and related regulations, our business, financial condition and results of operations and cash flows could be materially and adversely affected, and our stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations and may also include our assumption of specific procedural and financial obligations going forward under a corporate integrity agreement or other arrangement with the government.

If the government or a court were to conclude that errors and deficiencies constitute criminal violations and/or that such errors and deficiencies resulted in the submission of false claims to federal healthcare programs, or were to discover other problems in addition to the ones identified by the probe reviews that rose to actionable levels, we and certain of our officers might face potential criminal charges and civil claims, administrative sanctions and penalties for amounts that could be material to our business, results of operations and financial condition. In addition, we or some of the key personnel of our independent operating subsidiaries could be temporarily or permanently excluded from future participation in state and federal healthcare reimbursement programs such as Medicaid and Medicare.

If any of our independently operated subsidiary facilities is decertified or loses its licenses, our revenue, financial condition or results of operations would be adversely affected. In addition, the report of such issues at any of our independently operated subsidiary facilities could harm our reputation for quality care and lead to a reduction in the patient referrals to and ultimately a reduction in occupancy at these facilities. Also, responding to auditing and enforcement efforts diverts material time, resources and attention away from our management team and our staff, and could have a materially detrimental impact on our results of operations during and after any such investigation or proceedings, regardless of whether we prevail on the underlying claim.
We are subject to extensive and complex laws and government regulations. If we are not operating in compliance with these laws and regulations or if these laws and regulations change, we could be required to make significant expenditures or change our operations in order to bring our facilities and operations into compliance.
 
We, along with other companies in the healthcare industry, are required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to, among other things:


40

licensure and certification;
adequacy and quality of healthcare services;
qualifications and vaccination (including boosting) of healthcare and support personnel;
quality of medical equipment;
confidentiality, maintenance and security issues associated with medical records and claims processing;
relationships with physicians and other referral sources and recipients;
constraints on protective contractual provisions with patients and third-party payors;
operating policies and procedures;
addition of facilities and services; and
billing for services.

The laws and regulations governing our operations, along with the terms of participation in various government programs, regulate how we do business, the services we offer, and our interactions with patients and other healthcare providers. These laws and regulations are subject to frequent change. As noted above, the Administration has called upon HHS and CMS to study and propose new rules regarding staffing requirements and reimbursement for the nursing home industry, including tying reimbursement to staffing levels, salary, benefits, and retention. CMS's guideline and sanction addressed topics including infection control, resident safety, arbitration of disputes, nurse staffing, and mental health disorders. In addition, CMS' new guidance including the use of masks and face coverings in connection with visitations to combat the transmission of COVID-19, testing of nursing home staff and residents regardless of COVID-19 vaccination status and verifying vaccination of all SNF and LTC facility staff could result in enhanced scrutiny by state surveyors and a potential increase in fines, penalties, sanctions, or administrative actions against our independent operating subsidiaries.

We believe that such regulations may increase in the future and we cannot predict the ultimate content, timing or impact on us of any healthcare reform legislation. Changes in existing laws or regulations, or the enactment of new laws or regulations, could negatively impact our business. If we fail to comply with these applicable laws and regulations, we could suffer civil or criminal penalties and other detrimental consequences, including denial of reimbursement, imposition of fines, temporary suspension of admission of new patients, suspension or decertification from the Medicaid and Medicare programs, restrictions on our ability to acquire new facilities or expand or operate existing facilities, the loss of our licenses to operate and the loss of our ability to participate in federal and state reimbursement programs. Additionally, in the future, different interpretations or enforcement of these laws and regulations could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses.

As discussed in greater detail in Item 1., under Government Regulation, we are subject to federal and state laws intended to prevent healthcare fraud and abuse, including the federal FCA, state false claims acts, the illegal remuneration provisions of the Social Security Act, the AKS, state anti-kickback laws, the Civil Monetary Penalties Law and the federal “Stark” Law. Among other things, these laws prohibit kickbacks, bribes and rebates, as well as other direct and indirect payments or fee-splitting arrangements that are designed to induce the referral of patients to a particular provider for medical products or services payable by any federal healthcare program and prohibit presenting a false or misleading claim for payment under a federal or state program. They also prohibit some physician self-referrals. Possible sanctions for violation of any of these restrictions or prohibitions include loss of eligibility to participate in federal and state reimbursement programs and civil and criminal penalties. If we fail to comply, even inadvertently, with any of these requirements, we could be required to alter our operations, refund payments to the government, enter into a corporate integrity agreement, deferred prosecution or similar agreements with state or federal government agencies, and become subject to significant civil and criminal penalties.

These anti-fraud and abuse laws and regulations are complex, and we do not always have the benefit of significant regulatory or judicial interpretation of these laws and regulations. While we do not believe we are in violation of these prohibitions, we cannot assure you that governmental officials charged with the responsibility for enforcing these prohibitions will not assert that we are violating the provisions of such laws and regulations. Our company is currently aware of an investigation by the DOJ related to allegations some of our California facilities may have violated the FCA or the AKS with respect to the relationships between certain of our SNFs and persons who served as medical directors, advisory board participants or other referral sources. While our operating entities maintain policies and procedures to promote compliance with the FCA, the AKS, and other applicable regulatory requirements, we cannot predict when the investigation will be resolved, the outcome of the investigation or its potential impact on our company.


41

We are unable to predict the future course of federal, state and local regulation or legislation, including Medicare and Medicaid statutes and regulations related to fraud and abuse, the intensity of federal and state enforcement actions or the extent and size of any potential sanctions, fines or penalties. Changes in the regulatory framework, our failure to obtain or renew required regulatory approvals or licenses or to comply with applicable regulatory requirements, the suspension or revocation of our licenses or our disqualification from participation in federal and state reimbursement programs, or the imposition of other enforcement sanctions, fines or penalties could have a material adverse effect upon our business, financial condition or results of operations. Furthermore, should we lose licenses or certifications for a number of our facilities or other businesses as a result of regulatory action or legal proceedings, we could be deemed to be in default under some of our agreements, including agreements governing outstanding indebtedness.
Public and government calls for increased survey and enforcement efforts toward LTC facilities, and potential rulemaking that may result in enhanced enforcement and penalties, could result in increased scrutiny by state and federal survey agencies. In addition, potential sanctions and remedies based upon alleged regulatory deficiencies could negatively affect our financial condition and results of operations.

As CMS turns its attention to enhancing enforcement activities towards LTC facilities, as discussed in Item 1., under Government Regulation, state survey agencies will have more accountability for their survey and enforcement efforts. The Administration’s fact sheet regarding enhanced penalties against SFFs, discussed in greater length within that section, represents further federal calls for oversight and penalties for low-ranked and underperforming LTC facilities. This fact sheet precedes greater focus by CMS in obtaining oversight over SFFs, and continuing that oversight even after those SFFs improve, and subjecting them to more exacting and routine oversight. The likely result may be more frequent surveys of our affiliated facilities, with more substantial penalties, fines and consequences if they do not perform well. For low-performing facilities in the SFF program, the standards for successfully emerging from that program and not being subject to ongoing and enhanced government oversight will be higher and measured over a longer period of time, prolonging the risks of monetary penalties, fines and potential suspension or exclusion from the Medicare and Medicaid programs.

As discussed in Item 1., under Government Regulation, from time to time in the ordinary course of business, we receive deficiency reports from state and federal regulatory bodies resulting from such inspections or surveys. The focus of these deficiency reports tends to vary from year to year and state to state. Based on its October 2022 guidance, CMS and its state surveyors will place greater emphasis on COVID-19 vaccination reporting and will potentially assess penalties for failing to comply with vaccination administration and reporting obligations. Although most inspection deficiencies are resolved through an agreed-upon plan of corrective action, the reviewing agency typically has the authority to take further action against a licensed or certified facility, which could result in the imposition of fines, imposition of a license to a conditional or provisional status, suspension or revocation of a license, suspension or denial of payment for new admissions, loss of certification as a provider under state or federal healthcare programs, or imposition of other sanctions, including criminal penalties. In the past, we have experienced inspection deficiencies that have resulted in the imposition of a provisional license and could experience these results in the future.

Furthermore, in some states, citation of one affiliated facility could negatively impact other affiliated facilities in the same state. Revocation of a license at a given facility could therefore impair our ability to obtain new licenses or to renew, or maintain, existing licenses at other facilities, which may also trigger defaults or cross-defaults under our leases and our credit arrangements, or adversely affect our ability to operate or obtain financing in the future. If state or federal regulators were to determine, formally or otherwise, that one facility's regulatory history ought to impact another of our existing or prospective facilities, this could also increase costs, result in increased scrutiny by state and federal survey agencies, and even impact our expansion plans. Therefore, our failure to comply with applicable legal and regulatory requirements in any single facility could negatively impact our financial condition and overall of operations results.

From time to time, we have opted to voluntarily stop accepting new patients pending completion of a new state survey, in order to avoid possible denial of payment for new admissions during the deficiency cure period, or simply to avoid straining staff and other resources while retraining staff, upgrading operating systems or making other operational improvements. If we elect to voluntary close any operations in the future or to opt to stop accepting new patients pending completion of a state or federal survey, it could negatively impact our financial condition and results of operation.

We have received notices of potential sanctions and remedies based upon alleged regulatory deficiencies from time to time, and such sanctions have been imposed on some of our affiliated facilities. We have had affiliated facilities placed on special focus facility status in the past, continue to have some facilities on this status currently and other operating subsidiaries may be identified for such status in the future. We currently have no facilities placed on special focus facility status.
42

Future cost containment initiatives undertaken by private third-party payors may limit our revenue and profitability.

Our non-Medicare and non-Medicaid revenue and profitability are affected by continuing efforts of third-party payors to maintain or reduce costs of healthcare by lowering payment rates, narrowing the scope of covered services, increasing case management review of services and negotiating pricing. In addition, sustained unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced payment rates. There can be no assurance that third party payors will make timely payments for our services, or that we will continue to maintain our current payor or revenue mix. Trade publications within the healthcare industry have reported on the trend of payors using the No Surprises Act as a means to force re-negotiation of reimbursement rates for providers and facilities, and this trend has led to ongoing litigation between these providers and/or facilities against payors. Although the services provided in our business generally are outside the scope of the No Surprises Act, subsequent rulemaking and potentially aggressive behaviors by payors may pose a risk to our business. We are continuing our efforts to develop our non-Medicare and non-Medicaid sources of revenue and any changes in payment levels from current or future third-party payors could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.
Changes in Medicare reimbursements for physician and non-physician services could impact reimbursement for medical professionals.

As discussed in greater detail in Item 1., under Government Regulation, MACRA revised the payment system for physician and non-physician services. Section 1 of that law, the sustainable growth rate repeal and Medicare Provider Payment Modernization will impact payment provisions for medical professional services. That enactment also extended for two years provisions that permit an exceptions process from therapy caps imposed on Medicare Part B outpatient therapy. There was a combined cap for PT and SLP and a separate cap for OT services that apply subject to certain exceptions. On February 9, 2018, the BBA was signed into law, which provides for the repeal of all therapy caps retroactively to January 1, 2018. The law also reduced the monetary threshold that triggers a manual medical review (MMR), in certain instances through 2028. The reduction in the MMR threshold will likely result in increased number of reviews for the foreseeable future, which could in turn have a negative effect on our business, financial condition or results of operations. 
We may be subject to increased investigation and enforcement activities related to HIPAA violations.

We are required to comply with numerous legislative and regulatory requirements at the federal and state levels addressing patient privacy and security of health information, as discussed in greater detail in Item 1., under Government Regulation. HIPAA, as amended by the HITECH Act, requires us to adopt and maintain business procedures and systems designed to protect the privacy, security and integrity of patients' individual health information. States also have laws that apply to the privacy of healthcare information. We must comply with these state privacy laws to the extent that they are more protective of healthcare information or provide additional protections not afforded by HIPAA. If we fail to comply with these state and federal laws, we could be subject to criminal penalties, civil sanctions, litigation, and be forced to modify our policies and procedures. Additionally, if a breach under HIPAA or other privacy laws were to occur, remediation efforts could be costly and damage to our reputation could occur.

In addition to breaches of protected patient information, under HIPAA and the 21st Century Cures Act (Cures Act), healthcare entities are also required to afford patients with certain rights of access to their health information. Recently, the Office of Civil Rights, the agency responsible for HIPAA enforcement, has targeted investigative and enforcement efforts on violations of patients’ rights of access, imposing significant fines for violations largely initiated from patient complaints. If we fail to comply with our obligations under HIPAA, we could face significant fines. Likewise, if we fail to comply with our obligations under the Cures Act, we could face fines from the Office of the National Coordinator for Health Information Technology, the agency responsible for Cures Act enforcement.

43

Security breaches and other cyber-security incidents could violate security laws and subject us to significant liability.

Healthcare businesses are increasingly the target of cyberattacks whereby hackers disrupt business operations or obtain protected health information, often demanding large ransoms. In 2021 alone, the healthcare sector saw a 45% increase in ransomware attacks, with the average cost to remediate being over $1 million per incident. Our business is dependent on the proper functioning and availability of our computer systems and networks. While we have taken steps to protect the safety and security of our information systems and the patient health information and other data maintained within those systems, we cannot assure you that our safety and security measures and disaster recovery plan will prevent damage, interruption or breach of our information systems and operations. Additionally, we cannot control the safety and security of our information held by third-party vendors with whom we contract. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may be difficult to detect, we (or third-party vendors) may be unable to anticipate these techniques or implement adequate preventive measures. In addition, hardware, software or applications we (or third-party vendors) develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of information systems. Unauthorized parties may attempt to gain access to our systems or facilities, or those of third parties with whom we do business, through fraud or other forms of deceiving our employees or contractors.

On occasion, we have acquired additional information systems through our business acquisitions, and these acquired systems may expose us to risk. We also license certain third-party software to support our operations and information systems. Our inability, or the inability of third-party vendors, to continue to maintain and upgrade information systems and software could disrupt or reduce the efficiency of our operations. In addition, costs and potential problems and interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or adequate support of existing systems also could disrupt or reduce the efficiency of our operations.

A cyber-attack or other incident that bypasses our information systems security could cause a security breach which may lead to a material disruption to our information systems infrastructure or business, significant costs to remediate (e.g., payment to cyber attackers to recover our data) and may involve a significant loss of business or patient health information. If a cyber-attack or other unauthorized attempt to access our systems or facilities were to be successful, it could result in the theft, destruction, loss, misappropriation or release of confidential information or intellectual property, and could cause operational or business delays that may materially impact our ability to provide various healthcare services. Any successful cyber-attack or other unauthorized attempt to access our systems or facilities also could result in negative publicity which could damage our reputation or brand with our patients, referral sources, payors or other third parties and could subject us to a number of adverse consequences, the vast majority of which are not insurable, including but not limited to significant payment to cyber attackers to recover data, disruptions in our operations, regulatory and other civil and criminal penalties, fines, investigations and enforcement actions (including, but not limited to, those arising from the SEC, Federal Trade Commission, Office of Civil Rights, the OIG or state attorneys general), fines, private litigation with those affected by the data breach, loss of customers, disputes with payors and increased operating expense, which either individually or in the aggregate could have a material adverse effect on our business, financial position, results of operations and liquidity.
We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations.

SNFs are required to perform consolidated billing for certain items and services furnished to patients and residents. The consolidated billing requirement essentially confers on the SNF itself the Medicare billing responsibility for the entire package of care that its patients receive in these situations. The BBA also affected SNF payments by requiring that post-hospitalization skilled nursing services be “bundled” into the hospital's diagnostic related group (DRG) payment in certain circumstances. Where this rule applies, the hospital and the SNF must, in effect, divide the payment which otherwise would have been paid to the hospital alone for the patient's treatment, and no additional funds are paid by Medicare for skilled nursing care of the patient. Although this provision applies to a limited number of DRGs, it has a negative effect on SNF utilization and payments, either because hospitals are finding it difficult to place patients in SNFs which will not be paid as before or because hospitals are reluctant to discharge the patients to SNFs and lose part of their payment. This bundling requirement could be extended to more DRGs in the future, which would accentuate the negative impact on SNF utilization and payments. We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations.

44

Increased competition for, or a shortage of, nurses and other skilled personnel could increase our staffing and labor costs and subject us to monetary fines.

Our success depends upon our ability to retain and attract nurses and other skilled personnel, such as Certified Nurse Assistants, social workers and speech, physical and occupational therapists. Our success also depends upon our ability to retain and attract skilled management personnel who are responsible for the day-to-day operations of each of our affiliated facilities. Each facility has a facility leader responsible for the overall day-to-day operations of the facility, including quality of care, social services and financial performance. Depending upon the size of the facility, each facility leader is supported by facility staff that is directly responsible for day-to-day care of the patients and marketing and community outreach programs. Other key positions supporting each facility may include individuals responsible for physical, occupational and speech therapy, food service and maintenance. We compete with various healthcare service providers, including other skilled nursing providers, in retaining and attracting qualified and skilled personnel.

We operate one or more affiliated SNFs in the states of Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. With the exception of Utah, which follows federal regulations, each of these states has established minimum staffing requirements for facilities operating in that state. Failure to comply with these requirements can, among other things, jeopardize a facility's compliance with the conditions of participation under relevant state and federal healthcare programs. In addition, if a facility is determined to be out of compliance with these requirements, it may be subject to a notice of deficiency, a citation, or a significant fine or litigation risk. Deficiencies (depending on the level) may also result in the suspension of patient admissions and the termination of Medicaid participation, or the suspension, revocation or non-renewal of the SNF's license. If the federal or state governments were to issue regulations which materially change the way compliance with the minimum staffing standard is calculated or enforced, our labor costs could increase and the current shortage of healthcare workers could impact us more significantly, including the increased scrutiny on staffing at the state and federal levels as a result of the COVID-19 virus. The broader labor market where we compete is in a unique state of disequilibrium where the needs of businesses such as ours outstrip the supply of available and willing workers. There is additional upward pressure on wages from different industries and more generally due to the reported rate of inflation for the preceding 12 months. Some of these industries compete with us for labor and others that do not, which makes it difficult to make significant hourly wage and salary increases due to the fixed nature of our reimbursement under insurance contracts as well as Medicare and Medicaid, in addition to our increasing variable costs. Due to the limited supply of qualified applicants who seek or are willing to accept employment, these broader concerns, as well as those specific to both federal COVID-19 vaccination mandates and existing state mandates, may increase our labor costs or lead to potential staffing shortages, reduced operations to comply with applicable laws and regulations, or difficulty complying with those laws and regulations at current operational levels.

Federal laws and regulations may increase our costs of maintaining qualified nursing and skilled personnel, or make it more difficult for us to attract or retain qualified nurses and skilled staff members. The proposed Nursing Home Improvement Act, if passed into law in substantially the same form as the proposed bill, may increase our responsibility to provide nursing coverage and the costs associated with that increased coverage. There has been an increase in the Administration's desire to have HHS and CMS study staffing level requirements for the nursing home industry and to tie Medicare and Medicaid reimbursement to the salary, benefits, and retention of staff. CMS has published guidance to surveyors addressing topics that specifically include nurse staffing and collection of payroll data to evaluate appropriate staffing levels, requiring the use of masks and face coverings by staff and testing of nursing home staff and residents regardless of COVID-19 vaccination status, emphasizing the scope of information to be gathered from and reported by facilities, including SNFs and LTC facilities and emphasizing the penalties for non-compliance, as well as the obligations of facilities seeking to demonstrate their corrective actions. These requirements may also increase our operating costs and require additional compensation to be paid to employees in the form of wages and benefits. We are monitoring our facilities for potential effects from CMS's IFR requiring employees of Medicare and Medicaid-participating medical facilities to be vaccinated, which may cause disruption to our affiliated facilities’ nursing staff and may additionally disrupt our operations if affected personnel decline to be vaccinated and replacement staffing cannot be located.


45

Similar state-level requirements in the states where our affiliated SNFs operate, whether such requirements are passed by statute, regulation, or executive order, may result in a shortage or inability to obtain nurses and skilled staff. As noted above, California, Washington, and Colorado have all mandated vaccinations for workers in health care facilities that include nursing homes. These administrative mandates precede, may be more restrictive than and are not likely to be preempted by CMS's IFR. As of July 14, 2022, however, Colorado’s Board of Health allowed its emergency rule requiring all healthcare workers be vaccinated against COVID-19 to expire, other than those working within Medicare and Medicaid-certified facilities. At this time, state vaccine mandates, including their status and enforcement, continues to be an area that varies widely from state to state, and as seen by Colorado permitting its mandate to expire, is subject to ongoing change. While federal litigation over the COVID-19 vaccination IFR has concluded, federal enforcement of this IFR remains an enforcement priority and could subject our affiliated SNFs to scrutiny and potential fines, penalties, and other consequences for non-compliance up to and including suspension or termination of their authorization to operate. State survey authorities that are tasked with enforcing their own state’s mandate have similar powers to screen for compliance and impose fines and penalties for non-compliance, including suspension or termination of operating licenses.

Increased competition for, or a shortage of, nurses or other trained personnel, or general ongoing inflationary pressures may require that we enhance our pay and benefits packages to compete effectively for such personnel. We may not be able to offset such added costs by increasing the rates we charge to the patients of our operating subsidiaries. Turnover rates and the magnitude of the shortage of nurses or other trained personnel vary substantially from facility to facility. An increase in costs associated with, or a shortage of, skilled nurses, could negatively impact our business. In addition, if we fail to attract and retain qualified and skilled personnel, our ability to conduct our business operations effectively could be harmed. Additionally, turnover in nursing staff, particularly among registered nurses, may adversely affect us and the ratings of the facilities we operate under the new five-star measurement formulation used by the Nursing Home Compare website, when quality measure thresholds were increased, making it more difficult for our affiliated SNFs to obtain the highest scores.
Annual caps and other cost-reductions for outpatient therapy services may reduce our future revenue and profitability or cause us to incur losses.

As discussed in detail in Item 1., under Government Regulation, sub-heading Part B Rehabilitation Requirements, several government actions have been taken in recent years to try and contain the costs of rehabilitation therapy services provided under Medicare Part B, including the MPPR, institution of annual caps, mandatory medical reviews for annual claims beyond a certain monetary threshold, and a reduction in reimbursement rates for therapy assistant claim modifiers. Of specific concern has been CMS's decision to lower Medicare Part B reimbursement rates for outpatient therapy services by 9%, beginning on January 1, 2021. These reductions continued in 2022 and are expected to continue in 2023 pursuant to the 2023 PFS final rule. Such cost-containment measures and ongoing payment changes could have an adverse effect on our revenue.
The Office of the Inspector General or other regulatory authorities may choose to more closely scrutinize billing practices in areas where we operate or propose to expand, which could result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.

As discussed in greater detail in Item 1., under Government Regulation, Civil and Criminal Fraud and Abuse Laws and Enforcement, the OIG regularly conducts investigations regarding certain payment or compliance issues within various healthcare sectors. Following these investigations, the OIG publishes reports, in part, to educate involved stakeholders and signal future enforcement focus. Reports published in 2019 and 2020 demonstrate the OIG’s increased scrutiny on post-hospital SNF care and continues to identify SNF compliance as an issue in its 2021 and 2022 semi-annual reports to Congress. This may impact the SNF industry by motivating additional reviews and stricter compliance in the areas outlined in the recent reports, expending material time and resources. Recent publications and statements by the Administration have also called for greater scrutiny of SNF and LTC facilities based on OIG's 2022 findings that these facilities did not implement appropriate infection control measures during the COVID-19 pandemic, and calling for more authorities to impose penalties and other remedies on facilities that violate federal laws and regulations.


46

Additionally, OIG reports published in 2010 and 2015 show the OIG’s concerns related to the billing practices of SNFs based on Medicare Part A claims and financial incentives for facilities to bill for higher levels of therapies, even when not needed by patients. In its fiscal year 2014 work plan, and again in 2017, OIG specifically stated that it will continue to study and report on questionable Part A and Part B billing practices amongst SNFs. Recently, in its 2021 work plan, OIG stated it will evaluate whether payments to SNFs under PDPM complied with Medicare requirements. OIG’s 2022 work plan states it will use a series of audits to confirm compliance with COVID-19 vaccination requirements for LTC facility staff and will study nursing home emergency preparedness—particularly with managing resident care and collaborating with other health care providers. The study findings of nursing home emergency preparedness will be used to develop a key performance indicator to track challenges faced by nursing homes over time. On May 19, 2022, the OIG updated its Nursing Homes webpage, stating its key goals for nursing home oversight were (1) to protect residents from fraud, abuse and neglect, and to promote quality of resident care; (2) promote emergency preparedness and response efforts; and (3) to strengthen frontline oversight. Each of these priorities could signal an increased focus on compliance with the Requirements of Participation and other laws and regulations applicable to SNF and LTC facilities. OIG last updated its website regarding nursing homes in November of 2022, noting that an additional purpose of OIG’s mission was to support the federal monitoring of nursing homes to mitigate risks to residents.

Our business model, like those of some other for-profit operators, is based in part on seeking out higher-acuity patients whom we believe are generally more profitable, and over time our overall patient mix has consistently shifted to higher-acuity and higher-resource utilization patients in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording activities of daily living services, among other things. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others.
State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.

Some states require healthcare providers, including SNFs, to obtain prior approval, known as a certificate of need, for: (i) the purchase, construction or expansion of healthcare facilities; (ii) capital expenditures exceeding a prescribed amount; or (iii) changes in services or bed capacity.

In addition, other states that do not require certificates of need have effectively barred the expansion of existing facilities and the establishment of new ones by placing partial or complete moratoria on the number of new Medicaid beds they will certify in certain areas or in the entire state. Other states have established such stringent development standards and approval procedures for constructing new healthcare facilities that the construction of new facilities, or the expansion or renovation of existing facilities, may become cost-prohibitive or extremely time-consuming. In addition, some states require the approval of the state Attorney General for acquisition of a facility being operated by a non-profit organization.

Our ability to acquire or construct new facilities or expand or provide new services at existing facilities would be adversely affected if we are unable to obtain the necessary approvals, if there are changes in the standards applicable to those approvals, or if we experience delays and increased expenses associated with obtaining those approvals. We may not be able to obtain licensure, certificate of need approval, Medicaid certification, state Attorney General approval or other necessary approvals for future expansion projects. Conversely, the elimination or reduction of state regulations that limit the construction, expansion or renovation of new or existing facilities could result in increased competition to us or result in overbuilding of facilities in some of our markets. If overbuilding in the skilled nursing industry in the markets in which we operate were to occur, it could reduce the occupancy rates of existing facilities and, in some cases, might reduce the private rates that we charge for our services.

Newly enacted legislation in the States where our independently operating entities are located may impact the volume of cases filed and the overall cost of those cases from a defense and indemnity standpoint.

For example, AB 35 in the State of California was recently signed into law, which increases the cap of non-economic damages awarded to plaintiffs who are successful in medical malpractice litigation. The cap increases from $0.25 million to $0.35 million beginning on January 1, 2023, with incremental increases over the following 10 years until the cap reaches a maximum of $0.75 million. In wrongful death cases, the cap increases from $0.25 million to $0.5 million on January 1, 2023, with incremental increases over the following 10 years until the cap reaches a maximum of $1 million. Due to the influence of California on other states, other jurisdictions where we operate may enact similar laws and increase their current limits on damages in medical malpractice litigation depending on the outcomes of upcoming elections.

47

Additionally, California’s adoption of AB 1502, discussed in Item 1., Government Regulation, imposes new requirements for obtaining licenses to operate SNFs. These new requirements may delay the ability to obtain new SNF licenses within that state, whether through acquisition of existing facilities or opening a new facility. The additional background research that California’s Department of Public Health is required to engage in may increase the costs of obtaining licensure, make applications more time-consuming and complex, and may result in civil penalties and other sanctions against our affiliated facilities in the event they are not compliant with these new licensure application requirements. As a result, this new law may delay or impede growth within California. As with AB 35, California’s influence on other states may result in this legislation becoming a model for other states and having similar, potentially adverse effects within those jurisdictions as well.
Changes to federal and state employment-related laws and regulations could increase our cost of doing business.

Our operating subsidiaries are subject to a variety of federal and state employment-related laws and regulations, including, but not limited to, the U.S. Fair Labor Standards Act which governs such matters as minimum wages, overtime and other working conditions, the ADA and similar state laws that provide civil rights protections to individuals with disabilities in the context of employment, public accommodations and other areas, the National Labor Relations Act, regulations of the EEOC, regulations of the Office of Civil Rights, regulations of state attorney generals, family leave mandates and a variety of similar laws enacted by the federal and state governments that govern these and other employment law matters.

On November 17, 2022, a coalition of 22 states formally called on the Biden-Harris administration to withdraw its vaccine mandate for healthcare workers and all related guidance. Other than this petition, the uncertain environment regarding COVID-19 vaccination mandates and potential attempts to enforce similar mandates in 2022 appear to have concluded and there is no nationally significant litigation concerning such mandates. Nonetheless, the possibility of future or related action regarding COVID-19 vaccination mandates is one we are monitoring, as it represents a risk of uncertainty to the Company that may result in limitations on staff availability, disruption caused by staff departure, potential claims under the ADA and other laws and potential government sanctions which could cause disruptions to the operations of our subsidiaries, limit our ability to grow and otherwise adversely affect our business and financial results. Furthermore, the Administration has requested HHS and CMS study and issue proposed rules regarding the sustainability of care-based careers, including improving access to training, increasing the attractiveness of compensation in care-based positions, and improving the retention and career progression of care workers. The Administration has sought proposed rules that tie some of these issues, such as wages and retention, to Medicare reimbursement for facilities. Rising operating costs due to labor shortages, greater compensation and incentives required to attract and retain qualified personnel and higher-than-usual inflation on items including energy, utilities, food and other goods used in our facilities and the costs for transporting these items could increase our cost and decrease our profits.

The compliance costs associated with these laws and evolving regulations could be substantial. For example, all of our affiliated facilities are required to comply with the ADA. The ADA has separate compliance requirements for “public accommodations” and “commercial properties,” but generally requires that buildings be made accessible to people with disabilities. Compliance with ADA requirements could require removal of access barriers and non-compliance could result in imposition of government fines or an award of damages to private litigants. Further legislation may impose additional burdens or restrictions with respect to access by disabled persons. In addition, federal proposals to introduce a system of mandated health insurance and flexible work time and other similar initiatives could, if implemented, adversely affect our operations. We also may be subject to employee-related claims such as wrongful discharge, discrimination or violation of equal employment law. While we are insured for these types of claims, we could be subject to damages that are not covered by our insurance policies or that exceed our insurance limits, and we may be required to pay such damages directly, which would negatively impact our cash flow from operations.
Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.

The operations of our operating subsidiaries must be licensed under applicable state law and, depending upon the type of operation, certified or approved as providers under the Medicare and/or Medicaid programs. In the process of acquiring or transferring operating assets, our operations must receive change of ownership approvals from state licensing agencies, Medicare and Medicaid as well as third party payors. The Administration has requested HHS and CMS issue proposed rules that may increase the scrutiny placed on companies that operate, directly or indirectly, multiple SNF and LTC facilities, and may subject our licensing and approval process to additional scrutiny or delays if such proposals are codified into regulations. If there are any delays in receiving regulatory approvals from the applicable federal, state or local government agencies, or the inability to receive such approvals, such delays could result in delayed or lost reimbursement related to periods of service prior to the receipt of such approvals, which could negatively impact our cash position.
48

Compliance with federal and state fair housing, fire, safety and other regulations may require us to make unanticipated expenditures, which could be costly to us.

We must comply with the federal Fair Housing Act and similar state laws, which prohibit us from discriminating against individuals if it would cause such individuals to face barriers in gaining residency in any of our affiliated facilities. Additionally, the Fair Housing Act and other similar state laws require that we advertise our services in such a way that we promote diversity and not limit it. We may be required, among other things, to change our marketing techniques to comply with these requirements.

In addition, we are required to operate our affiliated facilities in compliance with applicable fire and safety regulations, building codes and other land use regulations and food licensing or certification requirements as they may be adopted by governmental agencies and bodies from time to time. Like other healthcare facilities, our affiliated SNFs are subject to periodic surveys or inspections by governmental authorities to assess and assure compliance with regulatory requirements. Surveys occur on a regular (often annual or biannual) schedule, and special surveys may result from a specific complaint filed by a patient, a family member or one of our competitors. We may be required to make substantial capital expenditures to comply with these requirements.
We depend largely upon reimbursement from third-party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our affiliated facilities as well as payor mix and payment methodologies.

Our revenue is affected by the percentage of the patients of our operating subsidiaries who require a high level of skilled nursing and rehabilitative care, whom we refer to as high acuity patients, and by our mix of payment sources. Changes in the acuity level of patients we attract, as well as our payor mix among Medicaid, Medicare, private payors and managed care companies, significantly affect our profitability because we generally receive higher reimbursement rates for high acuity patients and because the payors reimburse us at different rates. For the years ended December 31, 2022 and 2021, 73.7% and 73.6%, of our revenue was provided by government payors that reimburse us at predetermined rates, respectively. If our labor or other operating costs increase, we will be unable to recover such increased costs from government payors. Accordingly, if we fail to maintain our proportion of high acuity patients or if there is any significant increase in the percentage of the patients of our operating subsidiaries for whom we receive Medicaid reimbursement, our results of operations may be adversely affected.

Initiatives undertaken by major insurers and managed care companies to contain healthcare costs may adversely affect our business. Among other initiatives, these payors attempt to control healthcare costs by contracting with healthcare providers to obtain services on a discounted basis. We believe that this trend will continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce the amounts they pay for services, we may lose patients if we choose not to renew our contracts with these insurers at lower rates. Additionally, trade publications within the healthcare industry have reported on the recent trend of payors using the No Surprises Act as a means to force re-negotiation of reimbursement rates for providers and facilities. This trend has led to ongoing litigation between these providers and/or facilities against payors and it may adversely affect us as well.

On November 5, 2021, CMS issued the IFR discussed under Item 1., Government Regulation, subheading Coronavirus requiring all eligible staff to be fully vaccinated against COVID-19. CMS has been empowered to enforce the IFR nationwide and require compliance with its vaccination requirements since March 21, 2022.

In the event we or our affiliated facilities do not comply with the IFR, our Medicare and Medicaid agreements could be terminated and the termination of those agreements may lead to other payors terminating their agreements with us or our affiliated facilities and operating subsidiaries, which would materially and adversely affect our business, financial condition and results of operations.

In addition to the IFR, the Administration has requested HHS and CMS conduct studies about additional requirements pertaining to staffing, data reporting, employee compensation and retention, and resident experience that may result in a reduction of our revenue from Medicare and Medicaid. CMS issued its first proposed rule seeking information regarding these priorities in 2022 and subsequently published requests for information from the public in the Federal Register to aid in ongoing or future studies and anticipated rulemaking. These study results may result in additional conditions of participation within those programs.

49

We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards.

The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents of our operating subsidiaries and the services we provide. The industry has experienced an increased trend in the number and severity of litigation claims, due in part to the number of large verdicts, including large punitive damage awards. These claims are filed based upon a wide variety of claims and theories, including deficiencies under conditions of participation under certain state and federal healthcare programs. Plaintiffs' attorneys have become increasingly more aggressive in their pursuit of claims against healthcare providers, including skilled nursing providers, employing a wide variety of advertising and solicitation activities to generate more claims. The increased caps on damages awarded in such actions, as discussed above, may trigger a larger number of these lawsuits against our independent operating subsidiaries in California and other states where we operate if they adopt similar legislation. The defense of lawsuits has in the past, and may in the future, result in significant legal costs, regardless of the outcome. Additionally, increases to the frequency and/or severity of losses from such claims and suits may result in increased liability insurance premiums or a decline in available insurance coverage levels, which could materially and adversely affect our business, financial condition and results of operations.

We have in the past been subject to class action litigation involving claims of violations of various regulatory requirements. While we have been able to settle these claims without an ongoing material adverse effect on our business, future claims could be brought that may materially affect our business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against us and other companies in our industry. For example, there has been a general increase in the number of wage and hour class action claims filed in several of the jurisdictions where we are present. Allegations typically include claimed failures to permit or properly compensate for meal and rest periods, or failure to pay for time worked. If there were a significant increase in the number of these claims against us or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, this could have a material adverse effect to our business, financial condition, results of operations and cash flows.

Beyond our skilled nursing business, we engage in numerous ancillary businesses through one or more of our subsidiaries. These ancillary businesses generally support and provide services complementary to our operations, including but not limited to non-emergent ground transportation for patients and residents of our facilities. Our ancillary businesses may also be the subject of claims, lawsuits, and regulatory oversight that are specific to the particular services they offer. Noncompliance with the laws and regulations that may apply to our ancillary businesses may result in fines, penalties, and civil claims paid by our affected independent subsidiaries. Specific to our non-emergent ground transportation business, the drivers employed by this business may be subject to additional state-specific regulations regarding working time allowed to be spent driving, waiting time, and break or rest periods, and violations of these rules may lead to regulatory fines, penalties, or claims to be paid to individual drivers, in addition to the general employment risks described above.

Our ancillary businesses also are susceptible to general liability claims based on facts and circumstances that are specific to their activities and operations. In the case of our non-emergent ground transportation business, this liability likely exists in the form of automobile-involved accidents, which may involve property, individuals, or other automobiles. The defense of automobile accident and general liability lawsuits relating to our ancillary businesses in the past, and may in the future, result in significant legal costs, regardless of the outcome. As our ancillary businesses grow, the independent subsidiaries may be subject to increased frequency and/or severity of losses from such claims and suits which may result in increased liability insurance premiums for those businesses or a decline in available insurance coverage levels, which could materially and adversely affect our business, financial condition and results of operations.

In addition, we contract with a variety of landlords, lenders, vendors, suppliers, consultants and other individuals and businesses. These contracts typically contain covenants and default provisions. If the other party to one or more of our contracts were to allege that we have violated the contract terms, we could be subject to civil liabilities which could have a material adverse effect on our financial condition and results of operations.

If litigation is instituted against one or more of our subsidiaries, a successful plaintiff might attempt to hold us or another subsidiary liable for the alleged wrongdoing of the subsidiary principally targeted by the litigation. If a court in such litigation decided to disregard the corporate form, the resulting judgment could increase our liability and adversely affect our financial condition and results of operations.


50

Congress has repeatedly considered, without passage, a bill that would require, among other things, that agreements to arbitrate nursing home disputes be made after the dispute has arisen rather than before prospective patients move in, to prevent nursing home operators and prospective patients from mutually entering into a pre-admission pre-dispute arbitration agreement. This bill, known as the Fairness in Nursing Home Arbitration Act, was introduced in the House of Representatives in 2021; as of December 31, 2022, neither bill made it out of the committees to which it was referred for discussion to be voted on by the entire House of Representatives. Our independently operating subsidiaries use arbitration agreements, which have generally been favored by the courts, to streamline the dispute resolution process and reduce our exposure to legal fees and excessive jury awards. CMS has identified these arbitration agreements as an area for further review and issued guidance to state surveyors regarding arbitration agreements and their requirements under federal regulations, with non-compliance potentially resulting in fines and other sanctions. If we are not able to secure pre-admission arbitration agreements, our litigation exposure and costs of defense in patient liability actions could increase, our liability insurance premiums could increase, and our business may be adversely affected.
We conduct regular internal investigations into the care delivery, recordkeeping and billing processes of our operating subsidiaries. These reviews sometimes detect instances of noncompliance which we attempt to correct, which can decrease our revenue.

As an operator of healthcare facilities, we have a program to help us comply with various requirements of federal and private healthcare programs. Our compliance program includes, among other things, (i) policies and procedures modeled after applicable laws, regulations, government manuals and industry practices and customs that govern the clinical, reimbursement and operational aspects of our subsidiaries; (ii) training about our compliance process for all of the employees of our operating subsidiaries, our directors and officers, and training about Medicare and Medicaid laws, fraud and abuse prevention, clinical standards and practices, and claim submission and reimbursement policies and procedures for appropriate employees; and (iii) internal controls that monitor, for example, the accuracy of claims, reimbursement submissions, cost reports and source documents, provision of patient care, services, and supplies as required by applicable standards and laws, accuracy of clinical assessment and treatment documentation, and implementation of judicial and regulatory requirements (i.e., background checks, licensing and training).

From time to time our systems and controls highlight potential compliance issues, which we investigate as they arise. Historically, we have, and would continue to do so in the future, initiated internal inquiries into possible recordkeeping and related irregularities at our affiliated SNFs, which were detected by our internal compliance team in the course of its ongoing reviews.

Through these internal inquiries, we have identified potential deficiencies in the assessment of and recordkeeping for small subsets of patients. We have also identified and, at the conclusion of such investigations, assisted in implementing, targeted improvements in the assessment and recordkeeping practices to make them consistent with the existing standards and policies applicable to our affiliated SNFs in these areas. We continue to monitor the measures implemented for effectiveness and perform follow-up reviews to ensure compliance. Consistent with healthcare industry accounting practices, we record any charge for refunded payments against revenue in the period in which the claim adjustment becomes known.

If additional reviews result in identification and quantification of additional amounts to be refunded, we will accrue additional liabilities for claim costs and interest, and repay any amounts due in normal course. Furthermore, failure to refund overpayments within required time frames (as described in greater detail above) could result in FCA liability. If future investigations ultimately result in findings of significant billing and reimbursement noncompliance which could require us to record significant additional provisions or remit payments, our business, financial condition and results of operations could be materially and adversely affected and our stock price could decline.
We may be unable to complete future facility or business acquisitions at attractive prices or at all, which may adversely affect our revenue; we may also elect to dispose of underperforming or non-strategic operating subsidiaries, which would also decrease our revenue.

To date, our revenue growth has been significantly impacted by our acquisition of new facilities and businesses. Subject to general market conditions and the availability of essential resources and leadership within our company, we continue to seek both single-and multi-facility acquisition and business acquisition opportunities that are consistent with our geographic, financial and operating objectives.


51

We face competition for the acquisition of facilities and businesses and expect this competition to increase. Based upon factors such as our ability to identify suitable acquisition candidates, future regulations affecting the ability to purchase facilities, the purchase price of the facilities, increasing interest rates for debt-financed purchases, prevailing market conditions, the availability of leadership to manage new facilities and our own willingness to take on new operations, the rate at which we have historically acquired facilities has fluctuated significantly. In the future, we anticipate the rate at which we may acquire facilities will continue to fluctuate, which may affect our revenue.

We have also historically acquired a few facilities, which were or have proven to be non-strategic or less desirable, and we may consider disposing of such facilities or exchanging them for facilities which are more desirable, either because they were included in larger, indivisible groups of facilities or under other circumstances. To the extent we dispose of such a facility without simultaneously acquiring a facility in exchange, our revenue may decrease.
We may not be able to successfully integrate acquired facilities and businesses into our operations, and we may not achieve the benefits we expect from any of our facility acquisitions.

We may not be able to successfully or efficiently integrate new acquisitions of facilities and businesses with our existing operating subsidiaries, culture and systems. The process of integrating acquisitions into our existing operations may result in unforeseen operating difficulties, divert management's attention from existing operations, or require an unexpected commitment of staff and financial resources, and may ultimately be unsuccessful. Existing operations available for acquisition frequently serve or target different markets than those that we currently serve. We also may determine that renovations of acquired facilities and changes in staff and operating management personnel are necessary to successfully integrate those acquisitions into our existing operations. We may not be able to recover the costs incurred to reposition or renovate newly operating subsidiaries. The financial benefits we expect to realize from many of our acquisitions are largely dependent upon our ability to improve clinical performance, overcome regulatory deficiencies, rehabilitate or improve the reputation of the operations in the community, increase and maintain occupancy, control costs, and in some cases change the patient acuity mix. If we are unable to accomplish any of these objectives at the operating subsidiaries we acquire, we will not realize the anticipated benefits and we may experience lower than anticipated profits, or even losses.

During the year ended December 31, 2022, we expanded our operations through a combination of long-term leases and real estate purchases, with the addition of twenty-three stand-alone skilled nursing operations and one campus operation. In addition, we added five senior living operations that were transferred from Pennant, three of which are part of campuses operated by our affiliated operating subsidiaries. This growth has placed and will continue to place significant demands on our current management resources. Our ability to manage our growth effectively and to successfully integrate new acquisitions into our existing business will require us to continue to expand our operational, financial and management information systems and to continue to retain, attract, train, motivate and manage key employees, including facility-level leaders and our local directors of nursing. We may not be successful in attracting qualified individuals necessary for future acquisitions to be successful, and our management team may expend significant time and energy working to attract qualified personnel to manage facilities we may acquire in the future. Also, the newly acquired facilities may require us to spend significant time improving services that have historically been substandard, and if we are unable to improve such facilities quickly enough, we may be subject to litigation and/or loss of licensure or certification. If we are not able to successfully overcome these and other integration challenges, we may not achieve the benefits we expect from any of our acquisitions, and our business may suffer.
In undertaking acquisitions, we may be adversely impacted by costs, liabilities and regulatory issues that may adversely affect our operations.

In undertaking acquisitions, we also may be adversely impacted by unforeseen liabilities attributable to the prior providers who operated those facilities, against whom we may have little or no recourse. Many facilities we have historically acquired were underperforming financially and had clinical and regulatory issues prior to and at the time of acquisition. Even where we have improved operating subsidiaries and patient care at affiliated facilities that we have acquired, we still may face post-acquisition regulatory issues related to pre-acquisition events. These may include, without limitation, payment recoupment related to our predecessors' prior noncompliance, the imposition of fines, penalties, operational restrictions or special regulatory status. Further, we may incur post-acquisition compliance risk due to the difficulty or impossibility of immediately or quickly bringing non-compliant facilities into full compliance. Diligence materials pertaining to acquisition targets, especially the underperforming facilities that often represent the greatest opportunity for return, are often inadequate, inaccurate or impossible to obtain, sometimes requiring us to make acquisition decisions with incomplete information. Despite our due diligence procedures, facilities that we have acquired or may acquire in the future may generate unexpectedly low returns, may cause us to incur substantial losses, may require unexpected levels of management time, expenditures or other resources, or may otherwise not meet a risk profile that our investors find acceptable.
52

In addition, we might encounter unanticipated difficulties and expenditures relating to any of the acquired facilities, including contingent liabilities. For example, when we acquire a facility, we generally assume the facility's existing Medicare provider number for purposes of billing Medicare for services. If CMS later determines that the prior owner of the facility had received overpayments from Medicare for the period of time during which it operated the facility, or had incurred fines in connection with the operation of the facility, CMS could hold us liable for repayment of the overpayments or fines. We may be unable to improve every facility that we acquire. In addition, operation of these facilities may divert management time and attention from other operations and priorities, negatively impact cash flows, result in adverse or unanticipated accounting charges, or otherwise damage other areas of our company if they are not timely and adequately improved.

We also incur regulatory risk in acquiring certain facilities due to the licensing, certification and other regulatory requirements affecting our right to operate the acquired facilities. For example, in order to acquire facilities on a predictable schedule, or to acquire declining operations quickly to prevent further pre-acquisition declines, we frequently acquire such facilities prior to receiving license approval or provider certification. Anticipated future regulations may cause delays in acquiring the required licenses and certifications, if it is possible to do so at all. We operate such facilities as the interim manager for the outgoing licensee, assuming financial responsibility, among other obligations for the facility. To the extent that we may be unable or delayed in obtaining a license, we may need to operate the facility under a management agreement from the prior operator. Any inability in obtaining consent from the prior operator of a target acquisition to utilizing its license in this manner could impact our ability to acquire additional facilities. If we were subsequently denied licensure or certification for any reason, we might not realize the expected benefits of the acquisition and would likely incur unanticipated costs and other challenges which could cause our business to suffer.
If we do not achieve or maintain competitive quality of care ratings from CMS or private organizations engaged in similar monitoring activities, our business may be negatively affected.

As discussed in Item 1., under Government Regulation, CMS, as well as certain private organizations engaged in similar monitoring activities, provides comparative public data, rating every SNF operating in each state based upon quality-of-care indicators. CMS’s system is the Five-Star Quality Rating System, intended to compare nursing homes more easily. The Five-Star Quality Rating System gives each nursing home a rating of between one and five stars in various categories, with five-star ratings harder to obtain over time. The ratings are available on a consumer-facing website, Nursing Home Compare. In cases of acquisitions, the previous operator's clinical ratings are included in our overall Five-Star Quality Rating. Based on CMS guidance issued in June of 2022, it is expected that more data will be collected by CMS and ultimately reported on the Nursing Home Compare website. Similarly, due to CMS's June 2022 guidance, we expect CMS will seek to make the data reported on the Nursing Home Compare website more readily accessible and understandable for consumers.

CMS continues to increase quality measure thresholds, making it more difficult to achieve upward and five-star ratings. Most recently, CMS increased its quality measure thresholds in October of 2022, making it more difficult for facilities to obtain or maintain four- and five-star ratings. CMS has indicated that it will increase these quality measure thresholds every six months. CMS acknowledges that some facilities may see a decline in their overall five-star rating absent any new inspection information. This is relevant to our business because the five-star ratings of our affiliated facilities may decline even as their quality measures remain unchanged, or even if their quality measures improve. This change could further affect star ratings across the industry. Additionally, on the Nursing Home Compare website, CMS recently began displaying a consumer alert icon next to nursing homes that have been cited on inspection reports for incidents of abuse, neglect, or exploitation. In July of 2022, CMS updated the scoring measures used for SNFs to include six dimensions of staffing and turnover, which may affect the rating of our facilities on the Nursing Home Compare website. CMS’s expanded evaluation and measurement of staffing and turnover, including measures of all nurses, registered nurses, and administrators, may adversely affect the scoring and evaluation of our facilities under CMS’s Five-Star Quality Rating System. See Item 1., under Government Regulation.

Providing quality patient care is the cornerstone of our business. We believe that hospitals, physicians and other referral sources refer patients to us in large part because of our reputation for delivering quality care. If we should fail to achieve our internal rating goals or fail to exceed the national average rating on the Five-Star Quality Rating System, including due to nursing and administrative staffing and turnover, or have facilities displaying a consumer alert icon for incidents of abuse, neglect, or exploitation, it may affect our ability to generate referrals, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.

53

If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected.

It may become more difficult and costly for us to obtain coverage for resident care liabilities and other risks, including property, automobile and casualty insurance. For example, the following circumstances may adversely affect our ability to obtain insurance at favorable rates:

we experience higher-than-expected professional liability, property and casualty, or other types of claims or losses;
we receive survey deficiencies or citations of higher-than-normal scope or severity;
we acquire especially troubled operations or facilities that present unattractive risks to current or prospective insurers;
insurers tighten underwriting standards applicable to us or our industry; or
insurers or reinsurers are unable or unwilling to insure us or the industry at historical premiums and coverage levels.

If any of these potential circumstances were to occur, our insurance carriers may require us to significantly increase our self-insured retention levels or pay substantially higher premiums for the same or reduced coverage for insurance, including workers compensation, property and casualty, automobile, employment practices liability, directors and officers liability, employee healthcare and general and professional liability coverages.

In some states, the law prohibits or limits insurance coverage for the risk of punitive damages arising from professional liability and general liability claims or litigation. Coverage for punitive damages is also excluded under some insurance policies. As a result, we may be liable for punitive damage awards in these states that either are not covered or are in excess of our insurance policy limits. Claims against us, regardless of their merit or eventual outcome, also could inhibit our ability to attract patients or expand our business and could require our management to devote time to matters unrelated to the day-to-day operation of our business.

With few exceptions, workers compensation and employee health insurance costs have also increased markedly in recent years. To partially offset these increases, we have increased the amounts of our self-insured retention and deductibles in connection with general and professional liability claims. We also have implemented a self-insurance program for workers compensation in all states, except Washington, and elected non-subscriber status for workers compensation in Texas. In Washington, the insurance coverage is financed through premiums paid by the employers and employees. Due to the nature of our business and the residents we serve, including the risk of claims from residents as well as potential governmental action, it may be difficult to complete the underwriting process and obtain insurance at commercially reasonable rates. If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, or if the coverage levels we can economically obtain decline, our business may be adversely affected.
Our self-insurance programs may expose us to significant and unexpected costs and losses.

We have maintained general and professional liability insurance since 2002 and workers compensation insurance since 2005 through a wholly-owned captive insurance subsidiary to insure our self-insurance reimbursements and deductibles as part of a continually evolving overall risk management strategy. We establish the insurance loss reserves based on an estimation process that uses information obtained from both company-specific and industry data. The estimation process requires us to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and our assumptions about emerging trends, we, along with an independent actuary, develop information about the size of ultimate claims based on our historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damages with respect to unpaid claims. It is possible, however, that the actual liabilities may exceed our estimates of loss. We may also experience an unexpectedly large number of successful claims or claims that result in costs or liability significantly in excess of our projections. For these and other reasons, our self-insurance reserves could prove to be inadequate, resulting in liabilities in excess of our available insurance and self-insurance. If a successful claim is made against us and it is not covered by our insurance or exceeds the insurance policy limits, our business may be negatively and materially impacted.

Further, because our self-insurance reimbursements under our general and professional liability and workers compensation programs applies on a per claim basis, there is no limit to the maximum number of claims or the total amount for which we could incur liability in any policy period.


54

We also self-insure our employee health benefits. With respect to our health benefits self-insurance, our reserves and premiums are computed based on a mix of company specific and general industry data that is not specific to our own company. Even with a combination of limited company-specific loss data and general industry data, our loss reserves are based on actuarial estimates that may not correlate to actual loss experience in the future. Therefore, our reserves may prove to be insufficient and we may be exposed to significant and unexpected losses.

The frequency and magnitude of claims and legal costs may increase due to the COVID-19 pandemic or our related response efforts.
The geographic concentration of our affiliated facilities could leave us vulnerable to an economic downturn, regulatory changes or acts of nature in those areas.

Our affiliated facilities located in Arizona, California, and Texas account for the majority of our total revenue. As a result of this concentration, the conditions of local economies, changes in governmental rules, regulations and reimbursement rates or criteria, changes in demographics, state funding, acts of nature and other factors that may result in a decrease in demand and/or reimbursement for skilled nursing services in these states could have a disproportionately adverse effect on our revenue, costs and results of operations. Moreover, since over 20% of our affiliated facilities are located in California, we are particularly susceptible to revenue loss, cost increase or damage caused by natural disasters such as electrical power shortages, fires, earthquakes or mudslides, or increased liabilities that may arise from regulations as discussed within Item 1., under Government Regulation.

In addition, our affiliated facilities in Iowa, Nebraska, Kansas, South Carolina, Washington and Texas are more susceptible to revenue loss, cost increases or damage caused by natural disasters including hurricanes, tornadoes and flooding. These acts of nature may cause disruption to us, the employees of our operating subsidiaries and our affiliated facilities, which could have an adverse impact on the patients of our operating subsidiaries and our business. In order to provide care for the patients of our operating subsidiaries, we are dependent on consistent and reliable delivery of food, pharmaceuticals, utilities and other goods to our affiliated facilities, and the availability of employees to provide services at our affiliated facilities. If the delivery of goods or the ability of employees to reach our affiliated facilities were interrupted in any material respect due to a natural disaster or other reasons, it would have a significant impact on our affiliated facilities and our business. Furthermore, the impact, or impending threat, of a natural disaster may require that we evacuate one or more facilities, which would be costly and would involve risks, including potentially fatal risks, for the patients. The impact of disasters and similar events is inherently uncertain. Such events could harm the patients and employees of our operating subsidiaries, severely damage or destroy one or more of our affiliated facilities, harm our business, reputation and financial performance, or otherwise cause our business to suffer in ways that we currently cannot predict.
The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability.

We continue to maintain our right to inform the employees of our operating subsidiaries about our views of the potential impact of unionization upon the workplace generally and upon individual employees. With one exception, to our knowledge the staff at our affiliated facilities that have been approached to unionize have uniformly rejected union organizing efforts. Forthcoming proposed rules from HHS and CMS, which, based on the Administration's statements and guidance since February of 2022, are anticipated within the next year, may increase the likelihood of employee unionization due to increased emphasis on care-based careers in SNFs and LTC facilities. If employees decide to unionize, our cost of doing business could increase, and we could experience contract delays, difficulty in adapting to a changing regulatory and economic environment, cultural conflicts between unionized and non-unionized employees, strikes and work stoppages, and we may conclude that affected facilities or operations would be uneconomical to continue operating.
Because we lease the majority of our affiliated facilities, we are subject to risks associated with leased real property, including risks relating to lease termination, lease extensions and special charges, any of which could adversely affect our business, financial position or results of operations.

As of December 31, 2022, we leased 192 of our 271 affiliated facilities. Most of our leases are triple-net leases, which means that, in addition to rent, we are required to pay for the costs related to the property (including property taxes, insurance, and maintenance and repair costs). We are responsible for paying these costs notwithstanding the fact that some of the benefits associated with paying these costs accrue to the landlords as owners of the associated facilities.

55

Each lease provides that the landlord may terminate the lease for a variety of reasons, including the default in any payment of rent, taxes or other payment obligations or the breach of any other covenant or agreement in the lease. Termination of a lease could result in a default under our debt agreements and could adversely affect our business, financial position or results of operations. There can be no assurance that we will be able to comply with all of our obligations under the leases in the future.
Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our operating subsidiaries and cause us to lose facilities or experience foreclosures.

Our Amended Credit Agreement provides for a Revolving Credit Facility with borrowing capacity of up to $600.0 million in aggregate principal amount. As of December 31, 2022 and through the filing of this report, we had no outstanding borrowings under our Revolving Credit Facility. Twenty-three of our subsidiaries have mortgage loans insured with Department of Housing and Urban Development (HUD) for an aggregate amount of $153.5 million, which subjects these subsidiaries to HUD oversight and periodic inspections. The terms of the mortgage loans range from 25- to 35-years.

We also have two outstanding promissory notes with an aggregate principal amount of approximately $2.8 million as of December 31, 2022. The term of the notes are 10 months and 12 years. Because this mortgage loan is insured with HUD, our borrower subsidiary under the loan is subject to HUD oversight and periodic inspections.

In addition, we had $2.2 billion of future operating lease obligations as of December 31, 2022. We intend to continue financing our operating subsidiaries through mortgage financing, long-term operating leases and other types of financing, including borrowings under our lines of credit and future credit facilities we may obtain.

We may not generate sufficient cash flow from operations to cover required interest, principal and lease payments. In addition, our outstanding Amended Credit Agreement and mortgage loans contain restrictive covenants and require us to maintain or satisfy specified coverage tests on a consolidated basis and on a facility or facilities basis. These restrictions and operating covenants include, among other things, requirements with respect to occupancy, debt service coverage, project yield, net leverage ratios, minimum interest coverage ratios and minimum asset coverage ratios. These restrictions may interfere with our ability to obtain additional advances under our Revolving Credit Facility or to obtain new financing or to engage in other business activities, which may inhibit our ability to grow our business and increase revenue.

From time to time, the financial performance of one or more of our mortgaged facilities may not comply with the required operating covenants under the terms of the mortgage. Any non-payment, noncompliance or other default under our financing arrangements could, subject to cure provisions, cause the lender to foreclose upon the facility or facilities securing such indebtedness or, in the case of a lease, cause the lessor to terminate the lease, each with a consequent loss of revenue and asset value to us or a loss of property. Furthermore, in many cases, indebtedness is secured by both a mortgage on one or more facilities, and a guaranty by us. In the event of a default under one of these scenarios, the lender could avoid judicial procedures required to foreclose on real property by declaring all amounts outstanding under the guaranty immediately due and payable, and requiring us to fulfill our obligations to make such payments. If any of these scenarios were to occur, our financial condition would be adversely affected. For tax purposes, a foreclosure on any of our properties would be treated as a sale of the property for a price equal to the outstanding balance of the debt secured by the mortgage. If the outstanding balance of the debt secured by the mortgage exceeds our tax basis in the property, we would recognize taxable income on foreclosure, but would not receive any cash proceeds, which would negatively impact our earnings and cash position. Further, because our mortgages and operating leases generally contain cross-default and cross-collateralization provisions, a default by us related to one facility could affect a significant number of other facilities and their corresponding financing arrangements and operating leases.

56

Because our term loans, promissory notes, bonds, mortgages and lease obligations are fixed expenses and secured by specific assets, and because our revolving loan obligations are secured by virtually all of our assets, if reimbursement rates, patient acuity mix or occupancy levels decline, or if for any reason we are unable to meet our loan or lease obligations, we may not be able to cover our costs and some or all of our assets may become at risk. Our ability to make payments of principal and interest on our indebtedness and to make lease payments on our operating leases depends upon our future performance, which will be subject to general economic conditions, industry cycles and financial, business and other factors affecting our operating subsidiaries, many of which are beyond our control. If we are unable to generate sufficient cash flow from operations in the future to service our debt or to make lease payments on our operating leases, we may be required, among other things, to seek additional financing in the debt or equity markets, refinance or restructure all or a portion of our indebtedness, sell selected assets, reduce or delay planned capital expenditures or delay or abandon desirable acquisitions. Such measures might not be sufficient to enable us to service our debt or to make lease payments on our operating leases. The failure to make required payments on our debt or operating leases or the delay or abandonment of our planned growth strategy could result in an adverse effect on our future ability to generate revenue and sustain profitability. In addition, any such financing, refinancing or sale of assets might not be available on terms that are economically favorable to us, or at all.
Move-in and occupancy rates may remain unpredictable even after the COVID-19 pandemic is over.

Occupancy levels at SNFs are likely to remain vulnerable to the effects of COVID-19 even after the pandemic is over. Facilities experiencing decreases in move-in rates in 2021 cite resident or family member concerns as the basis for such decreases. These and other similar concerns may continue to impact our ability to attract new residents and our ability to retain existing residents.
A housing downturn could decrease demand for senior living services.
Seniors often use the proceeds of home sales to fund their admission to senior living facilities. A downturn in the housing markets, including reductions in sales prices caused by increasing mortgage interest rates, could adversely affect seniors’ ability to afford our resident fees and entrance fees. If national or local housing markets enter a persistent decline, our occupancy rates, revenues, results of operations and cash flow could be negatively impacted.
As we continue to acquire and lease real estate assets, we may not be successful in identifying and consummating these transactions.

As part of, and subsequent to the spin-off transaction in 2019, we lease 29 of our properties to Pennant’s senior living operations. In the future, we might expand our leasing property portfolio to additional Pennant operations or other unaffiliated tenants. We have very limited control over the success or failure of our tenants’ and operators’ businesses and, at any time, a tenant or operator may experience a downturn in its business that weakens its financial condition. If that happens, the tenant or operator may fail to make its payments to us when due. Although our lease agreements give us the right to exercise certain remedies in the event of default on the obligations owing to us, we may determine not to do so if we believe that enforcement of our rights would be more detrimental to our business than seeking alternative approaches.

An important part of our business strategy is to continue to expand and diversify our real estate portfolio through accretive acquisition and investment opportunities in healthcare properties. Our execution of this strategy by successfully identifying, securing and consummating beneficial transactions is made more challenging by increased competition and can be affected by many factors, including our relationships with current and prospective tenants, our ability to obtain debt and equity capital at costs comparable to or better than our competitors and our ability to negotiate favorable terms with property owners seeking to sell and other contractual counterparties. Our competitors for these opportunities include healthcare REITs, real estate partnerships, healthcare providers, healthcare lenders and other investors, including developers, banks, insurance companies, pension funds, government-sponsored entities and private equity firms, some of whom may have greater financial resources and lower costs of capital than we do. Potential regulations may affect the ability of these entities, as well as ourselves, to compete for these opportunities or enter into transactions for real estate related to our business. If we are unsuccessful at identifying and capitalizing on investment or acquisition opportunities, our growth and profitability in our real estate investment portfolio may be adversely affected.

57

Investments in and acquisitions of healthcare properties entail risks associated with real estate investments generally, including risks that the investment will not achieve expected returns, that the cost estimates for necessary property improvements will prove inaccurate or that the tenant or operator will fail to meet performance expectations. Income from properties and yields from investments in our properties may be affected by many factors, including changes in governmental regulation (such as licensing and government payment), general or local economic conditions (such as fluctuations in interest rates, senior savings, and employment conditions), the available local supply of and demand for improved real estate, a reduction in rental income as the result of an inability to maintain occupancy levels, natural disasters (such as hurricanes, earthquakes and floods) or similar factors. Furthermore, healthcare properties are often highly customized, and the development or redevelopment of such properties may require costly tenant-specific improvements. As a result, we cannot assure you that we will achieve the economic benefit we expect from acquisition or investment opportunities.
As we expand our presence in other relevant healthcare industries, we would become subject to risks in a market in which we have limited experience.
The majority of our affiliated facilities have historically been SNFs. As we expand our presence in other relevant healthcare industries, our existing overall business model will continue to change and expose our company to risks in markets in which we have limited experience. We expect that we will have to adjust certain elements of our existing business model, which could have an adverse effect on our business.
If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease.
We rely significantly on appropriate referrals from physicians, hospitals and other healthcare providers in the communities in which we deliver our services to attract appropriate residents and patients to our affiliated facilities. Our referral sources are not obligated to refer business to us and may refer business to other healthcare providers. We believe many of our referral sources refer business to us as a result of the quality of our patient care and our efforts to establish and build a relationship with our referral sources. If we lose, or fail to maintain, existing relationships with our referral resources, fail to develop new relationships, or if we are perceived by our referral sources as not providing high quality patient care, our occupancy rate and the quality of our patient mix could suffer. In addition, if any of our referral sources have a reduction in patients whom they can refer due to a decrease in their business, our occupancy rate and the quality of our patient mix could suffer.
We may need additional capital to fund our operating subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow.
Our ability to maintain and enhance our operating subsidiaries and equipment in a suitable condition to meet regulatory standards, operate efficiently and remain competitive in our markets requires us to commit substantial resources to continued investment in our affiliated facilities and equipment. We are sometimes more aggressive than our competitors in capital spending to address issues that arise in connection with aging and obsolete facilities and equipment. In addition, continued expansion of our business through the acquisition of existing facilities, expansion of our existing facilities and construction of new facilities may require additional capital, particularly if we were to accelerate our acquisition and expansion plans. Financing may not be available to us or may be available to us only on terms that are not favorable, including being subject to interest rates that are higher than those incurred in the recent past. In addition, some of our outstanding indebtedness and long-term leases restrict, among other things, our ability to incur additional debt. If we are unable to raise additional funds or obtain additional funds on terms acceptable to us, we may have to delay or abandon some or all of our growth strategies. Further, if additional funds are raised through the issuance of additional equity securities, the percentage ownership of our stockholders would be diluted. Any newly issued equity securities may have rights, preferences or privileges senior to those of our common stock.

58

The condition of the financial markets, including volatility and deterioration in the capital and credit markets, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our current portfolio of cash, cash equivalents and investments, including U.S. Treasury securities and U.S.-backed investments.

Our cash, cash equivalents and investments are held in a variety of interest-bearing instruments, including U.S. treasury securities. As a result of the uncertain domestic and global political, economic, credit and financial market conditions, including the recent significant increase in the federal funds rate, an increase in the Consumer Price Index of seven percent in 2021, which has continued at a comparable rate for 2022, investments in these types of financial instruments pose risks arising from liquidity and credit concerns. Given that future deterioration in the U.S. and global credit and financial markets is a possibility, no assurance can be made that losses or significant deterioration in the fair value of our cash, cash equivalents, or investments will not occur. Uncertainty surrounding the trading market for U.S. government securities or impairment of the U.S. government's ability to satisfy its obligations under such treasury securities could impact the liquidity or valuation of our current portfolio of cash, cash equivalents, and investments, a substantial portion of which were invested in U.S. treasury securities. Further, continued domestic and international political uncertainty, along with credit, and financial market uncertainty, may make it difficult for us to liquidate our investments prior to their maturity without incurring a loss, which would have a material adverse effect on our consolidated financial position, results of operations or cash flows.
We may need additional capital if a substantial acquisition or other growth opportunity becomes available or if unexpected events occur or opportunities arise. U.S. capital markets can be volatile. We cannot assure you that additional capital will be available or available on terms acceptable to us. If capital is not available, we may not be able to fund internal or external business expansion or respond to competitive pressures or other market conditions.
Delays in reimbursement may cause liquidity problems.
If we experience problems with our billing information systems or if issues arise with Medicare, Medicaid or other payors, including attempts by commercial health insurance companies to renegotiate rates by reducing or withholding payment, we may encounter delays in our payment cycle. From time to time, we have experienced such delays as a result of government payors instituting planned reimbursement delays for budget balancing purposes or as a result of prepayment reviews.
Some states in which we operate are operating with budget deficits or could have budget deficit in the future, which may delay reimbursement in a manner that would adversely affect our liquidity. In addition, from time to time, procedural issues require us to resubmit or appeal claims before payment is remitted, which contributes to our aged receivables. Unanticipated delays in receiving reimbursement from state programs due to changes in their policies or billing or audit procedures may adversely impact our liquidity and working capital.
The continued use and growth of Medicaid managed care organizations (MCOs) may contribute to delays or reductions in our Medicaid reimbursement.
In forty-one states, including some of the largest where we operate, state Medicaid benefits are administered through MCOs. Typically, these MCOs are also commercial health insurers that administer state Medicaid benefits under a managed care contract. Nationally, MCOs cover approximately 57 million Medicaid beneficiaries. Due to these MCOs’ experience in healthcare reimbursement, they may be more aggressive than state Medicaid agencies in denying claims or seeking recoupment of payments so that their services under these managed contracts are profitable. Additionally, the transfer of funds from state Medicaid agencies to these MCOs for disbursement may cause further delays in payment. The additional steps created by the use of MCOs in disbursement of Medicaid funds creates more risk of delayed, reduced, or recouped payments for our independent operating subsidiaries, and additional avenues for risks that include fines and other sanctions, including suspension or exclusion from participation in state Medicaid programs.

59

Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.
Twenty-three of our affiliated facilities are currently subject to regulatory agreements with HUD that give the Commissioner of HUD broad authority to require us to be replaced as the operator of those facilities in the event that the Commissioner determines there are operational deficiencies at such facilities under HUD regulations. Compliance with HUD's requirements can often be difficult because these requirements are not always consistent with the requirements of other federal and state agencies. Appealing a failed inspection can be costly and time-consuming and, if we do not successfully remediate the failed inspection, we could be precluded from obtaining HUD financing in the future or we may encounter limitations or prohibitions on our operation of HUD-insured facilities.
If we fail to safeguard the monies held in our patient trust funds, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties.

Each of our affiliated facilities is required by federal law to maintain a patient trust fund to safeguard certain assets of their residents and patients. If any money held in a patient trust fund is misappropriated, we are required to reimburse the patient trust fund for the amount of money that was misappropriated. If any monies held in our patient trust funds are misappropriated in the future and are unrecoverable, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties pursuant to federal and state laws.
We are a holding company with no operations and rely upon our multiple independent operating subsidiaries to provide us with the funds necessary to meet our financial obligations. Liabilities of any one or more of our subsidiaries could be imposed upon us or our other subsidiaries.

We are a holding company with no direct operating assets, employees or revenue. Each of our affiliated facilities is operated through a separate, wholly-owned, independent subsidiary, which has its own management, employees and assets. Our principal assets are the equity interests we directly or indirectly hold in our multiple operating and real estate holding subsidiaries. As a result, we are dependent upon distributions from our subsidiaries to generate the funds necessary to meet our financial obligations and pay dividends. Our subsidiaries are legally distinct from us and have no obligation to make funds available to us. The ability of our subsidiaries to make distributions to us will depend substantially on their respective operating results and will be subject to restrictions under, among other things, the laws of their jurisdiction of organization, which may limit the amount of funds available for distribution to investors or stockholders, agreements of those subsidiaries, the terms of our financing arrangements and the terms of any future financing arrangements of our subsidiaries.
If the separation of Pennant fails to qualify as generally tax-free for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities.

The spin-off in 2019 is intended to qualify for tax-free treatment to us and our stockholders for U.S. federal income tax purposes. Accordingly, completion of the transaction was conditioned upon, among other things, our receipt of opinions from outside tax advisors that the distributions would qualify as a transaction that is intended to be tax-free to both us and our stockholders for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code. The opinions were based on and relied on, among other things, certain facts and assumptions, as well as certain representations, statements and undertakings, including those relating to the past and future conduct. If any of these facts, assumptions, representations, statements or undertakings is, or becomes, inaccurate or incomplete, or if any of the parties breach any of their respective covenants relating to the transactions, the tax opinions may be invalid. Moreover, the opinions are not binding on the IRS or any courts. Accordingly, notwithstanding receipt of the opinion, the IRS could determine that the distribution and certain related transactions should be treated as taxable transactions for U.S. federal income tax purposes.

If the spin-off fails to qualify as a transaction that is generally tax-free under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code, in general, for U.S. federal income tax purposes, we would recognize taxable gain with respect to the distributed securities and our stockholders who received securities in such distribution would be subject to tax as if they had received a taxable distribution equal to the fair market value of such shares.

We also have obligations to provide indemnification to a number of parties as a result of the transaction. Any indemnity obligations for tax issues or other liabilities related to the spin-off, could be significant and could adversely impact our business.

60

Certain directors who serve on our Board of Directors also serve as directors of Pennant, and ownership of shares of Pennant common stock by our directors and executive officers may create, or appear to create, conflicts of interest.

Certain of our directors who serve on our Board of Directors also serve on the board of directors of Pennant. This may create, or appear to create, conflicts of interest when our, or Pennant's management and directors face decisions that could have different implications for us and Pennant, including the resolution of any dispute regarding the terms of the agreements governing the spin-off and the relationship between us and Pennant after the spin-off or any other commercial agreements entered into in the future between us and the spun-off business and the allocation of such directors’ time between us and Pennant.

All of our executive officers and some of our non-employee directors own shares of the common stock of Pennant. The continued ownership of such common stock by our directors and executive officers following the spin-off creates, or may create, the appearance of a conflict of interest when these directors and executive officers are faced with decisions that could have different implications for us and Pennant.

If Standard Bearer fails to qualify or remain qualified as a REIT, it will be subject to U.S. federal income tax as a regular corporation and could face substantial tax liability.

Standard Bearer currently operates, and intends to continue to operate, in a manner that will allows it to qualify to be taxed as a REIT for U.S. federal income tax purposes. Standard Bearer intends to elect to be taxed as a REIT for U.S. federal income tax purposes beginning with its taxable year ended December 31, 2022.

If Standard Bearer fails to qualify to be taxed as a REIT in any year, it would be subject to U.S. federal income tax, including any applicable alternative minimum tax, on our taxable income at regular corporate rates, and dividends paid to its shareholders would not be deductible by it in computing its taxable income. Any resulting corporate liability could be substantial and would reduce the amount of cash available for distribution to its shareholders. Unless it was entitled to relief under certain Code provisions, it also would be disqualified from re-electing to be taxed as a REIT for the four taxable years following the year in which it failed to qualify to be taxed as a REIT.

Legislative or other actions affecting REITs could have a negative effect on Standard Bearer.

The rules dealing with U.S. federal income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Department of the Treasury (the “Treasury”). Changes to the tax laws or interpretations thereof, with or without retroactive application, could materially and adversely affect Standard Bearer's investors or Standard Bearer. We cannot predict how changes in the tax laws, including any tax reform called for by the current presidential administration, might affect Standard Bearer or its investors. New legislation, Treasury regulations, administrative interpretations or court decisions could significantly and negatively affect its ability to qualify to be taxed as a REIT or the U.S. federal income tax consequences to Standard Bearer or its investors of such qualification. For instance, the “Tax Cuts and Jobs Act” (the “Act”) significantly changed the U.S. federal income tax laws applicable to businesses and their owners, including REITs and their shareholders. Technical corrections or other amendments to the Act or administrative guidance interpreting the Act may be forthcoming at any time. We cannot predict the long-term effect of the Act or any future law changes on REITs or their shareholders. Changes to the U.S. federal tax laws and interpretations thereof, whether under the Act or otherwise, could adversely affect an investment in our stock.

No prediction can be made regarding whether new legislation or regulation (including new tax measures) will be enacted by legislative bodies or governmental agencies, nor can we predict what consequences would result from this legislation or regulation. Accordingly, no assurance can be given that the currently anticipated tax treatment of an investment will not be modified by legislative, judicial or administrative changes, possibly with retroactive effect.

Standard Bearer could fail to qualify to be taxed as a REIT if income it receives from our tenants is not treated as qualifying income.

Under applicable provisions of the Code, Standard Bearer will not be treated as a REIT unless it satisfies various requirements, including requirements relating to the sources of its gross income. Rents received or accrued by it from its tenants will not be treated as qualifying rent for purposes of these requirements if the leases are not respected as true leases for U.S. federal income tax purposes and are instead treated as service contracts, joint ventures or other arrangements. If the leases are not respected as true leases for U.S. federal income tax purposes, Standard Bearer will likely fail to qualify to be taxed as a REIT.

61

Even if Standard Bearer remains qualified as a REIT, it may face other tax liabilities that reduce its cash flow.

Even if Standard Bearer remain qualified for taxation as a REIT, it may be subject to certain U.S. federal, state, and local taxes on its income and assets, including taxes on any undistributed income and state or local income, property and transfer taxes. For example, Standard Bearer may hold some of its assets or conduct certain of its activities through one or more taxable REIT subsidiaries (each, a “TRS”) or other subsidiary corporations that will be subject to U.S. federal, state, and local corporate-level income taxes as regular C corporations. In addition, it may incur a 100% excise tax on transactions with a TRS if they are not conducted on an arm’s-length basis. Any of these taxes would decrease cash available for distribution to its shareholders.

Risks Related to Ownership of our Common Stock
We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price.

Our ability to pay and maintain cash dividends is based on many factors, including our ability to make and finance acquisitions, our ability to negotiate favorable lease and other contractual terms, anticipated operating cost levels, the level of demand for our beds, the rates we charge and actual results that may vary substantially from estimates. Some of the factors are beyond our control and a change in any such factor could affect our ability to pay or maintain dividends. The Amended Credit Agreement restricts our ability to pay dividends to stockholders if we receive notice that we are in default under this agreement. The failure to pay or maintain dividends could adversely affect our stock price.
Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.

Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that may enable our Board of Directors to resist a change in control. These provisions may discourage, delay or prevent a change in the ownership of our company or a change in our management, even if doing so might be beneficial to our stockholders. In addition, these provisions could limit the price that investors would be willing to pay in the future for shares of our common stock. Such provisions set forth in our amended and restated certificate of incorporation or our amended and restated bylaws include:

our Board of Directors is authorized, without prior stockholder approval, to create and issue preferred stock, commonly referred to as “blank check” preferred stock, with rights senior to those of common stock;
advance notice requirements for stockholders to nominate individuals to serve on our Board of Directors or to submit proposals that can be acted upon at stockholder meetings;
our Board of Directors is classified so not all members of our board are elected at one time, which may make it more difficult for a person who acquires control of a majority of our outstanding voting stock to replace our directors;
stockholder action by written consent is limited;
special meetings of the stockholders are permitted to be called only by the chairman of our Board of Directors, our chief executive officer or by a majority of our Board of Directors;
stockholders are not permitted to cumulate their votes for the election of directors;
newly created directorships resulting from an increase in the authorized number of directors or vacancies on our Board of Directors are filled only by majority vote of the remaining directors;
our Board of Directors is expressly authorized to make, alter or repeal our bylaws; and
stockholders are permitted to amend our bylaws only upon receiving the affirmative vote of at least a majority of our outstanding common stock.
We are also subject to the anti-takeover provisions of Section 203 of the General Corporation Law of the State of Delaware. Under these provisions, if anyone becomes an “interested stockholder,” we may not enter into a “business combination” with that person for three years without special approval, which could discourage a third party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 203, “interested stockholder” means, generally, someone owning more than 15% or more of our outstanding voting stock or an affiliate of ours that owned 15% or more of our outstanding voting stock during the past three years, subject to certain exceptions as described in Section 203.


62

These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could discourage acquisition proposals and make it more difficult or expensive for stockholders or potential acquirers to obtain control of our Board of Directors or initiate actions that are opposed by our then-current Board of Directors, including delaying or impeding a merger, tender offer or proxy contest involving us. Any delay or prevention of a change of control transaction or changes in our Board of Directors could cause the market price of our common stock to decline.

Item 1B. UNRESOLVED STAFF COMMENTS

    None.


Item 2.     PROPERTIES

Service Center   Our Service Center is located in San Juan Capistrano, California. In June 2018, we acquired an office space for a purchase price of $31.0 million to accommodate our growing Service Center team. The property consists of approximately 108,058 square feet of usable office space. In addition, we lease a substantial portion of the space within the campus to third-party tenants. Additionally, in 2022, we entered into lease agreements for office space in Texas and Utah as we expanded our Service Centers in those states.

Operating Facilities We operate 271 affiliated facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin, with the operational capacity to serve approximately 31,000 patients as of December 31, 2022. Of the 271 facilities, we operate 192 facilities under long-term lease arrangements and have options to purchase 11 of those 192 facilities. The results of our operating facilities are reflected in our skilled services segment for our skilled nursing operations and in "All Other" category for our senior living operations.

 
The following table provides summary information regarding the location of our facilities, operational beds and units by property type as of December 31, 2022:
Operated Facilities
Leased without a Purchase Option Leased with a Purchase OptionOwned Total
Facilities Beds/UnitsFacilities Beds/UnitsFacilities Beds/UnitsFacilitiesBeds/Units
California 424,269111,224535,493
Texas 566,9325714212,7118210,357
Arizona 233,324131,942365,266
Wisconsin 21002100
Utah 121,31121597684212,154
Colorado 141,36611257822222,313
Washington 121,1212204141,325
Idaho 75515468121,019
Nebraska536423547718
Kansas 332544587783
Iowa 63996399
South Carolina232255447866
Nevada23582358
18120,317111,323799,51127131,151


63

The following table sets forth the location of our facilities and the number of operational beds and units located at our skilled nursing, senior living and campus facilities as of December 31, 2022:
Facility CountsBed / Unit Counts
Skilled Nursing OperationsSenior Living Communities Campus OperationsTotal Skilled Nursing Beds Senior Living Units Total Beds / Units
California 503535,2961975,493
Texas 7714829,84850910,357
Arizona 3015364,5077595,266
Wisconsin 22100100
Utah 1821211,9911632,154
Colorado 1651221,5887252,313
Washington 131141,227981,325
Idaho 11112998211,019
Nebraska4127413305718
Kansas 77570213783
Iowa 42636831399
South Carolina77866866
Nevada22358358
234112627128,1303,02131,151

Real Estate Properties As of December 31, 2022, we owned 108 real estate properties in Arizona, California, Colorado, Idaho, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin, which include 79 of the 271 facilities that we operate and manage. Of our 108 real estate properties, 29 senior living operations are leased to and operated by Pennant. One senior living operation leased by Pennant is located on the same real estate property as a skilled nursing facility that we own and operate. We further own the real estate property of our Service Center location and continue to lease a portion of the office space to third-party tenants. Our Standard Bearer segment reflects the results of operations for 103 of the 108 owned real estate properties.

The following table provides summary information regarding the location of our owned real estate properties as of December 31, 2022:
Owned and Operated by Ensign(1)
Owned and Leased to Pennant(1)
Service Center
Total Properties(1)
California112114
Texas(1)
21626
Arizona 13114
Wisconsin 21921
Utah 77
Colorado 77
Washington 22
Idaho 55
Nebraska22
Kansas 44
South Carolina55
Nevada11
79291108
(1) One senior living operation in Texas, which is owned by Ensign and leased to Pennant is located on the same real estate property as a skilled nursing facility that we own and operate. In this situation, the senior living operation is included in the total under "Owned and Leased to Pennant" and the skilled nursing operation is included in the total under "Owned and Operated by Ensign", however, the amount reflected under "Total Properties" only recognizes the operation as a single property.

64

Item 3.     LEGAL PROCEEDINGS
Regulatory Matters Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action with fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations are rules requiring vaccination of employees and HIPAA, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.
Cost-Containment MeasuresBoth government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.
IndemnitiesFrom time to time, we enter into certain types of contracts that contingently require us to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which we may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from our use of the applicable premises, (ii) operations transfer agreements, in which we agree to indemnify past operators of facilities we acquire against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which we may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with our officers, directors and others, under which we may be required to indemnify such persons for liabilities arising out of the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on our balance sheets for any of the periods presented.

In connection with the spin-off transaction in 2019, certain landlords required, in exchange for their consent to the transaction, that our lease guarantees remain in place for a certain period of time following the spin-off. These guarantees could result in significant additional liabilities and obligations for us if Pennant were to default on their obligations under their leases with respect to these properties.
U.S. Department of Justice Civil Investigative Demand — On May 31, 2018, we received a CID from the U.S. Department of Justice stating that it was investigating to determine whether there had been a violation of the False Claims Act and/or the Anti-Kickback Statute with respect to the relationships between certain of our independently operated skilled nursing facilities and persons who serve or have served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of our Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, our independent operating entities have established and maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. We have fully cooperated with the U.S. Department of Justice and promptly responded to its requests for information; in April 2020, we were advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.
LitigationWe and our independent operating entities are party to various legal actions and administrative proceedings, and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients by our independent operating entities have resulted in injury or death, and claims related to employment and commercial matters. Although we intend to vigorously defend against these claims, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. In certain states in which we have or have had independent operating entities, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law and/or public policy prohibitions. There can be no assurance that our independent operating entities will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available.


65

The skilled nursing and post-acute care industry is heavily regulated. As such, we and our independent operating subsidiaries are continuously subject to state and federal regulatory scrutiny, supervision and control in the ordinary course of business. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight from state and federal agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements which could result in civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their programs. We believe that there has been, and will continue to be, an increase in governmental investigations of LTC providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on our financial position, results of operations, and cash flows.

Additionally, and in 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, we and our independent operating subsidiaries received a document and information request from the House Select Subcommittee. We and our independent operating subsidiaries have cooperated in responding to this inquiry. In July 2022 and thereafter, we and our independent operating subsidiaries received follow up requests for additional documents and information. We and our independent operating subsidiaries have responded to these requests, and continued to cooperate with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act.

In addition to the potential lawsuits and claims described above, we and our independent operating subsidiaries are also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from Federally funded healthcare programs. Such exclusions could have a correlative negative impact on our financial performance. Under the qui tam or "whistleblower" provisions of the False Claims Act, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the Federal Government and receive a percentage of the Federal Government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the U.S. Department of Justice to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the involved qui tam relator is continuing on with the lawsuit and pursuing claims that one or more of the Company's independent operating entities have allegedly violated the False Claims Act and/or the AKS.

In addition to the Federal False Claims Act, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, we and our independent operating subsidiaries could face increased scrutiny, potential liability, and legal expenses and costs based on claims under state false claims acts in markets where our independent operating subsidiaries do business.

In May 2009, Congress passed the FERA which made significant changes to the Federal False Claims Act (FCA) and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that an FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.

Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and our independent operating entities are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements. We expect the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims.

66

We and our independent operating subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including healthcare and non-healthcare services. These claims include, but are not limited to potential claims related to patient care and treatment (professional negligence claims) as well as employment related claims. In addition, we and our independent operating subsidiaries, and others in the industry, are subject to claims and lawsuits in connection with COVID-19 and facility preparation for and/or response to the COVID-19 pandemic. While we have been able to settle or otherwise resolve these types of claims without an ongoing material adverse effect on our business, a significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of future claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, these claims could impact our ability to procure insurance to cover our exposure related to the various services provided by our independent operating subsidiaries to their residents, customers and patients.
Claims and suits, including class actions, continue to be filed against our independent operating subsidiaries and other companies in the post-acute care industry. We and our independent operating entities have been subjected to, and/or are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour law as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and other such similar causes of action. We do not believe that the ultimate resolution of these actions will have a material adverse effect on our business, cash flows, financial condition or results of operations.
Medicare Revenue RecoupmentsWe and our independent operating subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments resulting from reviews conducted via RAC, Program Safeguard Contractors, and Medicaid Integrity Contractors (collectively referred to as Reviews). For several months during the COVID-19 pandemic, CMS suspended its Targeted Probe and Educate Program. Beginning in August 2020, CMS resumed Targeted Probe and Educate Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. We anticipate that these Reviews could increase in frequency in the future. As of December 31, 2022 and since, 34 of our independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process.


Item 4.     MINE SAFETY DISCLOSURES

    None.
PART II.

Item 5.     MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information

Our common stock has been traded under the symbol “ENSG” on the NASDAQ Global Select Market since our initial public offering on November 8, 2007. Prior to that time, there was no public market for our common stock. As of January 30, 2023, there were approximately 297 holders of record of our common stock.

Notwithstanding anything to the contrary set forth in any of our filings under the Securities Act or the Exchange Act that might incorporate future filings, including the Annual Report on Form 10-K, in whole or in part, the Stock Performance Graph and supporting data which follows shall not be deemed to be incorporated by reference into any such filings except to the extent that we specifically incorporate any such information into any such future filings.

The graph below shows the cumulative total stockholder return of investment of $100 (and the reinvestment of any dividends thereafter) on December 31, 2017 in (i) our common stock, (ii) the Skilled Nursing Facilities Peer Group 1 and (iii) the NASDAQ Market Index. Our stock price performance shown in the graph below is not indicative of future stock price performance.

On October 1, 2019, Ensign completed the spin-off of The Pennant Group, Inc. (Pennant) with the pro rata distribution of 1.18 shares of Pennant’s common stock for every share of Ensign’s common stock to our stockholders, pursuant to which Pennant became an independent company. Pennant's stock traded at $6.15 at opening price on the first day of trading and closed at $15.09. Ensign's stock price was reduced by the same value on the same day. For the purpose of this graph, the effect of the final separation of Pennant is reflected in the cumulative total return of Ensign Common Stock as a reinvested dividend.
67


COMPARISON OF 60 MONTH CUMULATIVE TOTAL RETURN*
Among Ensign Group, the NASDAQ Composite Index and Our Peer Group
December 2022

ensg-20221231_g6.jpg
*Assumes $100 invested on December 31, 2017 in stock in index, including reinvestment of dividends.
Fiscal year ended December 31.
December 31,
201720182019202020212022
The Ensign Group, Inc.(2)
$100.00 $175.65 $224.56 $362.38 $418.24 $472.47 
NASDAQ Market Index100.00 97.16 132.81 192.47 235.15 158.65 
Peer Group(1)
100.00 121.42 150.55 148.58 155.55 132.19 
(1) The current composition of our Peer Group is as follows: Amedysis, Inc., CareTrust REIT Inc., Encompass Healthcare Corp., LTC Properties, Inc., National Healthcare Corporation, National Health Investors, Inc., Omega Healthcare Investors, Inc., Select Medical Holdings Corp. and Welltower Inc.
(2) The value displayed only incorporates the value of The Ensign Group, Inc. stock and does not incorporate the value shareholders received in connection with our spin-offs of CareTrust REIT Inc. and The Pennant Group, Inc.
Dividend Policy
We do not have a formal dividend policy, but we currently intend to continue to pay regular quarterly dividends to the holders of our common stock. We have been a dividend-paying company since 2002 and have increased our dividend every year for the last 20 years.
Issuer Repurchases of Equity Securities
Stock Repurchase Programs On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which we could repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, we are authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. We did not purchase any shares pursuant to this stock repurchase program in the year ended December 31, 2022. The share repurchase program does not obligate us to acquire any specific number of shares.

68

On February 9, 2022, the Board of Directors approved a stock repurchase program pursuant to which we could repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from February 10, 2022. Under this program, we were authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the second quarter of 2022, we repurchased 0.3 million shares of our common stock for $20.0 million. This repurchase program expired upon the repurchase of the fully authorized amount under the plan and is no longer in effect.
On October 21, 2021, the Board of Directors approved a stock repurchase program pursuant to which we could repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from October 29, 2021. Under this program, we were authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the first quarter of 2022, we repurchased 0.1 million shares of our common stock for $9.9 million. During the fourth quarter of 2021, we repurchased 0.1 million shares of our common stock for $10.1 million. This repurchase program expired upon the repurchase of the fully authorized amount under the plan and is no longer in effect.
A summary of the repurchase activity for the year ended December 31, 2022 is as follows (dollars in millions, except per share amounts):
PeriodTotal Number of Shares RepurchasedAverage Price Per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
First quarter of 2022(1)
133,328 $74.09 133,328 $20.0 
Second quarter of 2022(2)
270,720 73.85 270,720 — 
Third quarter of 2022— — — 20.0 
October 1 to October 31, 2022— — — 20.0 
November 1 to November 30, 2022— — — 20.0 
December 1 to December 31, 2022— $— — $20.0 
(1) These purchases were effectuated through a Rule 10b5-1 trading plan adopted by the Company on October 21, 2021.
(2) These purchases were effectuated through a Rule 10b5-1 trading plan adopted by the Company on February 9, 2022.

Item 6.     [RESERVED]

Item 7.     MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with the consolidated financial statements and accompanying notes, which appear elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Annual Report on Form 10-K. See Part I. Item 1A. Risk Factors and Cautionary Note Regarding Forward-Looking Statements.
For discussion of 2020 items and year-over-year comparisons between 2021 and 2020 that are not included in this 2022 Form 10-K, refer to “Item 7. – Management’s Discussion and Analysis of Financial Condition and Results of Operations” found in our Form 10-K for the year ended December 31, 2021, that was filed with the Securities and Exchange Commission on February 9, 2022.

69

Overview
We are a provider of health care services across the post-acute care continuum, engaged in the operation, ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare related properties and other ancillary businesses located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Our operating subsidiaries, each of which strives to be the operation of choice in the community it serves, provide a broad spectrum of skilled nursing, senior living and other ancillary services. As of December 31, 2022, we offered skilled nursing, senior living and rehabilitative care services through 271 skilled nursing and senior living facilities. Of the 271 facilities, we operated 192 facilities under long-term lease arrangements and have options to purchase 11 of those facilities. Our real estate portfolio includes 108 owned real estate properties, which included 79 facilities operated and managed by us, 29 senior living operations leased to and operated by The Pennant Group, Inc., or Pennant, as part of the spin-off transaction that occurred in October 2019, and the Service Center location. Of the 29 real estate operations leased to Pennant, one senior living operation is located on the same real estate property as a skilled nursing facility that we own and operate.
Ensign is a holding company with no direct operating assets, employees or revenues. Our operating subsidiaries are operated by separate, independent entities, each of which has its own management, employees and assets. In addition, certain of our wholly-owned subsidiaries, referred to collectively as the Service Center, provide centralized accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. We also have a wholly-owned captive insurance subsidiary that provides some claims-made coverage to our operating subsidiaries for general and professional liability, as well as coverage for certain workers’ compensation insurance liabilities and our captive real estate trust owns and operates our real estate portfolio. Our captive real estate investment trust, Standard Bearer, owns and manages our real estate business. References herein to the consolidated “Company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “our” and similar terms in this Annual Report, are not meant to imply, nor should they be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Ensign Group.
Recent Activities
Operational UpdateIn 2022, the public health emergency (PHE) was extended several times and was most recently extended through April 11, 2023. On January 30, 2023, the Biden Administration announced its plan to extend the PHE for a final time to May 11, 2023. Our primary focus continues to be the health and safety of our patients, residents, employees and their respective families. We continue to implement measures necessary to provide the safest possible environment within our sites of service, taking into consideration the vulnerable nature of our patients and the unique exposure risks of our staff.
We continue to execute on key initiatives to rebuild occupancy lost due to the pandemic. During the year, our combined Same Facilities and Transitioning Facilities occupancy increased by 2.9% compared to 2021. The improvements in occupancy were due to our operations developing innovative approaches to confront the occupancy declines, including strategic partnerships with upstream and downstream continuum partners and increasing clinical competencies to treat high-acuity patients, including those that are COVID-19 positive. We believe our operations will continue to gain additional market share as a result of relationships with acute care providers and other health care partners.
During the year ended December 31, 2022 and 2021, we recognized $81.8 million and $75.2 million, respectively, of state relief funding as revenue, including FMAP.
The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with approximately 50% of the deferred amount paid by December 31, 2021 and the remaining 50% by December 31, 2022. See Note 3, COVID-19 Update in the Notes to the Consolidated Financial Statements.
Captive Real Estate Investment Trust In January of 2022, we formed Standard Bearer Healthcare REIT, Inc. or Standard Bearer, a captive REIT. Standard Bearer is a holding company with subsidiaries that own most of our real estate portfolio. We expect the REIT structure will allow us to better demonstrate the growing value of our owned real estate and provides us with an efficient vehicle for future acquisitions of properties that could be operated by Ensign affiliates or other third parties. We believe this structure will give us new pathways to growth with transactions we would not have considered in the past. Standard Bearer intends to qualify and elects to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022.

70

During the year ended December 31, 2022, we acquired the real estate of ten skilled nursing facilities, all of which were leased to certain of our operating subsidiaries through the Standard Bearer Master Leases for a purchase price of $84.7 million. Of the ten, three were previously operated and managed by us. The resulting real estate portfolio in Standard Bearer consists of a select 103 of our 108 owned real estate properties. Of the 103 owned real estate properties in Standard Bearer, 75 facilities are operated by Ensign operating subsidiaries and 29 facilities are leased to and operated by Pennant. Of the 29 real estate operations leased to Pennant, one senior living operation is located on the same real estate property as a skilled nursing facility that we own and operate. In addition, as we expand our real estate portfolio through our acquisition strategy, we anticipate that the acquired real estate will be included in Standard Bearer.
As of December 31, 2022, the fair value of Standard Bearer's real estate portfolio is approximately $1.1 billion. The fair value was determined by a third party independent valuation specialist and incorporated each property's rental income, capitalization rate, rental yield rate and discount rate.
As part of the formation of Standard Bearer, certain of our operating subsidiaries and the Standard Bearer subsidiaries entered into five "triple-net" master lease agreements (collectively, the Standard Bearer Master Leases). Total annual rental income under the Standard Bearer Master Lease is approximately $62.5 million.
Standard Bearer has no employees. Personnel and services provided to Standard Bearer by the Service Center are pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee and an incentive management fee, payable in cash, among other terms. The base management fee for each applicable period is equal to 5.0% of the total revenue of Standard Bearer. The incentive management fee is equal to 5.0% of funds from operations (FFO) and is capped at 1.0% of total revenue. In addition, operating expenses incurred by the Service Center on Standard Bearer's behalf, which includes the cost of legal, tax, consulting, accounting and other similar services rendered by the Service Center, its advisers or other third parties, are reimbursed by Standard Bearer. During the year ended December 31, 2022, the Service Center management fee was $4.4 million, which represents 6% of total Standard Bearer rental revenue.
Standard Bearer will obtain its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Revolving Credit Facility to fund acquisitions and working capital needs. As part of the Amended Credit Agreement discussed in Note 16, Debt, the interest rates applicable to loans under the Revolving Credit Facility were amended, such that the rates are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum.
During the year ended December 31, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $0.1 million. These preferred shares were fully vested at the time of the contributions by the shareholders. In addition, as part of the formation of Standard Bearer in January of 2022, we established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). In 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6.5 million. We did not grant any stock options nor restricted shares during the year ended December 31, 2022.
During the year ended December 31, 2022, Standard Bearer met the requirement to distribute to its shareholders at least 90% of its annual taxable income through a declaration and payment of cash dividends totaling $30.4 million. Of that amount, $30.1 million was paid in the form of a distribution to the Company and $0.3 million was paid in the form of a distribution to noncontrolling interests.
Revolving Credit Facility Amendment On April 8, 2022, we entered into the Second Amendment to the Third Amended and Restated Credit Facility (such agreement, the Amended Credit Agreement, and the revolving credit facility thereunder, the Revolving Credit Facility), which increased the Revolving Credit Facility by $250.0 million to an aggregate principal amount of up to $600.0 million. Pursuant to the Amended Credit Agreement, the Company transitioned from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financing Rate (SOFR) as the applicable reference rate for borrowings under the Revolving Credit Facility. The maturity date of the Amended Credit Facility is April 8, 2027. Borrowings are supported by a lending consortium arranged by Truist Securities (Truist). The interest rates applicable to loans under the Revolving Credit Facility are, at our option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the Amended Credit Agreement). In addition, we will pay a commitment fee on the unused portion of the commitments, which will range from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. As part of the amendment, deferred financing costs of $0.6 million were written off and additional deferred financing costs of $3.2 million were capitalized during the year ended December 31, 2022.
71

Common Stock Repurchase ProgramOn July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from August 2, 2022. We did not purchase any shares pursuant to this stock repurchase program in the year ended December 31, 2022. On February 9, 2022, the Board of Directors approved a stock repurchase program pursuant to which we could repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from February 10, 2022. In the second quarter of 2022, we repurchased 0.3 million shares of our common stock for $20.0 million. This repurchase program expired upon the repurchase of the fully authorized amount under the plan and is no longer in effect.
Key Performance Indicators
We manage the fiscal aspects of our business by monitoring key performance indicators that affect our financial performance. Revenue associated with these metrics is generated based on contractually agreed-upon amounts or rate, excluding the estimates of variable consideration under the revenue recognition standard, Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606. These indicators and their definitions include the following:
Skilled Services
Routine revenue Routine revenue is generated by the contracted daily rate charged for all contractually inclusive skilled nursing services. The inclusion of therapy and other ancillary treatments varies by payor source and by contract. Services provided outside of the routine contractual agreement are recorded separately as ancillary revenue, including Medicare Part B therapy services, and are not included in the routine revenue definition.
Skilled revenue - The amount of routine revenue generated from patients in the skilled nursing facilities who are receiving higher levels of care under Medicare, managed care, Medicaid, or other skilled reimbursement programs. The other skilled patients who are included in this population represent very high acuity patients who are receiving high levels of nursing and ancillary services which are reimbursed by payors other than Medicare or managed care. Skilled revenue excludes any revenue generated from our senior living services.
Skilled mix The amount of our skilled revenue as a percentage of our total skilled nursing routine revenue. Skilled mix (in days) represents the number of days our Medicare, managed care, or other skilled patients are receiving skilled nursing services at the skilled nursing facilities divided by the total number of days patients from all payor sources are receiving skilled nursing services at the skilled nursing facilities for any given period.
Average daily rates The routine revenue by payor source for a period at the skilled nursing facilities divided by actual patient days for that revenue source for that given period. These rates exclude additional state relief funding, which includes payments we recognized as part of The Family First Coronavirus Response Act.
Occupancy percentage (operational beds) The total number of patients occupying a bed in a skilled nursing facility as a percentage of the beds in a facility which are available for occupancy during the measurement period.
Number of facilities and operational beds The total number of skilled nursing facilities that we own or operate and the total number of operational beds associated with these facilities.
Skilled Mix Like most skilled nursing providers, we measure both patient days and revenue by payor. Medicare, managed care and other skilled patients, whom we refer to as high acuity patients, typically require a higher level of skilled nursing and rehabilitative care. Accordingly, Medicare and managed care reimbursement rates are typically higher than from other payors. In most states, Medicaid reimbursement rates are generally the lowest of all payor types. Changes in the payor mix can significantly affect our revenue and profitability.

The following table summarizes our overall skilled mix from our skilled nursing services for the periods indicated as a percentage of our total skilled nursing routine revenue and as a percentage of total skilled nursing patient days:
Year Ended December 31,
Skilled Mix:20222021
Days31.8 %31.7 %
Revenue52.0 %52.3 %

72

Occupancy We define occupancy derived from our skilled services as the ratio of actual patient days (one patient day equals one patient occupying one bed for one day) during any measurement period to the number of beds in facilities which are available for occupancy during the measurement period. The number of beds in a skilled nursing facility that are actually operational and available for occupancy may be less than the total official licensed bed capacity. This sometimes occurs due to the permanent dedication of bed space to alternative purposes, such as enhanced therapy treatment space or other desirable uses calculated to improve service offerings and/or operational efficiencies in a facility. In some cases, three- and four-bed wards have been reduced to two-bed rooms for resident comfort, and larger wards have been reduced to conform to changes in Medicare requirements. These beds are seldom expected to be placed back into service. We believe that reporting occupancy based on operational beds is consistent with industry practices and provides a more useful measure of actual occupancy performance from period to period.

The following table summarizes our overall occupancy statistics for skilled nursing operations for the periods indicated:
Year Ended December 31,
Occupancy for skilled services:20222021
Operational beds at end of period28,130 25,032 
Available patient days9,614,460 8,895,949 
Actual patient days7,243,781 6,478,810 
Occupancy percentage (based on operational beds)75.3 %72.8 %
Segments
We have two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of select properties owned by us through our captive REIT and leased to skilled nursing and senior living operations, including our own operating subsidiaries and third party operators.
We also reported an “all other” category that includes operating results from our senior living operations, mobile diagnostics, transportation, other real estate and other ancillary operations. These businesses are neither significant individually, nor in aggregate and therefore do not constitute a reportable segment. Our Chief Executive Officer, who is our chief operating decision maker, or CODM, reviews financial information at the operating segment level.
Revenue Sources
Skilled Services
Within our skilled nursing operations, we generate revenue from Medicaid, private pay, managed care and Medicare payors. We believe that our skilled mix, which we define as the number of days Medicare, managed care and other skilled patients are receiving services at our skilled nursing operations divided by the total number of days patients are receiving services at our skilled nursing operations, from all payor sources (less days from senior living services) for any given period, is an important indicator of our success in attracting high-acuity patients because it represents the percentage of our patients who are reimbursed by Medicare, managed care and other skilled payors, for whom we receive higher reimbursement rates.
We are participating in supplemental payment programs in various states that provide supplemental Medicaid payments for skilled nursing facilities that are licensed to non-state government-owned entities such as city and county hospital districts. Numerous operating subsidiaries entered into transactions with various hospital districts providing for the transfer of the licenses for those skilled nursing facilities to the hospital districts. Each affected operating subsidiary agreement between the hospital district and our subsidiary is terminable by either party to fully restore the prior license status.

73

Standard Bearer
We generate rental revenue primarily by leasing post-acute care properties we acquired to healthcare operators under triple-net lease arrangements, whereby the tenant is solely responsible for the costs related to the property, including property taxes, insurance and maintenance and repair costs, subject to certain exceptions. As of December 31, 2022, our real estate portfolio within Standard Bearer is comprised of 103 real estate properties. Of these properties, 75 are leased to affiliated skilled nursing facilities wholly-owned and managed by us and 29 are leased to senior living operations wholly-owned and managed by Pennant. Of the 29 real estate operations leased to Pennant, one senior living operation is located on the same real estate property as a skilled nursing facility that we own and operate. During the year ended December 31, 2022, we generated rental revenues of $72.9 million, of which $58.0 million was derived from affiliated wholly-owned healthcare operators, and therefore eliminated in consolidation.
Other
Within our senior living operations, we generate revenue primarily from private pay sources, with a portion earned from Medicaid payors or through other state-specific programs. In addition, we hold majority membership interests in certain of our other ancillary operations. Payment for these services varies and is based upon the service provided. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk.
Primary Components of Expense
Cost of Services (exclusive of rent and depreciation and amortization shown separately) Our cost of services represents the costs of operating our operating subsidiaries, which primarily consists of payroll and related benefits, supplies, purchased services, and ancillary expenses such as the cost of pharmacy and therapy services provided to patients. Cost of services also includes the cost of general and professional liability insurance, rent expenses related to leasing our operational facilities that are not included in facility rent - cost of services, and other general cost of services with respect to our operations.
Facility Rent - Cost of Services Rent - cost of services consists solely of base minimum rent amounts payable under lease agreements to third-party real estate owners. Our operating subsidiaries lease and operate but do not own the underlying real estate and these amounts do not include taxes, insurance, impounds, capital reserves or other charges payable under the applicable lease agreements. Expenses related to leasing our operations are included in cost of services.
General and Administrative Expense General and administrative expense consists primarily of payroll and related benefits and travel expenses for our Service Center personnel, including training and other operational support. General and administrative expense also includes professional fees (including accounting and legal fees), costs relating to our information systems and stock-based compensation related to our Service Center employees.
Depreciation and Amortization Property and equipment are recorded at their original historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets. The following is a summary of the depreciable lives of our depreciable assets:
Buildings and improvementsMinimum of three years to a maximum of 59 years, generally 45 years
Leasehold improvementsShorter of the lease term or estimated useful life, generally 5 to 15 years
Furniture and equipment3 to 10 years
Critical Accounting Estimates
Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The preparation of these financial statements and related disclosures requires us to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that the application of the following accounting policies, which are important to our financial position and results of operations, require significant judgments and estimates on the part of management. For a summary of our significant accounting policies, including the accounting policies discussed below, see Note 2, “Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements.
74

Variable consideration within revenue recognition Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. We determine the transaction price based on contractually agreed-upon amounts or rates, adjusted for estimates of variable consideration. We use the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from our estimates, we adjust these estimates, which would affect net service revenue in the period such variances become known.
Self-insurance for general and professional liability The self-insured retention and deductible limits for general and professional liability for all states are self-insured through our wholly owned captive insurance subsidiary (the Captive Insurance), the related assets and liabilities of which are included in the accompanying consolidated balance sheets. Our general and professional liability as of the years ended December 31, 2022 and 2021 was $87.0 million and $69.7 million, respectively.
Our policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. We develop information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluate the estimates for claim loss exposure on a quarterly basis. We use actuarial valuations to estimate the liability based on historical experience and industry information.
RESULTS OF OPERATIONS
We believe we exist to dignify and transform post-acute care. We set out a strategy to achieve our goal of ensuring our patients are receiving the best possible care through our ability to acquire, integrate and improve our operations. Our results serve as a strong indicator that our strategy is working and our transformation is underway. Since 2018, our total revenue increased $1.3 billion, or 72.4%, representing a 14.6% compound annual growth rate (CAGR) while our diluted GAAP earning per share (EPS) from continued operations grew by $2.86 from 2018 to $3.95, representing a 38.0% CAGR.
Our total revenue for the year ended December 31, 2022 increased $398.0 million, or 15.1%, while our diluted GAAP earning per share grew by 15.5%, from $3.42 to $3.95, compared to the year ended December 31, 2021. Over the past year, we have continued to make progress on targeted initiatives related to increasing occupancy and hiring and developing our people. Our combined Same Facilities and Transitioning Facilities occupancy increased by 2.9% compared to 2021. We saw a recovery in our census starting in the first quarter of 2021, which has continued throughout 2022. Despite the emergence of COVID-19 variants and subvariants throughout 2022, we continue to experience healthy growth in both revenue and operational earnings. We also added over 4,000 team members, or 16%, to our operating subsidiaries and the Service Center.
Our net revenue for the year ended December 31, 2022 continued to be impacted by COVID-19, with the continual evolution of COVID-19 variants and subvariants in 2022. Accordingly, we continued to receive state relief funding in selected states, which have been designed to provide additional funding to cover COVID-19 related expenses. For the year ended December 31, 2022, we recorded state relief revenue of $81.8 million, which directly offsets against COVID-19 related expenses we incurred in those states. See Recent Activities for further information.
Additionally, we continue to seek out opportunities to expand our operations and real estate, adding 29 new operations and ten real estate properties, three of which we previously operated, during the year ended December 31, 2022. We remain confident that our operating model will continue to allow each operator to form their own market-specific strategy and to adjust to the needs of their local medical communities, including methods for attracting new healthcare professionals into our workforce and retaining and developing existing staff. We are excited to be adding new operations in several geographies. These transitions will take time, particularly given the continued labor pressures, but with each new operation we are creating new opportunities for the next generation of leaders and look forward to working together to help each operation reach its enormous clinical and financial potential.

75

The following table sets forth details of operating results for our revenue, expenses and earnings, and their respective components, as a percentage of total revenue for the periods indicated:
Year Ended December 31,
 20222021
REVENUE:
Service revenue99.4 %99.4 %
Rental revenue0.6 0.6 
TOTAL REVENUE100.0 %100.0 %
Expenses:
Cost of services77.8 76.9 
Rent—cost of services5.1 5.3 
General and administrative expense5.2 5.8 
Depreciation and amortization2.1 2.1 
TOTAL EXPENSES90.2 90.1 
Income from operations9.8 9.9 
Other income (expense):
Interest expense(0.3)(0.3)
Other income — 0.2 
Other expense, net(0.3)(0.1)
Income before provision for income taxes9.5 9.8 
Provision for income taxes2.1 2.3 
NET INCOME7.4 7.5 
Less: net income attributable to noncontrolling interests — 0.1 
 Net income attributable to The Ensign Group, Inc.7.4 %7.4 %

 Year Ended December 31,
 20222021
SEGMENT INCOME(1)
(In thousands)
Skilled services$408,732 $373,603 
Standard Bearer(2)
27,871 31,876 
NON-GAAP FINANCIAL MEASURES:
PERFORMANCE METRICS
EBITDA 359,209 313,377 
Adjusted EBITDA 383,570 336,572 
FFO for Standard Bearer
49,484 49,434 
VALUATION METRICS
Adjusted EBITDAR$536,619 
(1) Segment income represents operating results of the reportable segments excluding gain and loss on sale of assets, real estate insurance recoveries and losses, impairment charges and provision for income taxes. Included in segment income for Standard Bearer for the year ended December 31, 2022 are expenses for intercompany management fees between Standard Bearer and the Service Center and intercompany interest expense. Segment income is reconciled to the Consolidated Statement of Income in Note 8, Business Segments in Notes to Consolidated Financial Statements of this Annual Report on Form 10-K.
(2) Standard Bearer segment income includes rental revenue from Ensign affiliated tenants and related expenses.

76

The following discussion includes references to EBITDA, Adjusted EBITDA, Adjusted EBITDAR and Funds from Operations (FFO) which are non-GAAP financial measures (collectively, the Non-GAAP Financial Measures). Regulation G, Conditions for Use of Non-GAAP Financial Measures, and other provisions of the Securities Exchange Act of 1934, as amended (the Exchange Act), define and prescribe the conditions for use of certain non-GAAP financial information. These Non-GAAP Financial Measures are used in addition to and in conjunction with results presented in accordance with GAAP. These Non-GAAP Financial Measures should not be relied upon to the exclusion of GAAP financial measures. These Non-GAAP Financial Measures reflect an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting our business.
We believe the presentation of certain Non-GAAP Financial Measures are useful to investors and other external users of our financial statements regarding our results of operations because:

they are widely used by investors and analysts in our industry as a supplemental measure to evaluate the overall performance of companies in our industry without regard to items such as other expense, net and depreciation and amortization, which can vary substantially from company to company depending on the book value of assets, capital structure and the method by which assets were acquired; and
they help investors evaluate and compare the results of our operations from period to period by removing the impact of our capital structure and asset base from our operating results.

We use the Non-GAAP Financial Measures:

as measurements of our operating performance to assist us in comparing our operating performance on a consistent basis;
to allocate resources to enhance the financial performance of our business;
to assess the value of a potential acquisition;
to assess the value of a transformed operation's performance;
to evaluate the effectiveness of our operational strategies; and
to compare our operating performance to that of our competitors.

We use certain Non-GAAP Financial Measures to compare the operating performance of each operation. These measures are useful in this regard because they do not include such costs as other expense, income taxes, depreciation and amortization expense, which may vary from period-to-period depending upon various factors, including the method used to finance operations, the amount of debt that we have incurred, whether an operation is owned or leased, the date of acquisition of a facility or business, and the tax law of the state in which a business unit operates.

We also establish compensation programs and bonuses for our leaders that are partially based upon the achievement of Adjusted EBITDAR targets.

Despite the importance of these measures in analyzing our underlying business, designing incentive compensation and for our goal setting, the Non-GAAP Financial Measures have no standardized meaning defined by GAAP. Therefore, certain of our Non-GAAP Financial Measures have limitations as analytical tools, and they should not be considered in isolation, or as a substitute for analysis of our results as reported in accordance with GAAP. Some of these limitations are:

they do not reflect our current or future cash requirements for capital expenditures or contractual commitments;
they do not reflect changes in, or cash requirements for, our working capital needs;
they do not reflect the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;
they do not reflect rent expenses, which are necessary to operate our leased operations, in the case of Adjusted EBITDAR;
they do not reflect any income tax payments we may be required to make;
although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and do not reflect any cash requirements for such replacements; and
other companies in our industry may calculate these measures differently than we do, which may limit their usefulness as comparative measures.

77

We compensate for these limitations by using them only to supplement net income on a basis prepared in accordance with GAAP in order to provide a more complete understanding of the factors and trends affecting our business.

Management strongly encourages investors to review our consolidated financial statements in their entirety and to not rely on any single financial measure. Because these Non-GAAP Financial Measures are not standardized, it may not be possible to compare these financial measures with other companies’ Non-GAAP financial measures having the same or similar names. These Non-GAAP Financial Measures should not be considered a substitute for, nor superior to, financial results and measures determined or calculated in accordance with GAAP. We strongly urge you to review the reconciliation of income from operations to the Non-GAAP Financial Measures in the table below, along with our unaudited consolidated financial statements and related notes included elsewhere in this document.

We use the following Non-GAAP financial measures that we believe are useful to investors as key valuation and operating performance measures:

PERFORMANCE MEASURES
EBITDA

We believe EBITDA is useful to investors in evaluating our operating performance because it helps investors evaluate and compare the results of our operations from period to period by removing the impact of our asset base (depreciation and amortization expense) from our operating results.

We calculate EBITDA as net income, adjusted for net losses attributable to noncontrolling interest, before (a) other expense, net, (b) provision for income taxes, and (c) depreciation and amortization.
Adjusted EBITDA

We adjust EBITDA when evaluating our performance because we believe that the exclusion of certain additional items described below provides useful supplemental information to investors regarding our ongoing operating performance, in the case of Adjusted EBITDA. We believe that the presentation of Adjusted EBITDA, when combined with EBITDA and GAAP net income attributable to The Ensign Group, Inc., is beneficial to an investor’s complete understanding of our operating performance.  

Adjusted EBITDA is EBITDA adjusted for non-core business items, which for the reported periods includes, to the extent applicable:

stock-based compensation expense;
real estate transactions and other related costs;
legal finding;
acquisition related costs;
costs incurred related to new systems implementation;
results related to operations not at full capacity; and
gain on sale of assets and business interruptions recoveries.
Funds from Operations (FFO)
We consider FFO to be a useful supplemental measure of the operating performance of Standard Bearer. Historical cost accounting for real estate assets in accordance with U.S. GAAP implicitly assumes that the value of real estate assets diminishes predictably over time as evidenced by the provision for depreciation. However, since real estate values have historically risen or fallen with market conditions, many real estate investors and analysts have considered presentations of operating results for real estate companies that use historical cost accounting to be insufficient. In response, the National Association of Real Estate Investment Trusts (NAREIT) created FFO as a supplemental measure of operating performance for REITs, which excludes historical cost depreciation from net income. We define (in accordance with the definition used by NAREIT) FFO to consist of Standard Bearer segment income, excluding depreciation and amortization related to real estate, gains or losses from the sale of real estate, insurance recoveries related to real estate and impairment of depreciable real estate assets.

78

VALUATION MEASURE
Adjusted EBITDAR

 We use Adjusted EBITDAR as one measure in determining the value of prospective acquisitions. It is also a commonly used measure by our management, research analysts and investors, to compare the enterprise value of different companies in the healthcare industry, without regard to differences in capital structures and leasing arrangements. Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP. This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense, and is therefore presented only for the current period.

The adjustments made and previously described in the computation of Adjusted EBITDA are also made when computing Adjusted EBITDAR. We calculate Adjusted EBITDAR by excluding rent-cost of services from Adjusted EBITDA.

We believe the use of Adjusted EBITDAR allows the investor to compare operational results of companies who have operating and capital leases. A significant portion of capital lease expenditures are recorded in interest, whereas operating lease expenditures are recorded in rent expense.

The table below reconciles net income to EBITDA, Adjusted EBITDA and Adjusted EBITDAR for the periods presented:

Year Ended December 31,
20222021
Consolidated statements of income data:
(In thousands)
Net income $224,652 $197,725 
Less: net (loss) income attributable to noncontrolling interests
(29)3,073 
Add: Other expense, net7,736 2,461 
Provision for income taxes
64,437 60,279 
Depreciation and amortization62,355 55,985 
EBITDA$359,209 $313,377 
Stock-based compensation22,720 18,678 
Real estate transactions and other related costs(a)
— 5,689 
Legal finding(b)
4,280 — 
Gain on sale of assets and business interruptions recoveries
(4,380)(2,365)
Results related to operations not at full capacity— 585 
Acquisition related costs(c)
669 384 
Costs incurred related to new systems implementation
1,072 186 
Rent related to items above— 38 
Adjusted EBITDA$383,570 $336,572 
Rent—cost of services153,049 139,371 
Less: rent related to items above— (38)
Adjusted rent 153,049 139,333 
Adjusted EBITDAR $536,619 
(a) Real estate transactions and other related costs include costs incurred related to the formation of Standard Bearer and other real estate related activities.
(b) Legal finding against our non-emergent transportation subsidiary.
(c) Costs incurred to acquire operations that are not capitalizable.


79

Year Ended December 31, 2022 Compared to the Year Ended December 31, 2021
The following table sets forth details of operating results for our revenue and earnings, and their respective components, by our reportable segment for the periods indicated:
Year Ended December 31, 2022
 Skilled ServicesStandard BearerAll OtherEliminationsConsolidated
Total revenue $2,906,215 $72,937 $122,610 $(76,294)$3,025,468 
Total expenses, including other expense, net2,497,483 45,066 273,391 (76,294)2,739,646 
Segment income (loss)408,732 27,871 (150,781)— 285,822 
Gain from sale of real estate3,267 
Income before provision for income taxes $289,089 
Year Ended December 31, 2021
 Skilled ServicesStandard BearerAll OtherEliminationsConsolidated
Total revenue $2,523,234 $58,127 $102,685 $(56,585)$2,627,461 
Total expenses, including other expense, net2,149,631 26,251 250,600 (56,585)2,369,897 
Segment income (loss)373,603 31,876 (147,915)— 257,564 
Gain from sale of real estate
440 
Income before provision for income taxes$258,004 
Our total revenue increased $398.0 million, or 15.1%, compared to the year ended December 31, 2021. The increase in revenue was primarily driven by an increase in occupancy from our skilled services operations along with the impact of acquisitions. Total revenue from operations acquired on or subsequent to January 1, 2022 increased our consolidated revenue by $123.9 million during the year ended December 31, 2022, when compared to the same period in 2021. In addition, we recorded $81.8 million of state relief revenue during the year ended in 2022 compared to $75.2 million in 2021, which directly correlated to the additional COVID-19 related expenses incurred. All state relief revenue is included in Medicaid revenue.
Skilled Services Segment

Revenue

The following table presents the skilled services revenue and key performance metrics by category during the years ended December 31, 2022 and 2021:
Year Ended December 31,
 20222021Change% Change
TOTAL FACILITY RESULTS:(Dollars in thousands)
Skilled services revenue$2,906,215 2,523,234 $382,981 15.2 %
Number of facilities at period end234 211 23 10.9 %
Number of campuses at period end*26 25 4.0 %
Actual patient days7,243,781 6,478,810 764,971 11.8 %
Occupancy percentage — Operational beds75.3 %72.8 % 2.5 %
Skilled mix by nursing days31.8 %31.7 % 0.1 %
Skilled mix by nursing revenue52.0 %52.3 % (0.3)%
80

Year Ended December 31,
 20222021Change% Change
SAME FACILITY RESULTS:(1)
(Dollars in thousands)
Skilled services revenue$2,237,100 $2,084,537 $152,563 7.3 %
Number of facilities at period end167 167 — — %
Number of campuses at period end*20 20 — — %
Actual patient days5,450,136 5,269,464 180,672 3.4 %
Occupancy percentage — Operational beds76.4 %73.9 % 2.5 %
Skilled mix by nursing days33.7 %33.1 % 0.6 %
Skilled mix by nursing revenue53.9 %53.8 % 0.1 %
Year Ended December 31,
20222021Change% Change
TRANSITIONING FACILITY RESULTS:(2)
(Dollars in thousands)
Skilled services revenue$381,003 $336,338 $44,665 13.3 %
Number of facilities at period end27 27 — — %
Number of campuses at period end*— — %
Actual patient days1,002,904 929,058 73,846 7.9 %
Occupancy percentage — Operational beds74.9 %69.4 % 5.5 %
Skilled mix by nursing days27.5 %26.1 % 1.4 %
Skilled mix by nursing revenue47.4 %46.3 % 1.1 %
Year Ended December 31,
20222021Change% Change
RECENTLY ACQUIRED FACILITY RESULTS:(3)
(Dollars in thousands)
Skilled services revenue$288,112 $102,359 $185,753 NM
Number of facilities at period end40 17 23 NM
Number of campuses at period end*— NM
Actual patient days790,741 280,288 510,453 NM
Occupancy percentage — Operational beds69.4 %66.2 %NM
Skilled mix by nursing days23.5 %22.4 % NM
Skilled mix by nursing revenue42.3 %42.3 % NM
*Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective operating segment. In 2022, we converted three skilled nursing facilities into campuses.
(1)Same Facility results represent all facilities purchased prior to January 1, 2019.
(2)Transitioning Facility results represent all facilities purchased from January 1, 2019 to December 31, 2020.
(3)Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2021.

Skilled services revenue increased $383.0 million, or 15.2%, compared to the year ended December 31, 2021. Of the $383.0 million increase, the primary changes were from increases in Medicaid custodial revenue of $151.2 million, or 15.0%, Medicare revenue of $105.1 million, or 14.4%, managed care revenue of $69.0 million, or 15.1%, private revenue of $29.6 million, or 18.5% and Medicaid skilled revenue of $28.1 million, or 16.3%.

The increase in skilled services revenue was primarily driven by strong performance across our existing skilled services operations as our census continued to recover in fiscal year 2022 and the impact of operation expansions in 2022. Our consolidated occupancy increased by 2.5% and our skilled nursing days increased by 0.1% compared to 2021.


81

Revenue in our Same Facilities increased $152.6 million, or 7.3%, compared to 2021, due to increases in occupancy and skilled mix. Our diligent efforts to strengthen our partnership with various managed care organizations, hospitals and the local communities we operate in, increased our occupancy by 2.5% to 76.4%. Managed care and Medicare skilled days increased by 6.4% and 5.5%, respectively, coupled with an increase in our skilled revenue daily rate of 2.3%, resulting in an increase in skilled mix revenue.

Revenue generated by our Transitioning Facilities increased $44.7 million, or 13.3%, primarily due to improved occupancy growth of 5.5% and an increase in skilled mix days of 1.4%, compared to 2021, demonstrating our ability to transition these healthcare operations toward higher acuity patients. Skilled mix revenue increased by 1.1%, mainly from the increases in managed care and Medicare days of 22.3% and 8.6%, respectively, coupled with an increase in our skilled revenue daily rate of 1.7%.

Skilled services revenue generated by facilities purchased on or subsequent to January 1, 2021 (Recently Acquired Facilities) increased by approximately $185.8 million compared to the year ended December 31, 2021. The increases are primarily due to the expansion of 24 operations between January 1, 2022 and December 31, 2022 across six states.
In the future, if we acquire additional facilities that are underperforming and need to be turned around or invest in start-up operations, we expect to see lower occupancy rates and skilled mix and these metrics are expected to vary from period to period based upon the maturity of the facilities within our portfolio. Historically, we have generally experienced lower occupancy rates and lower skilled mix at Recently Acquired Facilities and therefore, we anticipate generally lower overall occupancy during years of growth.
The following table reflects the change in skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate (1):
Year Ended December 31,
 Same FacilityTransitioningAcquisitionsTotal
 20222021202220212022202120222021
SKILLED NURSING AVERAGE DAILY REVENUE RATES
Medicare$693.31 $687.26 $690.20 $681.34 $675.96 $707.03 $691.25 $687.18 
Managed care513.80 503.36 476.71 463.89 502.48 510.88 508.53 498.97 
Other skilled582.84 543.06 461.46 411.41 477.86 558.26 563.56 534.40 
Total skilled revenue599.02 585.58 578.03 568.30 583.74 624.26 595.26 584.72 
Medicaid262.11 251.35 245.74 234.38 245.87 245.52 257.67 248.41 
Private and other payors254.06 238.33 230.40 227.98 235.50 251.92 248.54 237.21 
Total skilled nursing revenue
$374.97 $360.80 $335.41 $320.95 $324.40 $330.88 $363.97 $353.79 
(1) These rates exclude additional FMAP and other state relief funding and include sequestration reversal of 1% for the second quarter in 2022 and 2% for the first quarter of 2022 and the year ended December 31, 2021.

Our Medicare daily rates at Same Facilities and Transitioning Facilities increased by 0.9% and 1.3%, respectively, compared to the year ended December 31, 2021. The increase is attributable to the 2.7% net market basket increase that became effective in October 2022 offset by the removal of sequestration suspension. In 2022, Medicare daily rates includes three months of sequestration suspension of 1%, three months of sequestration suspension of 2% and six months of no sequestration suspension compared to the sequestration suspension of 2% that was in place for the entire year of 2021.

Our average Medicaid rates increased 3.7% due to state reimbursement increases and our participation in supplemental Medicaid payment programs and quality improvement programs in various states. Medicaid rates exclude the amount of state relief revenue we recorded.
Payor Sources as a Percentage of Skilled Nursing Services We use our skilled mix as a measure of the quality of reimbursements we receive at our affiliated skilled nursing facilities over various periods.


82

The following tables set forth our percentage of skilled nursing patient revenue and days by payor source:

 Year Ended December 31,
 Same FacilityTransitioningAcquisitionsTotal
 20222021202220212022202120222021
PERCENTAGE OF SKILLED NURSING REVENUE
Medicare25.6 %25.9 %27.2 %27.9 %24.4 %25.2 %25.7 %26.1 %
Managed care19.6 19.4 16.8 15.1 10.6 9.0 18.3 18.4 
Other skilled8.7 8.5 3.4 3.3 7.3 8.1 8.0 7.8 
Skilled mix53.9 53.8 47.4 46.3 42.3 42.3 52.0 52.3 
Private and other payors7.0 6.8 8.0 7.7 6.9 6.1 7.0 6.9 
Medicaid39.1 39.4 44.6 46.0 50.8 51.6 41.0 40.8 
TOTAL SKILLED NURSING100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %

 Year Ended December 31,
 Same FacilityTransitioningAcquisitionsTotal
 20222021202220212022202120222021
PERCENTAGE OF SKILLED NURSING DAYS
Medicare13.9 %13.6 %13.2 %13.2 %11.7 %11.8 %13.5 %13.5 %
Managed care14.3 13.9 11.8 10.4 6.9 5.8 13.1 13.0 
Other skilled5.5 5.6 2.5 2.5 4.9 4.8 5.2 5.2 
Skilled mix33.7 33.1 27.5 26.1 23.5 22.4 31.8 31.7 
Private and other payors10.3 10.3 11.6 11.0 9.5 8.1 10.3 10.2 
Medicaid56.0 56.6 60.9 62.9 67.0 69.5 57.9 58.1 
TOTAL SKILLED NURSING100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %

Cost of Services

The following table sets forth total cost of services for our skilled services segment for the periods indicated (dollars in thousands):
 Year Ended December 31,Change
20222021$%
Cost of service$2,267,691 $1,944,461 $323,230 16.6 %
Revenue percentage78.0 %77.1 %0.9 %

Cost of services related to our skilled services segment increased by $323.2 million, or 16.6%, due to additional costs at new operation expansions, which accounted for $147.7 million of the increase to cost of services. The remaining increases are mainly due to higher staffing expenses. As the result of COVID-19 variants, our operations experienced staffing constraints due to isolation requirements and COVID-19 exposure, which resulted in additional overtime, benefits and bonuses to our staff as well as higher use of contracted labor. The increase in labor costs is offset by cost management in non-clinical expenses. Cost of services as a percentage of revenue increased to 78.0% from 77.1%.

83

Standard Bearer
 Year Ended December 31,Change
20222021$%
(Dollars in thousands)
Rental revenue generated from third-party tenants$14,970 13,962 $1,008 7.2 %
Rental revenue generated from Ensign affiliated operations57,967 44,165 13,802 31.3 
TOTAL RENTAL REVENUE$72,937 $58,127 $14,810 25.5 %
Segment income27,871 31,876 (4,005)(12.6)
Depreciation and amortization21,613 17,558 4,055 23.1 
FFO$49,484 $49,434 $50 0.1 %
Rental revenue Standard Bearer's rental revenue, including revenue generated from our affiliated facilities, increased by $14.8 million, or 25.5% to $72.9 million, compared to the year ended December 31, 2021. The increase in revenue is primarily attributable to ten real estate purchases as well as annual rent increases since the year ended December 31, 2021.
Segment income Standard Bearer's segment income decreased by 12.6% to $27.9 million, compared to the year ended December 31, 2021. The decrease is primarily attributable to increases in interest expense as a result of intercompany debt arrangements used to fund real estate acquisitions, management fee expense associated with the intercompany agreements between Standard Bearer and the Service Center and depreciation and amortization offset by increases in rental revenue as a result of the real estate acquisitions.
FFO Standard Bearer's FFO increased by 0.1% to $49.5 million, compared to the year ended December 31, 2021. The increase is similar to the change in segment income with the exclusion of depreciation and amortization. Excluding the expenses entered into in 2022, FFO increased by 26.4%.
All Other Revenue
Our other revenue increased by $19.9 million, or 19.4% to $122.6 million, compared to the year ended December 31, 2021. Other revenue for 2022 includes senior living revenue of $67.4 million and revenue from other ancillary services of $47.8 million and rental income of $7.4 million. The increase in other revenue is attributable to our senior living operation expansions in 2022.
Consolidated Financial Expenses
Rent — cost of services Our rent — cost of services as a percentage of total revenue decreased by 0.2% to 5.1%, primarily due to the growth in revenue outpacing the increase in rent expense and as our operation expansions include the acquisition of the related real estate properties.
General and administrative expense General and administrative expense increased $7.0 million or 4.6%, to $158.8 million. This increase was primarily due to increases in wages and benefits due to enhanced performance and growth. General and administrative expense as a percentage of revenue decreased by 0.6% to 5.2%, which demonstrates our refocused efforts on non-clinical spend management.
Depreciation and amortization Depreciation and amortization expense increased $6.4 million, or 11.4%, to $62.4 million. This increase was primarily related to the additional depreciation and amortization incurred as a result of our newly acquired operations. Depreciation and amortization remained consistent at 2.1%, as a percentage of revenue.
Other expense, net Other expense, net as a percentage of revenue increased by 0.2%, to 0.3%. Other expense primarily includes interest expense related to our debt and gain or loss on the deferred compensation investments. During the year ended December 31, 2022, we recorded a loss on those investments of $4.2 million compared to a gain of $1.6 million during the year ended December 31, 2021. There is an offsetting income and offsetting expense split between cost of services and general and administrative expenses in 2022 and 2021, respectively.

84

Provision for income taxes Our effective tax rate was 22.3% for the year ended December 31, 2022, compared to 23.4% for the same period in 2021. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, partially offset by non-deductible expenses. See Note 15, Income Taxes, in the Notes to the Consolidated Financial Statements for further discussion.

Liquidity and Capital Resources
Our primary sources of liquidity have historically been derived from our cash flows from operations and long-term debt secured by our real property and our Revolving Credit Facility. Our liquidity as of December 31, 2022 is impacted by cash generated from strong operational performance and increased acquisition and share repurchase activities.
Historically, we have primarily financed the majority of our acquisitions through mortgages on our properties, our Revolving Credit Facility and cash generated from operations. Cash paid to fund acquisitions was $101.1 million and $104.1 million for the years ended December 2022 and 2021, respectively. Total capital expenditures for property and equipment were $87.5 million and $69.6 million for the years ended December 31, 2022 and 2021, respectively. We currently have approximately $80.0 million budgeted for renovation projects for 2023. We believe our current cash balances, our cash flow from operations and the amounts available for borrowing under our Revolving Credit Facility will be sufficient to cover our operating needs for at least the next 12 months.

We may, in the future, seek to raise additional capital to fund growth, capital renovations, operations and other business activities, but such additional capital may not be available on acceptable terms, on a timely basis, or at all.
Our cash and cash equivalents as of December 31, 2022 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of December 31, 2022, we held investments of approximately $83.1 million. We believe our investments that were in an unrealized loss position as of December 31, 2022 do not require an allowance for expected credit losses, nor has any event occurred subsequent to that date that would indicate so.
As mentioned above, our primary sources of cash is from our ongoing operations. Our positive cash flows have supported our business and have allowed us to pay regular dividends to our stockholders. We currently anticipate that existing cash and total investments as of December 31, 2022, along with projected operating cash flows and available financing, will support our normal business operations for the foreseeable future.
On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, we are authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company did not purchase any shares pursuant to this stock repurchase program in the year ended December 31, 2022. The share repurchase program does not obligate us to acquire any specific number of shares.
On February 9, 2022, the Board of Directors approved a stock repurchase program pursuant to which we could repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from February 10, 2022. Under this program, we were authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the second quarter of 2022, we repurchased approximately 0.3 million shares of our common stock for $20.0 million. This repurchase program expired upon the repurchase of the fully authorized amount under the plan and is no longer in effect.
On October 21, 2021, the Board of Directors approved a stock repurchase program pursuant to which we could repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from October 29, 2021. Under this program, we were authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the first quarter of 2022, we repurchased approximately 0.1 million shares of our common stock for $9.9 million. During the fourth quarter of 2021, we repurchased 0.1 million shares of our common stock for $10.1 million. This repurchase program expired upon the repurchase of the fully authorized amount under the plan and is no longer in effect.

85

The following table presents selected data from our consolidated statement of cash flows for the periods presented:
Year Ended December 31,
 20222021
NET CASH PROVIDED BY/(USED IN):(In thousands)
Operating activities$272,513 $275,684 
Investing activities(186,182)(173,907)
Financing activities(32,262)(76,138)
Net increase in cash and cash equivalents54,069 25,639 
Cash and cash equivalents beginning of period262,201 236,562 
Cash and cash equivalents at end of period$316,270 $262,201 
Operating Activities
Cash provided by operating activities is net income adjusted for certain non-cash items and changes in operating assets and liabilities.
The $3.2 million decrease in cash provided by operating activities for the year ended December 31, 2022 compared to the same period in 2021 was primarily due to changes in working capital offset by higher net income. Changes in working capital were driven by timing of collections of accounts receivable and accrued wages and related liabilities.
Investing Activities
Investing cash flows consist primarily of capital expenditures, investment activities, insurance proceeds and cash used for acquisitions.
The $12.3 million increase in cash used in investing activities for the year ended December 31, 2022 compared to the same period in 2021, was primarily due to an increase in cash used for expansions and capital expenditures of $15.0 million partially offset by sale of assets.
Financing Activities
Financing cash flows consist primarily of payment of dividends to stockholders, issuance and repayment of short-term and long-term debt, payment for share repurchases, repayment of the Medicare Accelerated and Advance Payment Program funds and sale of subsidiary shares.
The $43.9 million decrease in cash used in financing activities for the year ended December 31, 2022 compared to the same period in 2021, was primarily due to $102.0 million of net repayments of the Medicare Accelerated and Advance Payment Program funds in 2021 and $6.7 million receipt of proceeds from the sale of preferred shares and common stock of Standard Bearer in 2022. This is offset by $19.8 million of share repurchases as part of our stock repurchase program in 2022 and $45.2 million in proceeds from HUD borrowings in the same period in 2021, that did not recur in 2022.
A discussion of our cash flows for the year ended December 31, 2020 is included in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources, included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on February 9, 2022.

86

Material cash requirements from known contractual and other obligations
Total long-term debt obligations outstanding as of the end of each fiscal year were as follows:
 December 31,
 20222021202020192018
 (In thousands)
Credit facilities and term loans$— $— $— $210,000 $123,125 
Mortgage loan and promissory notes156,271 159,967 117,806 120,350 122,955 
TOTAL$156,271 $159,967 $117,806 $330,350 $246,080 
Significant contractual obligations as of December 31, 2022 were as follows, including the future periods in which payments are expected:
  2023 2024 2025 2026 2027Thereafter Total
  (In thousands)
Operating lease obligations$157,963 $157,630 $157,455 $157,380 $156,860 $1,456,411 $2,243,699 
Long-term debt obligations3,883 3,950 4,086 4,227 3,897 136,228 156,271 
Interest payments on long-term debt4,754 4,623 4,487 4,346 4,207 58,527 80,944 
TOTAL$166,600 $166,203 $166,028 $165,953 $164,964 $1,651,166 $2,480,914 
Not included in the table above are our actuarially determined self-insured general and professional malpractice liability, workers' compensation and medical (including prescription drugs) and dental healthcare obligations, which are broken out between current and long-term liabilities in our financial statements included in this Annual Report on Form 10-K.
Credit Facility with a Lending Consortium Arranged by Truist
On April 8, 2022, we entered into the Amended Credit Agreement, which increased the amount of the revolving line of credit thereunder to $600.0 million in aggregate principal amount. The maturity date of the Revolving Credit Facility is April 8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Revolving Credit Facility are, at our option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the Amended Credit Agreement). In addition, we will pay a commitment fee on the unused portion of the commitments that will range from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio.
Mortgage Loans and Promissory Notes
As of December 31, 2022, 23 of our subsidiaries have mortgage loans insured with HUD for an aggregate amount of $153.5 million, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates at a range of 3.1% to 4.2%, including fixed interest rates at a range of 2.4% to 3.3% per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. For the majority of the loans, the prepayment fee is 10% during the first three years and is reduced by 3% in the fourth year of the loan, and is reduced by 1% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The term of the mortgage loans are 25 to 35 years.
In addition to the HUD mortgage loans above, we have two promissory notes. The notes bear fixed interest rates of 6.3% and 5.3% per annum and the term of the notes are 10 months and 12 years, respectively. The 12 year note, which was used for an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.

87

Operating Leases
As of December 31, 2022, 192 of our facilities are under long-term lease arrangements, of which 96 of the operations are under nine triple-net Master Leases and one stand-alone lease with CareTrust REIT, Inc. (CareTrust). The Master Leases consist of multiple leases, each with its own pool of properties, that have varying maturities and diversity in property geography. Under each master lease, our individual subsidiaries that operate those properties are the tenants and CareTrust's individual subsidiaries that own the properties subject to the Master Leases are the landlords. The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of the percentage change in the Consumer Price Index (but not less than zero) or 2.5%. At our option, we can extend the Master Leases for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. If we elect to renew the term of a Master Lease, the renewal will be effective as to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that we can exercise starting on December 1, 2024.
We also lease certain affiliated facilities and our administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, we lease certain of our equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases.
Fifty-eight of our affiliated facilities, excluding the facilities that are operated under the Master Leases from CareTrust, are operated under ten separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other affiliated facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of our leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in our outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.
U.S. Department of Justice Civil Investigative Demand

On May 31, 2018, we received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it is investigating to determine whether we have violated the False Claims Act and/or the Anti-Kickback Statute with respect to the relationships between certain of our skilled nursing facilities and persons who served as medical directors, advisory board participants or other referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of our Southern California skilled nursing facilities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, our operating entities maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. We have fully cooperated with the U.S. Department of Justice and promptly responded to its requests for information; in April 2020, we were advised that the U.S. Department of Justice declined to intervene in any subsequent action based on or related to the subject matter of this investigation.
Inflation

We have historically derived a substantial portion of our revenue from the Medicare program. We also derive revenue from state Medicaid and similar reimbursement programs. Payments under these programs generally provide for reimbursement levels that are adjusted for inflation annually based upon the state’s fiscal year for the Medicaid programs and in each October for the Medicare program. These adjustments may not continue in the future, and even if received, such adjustments may not reflect the actual increase in our costs for providing healthcare services.

Labor, supply expenses and capital expenditures make up a substantial portion of our cost of services. Those expenses can be subject to increase in periods of rising inflation and when labor shortages occur in the marketplace. To date, we have generally been able to implement cost control measures or obtain increases in reimbursement sufficient to offset increases in these expenses. There can be no assurance that we will be able to anticipate fully or otherwise respond to any future inflationary pressures.


88

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Risk We are exposed to risks associated with market changes in interest rates through our borrowing arrangements and investments. In particular, our Revolving Credit Facility exposes us to variability in interest payments due to changes in SOFR interest rates. We manage our exposure to this market risk by monitoring available financing alternatives. Our mortgages and promissory notes require principal and interest payments through maturity pursuant to amortization schedules.

Our mortgages generally contain provisions that allow us to make repayments earlier than the stated maturity date. In some cases, we are not allowed to make early repayment prior to a cutoff date. Where prepayment is permitted, we are generally allowed to make prepayments only at a premium which is often designed to preserve a stated yield to the note holder. These prepayment rights may afford us opportunities to mitigate the risk of refinancing our debts at maturity at higher rates by refinancing prior to maturity.
On April 8, 2022, we entered into the Amended Credit Agreement, with a revolving line of credit of up to $600.0 million in aggregate principal amount. The Amended Credit Agreement amended the reference for borrowings under the Revolving Credit Facility rate from LIBOR to SOFR. We have no outstanding borrowings under our Amended Credit Facility as of December 31, 2022 and January 30, 2023.

We have outstanding indebtedness under mortgage loans insured with HUD and two promissory notes to third parties of $156.3 million, all of which are at fixed interest rates.

Our cash and cash equivalents as of December 31, 2022 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of December 31, 2022, we held investments of approximately $83.1 million. We believe our investments that were in an unrealized loss position as of December 31, 2022 do not require an allowance for expected credit losses, nor has any event occurred subsequent to that date that would indicate so. Our market risk exposure is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. The primary objective of our investment activities is to preserve principal, while at the same time maximizing the income we receive from our investments without significantly increasing risk. Due to the low risk profile of our investment portfolio, an immediate 10.0% change in interest rates would not have a material effect on the fair market value of our portfolio. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our securities portfolio.

The above only incorporates those exposures that exist as of December 31, 2022 and does not consider those exposures or positions which could arise after that date. If we diversify our investment portfolio into securities and other investment alternatives, we may face increased risk and exposures as a result of interest risk and the securities markets in general.


89


Item 8.     FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 
THE ENSIGN GROUP, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
AND FINANCIAL STATEMENT SCHEDULE


90


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of
The Ensign Group, Inc.
San Juan Capistrano, California

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of The Ensign Group, Inc. and subsidiaries (the "Company") as of December 31, 2022 and 2021, the related consolidated statements of income, shareholders' equity, and cash flows, for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 2, 2023, expressed an unqualified opinion on the Company's internal control over financial reporting.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Self-Insurance Liabilities (General and Professional Liability Claims) - Refer to Notes 2 and 19 to the financial statements

Critical Audit Matter Description

The Company's self-insurance liabilities for general and professional liability claims totaled $87.0 million at December 31, 2022. The Company develops information about the size of the ultimate claims based on historical experience, current industry information, and actuarial analysis.

The determination of reserves for general and professional liability claims is highly subjective. Given the significant judgments in estimating the general and professional liability claims, we have determined this to be a critical audit matter. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the reasonableness of management estimates of reserves for open claims as well as for claims that are incurred but not reported (IBNR).

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures relating to management’s judgment regarding the estimation of the reserve for general and professional liability claims included the following, among others:
We tested the effectiveness of controls over the reserve for general and professional liabilities, including those related to both the determination of reserves for open claims and estimation of the IBNR claims.
We obtained an understanding of the factors considered and assumptions made by management and its external actuarial specialists in developing the estimate of the general and professional liability reserves, including the sources of data relevant to these factors and assumptions. We tested underlying claims data, including testing the completeness and accuracy of open cases handled by legal firms.
We involved our actuarial specialists to assist in our evaluation of the methodologies applied by management's specialist and to assess the accuracy of the Company's reserves. We also compared the reserves recorded to an independent range developed by our actuarial specialists.
We performed a retrospective review in which we compared the current portion of the total liability at the end of the prior year to actual paid claim emergence in the current year.


/s/ DELOITTE & TOUCHE LLP

Costa Mesa, California
February 2, 2023

We have served as the Company's auditor since 1999.
91

THE ENSIGN GROUP, INC.
CONSOLIDATED BALANCE SHEETS
December 31,
20222021
(In thousands, except par values)
ASSETS  
Current assets:   
Cash and cash equivalents$316,270 $262,201 
Accounts receivable—less allowance for doubtful accounts of $7,802 and $11,213 at December 31, 2022 and 2021, respectively
408,432 328,731 
Investments—current15,441 13,763 
Prepaid income taxes4,643 5,452 
Prepaid expenses and other current assets36,339 29,562 
Total current assets781,125 639,709 
Property and equipment, net992,010 888,434 
Right-of-use assets 1,450,995 1,138,872 
Insurance subsidiary deposits and investments 67,652 54,097 
Deferred tax assets39,643 33,147 
Restricted and other assets 37,291 29,516 
Intangible assets, net 2,465 2,652 
Goodwill76,869 60,469 
Other indefinite-lived intangibles 3,972 3,727 
TOTAL ASSETS$3,452,022 $2,850,623 
LIABILITIES AND EQUITY  
Current liabilities:  
Accounts payable$77,087 $58,116 
Accrued wages and related liabilities (Note 3)
289,810 278,770 
Lease liabilities—current 65,796 52,181 
Accrued self-insurance liabilities—current48,187 40,831 
Other accrued liabilities 97,309 89,410 
Current maturities of long-term debt3,883 3,760 
Total current liabilities582,072 523,068 
Long-term debt—less current maturities149,269 152,883 
Long-term lease liabilities—less current portion 1,355,113 1,056,515 
Accrued self-insurance liabilities—less current portion83,495 69,308 
Other long-term liabilities33,273 27,135 
TOTAL LIABILITIES$2,203,222 $1,828,909 
Commitments and contingencies (Notes 16, 18 and 21)
EQUITY  
Ensign Group, Inc. stockholders' equity:
Common stock: $0.001 par value; 100,000 shares authorized; 59,029 and 55,661 shares issued and outstanding at December 31, 2022, respectively, and 58,134 and 55,190 shares issued and outstanding at December 31, 2021, respectively
59 58 
Additional paid-in capital415,560 369,760 
Retained earnings946,339 733,992 
Common stock in treasury, at cost, 3,368 and 2,944 shares at December 31, 2022 and 2021, respectively (Note 22)
(114,626)(83,042)
Total Ensign Group, Inc. stockholders' equity1,247,332 1,020,768 
Non-controlling interest1,468 946 
Total equity$1,248,800 $1,021,714 
TOTAL LIABILITIES AND EQUITY$3,452,022 $2,850,623 
See accompanying notes to consolidated financial statements.
92

THE ENSIGN GROUP, INC.
CONSOLIDATED STATEMENTS OF INCOME

Year Ended December 31,
 202220212020
(In thousands, except per share data)
REVENUE
Service revenue$3,008,711 $2,611,476 $2,387,439 
Rental revenue16,757 15,985 15,157 
TOTAL REVENUE$3,025,468 $2,627,461 $2,402,596 
Expense:
Cost of services2,354,434 2,019,879 1,865,201 
Rent—cost of services 153,049 139,371 129,926 
General and administrative expense158,805 151,761 129,743 
Depreciation and amortization62,355 55,985 54,571 
TOTAL EXPENSES$2,728,643 $2,366,996 $2,179,441 
Income from operations296,825 260,465 223,155 
Other (expense) income:
Interest expense(8,931)(6,849)(9,362)
Other income 1,195 4,388 3,813 
Other expense, net$(7,736)$(2,461)$(5,549)
Income before provision for income taxes289,089 258,004 217,606 
Provision for income taxes64,437 60,279 46,242 
NET INCOME$224,652 $197,725 $171,364 
Less:
Net (loss) income attributable to noncontrolling interests(29)3,073 886 
Net income attributable to The Ensign Group, Inc.$224,681 $194,652 $170,478 
NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.
Basic $4.09 $3.57 $3.19 
Diluted$3.95 $3.42 $3.06 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic54,887 54,486 53,434 
Diluted56,871 56,925 55,787 
See accompanying notes to consolidated financial statements.
93

THE ENSIGN GROUP, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
 Common Stock Additional Paid-In Capital Retained Earnings Treasury Stock Non-Controlling Interest
(In thousands)Shares Amount   Shares Amount Total
BALANCE - JANUARY 1, 202053,487 $56 $307,914 $391,523 2,079 $(45,296)$1,947 $656,144 
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards979 1 12,654 — — — — 12,655 
Issuance of restricted stock, net of forfeitures872 1 3,085 — — — — 3,086 
Shares of common stock used to satisfy tax withholding obligations(20)— — — 20 (917)— (917)
Dividends declared ($0.2025 per share)
— — — (10,946)— — — (10,946)
Employee stock award compensation— — 14,524 — — — — 14,524 
Repurchase of common stock (Note 22)
(692)— — — 692 (25,000)— (25,000)
Net income attributable to noncontrolling interest— — — — — — 886 886 
Distribution to noncontrolling interest holder— — — — — — (2,683)(2,683)
Net income attributable to the Ensign Group, Inc.— — — 170,478 — — — 170,478 
BALANCE - DECEMBER 31, 202054,626 $58 $338,177 $551,055 2,791 $(71,213)$150 $818,227 
Issuance of common stock to employees and directors resulting from the exercise of stock options516 — 9,180 — — — — 9,180 
Issuance of restricted stock, net of forfeitures201 — 3,725 — — — — 3,725 
Shares of common stock used to satisfy tax withholding obligations(21)— — — 21 (1,711)— (1,711)
Dividends declared ($0.2125 per share)
— — — (11,715)— — — (11,715)
Employee stock award compensation— — 18,678 — — — — 18,678 
Repurchase of common stock (Note 22)
(132)— — — 132 (10,118)— (10,118)
Deconsolidation of an ancillary business— — — — — — (1,369)(1,369)
Capital contribution from noncontrolling interest holder— — — — — — 2,000 2,000 
Net income attributable to noncontrolling interest— — — — — — 3,073 3,073 
Distribution to noncontrolling interest holder— — — — — — (2,908)(2,908)
Net income attributable to the Ensign Group, Inc.— — — 194,652 — — — 194,652 
BALANCE - DECEMBER 31, 202155,190 $58 $369,760 $733,992 2,944 $(83,042)$946 $1,021,714 
Issuance of common stock to employees and directors resulting from the exercise of stock options688 1 12,676 — — — — 12,677 
Issuance of restricted stock, net of forfeitures207 — 5,241 — — — — 5,241 
Shares of common stock used to satisfy tax withholding obligations(20)— — — 20 (1,702)— (1,702)
Dividends declared ($0.2225 per share)
— — — (12,334)— — — (12,334)
Employee stock award compensation— — 22,720 — — — — 22,720 
Repurchase of common stock (Note 22)
(404)— — — 404 (29,882)— (29,882)
Acquisition of noncontrolling interest shares— — (1,539)— — — 835 (704)
Issuance of noncontrolling interests through subsidiary equity plan— — 6,693 — — — — 6,693 
Net loss attributable to noncontrolling interest— — — — — — (29)(29)
Distribution to noncontrolling interest holder and other changes— — 9 — — — (284)(275)
Net income attributable to the Ensign Group, Inc.— — — 224,681 — — — 224,681 
BALANCE - DECEMBER 31, 202255,661 $59 $415,560 $946,339 3,368 $(114,626)$1,468 $1,248,800 
See accompanying notes to consolidated financial statements.

94

THE ENSIGN GROUP, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31,
(In thousands)202220212020
Cash flows from operating activities:  
Net income $224,652 $197,725 $171,364 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization62,355 55,985 54,571 
Impairment of long-lived assets  2,681 
Amortization of deferred financing fees1,036 859 840 
Non-cash leasing arrangement 493 485 451 
Write-off of deferred financing fees566   
Deferred income taxes (6,496)(724)(27,809)
Provision for doubtful accounts 2,390 2,609 7,058 
Stock-based compensation22,720 18,678 14,524 
Cash received from insurance proceeds1,282 2,382  
Gain on sale of assets (3,467)(1,371) 
Loss (gain) on insurance claims, legal finding and asset disposals3,926 (977)625 
Change in operating assets and liabilities 
Accounts receivable (82,426)(30,771)2,171 
Prepaid income taxes809 (4,228)(485)
Prepaid expenses and other assets(9,141)(4,898)(2,897)
Deferred employer portion of social security taxes(24,155)(24,154)48,309 
Cash surrender value of life insurance policy premiums(7,614)(10,953)(6,577)
Deferred compensation liability7,637 11,078 6,615 
Operating lease obligations345 (5,814)(724)
Accounts payable17,870 7,117 6,627 
Accrued wages and related liabilities38,982 47,701 68,365 
Other accrued liabilities3,010 1,297 17,536 
Accrued self-insurance liabilities17,785 13,724 10,293 
Other long-term liabilities(46)(66)(187)
NET CASH PROVIDED BY OPERATING ACTIVITIES
$272,513 $275,684 $373,351 
Cash flows from investing activities:  
Purchase of property and equipment(87,545)(69,550)(50,326)
Cash payments for business acquisitions (Note 9)
(16,400)(6,000) 
Cash payments for asset acquisitions (Note 9)
(84,736)(98,224)(24,997)
Escrow deposits 100 (100)
Escrow deposits used to fund acquisitions  14,050 
Cash from insurance proceeds1,339 6,899 800 
Cash proceeds from the sale of assets8,630 1,854 412 
Deconsolidation of an ancillary business (1,984) 
Cash payments for Medicare and Medicaid licenses (106) 
Purchases of investments(21,975)(32,257)(21,708)
Maturities of investments14,356 27,481 24,479 
Other restricted assets149 (2,120)(1,276)
NET CASH USED IN INVESTING ACTIVITIES
$(186,182)$(173,907)$(58,666)
Cash flows from financing activities:  
Proceeds from debt (Note 16)
411 45,218 417,200 
Payments on debt (Note 16)
(4,106)(3,056)(629,745)
Issuance of common stock upon exercise of options12,677 9,180 12,654 
Repurchase of shares of common stock to satisfy tax withholding obligations(1,702)(1,711)(917)
Repurchase of shares of common stock (Note 22)
(29,882)(10,118)(25,000)
Dividends paid(12,168)(11,548)(10,830)
Proceeds from sale of subsidiary shares (Note 7)
6,693   
Non-controlling interest distribution(284)(2,908)(2,683)
Purchase of non-controlling interest(704)2,000  
Payments of deferred financing costs(3,197)(1,172) 
Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)
 11,637 246,955 
Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)
 (113,660)(144,932)
NET CASH USED IN FINANCING ACTIVITIES
$(32,262)$(76,138)$(137,298)
Net increase in cash and cash equivalents54,069 25,639 177,387 
Cash and cash equivalents beginning of period262,201 236,562 59,175 
Cash and cash equivalents end of period$316,270 $262,201 $236,562 

Year Ended December 31,
(In thousands)202220212020
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION  
Cash paid during the period for:  
Interest$7,604 $5,690 $9,920 
Income taxes$70,055 $65,547 $74,365 
Lease liabilities$151,870 $138,795 $129,569 
Non-cash financing and investing activity 
Accrued capital expenditures$4,800 $3,700 $3,400 
Accrued dividends declared$3,201 $3,035 $2,868 
Note receivable from insurance settlement $ $ $5,500 
Right-of-use assets obtained in exchange for new and modified operating lease obligations$370,753 $198,593 $24,599 

See accompanying notes to consolidated financial statements.
95

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Dollars, shares and options in thousands, except per share data)
1. DESCRIPTION OF BUSINESS
The Company — The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company's independent operating subsidiaries provide health care services across the post-acute care continuum, engaged in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of December 31, 2022, the Company's independent operating subsidiaries operated 271 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's independent operating subsidiaries have a collective capacity of approximately 28,100 operational skilled nursing beds and 3,000 senior living units. As of December 31, 2022, the Company's independent operating subsidiaries operated 192 facilities under long-term lease arrangements, and had options to purchase 11 of those 192 facilities. The Company's real estate portfolio includes 108 owned real estate properties, which included 79 facilities operated and managed by the Company's independent operating subsidiaries, 29 senior living operations leased to and operated by The Pennant Group, Inc. (Pennant) as part of the spin-off transaction in October 2019, and the Service Center location. Of those 29 senior living operations, one is located on the same real estate property as a skilled nursing facility that the Company owns and operates.
Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.
In January of 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The Company expects the REIT structure will provide it with an efficient vehicle for future acquisitions of properties that could be operated by Ensign affiliates or other third parties. Refer to Note 7, Standard Bearer for additional information on Standard Bearer.
Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Annual Report is not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its consolidated statements of income.
The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest.
ReclassificationsCertain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net income. Prior period results reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure as a result of the formation of Standard Bearer. Refer to Note 8, Business Segments. Reclassification adjustments have been made to reclassify investments associated with the Company's non-qualified deferred compensation plan with investments held by the Company's captive insurance subsidiary on the consolidated balance sheets.

96

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Estimates and Assumptions The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.
Fair Value of Financial InstrumentsThe Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. See Note 6, Fair Value Measurements.
Service Revenue RecognitionThe Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). See Note 4, Revenue and Accounts Receivable.
Rental Revenue Recognition The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842). See Note 4, Revenue and Accounts Receivable.
Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.
Cash and Cash Equivalents Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.
Insurance Subsidiary Deposits and Investments — The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution.
The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. The fair value of the investment funds is derived using Level 2 inputs.
When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.
Property and Equipment Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.

97

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Leases and Leasehold Improvements The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease at the inception of each lease. Leases commencing prior to the ASC 842 adoption date were classified as operating lease under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. For leases commencing subsequent to the ASC 842 adoption date, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December 31, 2022, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.
The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.
The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases.
Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the years ended December 31, 2022 and 2021. The Company recorded an impairment charge of $2,681 during the year ended December 31, 2020.
Intangible Assets and Goodwill Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any goodwill or intangible asset impairment during the years ended December 31, 2022, 2021, and 2020.

98

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,000 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider.
The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.
The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.
In addition, the Company has recorded an asset and equal liability in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 13, Restricted and Other Assets.
The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525, $500 and $300 for each covered person for fiscal years 2022, 2021 and 2020, respectively.
The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.

99

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.
Standard Bearer intends to qualify and elect to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer believes it has been organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions.
Noncontrolling Interest The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
Stock-Based CompensationThe Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.
Comprehensive Income The Company does not have any components of other comprehensive income recorded within its consolidated Financial Statements and, therefore, does not separately present a statement of comprehensive income in its consolidated Financial Statements.
Recent Accounting Pronouncements Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.
Recent Accounting Standards Adopted by the Company In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance,” which created FASB ASC Topic 832, Government Assistance (ASC 832). ASC 832 requires business entities to disclose information about certain government assistance they receive. The Company adopted this standard on January 1, 2022 and determined there was no material impact on the Company's Financial Statements.
100

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

In February 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848)," which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace London Interbank Offered Rate (LIBOR) reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2024. During the year ended December 31, 2022, the Company and its subsidiaries including Standard Bearer, entered into the Second Amendment to Third Amended and Restated Credit Agreement (such agreement, the Amended Credit Agreement, and the revolving credit facility thereunder, the Revolving Credit Facility), which increased the Revolving Credit Facility by $250,000 to an aggregate principal amount of up to $600,000. Pursuant to the Amended Credit Agreement, the Company transitioned from LIBOR to the Secured Overnight Financing Rate (SOFR) as the applicable reference rate for borrowings under the Revolving Credit Facility and determined there was no resulting material impact on the Company's Financial Statements.
3. COVID-19 UPDATE
The COVID-19 pandemic has continued to impact the Company's affiliated operations. In prior years, as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act), the Company received cash distributions of relief fund payments (Provider Relief Funds) and funds authorized by U.S. Department of Health and Human Services (HHS) to be used to protect residents of nursing homes and long-term care (LTC) facilities from the impact of COVID-19. During the year ended December 31, 2022, the Company did not receive Provider Relief Funds. During the year ended December 31, 2021 and 2020, the Company received and returned $11,637 and $141,700, respectively, in Provider Relief Funds.
In fiscal year 2020, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in 2020 and the remaining funds of $102,023 in March 2021.
The Families First Coronavirus Response Act was signed into law in 2020 to provide a temporary 6.2% increase to the Federal Medical Assistance Percentage (FMAP) effective January 1, 2020. The law permits states to retroactively change their state's Medicaid program rates effective as of January 1, 2020. The law provides discretion to each state and specifies the funds are to be used to reimburse the recipient for healthcare related expenses that are attributable to COVID-19 and associated with providing patient care. In addition, increases in Medicaid rates can come from other areas of the state's budget outside of FMAP funding. Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to COVID-19, the Company characterized such payments as variable revenue that required additional consideration and accordingly, the amount of state relief revenue recognized is limited to the actual COVID-19 related expenses incurred. As of December 31, 2022 and 2021, the Company had $1,001 and $1,781 in unapplied state relief funds, respectively. During the years ended December 31, 2022, 2021, and 2020, the Company received an additional $81,057, $70,484, and $51,927 in state relief funding and recognized $81,837, $75,231, and $45,407, respectively, as revenue.
The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with approximately 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020, and paid the first and second half of the payments in the fourth quarters of 2021 and 2022, respectively.
4. REVENUE AND ACCOUNTS RECEIVABLE
Service Revenue

The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

101

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.
Revenue from the Medicare and Medicaid programs accounted for 73.7%, 73.6% and 74.5% for the years ended December 31, 2022, 2021, and 2020, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the years ended December 31, 2022, 2021, and 2020.
Rental Revenue

The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue is recognized on a straight-line basis over the lease term if it has been deemed probable of collection. The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met.

Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.
Disaggregation of Revenue
The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.
Revenue by Payor

The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed.


102

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Service revenue for the years ended December 31, 2022, 2021, and 2020 is summarized in the following tables:
 Year Ended December 31,
202220212020
Revenue% of RevenueRevenue% of RevenueRevenue% of Revenue
Medicaid(1)
$1,183,156 39.3 %$1,022,460 39.2 %$900,249 37.7 %
Medicare832,160 27.7 727,103 27.8 727,374 30.5 
Medicaid — skilled200,878 6.7 172,770 6.6 149,846 6.3 
Total Medicaid and Medicare2,216,194 73.7 1,922,333 73.6 1,777,469 74.5 
Managed care525,710 17.5 456,728 17.5 367,095 15.4 
Private and other(2)
266,807 8.8 232,415 8.9 242,875 10.1 
SERVICE REVENUE$3,008,711 100.0 %$2,611,476 100.0 %$2,387,439 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP and other COVID-19 related state funding.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $16,757, $15,985 and $15,157 for the years ended December 31, 2022, 2021, and 2020.
Balance Sheet Impact
Included in the Company’s consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of December 31, 2022 and 2021, or activity during the years ended December 31, 2022, 2021, and 2020.

Accounts receivable as of December 31, 2022 and 2021, is summarized in the following table:
December 31,
20222021
Medicaid$157,878 $123,647 
Managed care95,940 79,722 
Medicare76,526 59,797 
Private and other payors85,890 76,778 
 416,234 339,944 
Less: allowance for doubtful accounts(7,802)(11,213)
ACCOUNTS RECEIVABLE, NET$408,432 $328,731 
Practical Expedients and Exemptions

As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.
5. COMPUTATION OF NET INCOME PER COMMON SHARE

Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.
103

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:

Year Ended December 31,
 202220212020
NUMERATOR:
Net income$224,652 $197,725 $171,364 
Less: net (loss) income attributable to noncontrolling interests (29)3,073 886 
Net income attributable to The Ensign Group, Inc. $224,681 $194,652 $170,478 
DENOMINATOR:
Weighted average shares outstanding for basic net income per share54,887 54,486 53,434 
Basic net income per common share:$4.09 $3.57 $3.19 

A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:

Year Ended December 31,
 202220212020
NUMERATOR:
Net income $224,652 $197,725 $171,364 
Less: net (loss) income attributable to noncontrolling interests(29)3,073 886 
Net income attributable to The Ensign Group, Inc. $224,681 $194,652 $170,478 
DENOMINATOR:
Weighted average common shares outstanding54,887 54,486 53,434 
Plus: incremental shares from assumed conversion (1)
1,984 2,439 2,353 
Adjusted weighted average common shares outstanding56,871 56,925 55,787 
Diluted net income per common share:$3.95 $3.42 $3.06 
(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 780, 198 and 956 for the years ended December 31, 2022, 2021 and 2020, respectively.
6. FAIR VALUE MEASUREMENTS

Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The fair value of cash and cash equivalents of $316,270 and $262,201 as of December 31, 2022 and 2021, respectively, is derived using Level 1 inputs. The Company's other financial assets include the captive insurance subsidiary's cash and cash equivalents, deposits and investments designated to support long-term insurance subsidiary liabilities and are carried at cost basis of $69,290 and $67,734 as of December 31, 2022 and 2021, respectively. Also included are contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans which are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. As of December 31, 2022, and 2021, the adjusted cost basis of the investment funds is $25,144 and $17,530, respectively.

As of December 31, 2022 and 2021, the cost basis of the Company's financial assets included in the captive insurance subsidiary's investments and the deferred compensation plan investment funds are considered to approximate the fair value of these financial assets and are derived using Level 2 inputs.

104

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company believes its investments that were in an unrealized loss position as of December 31, 2022 do not require an allowance for expected credit losses, nor has any event occurred subsequent to that date that would indicate so.

The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.
7. STANDARD BEARER
Standard Bearer's real estate portfolio consists of 103 of the Company's 108 owned real estate properties, of which 75 are operated and managed by the Company and 29 are leased to and operated by Pennant. Of those 29 senior living operations, one is located on the same real estate property as a skilled nursing facility that the Company owns and operates. Standard Bearer intends to qualify and elect to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. During the year ended December 31, 2022, Standard Bearer acquired the real estate of ten skilled nursing facilities for a purchase price of $84,656, three of which were previously operated and managed by Ensign's affiliated operations. Refer to Note 9, Operation Expansions for additional information.
As part of the formation of Standard Bearer, certain of the Company's operating subsidiaries, Standard Bearer and Standard Bearer's subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations. As these intercompany arrangements were entered into when Standard Bearer was formed in January 2022, the transactions related to these agreements are reflected in Standard Bearer's segment income during year ended December 31, 2022. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, Business Segments, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment.
Intercompany master lease agreements
Certain of the Company's operating subsidiaries and the 75 Standard Bearer subsidiaries entered into five "triple-net" master lease agreements (collectively, the Standard Bearer Master Leases) in January 2022. The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the operating subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The ten real estate properties acquired during year ended December 31, 2022 were added to the Standard Bearer Master Leases. Rental revenue generated from Ensign affiliated operations was $57,967, $44,165 and $40,946 for the years ended December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022, total annual rental income under the Standard Bearer Master Lease is approximately $62.5 million.
Intercompany management agreement
Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue. Management fee generated between Standard Bearer and the Service Center for the year ended December 31, 2022 was $4,367, which represents 6% of total Standard Bearer rental revenue. No management fees were recorded in 2021 and 2020, which was prior to the formation of Standard Bearer.
Intercompany debt arrangements

Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Revolving Credit Facility to fund acquisitions and working capital needs. The interest rate under the Amended Credit Agreement is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum.
105

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory notes are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 16, Debt, for additional information related to these debts.
Equity Instrument Denominated in the Shares of a Subsidiary
As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's affiliated subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to Standard Bearer at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. During the year ended December 31, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the year ended December 31, 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.
During the year ended December 31, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders. The value of Standard Bearer common and preferred shares held by the Company are eliminated in consolidation and the value held by other shareholders are classified as noncontrolling interests on the Company's consolidated balance sheets.
Dividends on Shares of a Subsidiary
During the year ended December 31, 2022, Standard Bearer met the requirement to distribute to its shareholders at least 90% of its annual taxable income through a declaration and payment of cash dividends totaling $30,379. Of that amount, $30,095 was paid in the form of a distribution to the Company and $284 was paid in the form of a distribution to noncontrolling interests.
8. BUSINESS SEGMENTS

In conjunction with the formation of Standard Bearer in January 2022, the Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, began reviewing the results of Standard Bearer instead of all real estate properties. Accordingly, the Company revised its former real estate segment to include only real estate properties that are part of Standard Bearer. This change in organizational structure demonstrates that Standard Bearer's real estate is a core part of the Company's expansion of its real estate investment strategy. As of the first quarter of 2022, the Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. Segment information for prior periods has been recast to reflect the change of the Company’s segment structure.

As of December 31, 2022, the skilled services segment includes 234 skilled nursing operations and 26 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 103 owned real estate properties. These properties include 75 operations the Company operated and managed and 29 senior living operations that are leased to and operated by third parties. Of the 29 real estate operations leased to third parties, one senior living operation is located on the same real estate property as a skilled nursing facility that the Company owns and operates.

The Company also reports an “All Other” category that includes results from its senior living operations, which includes eleven stand-alone senior living operations and the senior living operations at 26 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.



106

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.

The accounting policies of the reportable segments are the same as those described in Note 2, Summary of Significant Accounting Policies. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, real estate insurance recoveries and losses and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 7, Standard Bearer, as it is part of the CODM financial information.

The following tables set forth financial information for the segments:
 Year Ended December 31, 2022
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$2,906,215 $ $115,214 $(12,718)$3,008,711 
Rental revenue(3)
 72,937 7,396 (63,576)16,757 
TOTAL REVENUE$2,906,215 $72,937 $122,610 $(76,294)$3,025,468 
Segment income (loss)408,732 27,871 (150,781) 285,822 
Gain on sale of real estate assets and insurance recoveries, net3,267 
Income before provision for income taxes$289,089 
Depreciation and amortization33,224 21,613 7,518  62,355 
Interest expense(4)
$ $15,707 $1,870 $(8,646)$8,931 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column.

 Year Ended December 31, 2021
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$2,523,234 $ $95,276 $(7,034)$2,611,476 
Rental revenue(3)
 58,127 7,409 (49,551)15,985 
TOTAL REVENUE$2,523,234 $58,127 $102,685 $(56,585)$2,627,461 
Segment income (loss)373,603 31,876 (147,915) 257,564 
Gain on real estate insurance recoveries440 
Income before provision for income taxes$258,004 
Depreciation and amortization30,681 17,558 7,746  55,985 
Interest expense$ $6,842 $7 $ $6,849 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
107

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

 
Year Ended December 31, 2020
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$2,288,182 $ $105,548 $(6,291)$2,387,439 
Rental revenue(3)
 54,104 7,171 (46,118)15,157 
TOTAL REVENUE$2,288,182 $54,104 $112,719 $(52,409)$2,402,596 
Segment income (loss)327,812 27,299 (134,752) 220,359 
Loss on sale of real estate and impairment charges(2,753)
Income before provision for income taxes $217,606 
Depreciation and amortization28,585 16,134 9,852  54,571 
Interest expense$ $9,350 $12 $ $9,362 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.

Service revenue by major payor source were as follows:
 Year Ended December 31, 2022
 Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
Medicaid(1)
$1,158,309 $24,847 $1,183,156 39.3 %
Medicare832,160  832,160 27.7 
Medicaid-skilled200,878  200,878 6.7 
Subtotal2,191,347 24,847 2,216,194 73.7 
Managed care525,710  525,710 17.5 
Private and other(2)
189,158 77,649 266,807 8.8 
TOTAL SERVICE REVENUE$2,906,215 $102,496 $3,008,711 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

 Year Ended December 31, 2021
 Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
Medicaid(1)
$1,007,061 $15,399 $1,022,460 39.2 %
Medicare727,103  727,103 27.8 
Medicaid-skilled172,770  172,770 6.6 
Subtotal1,906,934 15,399 1,922,333 73.6 
Managed care456,728  456,728 17.5 
Private and other(2)
159,572 72,843 232,415 8.9 
TOTAL SERVICE REVENUE$2,523,234 $88,242 $2,611,476 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

108

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

 
Year Ended December 31, 2020
 Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
Medicaid(1)
$886,991 $13,258 $900,249 37.7 %
Medicare727,374  727,374 30.5 
Medicaid-skilled149,846  149,846 6.3 
Subtotal1,764,211 13,258 1,777,469 74.5 
Managed care367,095  367,095 15.4 
Private and other(2)
156,876 85,999 242,875 10.1 
TOTAL SERVICE REVENUE$2,288,182 $99,257 $2,387,439 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
9. OPERATION EXPANSIONS
The Company's subsidiaries expansion focus is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business, or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, a real estate affiliated subsidiary will acquire the property of facilities that have previously been operated under third-party leases.
FASB ASC Topic 805, Clarifying the Definition of a Business (ASC 805) defined the definition of a business to assist entities with evaluating when a set of transferred assets and activities is deemed to be a business. Determining whether a transferred set constitutes a business is important because the accounting for a business combination differs from that of an asset acquisition. The definition of a business also affects the accounting for dispositions. When substantially all of the fair value of assets acquired is concentrated in a single asset, or a group of similar assets, the assets acquired would not represent a business and business combination accounting would not be required.
2022 Expansions
During the year ended December 31, 2022, the Company expanded its operations through a combination of long-term leases and real estate purchases, with the addition of 23 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of seven of the stand-alone skilled nursing operations, which were leased back to Ensign affiliated entities. In addition, the Company purchased the real estate at three skilled nursing properties that the Company was already operating, further expanding the Company's real estate portfolio. Refer to Note 7, Standard Bearer, for additional information on the purchase of real estate properties. In addition, the Company added five senior living operations that were transferred from Pennant, three of which are part of campuses operated by the Company's affiliated operating subsidiaries. These new operations added a total of 3,058 operational skilled nursing beds and 674 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. The aggregate purchase price for these expansions during the year ended December 31, 2022 was $101,136.
In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
The aggregate purchase price for the transactions that were classified as asset acquisitions during the year ended December 31, 2022 was $84,736, consisting of real estate properties and indefinite-lived intangible assets. The remaining aggregate purchase price for transactions during the year ended December 31, 2022 was concentrated in goodwill of $16,400 and accordingly, the transactions were classified as business combinations.
Subsequent to December 31, 2022, the Company expanded its operations through a combination of long-term leases, with the addition of seventeen stand-alone skilled nursing operations. These new operations added 1,462 operational skilled nursing beds. The Company also invested in new ancillary services that are complementary to its existing businesses. In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
109

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

2021 Expansions
During the year ended December 31, 2021, the Company expanded its operations through a combination of long-term leases and a real estate purchase, with the addition of 17 stand-alone skilled nursing operations and five real estate purchases, four of which the Company previously operated and continues to operate. The remaining real estate purchase is operated by Pennant. These new operations added a total of 1,832 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The aggregate purchase price for these acquisitions during the year ended December 31, 2021 was $104,224.
In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
The aggregate purchase price for the asset acquisitions during the year ended December 31, 2021 was $98,224, consisting of real estate properties. The fair value of assets for the remaining additions was concentrated in goodwill of $6,000 and as such, the transaction was classified as a business combination.
2020 Acquisitions
During the year ended December 31, 2020, the Company expanded its operations through a combination of long-term leases and real estate purchases, with the addition of five stand-alone skilled nursing operations, one stand-alone senior living operation and one campus operation. Of these additions, four are related to purchases of owned properties, further expanding the Company's real estate portfolio. These new operations added a total of 507 operational skilled nursing beds and 298 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The aggregate purchase price for these acquisitions during the year ended December 31, 2020 was $24,997.
In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
The fair value of assets for the purchases of these properties was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions.
During the first quarter of 2020, the Company entered into a long-term lease agreement to transfer two senior living operations to Pennant. Ensign affiliates retained ownership of the real estate for these two senior living communities, which was subsequently sold in 2022.     
The table below presents the allocation of the purchase price for the operations acquired during the years ended December 31, 2022, 2021, and 2020, excluding assets that were contributed to Pennant that occurred during the spin-off transaction in 2019.
Year Ended December 31,
202220212020
Land$15,527 $19,928 $9,496 
Building and improvements65,070 77,975 14,178 
Equipment, furniture, and fixtures1,618 217 568 
Assembled occupancy367 29 107 
Goodwill16,400 6,000  
Leased asset1,909   
Other indefinite-lived intangible assets245 75 648 
TOTAL ACQUISITIONS$101,136 $104,224 $24,997 


110

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The assets added during the year ended December 31, 2022 and through the issuance of the Financial Statements were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the December 31, 2022 consolidated balance sheets of the Company, and the operating results have been included in the consolidated statements of operations of the Company since the date the Company gained effective control.
10. PROPERTY AND EQUIPMENT - NET
Property and equipment, net consists of the following:
December 31,
20222021
Land$134,864 $121,164 
Buildings and improvements728,231 646,221 
Leasehold improvements150,903 140,012 
Equipment295,739 262,246 
Furniture and fixtures4,544 4,305 
Construction in progress17,521 10,253 
 1,331,802 1,184,201 
Less: accumulated depreciation(339,792)(295,767)
PROPERTY AND EQUIPMENT, NET$992,010 $888,434 
The Company completed the sale of assets for a sale price of $8,607 and recorded a gain of $3,467 within the Company's consolidated statement of income as cost of services during the year ended December 31, 2022. In addition, the Company evaluated its long-lived assets and did not record an impairment charge for the fiscal years ended 2022 and 2021. The Company recorded impairment charges of $2,681 for the fiscal year ended 2020. See also Note 7, Standard Bearer and Note 9, Operation Expansions for information on acquisitions during the year ended December 31, 2022.
11. INTANGIBLE ASSETS - NET
Weighted Average Life (Years)December 31,
20222021
Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
Intangible AssetsNetNet
Assembled occupancy0.3$435 $(388)$47 $68 $(68)$ 
Facility trade name30.0733 (415)318 733 (391)342 
Customer relationships18.44,582 (2,482)2,100 4,582 (2,272)2,310 
TOTAL $5,750 $(3,285)$2,465 $5,383 $(2,731)$2,652 

During the years ended December 31, 2022, 2021, and 2020, amortization expense was $1,714, $1,435 and $1,813, respectively, of which $1,160, $1,158, and $1,223 was related to the amortization of right-of-use assets, respectively. The Company did not record any impairment charge to intangible assets during the years ended December 31, 2022, 2021, and 2020.

111

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Estimated amortization expense for each of the years ending December 31 is as follows:
YearAmount
2023$281 
2024234 
2025234 
2026234 
2027234 
Thereafter1,248 
 $2,465 
12. GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS

The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value.
The Company performs its goodwill impairment test annually and evaluates goodwill when events or changes in circumstances indicate that its carrying value may not be recoverable. The Company performs the annual impairment testing of goodwill using October 1 as the measurement date. The Company completed its goodwill impairment test as of October 1, 2022 and did not record any impairment charge to goodwill or other intangible assets for the fiscal years 2022, 2021 or 2020. The Company has recognized cumulative goodwill impairment losses of $7,410.
The Company anticipates that the majority of goodwill recognized will be fully deductible for tax purposes as of December 31, 2022.

All of the Company's acquisitions during the year ended December 31, 2020 were classified as asset acquisitions and accordingly, no goodwill was recognized for these acquisitions. There were no other activities in goodwill during the year ended December 31, 2020. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of and for the year ended December 31, 2022, 2021 and 2020:
Goodwill
 Skilled ServicesAll OtherTotal
January 1, 2020$45,486 $8,983 $54,469 
December 31, 2020$45,486 $8,983 $54,469 
Additions6,000  6,000 
December 31, 2021$51,486 $8,983 $60,469 
Additions16,400  16,400 
December 31, 2022$67,886 $8,983 $76,869 
During the year ended December 31, 2022, the Company acquired $245 in Medicare and Medicaid licenses compared to $181 and $648 in the fiscal years 2021 and 2020, respectively.

112

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Other indefinite-lived intangible assets consist of the following:
December 31,
20222021
Trade name$889 $889 
Medicare and Medicaid licenses3,083 2,838 
TOTAL$3,972 $3,727 
13. RESTRICTED AND OTHER ASSETS

Restricted and other assets consist of the following:
December 31,
20222021
Debt issuance costs, net$3,753 $1,953 
Long-term insurance losses recoverable asset10,512 6,755 
Capital improvement reserves with landlords and lenders6,446 7,103 
Deposits with landlords2,527 2,606 
Other14,053 11,099 
RESTRICTED AND OTHER ASSETS$37,291 $29,516 

Included in restricted and other assets as of December 31, 2022 and 2021 are anticipated insurance recoveries related to the Company's workers' compensation, general and professional liability claims that are recorded on a gross rather than net basis in accordance with an Accounting Standards Update issued by the FASB.
14. OTHER ACCRUED LIABILITIES

Other accrued liabilities consists of the following:
December 31,
20222021
Quality assurance fee$7,701 $6,474 
Refunds payable40,783 34,814 
Resident advances9,698 9,337 
Unapplied state relief funds1,001 1,781 
Cash held in trust for patients6,400 6,430 
Dividends payable3,201 3,035 
Property taxes10,926 9,124 
Legal finding accrued4,553  
Other13,046 18,415 
OTHER ACCRUED LIABILITIES$97,309 $89,410 

Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the consolidated balance sheets.


113

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

15. INCOME TAXES
The provision for income taxes on continuing operations for the years ended December 31, 2022, 2021 and 2020 is summarized as follows:
 Year Ended December 31,
 2022 2021 2020
Current:   
Federal$56,717 $49,105 $60,591 
State14,216 11,898 13,460 
 70,933 61,003 74,051 
Deferred: 
Federal(5,158)(716)(23,054)
State(1,338)(8)(4,755)
(6,496)(724)(27,809)
     TOTAL$64,437 $60,279 $46,242 

A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2022, 2021 and 2020, respectively, is comprised as follows:

 
 December 31,
 202220212020
Income tax expense at statutory rate21.0 %21.0 %21.0 %
State income taxes - net of federal benefit3.5 3.7 3.2 
Non-deductible expenses2.0 2.4 1.8 
Equity compensation(3.6)(3.3)(4.3)
Other adjustments(0.6)(0.4)(0.4)
TOTAL INCOME TAX PROVISION22.3 %23.4 %21.3 %

The Company's effective tax rate was 22.3% for the year ended December 31, 2022, compared to 23.4% for the same period in 2021 and 21.3% in 2020. The lower effective tax rate is due to higher tax benefits from stock compensation and lower tax expense from non-deductible expenses.


114

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company's deferred tax assets and liabilities as of December 31, 2022 and 2021 are summarized below.

 December 31,
 2022 2021
Deferred tax assets (liabilities): 
Accrued expenses$61,685 $58,640 
Revenue related reserves18,046 13,171 
Tax credits1,742 2,138 
Insurance11,910 8,712 
Lease liability 364,408 285,643 
State taxes 28 (165)
457,819 368,139 
Valuation allowance(789)(789)
TOTAL DEFERRED TAX ASSETS457,030 367,350 
Depreciation and amortization(49,146)(45,827)
Prepaid expenses(5,150)(4,265)
Right of use asset (363,091)(284,111)
TOTAL DEFERRED TAX LIABILITIES(417,387)(334,203)
NET DEFERRED TAX ASSETS$39,643 $33,147 
The Company had state credit carryforwards as of December 31, 2022 and 2021 of $1,742 and $2,138, respectively. These carryforwards almost entirely relate to state limitations on the application of Enterprise Zone employment-related tax credits. Unless the Company uses the Enterprise Zone credits beforehand, the carryforward will begin to expire in 2023. As of December 31, 2022 and 2021, the valuation allowance of $789, for both years, was primarily recorded against the Enterprise Zone credits as the Company believes it is more likely than not that some of the benefit of the credits will not be realized.
The Company's operating loss carry forwards for states were not material during the years ended December 31, 2022 and 2021.
As of December 31, 2022, 2021 and 2020, the Company did not have any unrecognized tax benefits, net of its state benefits that would affect the Company's effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material.
The Federal statutes of limitations on the Company's 2018, 2017, and 2016 income tax years lapsed during the third quarter of 2022, 2021, and 2020, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses for the years ended December 31, 2022 and 2021 had no impact on the Company's unrecognized tax benefits.
During the year ended December 31, 2021, the state of Wisconsin initiated and completed an examination of the Company's 2019, 2018, and 2017 state tax years with no adjustments. The Company is not under examination by any major income tax jurisdiction.
16. DEBT
Debt consists of the following:
December 31,
20222021
Mortgage loans and promissory notes$156,271 $159,967 
Less: current maturities(3,883)(3,760)
Less: debt issuance costs, net(3,119)(3,324)
LONG-TERM DEBT LESS CURRENT MATURITIES$149,269 $152,883 

115

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Credit Facility with a Lending Consortium Arranged by Truist

The Company maintains a revolving credit facility between the Company and its subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Revolving Credit Facility). Borrowings are supported by a lending consortium arranged by Truist. On April 8, 2022, the Company and its subsidiaries, including Standard Bearer, entered into the Amended Credit Agreement, which amended the Revolving Credit Facility to increase the revolving line of credit from $350,000 to $600,000 in aggregate principal amount. The Amended Credit Agreement also extended the maturity date of the Revolving Credit Facility to April 8, 2027 and modified the reference rate from LIBOR to SOFR. The interest rates applicable to loans under the Amended Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company and its subsidiaries, including Standard Bearer, will pay a commitment fee on the unused portion of the commitments that will range from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. Except as set forth in the Amended Credit Facility, all other terms and conditions of the Credit Facility remained in full force and effect as described below. As part of the entry into the Amended Credit Agreement, deferred financing costs of $566 were written off and additional deferred financing costs of $3,197 were capitalized during the year ended December 31, 2022.

Borrowings made under the Revolving Credit Facility are guaranteed, jointly and severally, by certain of the Company’s wholly-owned subsidiaries, and are secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of their personal property. The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Amended Credit Agreement, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six months period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of December 31, 2022, and January 30, 2023, there was no outstanding debt under the Revolving Credit Facility. The Company was in compliance with all loan covenants as of December 31, 2022.
Mortgage Loans and Promissory Notes

As of December 31, 2022, the Company's operating subsidiaries had $156,271 outstanding under the mortgage loans and notes, of which $3,883 is classified as short-term and the remaining $152,388 is classified as long-term. The Company was in compliance with all loan covenants as of December 31, 2022.

As of December 31, 2022, 23 of the Company's subsidiaries have mortgage loans insured with HUD in the aggregate amount of $153,488, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, we incur other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years.

In addition to the HUD mortgage loans above, the Company has two promissory notes. The notes bear fixed interest rates of 6.3% and 5.3% per annum and the term of the notes are 10 months and 12 years, respectively. The 12 year note which was used for an acquisition is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.


116

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Future principal payments due under the long-term debt arrangements discussed above are as follows:

Years Ending December 31,Amount
2023$3,883 
20243,950 
20254,086 
20264,227 
20273,897 
Thereafter136,228 
 $156,271 

Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.
Off-Balance Sheet Arrangements

As of December 31, 2022, the Company had approximately $6,710 of borrowing capacity under the Revolving Credit Facility pledged as collateral to secure outstanding letters of credit, which remained consistent from 2021.


17. OPTIONS AND AWARDS
Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s consolidated statements of income for the years ended December 31, 2022, 2021, and 2020 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.
The Company has one active stock incentive plan, the 2022 Omnibus Incentive Plan (the 2022 Plan), which was approved by the Company's stockholders on May 26, 2022, and replaced the Company's prior option plan, the 2017 Omnibus Incentive Plan (the 2017 Plan).
2022 Omnibus Incentive Plan (2022 Plan)  During the second quarter of 2022, the Company's shareholders approved the 2022 Plan. Including the shares rolled over from the 2017 Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. At December 31, 2022, the total number of shares available for issuance under the 2022 Plan was 2,861.
2017 Omnibus Incentive Plan (2017 Plan) — The 2017 Plan provided for the issuance of 6,881 shares of common stock which are to be proportionally adjusted in the event of any Equity Restructuring. The number of shares available to be issued under the 2017 Plan were adjusted to 8,118 shares of common stock in order to reflect the proportional adjustments as part of the spin-off transaction that occurred in October 2019. The number of shares available to be issued under the 2017 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) 2.5 shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Granted non-employee director options vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. The Company granted 165 stock options and 116 restricted stock awards from the 2017 Plan in the first half of 2022 prior to the retirement of the 2017 plan.
117

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Black-Scholes model required the Company to make several key judgments including:
The expected option term is calculated by the average of the contractual term of the options and the weighted average vesting period for all options. The calculation of the expected option term is based on the Company's experience due to sufficient history.
The Company utilizes its own experience to calculate estimated volatility for options granted.
The dividend yield is based on the Company's historical pattern of dividends as well as expected dividend patterns.
The risk-free rate is based on the implied yield of U.S. Treasury notes as of the grant date with a remaining term approximately equal to the expected term.
Estimated forfeiture rate of approximately 7.84% per year is based on the Company's historical forfeiture activity of unvested stock options.
Stock Options
The Company granted 581, 621 and 669 stock options from the available plans during the year ended December 31, 2022, 2021 and 2020, respectively. The Company used the following assumptions for stock options granted during the years ended December 31, 2022, 2021 and 2020:
Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
20225812.8%6.2 years42.1%0.3%
20216211.0%6.2 years42.4%0.3%
20206690.6%6.2 years39.4%0.4%
For the years ended December 31, 2022, 2021 and 2020, the following represents the exercise price and fair value displayed at grant date for stock option grants:
Grant YearGrantedWeighted Average Exercise PriceWeighted Average Fair Value of Options
2022581$85.74 $37.83 
2021621$80.19 $32.82 
2020669$52.20 $19.52 

The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended December 31, 2022, 2021 and 2020 and therefore, the intrinsic value was $0 at the date of grant.
118

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The following table represents the employee stock option activity during the year ended December 31, 2022, 2021 and 2020:
Number of Options OutstandingWeighted Average
Exercise Price
Number of
Options Vested
Weighted Average Exercise Price of Options Vested
January 1, 20204,428 $20.85 2,557 $12.82 
Granted669 52.20 
Forfeited(80)33.68 
Exercised(979)12.93 
December 31, 20204,038 $27.71 2,148 $16.66 
Granted621 80.19 
Forfeited(105)44.76 
Exercised(516)17.80 
December 31, 20214,038 $36.60 2,183 $21.02 
Granted581 85.74 — — 
Forfeited(98)59.52 — — 
Exercised(688)18.43 — — 
December 31, 20223,833 $46.72 2,069 $28.87 


The following summary information reflects stock options outstanding, vested and related details as of December 31, 2022:
Stock Options OutstandingStock Options Vested
 
Number OutstandingBlack-Scholes Fair ValueRemaining Contractual Life (Years)Vested and Exercisable
Year of GrantExercise Price
20136.76-9.7465 274 165 
20148.94-16.05399 1,930 2399 
201518.20-21.39211 1,645 3211 
201615.93-16.86198 1,162 4198 
201715.80-19.41236 1,387 5236 
201822.49-32.71449 4,341 6330 
201941.07-45.76590 9,275 7324 
202044.84-59.49545 10,734 8197 
202173.47-83.64567 18,597 9109 
2022$79.79$94.88573 21,689 10 
TOTAL 3,833 $71,034  2,069 
The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2022, 2021 and 2020 is as follows:
December 31,
Options202220212020
Outstanding$183,593 $191,242 $182,552 
Vested136,000 137,382 120,867 
Expected to vest43,232 48,548 53,366 
The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. The aggregate intrinsic value of options that vested during the year ended December 31, 2022, 2021 and 2020 was $27,955, $27,731, and $26,030, respectively. The total intrinsic value of options exercised during the year ended December 31, 2022, 2021 and 2020 was $47,441, $34,278, and $45,081, respectively.
119

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Restricted Stock Awards
The Company granted 233, 222 and 281 restricted stock awards during the years ended December 31, 2022, 2021 and 2020, respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the years ended December 31, 2022, 2021 and 2020 ranged from $73.17 to $94.88, $72.84 to $93.31 and $35.47 to $58.06, respectively. The fair value per share includes quarterly stock awards to non-employee directors.

A summary of the status of the Company's non-vested restricted stock awards as of December 31, 2022 and changes during the years ended December 31, 2022, 2021 and 2020 is presented below:
Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
Nonvested at January 1, 2020610 $31.35 
Granted281 48.73 
Vested(280)32.84 
Forfeited(20)31.71 
Nonvested at December 31, 2020591 $38.90 
Granted222 81.65 
Vested(244)47.45 
Forfeited(20)45.64 
Nonvested at December 31, 2021549 $52.16 
Granted233 81.57 
Vested(269)54.06 
Forfeited(26)57.29 
Nonvested at December 31, 2022487 $64.92 
During the year ended December 31, 2022, the Company granted 18 automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors from the 2017 and 2022 Plan. The fair value per share of these stock awards ranged from $75.33 to $86.34 based on the market price on the grant date.
Long-Term Incentive Plan
On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off transaction in 2019 are granted shares of restricted stock upon successful completion. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested shall be entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $836, $854, and $881 for the years ended December 31, 2022, 2021 and 2020, respectively.
Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December 31, 2022, 2021, and 2020 was as follows:

Year Ended December 31,
 202220212020
Stock-based compensation expense related to stock options$11,361 $8,459 $6,132 
Stock-based compensation expense related to restricted stock awards9,920 8,385 7,373 
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors1,439 1,834 1,019 
TOTAL$22,720 $18,678 $14,524 

120

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

In future periods, the Company expects to recognize approximately $43,388 and $29,149 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of December 31, 2022. Future stock-based compensation expense will be recognized over 3.6 and 3.4 weighted average years for unvested options and restricted stock awards, respectively. There were 1,764 unvested and outstanding options as of December 31, 2022, of which 1,666 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of December 31, 2022 was 6.0 years.


18. LEASES
The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 affiliated skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.
The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations under the Master Leases was approximately $64,178, $59,571 and $52,838 for the years ended December 31, 2022, 2021 and 2020, respectively.
Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December 31, 2022.
In connection with the spin-off transaction in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.
The Company leases certain affiliated operations and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $153,174, $139,458 and $129,990 for the year ended December 31, 2022, 2021 and 2020, respectively.
121

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Fifty-eight of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under ten separate master lease arrangements. During 2022, the Company amended two of its separate master leases to add operations and extend the initial terms, which increased the lease liabilities and right-of-use assets by $207,638 to reflect the new lease obligations. Additionally, during 2022, the Company added six new operations to two new master leases, which increased the lease liabilities and right-of-use assets by $54,755 to reflect the new lease obligations. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.
During 2022, Standard Bearer acquired the real estate of three skilled nursing operations, which were previously under separate long-term lease arrangements. The aggregate reduction in the carrying value of the Company's lease liabilities and right-of-use assets related to this acquisition is $10,080.

The components of operating lease expense are as follows:
Year Ended December 31,
202220212020
Rent - cost of services(1)
$153,049 $139,371 $129,926 
General and administrative expense125 87 64 
Depreciation and amortization(2)
1,160 1,158 1,223 
Variable lease costs(3)
16,938 14,077 12,774 
$171,272 $154,693 $143,987 
(1)Rent- cost of services includes deferred rent expense adjustments of $493, $485 and $451 for the years ended December 31, 2022, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $5,878, $3,702, $2,394 for the years ended December 31, 2022, 2021, and 2020 respectively.
(2)Depreciation and amortization is related to the amortization of favorable and direct lease costs.
(3)Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.

Future minimum lease payments for all leases as of December 31, 2022 are as follows:
YearAmount
2023$157,963 
2024157,630 
2025157,455 
2026157,380 
2027156,860 
Thereafter1,456,411 
TOTAL LEASE PAYMENTS2,243,699 
Less: present value adjustment (822,790)
PRESENT VALUE OF TOTAL LEASE LIABILITIES1,420,909 
Less: current lease liabilities(65,796)
LONG-TERM OPERATING LEASE LIABILITIES$1,355,113 
Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of December 31, 2022 and 2021, the weighted average remaining lease term is 15.0 and 14.8, respectively, and the weighted average discount rate used to determine the operating lease liabilities is 6.7% and 7.6%, respectively.
Subsequent to December 31, 2022, the Company expanded its operations through two separate master lease arrangements for 20 stand-alone skilled nursing operations, of which 17 will be operated by the Company's affiliated operating subsidiaries and the remaining three will be subleased to a third-party operator. The aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the two separate master lease agreements is estimated to be approximately $315,337.

122

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Lessor Activities

In connection with the spin-off transaction in 2019, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. As of December 31, 2022, Ensign affiliates retained ownership of the real estate for these 29 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years.


Total rental income from all third-party sources for the years ended December 31, 2022, 2021, and 2020 is as follows:

Year Ended December 31,
202220212020
Pennant(1)
$14,915 $14,073 $13,163 
Other third-party1,842 1,912 1,994 
$16,757 $15,985 $15,157 
(1) Pennant rental income includes variable rent such as property taxes of $1,318, $1,199, and $1,224 during the year ended December 31, 2022, 2021, and 2020.

Future annual rental income for all leases as of December 31, 2022 were as follows:
Year
Amount(1)
2023$16,408 
202415,826 
202515,391 
202615,166 
202715,166 
Thereafter79,171 
TOTAL$157,128 
(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2022.
19. SELF INSURANCE LIABILITIES

The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2022 and 2021:
 
Amount
Balance January 1, 2021
 $96,798 
Current year provisions 114,907 
Claims paid and direct expenses (101,183)
Change in long-term insurance losses recoverable (383)
Balance December 31, 2021
$110,139 
Current year provisions115,793 
Claims paid and direct expenses(98,007)
Change in long-term insurance losses recoverable3,757 
Balance December 31, 2022
$131,682 
 
 

123

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Included in the table above are accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, of $87,000 and $69,748 as of December 31, 2022 and 2021, respectively. Included in long-term insurance losses recoverable as of December 31, 2022 and 2021 are anticipated insurance recoveries related to the Company's general and professional liability claims that are recorded on a gross rather than net basis in accordance with GAAP.
20. DEFINED CONTRIBUTION PLANS

The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 90% of their annual basic earnings, subject to applicable annual Internal Revenue Code limits. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company. The Company expensed matching contributions to the 401(k) Plan of $2,418, $2,121, and $1,889 during the years ended December 31, 2022, 2021 and 2020, respectively.


During the year ended December 31, 2019, the Company implemented non-qualified deferred compensation plan (the DCP) that was effective in 2019 for certain executives. The plan was then offered to other highly compensated employees, which went into effect on January 1, 2020. These individuals are otherwise ineligible for participation in the Company's 401(k) plan. The DCP allows participating employees to defer the receipt of a portion of their base compensation and certain employees up to 100% of their eligible bonuses. Additionally, the plan allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to informally fund savings plans of this nature. The Company paid for related administrative costs, which were not significant during fiscal years 2022, 2021 and 2020.

As of the years ended December 31, 2022, 2021, and 2020, the Company accrued $33,017, $26,832 and $14,232, respectively, as long term deferred compensation in other long term liabilities on the consolidated balance sheet. Cash surrender value of the contracts is based on investment funds that shadow the investment allocations specified by participants in the deferred compensation plan. Refer to Note 6, Fair Value Measurements for more information on the funds.

For the year ended December 31, 2022, the Company recorded a loss on the investment acquired in connection with our deferred compensation plan of $4,188, which is included in other income (expense), net. During the same period, the Company recorded an offsetting reduction in expense of $4,051, which is allocated between cost of services and general and administrative expenses.

For the years ended December 31, 2021 and 2020, the Company recorded net income on the investment acquired in connection with our deferred compensation plan of $1,612 and $1,396, respectively, which is included in other income (expense), net. During the same periods, the Company recorded an offsetting expense of $1,758, and $1,355, respectively, which is allocated between cost of services and general and administrative expenses.
21. COMMITMENTS AND CONTINGENCIES
Regulatory Matters Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.
Cost-Containment Measures Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.

124

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Indemnities From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities arising out of the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s consolidated balance sheets for any of the periods presented.

In connection with the spin-off transaction in 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the transaction. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties.

U.S. Department of Justice Civil Investigative DemandOn May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it was investigating whether there had been a violation of the False Claims Act and/or the Anti-Kickback Statute with respect to relationships between certain of the Company’s independently operated skilled nursing facilities and persons who serve or have served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of the Company’s Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, the Company’s independent operating entities have established and maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. The Company fully cooperated with the U.S. Department of Justice and promptly responded to its requests for information; in April 2020, the Company was advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.
U.S. House of Representatives Select Subcommittee Request In 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee in connection with its investigation. The Company has cooperated in responding to this inquiry. In July 2022 and thereafter, the Company received follow up requests for additional documents and information. The Company has responded to these requests, and continued to cooperate with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act.
Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. In addition, the Company, its independent operating subsidiaries, and others in the industry are subject to claims and lawsuits in connection with COVID-19 and a facility's preparation for and/or response to COVID-19. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.


125

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

In addition to the potential lawsuits and claims described above, the Company and its independent operating subsidiaries are also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from Federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Under the qui tam or "whistleblower" provisions of the False Claims Act, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the Federal Government and receive a percentage of the Federal Government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the U.S. Department of Justice to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the involved qui tam relator has continued on with the lawsuit and is pursuing claims that the Company and certain of its independent operating subsidiaries have allegedly violated the False Claims Act and/or the Anti-Kickback Statute (AKS).
In addition to the Federal False Claims Act, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company and its independent operating subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.
In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a Federal False Claims Act violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.
Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.
Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent operating subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations.
The Company and its independent operating subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including healthcare and non-healthcare services. These claims include, but are not limited to, potential claims filed by residents, customers, patients and responsible parties related to patient care and treatment (professional negligence claims); to non-care based activities of certain of the subsidiaries; and to employment related claims filed by current or former employees. A significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, these claims could impact the Company's ability to procure insurance to cover its exposure related to the various services provided by its independent operating subsidiaries to their residents, customers and patients.

126

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company and its independent subsidiaries are also subject to requests for information and investigations by other State and Federal governmental entities (e.g., offices of the attorney general and offices of the inspector general). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar state and federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent operating subsidiaries under a corporate integrity agreement and/or other such arrangement.
Medicare Revenue Recoupments The Company's independent operating entities are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate Program. Beginning in August 2020, CMS resumed Targeted Probe and Educate Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of December 31, 2022 and since, 34 of the Company's independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process.
Concentrations
Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for 56.3% and 54.0% of its total accounts receivable as of December 31, 2022 and 2021, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 73.7%, 73.6% and 74.5% of the Company's revenue for the years ended December 31, 2022, 2021 and 2020, respectively.
Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of January 30, 2023, the Company's uninsured cash deposits are not material. All uninsured bank deposits are held at high quality credit institutions.
22. COMMON STOCK REPURCHASE PROGRAM
On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company did not purchase any shares pursuant to this stock repurchase program in the year ended December 31, 2022. The share repurchase program does not obligate the Company to acquire any specific number of shares.
On February 9, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from February 10, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended June 30, 2022, the Company repurchased 271 shares of its common stock for $20,000. This repurchase program expired upon the repurchase of the fully authorized amount under the plan and is no longer in effect.
127

THE ENSIGN GROUP, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

On October 21, 2021, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months that started on October 29, 2021. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company repurchased 133 and 132 shares of its common stock for $9,882 and $10,118 during the years ended December 31, 2022 and 2021, respectively. This repurchase program expired upon the repurchase of the fully authorized amount under the plan and is no longer in effect.
On March 4, 2020 and March 13, 2020, the Board of Directors approved two stock repurchase programs pursuant to which the Company was authorized to repurchase up to $20,000 and $5,000, respectively, of its common stock under the programs for a period of approximately 12 months. Under these programs, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the first quarter of 2020, the Company repurchased 503 and 189 shares of its common stock for $20,000 and $5,000, respectively. These repurchase programs expired upon the repurchase of the full authorized amount under the two plans and are no longer in effect.
Item 9.     CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES

    None.
Item 9A. CONTROLS AND PROCEDURES
(a) Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

 
 
The Company maintains disclosure controls and procedures that are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any system of controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

In connection with the preparation of this Annual Report on Form 10-K our management evaluated, with the participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report on Form 10-K.
(b) Management's Report on Internal Control over Financial Reporting

 
 
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) promulgated under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control - Integrated Framework (2013). As a result of this assessment, management concluded that, as of December 31, 2022, our internal control over financial reporting was effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

 
Our independent registered public accounting firm, Deloitte & Touche LLP, has audited the consolidated financial statements included in this Annual Report on Form 10-K and, as part of their audit, has issued an audit report, included herein, on the effectiveness of our internal control over financial reporting. Their report is set forth below.
(c) Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting, as defined in Rule 13a-15(f) promulgated under the Exchange Act, that occurred during the fourth quarter of fiscal 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
(d) Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of
The Ensign Group, Inc.
San Juan Capistrano, California

Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of The Ensign Group, Inc. and subsidiaries (the “Company”) as of December 31, 2022, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2022 of the Company and our report dated February 2, 2023, expressed an unqualified opinion on those financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ DELOITTE & TOUCHE LLP

Costa Mesa, California February 2, 2023

Item 9B. OTHER INFORMATION
    
    None.


Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
    
    Not applicable.

PART III.
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2023 Annual Meeting of Stockholders.

We have adopted a code of ethics and business conduct that applies to all employees, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), and employees of our subsidiaries, as well as each member of our Board of Directors. The code of ethics and business conduct is available on our website at www.ensigngroup.net under the Investor Relations section. The information contained in, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 10-K. We intend to satisfy any disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of the code of ethics by posting such information on our website, at the address specified above.
Item 11. EXECUTIVE COMPENSATION

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2023 Annual Meeting of Stockholders.
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2023 Annual Meeting of Stockholders.
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2023 Annual Meeting of Stockholders.
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2023 Annual Meeting of Stockholders. Our principal accountant is Deloitte & Touche LLP (PCAOB ID No.34).


128

PART IV.
Item 15. EXHIBITS, FINANCIAL STATEMENTS AND SCHEDULES

 
The following documents are filed as a part of this report:

 
(a) (1) Financial Statements:
The Financial Statements described in Part II. Item 8 and beginning on page 90 are filed as part of this Annual Report on Form 10-K.


 
(a) (3) Exhibits:  The following exhibits are filed or furnished with or incorporated by reference this Annual Report on Form 10-K.


Exhibit   File Exhibit Filing Filed
No.Exhibit Description*Form No. No. Date Herewith
Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on November 15, 200710-Q001-337573.1 12/21/2007 
Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on February 4, 202010-K001-337573.2 2/5/2020
Amendment to the Amended and Restated Bylaws, dated August 5, 20148-K001-337573.2 8/8/2014
Amended and Restated Bylaws of The Ensign Group, Inc.10-Q001-337573.2 12/21/2007 
Description of the Common stock of The Ensign Group, Inc.10-K001-337574.1 2/5/2020
Specimen common stock certificateS-1333-1428974.1 10/5/2007 
+The Ensign Group, Inc. 2007 Omnibus Incentive PlanS-1333-14289710.3 10/5/2007 
+Amendment to The Ensign Group, Inc. 2007 Omnibus Incentive Plan8-K001-3375799.2 7/28/2009 
+Form of 2007 Omnibus Incentive Plan Notice of Grant of Stock Options; and form of Non-Incentive Stock Option Award Terms and ConditionsS-1333-14279710.4 10/5/2007 
+Form of 2007 Omnibus Incentive Plan Restricted Stock AgreementS-1333-14289710.5 10/5/2007 
+Form of Indemnification Agreement entered into between The Ensign Group, Inc. and its directors, officers and certain key employeesS-1333-14289710.6 10/5/2007 
Form of Independent Consulting and Centralized Services Agreement between Ensign Facility Services, Inc. and certain of its subsidiariesS-1333-14289710.41 5/14/2007
Form of Health Insurance Benefit Agreement pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Medicare programS-1333-14289710.48 10/19/2007
Form of Medi-Cal Provider Agreement pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the California Medicaid programS-1333-14289710.49 10/19/2007
Form of Provider Participation Agreement pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Arizona Medicaid programS-1333-14289710.50 10/19/2007
Form of Contract to Provide Nursing Facility Services under the Texas Medical Assistance Program pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Texas Medicaid programS-1333-14289710.51 10/19/2007
129

Exhibit   File Exhibit Filing Filed
No.Exhibit Description*Form No. No. Date Herewith
Form of Client Service Contract pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Washington Medicaid programS-1333-14289710.52 10/19/2007
Form of Provider Agreement for Medicaid and UMAP pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Utah Medicaid programS-1333-14289710.53 10/19/2007
Form of Medicaid Provider Agreement pursuant to which a subsidiary of The Ensign Group, Inc. participates in the Idaho Medicaid programS-1333-14289710.54 10/19/2007
Corporate Integrity Agreement between the Office of Inspector General of the Department of Health and Human Services and The Ensign Group, Inc. dated October 1, 2013.10-K001-3375710.74 2/13/2014
Settlement agreement dated October 1, 2013, entered into among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General ("OIG-HHS") of the Department of Health and Human Services ("HHS") (collectively the "United States") and the Company.8-K001-3375710.75 5/8/2014
Form of Master Lease by and among certain subsidiaries of The Ensign Group, Inc. and certain subsidiaries of CareTrust REIT, Inc.8-K001-3375710.1 6/5/2014
Form of Guaranty of Master Lease by The Ensign Group, Inc. in favor of certain subsidiaries of CareTrust REIT, Inc., as landlords under the Master Leases8-K001-3375710.2 6/5/2014
Amended and Restated Credit Agreement as of February 5, 2016, by and among The Ensign Group, Inc., SunTrust Bank, now known as Truist, as administrative agent, and the lenders party thereto8-K001-3375710.1 2/8/2016
Second Amended Credit Agreement as of July 19, 2016, by and among The Ensign Group, Inc., SunTrust Bank, now known as Truist, as administrative agent, and the lenders party thereto8-K001-3375710.1 7/25/2016
The Ensign Group, Inc. 2017 Omnibus Incentive PlanDEF 14A001-33757A4/13/2017
Form of 2017 Omnibus Incentive Plan Notice of Grant of Stock Options; and form of Non-Incentive Stock Option Award Terms and Conditions10-K001-3375710.87 2/8/2018
Form of 2017 Omnibus Incentive Plan Restricted Stock Agreement10-K001-3375710.88 2/8/2018
Form of U.S. Department of Housing and Urban Development Healthcare Facility Note and schedule of individual subsidiary loans, by and among The Ensign Group, Inc.'s subsidiaries listed therein and U.S. Department of Housing and Urban Development8-K001-3375710.1 1/3/2018
Form of U.S. Department of Housing and Urban Development Security Instrument/Mortgage/Deed of Trust8-K001-3375710.2 1/3/2018
Third Amended and Restated Credit Agreement, dated as of October 1, 2019, by and among The Ensign Group, Inc., SunTrust Bank, now known as Truist, as administrative agent, and the lenders party thereto8-K001-3375710.4 10/1/2019
Lease Agreement, dated as of October 1, 2019, by and between The Ensign Group, Inc. and The Pennant Group, Inc.8-K001-3375710.5 10/1/2019
+The Ensign Services, Inc. Deferred Compensation Plan10-K001-3375710.1 2/3/2021
+First Amendment to The Ensign Services, Inc. Deferred Compensation Plan10-K001-3375710.2 2/3/2021
130

Exhibit   File Exhibit Filing Filed
No.Exhibit Description*Form No. No. Date Herewith
First Amendment to Third Amended and Restated Credit Agreement, dated as of February 8, 2022, by and among The Ensign Group, Inc., Standard Bearer Healthcare REIT, Inc., Truist Bank (as successor by merger to SunTrust Bank), as administrative agent, and the lenders party thereto10-K001-3375710.1 2/9/2022
Second Amendment to Third Amended and Restated Credit Agreement, dated as of April 8, 2022, by and among The Ensign Group, Inc. and Truist Bank, as administrative agent, and the lenders party thereto. 8-K001-3375710.1 4/12/2022
The Ensign Group, Inc. 2022 Omnibus Incentive PlanDEF 14A001-33757A4/14/2022
Form of 2022 Omnibus Incentive Plan Notice of Grant of Stock Options; and form of Non-Incentive Stock Option Award Terms and ConditionsX
Form of 2022 Omnibus Incentive Plan Restricted Stock AgreementX
Subsidiaries of The Ensign Group, Inc., as amendedX
Consent of Deloitte & Touche LLPX
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
101 Interactive data file (furnished electronically herewith pursuant to Rule 406T of Regulations S-T)
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
+Indicates management contract or compensatory plan.
*Documents not filed herewith are incorporated by reference to the prior filings identified in the table above.

Item 16.    FORM 10-K SUMMARY
Not applicable

131


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 THE ENSIGN GROUP, INC.
February 2, 2023BY: /s/ SUZANNE D. SNAPPER  
  Suzanne D. Snapper 
  Chief Financial Officer, Executive Vice President and Director (Principal Financial Officer and Accounting Officer and Duly Authorized Officer) 

 
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
 
SignatureTitle Date
/s/ BARRY R. PORTChief Executive Officer and Director (principal executive officer) February 2, 2023
Barry R. Port
/s/  SUZANNE D. SNAPPERChief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer)  February 2, 2023
Suzanne D. Snapper
/s/ CHRISTOPHER R. CHRISTENSENExecutive Chairman and Chairman of the Board February 2, 2023
Christopher R. Christensen
/s/  ANN S. BLOUINDirector February 2, 2023
Ann S. Blouin
/s/  SWATI B. ABBOTTDirector February 2, 2023
Swati B. Abbott
/s/  DAREN J. SHAWDirectorFebruary 2, 2023
Daren J. Shaw
/s/  JOHN O. AGWUNOBIDirector February 2, 2023
John O. Agwunobi
/s/  BARRY M. SMITHDirector February 2, 2023
Barry M. Smith

132
EX-10.2 2 ensg123122ex102.htm EX-10.2 Document



Exhibit 10.2
Notice of Stock Options

Optionee: «Participant_First_Name» «Participant_Last_Name»
Option Number: «Option_Number»
Plan: 2022 Omnibus Incentive Plan

Notice is hereby given of the following Option Award grant (the “Option”) to purchase shares of the Common Stock of The Ensign Group, Inc. (the “Corporation”):
Grant Date:    «Grant_Date»Number of Option Shares: ***«Options_Award»***
Type of Options: Non-Incentive
Exercise Price Per Share: «Exercise_Price_Per_Share»

V E S T I N G

Vesting Schedule: 20% annually, with the first block vesting on the first (1st) anniversary of the Grant Date.
    Expiration Date: Ten years from the Grant Date, or upon earlier termination of the Option

Except as otherwise provided in the Option Agreement, the Option may be exercised for vested Shares by Optionee in accordance with the following schedule:

On or after each of
the following dates
Number of Stock Options vested
«Vesting_Y1»
«OPTION_Y1»
«Vesting_Y2»
«OPTION_Y2»
«Vesting_Y3»
«OPTION_Y3»
«Vesting_Y4»
«OPTION_Y4»
«Vesting_Y5»
«OPTION_Y5»

By accepting this Option Award, Optionee acknowledges and agrees that the option rights herein are granted only subject to and in accordance with the terms of (i) the enclosed NON-INCENTIVE STOCK OPTION AWARD TERMS AND CONDITIONS (together with this Notice of Grant of Stock Options, the “Option Agreement”), and (ii) THE ENSIGN GROUP, INC. 2022 OMNIBUS INCENTIVE PLAN (the “Plan”), both of which are incorporated herein by this reference. Option Shares purchased pursuant to this Option Award can only be acquired subject to the terms set forth in the Plan and the Option Agreement, whether said options are purchased electronically or in person. All capitalized terms in this Notice of Grant of Stock Options shall have the meaning assigned to them in the Option Agreement or the Plan.

EXECUTIVED AND DELIVERED as of the Grant Date set forth above.



THE ENSIGN GROUP, INC.
    a Delaware corporation




    By: Chad A Keetch
    Chief Investment Officer, EVP and Secretary




THE ENSIGN GROUP, INC.
NON-INCENTIVE STOCK OPTION AWARD
TERMS AND CONDITIONS
These NON-INCENTIVE STOCK OPTION AWARD TERMS AND CONDITIONS are an integral part of the foregoing Notice of Grant of Stock Options (the “Notice,” and together with these Terms and Conditions, the “Option Agreement”) made by The Ensign Group, Inc., a Delaware corporation (the “Company”) to the individual “Optionee” named therein. All capitalized terms used herein but not defined in the Option Agreement shall have the meanings given to them in The Ensign Group, Inc. 2022 Omnibus Incentive Plan (the “Plan”), the terms and conditions of which are incorporated herein by this reference.
1.Grant of Option. The Company hereby grants Optionee, on the date such grant was approved by the Committee (the “Grant Date”), the option (the “Option”) to purchase all or any part of the number of Option Shares set forth in the Notice (the “Shares”) of Common Stock of the Company at the exercise price per share set forth in the Notice, according to the terms and conditions set forth in this Option Agreement and in the Plan. The Option will not be treated as an incentive stock option within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”). The Option is issued under the Plan and is subject to its terms and conditions. A copy of the Plan will be furnished upon request of Optionee.
The Option shall terminate at the close of business on the Expiration Date set forth in the Notice (the “Expiration Date”) unless sooner terminated or cancelled in accordance with this Option Agreement or the Plan.
2.Vesting of Option Rights.
(a)Except as otherwise provided in this Option Agreement, the Option may be exercised for vested Shares by Optionee in accordance with the schedule set forth in the Notice.
(b)During the lifetime of Optionee, the Option shall be exercisable only by Optionee and shall not be assignable or transferable by Optionee, other than by will or the laws of descent and distribution; provided however, that Optionee may transfer the Option to any “Family Member” (as such term is defined in the General Instructions to Form S-8 (or any successor to such Instructions or such Form) under the Securities Act), provided that the Participant may not receive any consideration for such transfer, the Family Member may not make any subsequent transfers other than by will or by the laws of descent and distribution and the Company receives written notice of such transfer.
3.Exercise of Option after Death or Termination of Service. The Option shall terminate and may no longer be exercised if Optionee ceases to provide Service to the Company or its affiliates, except that:
(a)If Optionee’s Service shall be terminated for any reason, voluntary or involuntary, other than for “Cause” (as defined in Section 3(e)) or Optionee’s death or disability (within the meaning of Section 22(e)(3) of the Code), Optionee may at any time within a period of 3 months after such termination exercise the Option to the extent the Option was vested and exercisable by Optionee on the date of the termination of Optionee’s Service.
(b)If Optionee’s Service is terminated for Cause, the Option shall be terminated as of the date of the act giving rise to such termination.



(c)If Optionee shall die while the Option is still exercisable according to its terms or if Optionee’s Service is terminated because Optionee has become disabled (within the meaning of Section 22(e)(3) of the Code) while providing Service to the Company and Optionee shall not have fully exercised the Option, such Option may be exercised at any time within 12 months after Optionee’s death or date of termination of Service for disability by Optionee, personal representatives or administrators or guardians of Optionee as applicable, or by any person or persons to whom the Option is transferred by will or the applicable laws of descent and distribution, to the extent of the full number of Shares Optionee was entitled to purchase under the Option on (i) the earlier of the date of death or termination of Service or (ii) the date of termination for such disability, as applicable.
(d)Notwithstanding the above, in no case may the Option be exercised to any extent by anyone after the Expiration Date.
(e)"Cause" shall mean, with respect to a Optionee, the occurrence of any of the following: (i) Optionee’s personal dishonesty, willful misconduct, or breach of fiduciary duty involving personal profit, (ii) Optionee’s continuing intentional or habitual failure to perform stated duties, (iii) Optionee’s violation of any law (other than minor traffic violations or similar misdemeanor offenses not involving moral turpitude), (iv) Optionee’s material breach of any provision of an employment or independent contractor agreement with the Company, or (v) any other act or omission by a Optionee that, in the opinion of the Committee, could reasonably be expected to adversely affect the Company’s business, financial condition, prospects and/or reputation. In each of the foregoing subclauses (i) through (v), whether or not a “Cause” event has occurred will be determined by the Committee in its sole discretion or, in the case of Optionees who are Directors or officers or persons subject to Section 16 of the Exchange Act, the Board, each of whose determination shall be final, conclusive and binding. A Optionee’s Service shall be deemed to have terminated for Cause if, after the Optionee’s Service has terminated, facts and circumstances are discovered that would have justified a termination for Cause, including, without limitation, violation of material Company policies or breach of noncompetition, confidentiality or other restrictive covenants that may apply to the Optionee. The foregoing definition shall not in any way preclude or restrict the right of the Company (or any Affiliate) to discharge or dismiss Optionee or other person providing Service to the Company (or any Affiliate) for any other acts or omissions but such other acts or omissions shall not be deemed, for purposes of this Option Agreement, to constitute grounds for termination for Cause.
4.Method of Exercise of Option. Subject to the foregoing, the Option may be exercised in whole or in part from time to time by serving written notice of exercise on the Company at its principal office or the Company’s designated agent for such purposes, within the Option period. The notice shall state the number of Shares as to which the Option is being exercised and shall be accompanied by payment of the exercise price. Payment of the exercise price shall be made (i) in cash (including bank check, valid personal check or money order payable to the Company), or (ii) with the approval of the Company (which may be given in its sole discretion), by delivering to the Company for cancellation shares of the Company’s Common Stock already owned by Optionee having a Fair Market Value (as defined in the Plan) equal to the full exercise price of the Shares being acquired. Only that portion of the Option covering vested Option Shares is exercisable at any time. Subject to Section 402 of the Sarbanes- Oxley Act of 2002, to the extent this Option is exercised for vested Shares, the Option may be exercised in whole or in part from time to time through a special sale and remittance procedure pursuant to which Optionee shall concurrently provide irrevocable instructions (1) to Optionee’s brokerage firm to effect the immediate sale of the purchased Shares and remit to the Company, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate exercise price payable



for the purchased Shares plus all applicable income and employment taxes required to be withheld by the Company by reason of such exercise, and (2) to the Company to deliver the certificates for the purchased Shares directly to such brokerage firm in order to complete the sale.
5.Miscellaneous
(a)Plan Provisions Control. The Option award memorialized in this Option Agreement is made solely upon the terms and conditions set forth herein and in the Plan and any related documents. The Option Agreement and the Plan together constitute the entire agreement between the parties hereto with regard to the subject matter hereof. In the event that any provision of the Option Agreement conflicts with or is inconsistent in any respect with the terms of the Plan, the terms of the Plan shall control.
(b)No Rights of Stockholders. Neither Optionee, Optionee’s legal representative nor a permissible assignee of this Option shall have any of the rights and privileges of a stockholder of the Company with respect to the Shares, unless and until such Shares have been issued in the name of Optionee, Optionee’s legal representative or permissible assignee, as applicable.
(c)No Right to Employment. The grant of the Option shall not be construed as giving Optionee the right to be retained in the employ of, or as giving a director of the Company or an Affiliate (as defined in the Plan) the right to continue as a director of the Company or an Affiliate with, the Company or an Affiliate, nor will it affect in any way the right of the Company or an Affiliate to terminate such employment or position at any time, with or without cause. In addition, the Company or an Affiliate may at any time dismiss Optionee from employment, or terminate the term of a director of the Company or an Affiliate, free from any liability or any claim under the Plan or the Option Agreement. Nothing in the Option Agreement shall confer on any person any legal or equitable right against the Company or any Affiliate, directly or indirectly, or give rise to any cause of action at law or in equity against the Company or an Affiliate. The Option granted hereunder shall not form any part of the wages or salary of Optionee for purposes of severance pay or termination indemnities, irrespective of the reason for termination of employment. Under no circumstances shall any person ceasing to be an employee of the Company or any Affiliate be entitled to any compensation for any loss of any right or benefit under the Option Agreement or Plan which such employee might otherwise have enjoyed but for termination of employment, whether such compensation is claimed by way of damages for wrongful or unfair dismissal, breach of contract or otherwise. By participating in the Plan, Optionee shall be deemed to have accepted all the conditions of the Plan and the Option Agreement and the terms and conditions of any rules and regulations adopted by the Committee and shall be fully bound thereby.
(d)Governing Law. The validity, construction and effect of the Plan and the Option Agreement, and any rules and regulations relating to the Plan and the Option Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Delaware.
(e)Severability. If any provision of the Option Agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or would disqualify the Option Agreement under any law deemed applicable by the Committee (as defined in the Plan), such provision shall be construed or deemed amended to conform to applicable laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee, materially altering the purpose or intent of the Plan or the Option Agreement, such provision shall be stricken as to such jurisdiction or the Option



Agreement, and the remainder of the Option Agreement shall remain in full force and effect.
(f)No Trust or Fund Created. Neither the Plan nor the Option Agreement shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Affiliate and Optionee or any other person.
(g)Headings. Headings are given to the Sections and subsections of the Option Agreement solely as a convenience to facilitate reference. Such headings shall not be deemed in any way material or relevant to the construction or interpretation of the Option Agreement or any provision thereof.
(h)Conditions Precedent to Issuance of Shares. Shares shall not be issued, and the Company shall not have any liability for failure to issue Shares, pursuant to the exercise of the Option unless such exercise and the issuance and delivery of the applicable Shares pursuant thereto shall comply with all relevant provisions of law, including, without limitation, the Securities Act of 1933, as amended, the Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, the requirements of any applicable Stock Exchange and the Delaware General Corporation Law. As a condition to the exercise of the purchase price relating to the Option, the Company may require that the person exercising or paying the purchase price represent and warrant that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation and warranty is required by law.
(i)Withholding. In order to provide the Company with the opportunity to claim the benefit of any income tax deduction which may be available to it upon the exercise of the Option and in order to comply with all applicable federal or state income tax laws or regulations, the Company may take such action as it deems appropriate to insure that, if necessary, all applicable federal or state payroll, withholding, income or other taxes are withheld or collected from Optionee.
(j)Consultation With Professional Tax and Investment Advisors. The holder of this Option Agreement acknowledges that the grant, exercise, vesting or any payment with respect to this Option Agreement, and the sale or other taxable disposition of the Shares acquired pursuant to the exercise thereof, may have tax consequences pursuant to the Code or under local, state or international tax laws. The holder further acknowledges that such holder is relying solely and exclusively on the holder’s own professional tax and investment advisors with respect to any and all such matters (and is not relying, in any manner, on the Company or any of its employees or representatives). Finally, the holder understands and agrees that any and all tax consequences resulting from the Option Agreement and its grant, exercise, vesting or any payment with respect thereto, and the sale or other taxable disposition of the Shares acquired pursuant to the Plan, is solely and exclusively the responsibility of the holder without any expectation or understanding that the Company or any of its employees or representatives will pay or reimburse such holder for such taxes or other items.





EX-10.3 3 ensg123122ex103.htm EX-10.3 Document



Exhibit 10.3
Notice of Restricted Stock Award

Optionee: «Participant_First_Name» «Participant_Last_Name»
Restricted Stock Number: «RSA_Number»
Plan: 2022 Omnibus Incentive Plan

Notice is hereby given of the following award (the “Restricted Stock Award”) of Common Stock of The Ensign Group, Inc. (the “Corporation”):
Grant Date:    «Grant_Date»Number of Restricted Stock Shares: ***«RSA_Award»***
Type of Award: Restricted Stock Award

V E S T I N G
Vesting Schedule: 20% annually, with the first block vesting on the first (1st) anniversary of the Grant Date.

Except as otherwise provided in the Restricted Stock Agreement, the Restricted Stock may be vested in the Grantee in accordance with the following schedule:

On or after each of
the following dates
Number of Restricted Stock Shares vested
«Vesting_Y1»
«RSA_Y1»
«Vesting_Y2»
«RSA_Y2»
«Vesting_Y3»
«RSA_Y3»
«Vesting_Y4»
«RSA_Y4»
«Vesting_Y5»
«RSA_Y5»

By accepting this Restricted Stock Award, Grantee acknowledges and agrees that the Restricted Stock Shares granted herein are subject to and in accordance with the terms of (i) the enclosed RESTRICTED STOCK AWARD TERMS AND CONDITIONS (together with this Notice of Restricted Stock Award, the “Restricted Stock Agreement”), and (ii) THE ENSIGN GROUP, INC. 2022 OMNIBUS INCENTIVE PLAN (the “Plan”), both of which are incorporated herein by this reference. All capitalized terms in this Notice of Restricted Stock Award shall have the meaning assigned to them in the Restricted Stock Agreement of the Plan.

EXECUTIVED AND DELIVERED as of the Grant Date set forth above.

    THE ENSIGN GROUP, INC.
    a Delaware corporation




    By: Chad A Keetch
    Chief Investment Officer, EVP and Secretary




THE ENSIGN GROUP, INC. RESTRICTED STOCK AWARD TERMS AND CONDITIONS

These RESTRICTED STOCK AWARD TERMS AND CONDITIONS are an integral part of the foregoing Notice Restricted Stock Award (the “Notice,” and together with these Terms and Conditions, the Restricted Stock Agreement” or this “Agreement”) made by The Ensign Group, Inc., a Delaware corporation (the “Company”) to the individual “Grantee” named therein. All capitalized terms used herein but not defined in this Restricted Stock Agreement shall have the meanings given to t hem in The Ensign Group, Inc. 2022 Omnibus Incentive Plan (the “Plan”), the terms and conditions of which are incorporated herein by this reference.
1.Definitions. For the purposes of this Agreement, the following terms shall have the meanings set forth below:
(a)"Cause" shall mean, with respect to a Grantee, the occurrence of any of the following: (i) Grantee’s personal dishonesty, willful misconduct, or breach of fiduciary duty involving personal profit, (ii) Grantee’s continuing intentional or habitual failure to perform stated duties, (iii) Grantee’s violation of any law (other than minor traffic violations or similar misdemeanor offenses not involving moral turpitude), (iv) Grantee’s material breach of any provision of an employment or independent contractor agreement with the Company, or (v) any other act or omission by a Grantee that, in the opinion of the Committee, could reasonably be expected to adversely affect the Company’s business, financial condition, prospects and/or reputation. In each of the foregoing subclauses (i) through (v), whether or not a “Cause” event has occurred will be determined by the Committee in its sole discretion or, in the case of Grantees who are Directors or officers or persons subject to Section 16 of the Exchange Act, the Board, each of whose determination shall be final, conclusive and binding. A Grantee’s Service shall be deemed to have terminated for Cause if, after the Grantee’s Service has terminated, facts and circumstances are discovered that would have justified a termination for Cause, including, without limitation, violation of material Company policies or breach of noncompetition, confidentiality or other restrictive covenants that may apply to the Grantee. However, if the term or concept has been defined in an employment agreement between the Company and Grantee, then Cause shall have the definition set forth in such employment agreement. The foregoing definition shall not in any way preclude or restrict the right of the Company (or any Affiliate) to discharge or dismiss Grantee or other person providing Service to the Company (or any Affiliate) for any other acts or omissions but such other acts or omissions shall not be deemed, for purposes of this Agreement, to constitute grounds for termination for Cause.
(b)"Disability" shall mean Grantee’s inability, due to illness, accident, injury, physical or mental incapacity or other disability, to carry out effectively his or her duties and obligations as an employee of the Company or to participate effectively and actively in the management of the Company for a period of at least 90 consecutive days or for shorter periods aggregating at least 120 days (whether or not consecutive) during any twelve-month period, as determined in the reasonable judgment of the Board.
(c)"Vested Shares" shall mean (i) all Shares issued pursuant to this Agreement that are vested pursuant to Section 3 hereof and (ii) all Shares issued with respect to the Common Stock referred to in clause (i) above by way of stock dividend or stock split or in connection with any conversion, merger, consolidation or recapitalization or other reorganization affecting the Shares. Vested Shares shall continue to be Vested Shares in the hands of any holder other than Grantee (except for the Company and purchasers pursuant to a public offering under the Securities Act), and each such transferee thereof shall succeed to the rights and obligations of a holder of Vested Shares hereunder.



2.Issuance of Stock. In partial consideration for Grantee’s services to the Company, Grantee has been issued the number of Shares as set forth in the Notice (the “Restricted Stock”).
3.Vesting.
(a)Normal Vesting. Except as set forth in this Restricted Stock Agreement, the Restricted Stock shall vest in accordance with the schedule set forth in the Notice and shall become fully vested on the fifth anniversary of the date hereof (the “Vesting Date”). The Corporation shall deliver a certificate(s) (or other evidence of ownership, such as book entry) for the Vested Shares to Grantee as soon as practical after each Vesting Date pursuant to the Section 4(d) hereof.
(b)If Grantee’s employment with the Company terminates for any reason prior to the Vesting Date (except as provided in Section 3(c)) all unvested Restricted Stock shall be forfeited and automatically transferred to the Company without consideration on the date of Grantee’s employment termination and Grantee shall have no further rights with respect to the Restricted Stock. For purposes of this Agreement, employment with a Subsidiary of the Corporation shall be considered employment with the Corporation.
(c)Effect on Vesting in Case of Employment Termination. Notwithstanding Section 3(b) above, the following special vesting rules shall apply if Grantee’s employment with the Company terminates prior to the Vesting Date:
(i)Death or Disability. If Grantee dies or becomes subject to any Disability prior to the Vesting Date, his or her Restricted Stock shall vest on a pro rata basis according to the number of days elapsed since the date hereof and the date of his or her death or Disability. Any portion of Grantee’s Restricted Stock that was not vested on the date of Grantee’s death or Disability pursuant to this Section 3(b)(i) shall be forfeited to the Company.
(ii)Termination by the Company Without Cause. If Grantee is terminated by the Company without Cause prior to the Vesting Date, his or her Restricted Stock shall vest in accordance with the schedule set forth in the Notice. Any portion of Grantee’s Restricted Stock that was not vested on the date of such termination without cause pursuant to this Section 3(b)(ii) shall be forfeited to the Company.
4.Restrictions on Transfer.
(a)Non-Transferability. Restricted Stock, and any rights and interests with respect thereto, issued under this Agreement and the Plan shall not, prior to vesting, be sold, exchanged, transferred, assigned or otherwise disposed of in any way by the Grantee (or any beneficiary(ies) of the Grantee), other than by testamentary disposition by the Grantee or the laws of descent and distribution. Any such Restricted Stock, and any rights and interests with respect thereto, shall not, prior to vesting, be pledged or encumbered in any way by the Grantee (or any beneficiary(ies) of the Grantee) and shall not, prior to vesting, be subject to execution, attachment or similar legal process. Any attempt to sell, exchange, transfer, assign, pledge, encumber or otherwise dispose of in any way any of the Restricted Stock, or the levy of any execution, attachment or similar legal process upon the Restricted Stock, contrary to the terms and provisions of this Agreement and/or the Plan shall be null and void and without legal force or effect.
(b)Securities Laws Restrictions on Transfer of Vested Shares. Grantee understands and hereby acknowledges that, in addition to transfer restrictions in this Agreement, federal and state securities laws govern and restrict Grantee’s right to offer, sell or otherwise dispose of any Vested Shares unless such offer, sale or other disposition thereof is registered or qualified under the Securities Act and applicable state securities laws, or in the opinion of the Company's counsel, such offer, sale or other disposition is exempt from



registration or qualification thereunder. Grantee agrees that he or she shall not offer, sell or otherwise dispose of any Vested Shares in any manner which would: (i) require the Company to file any registration statement with the Securities and Exchange Commission (or any similar filing under state law) or to amend or supplement any such filing or (ii) violate or cause the Company to violate the Securities Act, the rules and regulations promulgated thereunder or any other state or federal law. Grantee further understands that the certificates for any Vested Shares shall bear such legends as the Company deems necessary or desirable in connection with the Securities Act or other rules, regulations or laws. Grantee may not sell, transfer or dispose of any Vested Shares (except pursuant to an effective registration statement under the Securities Act) without first obtaining from the Company an opinion of the Company’s counsel that registration under the Securities Act or any applicable state securities law is not required in connection with such transfer. If requested, Grantee agrees to provide the Company with written assurances, in form and substance satisfactory to the Company, that (1) the proposed disposition does not require registration of the Shares under the Securities Act or (2) all appropriate action necessary for compliance with the registration requirements of the Securities Act or any exemption from registration available under the Securities Act (including Rule 144) has been taken. When shares of Restricted Stock awarded by this Agreement become Vested Shares and after the conditions of this section 4(d) have been satisfied, the Grantee shall be entitled to receive unrestricted Shares and if the Grantee’s stock is certificated and contain legends restricting the transfer of such Shares, the Grantee shall be entitled to receive new stock certificates free of such legends (except any legends requiring compliance with securities laws). In connection with the delivery of the unrestricted Shares pursuant to this Agreement, the Grantee agrees to execute any documents reasonably requested by the Company.
(c)Restrictive Legend. The certificates representing the Restricted Stock, if any, shall bear the following legend:
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE WERE ORIGINALLY ISSUED ON , HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION THEREUNDER. THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE ALSO SUBJECT TO ADDITIONAL RESTRICTIONS ON TRANSFER, REPURCHASE RIGHTS AND FORFEITURE PROVISIONS AND CERTAIN OTHER AGREEMENTS SET FORTH IN A RESTRICTED STOCK AGREEMENT BETWEEN THE COMPANY AND DATED AS OF , _, A COPY OF WHICH MAY BE OBTAINED BY THE HOLDER HEREOF AT THE COMPANY'S PRINCIPAL PLACE OF BUSINESS WITHOUT CHARGE."
(d)Restrictions on Transfer after Vesting. The transfer or sale of Vested Shares in accordance with this Section 4 of this Agreement shall be subject to the Company Policy Regarding Insider Trading, as amended from time to time, including any preclearance procedures or black-out periods that specifically apply to Grantee.
5.Conformity with Plan. The Restricted Stock is intended to conform in all respects with, and is subject to all applicable provisions of, the Plan (which is incorporated herein by reference). Inconsistencies between this Agreement and the Plan shall be resolved in accordance with the terms of the Plan. By executing and returning the enclosed copy of this Agreement, Grantee acknowledges receipt of this Agreement and the Plan and agrees to be bound by all of the terms of this Agreement and the Plan.
6.Rights of Employment. Nothing in this Agreement shall interfere with or limit in any way the right of the Company to terminate Grantee’s employment at any time (with or without Cause), nor confer upon Grantee any right to continue in the employ of the Company for any period of time or



to continue his or her present (or any other) rate of compensation, and in the event of Grantee’s termination of employment (including, but not limited to, termination by the Company without Cause), any portion of Grantee’s Restricted Stock that was not previously vested shall be forfeited, except as otherwise provided herein. Nothing in this Agreement shall confer upon Grantee any right to be selected again as a Plan participant, and nothing in the Plan or this Agreement shall provide for any adjustment to the number of shares of Restricted Stock upon the occurrence of subsequent events except as provided in Section 8 below.
7.Withholding of Taxes.
(a)The Grantee shall, immediately upon notification of the amount due, if any, pay to the Company in cash or by check or direct a broker to sell a sufficient number of shares from the Grantee’s brokerage account and deliver the proceeds to the Company, in either case in the amount necessary to satisfy any applicable federal, state and local tax withholding requirements. If additional withholding is or becomes required (as a result of the vesting of any Restricted Stock or as a result of disposition of Vested Shares) beyond any amount deposited before delivery of the certificates, the Grantee shall pay such amount to the Company, in cash or by check, on demand. The Company shall be entitled, if necessary or desirable, to withhold from Grantee any amounts due and payable by the Company, including wages, to Grantee (or secure payment from Grantee in lieu of withholding), the amount of any withholding or other tax due from the Company with respect to any Restricted Stock issuable under this Agreement, and the Company may defer such issuance unless indemnified by Grantee to its satisfaction. Grantee acknowledges that he or she has reviewed with his or her own tax advisors the federal, state, local and foreign tax consequences of this investment and the transactions contemplated by this Agreement. Grantee is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. Grantee understands that he or she (and not the Company) shall be responsible for any tax liability that may arise as a result of the transactions contemplated by this Agreement. Grantee further understands that Section 83 of the Code, taxes as ordinary income the difference between the purchase price, if any, for the Shares and the fair market value of the Shares as of the date the forfeiture provisions in Section 3 lapse. Grantee understands that the he or she may elect to be taxed at the time the Restricted Stock is issued rather than when and as the forfeiture provisions lapse expires by filing an election under Section 83(b) of the Code with the IRS within 30 days from the date of hereof. THE FORM FOR MAKING THIS SECTION 83(b) ELECTION IS ATTACHED TO THIS AGREEMENT AS EXHIBIT A AND GRANTEE (AND NOT THE COMPANY OR ANY OF ITS AGENTS) SHALL BE SOLELY RESPONSIBLE FOR APPROPRIATELY FILING SUCH FORM, EVEN IF GRANTEE REQUESTS THE COMPANY OR ITS AGENTS TO MAKE THIS FILING ON GRANTEE’S BEHALF.
8.Adjustments. In the event of a reorganization, recapitalization, stock dividend or stock split, or combination or other change in the Shares, the Board or the Committee shall make such adjustments in the number and type of shares of Grantee’s Restricted Stock as the Board or Committee reasonably determine to be appropriate, provided that any such adjustments shall not adversely affect the Grantee.
9.Rights as a Shareholder. Except as otherwise provided in this Agreement and the Plan, Grantee shall have all of the rights of a shareholder of the Company with respect to the Shares of Restricted Stock, including the right to vote such shares and the right to receive dividends. There is no guarantee by the Company that dividends will be paid. All dividends and other distributions paid with respect to Restricted Stock, including with respect to unvested Restricted Stock and whether paid in cash, Shares, or other property, shall be paid by the Company on the same date that dividend payments are made with respect to all of the Company’s outstanding Shares.
10.Remedies. The parties hereto shall be entitled to enforce their rights under this Agreement specifically, to recover damages by reason of any breach of any provision of this Agreement and



to exercise all other rights existing in their favor. The parties hereto acknowledge and agree that money damages would not be an adequate remedy for any breach of the provisions of this Agreement and that any party hereto shall be entitled to specific performance and/or injunctive relief (without posting bond or other security) from any court of law or equity of competent jurisdiction in order to enforce or prevent any violation of the provisions of this Agreement.
11.Amendment. Except as otherwise provided herein, any provision of this Agreement may be amended or waived only with the prior written consent of Grantee and the Company.
12.Successors and Assigns. Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and permitted assigns of the parties hereto whether so expressed or not.
13.Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.
14.Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall constitute an original, but all of which taken together shall constitute one and the same Agreement.
15.Descriptive Headings. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a part of this Agreement.
16.Governing Law. The corporate law of the state of Delaware shall govern all questions concerning the relative rights of the Company and its stockholders. All other questions concerning the construction, validity and interpretation of this Agreement shall be governed by the internal law, and not the law of conflicts, of the state of Delaware.
17.Entire Agreement. This Agreement and the Plan constitute the entire understanding between Grantee and the Company, and supersedes all other agreements, whether written or oral, with respect to the acquisition by Grantee of Common Stock of the Company. If there are any conflicts in terms and conditions between this Agreement and the Plan, the terms and conditions of the Plan shall govern, unless otherwise determined by the Committee or the Board.












EX-21.1 4 ensg123122ex211.htm EX-21.1 Document



EXHIBIT 21.1
Legal NamePresident Company/ OwnerJurisdiction of Organization / Formation
2016 Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
2020 Health Holdings LLCThe Ensign Group, Inc.Nevada
2410 Stillhouse Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
24th Street Healthcare Associates LLCBandera Healthcare LLCNevada
Adipiscor, LLCThe Ensign Group, Inc.Nevada
Agape Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Alice Branch Healthcare LLCKeystone Care LLCNevada
Allen Creek Healthcare, Inc.Pennant Healthcare LLCNevada
Alvarado Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
American Lake Healthcare, Inc.Pennant Healthcare LLCNevada
American Robin Healthcare, Inc.Keystone Care LLCNevada
Ann Arbor Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Anza Healthcare, Inc.Flagstone Healthcare South LLCNevada
Apache Trail Healthcare, Inc.Bandera Healthcare LLCNevada
Appaloosa Healthcare, Inc.Ellis Pointe Health Holdings LLCNevada
Apple Springs Healthcare, Inc.Keystone Care LLCNevada
Armstrong Healthcare, Inc.Keystone Care LLCNevada
Arris Health Services LLCCovalence Health Holdings LLCNevada
Arvada Healthcare, Inc.Endura Healthcare LLCNevada
Ascent Health Services LLCBridge Holding Company, LLCNevada
Atlantic Memorial Healthcare Associates, Inc.Flagstone Healthcare South LLCNevada
Avalanche Healthcare, Inc.Endura Healthcare LLCNevada
Avenues Healthcare, Inc.Milestone Healthcare LLCNevada
Avocado Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
AZ Nursing Careers, Inc. Bandera Healthcare LLCNevada
Aztec Healthcare, Inc.Bandera Healthcare LLCNevada
Bainbridge Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Bakorp, L.L.C.PMD Investments, LLCArizona
Bandera Healthcare LLCThe Ensign Group, Inc.Nevada
Banner Holdings LLCThe Ensign Group, Inc.Nevada
Bannock Health Holdings LLCThe Ensign Group, Inc.Nevada
Bardwell Healthcare, Inc.Endura Healthcare LLCNevada
Baseline Healthcare, Inc.Endura Healthcare LLCNevada
Bayside Healthcare, Inc.Flagstone Healthcare South LLCNevada
Baywood Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Beacon Hill Healthcare, Inc.Pennant Healthcare LLCNevada
Beacon Purchasing LLCBanner Holdings LLCNevada
Bear Creek Senior Living, Inc.Pennant Healthcare LLCNevada
Bell Villa Care Associates LLCFlagstone Healthcare South LLCNevada
Bennett Healthcare LLCPennant Healthcare LLCNevada
Bernardo Heights Healthcare, Inc.Flagstone Healthcare South LLCNevada
Bertetti Healthcare, Inc.Keystone Care LLCNevada
Best SW Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Big Blue Healthcare LLCGateway Healthcare LLCNevada
Bijou Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Bijou Healthcare LLCEndura Healthcare LLCNevada
Black Ridge Canyon Healthcare LLCKeystone Care LLCNevada
Blackbird Senior Living, Inc.Bandera Healthcare LLCNevada
Bluebird Healthcare, Inc.Hopewell Healthcare LLCNevada
Bluebonnet Healthcare, Inc.Keystone Care LLCNevada
Bouverie Healthcare Services, Inc.Flagstone Healthcare North LLCNevada
Brackenridge Healthcare, Inc.Keystone Care LLCNevada
Brenwood Park Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Bridge Holding Company, LLCCovalence Health Holdings LLCNevada
Bridgestone Living LLCThe Ensign Group, Inc.Nevada
Broken Ridge Healthcare, Inc.Endura Healthcare LLCNevada
Brownsville Care Associates, Inc.Keystone Care LLCNevada
Bruce Neenah Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Buffalo Creek Healthcare LLCKeystone Care LLCNevada
Burch Creek Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
C Street Health Associates LLCFlagstone Healthcare Central LLCNevada
Calavaras Creek Healthcare LLCKeystone Care LLCNevada
California Nursing Academy, Inc.Flagstone Healthcare South LLCNevada
Camarillo Community Care, Inc.Flagstone Healthcare Central LLCNevada
Canary Bend Healthcare LLCKeystone Care LLCNevada
Cane Island Healthcare, Inc.Keystone Care LLCNevada
Canyon Springs Senior Living, Inc.Bridgestone Living LLCNevada
Capstone Resources, Inc.Capstone Transportation Investments, Inc.Nevada
Capstone Transportation Investments, Inc.The Ensign Group, Inc.Nevada
Cardiff Healthcare, Inc.Milestone Healthcare LLCNevada
Cardinal Healthcare, Inc.Bandera Healthcare LLCNevada
Carolina Healthcare LLCHopewell Healthcare LLCNevada
Carrollton Heights Healthcare, Inc.Keystone Care LLCNevada
Castle Pines Healthcare LLCEndura Healthcare LLCNevada
Cedar City Healthcare LLCMilestone Healthcare LLCNevada
Central Avenue Healthcare, Inc.Gateway Healthcare LLCNevada
Chaparral Healthcare, Inc.Keystone Care LLCNevada
Chateau Julia Healthcare, Inc.Endura Healthcare LLCNevada
Cherokee Healthcare, Inc.Gateway Healthcare LLCNevada
Cherry Hills Healthcare, Inc.Endura Healthcare LLCNevada
Chickadee Healthcare LLCKeystone Care LLCNevada
Circle Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
City Heights Health Associates LLCFlagstone Healthcare South LLCNevada
Claremont Foothills Health Associates LLCFlagstone Healthcare Central LLCNevada
Clark Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Claydelle Healthcare LLCFlagstone Healthcare South LLCNevada
Clear Skies Healthcare, Inc.Flagstone Healthcare South LLCNevada
Cloverleaf Healthcare LLCGateway Healthcare LLCNevada
Coldwater Springs Healthcare, Inc.Bandera Healthcare LLCNevada
Columbia River Healthcare, Inc.Pennant Healthcare LLCNevada
Concord Avenue Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Congaree Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Conrad Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Constitution Road Healthcare, Inc.Endura Healthcare LLCNevada
Conway Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Copeland Healthcare, Inc.Keystone Care LLCNevada
Cornet Limited, Inc.The Ensign Group, Inc.Arizona
Costa Victoria Healthcare LLCFlagstone Healthcare South LLCNevada
Covalence Health Holdings LLCThe Ensign Group, Inc.Nevada
Cow Creek Healthcare, Inc.Keystone Care LLCNevada
Cress Creek Healthcare LLCPennant Healthcare LLCNevada
Crown Hill Healthcare LLCEndura Healthcare LLCNevada
Crystal Lake Healthcare, Inc.Keystone Care LLCNevada
Cypress Creek Healthcare, Inc.Keystone Care LLCNevada
Da Vinci Healthcare, Inc.Bandera Healthcare LLCNevada
Daffodil Healthcare, Inc.Keystone Care LLCNevada
Dark Sky Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Davis Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
De Moisy Healthcare LLCMilestone Healthcare LLCNevada
Deer Creek Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Deergrass Healthcare, Inc.Flagstone Healthcare North LLCNevada
Desert Cove Healthcare, Inc.Bandera Healthcare LLCNevada
Desert Lily Healthcare, Inc.Bandera Healthcare LLCNevada
Desert Mallow Healthcare, Inc.Flagstone Healthcare South LLCNevada
Dessau Healthcare, Inc.Keystone Care LLCNevada
Devonshire Healthcare, Inc.Flagstone Healthcare South LLCNevada
Diamond Valley Health Holdings LLCThe Ensign Group, Inc.Nevada
Discovery Trail Healthcare, Inc.Gateway Healthcare LLCNevada
Dorothy Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Downey Community Care LLCFlagstone Healthcare South LLCNevada
Duck Creek Healthcare, Inc.Keystone Care LLCNevada
Dusk Healthcare, Inc.Flagstone Healthcare South LLCNevada
Eagle Harbor Healthcare LLCPennant Healthcare LLCNevada
East Mesa Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
East River Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Echo Canyon Healthcare, Inc.Bandera Healthcare LLCNevada
Eiffel Healthcare LLCKeystone Care LLCNevada
Elati Health Holdings LLCTurnberry Health Holdings LLCNevada
Elkhorn Health Holdings LLCThe Ensign Group, Inc.Nevada
Ellis Pointe Health Holdings LLCKeystone Care LLCNevada
Empirecare Health Associates LLCFlagstone Healthcare Central LLCNevada
Endura Healthcare LLCThe Ensign Group, Inc.Nevada
Ensign Cloverdale LLCFlagstone Healthcare North LLCNevada
Ensign Montgomery LLCFlagstone Healthcare North LLCNevada
Ensign Palm I LLCFlagstone Healthcare Central LLCNevada
Ensign Panorama LLCFlagstone Healthcare Central LLCNevada
Ensign Pleasanton LLCFlagstone Healthcare North LLCNevada
Ensign Sabino LLCBandera Healthcare LLCNevada
Ensign San Dimas LLCFlagstone Healthcare Central LLCNevada
Ensign Santa Rosa LLCFlagstone Healthcare North LLCNevada
Ensign Services, Inc.The Ensign Group, Inc.Nevada
Ensign Sonoma LLCFlagstone Healthcare North LLCNevada
Ensign Whittier East LLCFlagstone Healthcare South LLCNevada
Ensign Whittier West LLCFlagstone Healthcare South LLCNevada
Ensign Willits LLCFlagstone Healthcare North LLCNevada
Fawn Meadows Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Flagstone Healthcare Central LLCThe Ensign Group, Inc.Nevada
Flagstone Healthcare North LLCThe Ensign Group, Inc.Nevada
Flagstone Healthcare South LLCThe Ensign Group, Inc.Nevada
Flintrock Falls Healthcare, Inc.Keystone Care LLCNevada
Floyde Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Forney Lake Healthcare, Inc.Keystone Care LLCNevada
Forrest Hill Healthcare LLCKeystone Care LLCNevada
Fossil Creek Healthcare, Inc.Keystone Care LLCNevada
Fox Sparrow Healthcare, Inc.Keystone Care LLCNevada
Franklin Avenue Healthcare, Inc.Endura Healthcare LLCNevada
Franklin Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Fullerton Healthcare, Inc.Flagstone Healthcare South LLCNevada
Garwood Health Holdings II LLCStandard Bearer Healthcare OP, LPNevada
Gate Three Healthcare LLCFlagstone Healthcare South LLCNevada
Gateway Healthcare LLCThe Ensign Group, Inc.Nevada
Gem Healthcare, Inc.Pennant Healthcare LLCNevada
Getzendaner Healthcare, Inc.Keystone Care LLCNevada
Glendale Healthcare Associates LLCBandera Healthcare LLCNevada
Glimmer Healthcare, Inc.Flagstone Healthcare South LLCNevada
Golden Eagle Senior Living, Inc.Flagstone Healthcare Central LLCNevada
Golden Oaks Healthcare, Inc.Gateway Healthcare LLCNevada
Golden Years Program, Inc.Milestone Healthcare LLCNevada
Goldenstar Healthcare, Inc.Flagstone Healthcare Central LLCNevada
Goldfield Mountain Healthcare LLCBandera Healthcare LLCNevada
Good Hope Healthcare, Inc.Gateway Healthcare LLCNevada
Gooding Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Graceland Senior Living, Inc.Gateway Operated, Bridgestone OwnedNevada
Grand Avenue Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Grand Villa PHX, Inc.Keystone Care LLCNevada
Grassland Healthcare and Rehabilitation, Inc.Keystone Care LLCNevada
Green Bay Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Green Heron Senior Living, Inc.Bandera Healthcare LLCNevada
Green Mountain Healthcare LLCKeystone Care LLCNevada
Green Mountain Personalized Care, Inc.Keystone Care LLCNevada
Green Valley Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Gypsum Creek Healthcare, Inc.Gateway Healthcare LLCNevada
Harlan Heights Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Harlingen Healthcare, Inc.Keystone Care LLCNevada
Harmony Health Holdings LLCThe Ensign Group, Inc.Nevada
Harrison Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Hartwell Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
HB Healthcare Associates LLCFlagstone Healthcare South LLCNevada
Healthlift Medical Transportation, Inc.Capstone Transportation Investments, Inc.Nevada
Heartland Health Holdings II LLCStandard Bearer Healthcare OP, LPNevada
Highland Healthcare LLCBandera Healthcare LLCNevada
Higley Healthcare, Inc.Bandera Healthcare LLCNevada
Hill Country Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Holford Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Hollyleaf Healthcare, Inc.Flagstone Healthcare South LLCNevada
Homedale Healthcare, Inc.Pennant Healthcare LLCNevada
Hopewell Healthcare LLCThe Ensign Group, Inc.Nevada
Hoquiam Healthcare, Inc.Pennant Healthcare LLCNevada
Hub City Healthcare LLCKeystone Care LLCNevada
Hueneme Healthcare, Inc.Milestone Healthcare LLCNevada
Huntington Beach Convalescent Hospital Asset LLCLongboard Health Holdings LLCDelaware
Hutchins Healthcare, Inc.Keystone Care LLCNevada
Hyrum Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Immediate Clinic Seattle, Inc.Immediate Clinic Healthcare, Inc.Nevada
Insight Healthcare LLCThe Ensign Group, Inc.Nevada
Ionic Health Services LLCCovalence Health Holdings LLCCalifornia
Iron Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Iron Horse Healthcare LLCGateway Healthcare LLCNevada
Jack Finney Healthcare, Inc.Keystone Care LLCNevada
JARR Transportation Group, Inc.Capstone Transportation Investments, Inc.Arizona
Jefferson Healthcare LLCFlagstone Healthcare South LLCNevada
Jordan Health Associates, Inc.Milestone Healthcare LLCNevada
JRT Healthcare, Inc.Pennant Healthcare LLCNevada
Kenosha Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Kettle Creek Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Keystone Care LLCThe Ensign Group, Inc.Nevada
Kingston Falls Healthcare LLCHopewell Healthcare LLCNevada
Klement Healthcare, Inc.Keystone Care LLCNevada
Knight Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Krypton Health Services LLCCovalence Health Holdings LLCNevada
La Jolla Skilled LLCFlagstone Healthcare South LLCNevada
La Veta Healthcare, Inc.Flagstone Healthcare South LLCNevada
Lake Cassidy Health Holdings LLCThe Ensign Group, Inc.Nevada
Lake Island Healthcare LLCKeystone Care LLCNevada
Lake Pleasant Healthcare, Inc.Bandera Healthcare LLCNevada
Lake Pointe Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Lake Washington Healthcare, Inc.Pennant Healthcare LLCNevada
Lakewood Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Lakewood Healthcare, Inc.Endura Healthcare LLCNevada
Ledbetter Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Legend Lake Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Lemon Grove Health Associates LLCFlagstone Healthcare South LLCNevada
Lightning Healthcare, Inc.Flagstone Healthcare North LLCNevada
Lil’ Tots Day Program, Inc.Milestone Healthcare LLCNevada
Lilly Road Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Lindahl Healthcare, Inc.Gateway Healthcare LLCNevada
Little Blue Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Little Mountain Healthcare, Inc.Pennant Healthcare LLCNevada
Little Village Day Care, Inc.Keystone Care LLCNevada
Littleton Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Livingston Care Associates, Inc.Keystone Care LLCNevada
Lone Pine Ridge Healthcare, Inc.Milestone Healthcare LLCNevada
Lone Star MTC, Inc.Capstone Transportation Investments, Inc.Nevada
Longboard Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Lookout Mountain Healthcare LLCBandera Healthcare LLCNevada
Lowell Healthcare, Inc.Endura Healthcare LLCNevada
Lucky Peak Healthcare, Inc.Pennant Healthcare LLCNevada
Ludden Healthcare LLCBandera Healthcare LLCNevada
Lynnwood Health Services, Inc.Pennant Healthcare LLCNevada
Madison Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Madison Pointe Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Magic Valley Senior Living, Inc.Bridgestone Living LLCNevada
Manitowoc Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Manor Park Healthcare LLCPennant Healthcare LLCNevada
Manzanita Healthcare, Inc.Flagstone Healthcare South LLCNevada
Maple Hills Healthcare, Inc.Gateway Healthcare LLCNevada
Marguerite Holdings LLCThe Ensign Group, Inc.Nevada
Mariano Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Marion Health Associates, Inc.Endura Operated, Bridgestone OwnedNevada
MavStar Medical Transportation, Inc.Capstone Transportation Investments, Inc.Nevada
McAllen Care Associates, Inc.Keystone Care LLCNevada
McAllen Community Healthcare LLCKeystone Care LLCNevada
McCall Healthcare LLCPennant Healthcare LLCNevada
McFarland Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
MedStar Medical Transportation, LLCJARR Transporation Group, Inc.Arizona
Menomonee Health Holdings LLCThe Ensign Group, Inc.Nevada
Meridian Healthcare LLCPennant Healthcare LLCNevada
Midland Nampa Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Midland Nampa Healthcare LLCPennant Healthcare LLCNevada
Midnight Healthcare, Inc.Flagstone Healthcare South LLCNevada
Milestone Healthcare LLCThe Ensign Group, Inc.Nevada
Mission Trails Healthcare LLCFlagstone Healthcare South LLCNevada
Misty Willow Healthcare, Inc.Keystone Care LLCNevada
Mockingbird Healthcare, Inc.Keystone Care LLCNevada
Monroe Healthcare, Inc.Gateway Healthcare LLCNevada
Montebella Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Moon Cove Healthcare, Inc.Pennant Healthcare LLCNevada
Moonflower Healthcare, Inc.Keystone Care LLCNevada
Moonrise Healthcare, Inc.Flagstone Healthcare South LLCNevada
Morning Glory Healthcare, Inc.Flagstone Healthcare Central LLCNevada
Mount Lemmon Healthcare LLCBandera Healthcare LLCNevada
Mountain View Retirement, Inc.Milestone Operated, Bridgestone OwnedNevada
Mountain Violet Healthcare, Inc.Flagstone Healthcare North LLCNevada
Murphy Health Holdings II LLCStandard Bearer Healthcare OP, LPNevada
Mussel Rock Healthcare, Inc.Flagstone Healthcare North LLCNevada
Mustang Ridge Healthcare, Inc.Keystone Care LLCNevada
Myrtle Springs Healthcare, Inc.Ellis Pointe Health Holdings LLCNevada
Nautilus Healthcare, Inc.Flagstone Healthcare South LLCNevada
NB Brown Rock Healthcare, Inc.Keystone Care LLCNevada
New England Medical Transportation, Inc.Capstone Transportation Investments, Inc.Nevada
Nightfall Healthcare, Inc.Flagstone Healthcare South LLCNevada
Nobel Health Properties LLCStandard Bearer Healthcare OP, LPNevada
Nordic Valley Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
North Mountain Healthcare LLCBandera Healthcare LLCNevada
North Parkway Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
North Parkway Healthcare LLCMilestone Healthcare LLCNevada
Northern Oaks Healthcare, Inc.Keystone Care LLCNevada
Oak Point Healthcare, Inc.Keystone Care LLCNevada
Oceanview Healthcare, Inc.Keystone Care LLCNevada
Ocotillo Healthcare, Inc.Bandera Healthcare LLCNevada
Old Pueblo Medical Transportation, Inc.Capstone Transportation Investments, Inc.Nevada
Olmstead Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Olympus Health, Inc.Milestone Healthcare LLCNevada
Ottawa Healthcare LLCGateway Healthcare LLCNevada
Pacific Mobile Diagnostics Holdings, LLCPMD Investments, LLCNevada
Padua Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Palm Valley Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Panorama Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Park Waverly Healthcare LLCBandera Healthcare LLCNevada
Parkside Healthcare, Inc.Flagstone Healthcare South LLCNevada
Pennant Healthcare LLCThe Ensign Group, Inc.Nevada
Peoria Healthcare LLCBandera Healthcare LLCNevada
Percheron Healthcare, Inc.Ellis Pointe Health Holdings LLCNevada
Permunitum LLCThe Ensign Group, Inc.Nevada
Perris Hills Healthcare LLCFlagstone Healthcare Central LLCNevada
Pikes Peak Healthcare, Inc.Endura Healthcare LLCNevada
Pine Forest Healthcare, Inc.Flagstone Healthcare South LLCNevada
Piney Lufkin Healthcare, Inc.Keystone Care LLCNevada
Pleasant Run Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
PMD Investments, LLCThe Ensign Group, Inc.Nevada
PMD X-Ray Services, LLCBakorp L.L.C.Nevada
PMDAZ, LLCBakorp L.L.C.Nevada
PMDCO, LLCBakorp L.L.C.Nevada
PMDTC, LLCBakorp L.L.C.Nevada
PMDUT, LLCBakorp L.L.C.Nevada
Pocatello Health Services, Inc.Pennant Healthcare LLCNevada
Pointe Meadow Healthcare, Inc.Milestone Healthcare LLCNevada
Pomerado Ranch Healthcare LLCKeystone Care LLCNevada
Ponderosa Pine Healthcare, Inc.Bandera Healthcare LLCNevada
Portside Healthcare, Inc.Flagstone Healthcare South LLCNevada
Powderhorn Mountain Healthcare LLCKeystone Care LLCNevada
Powers Park Healthcare, Inc.Flagstone Healthcare Central LLCNevada
Prairie Creek Healthcare, Inc.Gateway Healthcare LLCNevada
Prairie Ridge Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Presidio Health Associates LLCBandera Healthcare LLCNevada
Price Healthcare, Inc.Milestone Healthcare LLCNevada
Primrose Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Primrose Healthcare, Inc.Keystone Care LLCNevada
Quail Creek Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Queenston Healthcare, Inc.Keystone Care LLCNevada
Quorum Services, Inc.The Ensign Group, Inc.Nevada
Quorum Ventures, Inc.The Ensign Group, Inc.Nevada
Racine Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Radiant Hills Health Associates LLCBandera Healthcare LLCNevada
Ramon Healthcare Associates LLCFlagstone Healthcare Central LLCNevada
Randolph Healthcare, Inc.Gateway Healthcare LLCNevada
Red Cliffs Healthcare, Inc.Milestone Healthcare LLCNevada
Red Mountain Healthcare LLCBandera Healthcare LLCNevada
Redbrook Healthcare Associates LLCFlagstone Healthcare Central LLCNevada
RenewCare of Scottsdale, Inc.Bandera Healthcare LLCNevada
Richmond Senior Services, Inc.Keystone Care LLCNevada
Rio Hondo Healthcare, Inc.Flagstone Healthcare South LLCNevada
Rio Mesa Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Riverside Healthcare, Inc.Gateway Healthcare LLCNevada
Riverview Healthcare, Inc.Milestone Healthcare LLCNevada
Riverview Village Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Riverwalk Healthcare, Inc.Keystone Care LLCNevada
Roadrunner Healthcare, Inc.Keystone Care LLCNevada
Rock Canyon Healthcare LLCEndura Healthcare LLCNevada
Rock Hill Healthcare LLCHopewell Healthcare LLCNevada
Rocky Mountain Medical Transportation Company, Inc.Capstone Transportation Investments, Inc.Nevada
Rose Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Rose Park Healthcare Associates, Inc.Flagstone Healthcare South LLCNevada
Rosemead Health Holdings LLCThe Ensign Group, Inc.Nevada
Rowlett Creek Healthcare LLCKeystone Care LLCNevada
Royal View Healthcare LLCBandera Healthcare LLCNevada
Sage Meadow Healthcare, Inc.Keystone Care LLCNevada
Sage Terrace Healthcare LLCKeystone Care LLCNevada
Sagebrush Healthcare, Inc.Flagstone Healthcare North LLCNevada
Salado Creek Senior Care, Inc.Keystone Care LLCNevada
Sand Hollow Healthcare LLCMilestone Healthcare LLCNevada
Sandpiper Senior Living LLCFlagstone Healthcare South LLCNevada
Santa Catalina Healthcare, Inc.Flagstone Healthcare South LLCNevada
Santa Maria Healthcare, Inc.Flagstone Healthcare Central LLCNevada
Santiago Healthcare LLCKeystone Care LLCNevada
Santiago Personal Care, Inc.Keystone Care LLCNevada
Savoy Healthcare, Inc.Keystone Care LLCNevada
Sawtooth Healthcare, Inc.Pennant Healthcare LLCNevada
Scandinavian Court Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Second West Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sedgewood Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sentinel Peak Healthcare LLCBandera Healthcare LLCNevada
Sheboygan Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sherman Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sherwood Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Shoshone Health Holdings LLCThe Ensign Group, Inc.Nevada
Sidewinder Healthcare, Inc.Endura Healthcare LLCNevada
Siena Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Somers Kenosha Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Songbird Healthcare, Inc.Keystone Care LLCNevada
South C Health Holdings LLCThe Ensign Group, Inc.Nevada
South Valley Healthcare, Inc.Milestone Healthcare LLCNevada
Southern Charm Healthcare LLCHopewell Healthcare LLCNevada
Southern Oaks Healthcare LLCKeystone Care LLCNevada
Southland Management LLCFlagstone Healthcare South LLCNevada
Southside Healthcare, Inc.Gateway Healthcare LLCNevada
Stagecoach Healthcare, Inc.Flagstone Healthcare Central LLCNevada
Standard Bearer Healthcare OP GP, LLCStandard Bearer Healthcare REIT, Inc.Delaware
Standard Bearer Healthcare OP, LPStandard Bearer Healthcare REIT, Inc.; Standard Bearer Healthcare OP GP, LLCDelaware
Standard Bearer Healthcare REIT, Inc.The Ensign Group, Inc.Maryland
Standardbearer Insurance Company, Inc.The Ensign Group, Inc.Arizona
Stanton Lake Healthcare, Inc.Gateway Healthcare LLCNevada
Starburst Healthcare, Inc.Flagstone Healthcare South LLCNevada
Starling Healthcare, Inc.Hopewell Healthcare LLCNevada
Statler Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Steelhead Healthcare, Inc.Pennant Healthcare LLCNevada
Stevens Point Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Stoney Hill Healthcare LLCHopewell Healthcare LLCNevada
Storm Healthcare, Inc.Flagstone Healthcare North LLCNevada
Stoughton Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Subacute Facility Services, Inc.Gateway Healthcare LLCNevada
Successor Healthcare LLCMilestone Healthcare LLCNevada
Summit Healthcare, Inc.The Ensign Group, Inc.Nevada
Summit Trail Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sunflower Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Sungazer Healthcare, Inc.Flagstone Healthcare South LLCNevada
Sunland Health Associates LLCBandera Healthcare LLCNevada
Sunny Acres Health Holdings LLCThe Ensign Group, Inc.Nevada
Sunny Acres Healthcare LLCEndura Healthcare LLCNevada
Sunrise Mountain Healthcare LLCBandera Healthcare LLCNevada
Sweet Bay Healthcare LLCKeystone Care LLCNevada
Terrace Court Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
The Ensign Group, Inc.N/ADelaware
TheraTroopers CA, Inc.Theratroopers Holdings LLCNevada
Theratroopers Holdings LLCThe Ensign Group, Inc.Nevada
TheraTroopers, Inc.Theratroopers Holdings LLCNevada
Thompson Peak Healthcare LLCBandera Healthcare LLCNevada
Thorntree Healthcare, Inc.Keystone Care LLCNevada
Thunder Healthcare, Inc.Flagstone Healthcare North LLCNevada
Thunderbird Health Holdings LLCThe Ensign Group, Inc.Nevada
Top City Healthcare LLCGateway Healthcare LLCNevada
Tortolita Healthcare, Inc.Bandera Healthcare LLCNevada
Towers Park Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Towers Park Healthcare LLCKeystone Care LLCNevada
Towers Park Personal Care, Inc.Keystone Care LLCNevada
Town East Healthcare, Inc.Keystone Care LLCNevada
Tradewind Healthcare, Inc.Keystone Care LLCNevada
Treasure Hills Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Treasure Valley Senior Living, Inc.Bridgestone Living LLCNevada
Treaty Healthcare, Inc.Keystone Care LLCNevada
Tree City Healthcare, Inc.Keystone Care LLCNevada
Tulip Healthcare LLCGateway Healthcare LLCNevada
Turnberry Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Tustin Hills Healthcare, Inc.Flagstone Healthcare South LLCNevada
Two Rivers Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Two Trails Healthcare, Inc.Gateway Healthcare LLCNevada
Union Hill Healthcare, Inc.Pennant Healthcare LLCNevada
Upland Community Care, Inc.Flagstone Healthcare Central LLCNevada
Valley Ranch Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Valley View Health Services, Inc.Pennant Healthcare LLCNevada
Velda Rose Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Victoria Ventura Healthcare LLCFlagstone Healthcare Central LLCNevada
Victory Medical Transportation, Inc.Capstone Transportation Investments, Inc.Nevada
Viewpoint Healthcare LLCBandera Healthcare LLCNevada
Vista Woods Health Associates LLCFlagstone Healthcare South LLCNevada
Wallsville Healthcare LLCKeystone Care LLCNevada
Washington Heights Healthcare LLCMilestone Healthcare LLCNevada
Waterfall Canyon Healthcare LLCMilestone Healthcare LLCNevada
Watson Woods Healthcare, Inc.Bandera Healthcare LLCNevada
Wellington Healthcare, Inc.Keystone Care LLCNevada
West 5600 Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
West 5600 Healthcare LLCMilestone Healthcare LLCNevada
West Ashby Healthcare, Inc.Keystone Care LLCNevada
West Escondido Healthcare LLCFlagstone Healthcare South LLCNevada
West Meadow Health Holdings II LLCStandard Bearer Healthcare OP, LPNevada
West Olive Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
West Owyhee Health Holdings LLCThe Ensign Group, Inc.Nevada
West Pine Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
West Van Buren Healthcare, Inc.Endura Healthcare LLCNevada
Western Canal Healthcare LLCBandera Healthcare LLCNevada
Western Edge Health Holdings LLCTurnberry Health Holdings LLCNevada
Whispering Pines Healthcare, Inc.Keystone Care LLCNevada
Wildcreek Healthcare, Inc.Pennant Healthcare LLCNevada
Wildwood Healthcare, Inc.Pennant Healthcare LLCNevada
Willard Peak Group Home, Inc.Milestone Healthcare LLCNevada
Willow Canyon Healthcare LLCBandera Healthcare LLCNevada
Willow Springs Creek Healthcare, Inc.Keystone Care LLCNevada
Windsor Lake Healthcare, Inc.Endura Operated, Bridgestone OwnedNevada
Wisconsin Rapids Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Wolf Point Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Wolf River Healthcare LLCGateway Healthcare LLCNevada
Wood Bayou Healthcare, Inc.Keystone Care LLCNevada
Woodard Creek Healthcare LLCPennant Healthcare LLCNevada
Yellow Rose Health Holdings LLCThe Ensign Group, Inc.Nevada
Yellowstar Healthcare LLCKeystone Care LLCNevada
Youngtown Health, Inc.Bandera Healthcare LLCNevada
Yucca Flats Health Holdings LLCStandard Bearer Healthcare OP, LPNevada
Zion Healthcare, Inc.Milestone Healthcare LLCNevada

EX-23.1 5 ensg123122ex231.htm EX-23.1 Document

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We consent to the incorporation by reference in Registration Statement No. 333-268018 on Form S-8 of our reports dated February 2, 2023, relating to the financial statements of The Ensign Group, Inc. and the effectiveness of The Ensign Group, Inc.’s internal control over financial reporting, appearing in this Annual Report on Form 10-K for the year ended December 31, 2022.

/s/ DELOITTE & TOUCHE LLP

Costa Mesa, California
February 2, 2023


EX-31.1 6 ensgq42022ex311.htm EX-31.1 Document

EXHIBIT 31.1

I, Barry R. Port, certify that:

1.I have reviewed this Annual Report on Form 10-K of The Ensign Group, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 2, 2023
     
 /s/ Barry R. Port   
 Name:  Barry R. Port 
 Title:  Chief Executive Officer and Director (principal executive officer) 



EX-31.2 7 ensgq42022ex312.htm EX-31.2 Document

EXHIBIT 31.2

I, Suzanne D. Snapper, certify that:

1.I have reviewed this Annual Report on Form 10-K of The Ensign Group, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: February 2, 2023
    
 /s/ Suzanne D. Snapper   
 Name: Suzanne D. Snapper  
 Title:  Chief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer) 


EX-32.1 8 ensgq42022ex321.htm EX-32.1 Document

EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of The Ensign Group, Inc. (the Company) on Form 10-K for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Barry R. Port, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
 1 The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 2 The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
     
 /s/ Barry R. Port 
 Name:  Barry R. Port  
 Title:  
Chief Executive Officer and Director (principal executive officer) 
 
 
 
February 2, 2023
 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


EX-32.2 9 ensgq42022ex322.htm EX-32.2 Document

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of The Ensign Group, Inc. (the Company) on Form 10-K for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Suzanne D. Snapper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
 1 The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 2 The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
     
 /s/ Suzanne D. Snapper   
 Name:  Suzanne D. Snapper  
 Title:  Chief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer) 
 
 
February 2, 2023
 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 


EX-101.SCH 10 ensg-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - COVID-19 UPDATE link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - STANDARD BEARER link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - BUSINESS SEGMENTS link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - OPERATION EXPANSIONS link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - PROPERTY AND EQUIPMENT— NET link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - INTANGIBLE ASSETS — NET link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - RESTRICTED AND OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - OTHER ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - OPTIONS AND AWARDS link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - SELF INSURANCE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - DEFINED CONTRIBUTION PLANS link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - COMMON STOCK REPURCHASE PROGRAM link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - BUSINESS SEGMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - OPERATION EXPANSIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - PROPERTY AND EQUIPMENT— NET (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - INTANGIBLE ASSETS — NET (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - RESTRICTED AND OTHER ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - OTHER ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - OPTIONS AND AWARDS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - SELF INSURANCE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - DESCRIPTION OF BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of Long-Lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recent Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - COVID-19 UPDATE (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Revenue from Medicare and Medicaid Programs (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - STANDARD BEARER (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - BUSINESS SEGMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - BUSINESS SEGMENTS - Schedule of Segment Reporting Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - BUSINESS SEGMENTS - Revenue by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - OPERATION EXPANSIONS (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - OPERATION EXPANSIONS - Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - PROPERTY AND EQUIPMENT— NET - Summary (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - PROPERTY AND EQUIPMENT— NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - INTANGIBLE ASSETS — NET - Schedule of Finite Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - INTANGIBLE ASSETS — NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - INTANGIBLE ASSETS — NET - Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Goodwill Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Indefinite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - RESTRICTED AND OTHER ASSETS - Summary (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - OTHER ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - INCOME TAXES - Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - INCOME TAXES - Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - INCOME TAXES - Narrative (YE) (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000079 - Disclosure - DEBT - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000080 - Disclosure - DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 0000082 - Disclosure - DEBT - Long-term Debt Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 0000083 - Disclosure - OPTIONS AND AWARDS - Stock Options, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000084 - Disclosure - OPTIONS AND AWARDS - Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 0000085 - Disclosure - OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000086 - Disclosure - OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 0000087 - Disclosure - OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details) link:presentationLink link:calculationLink link:definitionLink 0000088 - Disclosure - OPTIONS AND AWARDS - Intrinsic Values (Details) link:presentationLink link:calculationLink link:definitionLink 0000089 - Disclosure - OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000090 - Disclosure - OPTIONS AND AWARDS - Restricted Award Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 0000091 - Disclosure - OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 0000092 - Disclosure - OPTIONS AND AWARDS - Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000093 - Disclosure - LEASES - Lessee Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000094 - Disclosure - LEASES - Lessee Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 0000095 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000095 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000096 - Disclosure - LEASES - Lessor Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000097 - Disclosure - LEASES - Lessor Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000098 - Disclosure - LEASES - Lessor Future Minimum Lease Payments Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 0000099 - Disclosure - SELF INSURANCE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 0000100 - Disclosure - DEFINED CONTRIBUTION PLANS (Details) link:presentationLink link:calculationLink link:definitionLink 0000101 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 0000102 - Disclosure - COMMON STOCK REPURCHASE PROGRAM (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 ensg-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 ensg-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 ensg-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] All States Except Colorado All States Except Colorado [Member] All States Except Colorado [Domain] Rental revenue Operating Lease, Lease Income Provision for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Other third-party Third Party Tenants [Member] Third Party Tenants [Member] Cash held in trust for patients Cash Held in Trust for Residents Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds. Deferred tax assets Deferred Income Tax Assets, Net Mortgage loans and promissory notes Long-term debt, gross Long-Term Debt, Gross 2017 Exercise Price Range Five [Member] Exercise Price Range Five [Member] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Gain (loss) on deferral investment Gain (Loss) on Investments Debt Instrument [Axis] Debt Instrument [Axis] Property and equipment Property, Plant and Equipment, Gross Management fees, as a percentage of funds from operations Property Management Fee, Percent Fee of Funds from Operations Property Management Fee, Percent Fee of Funds from Operations October 21, 2021 Repurchase Program October 21, 2021 Repurchase Program [Member] October 21, 2021 Repurchase Program February 9, 2022 Repurchase Program February 9, 2022 Repurchase Program [Member] February 9, 2022 Repurchase Program Property, plant and equipment Property, Plant and Equipment, Additions Health Liability Insurance Health Liability Insurance [Member] Health Liability Insurance [Member] STANDARD BEARER Standard Bearer [Text Block] Standard Bearer Prepayment penalty reduced rate during the fourth year Prepayment Penalty Reduced Rate During The Fourth Year Percentage that the prepayment penalty percentage is reduced during the fourth year. Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Skilled Nursing Operations Skilled Nursing Operations [Member] Skilled Nursing Operations Interest rate margin Debt Instrument, Basis Spread on Variable Rate Operating leases of lessee, contingent rentals, basis spread on variable rate Lessee, Operating Lease, Discount Rate Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] NET DEFERRED TAX ASSETS Deferred Tax Assets, Net Issuance of restricted stock, net of forfeitures (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Operating lease, weighted average discount rate, percent Operating Lease, Weighted Average Discount Rate, Percent Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Liability for Claims and Claims Adjustment Expense [Table] Liability for Claims and Claims Adjustment Expense [Table] Additional paid-in capital Additional Paid in Capital, Common Stock Accounts receivable, gross Accounts Receivable, before Allowance for Credit Loss Real Estate Properties [Domain] Real Estate Properties [Domain] State Current State and Local Tax Expense (Benefit) Income taxes Income Taxes Paid Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive securities excluded from computation of earnings per share, amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Restricted and other assets RESTRICTED AND OTHER ASSETS Restricted And Other Assets, Noncurrent Restricted And Other Assets, Noncurrent Year Lessee, Operating Lease, Liability, to be Paid [Abstract] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Other adjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Share-based Payment Arrangement, Option, Exercise Price Range Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Equity Component [Domain] Equity Component [Domain] Assembled occupancy Assembled occupancy Assembled Occupancy Acquired [Member] Assembled occupancy acquired [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Ownership [Axis] Ownership [Axis] Number outstanding (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Payments of deferred financing costs Payments of Financing Costs Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Promissory Note, 5.3% Promissory Note, 5.3% [Member] Promissory Note, 5.3% SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Deferred: Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Plan Name [Domain] Plan Name [Domain] Entity Address, State or Province Entity Address, State or Province Share-based compensation, options outstanding, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type [Axis] Award Type [Axis] Deferred compensation liability Increase (Decrease) in Deferred Compensation Lease liabilities—current Less: current lease liabilities Operating Lease, Liability, Current Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Expense: Costs and Expenses [Abstract] Lender Name [Axis] Lender Name [Axis] Noncontrolling Interest Noncontrolling Interest [Policy Text Block] The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. Long-term debt—less current maturities Long-term debt—less current maturities Long-Term Debt, Excluding Current Maturities TOTAL LIABILITIES Liabilities Operating lease, weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Grant date intrinsic value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Aggregate intrinsic value of options that vested in period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Revolving credit facility with Truist Revolving Credit Facility [Member] Service and Rental Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Document Type Document Type Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] SOFR Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Self-Insurance Retention Per Claim Self-insurance retention per claim [Member] Self-insurance retention per claim [Member] Property, plant and equipment, useful life Property, Plant and Equipment, Useful Life Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Nonvested at beginning of period (in dollars per share) Nonvested at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Asset Acquisition [Axis] Asset Acquisition [Axis] Deferred income taxes Deferred Income Tax Expense (Benefit) General and Professional Liability Professional Malpractice Liability Insurance [Member] Exercise Price Range [Axis] Exercise Price Range [Axis] Cost of Sales and General and Administrative Expense Cost of Sales and General and Administrative Expense [Member] Primary financial statement caption encompassing cost of services and general and administrative expense Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag Debt Disclosure [Abstract] Debt Disclosure [Abstract] Accounts Receivable and Allowance for Doubtful Accounts Accounts Receivable [Policy Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Number of real estate properties leased with an option to purchase Number of Real Estate Properties Leased with an Option to Purchase Number of Real Estate Properties Leased with an Option to Purchase Current maturities of long-term debt Less: current maturities Amount outstanding, current Long-Term Debt, Current Maturities New Master Lease Agreement New Master Lease Agreement [Member] New Master Lease Agreement NET CASH USED IN FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Variable lease, cost Variable Lease, Cost Ensign Group, Inc. stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Customer [Axis] Customer [Axis] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Long-term debt, threshold for EBITDA ratio increase election Long-Term Debt, Threshold For EBITDA Ratio Increase Election Long-Term Debt, Threshold For EBITDA Ratio Increase Election Acquisition of noncontrolling interest shares Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Operating lease obligations Increase (Decrease) in Operating Lease Liability Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Share-based compensation, nonvested awards, cost not yet recognized, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition March 13, 2020 Repurchase Program March 13, 2020 Repurchase Program [Member] March 13, 2020 Repurchase Program Deferred employer portion of social security taxes Increase (Decrease) Due To Deferred Employer Taxes, CARES Act Increase (Decrease) Due To Deferred Employer Taxes, CARES Act Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Additional master lease agreement Additional Master Leaser Agreements Additional Master Leaser Agreements Payments to acquire businesses, gross Payments to Acquire Businesses, Gross Entity Registrant Name Entity Registrant Name Nonqualified Plan Nonqualified Plan [Member] Weighted Average Dividend Yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Exercise price, upper range limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Series of Individually Immaterial Business Acquisitions Series of Individually Immaterial Business Acquisitions [Member] Subleased To Third Party Subleased To Third Party [Member] Subleased To Third Party Real Estate Properties [Line Items] Real Estate Properties [Line Items] Leases [Abstract] Leases [Abstract] Total equity Balance at beginning of period Balance at end of period Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Various Landlords Various Landlords [Member] Various Landlords[Member] Revenue, FMAP payments received Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized Minimum Minimum [Member] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number INTANGIBLE ASSETS — NET Intangible Assets Disclosure [Text Block] 2021 Exercise Price Range Nine [Member] Exercise Price Range Nine [Member] Forfeited (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Granted restricted shares (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period TOTAL INCOME TAX PROVISION Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Defined Contribution Plan [Table] Defined Contribution Plan [Table] Estimates and Assumptions Use of Estimates, Policy [Policy Text Block] OPERATION EXPANSIONS Business Combination Disclosure [Text Block] Other (expense) income: Other Nonoperating Income (Expense) [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Concentration risk Percentage of Revenue Concentration Risk, Percentage Escrow deposits Payments for (Proceeds from) Deposits on Real Estate Acquisitions Cash surrender value of life insurance policy premiums Life Insurance, Corporate or Bank Owned, Change in Value INCOME TAXES Income Tax Disclosure [Text Block] Purchase of property and equipment Payments To Acquire Property And Equipment Payments To Acquire Property And Equipment Credit Facility [Domain] Credit Facility [Domain] Basic (in dollars per share) Basic net income per common share (in dollars per share) Earnings Per Share, Basic Award requisite service period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Other Service Revenue Corporate, Non-Segment [Member] Adjusted cost Assets, Adjusted Cost Assets, Adjusted Cost Non-controlling interest distribution Non-controlling interest distribution Payments to Noncontrolling Interests Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Lease Contractual Term [Axis] Lease Contractual Term [Axis] Ownership [Domain] Ownership [Domain] Entity Interactive Data Current Entity Interactive Data Current 2023 Lessor, Operating Lease, Payment to be Received, Year One Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Property, Plant and Equipment [Table] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Change in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Standard Bearer Master Leases Standard Bearer Master Leases [Member] Standard Bearer Master Leases Incentive Management Fee Management Service, Incentive [Member] Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total net debt ratio, minimum Total Net Debt Ratio, Minimum Total Net Debt Ratio, Minimum Repurchase of shares of common stock (Note 22) Payments for Repurchase of Common Stock Thereafter Long-Term Debt, Maturity, after Year Five Income Taxes Income Tax, Policy [Policy Text Block] Insurance Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance Current: Current Federal, State and Local, Tax Expense (Benefit) [Abstract] Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Current assets: Assets, Current [Abstract] New Master Lease Agreeement New Master Lease Agreeement [Member] New Master Lease Agreeement Asset Acquisition [Domain] Asset Acquisition [Domain] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Revenue related reserves Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss Weighted average exercise price of options vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Number of stand-alone leases Lessee, Operating Lease, Number Of Leases Lessee, Operating Lease, Number Of Leases Colorado COLORADO Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Intercompany Elimination Consolidation, Eliminations [Member] Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Segment income (loss) Segment Income (Loss) Segment Income (Loss) Other long-term liabilities Deferred rent and other long-term liabilities Rental expense in excess of actual rental payments and other long-term liabilities Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] California CALIFORNIA Total current income tax expense (benefit) Current Income Tax Expense (Benefit) Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Rent expense Operating Lease, Expense Purchase price Payments to Acquire Productive Assets Equity compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent TOTAL ACQUISITIONS Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Common stock, shares outstanding Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding Goodwill Balance at beginning of period Balance at end of period Goodwill Prepaid income taxes Prepaid Taxes Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Notes payable Notes Payable Capital contribution from noncontrolling interest holder Noncontrolling Interest, Increase from Subsidiary Equity Issuance Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Cash proceeds from the sale of assets Proceeds from Sales of Assets, Investing Activities Entity Public Float Entity Public Float Cost of services Cost of Goods and Services Sold Debt issuance costs, net Debt Issuance Costs, Line of Credit Arrangements, Net Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Retirement Plan Tax Status [Axis] Retirement Plan Tax Status [Axis] Accounts Receivable Accounts Receivable [Member] Common stock: $0.001 par value; 100,000 shares authorized; 59,029 and 55,661 shares issued and outstanding at December 31, 2022, respectively, and 58,134 and 55,190 shares issued and outstanding at December 31, 2021, respectively Common Stock, Value, Issued Real Estate Purchases Of Previous Operations Real Estate Purchases Of Previous Operations [Member] Real Estate Purchases Of Previous Operations Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] 2016 Exercise Price Range Four [Member] Exercise Price Range Four [Member] Health care facilities Number Of Health Care Facilities Number Of Health Care Facilities Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Axis] Less: Net Income (Loss) Attributable to Noncontrolling Interest [Abstract] Current liabilities: Liabilities, Current [Abstract] Issuance of common stock upon exercise of options Proceeds from Stock Options Exercised Resident advances Contract with Customer, Liability, Current Income Statement Location [Domain] Income Statement Location [Domain] Amendment Flag Amendment Flag Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Operating lease expense Operating lease expense Operating Lease, Cost Repayment of medicare accelerated and advance payment program Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act Number of real estate skilled nursing properties acquired Number Of Properties Acquired Number Of Properties Acquired Number of operations transferred from third parties Number of Living Operations Transferred From Third-Parties Number of Living Operations Transferred From Third-Parties Medicaid Medicaid [Member] Revenue from Medicaid for custodial services [Member] Goodwill Goodwill Additions Goodwill, Acquired During Period Construction in progress Construction in Progress [Member] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Share-based compensation, nonvested awards (in shares) Employee Service Share-based Compensation, Nonvested Awards Employee Service Share-based Compensation, Nonvested Awards Intangible Assets and Goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] Depreciation and amortization Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization Line of credit facility, unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Liability for Claims and Claims Adjustment Expense [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Debt Instrument, pre-payment fee reduction, term Debt Instrument, Pre-Payment Fee Reduction, Term Debt Instrument, Pre-Payment Fee Reduction, Term Lessee, operating lease, term of contract Lessee, Operating Lease, Term of Contract Counterparty Name [Axis] Counterparty Name [Axis] Number of asset acquisitions Number of Asset Acquisitions Number of Asset Acquisitions Non-California Non-California [Member] Non-California [Domain] Total net debt ratio, maximum Total Net Debt Ratio, Maximum Total Net Debt Ratio, Maximum Black-Scholes Fair Value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Fair Value Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range Total deferred income tax expense (benefit) Deferred Federal, State and Local, Tax Expense (Benefit) Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Lease liabilities Operating Lease, Payments Payments on debt (Note 16) Repayments of Long-Term Debt Stock Options Stock-based compensation expense related to stock options Share-Based Payment Arrangement, Option [Member] Allowance for doubtful accounts Less: allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Master lease agreements Master Lease Agreements Master Lease agreements Self insurance reserve Self Insurance Reserve Property taxes Accrual for Taxes Other than Income Taxes General Liability General Liability [Member] Common stock, shares authorized Common Stock, Shares Authorized 2015 Exercise Price Range Three [Member] Exercise Price Range Three [Member] Lease Arrangement [Domain] Lease Arrangement [Domain] Lease Arrangement Maximum Maximum [Member] New operations under separate master leases New Operations Under Separate Master Leases New Operations Under Separate Master Leases Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Base Management Fee Management Service, Base [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets, Net (Excluding Goodwill) [Abstract] Business Acquisition [Line Items] Business Acquisition [Line Items] COMMON STOCK REPURCHASE PROGRAM Stockholders' Equity Note Disclosure [Text Block] Beginning balance Ending balance Liability for Future Policy Benefit, before Reinsurance Remaining Company Remaining Company [Member] The Ensign Group, Inc. Unusual or Infrequent Items, or Both [Abstract] Forfeiture rate Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate Schedule of Aggregate Intrinsic Value of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security DESCRIPTION OF BUSINESS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Prepayment penalty reduced rate for the fifth through tenth years Prepayment Penalty Reduced Rate For The Fifth Through Tenth Years Percentage that the prepayment penalty percentage is reduced for the fifth through tenth years. Operational senior living units Operational Senior Living Units Operational Assisted Living and Independent Living Units Investments—current Short-Term Investments Transitional and Skilled Services and Senior Living Campuses Skilled Services and Senior Living Campuses [Member] Transitional and Skilled Services and Senior Living Campuses [Member] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Medicaid — skilled Medicare Medicaid-skilled [Member] Revenue from Medicaid for skilled services [Member] Purchase Option Purchase Option [Member] Purchase Option BUSINESS SEGMENTS Segment Reporting Disclosure [Text Block] Conversion to reduce shares availability Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability July 2022 Repurchase Program July 2022 Repurchase Program [Member] July 2022 Repurchase Program Cash, uninsured amount Cash, Uninsured Amount LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Proceeds from sale of subsidiary shares (Note 7) Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price WEIGHTED AVERAGE COMMON SHARES OUTSTANDING DENOMINATOR: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Accounts payable Accounts Payable, Current Number of businesses acquired Number of Businesses Acquired Number of master lease arrangements Number of Lease Arrangements Number of Lease Arrangements Cash received from insurance proceeds Proceeds from Insurance Settlement, Operating Activities 2014 Exercise Price Range Two [Member] Exercise Price Range Two [Member] Number of real estate properties leased Number of Real Estate Properties Leased Number of Real Estate Properties Leased Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Basic (in shares) Weighted average shares outstanding for basic net income per share (in shares) Weighted Average Number of Shares Outstanding, Basic Truist Truist Bank [Member] Truist Bank [Member] Gain on sale of assets Gain (Loss) on Disposition of Assets Operating Entity [Domain] Operating Entity [Domain] [Domain] for Operating Entity [Axis] Restricted Stock Awards Stock-based compensation expense related to restricted stock awards Restricted Stock [Member] Loss-Sensitive Limit Per Claim Loss-Sensitive limit per claim [Member] [Member] Loss-Sensitive limit per claim Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] General and administrative expense General and Administrative Expense [Member] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases and Leasehold Improvements Lessee, Leases [Policy Text Block] Insurance Coverage Limit Type [Domain] Insurance Coverage Limit Type [Domain] Insurance Coverage Limit Type [Domain] Stock options vested and exercisable (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Long-term debt—less current maturities Long Term Debt, net of Current Maturities and Debt Discount Long Term Debt, net of Current Maturities and Debt Discount Payor [Domain] Payor [Domain] Payor [Domain] OPTIONS AND AWARDS Share-Based Payment Arrangement [Text Block] Stop-Loss Insurance Limit Per Claim Stop-Loss Insurance limit per claim [Member] Stop-Loss Insurance limit per claim[Member] Stock repurchase program, period in force Stock Repurchase Program, Period in Force 2024 Lessor, Operating Lease, Payment to be Received, Year Two Non-Controlling Interest Noncontrolling Interest [Member] Senior living facilities Senior Living Facilities Number of Assisted and Independent Living Facilities Debt instrument, term Debt Instrument, Term Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Goodwill [Roll Forward] Goodwill [Roll Forward] Land Land Land [Member] Plus: incremental shares from assumed conversion (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Employee Stock Option Roll Forward Schedule of Common Stock Outstanding Roll Forward [Table Text Block] 2019 LTI Plan 2019 LTI Plan [Member] 2019 LTI Plan [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Cash payments for business acquisitions (Note 9) Payments to Acquire Businesses, Net of Cash Acquired Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Owned Properties Wholly Owned Properties [Member] Gains on sales property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment Employee stock award compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Cash dividends Dividends, Cash Cash from insurance proceeds Proceeds from Insurance Settlement, Investing Activities Schedule of Accounts Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Self-Insurance Self Insurance Reserve [Policy Text Block] Customer Concentration Risk Customer Concentration Risk [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Senior Living Facilities Senior Living Facilities [Member] Assisted Living Facilities [Member] 2020 Exercise Price Range Eight [Member] Exercise Price Range Eight [Member] Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Exercise price, lower range limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Spinoff Spinoff [Member] Third-Party Payor 524292 Third Party Administration of Insurance and Pension Funds [Member] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Prepayment penalty reduced rate during first three years Prepayment Penalty Reduced Rate During First Three Years Percentage that the prepayment penalty percentage is reduced during the first three years. Standard Bearer Real Estate Segment [Member] Real Estate Segment Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] CareTrust REIT CareTrust REIT [Member] CareTrust REIT [Member] Credit Facility [Axis] Credit Facility [Axis] Employer discretionary contribution amount Defined Contribution Plan, Employer Discretionary Contribution Amount EQUITY Equity [Abstract] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Lease liability Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability Schedule of Weighted Average Grant Date Fair Value and Exercise Price of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Accrued self-insurance liabilities—less current portion Self Insurance Reserve, Noncurrent SELF INSURANCE LIABILITIES Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block] Cash payments for asset acquisitions (Note 9) Payments To Acquire Asset Acquisitions Cash paid to acquire acquisitions. Liability for Future Policy Benefit, by Product Segment [Line Items] Liability for Future Policy Benefit, by Product Segment [Line Items] Remaining Contractual Life (Years) Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term 2019 Exercise Price Range Seven [Member] Exercise Price Range Seven [Member] Consolidated Entities [Domain] Consolidated Entities [Domain] Shares of common stock used to satisfy tax withholding obligations (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amended of separate master leases Amended Separate Master Leases Amended Separate Master Leases Entity Central Index Key Entity Central Index Key Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Shares of common stock used to satisfy tax withholding obligations Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Entity [Domain] Entity [Domain] State taxes Deferred Tax Assets, State Taxes City Area Code City Area Code Legal finding accrued Accrued Professional Fees, Current ASSETS Assets [Abstract] Facilities under medicare probe reviews Facilities Under Medicare Probe Reviews Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments Depreciation and amortization Depreciation And Amortization [Member] Depreciation And Amortization [Member] Notes Payable to Banks Notes Payable to Banks [Member] Owned Properties Owned Properties [Member] Owned Properties Aggregate Deductible Aggregate Deductible [Member] Aggregate Deductible [Member] 2023 Long-Term Debt, Maturity, Year One Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Prepayment penalty reduced rate during period Prepayment Penalty Reduced Rate During Period Prepayment Penalty Reduced Rate During Period Weighted Average Fair Value of Options (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Variable Rate [Axis] Variable Rate [Axis] Other Other Liabilities, Noncurrent LEASES Lessor, Operating Leases [Text Block] Other accrued liabilities Increase (Decrease) in Other Operating Liabilities Claims paid and direct expenses Liability for Future Policy Benefit, Expected Future Policy Benefit, Benefit Payment Loss (gain) on insurance claims, legal finding and asset disposals Gain (Loss) On Insurance Claims And Disposal Of Assets Gain (Loss) On Insurance Claims And Disposal Of Assets 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One TEXAS TEXAS Right-of-use assets obtained in exchange for new and modified operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 2022 Plan 2022 Plan [Member] 2022 Plan Customer [Domain] Customer [Domain] Transitional and skilled service facilities Skilled Service Facilities Skilled Service Facilities Total Medicare and Medicaid Total Medicaid and Medicare Medicaid and Medicare [Member] Total revenue from Medicaid and Medicare [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] TOTAL LEASE PAYMENTS Lessee, Operating Lease, Liability, to be Paid NET INCOME Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Entity Address, Postal Zip Code Entity Address, Postal Zip Code Number of option plans Number Of Option Plans Number Of Option Plans 2024 Long-Term Debt, Maturity, Year Two Lessee, operating lease, number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Proceeds from issuance of preferred shares Proceeds from Issuance of Convertible Preferred Stock All Other Other Segments [Member] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Depreciation and amortization Deferred Tax Liabilities, Property, Plant and Equipment Total net debt ratio, maximum after increase election Total Net Debt Ratio, Maximum After Increase Election Total Net Debt Ratio, Maximum After Increase Election Management fees Management Fee Expense Number of installments Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments Deferred compensation plan investments Deferred Compensation Plan Assets Other restricted assets Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Accrued dividends declared Dividends payable Dividends Payable Repurchase of common stock Repurchase of common stock, value Treasury Stock, Value, Acquired, Cost Method Net income attributable to The Ensign Group, Inc. Net income attributable to the Ensign Group, Inc. Net Income (Loss) Attributable to Parent Weighted Average Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Facilities under master lease arrangement Facilities Under Master Lease Arrangement Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Amended Master Lease Amended Master Lease [Member] Amended Master Lease Award vesting rights, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage LEASES Lessee, Operating Leases [Text Block] Payor [Axis] Payor [Axis] Payor [Axis] Common stock in treasury, at cost, 3,368 and 2,944 shares at December 31, 2022 and 2021, respectively (Note 22) Treasury Stock, Common, Value Plan Name [Axis] Plan Name [Axis] Operating facilities included in scope Loss Contingency, Independent Operating Facilities Included In Scope Loss Contingency, Independent Operating Facilities Included In Scope Lease Arrangement [Axis] Lease Arrangement [Axis] Information by group of related lease arrangements. Blanket Aggregate Blanket Aggregate [Member] Blanket Aggregate [Member] Goodwill [Line Items] Goodwill [Line Items] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Operating Entity [Axis] Operating Entity [Axis] Operating Entity [Axis] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] NET CASH PROVIDED BY OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Promissory Note, 5.0% Promissory Note, 5.0% [Member] Promissory Note, 5.0% Non-deductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Maximum annual contributions per employee (as a percent) Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent COVID-19 UPDATE Unusual or Infrequent Items, or Both, Disclosure [Text Block] Document Annual Report Document Annual Report Legal Entity [Axis] Legal Entity [Axis] Captive Insurance Subsidiary Subsidiaries [Member] The Pennant Group, Inc. Pennant The Pennant Group, Inc. [Member] The Pennant Group, Inc. Audit Information [Abstract] Audit Information Geographical [Axis] Geographical [Axis] Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards Stock Issued During Period, Value, New Issues Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Non-Vested Restricted Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Cash paid during the period for: Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Letter of credit increase Line of Credit Facility, Increase (Decrease), Net Restructuring Type [Axis] Restructuring Type [Axis] Segments [Axis] Segments [Axis] DEBT Debt Disclosure [Text Block] Deconsolidation of an ancillary business Cash Divested from Deconsolidation DEFINED CONTRIBUTION PLANS Compensation and Employee Benefit Plans [Text Block] Current year provisions Liability for Future Policy Benefits, Period Increase (Decrease) Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Concentration Risk [Table] Concentration Risk [Table] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Long-Term Debt, Maturity, Year Three Subsequent Event Subsequent Event [Member] Consolidation Items [Domain] Consolidation Items [Domain] Revenue Benchmark Revenue Benchmark [Member] Non-employee directors Share-Based Payment Arrangement, Nonemployee [Member] Document Period End Date Document Period End Date 2027 Lessor, Operating Lease, Payment to be Received, Year Five Other long-term liabilities Increase (Decrease) in Other Deferred Liability Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] TOTAL ASSETS Assets Skilled Services Skilled Services Segment [Member] Skilled Services Segment NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC. Earnings Per Share [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Accrued wages and related liabilities (Note 3) Employee-related Liabilities, Current Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Segments [Domain] Segments [Domain] Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Amortization of deferred financing fees Amortization of Debt Issuance Costs and Discounts Asset Acquisition Asset Acquisition [Member] These acquisitions were classified as asset acquisitions in accordance with ASC 805. COMPUTATION OF NET INCOME PER COMMON SHARE Earnings Per Share [Text Block] Deferred compensation liability, noncurrent Deferred Compensation Liability, Classified, Noncurrent Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Award Type [Domain] Award Type [Domain] Grantee Status [Axis] Grantee Status [Axis] Third Parties Third Parties [Member] Third Parties Operational skilled nursing beds Operational Skilled Nursing Beds Number of skilled nursing beds available for use at a skilled nursing facility Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares) Stock Issued During Period, Shares, New Issues Mortgages Mortgages [Member] Insurance [Abstract] 2017 Plan 2017 Plan [Member] 2017 Plan Customer relationships Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town Deconsolidation of an ancillary business Noncontrolling Interest, Decrease from Deconsolidation Issuance of restricted stock, net of forfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Non-controlling interest Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] 2026 Lessor, Operating Lease, Payment to be Received, Year Four Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Repaid Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds, Repayment Less: debt issuance costs, net Debt Issuance Costs, Net Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Treasury Stock Treasury Stock, Common [Member] Auditor Name Auditor Name RESTRICTED AND OTHER ASSETS Other Assets Disclosure [Text Block] Standard Bearer Standard Bearer Healthcare REIT, Inc. [Member] Standard Bearer Healthcare REIT, Inc. Workers' Compensation Workers' Compensation Insurance [Member] Common stock in treasury, at cost Balance at beginning of period (in shares) Balance at end of period (in shares) Treasury Stock, Common, Shares Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Equipment Equipment [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Coronavirus Aid, Relief, and Economic Security (“CARES”) funds received and returned Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Received And Returned Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Received And Returned Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Diluted Net Income Per Common Share Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Twenty Three Subsidiaries Twenty Three Subsidiaries [Member] Twenty Three Subsidiaries Number of options vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Cash and cash equivalents, fair value disclosure Cash and Cash Equivalents, Fair Value Disclosure Parent Company Parent Company [Member] TOTAL REVENUE Revenues Medicare Medicare Medicare Medicare [Member] Revenue from Medicare [Member] State Deferred State and Local Income Tax Expense (Benefit) Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] Note receivable from insurance settlement Noncash or Part Noncash Divestiture, Amount of Consideration Received Amortization of intangible assets Amortization of Intangible Assets Schedule of Goodwill Schedule of Goodwill [Table Text Block] Interest Interest Paid, Excluding Capitalized Interest, Operating Activities 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Per Occurence Per Occurence [Member] Per Occurence [Member] Share-based compensation, restricted awards, exercise price (in dollars per share) Share-based Compensation, Restricted Awards, Exercise Price Share-based Compensation, Restricted Awards, Exercise Price Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Total Ensign Group, Inc. stockholders' equity Stockholders' Equity Attributable to Parent Cash and cash equivalents beginning of period Cash and cash equivalents end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Tax credits Deferred Tax Assets, Tax Credit Carryforwards Real Estate Purchases Real Estate Purchases [Member] Real Estate Purchases Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization FMAP payments received Family First Coronavirus Response Act, Payments Received Family First Coronavirus Response Act, Payments Received 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three NUMERATOR: Net Income (Loss) Attributable to Parent [Abstract] 2027 Long-Term Debt, Maturity, Year Five Expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Dividends paid Payments of Dividends Retained Earnings Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] 2025 Lessor, Operating Lease, Payment to be Received, Year Three Lease, Cost Lease, Cost Common Stock Common Stock [Member] Transitional and skilled services and senior living campuses Skilled Services And Senior Living Campuses Transitional and Skilled Services and Assistant and Independent Living Campuses Number of reportable segments Number of Reportable Segments Schedule of Operating Lease Expenses Lease, Cost [Table Text Block] Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Schedule of Nonvested Restricted Stock Awards Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Statement [Table] Statement [Table] Series of Individually Immaterial Asset Acquisitions Series of Individually Immaterial Asset Acquisitions [Member] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Share-based compensation, options expected to vest, number (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan. Equipment, furniture, and fixtures Furniture and fixtures Furniture and Fixtures [Member] Long-term lease liabilities—less current portion LONG-TERM OPERATING LEASE LIABILITIES Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Repurchase of common stock (in shares) Repurchase of common stock (in shares) Treasury Stock, Shares, Acquired Other indefinite-lived intangibles Indefinite-Lived Intangible Assets (Excluding Goodwill) Leasehold improvements Leasehold Improvements [Member] Grantee Status [Domain] Grantee Status [Domain] Per Facility Per Facility [Member] Per Facility [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Escrow deposits used to fund acquisitions Proceeds from Deposits on Real Estate Sales Accounts receivable—less allowance for doubtful accounts of $7,802 and $11,213 at December 31, 2022 and 2021, respectively ACCOUNTS RECEIVABLE, NET Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Comprehensive Income Comprehensive Income, Policy [Policy Text Block] Number of promissory notes Debt Instruments, Number Of Instruments Debt Instruments, Number Of Instruments Statement [Line Items] Statement [Line Items] Nonvested at beginning of period (in shares) Nonvested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Other expense, net Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Skilled nursing, assisted living and independent living facilities Skilled Nursing, Senior Living and Independent Living Facilities Skilled Nursing, Senior Living and Independent Living Facilities Schedule of Rental Income from Third-Party Sources Operating Lease, Lease Income [Table Text Block] Right-of-use assets Operating Lease, Right-of-Use Asset Long-term debt threshold for EBITDA ratio increase election period Long Term Debt Threshold For EBITDA Ratio Increase Election Period Long Term Debt Threshold For EBITDA Ratio Increase Election Period Auditor Firm ID Auditor Firm ID Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic Net Income Per Common Share Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Income from operations Operating Income (Loss) Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Schedule of Real Estate Properties [Table] Schedule of Real Estate Properties [Table] Mortgage loans and promissory notes Collateralized Debt Obligations [Member] Other indefinite-lived intangible assets Indefinite-lived intangible assets Indefinite-Lived Intangible Assets Acquired Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Conversion to reduce shares availability Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion to Reduce Shares Availability Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion to Reduce Shares Availability 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Options granted (in shares) Options Granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Federal Deferred Federal Income Tax Expense (Benefit) Impairment of long lived assets Impairment, Long-Lived Asset, Held-for-Use Additional Paid-In Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Intrinsic value of options exercised in period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Prepaid expenses Deferred Tax Liabilities, Prepaid Expenses Gain on sale of assets, net Profit (Loss) from Real Estate Operations Diluted (in shares) Adjusted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Expected Life Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Building and improvements Buildings and improvements Building and Building Improvements [Member] Real Estate Property Ownership [Axis] Real Estate Property Ownership [Axis] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Amortization of deferred rent Deferred Rent Adjustment Adjustment to deferred rent arising from the difference between rent expense recognized and rental payments made in the current period. Base Rate Base Rate [Member] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Operating Segments Operating Segments [Member] Liability for Future Policy Benefit, by Product Segment [Table] Liability for Future Policy Benefit, by Product Segment [Table] Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value CPI increases and short term-lease cost Short-Term Lease, Cost Non-cash leasing arrangement Non-Cash Lease Expense Non-Cash Lease Expense Net (loss) income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Goodwill, accumulated impairment loss Goodwill, Impaired, Accumulated Impairment Loss Proceeds from debt (Note 16) Proceeds from Issuance of Long-Term Debt Aggregate purchase price of business and asset acquisitions Payments To Acquire Business And Asset Acquisitions Cash paid to acquire acquisitions. Common stock, shares issued Common Stock, Shares, Issued Concentration Risk [Line Items] Concentration Risk [Line Items] Accrued self-insurance liabilities—current Self Insurance Reserve, Current Unapplied state relief funds Accrued Liabilities, State Relief Contract Liabilities Accrued Liabilities, State Relief Contract Liabilities Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities Insurance Subsidiary Deposits and Investments Investment, Policy [Policy Text Block] Schedule of Segment Reporting Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Campus Operation Campus Operation [Member] Campus Operation Accrued wages and related liabilities Increase (Decrease) in Employee Related Liabilities Prepaid income taxes Increase (Decrease) in Prepaid Taxes Deposits with landlords Security Deposit Qualified Plan Qualified Plan [Member] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Income tax expense at statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Schedule of Purchase Price Allocation Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Balance at beginning of period, (in shares) Balance at end of period, (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Lessee leasing arrangements, operating leases, number of renewal terms Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms State income taxes - net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Cash payments for Medicare and Medicaid licenses Payments For Medicare and Medicaid Licenses Payments For Medicare and Medicaid Licenses Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net PROPERTY AND EQUIPMENT, NET Property, Plant and Equipment, Net Standard Bearer Equity Plan Standard Bearer Equity Plan [Member] Standard Bearer Equity Plan Schedule of Estimated Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Quality assurance fee Quality Assurance Fee Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days Mortgage loans and promissory notes Notes Payable Other Payables Notes Payable, Other Payables [Member] Dividends declared Dividends Private and other Private and other payors Private Pay and Other [Member] Revenue from self-pay and Other payors [Member] Long-term Debt Long-Term Debt Other income Other Nonoperating Income (Expense) Non-cash financing and investing activity Other Noncash Investing and Financing Items [Abstract] Schedule of Other Indefinite-lived Intangible Assets Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table Text Block] Total current assets Assets, Current Entity Small Business Entity Small Business Operating lease, variable lease income Operating Lease, Variable Lease Income Dividends per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Intangible assets, net Net Finite-Lived Intangible Assets, Net Offsetting (reduction in expense) expense Investment Expense (Income) Investment Expense (Income) Number of operating subsidiaries Number Of Operating Subsidiaries Number Of operating subsidiaries entered into mortgage loans that are insured with HUD. Distribution to noncontrolling interest holder and other changes Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Share-based compensation, nonvested awards, cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount 2022 Exercise Price Range Ten [Member] Exercise Price Range Ten [Member] Number of Options Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] PROPERTY AND EQUIPMENT— NET Property, Plant and Equipment Disclosure [Text Block] Management fees, as a percentage of total revenues Property Management Fee, Percent Fee of Total Revenues Property Management Fee, Percent Fee of Total Revenues Consumer price index Lessee, Operating Lease, Consumer Price Index Lessee, Operating Lease, Consumer Price Index Right of use asset Deferred Tax Liabilities, Right Of Use Asset Deferred Tax Liabilities, Right Of Use Asset Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Other States, Except California, Texas and Washington Other states, except California, Texas and Washington [Member] Other states, except California, Texas and Washington Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Number of real estate properties Number of Real Estate Properties Maturities of investments Proceeds from Sale, Maturity and Collection of Investments Consolidated Entities [Axis] Consolidated Entities [Axis] Proceeds from Equity Method Investment, Distribution Proceeds from Equity Method Investment, Distribution TOTAL EXPENSES Costs and Expenses Payables and Accruals [Abstract] Payables and Accruals [Abstract] Leased asset Leased Assets, Acquired During Period Leased Assets, Acquired During Period Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program Schedule of Liability for Future Policy Benefits, by Product Segment Schedule of Liability for Future Policy Benefits, by Product Segment [Table Text Block] PRESENT VALUE OF TOTAL LEASE LIABILITIES Operating Lease, Liability Lessor, operating lease, term of contract Lessor, Operating Lease, Term of Contract Medicare accelerated and advance payment Medicare Accelerated And Advance Payment, CARES ACT Medicare Accelerated And Advance Payment, CARES ACT Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two TOTAL Lessor, Operating Lease, Payments to be Received Total Management Fee Management Service, Total [Member] Management Service, Total Weighted Average Exercise Price (in dollars per share) Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Insurance subsidiary deposits and investments Insurance Subsidiary Deposits And Investments Captive insurance subsidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity. 2026 Long-Term Debt, Maturity, Year Four Auditor Location Auditor Location Write-off of deferred financing fees Write off of Deferred Debt Issuance Cost Entity Filer Category Entity Filer Category Federal Current Federal Tax Expense (Benefit) Asset acquisition, purchase price Asset Acquisition, Consideration Transferred Share-based compensation Stock-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Notes 16, 18 and 21) Commitments and Contingencies Security Exchange Name Security Exchange Name Balance at beginning of period (in dollars per share) Balance at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Life (Years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Reconciliation of Revenue from Segments Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Letters of credit outstanding, pledged amount Letters of Credit Outstanding, Amount Service revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Purchase of non-controlling interest Purchases of Non-Controlling Interest Purchases of Non-Controlling Interest Cover page. Cover [Abstract] Entity Voluntary Filers Entity Voluntary Filers Goodwill impairment Goodwill, Impairment Loss Managed care Managed care Managed care Managed Care [Member] Revenue from managed care payors [Member] REVENUE AND ACCOUNTS RECEIVABLE Revenue from Contract with Customer [Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Movement in Liability for Future Policy Benefits [Roll Forward] Movement in Liability for Future Policy Benefits [Roll Forward] Weighted Average Risk-Free Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Repurchase of shares of common stock to satisfy tax withholding obligations Payment, Tax Withholding, Share-Based Payment Arrangement TOTAL LIABILITIES AND EQUITY Liabilities and Equity Amended Master Lease Agreement Amended Master Lease Agreement [Member] Amended Master Lease Agreement Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total deferred tax assets Deferred Tax Assets, Gross Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Purchases of investments Payments to Acquire Investments Rent—cost of services Rent Cost Of Services Rent cost of services OTHER ACCRUED LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Less: present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted (in dollars per share) Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted Proceeds from sale of real estate Proceeds from Sale of Property, Plant, and Equipment Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Schedule of Restricted and Other Assets Schedule of Other Assets [Table Text Block] Consolidation Items [Axis] Consolidation Items [Axis] Exercise Price Range [Domain] Exercise Price Range [Domain] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Other Other Assets, Current TOTAL DEFERRED TAX ASSETS Deferred Tax Assets, Net of Valuation Allowance Thereafter Lessor, Operating Lease, Payment to be Received, after Year Five Medicare and Medicaid licenses Medicare and Medicaid Licenses [Member] Medicare licenses for home health and hospice segment and all other segment. Schedule of Annual Rental Income Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Standard Bearer Standard Bearer Segment [Member] Standard Bearer Segment Product and Service [Axis] Product and Service [Axis] Senior Living Operations Senior Living Operations [Member] Senior Living Operations Interest expense Interest expense Interest Expense March 4, 2020 Repurchase Program March 4, 2020 Repurchase Program [Member] March 4, 2020 Repurchase Program Facility trade name Trade name Trade Names [Member] Schedule of Other Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Retirement Plan Tax Status [Domain] Retirement Plan Tax Status [Domain] Long-term insurance losses recoverable asset Estimated Insurance Recoveries Schedule of Long-term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Total deferred payment of social security taxes Liabilities, Deferred Tax Payments Under CARES Act Liabilities, Deferred Tax Payments Under CARES Act Change in long-term insurance losses recoverable Liability for Future Policy Benefits, Other Increase (Decrease) Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] TOTAL DEFERRED TAX LIABILITIES Deferred Tax Liabilities, Gross Refunds payable Resident Refunds Payable Resident refunds payable includes amounts due to residents for overpayments and duplicate payments Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors Stock awards [Member] Stock awards [Member] 2018 Exercise Price Range Six [Member] Exercise Price Range Six [Member] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Number of lease agreement Number of Lease Agreement Number of Lease Agreement Number of stock repurchase programs Number Of Stock Repurchase Programs Number Of Stock Repurchase Programs Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Capital improvement reserves with landlords and lenders Other Restricted Assets Other than options, conversion to reduce shares availability Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability Accrued self-insurance liabilities Increase (Decrease) in Self Insurance Reserve Other accrued liabilities OTHER ACCRUED LIABILITIES Other Accrued Liabilities, Current General and administrative expense General and Administrative Expense Impairment of intangible assets (excluding goodwill) Impairment of Intangible Assets (Excluding Goodwill) Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Reduction of right-of-use asset operating lease liability due to acquiring leased assets Reduction Of Right-of-Use Asset Operating Lease Liability Due To Acquiring Leased Assets Reduction Of Right-of-Use Asset Operating Lease Liability Due To Acquiring Leased Assets Third Party Tenants Under Triple Net Lease Arrangements Third Party Tenants Under Triple Net Lease Arrangements [Member] Third Party Tenants Under Triple Net Lease Arrangements 2013 Exercise Price Range One [Member] Exercise Price Range One [Member] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Impairment of long-lived assets Asset Impairment Charges Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Cost of services Cost of Sales [Member] EX-101.PRE 14 ensg-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 ensg-20221231_g1.jpg GRAPHIC begin 644 ensg-20221231_g1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#Z17AI9@ 34T *@ @ ! $[ ( M 0 (2H=I 0 ! (6IR= $ @ 0TNH< < @, /@ M FMC.60G/SX- M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1& M('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z'!A8VME="!E;F0])W7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#Z*I1R124J M_>'UK00_RQZT>6/6GT5%V,9Y8]:/+'K3Z*+L!GECUH\L>M/HHNP&>6/6CRQZ MT^BB[ 9Y8]:/+'K3Z*+L!GECUH\L>M.9U12S, ,DD]*PM1\<>&]*4F]UBU1 MA_ ) 6/X5+FH[LF4HQ5Y.QM^6/6CRQZUYQJ7QR\,VF19K<7C#^ZNT'\:X_4_ MC_J4NX:3ID%N#T\\ER/R(KGEC*4?M'+/&T(?:/=_+'K5>YN[.R&;R[AMQZRR M!?YU\P:G\3_%FJ9$NJR11G_EG$ !_C7-7&I7MVY:ZNYI2>N^0FN:68K[*..> M:07PQ/J'4?B1X2TS<+C5XW(_YX@R?^@YKF+SX[>'8,_9;6[NOH-O\Z^?**YY M9A6>VARRS*L]K(]HN?C^V3]CT88[>:_^!JA_PO[6.VCV/_?3_P"->345B\97 M?VC!XW$/[1ZQ_P +^UG_ * ]C_WT_P#C1_PO[6?^@/8_]]/_ (UY/11];K_S M"^N8C^8]FMOC_+Q]LT=/?RG/]36_IOQS\.76!J$%S9>I*[Q_X[FOGJBJCCJZ MZFDM/HK2[-1GECUH\L>M/HHNP&>6/6HZG/2H*I""E7[P^M)2K M]X?6F!-11168PJOJ"74FGS+I\BQ7)0^4[C*ANV1Z58HH$]4>#WGQE\5Z!JDM MAK>GVSS0MA@%*9_G4Z?M#3A '\/(S=R+HC/_ ([7SU6V>WF0XPPX/T/>O'K2Q%!_%H>%B)XK#R^+0]? MD_:$41J8M!W/W!N< ?CMJM+^T+UM(CC@LN[%85Y\6_&%YG_ (F1@S_SP7;BN*HK-XBJ]Y,S MEBJTMY,TK[Q#J^ID_;]1N)\G)WN:SF9F^\2?J:2BLFV]S!MO<****1(4444 M%%%% !1110 4444 %%216\TYQ!#)(?\ 84G^5:EGX2U^_P#^/72+I^<R*49/9&/179VOPF\97(!.CO$I&07D3G]:TX?@AXJE8AQ;Q#'5GZ_E6J MH57]EFRPU9[19YS7<>!OB;JGA*X2"5VNM-+?/ Q^Z.Y6M3_A17B?_GM9_P#? M;?X56E^"GBR,MLAADV]-LG7\ZN-*O3?-%,UA1Q-*7-&+1]"Z)KECXATN*_TR M82PR#\5/H:T*\%\!:9XV\!Z\JW>D7#:9.P6=5=6'^\ #7O0YKVJ-1U(^\K,^ M@P]9U87DK,****W.@#TJ"ISTJ"JB(*5?O#ZTE*OWA]:H":BBBLQA1110 5C> M(_"FD^*;$V^K6JR''RR@8=/H:V:*3BI*S)E%25F?/'BKX(ZMI6^XT-_[0MAS MLX$BCZ=_PKS6ZL[FQG,-Y;RP2+U25"I_(U]HUG:GX?TG6(C'J>GP7"GKN7G\ MQS7G5,!%ZP=CRZV6PEK3=CXXHKZ/U7X'>&;W@1P5'X$9_6N.U'X M:E&Y.FZI#.AZ*Z;2/QS7%+!UH]+GGSP%>/2YY#17H%U\%O%]MDK;03+V\N4$ MG\*SI/A9XOC&?['F;_=!-8NC46\6<[P]9;Q9R%%=8OPP\7LP']BW(SW*&K4/ MPB\83$@:;LQ_?;%+V-1_98E0JO[+^XXFBO3+7X%>*)@#BC%.K MIC@*:^)W.N&64U\3;/&M-_9^ME8'5M6D?'\,"@ _F*Z_3/A'X2TW#?V?]HD' M\'UI*5?O#ZU0$U M%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BD9U12SL%4=23@5EWWB?0] M-4M>ZI:QXZCS 3^0YI-I;B//<#^1-82Q-&.\CFEBZ$-Y'L]%?/-W\>?$,Q/V6UMK;TXW8_, M5B77Q>\8W>=VI",?],HPO\JQ>.I+:YSRS*@MKL^H:*^39OB)XKG#!M;NUW?W M)2N/RJK_ ,)MXH_ZO_ I_\:S_ +0AV,_[4I_RL^O**^0_^$V\4?\ 0P:E M_P"!3_XU;A^(_BR'&W6KIL#'SR$T?VA#L"S2GUBSZQHKYDL_C+XOM#AKR.9? M22)2?SKHM/\ C_J41VZEI<,P_O1M@_ETK2..HO?0UCF-![W1[S17F>D?'/PY M?%5OX[BP;NTB@K_XZ2:[C3/$VBZQ&'TW4K><'H ^#^1YKIA6IS^%G7"O2J?# M(U****U-@HHHH #TJ"ISTJ"JB(*5?O#ZTE,FF%O"\S*SB-2Q5%RQQV [FJ8% MJBN,@^+'A&:0H^H^0P.")EV8-:]OXT\-70'V?6[*3/3;,#7.JL'LT9JM3EM) M&Y16='X@TB5PD>HVS,>@$@J5]8TZ)"TE[ JCJ2XJ^9=R^:/ZL"\^/VCQ _8]+N+@YXS($_I6AD!=A^((KE=2^)WBS4P5EU:2.,]4B _QKGECJ2VU.:>948[79]1 MW6H6=BNZ]NX;<>LL@7^=682?PHY)YI)_!$]YU+X_Z='E=,TR:8]GD.%_+K7(:I\P7H/+3:T5RRQ5:74XYXVO/[1MZCXR\0ZJ62)QT:-BI_,5'10,[KPY\6_$F@%8Y;C[?;C_EG<O\ MA3XO:#XAV07;C3KL\;)CA2?9NE?,U*"0<@X/K752Q52GUNCLHXVM2ZW7F?:R ML'4,A#*PR"#P12U\R^"OBMJ_AB:.WO':]T_.&C<_,@_V37T)X>\2Z9XGTY;S M2;A95/WES\R'T(KUZ.(A66FY[N'Q5.NM-'V-8]*@J<]*@KKB=04J_>'UI*5? MO#ZU0'AOQ?\ AP]G<2>(=&BS;R'-Q"HY0_WA[5Y &(Z$CZ&OM66))HFCE0.C M##*PR"*\.^(OP>DADFU7PO&&B^]):+U7_=]O:O%Q6$=^>!XF-P3NZE/YH\<\ MQQT=OSI?-D/61O\ OJDDC>&1HY49'4X*L,$4VO+/''>8_P#>;\Z;G/6BB@ H MHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !112@9.!R: $HJ];:+J M=ZP%KI]S+GIMB8C\ZWK'X8>+K]AY6C2JIZL[JN/S.:J,)RV1I&G.7PILY.BO M3K/X$>);E09[BSMO:1F/\@:V+?\ 9]NCC[5K$(YY\M2?YBMEA:S^R;QP==_9 M/&:*]SB_9[M,GS]JK>Z9+@]'C)^5QZ&O6I?V>[3(\C7)B.^^(#^54;K]GVY /V+ M68B>WFJ1_(4UA:\7=(%@L3!\R6IZKX2\56/BW0X[ZQ8!L8EB)YC;TK6KR+P9 M\/\ Q=X%\1+<0R6]Y9R?)<1Q.?F'J V.:]=KVL/.H(S7)6PM.KKLSBKX*E6UV9\4D%201 M@CJ#25]6Z]\-O#/B$L]W8+%,W_+:#Y6_P_2O-]:^ -RDC/H6I+(G:*=<'_OK M_P"M7FU,%5CMJ>14R^M#X=3QJBNNU/X7>+=+)\S2I9U7JUN-X_2N9N;&ZLY# M'=6\D3CJKJ0:Y)0E'XD<4JBE((ZBDJ3,**** "BBE )Z"@!**GM[* MYNGV6\$DC>BKFMZQ^'OBK4 #;Z+=;#T=HR!^=4HRELBXPE+X5 M)[G:;M[:U4^K[B/PXKK-,_9_L8BIU;599_40*$_GFMXX6M+H=,,%7E]D\(J> MVLKJ]?;9VTL[>D2%C^E?3^F_"GPCII#+IBW#CH\[$D?EBNHMM+L+) EK9PQ! M>FV,"NF.7R?Q,ZX97-_%(^7M+^&'BS5MIATJ6)6[W'[O'_?6*[#3/@#JDV&U M348;<=T0;F_/I7O=%=4<#26^IV0RVC'>[/,=+^!7ARS*M?37-Z>ZNVT?^.X- M=?I_@;PUI8'V31[8;>AD7?\ ^A9K?HKIC1IPVB=<,/2A\,410VT%NNVWACB' MHB!?Y5+116IN%%%% !1110 4444 !Z5!4YZ5!51$%*OWA]:2E7[P^M4!-111 M68PHHHH **** "H9[*VN4*7$$]8M,0S6 M9+\)O!\C[O[+5/9#@5V=%9NE3>Z1DZ--[Q1P9^#7@\L3]CE&?23_ .M3H_@[ MX/1L_89&]FDS_2NZHJ?84OY43]7H_P J./@^%?@^#_F$12<_\M!FM2V\%^&[ M/_CUT6SB_P!V(5N452IP6R12HTUM%$,-G;6\82""-%'0*HJ8 #H,445H:A14 M4UU;VXS<3Q1?[[A?YUCWGC;PW8,1=:Q:J1UVON_EFI?#<2DI:7TI!Z*J\_F:R>(I+>2,7BJ"WDCU" MBO*/^&@= _Z!6I?E'_\ %4Z+X_>'GD"MINH1C^\P3 _)J7UJC_,3]V: V)Z*\QA^.G MA\3-%J%I=VKJ<, N_!_2M)/C+X/=0?MDHSV,6,?K6"Q%)_:1SK%4']I'>45Q M#_%WP>B;O[1)]@N34$OQH\'1+N^U3O[)#D_SI^WI?S(?UBBOM([ZBO+;GX]> M'H\_9K2ZF^HV_P!*PK_]H*1B1IVC"/G@RR[L_D!6+->U7/V_5;F7/^WC^582Q] M-?"KG-+,Z:^%-GU/J'B[0-+0M>ZM:(1_#YREORSFN0U+XX>%[,E;3S[UAV1" MOZD5\XO(\AS([.?5CFFUS2Q]1_"K')/,ZK^%)'L6I_M 7LFY=*TJ&('HTY)( M_(XKD-3^*_BW4R0VI-!'_1=N=9U.\8M=:A MBF0LOY'(KT/P_P#'C4K5ECU^T2\C[RQC:_\ A^E>245K"M4I_"S> MGB*M/X9'UMX;\=:#XI1?[,O5\XC)@D^5Q^!ZUT5?%EO<36LRS6TKQ2*Q_#_XS.CQZ;XK;]>%NCQ.4D4JP."",$5]K5P'C? MX4:7XI+W=GML;_!.]1A7/^T!_.O-Q.#YGST]SR,7@.=\]+?L?,U%=!XC\$ZY MX8N6CU*RD\L'Y9HQN1AZY'3\:Y^O(E%Q=FCPY1E%VDK!1112)"BBB@ HHHH M**** "BBB@ HI0"QP!D^@K3L?#6M:DP6RTRZEST(B('YGBFDWL4HMZ(RZ*] MTKX,>*]0VFXMX[%3_%.X/'_ V&+>".+C'R*!4U;++UUD;K*UUE^!\@?\ "(Z__P! FY_[XJO)X?U> M)2SZ=<@+U_=FOL>BG_9\?YA_V7'^8\$^$OCR\T>]30=;6464IQ!)(I'E-Z?0 M_P!*][JI-I6GW+;KBRMY6ZY>(&K?3I791IRIQY6[GH8>E*E#DD[A1116YT > ME05.>E0541!2K]X?6DHJ@)Z*AS1FIY1DU%0YHS1R@345#FC-'* Z>WAN8C'< MQ)*AZJZA@?P-<-K_ ,'_ QK9:2&!K"=N2]N>I^AR*[?-&:B=&,U:2N9SIPJ M*TU<\)U/X!:K"2VEZC# M"*3_ %D2-_O*#4+:=9,TOP.=Y7VE^!\< $G &35A-.O9& MQ':3,?01DU]?_P!F6 _Y*WM/^$'B^_/\ QX+ O@% M.S6DD? M>5V"@_E@UZ1FC-;QP5&/0Z88*A'[)CZ=X(\-Z5C[%H]LN.A==_\ Z%FMN*&. M%-D,:1KZ(H IF:,UTJFH['7&,8_"K$U%0YHS3Y2B:BH GRAPHIC 16 ensg-20221231_g2.jpg GRAPHIC begin 644 ensg-20221231_g2.jpg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end GRAPHIC 17 ensg-20221231_g3.jpg GRAPHIC begin 644 ensg-20221231_g3.jpg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end GRAPHIC 18 ensg-20221231_g4.jpg GRAPHIC begin 644 ensg-20221231_g4.jpg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ensg-20221231_g5.jpg GRAPHIC begin 644 ensg-20221231_g5.jpg M_]C_X 02D9)1@ ! @$ 8 !@ #_[@ .061O8F4 90 !_]L 0P " 0$! M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D* M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\ $0@" M8@*H P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HK\T/^#DWXQ?%OX3?"OX7#X6?$_Q#X:.H>(- M1%^V@:S/9MV >!FL/XU_P#!,S_@HY^RQ\);_P#:!_9C_P"" MF_Q"\4:EXIG2?$Z6:;(KB01K)%=(G.Q9$;E>@=),87 K M3_:Y_P""L?[&G[&'C=/A=\4?&6HZEXI\E);CP[X7TMKVYM8V7%CB')*#ZO3Y>I]*45Y%^ MR%^W+^S9^W)X.O/&'[/7CHZD-,F2+6-,O+5K>\L'<$IYL3\[6"MM=2R-M8!B M58#C?VQ/^"K7[&?[#_BB'P#\9?'=Y<>(Y;=9W\/>'M.:[N;>)AE7EY5(MPY" MLX8@@@$'-:3S' 4\*L3*K%4WM*ZL_F7+%X6-#VSFN3O?0^CZ*\P_9,_;"^ _ M[;/PQ?XL_L_^*)M2TRWOVL;Z.[LI+>>SN51',4B.!SMD1LJ64AN"<''C?[1G M_!:S]@_]FGXF7WPC\3^--9UW7-(E:+7(?"FC->1Z;(IPZ2RED3*0!E.UAR&5AE6!/@?BK_@N M'_P3S\&Z%XCU;6OB;J2W7AOQ!)HTVBIHLAO;RY0L':",XW1#:,M*O]1TM] MFIV%EJ,4LUHV<;945BT9R",,!6K7XP?L5_MD? ']B;_@IA^UE\4/V@?%[:98 M7'B[6[73K:VM7GN;Z:*^:OVN/^"LW[&7[&/CA?A=\ M4/&6I:EXI\I);GP[X7TMKVYM$9=RF8Y6.,E<,$+[]I#;<$$]S^R'^W'^S;^W M'X-N_&7[//CK^TETR9(M7TV[MGM[S3W<$H)8G&0&"MM=2R-M8!B58#T89EE] M3%/#1JQ=1?9NKZ;Z>74ZXXS"SK.C&:N45\O?%__@L-^PQ\"_&WCGX< M_$?XA:A9ZUX!>*+5; :/(SW<\FW;#:]IG^8$] "Q.T$CVS]G;X]^ ?VH/@M MH'QZ^%[WC:#XDM6GT_\ M"V\F8!9'B8.F3@AT8<$CC()%.CF&!Q%9T:52,I* M]TFFU9V=_GH.GBL-5J.G":@_83\-_M*^(/B3X.O)WM]8M=4OI)XTC?36N_,:-I)%MYX&"AF0C<$(. M-VT>;C&KQA.D^64E%2NMWY;V/ MV+HKYY_;^MO^"@'BK1O#?PL_80&@Z-+XBFNX_%WCW6[E ?#MLBQ>688SN9Y) M=\H#+'(5\O\ @)#K\B_\&VOQ3^+/Q*MOC:GQ4^*/B#Q/+8:IHOD2Z]K,]V8W M<:AYC)YSMM+E%SCKM&>@K:KG$:6;T\ Z/4,?# M#_M6?#;]M;Q?XPDO\ 7TT[Q7IFN7FU65MQRN>8<11P5>K"-)SC2Y?:232Y>;:R>LM M-7;8G%9LL-5G%4W)0MS--:7VTZG[.45\V_M@_#S]IS]M+]G/P1;?L??'_P#X M5G!XHN+34_$/B"*25;Q-(FLWD$<#0@/YF]XLA7BR ?G R#^6G[6_A_\ ;+_X M(S?M:>"I? _[9?B7QZ-=M(]2:UO[BXC34%6X,[+=_@/&YI+!>^Z3=/2\KKKV6[/W=HKRW]L37_VI M= ^!M])^QQX)TG6_'EW=V]KIR:Y_ MX)=^+/VM- _X++^-_@G^TS^T+K/C'5=*\+Z@-:QK%P^G27(-H^88&VHB)YA5 M (T '15!Q73CLXC@L=1PSIR?M&ES;13=^O5Z;+;JS;$X]8;$TZ3@WS-*_17_ M #>A^N=%%%>P>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110!^5O_!T;_P DK^$7_8P:K_Z(@K] MOVGOCO\ #G]F[]E[Q%\6?B?KUI8Z?IWAN7RH[J95-Y<& B*VC!^_)(V%51US MZ FN$_X*(_\ !-[X9?\ !1GPGX;\+_$;QWKF@?\ ",:A/=65QHHA8R>:BHZN MLJ-G[BD$8Q@]M=9^+OQT^)OC2*T;*:=J.M0Q0R#(^1F6 M(RA3_L.A]Z^2JX;.L-FV*K8:DI*JH)-R22<8M7:LV]7^!X4Z.8T<=7J48)JH MHI-NUK*VJW9R?_!L3\.?$F@_LW_$+XF:G9RQ:?XB\66]MI;2*0)OLD!\R1<] M5W3[,CC=&PZ@U\^_L*:_^W9J_P#P4A_:&\9_LO>#?AEK?CQ/$6HQZVWQ.DNA M+9VQU*9&6T\B6-E 9(T<'("K$HQ7[._#?X;> _@_X%TOX9?##PK9Z)H&C6HM M],TNPBV101C)P!U)))8L4D"N1N*EBS'GQ'#^,P^78.EAWS.@V MVDU%NZ=W%M-73>E^AE5RJO2PF'A2=W3>MG9N^]F]-'M?HH:MXTU; MSUCAB9G58D.64EF.2SMT&,"_BKXH^&WC6ZV MG5-3\+R+Y=VZH(_.V95HY2@"LR. P&2I8LQ=&E>5.HYN$IIWYKZ M\UE&_5=%W!Y?7A0I2IPNX22_L^^$M TS5 MY&NM0U:ST"UAC,FK&S0HTT<0XE9%@/(RP*MSNR?Q_P#^"*5]_P %#)OAO\0= M>_8U^'WP:\0G4]?CC\7W_P 29;QM2D9H=R)^YG3= VZ5OF!W.9.3CC]5OV&? MV'?AS^PA\+]0^'7@+Q9KVOW&MZU)J^O:[XCNEEN;R[>-$9OE4!5Q&N!R6\;Q MQEB6\LLRJ3A0HPHVS/+LQQ4\-B:<+.'->$9)-:\8R2:OV;5O4L_P#!&#]@K]IK]B!_BF_Q_C\,V=GXRU33[W0]'\+Z@\T% MG)']K\_:K*/+0B6!%&6.(N3P"?FS_@A?\$OA)\3OVT_VC?&'Q&^'>DZ[J'A[ M7?*T675K);A;07-]?B8HC@J&80HN[&X+N (#,#^AG[$O[$_AG]BGP9K/AW2? MBMXN\::EXCU5=0UO7O&.I"YN)IA&L8"X4;5"KT)9LDY8C &!^Q/_ ,$X/AI^ MP_\ $CXC_$KP+X]UW6+GXD:E'=W]OJRPA+/9-;EAD]E'O12R2I" M6 2IVA2%2A:,')M-IVNG;UU^X^!O^"/'[./P M-US_ (*F?M$:9KWPOT;4+7P-KFK0>$[.^LEE@TU?[7F@!CC8% PB0(K8RHR! MC)KJ?^"37AO0_A__ ,%L_P!I3P#X,TR'3=%M;'6?LNEV<8C@@5=8M-BH@X55 M#L%4<*#@<5]H?LJ_\$X?AI^R?^TA\3?VE?"/CW7=3U+XG:A<7>HZ?J*PB"S, MUW)=,L91 Q >3 W'H.WZ'P7_ ,$O?AQ\%/B#_P %I?VD'^*?AK1-6U32_%?B M6Y\+VNLHDI2;^VY5EEBB?(9UC/WL$J&)&,DU>_9RT#PIX"_X.4O&/A;X#6-K M9^'#87JZS9Z0BI;PLVD037*;4X4"_P 97 "OQCBO?_B'_P $!_V-]+\7^,_%TWB'3->TVZBB?0IYIKB::&(*H\R)S<8.XAP(4PX^;=Z= M_P $]?\ @E+\#?\ @GUJ6M>-_#/B?5_%?C#Q!";?4?$^NA%D2W+B1H8D3[@= MU5W+,S,R+R ,5A@\DS2,Z%*=*,8PJNJYJ2NU=VC:U[O3K:UC*AEN-4J<)024 M9N;E?6UWI;S^ZUC\Z?V#-?\ V[M7_P""BW[0OC3]EWP;\,=;\=KXBU!-=;XG M270FL[8ZE,K+:>1+&RJ&2-'!R %B48KZV_X)F_L$?MJ? ;]NCXC_ +5G[1FD M> ]#TWQ[H-RMYH7@:_F:V_M&6\MI@\<,@)10$N"2SL+O\ :<^$/QL\9_"?QOJC%M9U/P;>>7'=R, 'EVJ4>.1P!O*2!7/S%2Q9 MCZ%^Q#_P3QTC]C?Q#K_C[5/VA?'OQ&\3>)+*"TU#5O&FK>>$AB9G58E.64EF M.2SMT&,,I1A.4E+G7+K?7EMS7=[-7MYFF#RW$4:\55BVHR M;3YE;6^MK7OT9\'_ %^!GPI^.__ <0_%S2?B]X*L=?L-"M[W5['3M3@$MN M;N-;&)'DC8%9 HFJBOUL\+^%/"W@?0;?PKX+\-:?H^EVBE;33=+L MTMX(06+$)'& JY8DG ZDGO7@GPF_X)P?#3X1_MU>,OV\-'\>Z[=:]XSTZ:TN M]$N5A^R6XE-N69"J!R19=4P%.LZL4I2J3E=6NTWIK^AZ6 M6826%A4YTDY2D_DWH>'_ +;/['WA7]M[PIIGPOUCXX^*_!T^B7ZZFS>#-72W MN94>.2)1*K*Q,9._!P.4/H:_+KX;Z3XP_P""-/\ P5R\._L]_#_Q5I?CW1O' M]WI-IJESJ&AV_P#:L5MJ-UY/EF< RQ3(X$NU7$B)I$6K^%[U526T66655=,*VX-,_P RR+D'!!P, M9PXW!8K$XR,Z=-1:D MGS\W1?W?Z]3[1K\I/^#8?_FO7_87T/\ ]R5?;'[>_P#P3_T+]O'2O#.F:W\; MO%_@P>&KBZEC;PK=K&+OSUB!$H8?-M\H;3VWMZU\Y_"+_@W@^#OP9\=Z5XY\ M)?M6_$F!]-UBUU"6UMIK>!+MH)1(J2%$&0<$9[;C75F='-:N=X?$4:"E"ES: M\Z5^>*6W2WSN;XRGCIYC2JTZ=XPOKS)7YDE\K?B?>GC?XE?#GX96,&I_$CQ_ MHGAZVNIQ!;7&N:K#:)-*03L5I64,V 3@<\5M@A@&4@@C@BOSC_X+(_ _XA_M M\?M4_!O]B+X=^%=2BL; 7.O^,_&!L9#9Z792LL6/,QL,H2&4A,Y+20C@,2/T M6TW3[72=.M]*L8RL%M D4*DYPB@ #/?@5Z^%QE7$XVO2Y+0IM)2_F=KR7_;N MB.^AB)UL14AR^[&R3[NUW]QY+^VY^VK\(/V$O@A>_&3XKW_F/S!H.A02@7.K MWA4E8(@>@[NY&$4$G)P#\/\ _!+_ /8P^-'[7_[2T_\ P5K_ &W].\BYU&Y% M[\.?#$L1544+LM[K8W*00Q@" 'YG8><3]UI/J'_@HO\ \$M_A;_P4>N/"=Y\ M1?B5XB\/R>$4O4LQHHA9)EN3"7WK*C8(,"X((X)SGC'S[!_P;?\ PAMR@B_; M%^**JF-H2XMQ@#T^7BO!S3#YQB#_VD_V;_BGK.4T>RU6Z^TSD?+'Y%Y8S M/GTRC9]]I]*[G_@YI\7: G[%?@?PJNHPO>ZK\2K>]L8E<$RV\.GWJR2+CJ ; MB$9'_/0>M?8/[9O[#GP4_;G^"2?!/XS17X@M+A+K1]:L)U6]T^Y1"@E1V5E; M*LRLK*58-T!"L/FCX$_\$ O@5\.?BEH'Q*^,GQW\9?$N+PF\;^'- \0.J65M MY;!HT=-**<:W+K?X;*SNNOR/>I_CW\-_V /^"?W@_QW^T-J[:?#X6\!:1ITEDH M!NKZ_CL8T%I"A(WRLR,,< ,S%55F'Q)^PA^S#\9_P#@J;^UVO\ P5'_ &P_ M#QTSP9IEW&?AOX3ER4NDMW8VP4, 6MH7+2,Y $\Q8@;-RU]I_P#!0_\ X)R_ M#C_@HOX,\.^#OB)X_P!>T!/#>IRWEI+HGE-YK21A&#K*K X &",$<^M?,=O_ M ,&W'P?&/\ M[ ^I_P#H%C7WC^T#^QCHWQ]_9-LOV4+OXM>*=$M+&STVW3Q)I5XJZA*+,1A6 MD8C#E]F6Z9)S7R';?\&VGP8LM;E\36?[7GQ-BU*<$3:A%);+/(#C(:0+N/0= M3V%=&=T_I\(?'K_ (*/?MT?M,SS-\9O MVH?%NIVMQGS-)M=2-E8$'M]EMO+A]ON9K[#!]?P/Z6OB_^V]^Q[\ 9I;/XR_M-^!_#MW#G?IVH^)+=;OC MKBW#F4_@M?.'Q&_X.(O^"77@.9[72?BWK?BB6/(=?#GA2[*Y] ]RL*-]0Q'O M7\Y'7K17TN'\/+?\ M@ZD_9%L)FC\#_L[?$74T&<2:F;"SW'V"3SH?\'8?@N*X*Z5^Q%JDT M79[CQ['$W_?(LG'ZU^+]%>G#@GAV*UIM^LI?HT>7/CCB.3TJI>D8_JF?LC#_ M ,'9=DUP5G_8+E6+)PZ?$X,WM\ITT#]:Z/0_^#KCX+W$RKXE_9"\46D9/SM8 M^);:X('L'BCSW[BOQ+HJY<%\.-:4;?\ ;TO\R(\;<2Q>M:__ &[#](G] '@G M_@YX_P"">/B62.W\3>$_B3X=9CB2;4/#UM-"GOFWNI'(_P" 9]J]Y^&'_!9[ M_@F'\6Y8K?PW^U_X:L9I2 (O$RSZ1M;T+7L<2?CNQ[U_,-17!7X R:HOW1A)>C3_!_H?V"^$O&W@SQ_HZ>(? GB[3-;T^3_ %=] MI%_'HZ#JLUG.N.F) M(F5A^=?87[//_!P;_P %)O@5+;V7B'XG6/Q TJ$@-I_C?35GD*]_]*A\NX+8 MZ%W< ]CR#\]C/#W&TU?#55/R:Y7^J_(^CP7B+@:C2Q5&4/-/F7Z/\S^CNBOS M,_9<_P"#G?\ 9,^)TUKX?_:5^'FM_#?4)<+)JEN3JNEANF6>)%GCR>WDN!W? MC)_0WX3_ !H^$?QX\)1>._@O\2]#\5:/-C9J.@ZG'=1!L9VL8R=C#NK88="! M7QN/RC,LLE;$TG'SZ?>M/Q/M,!G&69I&^%JJ7EU^:>OX'34445YQZ04444 % M%%% !1110 5X/_P5#^-7Q'_9Q_X)U?&KX[_!_75TOQ3X3^&^JZEX?U)K6.?[ M)=Q6[M'+Y*^7?^"VG_*(S]HS_ +)%K7_I,] 'Y_?\ M&Y7_ 6 _;G_ &A/VF;S]D[_ (**_%F/Q5<^._AG;>./A+KD^B65C)+ DC1W M5LOV2&(2YQ*?F4E38S8;! KSK_@X$_X+.?A5_P3U^-J>$/! M?P,\/Z/%\1=3@\/:??&^UW4IE,=OYEW;S;=D,B@(NT;H+G<20H'COQ+TSQ;^ MQM_P3%_X)T_\%I?A-X?>\U7X17$OA_QA;02>6^H:/=WU[(D#R8/EQLOV^WW8 M.&U!>#WY?XX_ [QI:?\ !M#\1?V]_C3$9/'_ .TU^T-9>,=:NY$*NUD+RZCM M4P>0AD:[G3MLNEQ0!^W7[17_ 61_8O_ &'? ?P[M/VJ_BEJV' M@_PMH%QJ6IW:/"&DN!;6R-Y41<2!6)=&MKYK'4XVM);6[TZZ50Q@N+>95DB;# C(VL#E2PYK\,O&VN?&'X M/?\ !PIJ/BC5OVZ_"G[-[^)OV>/#2_#OXD?$?P=::MI<]E_8^D1RV<1O9HH; M1GN+>^_?EQ\T4L76;!^R_P#@EK^Q]HGPV\(?MK_$W]G+_@I?X+_:)\>?%C1G MN-6F^&?A^WL+'2_$#VNJRPR(;6ZG@:2:6[) B*A3'SG(P 7_ /@I'_P<9_\ M!-#7/V?/CU^RW\"?VN+VW^),/PY\0V'ACQ!HEA?6]I)K"6/_@5J]_XJCCU+XKZ=IFI> M(-5U7;>:NBZ?*8)EN"A2-9-Y?;BS2,\-BOE#]B7]KW_@F5\/?^#9CXO?LK?& M#5_#$/Q@U6[U^"/P;J&D>=K%_KLH TN]BB*%\0CR1YW A,#Y(/!V/VZO^5.+ M]F;_ +*5#_Z4>(: /V:_;:_X+%?L!?\ !,FP\,>$OVL_C_,/$>MZ1%ZE>V_P!S[9)# A$".ZM@R% S!PF[8P'>_#3_ (*0?L7_ !9_8QF_X*!^ M$/C9:'X2VFGW-YJ'BF\L;F 6:6\ABF22!XQ,)%D4IL"%F.-@;'OCE\ M#/V._P#@ZR^(?Q8_;\\7:7X5T#Q!\#=+C^$_BOQ:1%86DC:?I$9>*:0;(,_9 MM5A\PD#>94SF3G[7_;&_X*3_ +*WPT_X(Y_%;]N?]B/X7>#OB9X0TG49[6WT MC_A'#%HFJ:G-J\5GM3R-LCC@FFB"AG;Y4$FS7MG\0MEU M9;K2[G@D6*!&\Q8,SJZ@7+.H4H2?R$_;Z_:H^.G[3GB#]B?XD?'3_@H'\%OB M7JVM?$;0]=T_X12K!(3#*$;S(6P&\LD??'_! M>O\ Y33_ /!.#_LIMW_ZDRK$DD[NRQ[Y)'"@[=TC M'&6.?D__ ()*_M3_ + _[%O[3_[?W@__ (*D^(?#>B^+-9^).H/JEOXUTS[3 M)XBTK[7J#SVMO&R,;GS'D23R5!,RS0L P7*_0O\ P9?I%'_P37^)J06KP(O[ M0>JA()$VM&/['T;"D'H1TQ0!^O=%?/'_ 4)^"/_ 4)^-?A3PYI_P#P3Z_; M8TKX+:K8:C-)XCO]5\!V6NKJ=NT8$<2K=QR"$HX+94 MNY/&#V?[&'PZ_:F^ M%7[/ND^"_P!LS]HBR^*?Q M[FZ?5O&>G^&;?2(KN-YW:!!;6ZI&OEQ%$)"C< M5RE6YN1;K&GV@&*(+AG=CM;,D(\R%=['ZS_X)K_ #_@HA^S\/&.@_MJ?M MWZ-\?/"]]'IMQ\-?$T'A6+2M2@!%R;Q;E(0R/&P:T:)O.F;B3E1M!\H_X+$Z MY_P1&^/OBG2OV&O^"J?Q$T'PWXC_ .$;'B;P=K&LW4VES:?;SS36S36FI;?) MC-O G[=O[1G['O[._[0NO?%/]E_P18K+X M+\3ZH':V@U!KN-8%MR0$C\V(WF_R@J3&U64*H(H ]Q_X+3_&OXR?#W_@LI^P M%X!\ _%KQ-H>A>)/'-Y%XBT71]>N+:TU6/[;IR;+F&-PDZ[7=<.",,PZ$U]D M> O^"DO[(O[2WQM^*G[(/P(^-%[>>-/AGHURWC+5=*\.7 _B)\4O\ @J!^P]\-?A%\29O!OBK7]4UO M3_#GBNWCWOI%[-<:?'#= >L;LK<<\<8.#6]_P;/_ !6^'GPM_9<^-_\ P3.^ M(WPKLO!'Q[^%>JZU<_$*W=B;KQ/$Y=%U%I'),WE$I;G;F,1FWD7_ %YH ^7_ M -NW]JCXM>$_^#=KP]\5O@+_ ,%7_B=\8M3N?VJ5L9/BF\.J^&]3BM_[(O9# MI1\VV\,"T)$IU&31K=+;9CG=YI3'OB M@#[9\:?\')?_ 2'\"?%B[^%FJ_M&WMS#INL?V5JGC'2_"6H76@6=[NV^2U] M%"8VYS^\3='@$[\ FOIS]IK]M+]F+]C[]GFZ_:I_:!^+FFZ+X%MX()(=^>MPMS+2Z\G>YC MCDMA.B!F./-5/_!07]@B'_@GM^U-XNM])/QW.F_$ MSPQ:3W^CM<0S:GH*6Z7MOE$N89(S>*F=Z$-,O!+K7[K5^ O_ 54_:V_X)Y_ MM8?\%DO^"?M_^PWXP\)^)M1\/?%718?&&O>$-.588[.;6-(_LNRDG5%#-$(; MXB#K")""%W8K]^J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKSO]IS]JSX"_L>?" M^Z^+O[0?Q!M-!TB#*0"4[[B^FQD06\*_/-(?[J@X&6.%!(NE2J5JBA33"@$DHXS'@YK\NO^"D'_!P'^T5^UO+??#/]GB2_^&_P^D+1 M.+.ZVZQJT?3_ $B>,_N48=88CCDAGD!P/SX)+$LQR3U)K](R7@-R2JYB[?W% M_P"W/]%]Y^:9YQ_&#='+5?\ OO;_ +=7ZO[CZ[_;5_X+:?MT?MGSW6A:A\0I M/!/A*?$R*#G9(H.V5#W1PRGN# M7(T5,X0J0<9JZ?1[%0G.E-3@[-;-:,_7W]AO_@Y[U^PN+/P)^WIX!2^MCMC_ M .$\\)6@CG3MON;($(X[EH"F .(F-?K7\#_C_P#!7]I3P';_ !-^ _Q,TCQ3 MH=SPE_I-T)!&^,F.1>'BD&1F-PK#N!7\D?AWP]KOB[Q!8^%/#&DSW^IZG>16 MFG6-K&7EN)Y'"1QHHY9F8@ =R:_J$_X)=_L,Z%^P!^R/H/P:6&"3Q)=K_:?C M748<'[5J,K&&P"QK\IXTR7)LMIQK4%R5)/X5LUU=NEM-M M/(_6^",[SK,JDZ-=\]."^)_$GT5^M]=]?,^B***CN[NUL+66^OKF.&"&-I)I MI7"I&@&2S$\ #]1M=? MGL?"FJ^))4CT[Q+ LA2.:"XX6%Y,96&;:2&0*78E1]S@@C(->CF>49GDU94L M;1E3DU=*2M==UT?RV>CU,:.(H8B/-2DFO(****\XV"LKQQX&\%?$[P=J?P\^ M(_A'3-?T#6K*2SUC1-9L8[FTOK>12KPRQ2 I(C D%6!!!K5HH X#4_V4OV8= M:^!$?[+NK_L[^";KX;0V\<$/@&X\+VKZ.D<!?&VFZ(N MW1+3Q+X7M;M=.7"KBW\Q"8!A5!";00 #QQ6G\!OV9?V=/V6O"DO@?]FSX%>$ MO >D3S":YT_PCX?M]/BN)0,>9((47S'QQO;+8[UR_P"U3^W_ /L6?L06]A-^ MUC^TMX3\"R:JC/I=EK>IJMU=HIPSQ6Z[I9$!X+*I4$@$Y(KH_P!GO]J7]G+] MK#X=?\+:_9K^-?AOQMX<$[P3:MX>U6.XB@F4!FBEVG,4@5E8HX5@&!Q@@T < MRO\ P3P_8+7XK:M\<_\ AC/X8-XPUZ*YCUGQ(_@>Q:[O1<(4N#)(8LL949ED M8\NKL&)#'.MKW[%?['OBGX):5^S3XF_99^'NH_#O0[A+C1O U]X.LI=)L959 MV62*T:,Q1MF64[E4']Z_]YLX?P _X*,_L(_M4_$K5?@[^SE^UEX&\9^)]%B> M6_T7P_K\5Q.(D<(\L84_OHU8J"\>Y1N7)&X9Z?4_VK/V>M(_:3TS]C^\^*%B M?B7JWA^77;3PC!%++W"Y/% %;]H/\ 8R_9)_:Q MT[3M*_:9_9K\$>/(='+?V0/%7AJVO6L=V-PA:5"T0.!D*0#@9S@5T.@? GX( M^%/A,/@)X8^#WA;3O PT^2P_X0RR\/VT6E?99,^9!]D5!$8VW-N3;AMQR#DU MU5% 'A7@W_@E_P#\$X?A]IT>D^"_V$OA)IUO%K]MK<4=OX T\;-1M@XM[I28 MLB2(22;&'*>8^W&XY]$^('[/'P$^+'CCPO\ $WXH_!7PIXC\1^";M[KP=KVN M>'[>ZO-#G8H6DM)I4+V[$QQG*$',:'JH([&B@#R?XC_L(?L4_&'XP6/[0/Q6 M_9-^'?B3QQIIB-GXKUOPA9W-_&8O]4?.DC+,8\#8224P-N,5UWPH^!OP6^!& MG:KH_P $OA+X;\(6FN:W/K.LVOAG1(+&.^U&8*)KN985423.$0-(V6(103@" MNJHH **** /-?VAOV-OV3/VM;.RLOVGOV;?!'CY=-)_LU_%GAFVOI+/)!;RG ME0M$#@9"D9[YK=^"WP$^"'[.'@B+X:?L_?"#PUX)\/0RM+'HOA71(+"V\QL; MI#'"JJ7.!EB"QQR376T4 <=X^_9X^ GQ5\>>&/BE\3O@KX4\1>)?!5R]QX/\ M0:WX?M[J]T25RI:2TFD0O;L2B'*$'**>J@BLG[+_ .S;%\:;W]I"/X ^#%^( M.IZ9_9VH^-U\,VHU:ZM-BIY$EUY?FNFQ$3:S$;45>@ KNJ* /('_ ."??[", MOP=A_9YE_8S^%K> K?7/[:@\%MX"T\Z7'J.TK]L%KY/E";:S)YFW=M)7.TXK MKK?]GCX!VGQJF_:1M?@IX4B^(5SI0TRX\<1^'[<:M)9#;BW:[">:8_E7Y"V, M*H["NQHH \(^('_!+O\ X)O_ !6^)%Q\7_B7^PC\)=>\37MS]IO]:U7P#83S MWDV,GBO4_&_P<^$GQ+^&=S\%OB'\,/#^N>#[RQ2RNO"VK M:/#<:?+;)C9";=U,91=J[5VX7:,8P*Z2B@#QKP+_ ,$[/V"?ACI>@Z-\/OV, M?AAI%OX7\1+K_AU+'P/8H=.U5<;;^%A%N2X7:N)0=XV+@C:,>RT44 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%? W_!8S_@M!X3_8,T.?X(?!*:SUKXM:E9[@CXEMO#<+ MK\MQ8@[HX#VP[_)M63LP& Q698J-##QO)_@N[[)'%F&883+,++$8B5HK M[V^R[MGH7_!3W_@KK\"O^"<_A)]#E>#Q/\2-0M=^A^#+6YP8@P^6YO'&3!!W M ^_)C"#&YT_GK_:N_; _:!_;5^*,_P 6_P!H7Q[<:SJ+[DL;0?N[338"&\'DE*Z]ZJ]Y?HNR_%]3\-X@XFQN>U;/W:2VC^K[ MO\%T"BBBOHSYH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBN__ &7/ MV<_B!^UI\?O"_P"SS\,;3S-7\3:FELDS(6CM(1EIKF3'/EQ1*\C=\(<-@%/3S9000T)K]Q:XK]G+X"?#_ /9>^!WA MGX _"[3OLVB>%]*CL[31SW9V-=K7\_Y]FT\YS*==_#M% M=HK;[]WYL_H?A_**>2Y9##KXMY/O)[_=LO)!7YB_\'+_ /P4?_X9F_9KB_9# M^&.O>3XU^*5E(FKR6\N)--T#)29CCE6N6#0+ZH+CH0IK]#_CI\:OA[^SE\'? M$GQU^*VM+I_A[PKI$VHZK\6?M+_$B1DN_$6HEK+3Q*6CTVR3Y+>T3_9CB"KG W-N8\L:^[\*N%/[< MSKZ[7C>C0:?E*?V5\OB?R3W(SW'_ %7#>RB_>E^"Z_Y'E-?H]_P2G_X.&OCS M^Q2^F?!C]I!M0^(/POB*06_G3[]7T"(<#[+*Y_?PJ/\ EWD. CQ@;6_.&B MOZ7SG),KS_!/"XZFIP?WI]XO=/S7Y'Q>&Q-?"5.>D[/^MS^RC]G_ /:'^"_[ M4OPLTWXT_ +X@Z?XE\-ZK'NM=0L),[6 &Z*1#AHI5SAHW"NIX(%=I7\DO_!/ M+_@I-^T=_P $W?B['\1O@KKQN=(O)$7Q/X.OYF_L_6H ?NR*/]7*H)V3*-Z$ M_P 2ED;^F7_@G_\ \%#?V>O^"C7P6B^+GP,UTIIAF])]8]E/L^SV?D]#[K+,VI8^/ M*])]N_FCW6OD;_@O'\?_ !O^S%_P2(^.?QA^&^L7&G:W;>%(]-T_4+20I-:- MJ%Y;Z>9HV'*.BW3,K#E64$8(KZYKPS_@I=^QZ/V_/V$/B;^R%%KL&F7?C3PX MUOI6H72L8;>_BECN;1Y H+>6+B&(M@$[QW-I>6Z3VMS"^Y)8W4,KJ1U!!!!]Z_ M"#Q1_P $[_\ @OA^VC^Q%\+?^"-_Q^_98\#_ \^'7P_U?3H=;^-3>.+._:^ MTJP$D=JL%E!.\N]8G&,HOF-%&&, +Y_2?]MFP_X*D_"KQ[^SI\._^"9O@?PO MJ?PYT_7(M.^,<_B6YM!/9Z+"UE%"4\^6-V'D"[+&W5Y=ZQX4#@@'YL?\%I/% MG@K]@;_@OQX0_;8^-WP;\,?M">&O''PX&E6WPBDDM[W6O#Q@B*&[AL)DD'ED MQRRQRE=K&6[7*,H<]3_P;J_L_P"C?M)?L.?MG_%OX$?$?PCX:U/]HJ]U>PT/ MX7^&+Y_)^&WF6^J)913+Y:&')O\ "%$V&&TC*DG.?^"K?[&W[*/AK]H70/B+X,M]&;P[J?C2TT?4?#92WL8'\J2\90N39 JT M0?,=Q(C*I^<^B?\ !"K_ ()K?M=_LV?M$_M!?MX?ME>!O#7P]\1?'/74NK/X M6>$=4CN[?1HA<3W#O-+ S0O(6F"KL9O^6K$@R;0 ?"?@^P_:6_X)M:Q^S!^U M!^TA^PSJ?PUB_98^'?B+P?/"^JZ=+F)922RW(>68W4DI0 MB-1<,,L$\S["_P""-O[0'[%'PB^//BC3_P!JG]K_ ,+^(_VU/C=XD;_A9-NL M-P8-)NXP/(\*65X8S:#[&FR)K>.9F,J[/G$<0'L7PC_9!_:+_;._X*8:G^WC M^WC\-9O#/@CX.7\^C_LU_#+4KZWNB9B0+CQ3=K!))&L\NU1 A.Z,*I(#1)(_ MQO\ !C_@CS_P4HT7Q#\+?V+_ !?\ ]$T_P _"_]L23XP3?'Z/QQ8RG6=-C? MS([6.P4F\2[E'REI$"*R1Y)"[J /V]HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBO /\ @I%^WW\.O^">'[.&H?&+ MQ9Y-]KEWNL_!WAQI=KZK?E4G9(P MQ.(HX2A*M6E:,5=L\<_X+.?\%:]"_P""?7PS'PW^%E]:7WQ9\369.C6CA9$T M2V.5.H3H>"<@B*-N'8$D%48-_.UXN\7>*/'WBC4/&WC;Q!=ZKK&K7DEWJ>IW M\[2SW4[L6>1W8DLQ)))-:_QI^,WQ(_:%^*FN?&CXN>)Y]8\1>(;][O4[Z<_> M8\!5'1$50$1!\JJJJ *Y>OW?A_(J&1X3D6M1_%+N^R\ET^\_ N(L_Q&>XS MG>E./PQ[+N_-]?N"BBBO?/GPHK]>O^"#D/[.G@3_ ()Z_$3XX_'3X/\ A37X M+/XP:5I%]J'B#0K>Z:VL[M]+M"Q:5&(CC^UR2E>GWN.:^?/%_P#P2Q)_X+B# M]B#3_#[Q>#=1\7+KL*1*5CC\-,IO9(U;L$B$EJ&_YZ(!SW\"&?X?ZY7H5(N* MI)N_1J*3E;TYE]Y]#/A[$_4L/7IR4G5:5K:QTBD )"C*DXQQ\U2_P#!!;6[SQ'JGP%\)_MO_#36/C=HVBG4=0^%-KYZR#$: MR&!+ML*TNUU.THN-P+%5^8+"<1X*MAE5K_NW>2L[MKE=FW9:*_5V7F/&<-8Z MCB72P_[Q6B^962?,KI*[U=NBNWV/S^K0LO"?BK4M!N_%6G>&=0GTNP=4OM2A MLG>"W9B HDD VH22, D9R*]Z_8"_X)M_%_\ ;W^*7B'P+H7B#3?"&D^"[%KO MQMXF\1AE@TB,,RA&48)D)CD.UBJA8I"6&WG[_P!-_9&TK]DK_@AE^TEI'A'] MH+PA\3O#GB'5[&^T/Q7X-O!+!*J7%A#)%(H9A%*CH83!UH MT(OFJ.4%;73G:5[VM>VJ6[7D8Y?D.+QM&5>2<::C.5]-7!-VM>]KZ-VLGYGX M\O;SQPI'/ M%'BM].^'WAS0="E@U<7CO<11K60RQF)"P(/ ( M-72SK!NT:LDI.4HI*\OAERW>FFN]]$]+LBKDF,5Y4HMQ48R;=H_%'FLO>=]- MK:M:V1\/45]'?LB_L(_#?]H3X97OQD^,W[;OPX^$VA6VN/I-I;>)+II]3O+A M(HI6>.S0JQA"S(/,W==PQQDUO^"@_P#P3Q\??L >+?#-GK?Q!T/QAX:\;Z)_ M:W@_Q;X?9OL^H6WRY^5L[6 DB?Y6=2LJ$,MM79VLV MNJ3.266XV.$^M./N::W6E]%=7ND^C:L?/5%??/QO_P""#WB[]G/X0ZW\9?C# M^V!\.]$L;?P1)K?A.POY_(N_$MY':/M03S7DRRDK#'<2)A;>1W!0*% M?+ JNYE*CD6?Y1*GSJK=>2D]E=]-EU>RZV.M\/9Q&IR2I6?FXK=V6[W?1;OI M<^#:*ZSXZ?!7X@_LY?&#Q%\#?BII2V7B#PQJM"<*D%.+NGJGY'D3A.G-PDK-:-=F%%%%42%?NQ_P &VO\ P3X_X4U\ M%[K]M;XEZ'Y?B7Q]:?9_"D5Q'A[+1 P;SAGHURZAO^N4<1!Q(PK\OO\ @D_^ MP?JO_!0#]KS1?A??6LR^$M(QJWCF^CROEZ?&XS"&'229RL2XY&]GP0AK^GC1 M](TKP_I-KH&A:=#9V-C;);V=I;1A(X(D4*B(HX50H ' K\ZX\SKV-%9?2? MO2UEY+HOGN_)>9^D\ 9)[:L\QJKW8Z1\WU?RV7F_(LT45X#_ ,%,_P!N;PG_ M ,$\_P!D#Q-^T/KI@GU6&'[!X0TF=L?VCJ\RL+>+&02BX:63'(CBD(YP*_,< M%@\1F&+IX:A'FG-J*7=O1'ZQ4J0I4W.;LEJ?EA_P=*_\%'_^$J\6:?\ \$[/ MA5KV[3]#EAU7XD36TORSWI4/:6!(ZB)6$[KR"[P]&B(K\<*UO'?CGQ;\3?&V MK_$;Q[KL^J:WKVI3ZAJ^I73;I+JYF M57D_YI/XG]^W9)+H?FN.Q<\;B959==O)= HHHKWSD"O5_P!C']M#X\?L'?'+ M3OCU\ /%!L=2M#Y6H:?/N:SU:T+ O:7,8(\R)L#N&5@&4JRJP\HHK#$X;#XS M#RH5XJ4)*S3U33Z,J$YTYJ479H_K?_X)S?\ !0_X)_\ !2+]G^T^,WPHNQ9Z ME;;+?Q9X6N)PUUHEZ5R8GQC?&V"TQN%XEM9T!.R:-LJPY!X92RLK'^3/$'@: MKPGC?;8>\L-4?NO^5_R-_P#I+ZKS3/OLIS2./IBBBOSD]@* M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** ,SQIXR\+?#OPAJGC[QOKEOIFC:+I\U]JNHW3[8[:WB0O)(Q[ M!54D_2OYC/\ @J7_ ,% O%?_ 4/_:AU'XH3O<6OA/2=^G^!M%F./LE@K?ZU MU' FF(\R0\XRJ9*QK7Z(?\','_!0R7P]HEE_P3]^%^LE+K5(8=4^(EQ;R8,= MMG?:V!(Z%R!.XX.U8>HD85^+M?K7 V1K#X?Z_67O3^'RCW]9?EZGY!QYGSQ. M(_L^B_7]IC1KC6;6*]F M^(.FM!:/<*LKCS]&Y52'OC_,9;;&)5D/&< 8R2,^Y_&G2/ MV^M _:BU?]IC]C_]G_\ 8_O/!VIS&\T3XWZKI]M#?"WFA D:[OXKE97;!=6> M,,'3'J0/P)HK"KPO&=:56-17DYW4HW5IRYK64EJKVOJGV-Z7%4H4(TI4W:*A M9QE9WA%1O=QEH[)VLFNY^H'_ 17^(FA_M#^#?VL/V3_ !+\0=$\/_$'XW^' MYI?#EW/.(+:]NI(]0CFC0]2JO=QML7#]0\=W>H:=JNK^&/#VM)1]H'"[>N:_(>BNJ MOD,JN+E4A5Y82E";CRWUA:UG?1-):6WUO;0Y M]U;5IMZWVTM?4_8KP9^T%\*_@3^PM^P%\2O'_B&R72_#WQ'F?7&$RNUC"XOH M6N'1,X7@$X%>6?\ !5K_ ()3?%'Q/\:?BU^W]:?'?X>GX7ZO:W/B M70]:F\2J\^IR?9U9-/MXU!625Y (XRKE2I4@Y^2OS(HI4,BJX3%>WH5K-\U[ MQO=2GSV6NC5[7UOV"OG]+%X7ZO7HW2Y;6E:THP4+O35-*]M+=S]1?^"7O[+7 MPN\>_P#!.;6_C'^SK^SE\+?B_P#'F#Q>UMK&@?%6YBEM-&TL8VRK;3311[=F M'$C%=Q9QN;RA'47_ <2^(=&UKX1?LMV.GZMX*GNM-\%ZI::G;?#R:,Z-:7$ M4>EQ2Q62H2$M5DCD2)>R(!VK\OZ*TADE19JL9*K>TI-)IW]Z+C:_-:RZ6BO. M^Y,\]IO*'@H4>7FC&+::M[LE+FMRWN[6=Y/RML?I5_P<->.=';]H?X$:KIVI MVVJVFE_"G3KB2U@NUDCW"[E9E."0I8(H/J /2OMG]J37?VA_VH?B#X,_:_\ M^"=/P _9C^*OAN;0;&ZA\:^/M$M9=>\.WT4KRJKW$EQ&\ B)1E5?WD4JR@@$ M G^?RBN:?#47AJ%.-17I*2NXW34M7=*2?337UN=$.)Y+%5ZDJ;M5<792LTXJ MRLW%KU]WTL>T?\%#_B)\6/BI^VE\0/&GQRU;PG?>+)=72UUJZ\#2M)I+RVT$ M5L/LS,6+(%B4$DDE@QKQ>BBOHZ%*-"A&E':*2TTV5MCYJO5EB*\ZLMY-O75Z MN^_4*=##-<3);V\322.P5$1 !U--K]%/^#=[_@GO_PT[^TJW[2_Q&T/ MSO!7PQNXI[5)X\QZCK> ]O%SPRPC$[^C" $$.:YLRQ]'+,%/$U=HK[WT7S>A MTY9E]?-,=#"TMY/[EU?R6I^H_P#P1:_X)^P_L%_LAV%CXMTA8?'OC01:OXUD M=?WENY3]Q8D^D$;$$4G=_UV6R\C^C,% M@Z& PD,/15HQ5E_GZO=^85_,_P#\'"7_ 4?_P"&X?VOIOAI\.M>^T?#OX8R MSZ7H;02YAU*_W!;R^&.&4N@BC;D&.(.N/-:OUE_X.$/^"C__ P[^R!-\-OA MUKWV?XB?$Z*?2]":"3$NFV&T+>7W'*L$<11G@B24.,^6U?S/5^[^#G"GQ9YB M8]XTK_=*?_MJ_P"WO(^=XBQ^V%@_.7Z+]?N"BBBOZ /DPHHHH **** "OTI_ MX-G_ -JO]ISX3_MBCX"?#/X>:YXP\ ^-63_A--.TZ/=%H++\L>L%V(2$)PDF M2/-0A0'D6):Y+_@E9_P0-_:)_;_GL/BO\4A>?#_X4R,L@UZ[ML7^MQYR5L(7 M'*D.L@P^7ULHC%5ZLU9J_NP?1MK[2>J2U36K M77Z+)LKQZ0MZ5ZV1Y;+-LSIX;HW=_ MX5J_\EYGD9[F<J5H_XGHO\WY(_);XZ?&?QU^T3\8O$GQQ^)>I?:]= M\4ZO-J&HRC.U7D;(C0'[L:+M15_A55':N4HHK^A(0C3@H15DM$?SI.;Q#;?"'3[JPU?Q )O.-[J=Q]G26$.,^88Q:QAF'62 M21?X,U\_+&9A#/8892C*$E)R233@DO=;=W?F>FR_4^AC@\NJ9!/$N,HSBXJ+ MW_@'PK?>*+#[;X<\*>+ M?%HM=7U&$IO!CMUC?!*D$J[*RY^8+SCY,^+OPE^(7P(^)FM_![XK^&IM'\1^ M';][/5M.G96,,J^C*2KJ00RLI*LI!!((-?O3JGP^_9K^.'[1'[-7QR_;W\1V MWPX_:6TSP[;R:!\,T\5*MOJDL,LDEH+C;"WV8M\)V>A^,KG71)?Z;ITYEMHK?R8Q:^3(0#+']F$.UR%+ M#DJIRHX\ASG&YCC)4ZS5N5O16UYFO==WSQMO):7MWL=V?Y+@LNP4:E%._,E= MN^G*I>\K+DE?:+UM?M M";J^6S?Q3X!\1#4;2VG8E520E(V&64KN"E0V%+!BH/T+_P &[]]XKN_$'QK^ M'?BOP):7'P=\4> 6M?BUXLOM8%@F@6JPW:QR"8]=\4MVI4;2 /,W*(\'TO\ M;H^&G@3X/_\ !%9? G_!-7Q=;_$7X+7WCPZA\2_&E[J_FZI:W'GP>1"UL(8A M"@D2T#'"N-L9\O$K248O.<;1SQ86+7)S06VEI)MWE?W9?RQM=Z;W#"9+@JV0 MO%23<^6;WUO%I*T;>]'^:5[1UVL?&O@+_@D+^U]\1?@E8?&?08_"<*+Q!JVCPXWWMO9D9>+!!&6!8,N =R@^$OAQH9U+Q/XI\57$?@^WPS\-:-;1VG_"-7$:Q>6FJ7=P9/ M/BBBB$DLJK$<#(&=H)L_'/\ 8@U_XU?LZ^"?V+/V./CCX \*_"O3/%5UI6F: MMXIU>:VNOBUXT@0B]NHA!#*&MXG22"(NVW='@;U$+"'G6/H5I4<3:#;6K6D8 MWE?J[Z)T66LCP%>C&MA;S23T3UE*T;=%;5OF71**WDK_DQ16IXY\%^ M)?AOXUUCX=^,],:RUC0=4N-.U:R=@3;W,$C12QD@D$JZL...*RZ^N34E=;'Q MTDXMI[A1113$%%%% '1?"3X5>./CC\3]!^#WPTT5]1U[Q+JL.GZ59I_'-(P4 M%C_"HSN9CPJ@D\ U_4]^Q#^R9X&_8C_9D\+_ +.G@54E31;(-JNI"/:VI7\G MS7%TW?YY"=H).U B9PHK\V/^#9K_ ()[_P!G:;?_ /!0/XG:'B>\6?2OAS%< M1\I%DQW=^N>[$-;H?19^S*:_7^OR#CG.OKF,6"I/W*>_G+_[7;UN?LG >2?4 M\&\=57OU-O*/_P!MOZ6"LKQUXX\)_#/P5J_Q&\>:[!I>B:#IL^H:OJ5TVV.U MMH4,DDC'T55)_"M6OQQ_X.E?^"C_ /PBGA+3_P#@G9\*M>VZCKL4.J_$B:VD M^:"R#![6P)'0RNHG=>"$CBZK*:\'AC(,1Q+G5+ 4M.9WD_Y8KXG]VW=M+J?: MXW%PP6&E5ETV\WT1^6'_ 4U_;G\6?\ !0S]K_Q-^T-KAG@TF67[!X/TF=O^ M0=I$+,((L<@.V6EDQP9)7QQ@5X!117]L8+!X?+\)3PV'CRP@E%+LEH?FM2I. MM4H4445TD!117U/_P $V_\ @D5^U3_P4J\6J?AOH?\ 8/@FTNA'KGQ MUJW86-MC&Z.!>#=S@?\ +)#@$KO:,,&KCS#,<#E6$EB<744*<=V_ZU;Z):OH M:4J-6O44*:NV?/'PL^%'Q*^-_C[3?A;\(? ^I^(_$6L7 ATW1](M&FGG?J<* MHX &26.%4 DD $U^ZW_!*7_@VG^'?P/_ +-^.O[?=KIWB[Q>FRXT_P !1L)] M(TE^H-T?NWTP[K_J%.?];\K#[<_X)\?\$OOV5O\ @F_X!_X1OX'^$OM.OWMN MJ>(/&VKHLFIZHPP2I<#$4.0"(8\(, G*V-S?FPF57I4=G+:< M_P#Y%>FKZM:H^RRW(:6'M4K^]+MT7^;_ &P00VT*6UM"L<<:A8XT4!54# M Z 4KND:&21PJJ,LS' ]:XC]H']H[X,_LN_#VX^)OQO\[37Q/S?\J\W\DS]%?'?_!:']D#PE^TSH/[.ND>(#K- MO?ZB;'7?&5E<+_9FDS,"L:^9R)P9-JNZD1QAMVYMK*/KJOY8Z_<+_@B5^W1) M^T[\ #\&_B!J_G>,_ %O%;R2S29DU'3/NP7!SRS)CRG//(C8G,E?;^(7ACAN M&\GI8[+G*48>[5OJW=Z3[)7?*TMO=\V?&\!>(^(XAS:K@LP48RGK3MHE9:P\ MW;WDW_>\D?;5%%%?BA^Q!1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 17M[::;9S:CJ%S'!!;Q-)/-*P58T49+$GH 2 M37\I/[>?[3&I?M@?M?>/?VA;ZXD:WU_7I3H\A6".,'IELGO M7]._[6_PL^(/QQ_9E\<_!KX6>,+30->\4^&[G2K'6+Z)WBM1.ACD8A/F!\MG M 8 +T7Y8#TMB$NCQZ1 M$>]?H? 57+<-4JU*]2,:CM%)NVF[W[NWW'YQX@4'+_2=1M6VW.GZG9O!/"WHT;@,I^HJA7ZP MFFKH_(VFG9A1113$%%%% 'Z ?\$QO^"L?[+O[#7[+WB?X%?$']F/Q#K6L^,- M1N&\0^)O#7B#^S[F[LFB6.* 7$;)/#Y8\W;Y;K@R,P(+&O&?VN_V@_\ @G=X MOT3P[??L+_L<:]\,/$VDZ^E[?ZOJ_C&ZU2.YA125B$=Q/*%(DV-N '"D'.:^ M9:*\N&482GC)8F+DI2=W[TK/2VL;V>FUUH>K4SG&5<%'"R47&*LOA]P_LA_\%3/@-^S[XR^.OPX\:?LO M3:A\$_C;J-T\OA#1M3%M=Z':.]P(H86&U640SA"H9-IC0HPP0TOQZ_X*8_LJ M^%_V(/$7[!__ 3]_9S\2>%/#OC;68]0\7Z_XUUM;J]F*/"WEQ(C.J[A;PKN MW !58!"SEQ\,T53R3 /$*LT[WB[>A]*_L[_ +:7P\_9._9'\9^$O@GX9UJ'XT?$-FTC6/'5S'"E MOH?AX\O;:>RR&7SYF \R0JFT;=OS1JU>J_L??\%1OV=?A-\ _A5\-/VA_@AX MMUS6O@1XRO\ Q'\.+SPMK5M;6U[+_$T;,J+-(7WQY)VH,8#!OA6BKK MY1@L2I*HFW)\S=VG>SCNNG*VK;6;ZNYGA\XQV&E%TVDHKE2LFK74MGUYDG?> MZ716.F^-/Q1UOXX?&+Q9\:?$MM##J/B_Q+?:U?PV^?+CFNKAYW5<\[0TA ]A M7,T45Z,(QA%1BM$>;.T?\$_?V./&'[=W[5'AK]GKPMY MT%K?7'VGQ'JD29_LW3(B#<7!SQNVD(@/#221K_%7B]?T/?\ !O\ ?\$^/^&1 M/V6$^-'Q"T3R?'GQ-@AO[M9X\2Z=I6-UI:\\JS!C-(.#F1%89B%?/\2YQ')L MLE4B_?EI'U[_ "W^Y=3Z'AG)I9UFD:KV^]]#[A^'?P_P#!_P ) M_ 6C?#'X?Z'#IFA^'],@T_2;" 82"WB0(B#UPH')Y)Y/)K9HHK\$E*4I.3=V MS^@HQC"*C%62/*OVVOVM/A[^P]^S#XL_:8^)$BO9^'=.+V6GB4+)J-ZYV6]H MG^U)*RKG!VJ68\*:_DD^.OQK^(7[1WQC\2?';XK:TVH>(?%6KS:CJER\[P5\+KV1=8 MDMY,QZEK^"DS''!6V4M OH[7'4%37YB5_5?A5PI_8>2_7J\;5JZ3\XPWBOG\ M3^2>Q\+GN/\ K6)]E%^['\7U_P @HHHK]4/""I]+TK4]N?L6?L%_M-_M^_%%/A;^S?\ #Z;4Y8V1 MM7UJZ)AT[2(F/^MNI\$1C@D*-TC[2$5B,5_1#_P2Z_X(>_LR?\$Y-,M?'=]; MP^-_B@\'^F>-=4M %L&88:.PA.1;K@E3)DRN"GE^58G'RNM(]W^G<^"O^"4O_ ;+:_XQ_LWX\_\ !1JQ MN=)TH[+C3/A=;SF.\NUZJ=1E0YMT(_Y8(1*^%=/T/1-)MEM],TG2K-+>VM8EZ)'&@"JH] *U*Q_'_ ,0O WPJ\(7WC_XD M>*[#1-%TV$RWVIZE(>)\\XNQRGBI-ZVA"-^5 M7Z1CU;[N[?<^VPV#PF6T&XZ)*[D_+JWV_ V*^/O^"@__ 5_^"?[&T-W\/? MIMO&/Q#52G]BVUQ_HNEOV:\E7H1U\E?WAQR8P0U?'G_!0S_@NIXS^*GV[X2? ML=7%[X<\.-NAO?&+J8M1U%>A^SCK:1G^]_K2,?ZOE3^=,TTUQ,]Q<2M)([%G M=VR6)Y))/4U^K\$^#]6ORXW/5RQW5);O_&ULO[JU[M;'XYQCXL4Z/-A,D?-+ M9U>B_P ">_\ B>G9/<[S]HS]ISXV_M6_$*;XE_''QQQB)R( M8(A\L2#T R3RQ9B2>!HHK^B(Q%?%5I5JTG M*4T5&,PF'Q^$J8:O'FA-.+7=-696$Q5? XJ&(HRM.#4D^S3NC^ MHWPIXHT#QOX7TWQIX4U.*]TO5["&]TZ\A.4G@E0/&Z^Q5@?QJ_7Y_P#_ ;_ M /[5C_%3]G?4OVL7\XM,_M/A_.*.?Y-1Q]/[:NUVDM)+Y--!1117 MB'LA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4452\0^(]!\*:6^M^)-5@LK2-E5[BX?:JEF"C)^I%5"$JDE&*NWLD3.<*<7 M*3LENV?@1^T'HG_"._'+X.^&O%MF%*QP^(-%ANO*SWC:128S[J01Z MU\0_M#_\&T_[ OQ8\_4_A#>>)?AKJ,F3&FD:@;ZP#'J6@NRSX_V4E0#L*_0; M2M8TC7;-=0T35+:\@;[L]K.LB'Z%215FN_"9IF>6RM0JRA;I?3YIZ?>CS\7E M>5YG&]>E&=^MM?DUK]S/P$_:'_X-E?VY_A>)]3^"/B;PQ\2;"/)B@M+O^S-0 M8#N8;D^2..RSL>V.F?ASXV?LP_M%?LWZK_8WQY^"/B?PE,7V1-KNC3013'_I MG(R[)1P>48CBOZWJJZWH6B>)M*GT'Q)H]KJ%C=1E+FROK=98I5/\+(P(8>Q% M?6X+Q S*C98F$:B[KW7^%U^"/D,=X>996N\-4E3?9^\OQL_Q9_'C17]+?[0_ M_!"[_@FK^T1Y]]>_ 2'P?JD^?^)KX!N#I;(3U(@4-:DYYRT)/ZU\)_M#_P#! MJS\1=*\_5OV6?VD],UB(9:'1?&U@]G, /X1X2[IQ51?W7K]SL_NN?DA17T%^T/_P $KO\ @H!^ MR[Y]W\6/V8O$B:;;Y,FMZ);#4[%4'\;3VAD6('_IIM/J >*^?2"#@C!'45]5 M0Q.'Q4.>C-27=--?@?*5\-B<+/DK0<7V::?XA1116Q@%%%% !1110 4444 % M%%7O#'AGQ!XT\2:?X.\)Z1/J&J:M?16>FV%K&7EN;B5PD<:*.K,S >II-I* M[&DV[(^Q_P#@AI_P3X/[<7[6UMK_ (YT3[1\/_A\T.J^*/.CS%?3;B;6P/8^ M:Z%G'0Q12#@LM?TA@ # & .@%?/G_!,;]AWP_P#L!?LD:!\$[>."7Q!.G]I> M,]2A /VO5)57S<-_$D8"PH>,I$#C+&OH.OP?BC.7G.9N47^[AI'TZOY_E8_? MN%LE62Y6H37[R>LO7HODOQN^H5\?_P#!;+_@HI:?\$[_ -C/4_%'A?58X_'_ M (P\S1O 5OD%XKED_>WVW^[;QG?G!!D:%3P]?7.IZGINB:;<:SK%_#:VEI \ MUU=7$H2.&-%+,[,>%4 $DG@ 5_*S_P %D_\ @H9J/_!17]LW6?B+HM_-_P ( M/X=W:-X LWRH%A&YW714])+A\RG(W!3&ASY8KW_#?A7_ %FSY.M&]"C:4^S_ M )8_]O-:_P!U/R.[.1RB275OHC\_C&4Y62NV<=7Z M4?\ !*7_ (-V_CC^V9_9OQK_ &H!J/P^^&4VR>TMWA\O6/$$1Y!@C<'[-"PY M\^126!!1'#;Q]^?\$I?^#:5L#=(Y9FP,GBNXJ'4=1T_2+"?5=6OH;6UMH6EN;FXE"1Q1J,L[, MV J@ DD\ "OS/_X*&?\ !>#2/#7V[X0_L1W4&HZ@-T-]X_FB#VUN>A%E&PQ, MV?\ ELX\OCY5D!##\BR/A[/N,,Q=/"QVQDU%?9BOBEY17ZZ)=6CZU_;B_X*0_L]_L,>'&'CG5O[7\57,&_2?!NES*; MN?/W7E/(MX<_\M'&3@[%<@BOQ0_;-_;[_:#_ &X?%_\ ;?Q7\1_9]&M9BVC> M%=-9DL+ <@$)G,DN#S*^6.2!M7"CR/Q5XK\3^.?$=YXO\:>(;W5M5U&=I[_4 M=1N6FGN)#U=W8DL?+N/ M\VXHFZ2?L\/T@GOYS?VGY;+M?4****_0CX,**** "BBB@#Z&_P""6?[24G[, M'[;/@_QG>W_D:-K%V-#\1%FPGV.Z94WL?[LZ#';:Q(S99KZV)M[ACZ;I(F<>S"OYV\].7RO*'X=D2X /L6D!_X#7O-?(_[;.OG5/C FD))\FF:7#$5S MT=RTA/Y.OY5]7P7A5B<_IM[03E]RLOQ:/DN-L6\+P]42WFU'[W=_@F>5Z)XB MU_PU=B_\.ZW=V$X_Y:V=PT;?FI%>E^$/VR/C%X;VP:M>6NLP+QMOX ) /9TV MG/NVZO***_8\9EF7X]6Q%*,O5:_?NC\6P>:9CE[OAJLH>CT^:V?S/JKPA^W) M\/-6VP>+]"OM(D/WI8\7$(_%0'_\=->I>%/B5X!\-;BY@7_EVU+%PF/3+Y91 M_ND5ZGX/_;R'RP>/? _^_=:3-_[3D/\ [/7R.-X&SK#7=)*HO)V?W.WX-GV. M!X\R/%655NF_-77WJ_XI'T97BG[0W_!.;]A[]JD3S_'+]FCPOJ]]<9\W6H+' M['J#$]S=VQCF//."Y'M79^#_ -H[X-^-=L6F^-;:WG;_ )=M1/V=\^@WX5C_ M +I-=NCI*@DC<,K#*LIR"/6OF94\QRNM[RE3G\XO]#Z>-3+ZXU8?*2_4 M_*G]H?\ X-9/@-XG\_5OV9?V@-?\*7#9:/2?$]HFIVA/9%D3RI8E]V\T_7M\ M)?M#_P#! +_@I3\ _/O]-^$EMX]TN')_M#P%?B\+-/P0MKXAT:&[6//=/-4[#_ +2X([&OB3]H?_@VS_X)]?%[S]3^%D7B M/X;:E)ED_L#4C=V6\]VM[O>$V,FR*?6='EBM MYC_TSFQYD>:%?JU_P;3?\$]_^%B?$>]_;N^)VA[M&\)SO8>!H;B/Y;K5"N)KL M ]5@C;:IZ>9*2"&AK\Y_V5/V;?B!^UW^T'X7_9W^&=MNU3Q+J:V_VAD+1V< M!>:YDQ_!%$KR-W(7 Y(%?U2?L]_ KX?_ +,OP3\-? 3X7:;]ET+POI4=E8H0 M-\F.7F1V[N['O7PW&^=?4<#]4I/WZF_E'K]^WI<^\X%R3Z_COKE5> MY3V\Y=/NW];'9445Q7[1GQ\^'7[+?P,\4?M!_%C5?L?A_P )Z1+?ZA("-\FT M82&,$C=)(Y2-%_B=U'>OR"E2JUZL:5-7E)I)+=MZ)+U/V>4HQBY/9'YR_P#! MSE_P4?\ ^% _ &W_ &)?A=KWE>+?B59-)XGEMY<2:?H 8HR''1KIU:+OF*.< M$#O^"C]E'=W0V7&E_"NVN MT,1ZJVI2H<2'O]GC.W@;W8%HQ_5N6U,B\+>%J=/&S7M9>])+64YO=17:.D4W M9:7;NSX.LL5GF.;I+W5HNR7GZ[GP;_P3!_X(I?M0?\%(]:M_%EG9R>#OAI#< M;=1\=ZM:,5N IPT5C"2INY,@@D$1H00SAL*W]$G[#O\ P3W_ &7_ /@GM\,E M^&_[.G@..SDN$3^V_$5]MFU/6)%'$EQ/@%@"25C4+&FX[47)S['H>AZ)X8T: MT\.>&M'M=/T^PMTM[&PL;=88;>) %2.-$ 5%4 * ,"K5?A'%_'V<<65'3 MF_9T$]*:>GK)_:?X+HD?4Y?E6'P$;K67?_+L%>8_M3?M@? ;]CGP"WC_ .-_ MC*.R20,--TJWQ)?:E(!_JX(<@N>1ECA%R"S*#FOF3_@H9_P6N^%/[,WV[X5_ ML^&Q\9>.H]T-S=+)OTS1Y!P?-=#^_E!_Y9(< Y#NI&P_CM\9OC=\5OVA/'UY M\3_C+XWOM?UN]/[V\O9,[$R2(XT&%BC&3A$ 4=A7TG!/A3F.?\E&#.V0"$P(U(&%+#>?EBBBOZ=RO M*Y"0 MS#Z,:^"\3BBOYY_P#@X]\7_MJ>(_\ @KWJ'@/]F']I+Q]X5G\$_LXCQIINE>&/%-Y9 MPEM/DO;N[<10R*OF&WBE;."S&-%.1Q7\8']>G]#%%?F/^U9_P6B^R?\ !NI8 M_P#!0_P#XB%GX\^(W@RU\.>'SI[;);;Q7<[[*[,&WH]M)#>W"<2VU'PS;IV4DW MB:W8(P>&,LN'V2POY89CB5#T920#]3Z*^7O^"D__ 51^$?_ 3CM_!7A'5/ MAQXG^(?Q'^)FKMIOP[^&G@JV274-7F4H'$_VQOVB?%W[%_Q>_9L\:?!7XS>#M(35[[P'XU:&7[9IS&,?:;:XB.V8 M*9HLC:.)%*EP'V 'V-6=X9\8^$?&ME+J/@WQ3INKV\%R]O//IE]'<)',F-T; M,A(#C(RIY&>:_.W]H3_@Y%^$'PJ_:U\;?LS?!?\ 8R^+GQ@T_P"$\S1_%WQI M\/=&%U;>&O+8K<-Y8!,BPLLB.TC0KNAE"E@A:O)O^#,R_MM5_P""?'Q9U2S8 MM#<_M!:I+$2,$JVDZ41QVX- 'Z^45\!?\'(/_!2OXE_\$S_^">4OCKX$WZ67 MCWQQXD@\,>&=5>%9#I7F0S3SWJHX*LZ10,B9! DF1B&"D'P_X$_\&XW[1FA> M _"_[0GB'_@KS^T!I/[0CK9ZKX@UA_$[7NBK$?$6OV/A;2GOI]$\):6;W4K[! $- MM "OF2,Q ) YR2 ":^$?"O_ <07'AG]H+X<_!K]LK_ ()I_&7X&Z1\6-=C MTCP/XN\:V\7DS7*-9MOB)8ZQ<6VH>&XXI6M6L8X2L/E,P:22:2>. M),$*I;+$#)'G>O?\'"?@WP3^SEX ^('C_P#8=^+.E?%CXJ>++W0O 'P$ETLK MK^HM;R1J;M_.2/R;9O-CPY0DLQ"JZH[J ?HE17QU_P $_P#_ (+ >$?VS/V@ M_&'[&GQ9_9O\9_!;XS>"M*35M3\ ^-6AE-UISF,"YMKB([9E!FAR-J\2JR%Q MN*_8M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !7PQ^T'JQUKXU^);PMG9JDD .>T6(O_9*^YZ_/KQG>G4_&&K:B MS9-QJ<\A/KND8_UK]%\.Z2>,KU.T4OO=_P!#\W\2*K6"H4^\F_N5OU,RBBBO MU<_(PHHHH **** "MSPG\3/B!X&<-X2\7W]BH.?)BN#Y1/NARI_$5AT5G5I4 MJ\.2I%279JZ_$TI5JM":G3DXM=4[/[T>W^#_ -N7X@Z5L@\8:!8ZM&/O2Q9M MYC[DJ"GY**]3\'_MC?!SQ+L@U6^NM&G;C;J$&4S[.FX8]VVU\>T5\SC>#,BQ MEVH-<_P %92J>T7:2O^*L_O9^AFB^(=!\268U#P]K5I?0 M'I-9W"R+^:DU]L[F,I<6MW"LDQKQ/ MP?\ MT^"=2V6_C/PQ>Z9(>#/:L+B(>Y^ZP^@#5ZGX1^+'PW\=A1X3\9V%W(W M2W6;;+_W[;#C\J^1QN29MESO7HRBEUW7WJZ_$^QP6>9/F2M0K1DWTO9_<[/\ M#YM_:'_X(@_\$U_VC?/OM8_9ZL_"VJ3Y/]K^!)CI4BD]6\F(?9W8GG+Q,<_4 MU\)?M#_\&JWC"P\_5?V5?VF+'44Y,&B>.M/:WD ';[7;!U=C[PH,]QGC]H** MZ<%Q-G> LJ=9M=I>\OQO;Y6.;'<,9%F%W4HI/O'W7^%K_.Y^>'_!"O\ X)*> M,_V#=+\4?&+]H_0["+XB:Y,VEZ;!:7D=TFG:4C!BRR1DC=<2 ,1U"11@[276 MOT/HHKSLQS#$YIBY8FN_>?;9>2\CT[=HM)L]29-T%G-,H/F-!$_ MF&!-[M)*,J/(+#]8ZR?!7@3P;\.=$_X1SP-X;M-+LC5S)+-( M>LDLCLSO(Q+.S%F)))KOR#.(Y#C?KL*:G5BO M'>*I^S;M%[VW:[?/K]Q\Q?\ !-'_ ((Z_LL?\$U?#4>H^"M*'B;Q__C%\:OA9^S_P" KSXG?&/QO8Z!HEBO M[Z]OI,;FP<1HHRTDAP<(@+-V!K\>?^"AG_!;+XI_M)_;OA5^SJU]X-\#2;H; MF^$GEZIK$9X(D=#_ */$1_RS0[F&=S$,4'S%^U5^V-\>_P!LGQZWCSXW>,9+ MSRF8:9H]KF.QTV,G[D$.2%Z %SEVP-S-BO+J_H_@GPHR[(>7%YE:MB-TMX0? MDG\37=Z+HKJY_.O&/B?C\[YL+EUZ5#9O[9M" M/Q$Y'XUX378_L[Z__P (I^T!X%\4;]O]F^,=,NMV>GEW<3Y_2O.S?#K%Y3B* M#^W"/CCKGQ,$=Y:R,ES9+':M8-*S?*T4WEV8"#H=1N3 MEMW'L,_Q/_; _9L_;;_X*I?'+]CCP;J%S\0-)M=&E\/30Z*;MX(GU%%N;N*% MD99GAM'GG4$,O[K<58 J?Z!:* /Y5_CE\8?!_P"U-9?LG_$CP+^VY^TM\>/& M,?Q2\-R?%N+Q_;W)\*^#]:N'A8V%FC6L:17+-'.%\N696B@8[@>*_3?_ (+V M:%J>J_\ !9'_ ()Q7-KHT]S!!\4KMIY([=G2/&I:*V6(&!@ GGTSVK]<(XXX MEVQ1JH+$D*,^?=I;MY M>?(\1+\S 8SR@Y/=1Z5\8_M,?MK_ !J_:!^-/[5OP _X* ?ME_M,>!OB-IVH MZOH7P+_9W^#&D36MAXELW2YBMX[D0VDJWEJZ^29'E>/S87=TD?<%7^CVD,<9 MD$IC7>%(#8Y .,C/X#\J /P7^'']H>'_ /@R+U*UU'P58Z@\NG:I&]EKM[]C M6$-XUF(N5+,F^6+B:*//[R2-%VOG8WF7_!/_ /:!_9$N?VF_V9OB'_P4C_;; M_:'UBU^'EG:6?P&T;XF_!&'P]X?TN\F@MXHM^HV]S<-?HK) 5N&5 1'"TC^6 MK _MC_P5!_X)V_#K_@J-^R'K/[)GQ)\;:MX;MM0O[74-/US1U5Y+.[MWW1NT M3X6:/EE:,D9#9#*P##Y-O/\ @@-^TI^T9X@^'.B?\%*O^"K&O?&GX=_"S6K? M4O#7@'3OA9IWAQ+J:W4)$;NZMYI))QL'EMN!U']HK]D7]LG]JOX\?$'0OAO=0W_CCX MTWDEYI5M9-/;0_8S=7-A;SM<9FW1Q9*;$F8#*BOV&IL444$8BAC5$4855& / MPH _ /\ 8'_;Q\-_\$-/V^/VO_V;OVN_@'\0M7\8?$KXE/KWPOA\)^&6O9_& M,;7-\]O%$<@L)ENHG1AN4,\RMM=-K?27_!GGX6\7^#OV$?C#H/CGPC>:'JEM M^T3J\5[I=["4>VF33-+22(Y R4<,IQW4U^M91&8.4!9?NDCD4M 'YK_\'2O_ M 3^^,W[>/\ P3EMF_9Y\*W>O^+OAOXOA\20>'M.B,EUJ=D+>>WN8;>,N?'VXAM=-UCX:Z M#X61M^J_)',ZRF3>D!&U>>8!E908]Q5 M@I4_S[_&SXO^#?VI7_9*^)'@+]MO]I;X\^+XOBIX;D^+2_$&WN3X5\(:U<20 M,;"R1[6-(KAFCN-HCEF5HH&.X=*_JEI(XXXEVQ1JH+$D*,VD7Q+NVN#]D,D:;=1T=\MP0,;=W/3&>U>=?\'- MOP0\7>#O^"A/[.?[>GCK7OBWX>^#V@://X>\;>/?@G?-;:[X0D,\[B[BG5'^ MS^8MT!N*G>D$L8(9ES^W-% 'X^?\$3_!G_!*KXP_\%%]7_:._9!_;%_:I^._ MQ T;X;W-OJ7CKXU7"-D6C>-[N2!.!:WK">/'H!)G M:/\ =Q7J?@_]O&^CVP>//!$:*\7&\/9-F%W6HJ M_=>Z_O5K_,]O \1YWEUE1KNW9^\ON=[?(^VO!_[3GP7\9;8K7QA%8SM_R[ZH MOV=@?3/^$&UI?A]X MIO<:1J$W^B32-Q:3GW[(W0]@<'C+&OAL[X%AAL+*O@I.7+KRNS=NMFK;=K:^ MI][D7'L\5BHX?'04>;3F5TK]+IWW[WT[6/J^J'B?Q1X:\$^'KSQ;XQU^STK2 M]/@:>_U'4+E88+>-1DN[L0% ]2:OU3\0>'M \6:)=>&O%6AV>I:=?0F&]L-0 MMEFAGC/5'1P593Z$8K\YI\G.N>_+?6V]NMO,_2I\_(^3?I?:_F?E5_P4,_X+ MPZGKWV[X0_L174UC9'=#?_$">$I/..A%E&PS$O\ TV<;^?E5" Y_,O4M3U+6 MM1GU?6-0GN[NZF:6YNKF4R232,237ZZ_MM_\$!/AYX]^V>/_ M -CK6(?"^KMNED\(ZG*S:;V8\X4[X\D >6!FORQ^-7P&^,/[.OC: M;X>?&SX>ZEX=U>')^SW\.%F3./,BD&4F0GHZ%E/K7]?>'&,X'EEJH9&U&=KS M4K>U;[R_F7^&\5TML?RCX@X3C*.8.MG*3:$<[#+$9H_+ /ZI?AO\1? _P 7_A]H?Q6^&7B:UUKP[XDTFWU/0M7LGW0W MEI/&LD4J$\[61E(S@\\XKA?VO_VU_P!E_P#8-^$-U\9,I *3%U?S$PNR3>N%Q@8W_!1[]E+]G#X_? G7_B MC\;/@WH7BK7/AYX#\27/@N\URS%PNDSSV!\R:*-\Q^;F"$K(5+(4!0J M_8'_ &]?@+_P4A_9[M_VF?V;Y-9;PS$_\ !H3_ ,H<-(_[*'KO_HR.OF#]L?\ X)U?M"?\$[_@7?P? MM"_%CX:_\,T>!?VJ?^%UZ/JNGWM]_P )IX@O6#)9^&8+0P>1]HF=BGG"0A 6 MF/RQM'0!^MO[0O\ P4#^"/[._P"TI\+_ -D/5-&\1^)OB)\6+]TT+PUX1L8; MF;3["//GZM?>;-&+>RB"N6DRSMY;B-'*,![G7X>_L=_\%&_A7^Q%\??B]^V5 M_P %$_@W\3_%OQVUQ-%F^-WBCP?X5BO-"^">@ZDZ?V-X@"S1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !7Y\^,[(Z;XPU;3B,&WU*>/'^[ M(P_I7Z#5\,?M!Z2=%^-?B6R*;=^J23@>TN)1_P"AU^B^'=5+&5Z?>*?W.WZG MYOXD4F\%0J]I-?>K_H<=1117ZN?D84444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% 'U=^R3\>/^$WT9?AWXJOQV]R]M<^1("T$Z'#Q2+UCD4\%& 8'J*^ ]"US5?#. MLVWB#0[U[>[M)A+;S(>58?S'J.A'%=%^T[8_$S5/#/\ PWK^Q_X@N=$\9:+; MI%\2- L/GBU*WC7BXDA.5FV*"?F!)C&00T7/YSFG!6%Q6;+V=14HUG:+?P1J M/:,K:QC/925U&6C5FFOUWA3BJ>(P?U:NN:I37SE!=N\H]5U6NZ9]UUQOQQ_9 M\^#'[27@F7X>_&_X>:=XATJ3)2*]B_>6[D8\R&5_9+_P"" MQ_PJ^*?V;P;^T/:6_@[77PB:NCDZ7=-ZEF):V)]')08Y<=*^S[.\L]1M(M0T M^ZCG@GC$D,\,@9)$(R&4C@@CD$5\5F^1<0\(9@H8NG*C43O&2>CMUA-:/Y.Z MZV9]S3K8#-<,XZ3@]&FK_)I_J?C_ /MM_P#! CXF_#?[7X__ &0=6G\7:*FZ M23PK?NJZI:KU(A?A+I0,\?))T 60\U^>.MZ'K7AK5[GP_P"(]'NM/O[.9HKN MQO;=HIH)%."CHP#*P/4$9%?U)5X;^V!_P3O_ &8OVUM(=?BOX*6VUY(=ECXM MT;;!J-O@?*#)@B9!_JL_\ M3/R/BCPBP>+YL1D\O9S_ )'\+_PO5Q]'=?X4?SJT5]:?MM?\$>OVG?V0S=^, M-$TYO''@J#<__"1:':MYUI&.]U; L\.!DEU+Q@=7!.*^2Z_H;*LXRS.\(L3@ M:JJ0?5/;R:W3\FDS\%S/*LQR;%/#XVDZ+8=0QC_ )]%:[S^'DY_"O.SC$+!Y3B*[^Q" MAE.'>+S2A07VYQC]\DC^B*OS[_ ."TO_!.G_@II_P4=T75/@!^SY^U MS\/_ ?\&/$OAFQM?%'A+Q'X8::]NM0M[]KHSI=1PO(B'R[0!59>8FX^8D_H M)17\"']R'PM_P3B_X)T_MQ?!7]CWQC^PO^WW^TYX2\>?#Z]^'=MX+\"V?@G0 M38W.C:8;.ZL[H23M$C3.T4D 1GWD&)CGDY^2?"'_ 0@_P""TOP@_9'\0?\ M!+[X3?\ !0;X0?\ #/\ K\UY;R:AJG@ZZ'B"#3[N9I;F%(UB:,>86Q" M^/+J>>UFU*!7FEO%9[4-);^=/,9MJ;@ HC)*DFNM_;X_9?\ ^"G7QI_9L\&_ M!/\ 9"_;!\&^%]4'AJXT?XJZWXP\*B\_X219;.*!I80(I/L[,PN'.W!_>K@_ M+7U[10!^;/\ P1#_ ."57_!2C_@ELUO\%_BG^UU\/?$WP7MXM0NT\(Z#X;D6 M^_M2X:,K/]JEA5]@VME2Q'/3N/8OB]_P3R^,'[6G_!2WPU^TG^U;XL\-7WP6 M^#UK%??!SX:Z5.-Y0-J/N0F1)/L2B@#\LOV MSO\ @A5^UI\:/C/^T5IG[/W[2?@+0?A3^U=>^&[KXH0>)M O+C7=#DTJ17/] MF&)Q!*)6#D^=MP'VC!7>?TW\!^#='^'/@;1?A[X=$@T_0=)MM.L1,^Y_)@B6 M)-Q[G:HR:UJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD?]MG0#I? MQ@35U7Y-3TN*4M_MH6C(_)%_.OKBO!OV[O"QO/".C>+X8LM8WKV\S =$E7() M]@T8'_ J^KX+Q2PV?TT]IIQ^]77XI'R7&V%>*X>J-;P:E]SL_P &SY@HHHK] MQ/P@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK/@Y\5=4^$GC M&+7[1#/9RCRM3L2?EN(3U&#QN'4'U]B0>3HK'$8>CBJ$J-57C)6:-L-B*V$K MQK4G:47=,\8_X*3?L;Z7\%O$UK\=_@U:B;X=^,93+:?9T^32KMLLUL1_"APQ M0=MK(1\@)X?]EC]OW]H3]E"[BL?!WB/^U/#OF9N/"^L,TEJ03R8N=T#=3E" M3RRMC%?"_%7AG5/V=/C5:K>>#_%41@D$S8^Q3MC;*K'[GS!2&_A=5 M;C!S^?7[67[,GC3]D_XQW_PN\6*T]NI\_1=5$>U-0LV)V2CT;@JR_P +*PY& M"?L>%156<%>+FK^UIK12_Z^0VDUKM);NWZ1A\:L30CC\(^5[2 M2^S+_P"1ENONZ'ZL?LG_ /!2']GO]JF.WT&QU;_A'/%,B@/X:UF95>5^XMY> M%N!UP!A\#)0"OH&OYW(Y)(9%EBJ_P M2>C])6?]YL^IR_B6,K0Q2M_>7ZK_ "^X_6CKUKXS_;;_ ."*O[-?[47VSQK\ M-+>+X?\ C*;=(U_I-H/L%](>?](M1@ D]9(]K9)9A)TKZ,_9_P#VHO@A^TYX M;_X2/X/^.+?4#&@:]TV0^7>69/:6%OF7GC=RIQ\K&O0*_%,'C\_X2S-NC*=" MM'1III^DHO1KR::/7S'*\HX@P7LL73C5IO;R\TUJGYIIG\X?[6'["G[2O[&/ MB+^R/C7X"EAT^68QZ?XCT\F?3;[T\N8 ;6(&?+<(X')7%>/U_49XK\)>%?'? MAV[\(>-O#=CJ^E7\)BOM-U.T2>"X0]5='!5A[$5^;_[;?_!O[X4\3_:_B!^Q M;K<>B7[;I9?!6LW#-9S'J1;7#9: ^B2;DR?O1J,5^_\ "?C+E^/Y$>/P/-B,HDZL/Y'\:].DOP?DS\DZ*Z;XM_!GXJ_ ; MQI<_#OXQ> M2\.ZS:G]Y8ZG;E&9Q-\PXQPRMI!N;\N577_DUC]':***_C$_KP**** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6^-?@T^/OA9K7 MAB*+?--9E[50.3-&0Z#\64#\:ZFBML/7J8:O"M#>+37JG_%O5-*A@V6EU+]LL<# \J0DX'LK;E_X#7#5_1V$ MQ-/&8:%>GM))KYG\TXO#5,%BIT*GQ0;3^04445T'.%%%?G=^V9_P7#\7?LD? MMOZ]^SC$O"0TJ7Q'X@BU61;N&VNX;61YU0(5 0W:(%/WF ^9=W'# MF&98/*Z*JXF7+%NU[-ZV;Z>29WY=EF,S6LZ6&CS22O:Z6ETNOFUH?HC17C_[ M:G[7WA#]CW]E+Q!^T]>VT.L0:=8PMHEC'=A%U.YG=4MXU$?C/\ ![X@:U<^&_ 7Q7\-:WJ-D";RPTC7;>YG@ ."72-RRX/'('-7 M?&WQ!\ _#71QXB^(WC?1_#^GF41"^UO4XK2'>:-\-;;7=#DL MK56EDGDCTU_,^T*Q\Q#]KEQCC&W'3GT;]A[XN?M7?%)/'S_M3:'X!L!HWBN2 MS\,_\(/K4=WNM%W9^T[+B;RY!\N WEORVY%P*XJ&98?$5.2"?Q2C>VEX;W?9 M].YW8C*\1AJ?/-KX82M?6T]K+JUU['O5%<[X.^+WPF^(NI7>C_#[XH>'==O+ M#_C^M=&UN"ZDMN&O#LURNZVAUW7 M;>T:49QE1*ZEA]*[/:TN3GYE;O?0XO8U>?DY7?M;4Z6BN7^)WBGQ-:?!GQ#X MT^$#Z-J.LP^&;N\\,'4KP+I]S=+;N]OYLH90(&<)N<, %).X=:X/]D7XR?%O MQ-^RII/Q=_;!N_!&@Z\PNI-:NO#>MPR:3#"EPZ1O]H$\L0.P+NQ*P#9&0?E$ M/$0C75)IZIRO;2RLM^^II'#3E0=5-:-1M?6[OTWMH>R45\:?'_\ ;\\=>'_^ M"A_P#^ OP4\:^&]8\ _$:UO'UN[L1%>?:&C,JCRKB-R%VE!TSSG-?9=9X;&4 M<7.I&G]AV?K9/3RLT7BL%7PD*+;N&W\<>'(7N?!&MW'63"\P.W4JP 5O8*^"8SG@:M:+K.I^'=6MM=T M6\>WN[299;>:,\HP.0?_ *W>N3%4*TW"MAY\E:F^:$OY9+OWB]I+9IM'K9/F MD\KQ7.US0EI./=?YK=/HS\^?%GA3Q%X%\37_ (-\7:1-I^J:7=O;7]E<+AX9 M48JRGZ$?0]JSZ_1#]O[]G+3/VLOA,W[6WPDT9$\9>'K58O'.C6J?->VZ+Q<* M!RSHH)'=HP5R3$ ?SOK]JX5XCH\299[:W)5@^6I#K":W]8O>+ZI][GVM>E"F MXSIOFA)7B^Z_S6S71FIX+\<>,?ASXDMO&'@+Q/?:/JEF^ZVO].N6BEC/LRD' M!Z$=".#D5]^?LE_\%JG3[-X*_:TTC<.(T\8Z1:\_[US;H.?=XAZ?N^IK\[Z* M7$G!^0<5X?V684DVMIK2Z-L'F&*P,^:E*WET?R_IG]!W@CQYX+^) M?AFV\9?#_P 4V.LZ5>)NMK_3KE98W]1E3P1T(/(/! -:U?@S\ OVG/C;^S-X MF_X2;X/^.+G33(X-Y8,?,M+P#^&6%OE?C(#8##)VD'FOTF_9+_X*^?!?XT_9 MO"'QKC@\$^)),(MQ/-G3+M_]B9N8"?[LO X =B<5_,/%_A#G_#W-B,%?$4%K M>*]^*_O1ZV[QOW:B?:9?Q!A<7:%7W)>>S]'_ )_B?0O[0'[,_P #/VH_!;^ MOCI\.K#7[#YC;/<(5GM'(QYD$RXDA;IRA&>AR.*_*7]MO_@@I\8OA%]K\>_L MIZA<^.?#R;I'\/SJHUBT3KA H"78 _N!9#D 1MR:_9.*6*>)9X)%='4,CHV0 MP/0@]Q3J^2X9XWX@X4J_[)4O3OK3EK!_+[+\XV?>YQ\1\&Y%Q/3_ -JIVJ=) MQTDOGU7E*Z[6/Y:M2TW4=&U"?2=7L)[2[MI6BN;:YB,$AIGB81;;3QAH:K#?1D#"B0XVW"#@;9 M<#.TH3FOR&_;8_X))_M0_L;/=>*9-'_X2_P7"2R^*M!MV86\?K=0[?-' MR!YA/%?TKPGXG9\MT445^D'Y\%%%% "JK,P55)). .M?T=_L"_ B;]FO]CS MP!\'[^T$&H:=H,K MO&'X.].@W76B.1<;1RULY /UVMM/L"QKY2K]$M2TZRU?3Y]*U*W6:WN86BGB<< M.C @@_4&OA'XM_#N_P#A=X^O_"%X&:.&3?9S,/\ 70-RC_EP?0@CM7ZSP#FR MK866!F_>AK'_ O=?)_GY'Y%X@Y0Z.*CCZ:]V>DO\2V?S7Y'-T445^AGYP%? MDS\7OV>+;]JS_@L#^US\!7MTDNM>^ %N-(,F,)?Q0^'9K1B3T GCB)]LU^LU M>2>$/V+O@YX)_; \5?MO:+)JY\:>,/#T6C:NDU\K68MHUM54QQ; 5?%G#DEB M.&XYKQ\XRZ690HT[)Q4[R_P\LHO\SVTTHLEG&^>>;53"V<_O+ MA>A%C5^M?[/'_!.;]F?]F#]H+QK^TO\*]%U&'Q)XZ>4*2"6QL4# &*H^%/^"87[)WAKPS\5_!=_X:U+6](^,VMG5?&6GZUJ M'F)]H\V293;F-4:'9)*74@EE*J=W%?-+AO-)T%[2:]I:<7*_V?9\D/\ -^K/ MJ'Q/E4*\O9TW[.\)*-OM>T]I/_)?X4?!7AK]AK]JS5O$_P "?B?^R[_P3:T? MX2W7@K5M.O;[QWI?QAT[4&U[36$1E:YC01M)YB;F)RY*2.F"&Q7H7[5 M982MO'"F55T5MI8@XP35KNQ\9_\$_/@?\(OV&_U@W,=VDEQ'/+RUK4?,*W);>K0/& MJ-%LL[)Z1]HK12T6BV>FW0U7$F71Q+J2YIJU M%:K67LW>3>KU>ZUWZF#^QW_P3E_87_9\/PX^-WP8\)PV'B=/"RQ6.O0:[,S: MZEQ9AI9)(WD*3%ES*-JC;VPHP/F']I&T_9@_:2_:^^,WA'X'_P#!,Z\^-WC7 M1%CA^(OB_7?B&FC6FE3+;BW1+7SV<#9Y##Y%5B\;XRH#5]1?LF?\$B_V7OV/ M/B?9_%SP%XD\*_$@N;?2(IEVRK;Q1Q1JNY21\V[KGKS4/Q: M_P""/O[*WQ:^.>O?'>;Q-X_\.W?BX >-="\)>+GL--\1+QO6[C1"[*^/F5)$ M!)+8W$D]]?+,95R^%*G0IPM*[BN5Z-E)\RUYKV:C-2:MM[R7-TL?-?_ 2J\1ZWKO\ P0<^*UCJ^IS7$6E:/XQL M]/25RP@@_LSS?+7/1=\LC8]6-?+:32>//V#_ -AW]FCQCKMS8> O'?Q2UV/Q M>8K@Q)*J>((X%W,.%VQW=P03P"P;^&OUU^!O[ OP$_9Z_9J\3?LH?#M=93PG MXK.I?VDEYJ"R7"+?0""98Y @V@( %R"1C)S7&>)?^"1/['OB[]D#0/V+=>TO M7IO#7A:_N+[P]J_]J*-4L;B>:661TF$>PY,SJ5:,H1MRI*JPXJW#^8U,%2I7 M5XTN1ZZ-J<)6VV:BU?S.VCQ%EM/&U:MG:5;G6FJ3A.-]]TY)V\CXU^*_[)7[ M-W[(?_!;G]GGP=^S?HPT6SU6*2^U3P['JTES':3>7<1K*JRN\D?F*@SEL$QY M&.:_6FOD[X+_ /!&7]COX&?$SP?\9O"]QXPOO%G@_4;B]B\0:WXA%S<:I)+$ ML0%V3& ZQHN$6,1@;FSG-?6->YDF K8%5G.$8*<^91B[I+EBK;+JGTL>%GN8 M4<>Z"A.4W"'*Y25FWS2=]WT:ZW"BBBO/\ @I;^QSI'PHUZV_:,^"=HLOP_\82^8([9 M/DTF\?):$@?#?%41M[J* M=N+65L;9%/\ !R%.X?=95<8PL_\)!X71@)/#.LR MLT4:]_L\G+6YZ\+E,G)1J_3;]E;_ (*"?L]_M7VL6F^%/$']D>)"F9_"^L.L M=SD#DQ'.V=>IRAW #+*O2OQ,J2TN[JPNH[ZQN9(9H9 \,T3E61@1_1! M2.B2(8Y$#*PPRL,@CTK\J_V3/^"QGQ:^%'V;P=^T%:W'C/0$PBZH' U2U3UW ML0MR!Z2$.<_ZSC%?I!\#_P!HCX-_M&^%AXN^#WCFSU>V 'VF"-MMQ:,?X)HF MP\9Z]1@XR"1S7\N\5*/^$;^.7P]N+"&64II^MVV9M/O\"OB7X6O/!'Q#\*:?K>CW\7EWNF:I:)/!,OH MR."#Z@]0>17O\)^*V?HM>>;XD34+- MHI+#3HSNGN!N&&!48C895W= "=P-?T5E''7#.=9;4QE"NDJ<7*<9:2BDKN\? MU5TWHF?@.:\%\19/F$,)7HMN9$PT6EV[,D>,\CS)?-<]F58CZ5]]U0\*^%] \$>&- M.\&>%-+BL=+TBQAL].LX!A(((D"1QK[!5 'TJ_7\>\1YU6XASNOF%7>I*Z7: M*TBOE%)']93^;;84445XA[ 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7DG[6_P>;XA>"O M^$JT2UWZMHL;.JHOS3V_5T]R/O#Z,!]ZO6Z*[BO7/VKO@>WPY\4'Q?X?M,:)JTQ(5%^6UG/+ M1^RGEE_$?P\^1U_067X_#YG@X8FB_=DON?5/S1_.N8Y?B,KQD\-65I1?WKHU MY,***_-3_@K#\!_V"K?Q+X_^(O[6?[:_B^W\<7GAPZCX#\$0^(R(M)"VYBMT MM;)$8L);B%RQ)4'2BMN[3^2L:99@H9ABE1E)J_\ ML7-[KHFO5NY^E=%?G9^Q5\5OVP?@M_P0S\5?&3XC7&K2^*M&\/ZO?^!;G70T MUW!I@B7[-.XERS+&QFE0/D>4L?\ !BOCCQ1\,_AAX)_X)K^'/^"C_@3]LWQ MW[0#ZU#>ZC/-X\62ZN)7OV@DM1;LWFEHTVRMG=N5'+ HV!Y&(XD]C1A4C1>M M/VC3DHM1TVT]Y]EIZZGL8?AGVU>=.59:5/9)J+DG+7?5YM(IF ]@7-?GQ_P40U:R_:4_X* MU>"/V(?VB_C#J?A'X21>"SJLEA9ZX--BUB^9+EU,DK?*Q+1+&N[./*<)M:0F MO4Q^91P>%A6C'FRO+:[ULODSRLORR>-Q*+7XT67C;Q-=?M.RZW MJ%^!9Z'#([,^H1RGR8XDMP"@ '[S(^\$ \O_ %EIJG3DZ=G*4HOWMG&48NSM M[S]ZZVO%-]#U?]6*CJ58JI=1C&2]W=2A*:;5_=7N\KW]YI=3]LR0" 2.3Q[T M5\2_L;:+KG[=?[2*_P#!1GXV6LEAX=TZ&XL?V>_!6HN$D@T\DI-KDL)/^NN, M$(Y@L4\92=51M%OW?-=)6Z7Z+M9];+PL=A%@JJI.5Y)>]V3 MZQOUMLWWNM;7911176<84444 %%%% !1110 4444 >A^(?A_X8_;I^ \O[/? MCF\AMO%^APO<^!M=N/O!U7_4N>I4@!7'.5 ;!:,&OS$\:^#/$_P[\6ZCX%\: M:/-I^JZ3=O;7]G.N&BD0X(]".X(X(((R#7Z Z1J^I:#JEOK6CWCV]U:S++;S MQG#(X.014G[>7[.NF_MB_!\_M1_"K1T7QWX8M!%XPT>U3Y]1M47/FJHY9T4% ME[L@9,DQJ*]#A7/?]5LS^JUW;"5Y:/I2JR_*%1[](SUT39]_E&._M?">QF_W M]-:?WX+\Y1_&/H?G-1117[H:A1110 5N?#OXE>/_ (2^*;?QM\-/%]_HFJVI M_C35TUV:>XXRE%W3LS]( M_P!DO_@M1H^K?9O!7[6&DK87!Q&GB[2;/*Y/W% S7WCX7\ M5^&/&^@6WBKP;X@LM5TR]C\RTO\ 3[E9H9E]5=20:_GKKTK]G/\ :W^._P"R MSK_]L_"3QI+;6TL@>^T6[S+8WF/^>D).,XXWKM<#HPK\-XO\%,MS'FQ.2R5& MIOR/^&_3=P_&/1)'TV7\25J-H8EF/J::T^G0&\C@:".[ M,*^:L3,K,@;&0I*J2,X)4'L*^9/V+O\ @J+\*/VI]3L_AQXCTB?PUXUN480Z M:P::UOBB%G,$H'RD*K,4D ( X9\$U]15_-><9)FW#V.>$Q])TZBZ/JMKIK1I MZZIM;H^QP^(P^,I*I2?,OZ^YA1117DG0%%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &=XM\*:'XX\.7?A M;Q'9B>SO(BDJ'J/1E/9@<$'L17Q%\7_A1KWPA\72^'-74R0/E]/O0N%N(L\- M[,.A'8^Q!/W=7,?%CX5^'/BYX4E\-Z]'LD&7LKQ%R]M+CAAZCL5[C\"/J>%^ M(IY)B>2IK2ENNS_F7Z]UZ(^4XJXE:'PONOY7^G9^K/@ZOSU_;X_; M8_8=M_'7C+X1?M:_\$Z_%OB3Q+I\$FEZ!K4OP_MKD:Q;[6:![/4&99H4+R,0 M4^X68KELBOTF^(7P]\3?#+Q--X6\4V1CFB.8I5Y2>/M(A[J?T.0<$$5AU^PX MJD\RPD7AZBY9:W<5--/R;1^,X2JLLQ+--^(?BW6+9-:\2Z_H=S:VGAFT M299)6/F3RQ6Q)4(Q154(74$E@I_;:BO,J\.4ZF I8/G7)!):E+'U<9R/GF^9)2<8W6W-%?%WU:N_4^8OVI?VFKO\ X)C?LY_# M7PUX+^ 'B'XD00OI_A6"UT)VC>WA@M0BRMMBERS"(!4P Q)&X8Y\_P#^"J/Q M%_X)VZ/X]\/^#?VZ/V2?%_C*4:)]LT+Q-H/AV62) TTB-9?:K>XBD$@,8G.FIKD?+:,H*2C;?2ZO?3?:VAYN&S"C0J0JN#YUS< MTHS<92OMK9\MM=EK?4_.?_@B]^RSJ>G_ !^^*7[;T'[/ES\+/"'BJSAT3X;> M#K^U:"Y73$,3/<21N=R[_L]NVXD^8[RL"1AF[S]I :Y_P4E_:HF_8I\()=6O MP@^'M];WGQNU^ -$-?OXVWV^@12#&Y58;YB#\I4C*LB[_MRBL:.2TZ.!CA%+ MW+MST2YKMMK31)O=)?#[O6YO6SNK6Q\L6X^_9*&K?)9))ZZMI;-OXO>Z6/Q3 M^-7PH\10_&WXD>"K#X4^*8_VAG_:+L9_A#JEAH=ZL5GX3A?;:FWN$3[/#9Q0 M!5*[AM79D8C;;^UE%%:99E4NKTNDM-#/-,VEF<*<7&W M(N]^D5IIHO=NEK9MZZA1117K'CA1110 4444 %%%% !1110 5T_PB^*.M?"3 MQG;^*=*)DB_U=]:;L+<0D_,I]^X/8@>XKF**RKT*6*HRI55>,E9KR-L/B*V% MKQK4G:47=/S/+/\ @II^QWHOP\U2W_:A^!UD)/ ?BZ;S+N"VCPND7SDED*C[ MD;MNP.B.&3@; ?D:OU1^"OCKPI<:7J?P.^+]E'?^#/%4+6U_;W)^6W=Q@2 _ MPC(7+#!4JK@@K7P1^V;^RCXK_9%^,EU\/]8,EUI%UNN?#>L,F%O;0GC)' D3 M[KKV(R/E92?NN N)*LG_ &)CYWJTU>G-[U*:[OK.&TNK5I=V?HD*]',\(L;1 M5NDX_P LO_D9;KYKH>2T445^GF(4444 %%%?2?\ P39_8DOOVL?BNNO>++%U M\$>&[A)=B^]W>[/U#!82G@L-&C#I^+ZL****\$Z@HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** .6^+/PC\+?%_PX=#\0P[)H\M8W\:CS+9SW'J#QE>A]B 1 M\:?$[X5^+?A-XA;0?%%E@,2;2[C!,5R@_B0_ED'D=Z^]*Q_''@3PM\1= E\- M^+=+2ZMI.5SP\3=G1NJL/4?0Y!(KZOASBC$9+/V53WJ+W75>Z\UH?G_17I?QO_9I\6_"2>35[%7U+0RWR7\:?- "> M%E4?=]-P^4^Q.*\TK]GP6-PN88=5L/-2B^WY/L_)GXGC<#B\NQ#H8B#C)=_S M7=>:"BBBNHY HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O1]1\ M#^$_VX/@3/\ LV?$2]BMO$VE1-<^!M?G&6BE5>(V/4K@;67^).0-T8-><5J> M"K'Q;J'BFRA\#6US+JJSJ]D+09=74Y#>P'4D\ =>*XL=1E*$:U.?LZE-\\)_ MRR77T>TD]&FTSU\ES&MEV-4HQYHR]V4?YD^GKV\S\]_'_@/Q9\+_ !IJ?P]\ M=:-+I^KZ1=O;7]I,.4=3V/1E(P0PX8$$$@BL>OU+_P""FO["_B+X\_">T^/_ M (=\/6Z?$/P_I:_\)!8:;EQJMJBY8+Q\TL?++U)7<@+82ORTK]CX+XLPG%^3 MK$TVE4C[M2*=^62[=XRWB^JTW3/N\?@IX*MRM/E>JOH[>?FMF@HHKN/V?/V> M_B9^TS\2;3X8_"[1C7 MGE8?>D<\D].@ YW]DS]E+X=?LC?"V#X?>"(!/=S;9=;9^AY-E,< MOI<\]:CW\O)?J(?!&M> M%)+;4'M[5XQ-)']G6-60"4,1YZOM0XR<*?V[_:O_ .36OB5_V(&L_P#I#-7X M ?\ !$3_ ()8_MQ_\%*/^"5K?#"V_P""E=Q\.OV?]:\<7\&O_#;1? =K<7M_ M)%) \Q-]NCEV2,L?R,[QC;S&P^4_F![9^X/["?[>G@C]L7_@GKX._;]UO2U\ M*:/KGA*XUC7[6YF,L>E-:/-%>X<*"\226\Q5MH+( < G%>;^*O\ @LA_P3V^ M-/A.X^$7[-?[?/A*R^(7C?X;Z[K'@'4AIES=+IWV6QO)C?W$;0%8A +66GQQ^UD/@3X8N?B9 MJ7A#X@2MXZOM'BGU2U\NRO[!8[>YD4R6T?V;?&4B*JPEDR#O;(!]F_\ !+C_ M (*/_"C2_P!GCX0?"']K3_@I9X/^+OQ2^*>I:JO@WQ-H^AW-E!KZQ7LD(MX] MUI \3+Y694B9FP &X9OJOQM^V;^S#\.OVF/"?[''C/XOZ=8_$[QQILVH>%? M![13/0Z#/ABM[&\9(^\JQ7C$<<:D/6@#[7^*G_ M 7L_P""0/P5^*]W\$_B-^W5X3M/$>GW[66H6UI;7MY!:7"N4>*6YMH)((V1 M@58-(-A!#8P:U_\ @J%_P5"^$/\ P3P_87O_ -KJU\2^'MZS?L\5RMS"82D*W:%\#X;W1;C4;%+B33YHKGREG@9P3$Z0 MET#K@A"PS@F@#ZY_8?\ ^"['["_[3W[%8_:G^)O[0'@SP??>&?#^FW7Q4TB; M4I5B\-7MYYJQ6N^5%,SN\$JHD8=F*X )QGU?]C?_ (*J?\$^/^"@.N:EX6_9 M#_:@T+QAJVD6WVB_T:*"YLKU(-P4S+;W<44DD09E4R(I52R@D%AG^?#]K[6_ M@_B6.TQ.\*QC66)]QD!PD40.#L7 !^O\ 7R'\5/\ @O9_P2!^"OQ7 MN_@G\1OVZO"=IXCT^_:RU"VM+:]O(+2X5RCQ2W-M!)!&R,"K!I!L((;UX M3@9K^;GX_P#[:/B[]O3_ ()G_M'_ !C^ O[.'['_ ,&?@EIWB&_TZ;0_$6FR MCQ[K-^SQ7*W,)A*0K=RO-&R,R%O,6106$>X@'] 7QI_:T_9P_9Z_9ZN/VL/B M]\7M)TKX<6UE9W;^+XY&NK-[>[DBBMI8VMU7;?:Q']F6=F8)Y)E$F M\A-N[Y:_-[]JN\N[[_@RBT&>]N'E=? ?A&,-(V2$3Q/8(J_0*H ] !7BG_!9 MG]D?]F;]G7_@WY_8S^-OP/\ @?X;\,>,;G7_ ;<7OBG2-+CBU&[FU#PW=W] MV\UR!YLQDN8(I/G8[3&H7:% !^Y'[8__!0C]C'_ ()^^%],\7_MA_'_ $;P M19ZU7_ /!3>;X(/_P=3?L^0_MV-H0^%T?PC8^'AXU,7]B?V@?[8\HS>?\ MN=WVL18W_P 8M\\;:P_^"84_[']S_P '7?QKF_8;/A8^ C\'KKRV\$A!I3:A MOT;[:;;R_P!UM^T>9DQ?NRVXKQ0!^YW3K7R!XI_X+Z_\$=O!GQ;E^"/B+]O? MP7#K\%]]CN#$+J:PAFW%2KW\<+6B8((8F4!<5V_-N QSBOQE^!U]_P $HH/^#377 M[?Q+-\,?^%BR>&=7%Y'=&R_X2-O%G]HS?82 ?])W@?9BFWC[-_L;J /T>_X+ MC?\ !<7P3_P2<^#/A/Q%\.M-\->./'/B[5+:72_"5]JLL*SZ&T' M5WM-$DNH(=29_M2S*FYTVVNW(SG8%Y.#\P?\%3?AGX@A_P"#4+]E'QU\6_!4 M+^--/\1Z1:VNMWVG*;^UT.:VUF2S@$S+YB0-;BR.S(4[8^,@5ZO^VK\)?V / MVD?^#@W]C'X6_"/P7\,/%'PJU7P91V6&(!$W2()#M RY9CRQ)^*?^"0 MW@?]KWX\? ;]ISX,P_%C]D[0O$'B_P =:Q9?&.U_:"L;UO%#/- $EGCECD55 MMTG:Y*%E+1W"RL>JT ?T0_%[]L#]F7X$_LY3?M=_%'XS:-I_PTALK.\/C."9 MKNRDM[N6**VEC:W$AE21YH@K(&!W@].:YW]GK_@HS^Q)^UA\8?$WP$_9Q_:( MT3QAXK\'V,=YXCTW1DFD2TA=E4'SS&(9"&8*RH[,C?*X4@BORP_;6_9NU?\ M9)_X,^_$?P#U7]H'PI\3TT.ZT[[#XO\ ^I_;=*N()?&MM*L5O/_ ,M5B+M& M3QM9&4#"U]^_\$5OV./V7/VK37EE!>3FYN]OG3*9Y&8(S%4PJJ%50 ?7M%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 V6**XB:">)71U*NCKD,#U!'<5X9\9?V,]%\0M-X@^%TD6FWC99]+ MDXMY3_L'_ED?;E>GW:]UHKT:4=%\7Z#;W]N>52=.4/JK#E#[@@UX%\2_P!ANZB,FI_"S7!*O)&F:DV& M'LDHX/L& ]V-?J64<SGW^R_GT^>GF?E&<+/ OC#P+??V=XO\.7>GRY^7[1$0K^ZM]UA[@D5DU]M3J4ZL%. M#33ZK5'PU2G4HS<*D6FMTU9_<%%%%60%%%% !1110 4444 %%%% !112JK.P M1%)). .2: $HKTCX=?LL?%CX@-'=2Z/_9%B^";S5 8R1_LQ_?;VX /K7T)\ M+OV5?AG\.&CU&\M#K.I)@B\OXP41O5(^57ZG<1V-?,YKQ9E&5IQY^>?\L=?O M>R_/R/J,IX0SC-6I!_A/I7]G>$]*"RNH%S?38:><_[3>G^R, > ME=/17Y7G7$V99T^6;Y:?\JV^??\ +LD?K.2<+Y;DBYH+FJ?S/?Y+I\M>[85^ M6'_!6C]A/_A3?BZ7]HOX6Z-M\*Z]=_\ $[LK:/Y-*OG/W@!]V&4\CLKDKP&0 M5^I]9?C7P7X7^(OA+4? OC31H=0TG5K1[:_LYURLL;#!'J#W!'((!!!%=O!7 M%N,X.SN.,I:TWI4C_-'_ #6\7W\FST\RP%/,,,Z!?AMIA::;:^L:S%B](7UE M;:4[;OM':/F]3FRK)Z.71YI:S?7MY+_/J%%%%?FA[)3\0:!HWBK0;[POXBTZ M.[T_4K.6UOK2892:&1"CHWL5)!^M<5^S+^RI^SS^QK\+H_@M^S%\+-.\'>%H MKZ:\31],:0QB>4@R29D9F); ZGL*]!KS'XG_ +;/[&7P1\;1?#3XS_MR!L;=L$\RR'.1C YS0!WWBWPIX=\>>%-3\#^+])BO M])UG3YK'5+"<'9 MA?#N>TOK6?PK:F1K>2&\+FY0EV+D2>:^?F_BXQ7I,4L>"@LCVDL5S(TLP.]B^6=V;.[(."" M,#%_]E7]C;]F#]B'X>W7PJ_91^#.D>"/#]]JLFIWFFZ0K[9[MXXXVF=I&9F8 MI%&O)X" "M[X1_M _ 7]H#3[S5O@/\;O"'C:UTZ80ZA<^$?$MKJ4=M(#5;P_^TY^S9XL^*]]\!_"O[0O@?4_'.F!SJ7@S3_%EG-JUH$^^ M9;1)#-'M[[E&.] 'A.M_\$-?^"2?B3XN:Y\8V\ MS7*NLTJVOF?9XI6WN?-2-9 QW!@W->Z^#OV:?@)X!_9_@_96\+?"K2(/AU;Z M#)HJ>#YK?S[)M/D5DDMG24MYD;*[!@V M'-#\1^-+F6W\(:#JVM06]YK4L2AI$M878/.4#*6" XW#/45U5 'R[\._^"*W M_!*_X5?"_P 8?!CP5^Q/X/A\,>/9[6;Q7I%]'/>I>R6QE-NX:YDD:%HC/*4, M10H9"5Q5S]D__@CQ_P $T?V'?B+_ ,+<_9<_9)\/^%_$ZP2PPZ\+J[O;JWCE M!618I+N:4PAE)4[-N5)7H<5]+44 %?*.M_\ !#7_ ())^)/BYKGQRUW]A+P1 M=>)/$:70UBYFMYC;S-Y\U(UD#'<&#2^(/V$_V M1O%7[*,7[#?B'X&:1=?":"RMK2'P1(TOV18;>X2XA0$/O^6:-'!W9RO)-0_& M?]@3]CK]H;X%>%OV9?C3\ ]%\0> _!,UC+X5\,WOFBWTU[.V>UMC'L<-^[@D M>, D_*QSFO8** /&?VQ/^">O[%W[?_A_2_#7[8/[/FB>.+?0YWET:;4#-#[[XN-\;[K]@/P(VO->_:W7[/.-/:;=NW'3Q+]C(SSM\G'M7 MUU10!PWQ_P#V:?@)^U-\'[_X!?M"?"K2/%?@[4TC6[T#4[?,)\M@T;)M(:-D M905="K*1P17DGP+_ ."/G_!-/]FGQCX1^(7P._9(\.Z!KO@1KI_"FK03W4MQ M8-*KZ42ZCK-O-=V$E](!CS+@6DT2W#D8!>0,QP,DX%?4]% 'D_B?] MA;]D/QA^RNO[$6O? 'P_)\)TM8+=/ L%LT%BL<-RMU& L3*P(G19<@Y+Y))) M.?0O 7@7PC\+_ VB_#3P!H4.EZ#X=TFVTS1-,ML^7:6EO$L4,*9).U(T51DG M@5K44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %?5-)TK6[)]-U MG3;>[MY!B2"ZA61&^JL"#7E_C7]C?X1>*"]SHMO-\@#V4K M7K%%=V#S+'Y?+FPU5Q]'I\UL_F<.-RS+\QCRXFDI^JU^3W7R9\I>*_V'/B3I M):7PKK>GZM$/NHS&WE/_ %LK_X_7GGB'X)_%KPJS?VW\/=4C5/O316IEC'_ M ./A*5-^O,OQU_$_.B2. M2)S'*A5E.&5A@@TE?H9JOA[0-=3R];T.SO%Q]VZMDD'_ (\#7/:A\!O@SJ9+ M7/PST<$]3!9+%_Z!BOT)+T:?YI'@UO#?%I_NL1%^J:_)L^%**^V M)_V6?@)<9,GP]A&?^>=[<+_Z#(*B3]D_]G^-MR_#\9_VM3NC_.6NM>(63VUI MU/NC_P#)'&_#K.KZ5*?WR_\ D3XLHK[?M/V:_@99$&'XSR2?^A,: MV],^%WPUT4AM)^'^BV[+T>+3(@WY['&8M_O*T% MZ)O]$?">B^%_$OB.7R?#WAZ^OWSC;9VCRG_QT&NZ\,_LG_&_Q*5=O"JZ=$W_ M "VU.X6+'U09?_QVOL](TB01QH%4# 51@"EKQ\3XAXZ:M0HQCZMR_P#D3V<+ MXO!_[!VG0LEQX\\;2S?WK72X0@_P"_CY)'_ 17KG@? MX+?#'X=A7\*^$+6&=?\ E\E7S9O^^WR1]!@>U=317RN/S_.,R35>LVNRT7W* MR?S/K^);ZY^*'QPU+P8]_H^GW<]Y M*D-O%?27D3;Q%LED:)?-,DK@%]JJO](7[6?P*M?VH?V6OB1^S9>ZF+&/Q_X% MU;P\;XJ6^S&\LY;<2X'789 V/]FOPLT7X'?\%N;/_@D]=_\ !O\ 3_\ !+6_ MGNI-=>PM_C)/XJMAH4.E-K0U4S;BNQB)-P5O,WB,C]UYB[" ?OE\(O%GPZ\> M_"CPQXX^$&K6U_X3UGP_9WOAB^LRWDW&GRP(]O(F[G:T3(1GG!YK\_\ _@NS M\:?B1^T1XL^'O_!$C]EKQ!):>./CY-Y_Q&UJT^8^&?!$+DWMQ)C&TW CDC4$ MXD6*6(X,J9ZO]I"+_@I)_P $P/\ @F[\"O@/_P $S_V=M#^-7B_PC;:-X5\4 MIK44IB%E;Z>R2W<<:75NR!YXU 9G98U?YE/44_VT/^#?[X9_ME?MA:Q^W!;_ M +9_QJ^%_C'Q!X?LM)U&+X;^)(;&-;>"*-!$L@A\THQB1V4L5+KNP., 'S/_ M ,&GGPUT'X2?$3]MGX/_ _,MKI?ACXQQ:-HAN'\UX;>VFU2"'<3]\A47)/4 MBOE3X&_ SXK_ +&5A^S[X@_:*_8Q\;_#7Q9^S3\:/$?C;]H;]H+7?"@M]+UO M0VN-ZQ6VKY_XF\MVC):Q0(SLTC*H&)":^MO^#=?_ () ?M-_L9?MC?'?XW?M M Z_\4="T^P\6WFE>#['6M]C0L;B=56)UE.WYKASZ@?0W M[1?[.OQX_P""JO\ P46L?A+\=_A5KGAK]E?X"ZC;ZOH7Z2"4Y D=)QL $[1K^LU?@= M^UG_ ,$P?V\?&OQ$_:0_9*\.?L6:QK.M?&_]J*Q\?> _V@(9K#^RO#^@"X:4 MK- GRAPHIC 20 ensg-20221231_g6.jpg PERFORMANCE GRAPH begin 644 ensg-20221231_g6.jpg M_]C_X 02D9)1@ ! @$ 8 !@ #_[@ .061O8F4 90 !_]L 0P " 0$! M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D* M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\ $0@" MO 7< P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IZ_P"(O#_A/2)_$'BG M7;/3;"V7=&WN'ACN6" %%E";U!'0C!8 _$%QX3\<_M!^!]&U6T*B[TS5O%EG;7$)*A@'CDD#+E2",CD$'O7F_P"R M7X;_ .">)],FT/5M6^'$^KPV]LNGQB5 MA*EO((UW;2>><=\4 ?H7X,\=>"/B/H,?BKX>>,=*U[2YG9(=2T;4(KJW=E.U M@)(F920000#P17.1_M-_LX2^/_\ A5$7Q^\%MXG^T>1_PCR^*+0WOG9QY7D^ M9OWY_@QN]J\ _:<^.OP4^$?_ 2O\:_&#]A^]T"P\/G2OL^@W/@^V2UAMKB\ MNXK621415,4R-.6((#JR@D BLCXG_P#!.?\ 9ET'_@FMJOA#2_A)H47B'1OA MS)JMMXK338QJ3:M!:&X^TM= >:2TR\C=C8Q0 +@ ^PO$'B+P_X2T6Y\2>*M M=L],TZSB,EY?ZA=)#! @ZL[N0JCW) KG_AE\>?@?\:A],&3@;Q$[;<]B>O:O@V#Q_J7[<6K?L=_ CXO7&\T\<"N_\ VT/A1\-_V4_VJ?V=OC_\"/ VD^$K MO5_B/;^#?$<'AW3X[.#4;"_ 0+-%$%1_+"N5)&<[?[B;0#[?HHHH **XSXS? M$WQ?\,M,LK_PA\'=:\8R74[1S6VBR1JUNH7(=MY'!/'%>??\-8?&S_HQ_P = M_P#@5;?_ !5 'NE%8-CXMUR[L8;J?P-?P/+$KO"[KNC)&2I]QTJ;_A)=7_Z% M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK' M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)= M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A) M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0 MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%" M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@# M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[ MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_ M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$ MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z% M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK' M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)= M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A) M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0 MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%" M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@# M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[ MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_ M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$ MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z% M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK' M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)= M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A) M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0 MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%" M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@# M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[ MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_ M[Z6I+/7M2N;I()O#-U"K-AI79<+[F@#4HHHH **** "BBB@ KQ[]HS]N'X'? MLI>+--\._'>/Q#I&F:K8-<0>*H_#EQ=Z6CARAMY)8%=DEX#8*8VL#FO8:Y+X M\?!_0_V@/@YXC^"OB;5[^PT_Q-IW>F.BSQQOPVPNK+DCCE3P30!\5_") M_A/^T3_P4[\&?M#?L)^!+RQ\'Z-X=U./XG^,K+P_-I>EZTTT++;VZI+''Y\P ME*.S;L^'=0N+'4M#U7P]>ITU2+:PM([:W#'D(BA5SCV J2 MXTS3;NYBO;K3X)9H#F"62)6:,_[)(R/PH _./X4_LE?%+XR?\$WOVB;+0/AO M?^';;XI^-[[Q1\./!=[;>1/'9Q7$%U;((>!$TOV=8U7@$*A'RL#76^,O^"H/ MP4^(G[#MS\(O!DVJW_QB\0^#&\,1_#B#0KHZC#K$ML;6564Q[0D;EY-Q(RJX MX8[1][5 FF:;'?-JD>GP+_LK? MM"^+='NKSP]\,O#ESX:^)UWIEL]P-,%[:X-T1&"QA2>63_;V1 M_P#053_\#C_F8?6<-_.OO1]845\G_P##\/\ X)=?]'/?^65K?_R%7UA77A 55//D<>Q5" M>G'6O%QG$628#2M7BGV3YG]T;O\ YZF*P]+XI(_&FBBBOYM/DPK^L"OY/Z_ MK K]6\,?^8O_ +A_^WGM9/\ ;^7ZA1117ZL>T%%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 445X/^UW^UCX\^#GC_P)^SY\"?AS8>)OB'\1IKP: M)!K6HM:Z?8V]K%YL]S<.H+L N<(F"VUN<@*P![Q17S'^P5\-OVT_@#?:E\)/ MVA/!G@_4="U*]U/7U\:^%?$<\Q2_NKL3-:26]S''(01+)M=1M418;)8&NP_; MA_:HUO\ 9H^'^F67PS\-6OB#X@>+M3&G>"_#UVS>5/(H\RXN)MA#"""$,[L" M,94$C=D 'ME%?/7[/7[7OCKXM?\ !.4?MD>(O#>DP:^/"&M:LVF62RK9F6R> MZ5$ 9V<*WV=<_,3\QP>E/C5\-O#/Q<\/^"_V>X=%\3Z3:ZG: M1W=WK27"6\Z+(H95+*KA6Y )&>YH ^Q**\._;-_:K\6? 2;P;\+?@WX'M/$O MQ'^(^L2:?X1TG4;EH;2)8D#W%Y3$C*6"X8YX(P:X3PO^U7^UQ\#/VC? M!?P(_;>\*> 9]-^)#SVOA3Q=\/&O(X+?4(U#?9+F*[+-E]RJC+C)9>OS[ #Z MLHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH ***1W2)#)(X55&69C@ >M "T5XE\9? M^"D'[#/P#\V'XE_M-^%H+J#(ETW3+[^T+M".S06@DD4_517R=\9/^#DO]FCP MN9;#X(_!CQ3XNN5R([G4Y8M+M7/8J?WTI'L8U->/C.(,ER_^/7BGVO=_ILLL5O$T\\JHB*6=W; 4#J2>PK\EO\ AX;_ ,%QOVP?W'[, MG[+[>$M+N>+75;;PQM5E/K>:HWV=CCNJKBG1?\$9O^"GW[5LJZA^V?\ MGBQ MLIF#/I<^LW6L/!W(%LK16J?\ DQ7E_ZT5,5I@,)4J^;7)'_P*7^1C]<<_P"% M!O\ !?>?>OQF_P""E_["'P$\V'XB_M.>&%NX M_*OD_P",7_!R=^SOX>>33O@7\#?%'BRY!VQW.L7$6F6SGL5QYTK#V*(3TXZU MUOP:_P"#=O\ 8?\ /E7OQ0UCQ5XZNEQYT-_J?V&S8CTCM0LH^AF:OK#X._L M@_LN?L_)&?@S\ ?"GAZ>(86_L-&B%V?]ZX8&5O\ @3&CDXQQN\J>'CY)SE^/ MNA;'U.JC^+_R/S;_ .&]O^"ZW[8?[G]G']FE_!NE7/%MJ=MX8$*LA[_;-5;R M6./XHU4CMS3[?_@BI_P4G_:FN$U3]M/]M3[-:RN';39-6N]:D@[D"#=%;Q_\ M 3ERQ_\!C:WWA]2C/\ BRRO]^_XF M].A1I?#%(_GO_P"''G_!47_HV'_R]=$_^3:/^''G_!47_HV'_P O71/_ )-K M^A"BOD?^(;Y'_P _*GWQ_P#D#A_LG#=W^'^1_/?_ ,.//^"HO_1L/_EZZ)_\ MFU_0A117T.1<-X'A[VGU>4GSVOS-/X;VM9+NSJPV$IX6_(WKW"BBBOH#J"BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\4_;!_8OTC]J9O#7C'0 M?B3J_@?QUX(NY;GP?XRT15>2S:5566.2)B!-$X5F,[6=6]KKYQ_X*!^ M?VC-.\$ZC^T7^S'\>_&&@^(O"OAR80^#]'T:+5;/72'+JALY$;$Q+%?-4,P7 M''% '+?!S]IC]K?X)?M6>&?V-OVT4\-^)1XVTZ\G\$?$+PO;M:M=R6L32RQ7 M=L<*C[%ZQA5!9 -^XE?$/ G_ 4 _8]^(WQY^)7[3WQY^-UCI>IVVG7OA/X5 M^&+NQNI'T[2U5A+>-LB9%GNY>>NY(UV$D'CZ8_9U_8G\5Z5\5-(_:L_:C^.F ML_$7XA66A&UT8WNDV^FV.@)/'^^2"U@&T2$,T9D)R5)R,\CWCQ'X.T7Q!H-_ MHK6%M$;ZTE@,WV56*;U*[L<9QG/6@#XR_P""2_C+X1_M$?\ !-.+]E/0_'Z' M7K'PMJFF>*K2WMW\[2TU"ZOA%)\ZA')1BP"DCC!Q4/QA^"O[9W_!/']FD_%/ MX+?MJ7'B;0OAQI%N)? WBWPA9"TNM.A*1^4DT0$L95,8PVYL8W GGW?X$_L= MZ]\!/V*M/_91\&_&R[L=8TVQGBM?'>E:/'#/'*]Y)?>-/V"?VK?V@=)3X9_M6?MW2>(O ;7,4FK:#X:\!VVCW&M+&X=8Y[A)', M:;E!*HN#[$ @ Y/Q=\1;;XH_\%)_V4/BS-8/9V/BSX7:QJ.DVUPV3#-<::T[ M1Y[L(W53ZUT7_!4U?M?Q%_9ETS3N=2?]H/1IK=5^\(8VS,W^Z 4)]J]._:I_ M8H\/_M!>%_!P\ ^-KGP#XI^'%\EWX \3:39)/_99"*AA:!R%E@98XPT>1GRU MR2,JW/\ PL_8D^*=Y\=M$_:-_:\_:,_X6+KOA&UGA\%Z78>&HM+T[27G7;-< M^6CN9IF4 !FQMXX)5"H!]'T444 <9\9M$^.6MZ991? [QOHNAW:3L;Z76M,: MY66/;PJ@$;3GG->??\(#_P %!/\ HO\ X$_\)23_ .*KW2B@#!L=/^(4=C#' MJ'B"PDN%B43R):$*SX^8@9X&9,/QA%>1C, M^R;+[JO7BGVO=_FLVOAJ2?&>F;W4"+0_ M]\#UI1_P2/\ ^"M?[6Y%U^V)^V&-'TVY_P!?H]SK\^HF+/7%G;%+0?\ 9!7 ME?ZTRQ6F7X2I5\[A#,9)?SB%=7\&O^#1KSCIFX?=*WXL:]EHKV,'DF49?_ +O0C%][:_>[ MO\3>GAZ%+X8I&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q17J&QC_8O M&_\ T&[+_P !C_C1]B\;_P#0;LO_ &/^-;%% &/]B\;_P#0;LO_ &/^-'V M+QO_ -!NR_\ 8_XUL44 8_V+QO_ -!NR_\ 8_XT?8O&_\ T&[+_P !C_C6 MQ10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_ &/^-;%% &/]B\;_P#0;LO_ M &/^-'V+QO_ -!NR_\ 8_XUL44 8_V+QO_ -!NR_\ 8_XT?8O&_\ T&[+ M_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_ &/^-;%% &/]B\; M_P#0;LO_ &/^-'V+QO_ -!NR_\ 8_XUL44 8_V+QO_ -!NR_\ 8_XT?8O M&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_ &/^-;% M% &/]B\;_P#0;LO_ &/^-26=IXM2Z1[[5K5X@W[Q$MR"1[&M2B@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBOD_P#X+A_\HNOB?_W!?_3W85R8_%?4<#5Q-K\D92MM?E3= MKZVO;L15G[.G*?9-GUA17\G]%?FG_$3O^H3_ ,J?_:'D?VQ_<_'_ (!_6!17 M\Y/_ 2=^,7PT^ /[?W@/XN_&#Q7#H?AS1TU9M2U2XB=UA$FDWD2?+&K,Q:2 M1% ))85^F'QF_X.-/V-_!'FV7PC\$^+/'%TF?*N%M5TVSD_[:3DS#_OS7T> M5<;97C<#+$8IQHM2:Y7+F;22=[))];;=-SKHYA1J4W*?NZ[7N?H-17Y*'_@K M3_P5R_:X)MOV/?V/_P"QM-N3_H^L6WA^?4#'GIF\NMEI_P!]1BC_ (=>?\%F M/VO/W_[6?[6A\.Z9<_\ 'UHUUXDDN<9ZXLK#;:'_ +['I6_^M2Q.F7X6I6\^ M7EC_ .!2_P BOKO/_"@Y?@OO9^B'QE_;Q_8V_9^\V+XN?M(^$]*NH,^;IJZH MMS>+C_IV@WS?^.5\G?&7_@X[_9"\%^;9?!_X>>+/&UTF?+GDA33+.3T_>2[I MA^,-1_!K_@W _9+\&^5>_&/XF>*_&ERF/,MX'CTNSD]/SG M)?\ MH?[?4[1_%_Y'YY_\/4_^"Q/[7?^C_LB?LC_ -@Z9<_\>NLVOAR6\V9Z M9O;W;:?G&._:@?\ !*7_ (+!?M=?Z1^UY^UW_86F7/\ Q\Z-=>(IKW9GKBSL M]MI^4@_*OUKHH_U5^LZX_%5*WE?EC_X#'_,/J7/_ !9N7X+[D?GK\&O^#<;] MC_P5Y5[\7_B!XL\;728\V!9TTRSD]?W<.Z8?A-7UC\&OV$_V.OV??*E^$7[. M'A/2;F#'E:D=*2XO%Q_T\S[YC_WW7K-%>M@\BR?+[/#T(Q?>UW][N_Q-J>&H M4OAB@HHHKUC<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***IZ_XB\/\ MA/2)_$'BG7;/3;"V7='[;Q9X( M\3:?K.E7BEK34]*O8[BWG 8J2DD9*L P(.#U!':N7C_:;_9PE\?_ /"J(OC] MX+;Q/]H\C_A'E\46AO?.SCRO)\S?OS_!C=[4 =Q15/Q!XB\/^$M%N?$GBK7; M/3-.LXC)>7^H720P0(.K.[D*H]R0*Y_X9?'GX'_&H7)^#WQA\+^*OL1 O!X= MUZWO3!DX&\1.VW/8GKVH ZRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **Y?XG? M&[X-?!73/[9^+_Q6\.^%[4J62;7]9AM X_V?,8;C[#)-?*/QI_X+Y_\ !/OX M5^;9^$_%6N>.;V/*^3X7T9A$']YKHPH5_P!I-_MFN#&9KEN7K_::T8>3:O\ M=NS*I6I4OCDD?:U%?D[K'_!>/]M?]HO4IO#/[$7[$[S.7\L74MG=ZY.@_OE; M=8HX3W^?>H[YJK_PR+_P7V_;-_>_&_X[2^ =&NN9+&X\0QZ>K1'^$VNE*2_^ M[-@\,6H_.4K6^XY_KL)?PHN7HM/O9^EOQB_:K_9K_ M &?H'E^-7QT\+>&I%7<+35-9BCN7'7Y(-WF/]%4U^='_ 5B_P""PO[&W[0G M[)OB_P#9C^"&KZ_XAU7Q"]@+?6(M%:VL(1;ZA;7+EFN#'*G0NYY(=Y#/)(/\ :!0GKQ6E M_P %._\ @G9^Q?\ LK_\$S_B-XD^"?P#T;3=9M$T=;?7[OS+R_BWZQ8HY2>X M9WC+(S*=A4%6(Q@XKSLVK<5XO*J\ITJ=&GR3NFW.;7*[I->[JC*O+&SHR;2B MK/S>WW'XLT445^('SI[W_P $P_@!\-_VHOVY? WP+^+EA3J M5YIPO;Q,>EQ]E5.FZ+DUK?]$ 4!5& .@%%%%?I1ZP4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?%'_!5O2X]-^+/P M8^*GQJ^'FJ^+/@EX:U749/B#I&G6CW,-O<20*EI=W4"_ZR&-\GG( #J2[UV:T$J$$(-!CMYM/N+ M+6)[EXCN MY=3T'Q%X6O/$WCNSGD)77+G3[5HX//'\:F:&1G4\-YIXX%=_^VA\*/AO^RG^ MU3^SM\?_ ($>!M)\)7>K_$>W\&^(X/#NGQV<&HV%^ @6:*(*C^6%^&7ARY\-?$Z[TRV>X&F"]M<&Z(C! M8PI/+.2P'\* 9+@5TOQ=^-7P[_X*-?M4_!7X<_LPZM-XG\.?#SQG'XS\<^*+ M:PFCL=/-J UI;>9(B[Y97W#8,X!!Y ?: ?<]%%% ',_$SXR_"[X-V-KJ?Q0\ M:V6B6][,8K66]<@2.!DJ, \XYKCO^&Y_V1_^B]:#_P!_G_\ B:]*UGPYX>\1 MQ)!XAT&ROTC;=&E[:I*$/J P.#6?_P *N^&?_1.]"_\ !1#_ /$T 3VGCOPA M?6L=[::_;O%-&KQ.&.&4C(/Y5)_PF/AC_H-0?]]5;CTK3(HUBBTZ!54 *JPJ M .PXI?[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^ M?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_ F/AC_H-0?]]5<_ ML[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_ F/AC_H-0?]]4?\)CX8_P"@U!_W MU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0 M?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H- M0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"@"G_ ,)CX8_Z#4'_ 'U1_P ) MCX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5' M_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0? M]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0 M?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/ M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ M"8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@" MG_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0 MH I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ MOT* *?\ PF/AC_H-0?\ ?5'_ F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ M^?&'_OT* *?_ F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[. MT_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C M^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA_P"_ M0H_L[3_^?&'_ +]"@"G_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?57/[.T_P#Y M\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3 M_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[ M.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5 MS^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U M!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ M *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8 M^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_" M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ M?5'_ F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_ F/AC_H M-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8 M_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8 M^&/^@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"@"G_ M ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[] M"@"G_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?& M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ MGQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T_ M_GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT* M/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8? M^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"? M&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^ M?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_ F/AC_H-0?]]5<_ ML[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_ F/AC_H-0?]]4?\)CX8_P"@U!_W MU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0 M?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H- M0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"@"G_ ,)CX8_Z#4'_ 'U1_P ) MCX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5' M_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0? M]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0 M?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/ M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ M"8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@" MG_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0 MH I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ MOT* *?\ PF/AC_H-0?\ ?5'_ F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ M^?&'_OT* *?_ F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[. MT_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C M^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA_P"_ M0H_L[3_^?&'_ +]"@"G_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?57/[.T_P#Y M\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3 M_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?5.UF MZ\+>'=-EUKQ!<:?8V=NNZ>[O'2**-?5F; ^IKYR^-/_ 5N_P"""CS8BI&"\VE^9$ZE.FKR M:1]%_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU7YC_ !-_X.--!UW5/^$5_94_ M9#U37;ZX8I97'B.=4=V[8M+196DSZ"537+_\)7_P<(_MH\>'O S_ QT.Z^\ MR:9!H*Q*>C!KHO?8QW0GU]*^?GQ?EDY.&$C.O+M"+?XNR^>IRO'46[03D_)' MZF>+/C-\)O 6DOK_ (Y^(^BZ+8Q_?O=6U&.VA7ZO(0H_.OFWXS?\%P?^"=?P M?66VMOC!/XNOHLYL?!NER7>[_=G?R[<_A+7S!X(_X-V/BU\3-83QA^V1^V3= M:I?O_P ?,.C)/J$[YY/^F7K C\86KZB^"W_!$3_@G9\&O*NIO@Y+XNOHL8OO M&FHO>;O]Z!=EN?QBJ/KG%N._@X>%&/>I+F?W1V?DP]ICJGPQ4?5W_(^6_'7_ M <4_%KXDZL_A+]CO]CFXU&^;BVGUN2?4)GSP";.R52/^_S5S;Z9_P %^_VS M6(\2_$D_#+1+KA5;4X="6)3U4K:![[&.S@^GK7ZQ^$/AM\.OA]HZ>'O 7@'1 M=$L(_P#5V.D:5#;0K]$C4*/RK4_L[3_^?&'_ +]"G_J[F&+UQ^.G)?RPM3CZ M.U[H/JM6?\6HWZ:(_*_X8_\ !O5X&UO5/^$J_:I_;&U/7;ZX8/?6_ARUV.[= M\W=V96DSZF)37U;\%O\ @EI_P3,^!WE76A? [0]:OHL$ZAXND?5'9AT;R[@M M$I]T1:^H_P"SM/\ ^?&'_OT*/[.T_P#Y\8?^_0KOP?#.18%WI4(W[R]Y_?*_ MX&E/"8:GM%?G^9DZ/K'@#P]IL.C:!+I]C9VZ;8+2SA6**-?154 ?05:_P"$ MQ\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A7N))*R.DI_\)CX8_P"@ MU!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT*8%/_A,?#'_ M $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ M .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^ MA0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/ M_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/ MC#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9V MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ MSXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9V MG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J# M_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0 M:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ M $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q M\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ M +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,? M]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\, M?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A, M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A M0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C# M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ M\^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG M_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A M1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZI]MXH\/WDZVMKJL3R.<(BGDFK M/]G:?_SXP_\ ?H4J6-E&P>.SB5AT*Q@$4 2T444 %%%% !1110 5R7QX^#^A M_M ?!SQ'\%?$VKW]AI_B;2Y+"]N],=%GCC?AMA=67)''*G@FNMHH J:#HMEX M;T*R\/::I%M86D=M;ACR$10JYQ[ 5;HHH 155%"(H P !TJ%-,TV.^;5(]/ M@6Y=-KW(B D9?0MC)'M4]% ",JNI1U!!&"".M16.G:?I=N+33+&&VB!)$4$0 M1$_&G_@IS^P;\ _.@^(/[3/AMKR'(?3=$N3J=RK?W&CM M!(R'_?VCUP*^#8?^"-W_ 5$_:SE74/VTOVRO[.L9F#2:5/K-SJ[PGJ<6L;1 M6J?\ DQ7NWP6_P"#>']AOX>^5>_$[4/%'CR[7!ECU+4_L5HQ']V*U"2 >S2M M67]J<38W_=<&J:_FJR_]MCJ+VV+J?!3MYR?Z(X;XP_\ !R=\%-+G;1_V>_V? M?$GBF[=O+@NM=NH].A=R< HD8GDD'3Y2(R?:N _X:U_X+\?MG?NO@G\"Y? & MC77"7MOX>CTY6B/\0NM58LW^]#@\<#M7Z6_![]E;]FS]GZ!8?@M\#/"WAIU7 M:;K2M&BCN''3YYMOF.<=V8FN_H_L3/,9_ON.DE_+22A_Y-N_F@^KXBI_$J?) M:?B?D[HW_!!K]M+]HG4X?$W[;O[;#SN6\PVL-W=ZY.@/\ >Y>*.$]OD#J.P- M?1WP6_X('?\ !/KX5>3>>*O">N>.;V/#>?XIUEA%O]H;40H5_P!EP_OGK7VI M173A>$\APTN=T>>7>;U*A7AT#1H;0.!_>\I1N/N,*]?"\.5ZM&;C)GYH^3_P#A^'_P5%_Z M.>_\LK1/_D*C_A^'_P %1?\ HY[_ ,LK1/\ Y"KY/HK\._M[//\ H*J?^!R_ MS/G/K.)_G?WL_;C_ ((0?MQ?M1_MF?\ "U/^&D_B?_PDG_"-_P!A_P!B_P#$ MELK/[/\ :/[0\[_CUABW[O(B^]G&WC&3G[+^,'[4O[-_[/\ ;M/\:?CCX7\- M,J;A:ZMK4,5Q(.OR0EO,<^RJ37X3?\$ROV3?VT/VM?\ A-O!_P"RM\<_^$(T M>U_LT^-IF\17=BEVLGVK[,I2U5FGQLN,*V%&[DC-?<_P?_X-L/@SIMPNL_M# M?M"^)/%%V[^9/:Z#:1Z?$[GDAY)3/)(/]H>63[5^H<.YQQ'B,GI0H8=U'[UZ ME2>C]Y]_>=MOE8]G"U\5.@E&-_-OS^\[WXT_\'#?[#/P\\VR^&=GXG\>7:Y$ M4FEZ7]BM"P[-+=E) /=8FKPB?_@LO_P4]_:RF?3?V*_V-/L%E,Q5-5@T>YUA MX#T!:Y=8K5/^!QXS7W?\%O\ @F%^P5\ _)N/ '[,WAM[R'!34M=MCJ=RK?WU MDNS(4/\ N;1Z8%>\000VT*6UM"L<<:A8XT4!5 X '05[?\ 9?$V-_WK&*FO MY:4?_;I:HZ/8XRI\=2WDE^K/R5/_ 3:_P""U_[8W[_]JS]J5O"VE77-WH]U MXD+C!]+'30+5CCLSJ1T]:]9^"_\ P;??LH>#?*O?C1\4/%7C6Z3'F6]J8]+L MY/7*1^9-^4PK]$Z*UH\(9+"?M*T75GWJ22YGYNYY)\%OV#? MV-_V>?)E^$'[.'A72;J#'E:F^F+9]\W_C]>MT45]#1P]##0Y*,%%= MDDE^!U1C&"M%6"BBBMB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ KS;]I']J_P"#O[*^B:9J7Q/U&_EO==O#:>'M T339+W4 M=6G !,=O!&"7(!7).%&Y03EE!])KYE_;K_9Y_: \2?%OX9?M;_LPZ=I&M^*_ MAA-J"/X1URZ$$6KVEY"(I5BE.%BF"[@"Q ^<'/R!6 &_L%?MG>+?C/?:E\)? MC_X2\8>'/'YO=3U;3M*\5>"9M*#Z*+L+;B-BBK(8XY8%;/S$MG+8+5J?%C_@ MH_\ #SX;^+=>\*^&/@)\6/':>%+AX/%&K^"/!375CIDJ#,D;S2R1AW0*8 4OH5!+R6=RN% MN% #'.U_M"7VGZG' M'+8ZE:_#$RV\T3X*RK(DY#(000PR".17,?\ !/;X:>"/$G_!*OQ!\+?@;\0; M?Q1JVO:1KUKJTK6S62VVMW5NZM:-%( T(CWQ+E@-PPX # "AX/\ VD_VQO\ M@GW^SAX2TO\ :)_8PM[KP)X+T'3])UKQ1X3\7Q0!]0_M)?M.?"G]E7P)%X[^*=_>%;V_CL-'TG2;-KF^U6\DSLMK:%>9)# M@]P!CDBN&^"/_!0CX9?%WXM0? CQ5\+?'_PX\7ZA8O>:)HGQ&\.#3Y-6@0%G M:W99)%??\-8?&S_HQ_P =_P#@5;?_ !5 'NE%8-CXMUR[L8;J?P-?P/+$ MKO"[KNC)&2I]QTJ;_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[ MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_ M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$ MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z% M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK' M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)= M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A) M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0 MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%" M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@# M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[ MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_ M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$ MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z% M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z M6OF7]M__ (*]?L]?L46]QX9UNTE\0^-A%FW\(:7>Q^9$Q&5-U(-PMEY!P07( M(*H1R.7&8W"9?0=;$348KJ_ZU?DM2*E2%*/--V1]0^+?%WA7P%X;O/&7CCQ) M8Z/I.G0&:_U/4[I((+>,=6=W(51[DU^'?_!*S:/LUI:LP:[DP2/M,K;1EMK8'EU]G:!_P1G_ M .">.F> =(\":]^RK?:TVD^:QUJ]\17<%]>22! [SR6LT0D_U:[4P$3+;%7> M^[XC,I9WQ=@IT<'35.@[>]4NG.S35DDVEI>]M?O1YU9XC'4W&FK1[OJ?@517 M[\?\.8?^":'_ $9C>_\ A;ZS_P#)M'_#F'_@FA_T9C>_^%OK/_R;7RG_ !#? M//\ GY3^^7_R!Q?V3B>Z_'_(^9_^#8'_ )KA_P!RU_[E:_6"O#_V7_V0OV<_ MV,_[<_X9L^ %[X;_ .$D^S?VU_Q/;N\^T?9_-\G_ (^IY=FWSY?NXSNYS@8] M8_X275_^A0O?^^EK]1X=RVOE&34L)6:V=!L45C_\)+J__0H7O_?2 MT?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+ M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ M?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0! ML45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2 MT?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+ M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ M?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0! ML45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2 MT?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+ M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ M?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0! ML45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2 MT?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+ M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ M?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0! ML45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2 MT?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+ M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ M?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0! ML45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2 MT?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+ M0!L45C_\)+J__0H7O_?2U)9Z]J5S=)!-X9NH59L-*[+A?!_MJ_M$?M,?LN:=)\9/ 'P7\.^,_A]HVARW/BJ";Q&=-U.SD1B3+& MSH\#_"GC_PU>^#/''ARRU?2-1A,-_IFI6RS07$9 MZJZ,"&' X(H ^4_A7\)/VF?VK/VM/ 7[:7[07POT?X*M;\,6_P"P'#XR MMEU*X'A?Q#X;^(-G:VUW:^8WD?:8KK]Y;R!-F\\J6W;<#%?1L$$%K EK;0I' M'&@6.-% 55 P .@ I] 'RG^QM^S=^TE^RE^SI\0/&UYX>T#6_BKX[\6WGBJ MY\+PZD8-.AGF=3]B6?!"D+YAW\J&95R57<>:_:$US_@H/^V=\*=3_9CLOV+( M_AI:^)TCL_$OC'Q+XYL;^WL+7>K2B"*U^>X=@"H8 9YP2&7[1HH ^3OVGOV M0?BMX,/P1^,W[)&BVVO>)?@7:?V5;^&]2U!+0Z[H[VB6LL(G?Y(YA&AVEL+^ M\<\E54TH/AW^U)^VK^TM\.OB;\>?@%_PJ_P)\+-0EUFRT?4?$-OJ%_KFKE0L M#XM\K#%"5#9;EN<9W93Z^HH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;XQ_&WX3_L^^!+OXF? M&CQ[IWAW0[(?OK_49]H9L$B-%&6ED.#A$!9NP-?)'[??_!;WX!_LJO>?#;X* MK;?$'Q]&6A:ULKC.FZ9+TQ<3I_K'!ZPQ$MD%6:,XKYG^#G_!-3]NO_@J/X[M M/VBO^"BGQ$UCPSX68^9I>@-$(;U[=B#Y=K:$;+"(C'[R13(V 2CYWU\QCN(U M]8>$RV'MJW6WP1\Y2V^2]-&<=3%>]R4ES2_!>K-#]H'_ (*X?M/YOV9 M?^"87PVUO3[.YS'>>*4C":C+"3M,OF$^7IL'_31F\P_+AHV.RO:OV#O^"$WP MC^!]Y;_%S]K&_MOB+XY>7[2;&X#2Z58SD[BQ60;KR3.27E 7)XCR Q^Q?V?O MV;?@C^RWX!A^&GP)^'MAX?TJ+#2K:IF6ZD QYL\K9>:0_P!YR3C@8 KN:G! M\..K76+S6?MJJV7V(?X8_J_6U]0IX7FESUGS2_!>B$CCCAC6*) JJ %51@ # MH *6BBOJ3L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **AO[^PTJQFU35+V&VMK:)I;BXN) D<2*,LS,>% ))/ K\ZOVX?\ M@O#X6\*ZT_P,_8+\/#Q_XQNY_L<7B&&U>XL(9V.T+:Q)\]]+GH1B+."#*,K7 MFYEFV RFC[3$SM?9;MOLEN_ZN95J]*A&\V?:'[3_ .U[^S[^QYX%;Q]\>OB! M:Z3 ZL-/T]3YE[J,@'^KMX%^:0\@$\*N0691S7YB_$;]M7_@HC_P6-\97WP0 M_8P\#WW@KXSIG*QW,J';:1#/%O!A@#C,1&VOTY^' M/PU^'_PA\&V7P]^%_@W3M T33HO+LM,TNU6&&(=SM4Y#MU?KV/EO]@3_@C9^SA^Q1I\G_ $YP'(B(_P">K%I.N"@)6OL"BBOI\#@, M'EN'5'#048KM^;>[?F]3KITJ=*/+!604445V&@4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%?)O_!0OXU?$?1_CO\ !O\ 9A\._&:?X9^'OB/?:D/$/CJS M6);E/LT*-#9V\LH*0/+(ZIO^]EX\<;E8 ^DOAM\5/ 'Q>T6Z\1?#CQ''JEE9 M:M=:9X\(^+Q;7>-0FF65KV.YBCB9"3YNY-I#F7<3E167\:_V+/&7 MQ,UGQ/\ $KXA_MZ_%'PU;!IKC0;7PAKR:)IOA^V125,J(#]I*@%GDD=<@L/E MZ@ ^D**^(/V:_P!NKXP>&_\ @D7J_P"UK\89QK>O^'+>_M='U6]A*+K!6Y%K M9SR !=P,SJC$8+",DG<2:S/&7[+'[5'@[]DFZ_:^A_;C^*,OQ8TSPJ?%5[IT MNNJ= =TA^U2V"Z=L\KRP@9%[%P&V@': #[RHKXE^*7[7'Q6_:>\-_L[?!7X) M^,Y_!6K_ !RTJ35_%GB#1\&YT>PM+437<5JS9V2/()423JOEC^]2>*]%^*/_ M 3N_:@^$D.B?M&>/O&_P^^*'B3_ (1?Q!HWQ$U\ZI-9:A, +6YMIV4-'N._!?PS\*7OCKXA^*M/T31M-A,M_JFJ7:000(.[.Y '/ ] M20!S2E*,(N4G9(&TD:M>#_MJ_P#!1K]F;]A;PZ;KXL>+!=^()X#)I?A#2&67 M4+O^ZQ3($,9(/[R0JO!V[B-I^+?VK_\ @M[\5/CSXU/[,_\ P2\^'^J:QJVH MNUNOC#^RS)(A\?\ _@HEXJE\ M;^++Z<7DWAB347N;99CSNO;@G=>29QE ?+X()E4U\E7X@Q.8U7ALFASM:.H_ MXSD9KWW1]&TCP]I5MH6@:5;6-C9PK#:65 MG L44$:C"HB* %4 8 JS7;EG#V'P=;ZUB9.M7>\Y=/\*VBO37Y:&E'"QI MRYYOFEW?Z=@HHHKZ$Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ KSOX[_#+]FG]HJS'[/_QYTCP]KTMU!]OM?#VH7:K>J@+)]I@"LLT>/F7S M8R/XAGJ*]$KP3]OW]B/P%^V#\'M6LE\ Z#=^/+72)8/!OB#599;=M/G8Y4F: M$%]@.6VD,N?X>30!X9\,?#FN_L/_ /!1WP)^R?\ [XU:_XE\ ^-O#^HW.M^ M!=?U4W[>%/L\#R0SPNWS01.RA%4XW?-DL2A7VS]HO]A3]E?]MBYU#Q7XX\2Z MU=2K"=,N;GP_XRF6VMI+=W#*T =K?S8WW!@\9((PPXKJ_P!E_P#8P_9Y_9.T M-8?A'\+M+TK5KJQBAUG68S)/=7C ONGF9I-A<;MF0N<''%#4-=NGN-?&C^([^QAU.1V+.TT5O.B,6)8L0 6+$DDF@#X^? MQE\5OC__ ,$=?CW\+=2U:'Q):?#7Q2=(\,>)M.L8X(]4TC3;VSN?,V1 (0D, M;-N48V%(;0Z1J?PFE:QF\Y=LL]Q8F** ?\ M30S.L6WJ&R",@U['\//@_P#"[X3_ \MOA-\.O FF:3X;M;=X(M&M;8>04?. M\,#G>6R2Q;)8DDDDFO&=#_X)1?L&>'_&4/C+3_@9&WV;4/MUIHUSK5[-ID-S MG/F+9/,8.N?E*%!V4<4 ?+OP=\)ZE^SC\:?V'_$'Q*1M/L]1^'NJ:)/-=?*+ M6^NK9IX8'S]QV>ZCC"GG(([&O;?^"E4]OX[_ &A_V9?@9H,RSZY-\8+3Q+-9 MPMNDBT_3P9)YF Y5=I;!/!V-C.TX^C?CI^S]\'/VE? 4OPR^-_@2TU_199EF M6VN6=&AE4$++%)&RO$X!8;D8'#$9P2#RG[/?["W[,7[,/B&\\9_";X>-#KM] M;_9[G7M6U2YU"\,&0?*66YD??\.]_@G_T-OCO_P +*Y_QKW2B M@#!L?AYH>GV,-A!=WY2")8T+WK%B%&!D]SQ4W_"#Z1_S\WO_ (%M6Q10!C_\ M(/I'_/S>_P#@6U'_ @^D?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D? M\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/ MI'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _ M-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S> M_P#@6U'_ @^D?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"! M;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^ M!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q M10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_ M @^D?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8_ M_"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I M'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#" M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_ @^D?\ M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\ MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ M@6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO M_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_ @^D?\ /S>_^!;5 ML44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1 M_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% & M/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"# MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_ @^D?\ /S>_^!;5L44 8_\ MP@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ M #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\ M_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ M (%M6Q10!C_\(/I'_/S>_P#@6U'_ @^D?\ /S>_^!;5L44 8_\ P@^D?\_- M[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6 MU;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!; M4?\ "#Z1_P _-[_X%M6/\;.>MB: M=#1ZOHEN?4_[>_\ P5#_ &4_V(8+KPA'K%UXP\>HA$7A+1]5XM7QP;R<96W' M^QAI#D'9@[A\9_#;]D3_ (*)?\%E/%%G\5_VE_%EWX%^%HG%QI-I)#(D3Q'I M]ALW;=(2IQ]JF."&^5G V5]1_L$?\$,?@E^SG/:_%+]I&XM?B)X[WBX$=U$7 MTK3ILYW1Q2#-S(#D^;*,9P5C0C=7WB % 50 . *\:.4YIGTE4S67)2W5&+W M_P _^!;4?\(/I'_/S>_\ @6U;%%:E&/\ \(/I M'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_- M[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__ @^D?\ M/S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@ M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ M@6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q1 M0!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__ @^D?\ /S>_^!;4 M?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &/ M_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z M1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"# MZ1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__ @^D?\ /S>_^!;4?\(/I'_/ MS>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ MX%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_ M (%M1_P@^D?\_-[_ .!;5L44 8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L M44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6 MU'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10! MC_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@ M^D?\_-[_ .!;5L44 8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P M@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_ MS\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1 M_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ M .!;5L44 8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[ M_P"!;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U M;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X M%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 M 8__ @^D?\ /S>_^!;5)9^$M-L;I+N&XNBT;94//'L&GF5&.FZ-;8EO\ 4F'\,$ .YN< MN<(N1N903LCU4D 9)P!U)KX1_;W_X+F? _ M]FZ>Z^%W[.D%K\1/'8J,R$J<_98 /MC]@C_@D#^S7^Q'!:^,;BR7QCX]1 TGBO6+5=MH^.19P$E;6D.3\X M!VCY*6;9IGTG3RJ/)2V=:2_](B]_5Z>AQ>WK8EVHJR_F?Z(^0/@=_P $LOVU M/^"DOCZV_:4_X*5?$?6M#T27]YIWAMP(M0D@)!\J&WQY>FPGCJID;!)3)\RO MU ^!G[/WP:_9J\ VWPR^!WP^T_P[HUMS]FL8OFF?&#)+(V7FD( R[EF.!SQ7 M8T5[&59%@'M T339+W4=6G !,=O!&"7(!7).%&Y03EE! M /2:*^8_V"OVSO%OQGOM2^$OQ_\ "7C#PYX_-[J>K:=I7BKP3-I0?11=A;<1 ML459#''+ K9^8ELY;!:KWQ@_X*9?"GX6>+M?\)Z#\$OBMXY7PE[L-)E0!I$EGDDC7<@.6V[@ #D\&@#Z.HKS;P#^UA\%_BC^SA/^U3X!U^;4 MO"=KHUWJ5S)#;E;B);9':>)HF(*RKL8;2<$X()!!/C?AC_@K/\/O&5A8:SX8 M_8]_:$OM/U...6QU*U^&)EMYHGP5E61)R&0@@AAD$W\=AH^DZ39M*OA;X_^''B_4+%[S1-$^(WAP:?)JT" L[6[+)(KE5!)4D$;6P# MM. #WNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JOJ^KZ3H&EW&N:[J=O965 MI"TUW>7(C\ ?\ @GCX6D\<>+;Z?['!XGCT M][FU68\;;*W4;KR3.<.0(L@$"537,_LI_P#!$7XM?M >-A^TS_P5%^(.J:MJ MNH.MP?"']J&2YF'54O+A#B% .!;P$;00-Z8*5]I?L4_\$X?V9?V%O#P@^%/A M3[;XAG@$>J>,-859=0NL_>56QB",G_EG&%!P-VXC=7O5<5#A_%9E56)SF?.U MJJ:_AQ]5]I^NG35&<<+.K+GKN_ET7^9D^!? 7@GX8>$[+P)\.O">GZ'HVFPB M*PTO2[1((($]%1 .>2>I))/)K6HHKZV,8PBHQ5DCN2204444P"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYE_ M;K_9Y_: \2?%OX9?M;_LPZ=I&M^*_AA-J"/X1URZ$$6KVEY"(I5BE.%BF"[@ M"Q ^<'/R!6^FJ\#_ &U?VB/VF/V7-.D^,G@#X+^'?&?P^T;0Y;GQ5!-XC.FZ MG9R(Q)EC9T>.2+81\@4N6!QU% %;]FW_ (*$>%?C/\4W_9U^*OPD\2_#'XEQ MV+7:^%/%, *7T*@EY+.Y7"W"@!CG:N0K%0P5B/1OVF/V@_AW^RK\$]<^,_Q" MNHXK+3+=C;6:L!)J%V^?*MHA_%)(_'L,L&+37TU/4=0EOH#&TMS-$BQI&(WW!!\P88(.6-<)\7O M!7[?7C?]MF[^,OQ'_87E^(G@WP3J$L?PGTZ1I]A 5<@:K/%,[O-Z'KE^-&F/E+8SW] MLT<%N^?]60@B+ _<9F4_=K"\'_M)_MC?\$^_V<$AE M)OCIXHT'XN_\%/\ ]F+[)>QZAX_:>_9!^*W@P M_!'XS?LD:+;:]XE^!=I_95OX;U+4$M#KNCO:):RPB=_DCF$:':6PO[QSR553 M2@^'?[4G[:O[2WPZ^)OQY^ 7_"K_ )\+-0EUFRT?4?$-OJ%_KFKE0L#XM\K M#%"5#9;EN<9W90 ^OJ*** .,^,WQ-\7_ RTRRO_ A\'=:\8R74[1S6VBR1 MJUNH7(=MY'!/'%>??\-8?&S_ *,?\=_^!5M_\57NE% ^+=>!] N8_&WC^)2@\- MZ3=#R;"3M]LG&1%C_GFH:3IE5!#5QX['X/+<.ZV)FHQ7?\DMV_)&=2K3I1YI MNR/HOXA_&SPQ\)?!][\0/B<8M!T33HO,O=4U6]CAAB';+,0,D\ #DD@ $G%? MFU^TU_P6P^//[4?C(_LT_P#!+_X9:O<7^H%HF\5BP\R^F3HSVT+#;:Q@'FXF MY4'.(B UWNHN! M_K+B=OFD.22%X5&A:^[W;?=O=_EV.JC0IT(V@C'_X275_^A0O?^^EH_P"$ MEU?_ *%"]_[Z6MBBO2-3'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ M .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7 M_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)= M7_Z%"]_[Z6C_ (275_\ H4+W_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z M%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ MZ%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^ M^EK8HH Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[ MZ6C_ (275_\ H4+W_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6M MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^ MEH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q M_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (27 M5_\ H4+W_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X2 M75_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_ M^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ M .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W M_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6OEO\ X*B_\%1?"'[$ M'A!_ 7@*:UU;XF:M:[M-TUB'BTF)A@7=R!^:1=7(R<*"3^>'_!/+_@K[\7?V M:_B[??\ "_/%&J^+?!OBW56NO$?VN8S75A=2'YKVWS^&^(85E V@$#/Z#DOA MMQ'GF15,SHQLEK"+^*HNO+^E_B>B/A,X\0^'\ESNGEU:5V])R7PT^W-^MOA6 MK/VS_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:?X'\<>$/B5X1T[Q]X!\16 MNK:-JUJESIVHV4H>*>)AD,I'Y$=000<$$5JU\!.$ZJ MNC AAP."*TJ* &0006L"6MM"D<<:!8XT4!54# Z "GT44 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 5_/?_ ,/P_P#@J+_T<]_Y96B?_(5?T%:AJ.GZ192ZGJM_#:VT M*[IKBXE")&OJS' ^M?RBU^9^(F/QV">&^K590OSWY9.-[_\LK1/_D* MOD^BOS3^WL\_Z"JG_@/+O]G/\ MX)S_ ZUCPWX8<^7JGB!9!#>O;L2/,N;H'981$ X2-C(V" [9V5])_L"?\$/ M_@+^RU)9_$KXX/:_$+Q[&PF6XO;?=IFFR]O =I\,O@KX!T[P[H=F/W5CIT.T,V #)(QRTLAP,NY9F[DUU5?N&!X M<3Q"Q>93]M6Z7^"/E&.WS?K9,^BIX3WN>L^:7X+T04445].=@4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 45R?Q&^//P/^$$33?%; MXP^%_#85U)'L)'!/T'6OGSXF?\%KO^"=_PW\R"W^,EQXCNH\YM?#. MB7%QN^DKJD)_"2O6P&0YWFEOJ>&J5/.,)-?>E8\O'9YDV6_[UB(4_*4DG]S= MSZOHK\T/B#_P<>>!GNCI7P-_9=U[69YFV6LFOZO%:,6[?N;=)R_^Z''UKFO^ M&^/^"X_[2!\OX'?LK-X6M)O^/6_B\'/$"#T/VC5',#_4*![5]52\,^*%!5,8 MJ>'B^M6I&*^Y-O\ ^8J>(W#3FX81SQ$NU*G*3_%)?B?JI7*_$3XY_!7X10- M<_%7XN^&?#:*N[.NZ[;VA(]A*X)]@.M?FK_P[P_X+9?M'_O?CS^UH?#=E-_Q M]:=-XQFQS_T[:[#VKJ?AW_ ,&X/PRBG&H?&O\ ::\1:U+(V^XC\/Z5 M#8DL>H\R=K@M]=H)]!6G^JW"& _W_.(R?\M&$JE_2>D?O1'^LW%>-_W'*9)? MS5IQA;UCK+\3W_XF?\%J/^"=_P -O,MXOC3+XBNH\YM?#.C7%SN^DK(D)_[^ M5\V_&[_@XNT#4]#OO#?[,7P!UJ36;R)H=*U;Q//$HMY6X$GV6 R^<1V3S%&< M9R 0?I;X9_\ !%W_ ()W?#7RYS\$#X@NH\?Z5XFU>XNMWUB#K"?^_=?0/P]^ M"?P;^$EN+3X5_"?PUX;C"[=N@Z';VF1[^4BY_&JCF/AKEDE*A@ZV)DO^?LXP MBWZ03NO)_,F6 \1,QBU6Q='#I_\ /N#G)+UFUKYKY'\T_P 3O$/Q%\6>/]6\ M3_%N^U.Y\2:A>-<:Q<:PK"YDF?DEPX!'!&!@ # Q6%7[P?\%1?^"77A#]M M_P (/X]\!0VND_$S2;7;INI, D6K1*,BTN2/R27JA.#E20/SP_X)Y?\ !(+X MN_M*?%V^_P"%^>%]5\)>#?"6JM:^(_M<)ANK^ZC/S65OG\-\HRJJ1M))&/W[ M(?$KAO,.'IXZK)47124Z?5=$H+3F3VC9>3L?AN>>'G$.!SZ."IQ=;VK?+/H^ MK-L ML*Q9>-6Y\P!6!P#MWOXOG.8BL3P#\2OAY\5?#T M?BSX9>.M(\0Z7-_J]0T748KJ$GKC?&Q&?;J*VZ^'J4ZE*;A---;IZ-'VD)PJ MP4X.Z>S6J"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BN?^&WQ4\ ?%[1;KQ%\./$<>J65EJUUIES<10R($NK:4Q31_.JD[ M74C<,J<9!(YKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBFRRQPQM--(J(BEG=C@*!U)/:@!U%>,_%K_ (*'_L/_ .\ MV+XE?M0>$+.XASYUA9ZJM[=)CU@M?,E'_?-?,'Q:_P"#C;]C'P=YMI\+O!'C M#QE'T)N (;=?JZ$4W_ADG M_@X)_:Q^?XP?M 2^!-.N>9+:7Q3%IRF,_P )@T=&+URZG??>0^'=,2V8MWS<7+3%_J8U M-?3/PD_X(M?\$Y?A'Y5S;_ "W\17D>,WGBV_FO\ ?C^]"[>1^48H^L\88S^' M0IT5_?DYO_R73[PY\=4VBH^KO^1\K^-O^#C[Q-XRU4^%?V6?V.=0U:^E)^R2 MZWJ#SROZ?Z':1DG\)JQO^%L_\'%G[6G'A+X=3_#K2KG_ %A71K711&IZ$-J# M/=C_ ( 2:_5#P3\.?A[\--)&@_#CP)HWA^Q7&VRT32XK2(8Z?)$JC]*V:/[ MS;%?[[CYM=J:5->EU=L/JM:?\2J_EH?DYIW_ 03_;5^/U[%K?[9?[ M8T,=U?:[*O\ LAKIX4C/;Y=P';(K\HJ_K KY/_X<>?\ !+K_ *-A_P#+UUO_ M .3:\#/> 5B?9O+VDU?GOV]LY]@DCAF/L 2:^>_B9_P6Y_X)X?#G MS(++XLWWB:YBSNMO#.A7$V?I+*L<+?@YKU\!D&>9I;ZGAJE1/K&$FOOM;\3R ML=GN2Y;?ZUB80?:4DG]U[GUK17YE^//^#CGPS>7O]C? C]E76M7N)VVVLFO: MPD#D]OW%NDQ<^PD'UKGO^&XO^"[/[27R?!;]F%_"5K/Q;7L7@_[."IZ'S]6< MQ-_O 5]53\,^)XP4\9[/#1?6K4C%?@V_P #YFIXC<-RFX83VF(EVI4Y2?XI M+\3]5:Y'XC_M ? KX/1M+\5_C+X6\-[5R5US7K>U8_19'!)]@,FOS9_X=L_\ M%GOVC?WO[0/[7IT&QG_X^=,E\87,@YZ_Z-8H+=O^^A77?#C_ (-P?A%9RK>_ M&;]I'Q+KDK-OGCT#3(-/#,3D@O,;@M[G )]JO_5?@[ ?[_G$9/\ EHTY3OZ3 MTC]Z(_UEXMQO^XY3**_FK3C"WK#67XGNGQ,_X+:?\$[_ (<>9!:_%^[\2W,> MNW4>,W7B;5+B\W_6)G$/\ Y#KZ M \ _!_X2_"FT^P?"_P"%_AWPW!MV^3H.BP6BX],1(M']H>&F7_P,'6Q+7_/V MHJ:^ZGK;U#ZAXB8_^-BZ.'7_ $[@YO[YZ7]#\SO^&[/^"Z'[27[OX)?LN-X4 MM)^+6^B\'- "#W\_57,+?4 #VH_X=R_\%J?VCCYOQ]_:X/AZRG_X^M-E\87! M'/\ T[:>GV=L?[P]J_52BC_B(4L)IEF7X>AVE[/GG_X%)_H'^H<<5KF./KUN MZY^6'_@,5^I^:_PY_P"#<'X56TRWWQI_:5\1ZW*[;YXM TN&PRQY(\R8W!;G MO@$^U?07PS_X(Q_\$[OAIY\8YE=5L;-+M%\B^Z'*CU,#P/PEE]G2P<+]Y+G?WSYCFOA_\&?A!\)[;[%\ M+?A7X<\-Q;=OEZ#HD%H"/0^4BYKI:**^5JU:M:;G4DY-]6[L^GITJ=&"A3BD MET2L@HHHK,L**** "BBB@ HHHH *\$_:'_X)D?L3_M->???$'X(:;9ZM/DMK M_AU?[/O-Y_C9H<+,W_757'M7O=%=F!S''Y97]MA*LJTDFOQ/RX\??\$)?VB/@+XAD^(O[ _[5E_9WD?,5AJ=[)IMX5!R(_M5 MM^[FS_=>.->N3S639_\ !3O_ (*J?L*W<>@?MN?LZ2>)M'A<1G6KRR%J\G. M$O[17M9#CU1F/&3S7ZNU%>65GJ-I+8:A:13P3(4F@FC#)(I&"K \$$=C7W%/ MQ"KXZ"I9[A:>+CMS27)42\JD4FONOYGQD^ Z."FZF28JIA9;V3YZ;?G"6C^^ MWD?(_P"SQ_P6Y_88^.GD:7XB\:W/@+5Y<*;+QA"(8"W?;=(6A"^\C1D^E?66 MAZ]H?B?28->\-ZS::A8W2;[:]L;A98I5_O*Z$AA[@U\R_M#_ /!'+]A+]H/S M]1?X6#PAJ\V3_:W@J1;$[CW:#:UNV3R3Y>X\_-7R;KG_ 1^_P""AW['6K3^ M,/V"?VH)M3M@_F-HZ7YTNXG/97@E9[2XQCK(RYX^7TO^R. L]UP&,EA*C^Q7 M5X7\JD=EYRNR/[5XXR73'82.*IK[=%VG\Z6OO7U]^SQ_P5K_ &%OVCO( MT_0?C%;^'=7GP!HGC)1ITVX]%61V,$C'H%21C[5Y.:\!\3Y32]M*C[2ETG2? MM(-=[QU2\VD>IEG&_#>:5/8JM[.KUA47))/M:6C?HV?2E%-BEBGB6>"171U# M(Z-D,#T(/<4ZOCCZT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^3?^"A M?QJ^(^C_ !W^#?[,/AWXS3_#/P]\1[[4AXA\=6:Q+=_'?X9?LT_M%68_9_^/.D>'M>ENH/M]KX>U"[5;U4!9/M, M 5EFCQ\R^;&1_$,]10!P_P"RE^P]J7[(GBBXC\#?M,>--?\ !MY;7+W'A'Q> M+:[QJ$TRRM>QW,4<3(2?-W)M(WQ3\/ M-<7$C>$])\#:HFDZ?H\('[M9HXP6O&!&6=G0G) QP1Y%\,?#FN_L/_\ !1WP M)^R?\#OC5K_B7P#XV\/ZC#M+E&'4L#\UY*A*I& M"&4'.5/S( <'^R[^W_\ %C2_^"37BC]J?XN7D.O>(O!#OV2;K]KZ']N/XHR_%C3/"I\57NG M2ZZIT!W2'[5+8+IVSRO+"!D7L7 ;: =H[#_@H#^S#X:^$_\ P2$\8_L]_!?1 MI4TWPSX?LYX(_O22I:ZA;WES/(0!N=A'-*YP!DDX XKN_C+\??AVW_!,77/C M@GB&T.D:G\)I6L9O.7;+/<6)BB@'_30S.L6WJ&R",@T >6?%+]KCXK?M/>&_ MV=O@K\$_&<_@K5_CEI4FK^+/$&CX-SH]A:6HFNXK5FSLD>02HDG5?+']ZD\5 MZ+\4?^"=W[4'PDAT3]HSQ]XW^'WQ0\2?\(OX@T;XB:^=4FLM0F %KI?LX_&G]A_Q!\2D;3[/4?A[JFB3S77RBUOKJV:>& M!\_<=GNHXPIYR".QKVW_ (*53V_CO]H?]F7X&:#,L^N3?&"T\2S6<+;I(M/T M\&2>9@.57:6P3P=C8SM. #Z_HHHH **XSXS? SPA\<],LM)\7ZIK5K'8SM-" MVBZM):,S%=I#%/O#'8UY]_P[W^"?_0V^._\ PLKG_&@#W2BL&Q^'FAZ?8PV$ M%W?E((EC0O>L6(48&3W/%3?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6 MU'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45 MC_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@ M^D?\_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P M@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_ MS\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1 M_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ M .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[ M_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U M &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1_P _-[_X M%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;% M%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\ M(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ M\(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D M?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__ @^ MD?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S> M_P#@6U &Q16/_P (/I'_ #\WO_@6U>7?%O\ :@_8P^!/FQ?%G]I?PYHMS#G? MI\_B='N^.N+>-FE/X+65:O1P\.>K)17=M)?B*4HQ5V['M-%?GQ\6_P#@O)_P M3W\!^;;?#Y_'/C:X7(BDTFP:TMF/^T]VT3@>XC;Z5X7??\%L/VQOV@+V31OV M-?V([VY)?RQ,XU#794_VB+984C/?YMP'?->!B.+L@H2Y%6YY=H)RO]RM^)RR MQV&B[_\ @X3_ &J#O\6?$*Y^'NEW/W/M'B"#2!&IZ@I8![H?1QFNG\#?\&WF MN>+-3'BC]J']L+4-5O92/M<.A::TLK>O^EW%[Z__L#]G+]E+7=;NIVV62CZ*_YGYI?\-7?\'!O[61V?"/X!R^ ].N>$N(O"\6FJ8S_ !";5W9FX_BC MP3V':G1_\$4/^"E7[3,BWG[8G[;ZQ6L[!GL)=9OM:>'U @8PP)]$3J%WI*WMVF/2XN?,E'_?5>F?\(/I'_/S>_\ M@6U'_"#Z1_S\WO\ X%M7K83(LFP/\"A%/O:[^]W?XFT,-AZ?PQ1KQQI$BQ1( M%50 JJ, #T%+6/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M7K&YL45C_ /"# MZ1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/ MS>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ M (%M1_P@^D?\_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 M;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6 MU'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45 MC_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@ M^D?\_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P M@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_ MS\WO_@6U &Q16/\ \(/I'_/S>_\ @6U>5_M??M#_ +_ &+?A%=?%?XKZ[>] MXM&T:WOC]JU6ZQE88E)_%G/RHO)[ ]&$PF)Q^)AA\/!SG-V26K;9SXK%8?!8 M>5>O)1A%7;>R1L_M??M??"+]BWX177Q7^*^J>L6C:-;N/M6JW6,K#$I_-G/R MHO)[ G[(/[7WPB_;2^$5K\5_A1JGI%K.C7#C[5I5UC+0RJ/S5Q\KKR.X'X!? MM6_M6?%/]K[XJW7Q.^)NIMC+1Z/I$_P#X_P#[7MYG]*%%?E5XL_X+ M_P"AZPT6B_!+]E'7M1U&X0"/^UO%#963'*K#;Q.THSGG>I('09P,J+]IC_@N M?^T>=OPB_9OO?"5K.<6]ROAPV:E3W\[5Y"C?[R@#TQ7YW#PRXFIQY\'&09,6LZ_;V\A]@CN&8^P!-?FO;_ /!+'_@KU^T$/,_:#_:[71;&;_7Z M;/XMN[DKGKBVM5%N?^^Q7=?#;_@W!^"6FE+GXP?M$>*-=DSNECT'3H-.1CZ$ MR_:&(]^"?:J_U8X-P'^_YO&3_EHTY3OZ3=H_@3_K)Q=CO]RRIQ7\U:<8??!7 ME^)[3\3/^"W_ /P3Q^'7F0Z?\4]1\47,6=UMX9T&>3)]!),(HF_!R*\!\=?\ M'&^B:C??V)\!/V4M8U:YG;;:2:[K"Q.3V_T>WCE+GV$@KZ1^'G_!&7_@GC\. MQ'+!\#5UBX3K<^(=3GO-_P!8W;ROR05[AX)_9Y^#_P -;/\ L[X<^!M/T"WV M[?(T2TCM4QZ;8E44?VCX:Y?_ ,%6Q+76K45-?=3Z>3#^S_$/'_QL91PZ[4Z M;F_OJ=?0_.#_ (;6_P""\/[2?R?!O]F=_"%K/_Q[74 M ?2C_AV?_P %E/VC1YO[0O[8/]B6,_\ Q\:9-XONIL9ZXMK-1;G_ +[%?IY_ MP@^D?\_-[_X%M1_P@^D?\_-[_P"!;4?\1#J833+,!AZ'9JGS3_\ I-W^X/] M0J>*US''5Z_=.?+#_P !C:WWGYZ?#?\ X-P?@U82+=_&/]HWQ-KLA.^6/0=- M@T]6;J06E-P2/?@GVKZ#^&?_ 1N_P""=_PR\N>#X!0:Y=1XS=>)M2N+W?CU MB=_)_*,5]$?\(/I'_/S>_P#@6U'_ @^D?\ /S>_^!;5Y&/X\XPS*ZK8VI9] M(OD7W0Y4>K@>".$\NLZ.#A==9+G?WSYF5O ?PE^%7PKL_P"SOAC\,_#_ (_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@ M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ M@6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L M45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__ @^D?\ /S>_^!;4 M?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/ M_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z M1_S\WO\ X%M0!8\4^$O"GCG0Y_#'C7PSI^L:;_P#@6U'_ @^D?\ /S>_^!;5ZV59]G.1U?:8"O*F_P"Z]'ZK9_-, M\O,\DRC.:?)CJ$:B\UJO1[KY-'Y;R_\ !/O_ (*^_L"2MJ?[(/QVD\8^';9B MRZ+87@&4'4MIMZ6AR1Q^Y9W].@KH?AE_P7U^*/PH\0+\.OV[?V6=2TC4H,+= M7NB6LEE=(.FYK&\(R3U+"51UPOI^D_\ P@^D?\_-[_X%M7/?$?\ 9O\ @S\8 M-";PQ\5/ ]GXBT\YQ::S"MPBD_Q*'!VM_M#!'K7V/^O.7YO[N?Y?3K-_\O*? M[JKZMQTEZ-)'R7^I>/RKWLBQTZ*7_+N?[RGZ)2UCZIMG&_L\_P#!1']CC]J# MR+/X3_''2)=4GP%T'59#97^[^ZL,^UI2/6/>OO7M=? O[0'_ ;Y?LK?$))M M5^!WB[6_ .I-EH[??_:.GYZ_ZJ5A*O/I+@=E[5X5?_LZ_P#!;3]@,^;\,_%5 MW\2O"EG]RRTZ[?5HA&.B?9)MMU%QU$' _O'N?ZL<)YWKDV8JG-_\NL0N1^BJ M+W&^R2^8?ZR<4Y-IF^ " M_P!KSX'>(_">JV\GDWNH:#1+ZO;2;9D'NR"OG,YX0XCR#WL;AI1A_,O>A_P"! M1NOO=SZ#*.*^'L\]W"8B+E_*_=E_X#*S^Y6/7Z*Q_P#A!](_Y^;W_P "VH_X M0?2/^?F]_P# MJ^;/H38HK'_ .$'TC_GYO?_ +:C_A!](_Y^;W_ ,"VH V* M*Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ MX0?2/^?F]_\ MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ M )^;W_P+:@#8HK'_ .$'TC_GYO?_ +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC M_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F] M_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F M]_\ MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VJ2S\):;8W27<-Q=%H MVRH>Y8C\10!J4444 %%%% !1110 5X)^W[^Q'X"_;!^#VK62^ =!N_'EKI$L M'@WQ!JLLMNVGSL, "^Z>9FDV%QNV9"YP<<5QGC7_@D_^P)\0_'&L_$? MQ;\"I;C6?$.IS:AK%Y%XOU>#[1&-6\&?!;X?\ ]EZ7KDWFZM97>K7=^ERVSR^?M

  •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

    2N]5F=2R MY!&1QD&M'P5\1/A_\2=,;6OAUXZT;7[-6VM=Z+J<5U$#Z%HF89_&OD/XX?#+ MX;_%G_@LYX2\*?%3X?:'XFTO_A0_X*!_ GX=_P#!/]/#?[>_[*'AFW\%7WA_Q/967C30?#Z?9M.UW2)Y-DD, MELF(PP;: 548WEOO(A4 ^\KR\L].LY=0U"ZC@MX(VDGGFD"I&BC+,S'@ $D MGI6;X+\>^!OB3H2>*?AUXTTG7],DD:./4=%U&*Z@9U.&421,RD@\$9XKP/\ MX*E_$37]$_9C_P"%-?#^Z"^*?BWKMGX+T *-OAZ+J0DO;R(EO>H">N)40 #M$Y]< ' MV'XG\5^%_!.AW'B?QGXDL-(TRT7==:CJEXEO!"N<9>20A5&?4US?PW_:-_9] M^,=_+I7PD^.?A#Q/=P(7FM?#_B2UO)8U!QN*1.Q ]\8KY8\;^#-$_;C_ ."I M7B#X+_&6 ZK\/_@IX5L+R'PE.Y^QZCK%['',MQ<)G$H6*0J%;(^0#&&<-;_X M*6?L9?!/P+^S3J_[2'[/GPYT7P#X]^&R1ZYX>\0>$-+AT^0"&13+%((%594, M9? 8'! [%E8 ^SZH>)O%/AGP7HEQXF\8^([#2=-M5W76H:G>)!!"N<9>1R%4 M9]36)\"?B')\7?@AX-^+$ULL+^)_"NG:L\*=(SPWXKY+\<^#M'_;M M_P""I'B#X)?&*)M3^'?P2\,6-VGA220_9-3UF]CCE6>X0']Z$BD*[3QF,#H[ MA@#ZU^'/QR^"?QB,X^$?QA\+>*?LHS<_\(YX@MK[R1_M>2[;?QKJ:\JT+]B' M]E/P?\5="^-7P^^!^@^&/$7AX3I8WGA>Q33DECF@>!XYHK<+',NU\C>I*E5( M(Q7D^G?MI?M6?M$^)?$UQ^Q+^S]X8UCP?X4UJ;29/%7C7Q+):#6[N''G)9Q1 M1L0@) $KG:V1T(( !]6T5\V> /\ @H*OQ!_9#^)7QY'PQET3QA\*[;5H/%G@ MC4[T/]DU*R@:0P^)"FLSP2^6DE[;0!-JVXD<^7O):1 LA"*V5 /MRBOC3XE?\ !1W] MI'X=>!;+]J_4_P!DR&V^",]]:I)?W^N[/$ L+B58XM2-H%*1QL70K$6+G>F2 MH;(](_;&_;:U_P#9@\?_ O\'^$/A!=>-V^(]QJ=M:V6E7(2Z:>&WB>V6/=\ M@6269 \C$".,,_.W% 'T'17RUX7_ &U/VDOAO^T1X/\ @C^V3\ M \,V7Q'> M:#PAX@\+>(GOH8;V-0WV*Z#HI\QMRJ'7"EF& PW%-/XG?MB?'#Q5^T)KO[,? M[&OP:T;Q/K/@ZSMI_&OB7Q5K3V>EZ5+<+OAM0(D:2:5DRQVX"[2.2&V@'TE1 M7SW^S9^VQXB\?>-?''P-_:+^%J^"?B!\/M/34M6T^PU#[=9ZCIKKN6\M9 H9 MEY4%",@NHR3N5,']FS]K']LC]I?2_#GQT\(_L]>"D^&'B75O(@B?QG)_;MI8 MBY:![V1/)^SMMVLY@5]_RE0COD-Y#:LP43-$#N";F4;B,?,OJ,[U?.4?Q2TP_\%"/'/PN\%? GPR_C'3_@ M]%JMIXPF;R;S42UPJ1V$THC++!O$9+98C:#@X 'B'_!.SXE?MMZO^T'\7]/U M'X;>&;O2W^,$J>,Y+KQC.S:&Q51+%9(8B)T5!E<[,D 8'6@#[\HKYJ\1?M+O@_^Q?\'O#&LVWP_NTL?%?BSQMKTUI9-J!7+<+:7D6#OBE4 M2PNIRK8'1AR &(!Z]1110!P?B+]J;]F/PAKEUX8\6?M&> ]+U*RE,5[I^H^+ M[*">W<=4>-Y0R,/0@&I_!W[2?[.OQ$\00^$_A_\ 'SP5KNJW"N;?3-'\56EU M<2A5+,5CCD9FPH).!P 37@?_ 5$_9K_ &=(_P!CKXK_ !9C^ 7@I?%1T&6[ M_P"$F'A6S&H?:"Z9F^T>7YF__:W9]Z[K]C_]GC]FGX?? OX??%_0O@7X&T77 MHO >GW5SXGL_"]G;WBF2P3SY6N%C#Y96?>Q;Y@S9SDT >[T5\B^#_P!M?]M7 M]H_PY>_&?]DC]E?PWJ/P^@N[B+0[KQ=XIDL]1\21P.R/+;1)&4@4NK*OFMU7 MD]0.>_:8_;&\;_M+_P#!+SQ+\_!45D+C2M1L/'%EK&L/;7OAQH499UB, M:?OI5;:5!V91P2%)*@ ^VZ*^;OV+_B/^UF_[*MAXD^)WP5T>\33?AUIESX+@ MT+Q49[[Q$PLMRI.9XT2WDD BY+, TC9SC-J:$MQ((UEFW0K#.%8@$1GDDU.?G9=W09/%==7R;^U M/_RE4_97_P"O#QI_Z::^LJ .!B_:M_9_$QA-DGC&Q,PD!P4 MV>;NW \8QG-=ZK*ZAT8$$9!!X(K\HOV)O%/_ 2QLOV-]:T7]K;1_ 5YXLD\ M0:RL\$VB13:_+$T["%()(XS<;SG";6&"1T%?3?[$GQ(\8?L5?\$I=+^*'[7, M&JVG_"+Z;*D9$2)N.PC?NSGC- 'W=17S]\3/VKOB[\%[WX*>%?B5\+]$AU_XF>,?[ M#U^UT[69)X-+R&(>&0QJ93C8<, .2/>M_P#:7_:>U?X#?%3X2?#S3O"EMJ,7 MQ(\9-HMW8@ (8Y(X.!@>] 'L5%?*WQS_;N^.7A;]K;4OV./@- M^SS;>+?$C>&;/5-(O+K53;6MNLC/Y\UX^,1PQ@(%"_,[R*HY(J3XX_MU?';X M ^)_A!\,=?\ V:X]?\9_$G2=3^V>'/#VLAC!J5M'"4BCF<;! 6E+22O_ *N- M&;#;2" ?4M%?,WP?_;$_:$T[]J32_P!E7]KCX(:'X:U3Q9H=SJG@W6/"VNO> MVET+<%IK63S$5A(B!F+# X'&&!JM+^U[^U3\7_C#X_\ _[)OP3\&:GI'PRU ML:1KMSXQ\4S6=WJEZ$W21VL<,+K$HY422G:V,CN ?45%5="N]3O]$L[[6M( M_L^\FM8Y+NP\]9?LTI4%XMZ\/M)*[AP<9%6J "BBB@ HHKD_BS\=?A#\"M.M M-6^+OCZPT"VOYFALYK]RHE<#<5& >0.:UH8>OBJJI48.4GLDFV_1+4<8RD[) M79UE<[\6_B=X9^#'PSUSXJ>,;CR]-T+3I+NYP0&DVCY8USU9VVHH[LP%>>?\ M/"_V*?\ HX[PY_W_ '_^)KXU_P""MO[=?@'XP>%M$^!WP+\;V^L:3-+_ &CX MCO[!F\N1D)$%OD@;L'=(PZ9$7<&OL>&N",ZSG.Z.%KX>I3IM^_*4)12BM7JT ME=K1>;1UX?!UJU91<6EUTZ'Z&_"3XG>&?C/\,]#^*G@ZX\S3==TZ.[MLD%H] MP^:-L=&1MR,.S*1715^:'_!)+]NOP#\'_"VM_ [XZ>-[?1])AE_M'PY?W[-Y M<;.0)[?(!VY.V11TR9>Y%?97_#PO]BG_ *..\.?]_P!__B:.)>",ZR;.ZV%H M8>I4II^Y*,)23B]5JDU=+1^:88C!UJ-9QC%M=-#V6J/B7Q/X;\&:%<^*/&'B M&QTG3+*/S+S4=2NT@@@3.-SR.0JC)')(ZURGPF_:6^ _QUU&[TGX1?$_3-?N M;"%9KR&PD9C$A.T,<@<$\5Y-_P %>_\ E'%\4/\ L%VG_I?;5\AB<+B<'5=+ M$0<)+I)-/[GJQ>"OVA?@%\2M6&@_#GXX^#]?OBI866B>)K6ZE( M R3LBD8XQ[5V%?FY^W]\(OV+OA[^P/X?\=_##P?X0\-?%9+?0I? UYX)M+>S MU>[U,R6^_:+4+),=AE8E@<'!'S;<_3_QD_:Q^*'PQU#X=_L]_#_X9VWBWXO> M-=$%W/IM[J0LK#2XH8E^TWEU*JL1&)-RJB+ERK '(4-@2?0E%?/?P1_:P^,7 M_#1)_9-_:N^%FB>'?%E[X??6O#.L>%=8DO-+UFVC?9-&GG1I)%+&?#91 MPQ/A4) $LC!&SD8P: /J*BOE_4?^"C<5[^P%XK_;%\-_#1K?7/!UQ+IVO^#= M6O.;'4X;J*":V>5%^8+YJN& &59,OV=['PE\ M,M8T5KSPKJ%[K6_5YSOC\EI[8#$231M)(HZJ%4$G<,@'O%<'XM_:F_9C\ ^) M6\&>.OVB_ NBZPK['TK5?%MG;W*MZ&.20,#]17D7_!53XT_$?X7?L^Z-X"^# MNNR:3XH^)WC;3O!^E:O"Q633Q=E_,G0CE6VH4###*9-P((!&==?LS?\ !*S] MC#P!I'P\^-/A;X:6CZG;2!=7^(5M:3W^L21A?.F::Y4NS;I%8A2%0N-H7@4 M?4FGZCI^K6,.J:5?0W-M<1B2WN+>4/'*A&0RL,A@1T(J:OFF]^*?[/O['?[ M7B;XS?L:6NC>(/"?AX7-_I-A8Z\]S9&>2Z598DEW.8U#NQV X7H ,U;_ &>? MVKOVAOBM%=?&WXH? 73?!'P>D\,7&KZ5KNI:UNU4Q1!'$\]L!B.*2+S9%'W@ MJJ23N&0#Z+HKY \-?MK?MX?&?X>R_M%_ #]CKP]=_#]EFN-$T_Q#XM>#7= _@;X#^ M!ESXXU+QYI6HR:78Z??""9KN#RO+1F<;(H<.[R2M]Q$+8.,$ ^B:*^8OAE^V M;^T!X8_:=T#]E_\ ;%^".A>&+[QQIUU=>"-?\+:Z]Y97C^%/CSI^IW%IH5])=V"Z9J36S"1TV-N(!W#':OR M1_X+;_\ !/O]G3]A/_A67_"@=-U:W_X2G^VO[6_M35&N=WV;[!Y6WE?N=7R?_P4_P#^"8'_ \A_P"$'_XOA_PAG_"&?VG_ ,RU_:/VS[7] MD_Z>8?+V?9?]K=O[;>?DN*L@I9GEM66'HQEB'RV>B>DE?5V^S?KY'#C<,JU* M3C&\M/S_ ,C^>^BOU@_XA@?^KX/_ #&G_P!\J/\ B&!_ZO@_\QI_]\J_*_\ M4CBC_H'_ /)X?_)'C?V=C/Y?Q7^9XC_P1(_X)]_LZ?MV?\+-_P"%_:;JUQ_P MBW]B_P!D_P!EZHUMM^T_;_-W;0=W_'O'CTP?6OU2_8__ .";7[,?[#GB36/% M?P&TK6;>[UVQCM+]M3U=KE3&C[UV@@;3GO7%_P#!,#_@F!_P[>_X3C_B^'_" M9_\ "9_V9_S+7]G?8_LGVO\ Z>9O,W_:O]G;L[[N/K"OU+A?AZAE^6T98FA& M.(CS7>C>LG;57^S;KY'LX/"QI4HN<5S*_P"?^05\C?\ !.E6'[5/[5)(/_)4 MX?\ T3)7US2!5!)"@9.3@=:^O.X^3[X'_A]]9G!Q_P ,RGG_ +CST!6_X??% M@IQ_PS+RKZPVKNW[1G&,XYQ1M7=OVC=C&<,+^XTRX'B[6-.T_6]+D<-!=VWV5Q$Y/.> W3.3N"_ M='[!7A7]E_PY\$;C4OV1X=5;PKKOB*[U&2_UAKYI=0O&"12W(:]_>LK"),-] MUMI(R22?9+W3=.U((-1T^"X$;[XQ-$'V-ZC(X/O4] 'Q;_P5O\;>$?AE\0?V M<_B3\0]16R\/Z'\6H[K6+Z2W>5(($C#,Q5%9FX!. "3@X!KUOX&?\%$OV&?C MY\1K3X5? _XQV.J^(=1BE>UT^WT&]MVE6*-I'^>6W1!A%8\MVXYKW>B@#Y._ MX)NJP^.G[3Y(/_);+K_T4*Y/]DCQ9\/_ (W[7WBGXLZ-+?^&+?XQZH-?LX] M+>]\VT=%24- BL9$V.2P /R[C@U]N!54DJH!8Y8@=3TH"JI)50"3DD#J: /S MH^ _C7X.> OVPOASX#_X)C?'?Q!XF\%>(KN[D^(/P^,UU>Z+H.G^676[C>Y3 M=9/O)PNXLS*JG .UNU^$TVI6GQV_;KNM)T>PO[N.STYK6PU>=8K2YD&BW96* M9V952-C@,Q90%))(ZU]NVFG:?IYD-A80P&9]\IAB"[V_O''4^]'I/$]AX1OCJYTWR!;D"!I MQ;+*8LKD<#M@\U]&_!'X0^%_@-\(?#7P9\(--)IOAC2(;"SFNV#2R"--ID8@ M ;F.6. !EC@ <4 ?/'[>RD_MG?LJ$+G'CO5N:5X:TW5KW_ (07QI=Z%+>:/KVF7$SS>2YBC<++ND=F0@@;RK;=H+7/ MV9/&WP,^/'_!6,?%K]D;P[%-X#TCX*2:3JFMZ-X7ET_3_P"TSJ32%,M#&&D, M;Q\XRP0XR$./O:[L[34+=[._M8YX7&'BF0,K#W!X-+;V]O:0K;6L"11H,)'& MH55'H .E 'RC_P $S01\4OVFL@C_ (O]JO\ Z"E<9I/QB\%_L"?\%$OC+KG[ M3%U<:#X4^+L&C:IX2\93V$TED\UI;R136H6<4\+_?BFC#*WU!X- 'QQ^SIXDLOVPO\ @I5K'[8O MPKL+V3X<^$_ABGA+2_$UQ8R6\6NW[WK7$AMQ*JM)%&KNI;'#*O9@:X7]B']L M#X0?L4>%?B+^S-\>3K-CX]TCXFZO<:1X3LM"N;F\U^&YD5K9K-8T*R^:00N2 M!@JQ(4YK]!8XXXHUBB0*J@!548 ["HWL;*2[2_DLXFGC0K',8P753U /4 T M ?FC\(3J1_X(>_&EM8TJ2QNSKOB(W5E,P+V\GVR/=&2."5.02.XKIOB!_P % M&?@;XG_X)US?LXZ/IVO'XIZ]\.HO"=E\.9_#]S_:$EU<62VRRH!'LDA*/YZ2 M!L,FW'S';7V'^U]\$M:_:*_9D\:? [POJMGI]_XET:2TM+N]#>3%(S!MS[ 6 MQQS@$\UTWPJ\!KX!^'7AGPGJ(MKB_P!"\.V>F2WT47WS#"D;;21N"DJ3B@#Q MSPK\4/"G_!/S]EKX)_"[XSVFJ7&IZC_8?@R*/1K9+@IJDMO@[LNO[I71QN7< M<8PIKZ'KS3XB?LTZ%\5/V@?!GQM\;Z_+>6?@*TN9/#OAEK8?9TU28J#J$C9_ M>.D:A8U*_(Q+@Y/'I= 'QW^P:K?\-*_M?B%%CC_IVFJ]_P $@U;_ (=1 M^"%*G)T_7^,?]16_KZU"J"2% RZ/91EYKNTM=9U%9511RV%EWG_90GM7V1\)?^"E_ M[)WQ\\<>'?AS\$?%FJ>*-8\0!GEM=,T&Y T>)8FD:6]>1%6!05\OJ2790 0< MU[ZJJBA44 #H *BM;"PL6D>RLH83,^^8Q1A2[?WCCJ?=_!#]JCX:_'_X M@_$'X:^![+6(M0^&VOC2/$#ZE8B**2AQA@3Z52+'&A9D M0 N MO=6*Z;J+6["1TV'<0#D8[5\^>(_^" 7[!NJ:#>:=H,7BS2[V:W9;344U\S&W MD(^5]CKM< XRIZC(R.H^WJ*]_+^*N(\IH1H8/%SIPB[J*DTM7=Z;:O<\+'\, M\/YI7E6Q>%A.;T!W)_9_ M^(V?\8U_"_VWX=OHOKYA-Q(!\S[$7:@)SA1T&!D]3[3^R3_P3 MJ_9K_8H\1:OXH^!FEZO;W>MV26M^=2U9KA3&C[QM! P<]Z]UHK\;QW%O$V94 M)T,5BZDX2WBY.SUOMMN?K>#X6X(+_0[*7EHK^^AL4MH^GS[)IEW8[(W3%>A?L[_P#! M,C]I7P;^S3HWPP'[=?B3PY8:GH9DUWPI;^#]/GAAGO$,EW TDH,DOSRR*68Y M(]!@#[E95<8=01D'!%+0!\&_L#_M*6W[''[._P 0_P!GWXWV&OZM)\"?'C:1 M3/):W[1 [O)SYS'&XK'LP#TKBOVY_C1^RG^W1K_@"P_8:F_X M2?XTKXQT^ZTOQ-X>T&YMI](LHWS)->3O$F(4^4[7)*D9P!G/Z3"-%8NJ ,WW MB!R:AL],TW3FD;3]/@@,S[YC#$J[V]3@HJK^TS\8=._X*MS^%OV M7?V6/#6NZKX$?Q1::I\1/B)?:'<66FP6%NQ;[+ UPB--,Y.0 HY5<94NR?>U M% 'PS\?_ 7\0_VW?^"ED?PY^&7Q M'K6S:RT6]WQ3OFW \Q06P%8'#R*1CFOT4"JI)"@$GD@=:'1)%*2(&4]0PR* M/B#XR^+IOV"?^"B^M?M=?$#0-2N/A3\5O"=E8>(/$^E6,ETFA:E:K'%"\ZQ! MF$311K@@98R' )0@\A_P4>_X*??LX?&G]FK5O@)^S;X^77]0\93VFE:MXA;3 MKJWTOP_9S7"*\]W/+$H4, 4 &<;F8XV@-^ASJKJ4=05(P01P165K'@/P1X@\ M+WG@G7?!^F7FC:C$T5_I5S81O;W"-]Y7C(VL#[B@#-^"7AKPQX*^#7A/P7X* MUR#4]'T;PU8V&EZC:S+)'._"NJWGPI^*OAFSL/$WB#2-/DN?^$?U*T2.**2=(P6$1CB'(&296P"4V MM]3?L\_LS_!_]EGPIJ/@7X)>'Y])T;4=:EU-M-?4)IXK>:1(T=8?-9C'&?+! MV X!+$=:[QE5U*.H((P01P10!X+\)?\ @I!^S5^T)\5=)^%/[/5_KGC2:^$K MZKK.D^';J/3]%B2!Y5>ZGG2,+O95C55W$LX!Q7SO^P/^UC\$O^"?7PFUS]D' M]L#Q3-X*\3^#/$^HR6SZGI5R\>MV,TS2Q7EN\<;"4-D@ G:??O%)?6$,S0OOA:6(,8V]5ST/N* /SZ^'W MA/Q=K/[%'[7O[4?B#PEJ&@Z?\5[?7M4\+Z7JEN8;EM,BL9UAN9(SRAEWL<'J M%W#*E2>Z^,*G_AP]:*5.1\!=#XQ_TY6E?:) 8%6&0>H-(41D,;("I&"I'&/2 M@#XM_P""@BG_ (1X"\+\8_Z>M.K&_X*%_$F'X._'?]DKXEWGA;5M8M M]&O-9GO-/T2T,]TT']GVJRO'&.7*(6D*CDA#7W6RJZE'4$'J".M>,?M"_LS> M*/C#^TC\%_C5HWB&PM;'X9ZMJMWJEI=!_-NUNK5(D$6T$9#)D[B.#QGI0!\Z M?&7]H'X7_P#!0W]K/X#^ /V5-8G\46'@7QFGC#QEXAMM-GAMM*M[<*T4,CRH MI$DK!EVXX)4>N+/P\^-_@'_@G]^W'\;]'_:EU&?PUH7Q-UFS\0^"_%UU8326 M-\!$XFM3+&C;)(V? 4_W6Z;DW?3RHPNYCU8XZGWHO;" MQU*W-IJ-E%<1,03%-&'4X]CQ0!\7?LV^,['X^_MT_$S_ (* ^#= U:7X:Z)\ M,$\+Z'JS:3*C^(WCG2\N)K6%U#RJGE&,.;1/$?PBTJ*[DT>YLI'/VR>XLYXP+ Q@PACGGQYTR1 /)CIN(Y/XT ?*G@96_X?1>. M&PHS0!^8^A_#O\ 97^ O[4_QD\#_MV>,_&'@NY\2?$"]\3>"=>M/%&J MZ;INL:=>.9=JO9NL331,=KEOFR=N?EP/KO\ X)]^%_V/++PAXH\:_L=W>LZC MI>L^( FM:]K-QJ,QU*ZBA0[XY+[YI4"R[=Z_*6W#)Q7OE]IVGZG#]FU*QAN( MPP81SQ!UR.AP>]2JJHH1% & . * /,?VC/V2/A7^U"^D2?$K4?$MN=%$XL M_P#A'_$]UIP;S?+W>8('42?ZM<$].<=373?!GX0>$_@3\.K'X8>"+G5)M-T] MI6@DUC59KVX)DD:1MTLS,S?,YP">!@#I74T4 >!_\%1@3_P3Z^*P _YE63_T M-*Z#X5^$+OQ]^P=X;\!65T+>?6OA'9Z?%.V0(GFTM(PQQSP6S^%>MLJLI5E! M!&"".M+0!\$_L/?\%!_V=OV3_P!E/2?V=?VH-:OO!?C[X>Q7&FZMX3O=%N6N M;MEGD:)[;9&5F$JLN"#@L2<[2&,7P>^ ?Q>L?^"2WQLG\0> K_3_ !#\3KGQ M+XMLO"TD#?:[6*YB3RK 8#9%?>LVG:?(%H\]=I/(_"IJ /BWX8_MK:5XV_X)FWR_L<>(CKOQ&^'WPETM+W28=)F>;3 M+I;987RKQ[)9$\F=E0;]QB'!##/R3^UCXR_9C^(O[%=EK7@;]IGXI_$WXB3Q MZ3>>)8M3\1:E=66E,UQ!]H>\MFVVUJ@E;R8UP3O:,+NP7'[!V]E9V9D-I:11 M&5R\ICC"[V/5CCJ?>DM]/L+0RM:6,,1FDWS&.(+YC?WFQU/N: /E3]J96/\ MP53_ &6" 6$XN&$-Q'+C>K1O@C!P0"IR"0)+N_%UD$VCV@=B[K(-N<%&O@+\#0!\5?\ !0GXL>#_ !1X M,^ ?[;O@*>ZU[X>^$?BE;:GKFL:;I\SB7A>[\MD#^6KQD9QR67&0P-->8*(=1MR8[>WN+,QF*]A MF94"R@8975F8A=M?HH54L&*C(Z''2HI=.T^:\CU&:PA>XA4K%.T0+H#U ;&1 M0!R_P!UKXC^(_@9X.\0?&'218>*[[PQ8S^)+(1>7Y%\\"-,A3^ ARP*_PGCM M77444 %%%% !7FO[2G[*'PA_:OT/3/#WQ>LK^:VTF[>XLQ87Q@(=EVG) Y&. MU>E45TX/&8O+\3'$8:;A..TD[-=-'Z%0G*G+FB[,^-/BW_P2[_8"^#'PSUSX MJ>,=*\11Z;H6G27=SCQ"X:3:/EC7(Y9VVHH[LP%?E??S6US?37%E9BVADE9H MK=7+")220N3R<#C)Y.*_;7]MO]E;Q-^U]\,[3X5Z7\7_ /A$]-745N]5VZ&; MQK[8/W49_?Q;55B7(^;+!#QMY^5?^'"7_5UO_EB__=U?T!X?>(.49?EM2IGN M93E6G+2,E5GRQ6VJBU>3NW9[6ZW/=P&.I4Z;=>HVWZNQ^>EA-;6U]#<7MF+F M&.56EMV#M*\12:;KNG1W= MMGQ"Y:/=?\ #A+_ *NM_P#+%_\ NZOJK]B3]E;Q-^R# M\,[OX5ZI\7_^$LTUM1:[TK=H9LVL=X_>QC]_+N5F <#Y<,7/.[A^(/B#E&89 M;3J9%F4XUH2UC%58U_(,?CJ52FG0J-->JN3_LU_L/? ;]E# M7-3\0?"'3]3AN=6M$M[PW^I-."BMN& 1P(FT*SN1K#V7G7$4[P(S21O*6,;$D\I@ M\FO!?^"D'PV\!^%OVZO '[2G[1*>)[7X77G@:;PSK'B/PQJ%[;'1+Y+F:XAD MN)+)A*L4GG;.ZDJ21\M??%(Z)(ACD0,K##*PR"/2N,@^.?V0_#G_ 3/\3?M M)6?B/]FGX@>(O&?C30=$NI8-3N_$&LZG;:=;2!8I%,MRQA5G$F F=QP3CC-? M.G[/WP^_8U_9YUCQM\"_V[OB%XS\">+=*\9:A& 1@CP]99'_ &P2N@95=2CJ M"",$$<$4M 'SE_P4]_9T^)'[0/[/%E?_ 5A2;QKX"\567BOPO9NP O+FUWY M@R2!EDD8J"0"Z*,C.1P'_#U#_@G5\1/"UM-^U+I4?AOQ9I$134_!?C?P-&Y%34O$?PB;3-/+OM7SYM,\N,,3T4LP M!]B:]D95=2CJ"",$$<$4M 'PO^RI_P %.?V9_@-^R-X:^$GQEU'4] ^(?@+P M]#H6I?#VXT*Z&I7%Y:QB&..)!&58S;4(.< O\QG?BC]ECXV^!?^"(%QX> MUCP+>?\ "4CQ!'XPU'PS#"QGM;=M26=HMF,ADM\2.N,KAP1E<5^DTFG:?+>I MJ4MC"UQ&I6.=H@74'J W4"IJ /S?_P""DO[?GP"_:I_99L/"7[/%WJWB=G\2 M:)J/B"^MM'GBMM A^UQA$NI9%51,\KK&L:EB<,W 4$^@?\% OC#I'P%_X*-_ ML^?%7Q%X>U;4=,TOP_XE.J)HMBUS/;VSVZQR7/E("SI$K&5]H)"(Q .,5]M6 MUA86<;16EE#$KR&1UCC"AG)R6..ISWKQWXJ?LS>*/'O[:/PJ_:9T_P 0V$&E M^ =)UJTU'3Y@_P!HN6O;?RHS'@;<* XML 21 R1.htm IDEA: XBRL DOCUMENT v3.22.4
    Cover - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Jan. 30, 2023
    Jun. 30, 2022
    Cover [Abstract]      
    Document Type 10-K    
    Document Annual Report true    
    Document Period End Date Dec. 31, 2022    
    Current Fiscal Year End Date --12-31    
    Document Transition Report false    
    Entity File Number 001-33757    
    Entity Registrant Name ENSIGN GROUP, INC    
    Entity Incorporation, State or Country Code DE    
    Entity Tax Identification Number 33-0861263    
    Entity Address, Address Line One 29222 Rancho Viejo Road, Suite 127    
    Entity Address, City or Town San Juan Capistrano    
    Entity Address, State or Province CA    
    Entity Address, Postal Zip Code 92675    
    City Area Code 949    
    Local Phone Number 487-9500    
    Title of 12(b) Security Common Stock, par value $0.001 per share    
    Trading Symbol ENSG    
    Security Exchange Name NASDAQ    
    Entity Well-known Seasoned Issuer Yes    
    Entity Voluntary Filers No    
    Entity Current Reporting Status Yes    
    Entity Interactive Data Current Yes    
    Entity Filer Category Large Accelerated Filer    
    Entity Small Business false    
    Entity Emerging Growth Company false    
    ICFR Auditor Attestation Flag true    
    Entity Shell Company false    
    Entity Public Float     $ 2,400,450
    Entity Common Stock, Shares Outstanding   55,732,114  
    Entity Central Index Key 0001125376    
    Document Fiscal Year Focus 2022    
    Document Fiscal Period Focus FY    
    Amendment Flag false    
    XML 22 R2.htm IDEA: XBRL DOCUMENT v3.22.4
    Audit Information
    12 Months Ended
    Dec. 31, 2022
    Audit Information [Abstract]  
    Auditor Name DELOITTE & TOUCHE LLP
    Auditor Location Costa Mesa, California
    Auditor Firm ID 34
    XML 23 R3.htm IDEA: XBRL DOCUMENT v3.22.4
    CONSOLIDATED BALANCE SHEETS - USD ($)
    $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Current assets:    
    Cash and cash equivalents $ 316,270 $ 262,201
    Accounts receivable—less allowance for doubtful accounts of $7,802 and $11,213 at December 31, 2022 and 2021, respectively 408,432 328,731
    Investments—current 15,441 13,763
    Prepaid income taxes 4,643 5,452
    Prepaid expenses and other current assets 36,339 29,562
    Total current assets 781,125 639,709
    Property and equipment, net 992,010 888,434
    Right-of-use assets 1,450,995 1,138,872
    Insurance subsidiary deposits and investments 67,652 54,097
    Deferred tax assets 39,643 33,147
    Restricted and other assets 37,291 29,516
    Intangible assets, net 2,465 2,652
    Goodwill 76,869 60,469
    Other indefinite-lived intangibles 3,972 3,727
    TOTAL ASSETS 3,452,022 2,850,623
    Current liabilities:    
    Accounts payable 77,087 58,116
    Accrued wages and related liabilities (Note 3) 289,810 278,770
    Lease liabilities—current 65,796 52,181
    Accrued self-insurance liabilities—current 48,187 40,831
    Other accrued liabilities 97,309 89,410
    Current maturities of long-term debt 3,883 3,760
    Total current liabilities 582,072 523,068
    Long-term debt—less current maturities 149,269 152,883
    Long-term lease liabilities—less current portion 1,355,113 1,056,515
    Accrued self-insurance liabilities—less current portion 83,495 69,308
    Other long-term liabilities 33,273 27,135
    TOTAL LIABILITIES 2,203,222 1,828,909
    Commitments and contingencies (Notes 16, 18 and 21)
    Ensign Group, Inc. stockholders' equity:    
    Common stock: $0.001 par value; 100,000 shares authorized; 59,029 and 55,661 shares issued and outstanding at December 31, 2022, respectively, and 58,134 and 55,190 shares issued and outstanding at December 31, 2021, respectively 59 58
    Additional paid-in capital 415,560 369,760
    Retained earnings 946,339 733,992
    Common stock in treasury, at cost, 3,368 and 2,944 shares at December 31, 2022 and 2021, respectively (Note 22) (114,626) (83,042)
    Total Ensign Group, Inc. stockholders' equity 1,247,332 1,020,768
    Non-controlling interest 1,468 946
    Total equity 1,248,800 1,021,714
    TOTAL LIABILITIES AND EQUITY $ 3,452,022 $ 2,850,623
    XML 24 R4.htm IDEA: XBRL DOCUMENT v3.22.4
    CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
    shares in Thousands, $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Statement of Financial Position [Abstract]    
    Allowance for doubtful accounts $ 7,802 $ 11,213
    Common stock, par value (in dollars per share) $ 0.001 $ 0.001
    Common stock, shares authorized 100,000 100,000
    Common stock, shares issued 59,029 58,134
    Common stock, shares outstanding 55,661 55,190
    Common stock in treasury, at cost 3,368 2,944
    XML 25 R5.htm IDEA: XBRL DOCUMENT v3.22.4
    CONSOLIDATED STATEMENTS OF INCOME - USD ($)
    shares in Thousands, $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Income Statement [Abstract]      
    Service revenue $ 3,008,711 $ 2,611,476 $ 2,387,439
    Rental revenue 16,757 15,985 15,157
    TOTAL REVENUE 3,025,468 2,627,461 2,402,596
    Expense:      
    Cost of services 2,354,434 2,019,879 1,865,201
    Rent—cost of services 153,049 139,371 129,926
    General and administrative expense 158,805 151,761 129,743
    Depreciation and amortization 62,355 55,985 54,571
    TOTAL EXPENSES 2,728,643 2,366,996 2,179,441
    Income from operations 296,825 260,465 223,155
    Other (expense) income:      
    Interest expense (8,931) (6,849) (9,362)
    Other income 1,195 4,388 3,813
    Other expense, net (7,736) (2,461) (5,549)
    Income before provision for income taxes 289,089 258,004 217,606
    Provision for income taxes 64,437 60,279 46,242
    NET INCOME 224,652 197,725 171,364
    Less:      
    Net (loss) income attributable to noncontrolling interests (29) 3,073 886
    Net income attributable to The Ensign Group, Inc. $ 224,681 $ 194,652 $ 170,478
    NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.      
    Basic (in dollars per share) $ 4.09 $ 3.57 $ 3.19
    Diluted (in dollars per share) $ 3.95 $ 3.42 $ 3.06
    WEIGHTED AVERAGE COMMON SHARES OUTSTANDING      
    Basic (in shares) 54,887 54,486 53,434
    Diluted (in shares) 56,871 56,925 55,787
    XML 26 R6.htm IDEA: XBRL DOCUMENT v3.22.4
    CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
    shares in Thousands, $ in Thousands
    Total
    Common Stock
    Additional Paid-In Capital
    Retained Earnings
    Treasury Stock
    Non-Controlling Interest
    Balance at beginning of period (in shares) at Dec. 31, 2019   53,487        
    Balance at beginning of period at Dec. 31, 2019 $ 656,144 $ 56 $ 307,914 $ 391,523 $ (45,296) $ 1,947
    Balance at beginning of period (in shares) at Dec. 31, 2019         2,079  
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)   979        
    Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards 12,655 $ 1 12,654      
    Issuance of restricted stock, net of forfeitures (in shares)   872        
    Issuance of restricted stock, net of forfeitures 3,086 $ 1 3,085      
    Shares of common stock used to satisfy tax withholding obligations (in shares)   20     20  
    Shares of common stock used to satisfy tax withholding obligations (917)       $ (917)  
    Dividends declared (10,946)     (10,946)    
    Employee stock award compensation 14,524   14,524      
    Repurchase of common stock (in shares)   692     692  
    Repurchase of common stock (25,000)       $ (25,000)  
    Net (loss) income attributable to noncontrolling interests 886         886
    Distribution to noncontrolling interest holder and other changes (2,683)         (2,683)
    Net income attributable to the Ensign Group, Inc. 170,478     170,478    
    Balance at end of period (in shares) at Dec. 31, 2020   54,626        
    Balance at end of period at Dec. 31, 2020 818,227 $ 58 338,177 551,055 $ (71,213) 150
    Balance at end of period (in shares) at Dec. 31, 2020         2,791  
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)   516        
    Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards 9,180   9,180      
    Issuance of restricted stock, net of forfeitures (in shares)   201        
    Issuance of restricted stock, net of forfeitures 3,725   3,725      
    Shares of common stock used to satisfy tax withholding obligations (in shares)   21     21  
    Shares of common stock used to satisfy tax withholding obligations (1,711)       $ (1,711)  
    Dividends declared (11,715)     (11,715)    
    Employee stock award compensation 18,678   18,678      
    Repurchase of common stock (in shares)   132     132  
    Repurchase of common stock (10,118)       $ (10,118)  
    Deconsolidation of an ancillary business (1,369)         (1,369)
    Capital contribution from noncontrolling interest holder 2,000         2,000
    Net (loss) income attributable to noncontrolling interests 3,073         3,073
    Distribution to noncontrolling interest holder and other changes (2,908)         (2,908)
    Net income attributable to the Ensign Group, Inc. $ 194,652     194,652    
    Balance at end of period (in shares) at Dec. 31, 2021 55,190 55,190        
    Balance at end of period at Dec. 31, 2021 $ 1,021,714 $ 58 369,760 733,992 $ (83,042) 946
    Balance at end of period (in shares) at Dec. 31, 2021 2,944       2,944  
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)   688        
    Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards $ 12,677 $ 1 12,676      
    Issuance of restricted stock, net of forfeitures (in shares)   207        
    Issuance of restricted stock, net of forfeitures 5,241   5,241      
    Shares of common stock used to satisfy tax withholding obligations (in shares)   20     20  
    Shares of common stock used to satisfy tax withholding obligations (1,702)       $ (1,702)  
    Dividends declared (12,334)     (12,334)    
    Employee stock award compensation 22,720   22,720      
    Repurchase of common stock (in shares)   404     404  
    Repurchase of common stock (29,882)       $ (29,882)  
    Acquisition of noncontrolling interest shares (704)   (1,539)     835
    Capital contribution from noncontrolling interest holder 6,693   6,693      
    Net (loss) income attributable to noncontrolling interests (29)         (29)
    Distribution to noncontrolling interest holder and other changes (275)   9     (284)
    Net income attributable to the Ensign Group, Inc. $ 224,681     224,681    
    Balance at end of period (in shares) at Dec. 31, 2022 55,661 55,661        
    Balance at end of period at Dec. 31, 2022 $ 1,248,800 $ 59 $ 415,560 $ 946,339 $ (114,626) $ 1,468
    Balance at end of period (in shares) at Dec. 31, 2022 3,368       3,368  
    XML 27 R7.htm IDEA: XBRL DOCUMENT v3.22.4
    CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Statement of Stockholders' Equity [Abstract]      
    Dividends per share (in dollars per share) $ 0.2225 $ 0.2125 $ 0.2025
    XML 28 R8.htm IDEA: XBRL DOCUMENT v3.22.4
    CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Cash flows from operating activities:      
    Net income $ 224,652 $ 197,725 $ 171,364
    Adjustments to reconcile net income to net cash provided by operating activities:      
    Depreciation and amortization 62,355 55,985 54,571
    Impairment of long-lived assets 0 0 2,681
    Amortization of deferred financing fees 1,036 859 840
    Non-cash leasing arrangement 493 485 451
    Write-off of deferred financing fees 566 0 0
    Deferred income taxes (6,496) (724) (27,809)
    Provision for doubtful accounts 2,390 2,609 7,058
    Stock-based compensation 22,720 18,678 14,524
    Cash received from insurance proceeds 1,282 2,382 0
    Gain on sale of assets (3,467) (1,371) 0
    Loss (gain) on insurance claims, legal finding and asset disposals 3,926 (977) 625
    Change in operating assets and liabilities      
    Accounts receivable (82,426) (30,771) 2,171
    Prepaid income taxes 809 (4,228) (485)
    Prepaid expenses and other assets (9,141) (4,898) (2,897)
    Deferred employer portion of social security taxes (24,155) (24,154) 48,309
    Cash surrender value of life insurance policy premiums (7,614) (10,953) (6,577)
    Deferred compensation liability 7,637 11,078 6,615
    Operating lease obligations 345 (5,814) (724)
    Accounts payable 17,870 7,117 6,627
    Accrued wages and related liabilities 38,982 47,701 68,365
    Other accrued liabilities 3,010 1,297 17,536
    Accrued self-insurance liabilities 17,785 13,724 10,293
    Other long-term liabilities (46) (66) (187)
    NET CASH PROVIDED BY OPERATING ACTIVITIES 272,513 275,684 373,351
    Cash flows from investing activities:      
    Purchase of property and equipment (87,545) (69,550) (50,326)
    Cash payments for business acquisitions (Note 9) (16,400) (6,000) 0
    Cash payments for asset acquisitions (Note 9) (84,736) (98,224) (24,997)
    Escrow deposits 0 100 (100)
    Escrow deposits used to fund acquisitions 0 0 14,050
    Cash from insurance proceeds 1,339 6,899 800
    Cash proceeds from the sale of assets 8,630 1,854 412
    Deconsolidation of an ancillary business 0 (1,984) 0
    Cash payments for Medicare and Medicaid licenses 0 (106) 0
    Purchases of investments (21,975) (32,257) (21,708)
    Maturities of investments 14,356 27,481 24,479
    Other restricted assets 149 (2,120) (1,276)
    NET CASH USED IN INVESTING ACTIVITIES (186,182) (173,907) (58,666)
    Cash flows from financing activities:      
    Proceeds from debt (Note 16) 411 45,218 417,200
    Payments on debt (Note 16) (4,106) (3,056) (629,745)
    Issuance of common stock upon exercise of options 12,677 9,180 12,654
    Repurchase of shares of common stock to satisfy tax withholding obligations (1,702) (1,711) (917)
    Repurchase of shares of common stock (Note 22) (29,882) (10,118) (25,000)
    Dividends paid (12,168) (11,548) (10,830)
    Proceeds from sale of subsidiary shares (Note 7) 6,693 0 0
    Non-controlling interest distribution (284) (2,908) (2,683)
    Purchase of non-controlling interest (704) 2,000 0
    Payments of deferred financing costs (3,197) (1,172) 0
    Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) 0 11,637 246,955
    Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) 0 (113,660) (144,932)
    NET CASH USED IN FINANCING ACTIVITIES (32,262) (76,138) (137,298)
    Net increase in cash and cash equivalents 54,069 25,639 177,387
    Cash and cash equivalents beginning of period 262,201 236,562 59,175
    Cash and cash equivalents end of period 316,270 262,201 236,562
    Cash paid during the period for:      
    Interest 7,604 5,690 9,920
    Income taxes 70,055 65,547 74,365
    Lease liabilities 151,870 138,795 129,569
    Non-cash financing and investing activity      
    Accrued capital expenditures 4,800 3,700 3,400
    Accrued dividends declared 3,201 3,035 2,868
    Note receivable from insurance settlement 0 0 5,500
    Right-of-use assets obtained in exchange for new and modified operating lease obligations $ 370,753 $ 198,593 $ 24,599
    XML 29 R9.htm IDEA: XBRL DOCUMENT v3.22.4
    DESCRIPTION OF BUSINESS
    12 Months Ended
    Dec. 31, 2022
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    DESCRIPTION OF BUSINESS DESCRIPTION OF BUSINESS
    The Company — The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company's independent operating subsidiaries provide health care services across the post-acute care continuum, engaged in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of December 31, 2022, the Company's independent operating subsidiaries operated 271 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's independent operating subsidiaries have a collective capacity of approximately 28,100 operational skilled nursing beds and 3,000 senior living units. As of December 31, 2022, the Company's independent operating subsidiaries operated 192 facilities under long-term lease arrangements, and had options to purchase 11 of those 192 facilities. The Company's real estate portfolio includes 108 owned real estate properties, which included 79 facilities operated and managed by the Company's independent operating subsidiaries, 29 senior living operations leased to and operated by The Pennant Group, Inc. (Pennant) as part of the spin-off transaction in October 2019, and the Service Center location. Of those 29 senior living operations, one is located on the same real estate property as a skilled nursing facility that the Company owns and operates.
    Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.
    In January of 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The Company expects the REIT structure will provide it with an efficient vehicle for future acquisitions of properties that could be operated by Ensign affiliates or other third parties. Refer to Note 7, Standard Bearer for additional information on Standard Bearer.
    Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Annual Report is not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.
    XML 30 R10.htm IDEA: XBRL DOCUMENT v3.22.4
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    12 Months Ended
    Dec. 31, 2022
    Accounting Policies [Abstract]  
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    Basis of Presentation The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its consolidated statements of income.
    The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest.
    ReclassificationsCertain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net income. Prior period results reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure as a result of the formation of Standard Bearer. Refer to Note 8, Business Segments. Reclassification adjustments have been made to reclassify investments associated with the Company's non-qualified deferred compensation plan with investments held by the Company's captive insurance subsidiary on the consolidated balance sheets.
    Estimates and Assumptions The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.
    Fair Value of Financial InstrumentsThe Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. See Note 6, Fair Value Measurements.
    Service Revenue RecognitionThe Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). See Note 4, Revenue and Accounts Receivable.
    Rental Revenue Recognition The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842). See Note 4, Revenue and Accounts Receivable.
    Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.
    Cash and Cash Equivalents Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.
    Insurance Subsidiary Deposits and Investments — The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution.
    The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. The fair value of the investment funds is derived using Level 2 inputs.
    When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.
    Property and Equipment Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
    Leases and Leasehold Improvements The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease at the inception of each lease. Leases commencing prior to the ASC 842 adoption date were classified as operating lease under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. For leases commencing subsequent to the ASC 842 adoption date, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December 31, 2022, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.
    The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.
    The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases.
    Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the years ended December 31, 2022 and 2021. The Company recorded an impairment charge of $2,681 during the year ended December 31, 2020.
    Intangible Assets and Goodwill Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
    The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
    Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any goodwill or intangible asset impairment during the years ended December 31, 2022, 2021, and 2020.
    Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,000 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
    The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider.
    The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.
    The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.
    In addition, the Company has recorded an asset and equal liability in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 13, Restricted and Other Assets.
    The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525, $500 and $300 for each covered person for fiscal years 2022, 2021 and 2020, respectively.
    The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.
    Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
    In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.
    Standard Bearer intends to qualify and elect to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer believes it has been organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions.
    Noncontrolling Interest The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
    Stock-Based CompensationThe Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.
    Comprehensive Income The Company does not have any components of other comprehensive income recorded within its consolidated Financial Statements and, therefore, does not separately present a statement of comprehensive income in its consolidated Financial Statements.
    Recent Accounting Pronouncements Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.
    Recent Accounting Standards Adopted by the Company In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance,” which created FASB ASC Topic 832, Government Assistance (ASC 832). ASC 832 requires business entities to disclose information about certain government assistance they receive. The Company adopted this standard on January 1, 2022 and determined there was no material impact on the Company's Financial Statements.
    In February 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848)," which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace London Interbank Offered Rate (LIBOR) reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2024. During the year ended December 31, 2022, the Company and its subsidiaries including Standard Bearer, entered into the Second Amendment to Third Amended and Restated Credit Agreement (such agreement, the Amended Credit Agreement, and the revolving credit facility thereunder, the Revolving Credit Facility), which increased the Revolving Credit Facility by $250,000 to an aggregate principal amount of up to $600,000. Pursuant to the Amended Credit Agreement, the Company transitioned from LIBOR to the Secured Overnight Financing Rate (SOFR) as the applicable reference rate for borrowings under the Revolving Credit Facility and determined there was no resulting material impact on the Company's Financial Statements.
    XML 31 R11.htm IDEA: XBRL DOCUMENT v3.22.4
    COVID-19 UPDATE
    12 Months Ended
    Dec. 31, 2022
    Unusual or Infrequent Items, or Both [Abstract]  
    COVID-19 UPDATE COVID-19 UPDATE
    The COVID-19 pandemic has continued to impact the Company's affiliated operations. In prior years, as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act), the Company received cash distributions of relief fund payments (Provider Relief Funds) and funds authorized by U.S. Department of Health and Human Services (HHS) to be used to protect residents of nursing homes and long-term care (LTC) facilities from the impact of COVID-19. During the year ended December 31, 2022, the Company did not receive Provider Relief Funds. During the year ended December 31, 2021 and 2020, the Company received and returned $11,637 and $141,700, respectively, in Provider Relief Funds.
    In fiscal year 2020, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in 2020 and the remaining funds of $102,023 in March 2021.
    The Families First Coronavirus Response Act was signed into law in 2020 to provide a temporary 6.2% increase to the Federal Medical Assistance Percentage (FMAP) effective January 1, 2020. The law permits states to retroactively change their state's Medicaid program rates effective as of January 1, 2020. The law provides discretion to each state and specifies the funds are to be used to reimburse the recipient for healthcare related expenses that are attributable to COVID-19 and associated with providing patient care. In addition, increases in Medicaid rates can come from other areas of the state's budget outside of FMAP funding. Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to COVID-19, the Company characterized such payments as variable revenue that required additional consideration and accordingly, the amount of state relief revenue recognized is limited to the actual COVID-19 related expenses incurred. As of December 31, 2022 and 2021, the Company had $1,001 and $1,781 in unapplied state relief funds, respectively. During the years ended December 31, 2022, 2021, and 2020, the Company received an additional $81,057, $70,484, and $51,927 in state relief funding and recognized $81,837, $75,231, and $45,407, respectively, as revenue.
    The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with approximately 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020, and paid the first and second half of the payments in the fourth quarters of 2021 and 2022, respectively.
    XML 32 R12.htm IDEA: XBRL DOCUMENT v3.22.4
    REVENUE AND ACCOUNTS RECEIVABLE
    12 Months Ended
    Dec. 31, 2022
    Revenue from Contract with Customer [Abstract]  
    REVENUE AND ACCOUNTS RECEIVABLE REVENUE AND ACCOUNTS RECEIVABLE
    Service Revenue

    The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.
    Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.
    Revenue from the Medicare and Medicaid programs accounted for 73.7%, 73.6% and 74.5% for the years ended December 31, 2022, 2021, and 2020, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the years ended December 31, 2022, 2021, and 2020.
    Rental Revenue

    The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue is recognized on a straight-line basis over the lease term if it has been deemed probable of collection. The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met.

    Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.
    Disaggregation of Revenue
    The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.
    Revenue by Payor

    The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed.
    Service revenue for the years ended December 31, 2022, 2021, and 2020 is summarized in the following tables:
     Year Ended December 31,
    202220212020
    Revenue% of RevenueRevenue% of RevenueRevenue% of Revenue
    Medicaid(1)
    $1,183,156 39.3 %$1,022,460 39.2 %$900,249 37.7 %
    Medicare832,160 27.7 727,103 27.8 727,374 30.5 
    Medicaid — skilled200,878 6.7 172,770 6.6 149,846 6.3 
    Total Medicaid and Medicare2,216,194 73.7 1,922,333 73.6 1,777,469 74.5 
    Managed care525,710 17.5 456,728 17.5 367,095 15.4 
    Private and other(2)
    266,807 8.8 232,415 8.9 242,875 10.1 
    SERVICE REVENUE$3,008,711 100.0 %$2,611,476 100.0 %$2,387,439 100.0 %
    (1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP and other COVID-19 related state funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

    In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $16,757, $15,985 and $15,157 for the years ended December 31, 2022, 2021, and 2020.
    Balance Sheet Impact
    Included in the Company’s consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of December 31, 2022 and 2021, or activity during the years ended December 31, 2022, 2021, and 2020.

    Accounts receivable as of December 31, 2022 and 2021, is summarized in the following table:
    December 31,
    20222021
    Medicaid$157,878 $123,647 
    Managed care95,940 79,722 
    Medicare76,526 59,797 
    Private and other payors85,890 76,778 
     416,234 339,944 
    Less: allowance for doubtful accounts(7,802)(11,213)
    ACCOUNTS RECEIVABLE, NET$408,432 $328,731 
    Practical Expedients and Exemptions
    As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.
    XML 33 R13.htm IDEA: XBRL DOCUMENT v3.22.4
    COMPUTATION OF NET INCOME PER COMMON SHARE
    12 Months Ended
    Dec. 31, 2022
    Earnings Per Share [Abstract]  
    COMPUTATION OF NET INCOME PER COMMON SHARE COMPUTATION OF NET INCOME PER COMMON SHAREBasic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.
    A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:

    Year Ended December 31,
     202220212020
    NUMERATOR:
    Net income$224,652 $197,725 $171,364 
    Less: net (loss) income attributable to noncontrolling interests (29)3,073 886 
    Net income attributable to The Ensign Group, Inc. $224,681 $194,652 $170,478 
    DENOMINATOR:
    Weighted average shares outstanding for basic net income per share54,887 54,486 53,434 
    Basic net income per common share:$4.09 $3.57 $3.19 

    A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:

    Year Ended December 31,
     202220212020
    NUMERATOR:
    Net income $224,652 $197,725 $171,364 
    Less: net (loss) income attributable to noncontrolling interests(29)3,073 886 
    Net income attributable to The Ensign Group, Inc. $224,681 $194,652 $170,478 
    DENOMINATOR:
    Weighted average common shares outstanding54,887 54,486 53,434 
    Plus: incremental shares from assumed conversion (1)
    1,984 2,439 2,353 
    Adjusted weighted average common shares outstanding56,871 56,925 55,787 
    Diluted net income per common share:$3.95 $3.42 $3.06 
    (1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 780, 198 and 956 for the years ended December 31, 2022, 2021 and 2020, respectively.
    XML 34 R14.htm IDEA: XBRL DOCUMENT v3.22.4
    FAIR VALUE MEASUREMENTS
    12 Months Ended
    Dec. 31, 2022
    Fair Value Disclosures [Abstract]  
    FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
    Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

    The fair value of cash and cash equivalents of $316,270 and $262,201 as of December 31, 2022 and 2021, respectively, is derived using Level 1 inputs. The Company's other financial assets include the captive insurance subsidiary's cash and cash equivalents, deposits and investments designated to support long-term insurance subsidiary liabilities and are carried at cost basis of $69,290 and $67,734 as of December 31, 2022 and 2021, respectively. Also included are contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans which are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. As of December 31, 2022, and 2021, the adjusted cost basis of the investment funds is $25,144 and $17,530, respectively.

    As of December 31, 2022 and 2021, the cost basis of the Company's financial assets included in the captive insurance subsidiary's investments and the deferred compensation plan investment funds are considered to approximate the fair value of these financial assets and are derived using Level 2 inputs.
    The Company believes its investments that were in an unrealized loss position as of December 31, 2022 do not require an allowance for expected credit losses, nor has any event occurred subsequent to that date that would indicate so.The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.
    XML 35 R15.htm IDEA: XBRL DOCUMENT v3.22.4
    STANDARD BEARER
    12 Months Ended
    Dec. 31, 2022
    Segment Reporting [Abstract]  
    STANDARD BEARER STANDARD BEARER
    Standard Bearer's real estate portfolio consists of 103 of the Company's 108 owned real estate properties, of which 75 are operated and managed by the Company and 29 are leased to and operated by Pennant. Of those 29 senior living operations, one is located on the same real estate property as a skilled nursing facility that the Company owns and operates. Standard Bearer intends to qualify and elect to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. During the year ended December 31, 2022, Standard Bearer acquired the real estate of ten skilled nursing facilities for a purchase price of $84,656, three of which were previously operated and managed by Ensign's affiliated operations. Refer to Note 9, Operation Expansions for additional information.
    As part of the formation of Standard Bearer, certain of the Company's operating subsidiaries, Standard Bearer and Standard Bearer's subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations. As these intercompany arrangements were entered into when Standard Bearer was formed in January 2022, the transactions related to these agreements are reflected in Standard Bearer's segment income during year ended December 31, 2022. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, Business Segments, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment.
    Intercompany master lease agreements
    Certain of the Company's operating subsidiaries and the 75 Standard Bearer subsidiaries entered into five "triple-net" master lease agreements (collectively, the Standard Bearer Master Leases) in January 2022. The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the operating subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The ten real estate properties acquired during year ended December 31, 2022 were added to the Standard Bearer Master Leases. Rental revenue generated from Ensign affiliated operations was $57,967, $44,165 and $40,946 for the years ended December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022, total annual rental income under the Standard Bearer Master Lease is approximately $62.5 million.
    Intercompany management agreement
    Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue. Management fee generated between Standard Bearer and the Service Center for the year ended December 31, 2022 was $4,367, which represents 6% of total Standard Bearer rental revenue. No management fees were recorded in 2021 and 2020, which was prior to the formation of Standard Bearer.
    Intercompany debt arrangements

    Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Revolving Credit Facility to fund acquisitions and working capital needs. The interest rate under the Amended Credit Agreement is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum.
    In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory notes are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 16, Debt, for additional information related to these debts.
    Equity Instrument Denominated in the Shares of a Subsidiary
    As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's affiliated subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to Standard Bearer at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. During the year ended December 31, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the year ended December 31, 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.
    During the year ended December 31, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders. The value of Standard Bearer common and preferred shares held by the Company are eliminated in consolidation and the value held by other shareholders are classified as noncontrolling interests on the Company's consolidated balance sheets.
    Dividends on Shares of a Subsidiary
    During the year ended December 31, 2022, Standard Bearer met the requirement to distribute to its shareholders at least 90% of its annual taxable income through a declaration and payment of cash dividends totaling $30,379. Of that amount, $30,095 was paid in the form of a distribution to the Company and $284 was paid in the form of a distribution to noncontrolling interests.
    XML 36 R16.htm IDEA: XBRL DOCUMENT v3.22.4
    BUSINESS SEGMENTS
    12 Months Ended
    Dec. 31, 2022
    Segment Reporting [Abstract]  
    BUSINESS SEGMENTS BUSINESS SEGMENTS
    In conjunction with the formation of Standard Bearer in January 2022, the Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, began reviewing the results of Standard Bearer instead of all real estate properties. Accordingly, the Company revised its former real estate segment to include only real estate properties that are part of Standard Bearer. This change in organizational structure demonstrates that Standard Bearer's real estate is a core part of the Company's expansion of its real estate investment strategy. As of the first quarter of 2022, the Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. Segment information for prior periods has been recast to reflect the change of the Company’s segment structure.

    As of December 31, 2022, the skilled services segment includes 234 skilled nursing operations and 26 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 103 owned real estate properties. These properties include 75 operations the Company operated and managed and 29 senior living operations that are leased to and operated by third parties. Of the 29 real estate operations leased to third parties, one senior living operation is located on the same real estate property as a skilled nursing facility that the Company owns and operates.

    The Company also reports an “All Other” category that includes results from its senior living operations, which includes eleven stand-alone senior living operations and the senior living operations at 26 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.
    The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.

    The accounting policies of the reportable segments are the same as those described in Note 2, Summary of Significant Accounting Policies. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, real estate insurance recoveries and losses and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 7, Standard Bearer, as it is part of the CODM financial information.

    The following tables set forth financial information for the segments:
     Year Ended December 31, 2022
     Skilled ServicesStandard Bearer
    All Other(1)
    Intercompany EliminationTotal
    Service revenue(2)
    $2,906,215 $— $115,214 $(12,718)$3,008,711 
    Rental revenue(3)
    — 72,937 7,396 (63,576)16,757 
    TOTAL REVENUE$2,906,215 $72,937 $122,610 $(76,294)$3,025,468 
    Segment income (loss)408,732 27,871 (150,781)— 285,822 
    Gain on sale of real estate assets and insurance recoveries, net3,267 
    Income before provision for income taxes$289,089 
    Depreciation and amortization33,224 21,613 7,518 — 62,355 
    Interest expense(4)
    $— $15,707 $1,870 $(8,646)$8,931 
    (1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
    (2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
    (3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
    (4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column.

     Year Ended December 31, 2021
     Skilled ServicesStandard Bearer
    All Other(1)
    Intercompany EliminationTotal
    Service revenue(2)
    $2,523,234 $— $95,276 $(7,034)$2,611,476 
    Rental revenue(3)
    — 58,127 7,409 (49,551)15,985 
    TOTAL REVENUE$2,523,234 $58,127 $102,685 $(56,585)$2,627,461 
    Segment income (loss)373,603 31,876 (147,915)— 257,564 
    Gain on real estate insurance recoveries440 
    Income before provision for income taxes$258,004 
    Depreciation and amortization30,681 17,558 7,746 — 55,985 
    Interest expense$— $6,842 $$— $6,849 
    (1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
    (2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
    (3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
     
    Year Ended December 31, 2020
     Skilled ServicesStandard Bearer
    All Other(1)
    Intercompany EliminationTotal
    Service revenue(2)
    $2,288,182 $— $105,548 $(6,291)$2,387,439 
    Rental revenue(3)
    — 54,104 7,171 (46,118)15,157 
    TOTAL REVENUE$2,288,182 $54,104 $112,719 $(52,409)$2,402,596 
    Segment income (loss)327,812 27,299 (134,752)— 220,359 
    Loss on sale of real estate and impairment charges(2,753)
    Income before provision for income taxes $217,606 
    Depreciation and amortization28,585 16,134 9,852 — 54,571 
    Interest expense$— $9,350 $12 $— $9,362 
    (1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
    (2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
    (3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.

    Service revenue by major payor source were as follows:
     Year Ended December 31, 2022
     Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
    Medicaid(1)
    $1,158,309 $24,847 $1,183,156 39.3 %
    Medicare832,160 — 832,160 27.7 
    Medicaid-skilled200,878 — 200,878 6.7 
    Subtotal2,191,347 24,847 2,216,194 73.7 
    Managed care525,710 — 525,710 17.5 
    Private and other(2)
    189,158 77,649 266,807 8.8 
    TOTAL SERVICE REVENUE$2,906,215 $102,496 $3,008,711 100.0 %
    (1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

     Year Ended December 31, 2021
     Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
    Medicaid(1)
    $1,007,061 $15,399 $1,022,460 39.2 %
    Medicare727,103 — 727,103 27.8 
    Medicaid-skilled172,770 — 172,770 6.6 
    Subtotal1,906,934 15,399 1,922,333 73.6 
    Managed care456,728 — 456,728 17.5 
    Private and other(2)
    159,572 72,843 232,415 8.9 
    TOTAL SERVICE REVENUE$2,523,234 $88,242 $2,611,476 100.0 %
    (1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
     
    Year Ended December 31, 2020
     Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
    Medicaid(1)
    $886,991 $13,258 $900,249 37.7 %
    Medicare727,374 — 727,374 30.5 
    Medicaid-skilled149,846 — 149,846 6.3 
    Subtotal1,764,211 13,258 1,777,469 74.5 
    Managed care367,095 — 367,095 15.4 
    Private and other(2)
    156,876 85,999 242,875 10.1 
    TOTAL SERVICE REVENUE$2,288,182 $99,257 $2,387,439 100.0 %
    (1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
    XML 37 R17.htm IDEA: XBRL DOCUMENT v3.22.4
    OPERATION EXPANSIONS
    12 Months Ended
    Dec. 31, 2022
    Business Combination and Asset Acquisition [Abstract]  
    OPERATION EXPANSIONS OPERATION EXPANSIONS
    The Company's subsidiaries expansion focus is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business, or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, a real estate affiliated subsidiary will acquire the property of facilities that have previously been operated under third-party leases.
    FASB ASC Topic 805, Clarifying the Definition of a Business (ASC 805) defined the definition of a business to assist entities with evaluating when a set of transferred assets and activities is deemed to be a business. Determining whether a transferred set constitutes a business is important because the accounting for a business combination differs from that of an asset acquisition. The definition of a business also affects the accounting for dispositions. When substantially all of the fair value of assets acquired is concentrated in a single asset, or a group of similar assets, the assets acquired would not represent a business and business combination accounting would not be required.
    2022 Expansions
    During the year ended December 31, 2022, the Company expanded its operations through a combination of long-term leases and real estate purchases, with the addition of 23 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of seven of the stand-alone skilled nursing operations, which were leased back to Ensign affiliated entities. In addition, the Company purchased the real estate at three skilled nursing properties that the Company was already operating, further expanding the Company's real estate portfolio. Refer to Note 7, Standard Bearer, for additional information on the purchase of real estate properties. In addition, the Company added five senior living operations that were transferred from Pennant, three of which are part of campuses operated by the Company's affiliated operating subsidiaries. These new operations added a total of 3,058 operational skilled nursing beds and 674 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. The aggregate purchase price for these expansions during the year ended December 31, 2022 was $101,136.
    In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
    The aggregate purchase price for the transactions that were classified as asset acquisitions during the year ended December 31, 2022 was $84,736, consisting of real estate properties and indefinite-lived intangible assets. The remaining aggregate purchase price for transactions during the year ended December 31, 2022 was concentrated in goodwill of $16,400 and accordingly, the transactions were classified as business combinations.
    Subsequent to December 31, 2022, the Company expanded its operations through a combination of long-term leases, with the addition of seventeen stand-alone skilled nursing operations. These new operations added 1,462 operational skilled nursing beds. The Company also invested in new ancillary services that are complementary to its existing businesses. In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
    2021 Expansions
    During the year ended December 31, 2021, the Company expanded its operations through a combination of long-term leases and a real estate purchase, with the addition of 17 stand-alone skilled nursing operations and five real estate purchases, four of which the Company previously operated and continues to operate. The remaining real estate purchase is operated by Pennant. These new operations added a total of 1,832 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The aggregate purchase price for these acquisitions during the year ended December 31, 2021 was $104,224.
    In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
    The aggregate purchase price for the asset acquisitions during the year ended December 31, 2021 was $98,224, consisting of real estate properties. The fair value of assets for the remaining additions was concentrated in goodwill of $6,000 and as such, the transaction was classified as a business combination.
    2020 Acquisitions
    During the year ended December 31, 2020, the Company expanded its operations through a combination of long-term leases and real estate purchases, with the addition of five stand-alone skilled nursing operations, one stand-alone senior living operation and one campus operation. Of these additions, four are related to purchases of owned properties, further expanding the Company's real estate portfolio. These new operations added a total of 507 operational skilled nursing beds and 298 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The aggregate purchase price for these acquisitions during the year ended December 31, 2020 was $24,997.
    In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
    The fair value of assets for the purchases of these properties was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions.
    During the first quarter of 2020, the Company entered into a long-term lease agreement to transfer two senior living operations to Pennant. Ensign affiliates retained ownership of the real estate for these two senior living communities, which was subsequently sold in 2022.     
    The table below presents the allocation of the purchase price for the operations acquired during the years ended December 31, 2022, 2021, and 2020, excluding assets that were contributed to Pennant that occurred during the spin-off transaction in 2019.
    Year Ended December 31,
    202220212020
    Land$15,527 $19,928 $9,496 
    Building and improvements65,070 77,975 14,178 
    Equipment, furniture, and fixtures1,618 217 568 
    Assembled occupancy367 29 107 
    Goodwill16,400 6,000 — 
    Leased asset1,909 — — 
    Other indefinite-lived intangible assets245 75 648 
    TOTAL ACQUISITIONS$101,136 $104,224 $24,997 
    The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The assets added during the year ended December 31, 2022 and through the issuance of the Financial Statements were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the December 31, 2022 consolidated balance sheets of the Company, and the operating results have been included in the consolidated statements of operations of the Company since the date the Company gained effective control.
    XML 38 R18.htm IDEA: XBRL DOCUMENT v3.22.4
    PROPERTY AND EQUIPMENT— NET
    12 Months Ended
    Dec. 31, 2022
    Property, Plant and Equipment [Abstract]  
    PROPERTY AND EQUIPMENT— NET PROPERTY AND EQUIPMENT - NET
    Property and equipment, net consists of the following:
    December 31,
    20222021
    Land$134,864 $121,164 
    Buildings and improvements728,231 646,221 
    Leasehold improvements150,903 140,012 
    Equipment295,739 262,246 
    Furniture and fixtures4,544 4,305 
    Construction in progress17,521 10,253 
     1,331,802 1,184,201 
    Less: accumulated depreciation(339,792)(295,767)
    PROPERTY AND EQUIPMENT, NET$992,010 $888,434 
    The Company completed the sale of assets for a sale price of $8,607 and recorded a gain of $3,467 within the Company's consolidated statement of income as cost of services during the year ended December 31, 2022. In addition, the Company evaluated its long-lived assets and did not record an impairment charge for the fiscal years ended 2022 and 2021. The Company recorded impairment charges of $2,681 for the fiscal year ended 2020. See also Note 7, Standard Bearer and Note 9, Operation Expansions for information on acquisitions during the year ended December 31, 2022.
    XML 39 R19.htm IDEA: XBRL DOCUMENT v3.22.4
    INTANGIBLE ASSETS — NET
    12 Months Ended
    Dec. 31, 2022
    Intangible Assets, Net (Excluding Goodwill) [Abstract]  
    INTANGIBLE ASSETS — NET INTANGIBLE ASSETS - NET
    Weighted Average Life (Years)December 31,
    20222021
    Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
    Intangible AssetsNetNet
    Assembled occupancy0.3$435 $(388)$47 $68 $(68)$— 
    Facility trade name30.0733 (415)318 733 (391)342 
    Customer relationships18.44,582 (2,482)2,100 4,582 (2,272)2,310 
    TOTAL $5,750 $(3,285)$2,465 $5,383 $(2,731)$2,652 

    During the years ended December 31, 2022, 2021, and 2020, amortization expense was $1,714, $1,435 and $1,813, respectively, of which $1,160, $1,158, and $1,223 was related to the amortization of right-of-use assets, respectively. The Company did not record any impairment charge to intangible assets during the years ended December 31, 2022, 2021, and 2020.
    Estimated amortization expense for each of the years ending December 31 is as follows:
    YearAmount
    2023$281 
    2024234 
    2025234 
    2026234 
    2027234 
    Thereafter1,248 
     $2,465 
    XML 40 R20.htm IDEA: XBRL DOCUMENT v3.22.4
    GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS
    12 Months Ended
    Dec. 31, 2022
    Goodwill and Intangible Assets Disclosure [Abstract]  
    GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS
    The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value.
    The Company performs its goodwill impairment test annually and evaluates goodwill when events or changes in circumstances indicate that its carrying value may not be recoverable. The Company performs the annual impairment testing of goodwill using October 1 as the measurement date. The Company completed its goodwill impairment test as of October 1, 2022 and did not record any impairment charge to goodwill or other intangible assets for the fiscal years 2022, 2021 or 2020. The Company has recognized cumulative goodwill impairment losses of $7,410.
    The Company anticipates that the majority of goodwill recognized will be fully deductible for tax purposes as of December 31, 2022.

    All of the Company's acquisitions during the year ended December 31, 2020 were classified as asset acquisitions and accordingly, no goodwill was recognized for these acquisitions. There were no other activities in goodwill during the year ended December 31, 2020. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of and for the year ended December 31, 2022, 2021 and 2020:
    Goodwill
     Skilled ServicesAll OtherTotal
    January 1, 2020$45,486 $8,983 $54,469 
    December 31, 2020$45,486 $8,983 $54,469 
    Additions6,000 — 6,000 
    December 31, 2021$51,486 $8,983 $60,469 
    Additions16,400 — 16,400 
    December 31, 2022$67,886 $8,983 $76,869 
    During the year ended December 31, 2022, the Company acquired $245 in Medicare and Medicaid licenses compared to $181 and $648 in the fiscal years 2021 and 2020, respectively.
    Other indefinite-lived intangible assets consist of the following:
    December 31,
    20222021
    Trade name$889 $889 
    Medicare and Medicaid licenses3,083 2,838 
    TOTAL$3,972 $3,727 
    XML 41 R21.htm IDEA: XBRL DOCUMENT v3.22.4
    RESTRICTED AND OTHER ASSETS
    12 Months Ended
    Dec. 31, 2022
    Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
    RESTRICTED AND OTHER ASSETS RESTRICTED AND OTHER ASSETSRestricted and other assets consist of the following:
    December 31,
    20222021
    Debt issuance costs, net$3,753 $1,953 
    Long-term insurance losses recoverable asset10,512 6,755 
    Capital improvement reserves with landlords and lenders6,446 7,103 
    Deposits with landlords2,527 2,606 
    Other14,053 11,099 
    RESTRICTED AND OTHER ASSETS$37,291 $29,516 
    Included in restricted and other assets as of December 31, 2022 and 2021 are anticipated insurance recoveries related to the Company's workers' compensation, general and professional liability claims that are recorded on a gross rather than net basis in accordance with an Accounting Standards Update issued by the FASB.
    XML 42 R22.htm IDEA: XBRL DOCUMENT v3.22.4
    OTHER ACCRUED LIABILITIES
    12 Months Ended
    Dec. 31, 2022
    Payables and Accruals [Abstract]  
    OTHER ACCRUED LIABILITIES OTHER ACCRUED LIABILITIES
    Other accrued liabilities consists of the following:
    December 31,
    20222021
    Quality assurance fee$7,701 $6,474 
    Refunds payable40,783 34,814 
    Resident advances9,698 9,337 
    Unapplied state relief funds1,001 1,781 
    Cash held in trust for patients6,400 6,430 
    Dividends payable3,201 3,035 
    Property taxes10,926 9,124 
    Legal finding accrued4,553 — 
    Other13,046 18,415 
    OTHER ACCRUED LIABILITIES$97,309 $89,410 

    Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the consolidated balance sheets.
    XML 43 R23.htm IDEA: XBRL DOCUMENT v3.22.4
    INCOME TAXES
    12 Months Ended
    Dec. 31, 2022
    Income Tax Disclosure [Abstract]  
    INCOME TAXES INCOME TAXES
    The provision for income taxes on continuing operations for the years ended December 31, 2022, 2021 and 2020 is summarized as follows:
     Year Ended December 31,
     2022 2021 2020
    Current:   
    Federal$56,717 $49,105 $60,591 
    State14,216 11,898 13,460 
     70,933 61,003 74,051 
    Deferred: 
    Federal(5,158)(716)(23,054)
    State(1,338)(8)(4,755)
    (6,496)(724)(27,809)
         TOTAL$64,437 $60,279 $46,242 

    A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2022, 2021 and 2020, respectively, is comprised as follows:

     
     December 31,
     202220212020
    Income tax expense at statutory rate21.0 %21.0 %21.0 %
    State income taxes - net of federal benefit3.5 3.7 3.2 
    Non-deductible expenses2.0 2.4 1.8 
    Equity compensation(3.6)(3.3)(4.3)
    Other adjustments(0.6)(0.4)(0.4)
    TOTAL INCOME TAX PROVISION22.3 %23.4 %21.3 %

    The Company's effective tax rate was 22.3% for the year ended December 31, 2022, compared to 23.4% for the same period in 2021 and 21.3% in 2020. The lower effective tax rate is due to higher tax benefits from stock compensation and lower tax expense from non-deductible expenses.
    The Company's deferred tax assets and liabilities as of December 31, 2022 and 2021 are summarized below.

     December 31,
     2022 2021
    Deferred tax assets (liabilities): 
    Accrued expenses$61,685 $58,640 
    Revenue related reserves18,046 13,171 
    Tax credits1,742 2,138 
    Insurance11,910 8,712 
    Lease liability 364,408 285,643 
    State taxes 28 (165)
    457,819 368,139 
    Valuation allowance(789)(789)
    TOTAL DEFERRED TAX ASSETS457,030 367,350 
    Depreciation and amortization(49,146)(45,827)
    Prepaid expenses(5,150)(4,265)
    Right of use asset (363,091)(284,111)
    TOTAL DEFERRED TAX LIABILITIES(417,387)(334,203)
    NET DEFERRED TAX ASSETS$39,643 $33,147 
    The Company had state credit carryforwards as of December 31, 2022 and 2021 of $1,742 and $2,138, respectively. These carryforwards almost entirely relate to state limitations on the application of Enterprise Zone employment-related tax credits. Unless the Company uses the Enterprise Zone credits beforehand, the carryforward will begin to expire in 2023. As of December 31, 2022 and 2021, the valuation allowance of $789, for both years, was primarily recorded against the Enterprise Zone credits as the Company believes it is more likely than not that some of the benefit of the credits will not be realized.
    The Company's operating loss carry forwards for states were not material during the years ended December 31, 2022 and 2021.
    As of December 31, 2022, 2021 and 2020, the Company did not have any unrecognized tax benefits, net of its state benefits that would affect the Company's effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material.
    The Federal statutes of limitations on the Company's 2018, 2017, and 2016 income tax years lapsed during the third quarter of 2022, 2021, and 2020, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses for the years ended December 31, 2022 and 2021 had no impact on the Company's unrecognized tax benefits.
    During the year ended December 31, 2021, the state of Wisconsin initiated and completed an examination of the Company's 2019, 2018, and 2017 state tax years with no adjustments. The Company is not under examination by any major income tax jurisdiction.
    XML 44 R24.htm IDEA: XBRL DOCUMENT v3.22.4
    DEBT
    12 Months Ended
    Dec. 31, 2022
    Debt Disclosure [Abstract]  
    DEBT DEBT
    Debt consists of the following:
    December 31,
    20222021
    Mortgage loans and promissory notes$156,271 $159,967 
    Less: current maturities(3,883)(3,760)
    Less: debt issuance costs, net(3,119)(3,324)
    LONG-TERM DEBT LESS CURRENT MATURITIES$149,269 $152,883 
    Credit Facility with a Lending Consortium Arranged by Truist

    The Company maintains a revolving credit facility between the Company and its subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Revolving Credit Facility). Borrowings are supported by a lending consortium arranged by Truist. On April 8, 2022, the Company and its subsidiaries, including Standard Bearer, entered into the Amended Credit Agreement, which amended the Revolving Credit Facility to increase the revolving line of credit from $350,000 to $600,000 in aggregate principal amount. The Amended Credit Agreement also extended the maturity date of the Revolving Credit Facility to April 8, 2027 and modified the reference rate from LIBOR to SOFR. The interest rates applicable to loans under the Amended Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company and its subsidiaries, including Standard Bearer, will pay a commitment fee on the unused portion of the commitments that will range from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. Except as set forth in the Amended Credit Facility, all other terms and conditions of the Credit Facility remained in full force and effect as described below. As part of the entry into the Amended Credit Agreement, deferred financing costs of $566 were written off and additional deferred financing costs of $3,197 were capitalized during the year ended December 31, 2022.

    Borrowings made under the Revolving Credit Facility are guaranteed, jointly and severally, by certain of the Company’s wholly-owned subsidiaries, and are secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of their personal property. The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Amended Credit Agreement, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six months period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of December 31, 2022, and January 30, 2023, there was no outstanding debt under the Revolving Credit Facility. The Company was in compliance with all loan covenants as of December 31, 2022.
    Mortgage Loans and Promissory Notes

    As of December 31, 2022, the Company's operating subsidiaries had $156,271 outstanding under the mortgage loans and notes, of which $3,883 is classified as short-term and the remaining $152,388 is classified as long-term. The Company was in compliance with all loan covenants as of December 31, 2022.

    As of December 31, 2022, 23 of the Company's subsidiaries have mortgage loans insured with HUD in the aggregate amount of $153,488, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, we incur other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years.

    In addition to the HUD mortgage loans above, the Company has two promissory notes. The notes bear fixed interest rates of 6.3% and 5.3% per annum and the term of the notes are 10 months and 12 years, respectively. The 12 year note which was used for an acquisition is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.
    Future principal payments due under the long-term debt arrangements discussed above are as follows:

    Years Ending December 31,Amount
    2023$3,883 
    20243,950 
    20254,086 
    20264,227 
    20273,897 
    Thereafter136,228 
     $156,271 

    Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.
    Off-Balance Sheet Arrangements

    As of December 31, 2022, the Company had approximately $6,710 of borrowing capacity under the Revolving Credit Facility pledged as collateral to secure outstanding letters of credit, which remained consistent from 2021.
    XML 45 R25.htm IDEA: XBRL DOCUMENT v3.22.4
    OPTIONS AND AWARDS
    12 Months Ended
    Dec. 31, 2022
    Share-Based Payment Arrangement [Abstract]  
    OPTIONS AND AWARDS OPTIONS AND AWARDS
    Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s consolidated statements of income for the years ended December 31, 2022, 2021, and 2020 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.
    The Company has one active stock incentive plan, the 2022 Omnibus Incentive Plan (the 2022 Plan), which was approved by the Company's stockholders on May 26, 2022, and replaced the Company's prior option plan, the 2017 Omnibus Incentive Plan (the 2017 Plan).
    2022 Omnibus Incentive Plan (2022 Plan)  During the second quarter of 2022, the Company's shareholders approved the 2022 Plan. Including the shares rolled over from the 2017 Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. At December 31, 2022, the total number of shares available for issuance under the 2022 Plan was 2,861.
    2017 Omnibus Incentive Plan (2017 Plan) — The 2017 Plan provided for the issuance of 6,881 shares of common stock which are to be proportionally adjusted in the event of any Equity Restructuring. The number of shares available to be issued under the 2017 Plan were adjusted to 8,118 shares of common stock in order to reflect the proportional adjustments as part of the spin-off transaction that occurred in October 2019. The number of shares available to be issued under the 2017 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) 2.5 shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Granted non-employee director options vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. The Company granted 165 stock options and 116 restricted stock awards from the 2017 Plan in the first half of 2022 prior to the retirement of the 2017 plan.
    The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Black-Scholes model required the Company to make several key judgments including:
    The expected option term is calculated by the average of the contractual term of the options and the weighted average vesting period for all options. The calculation of the expected option term is based on the Company's experience due to sufficient history.
    The Company utilizes its own experience to calculate estimated volatility for options granted.
    The dividend yield is based on the Company's historical pattern of dividends as well as expected dividend patterns.
    The risk-free rate is based on the implied yield of U.S. Treasury notes as of the grant date with a remaining term approximately equal to the expected term.
    Estimated forfeiture rate of approximately 7.84% per year is based on the Company's historical forfeiture activity of unvested stock options.
    Stock Options
    The Company granted 581, 621 and 669 stock options from the available plans during the year ended December 31, 2022, 2021 and 2020, respectively. The Company used the following assumptions for stock options granted during the years ended December 31, 2022, 2021 and 2020:
    Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
    20225812.8%6.2 years42.1%0.3%
    20216211.0%6.2 years42.4%0.3%
    20206690.6%6.2 years39.4%0.4%
    For the years ended December 31, 2022, 2021 and 2020, the following represents the exercise price and fair value displayed at grant date for stock option grants:
    Grant YearGrantedWeighted Average Exercise PriceWeighted Average Fair Value of Options
    2022581$85.74 $37.83 
    2021621$80.19 $32.82 
    2020669$52.20 $19.52 

    The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended December 31, 2022, 2021 and 2020 and therefore, the intrinsic value was $0 at the date of grant.
    The following table represents the employee stock option activity during the year ended December 31, 2022, 2021 and 2020:
    Number of Options OutstandingWeighted Average
    Exercise Price
    Number of
    Options Vested
    Weighted Average Exercise Price of Options Vested
    January 1, 20204,428 $20.85 2,557 $12.82 
    Granted669 52.20 
    Forfeited(80)33.68 
    Exercised(979)12.93 
    December 31, 20204,038 $27.71 2,148 $16.66 
    Granted621 80.19 
    Forfeited(105)44.76 
    Exercised(516)17.80 
    December 31, 20214,038 $36.60 2,183 $21.02 
    Granted581 85.74 — — 
    Forfeited(98)59.52 — — 
    Exercised(688)18.43 — — 
    December 31, 20223,833 $46.72 2,069 $28.87 


    The following summary information reflects stock options outstanding, vested and related details as of December 31, 2022:
    Stock Options OutstandingStock Options Vested
     
    Number OutstandingBlack-Scholes Fair ValueRemaining Contractual Life (Years)Vested and Exercisable
    Year of GrantExercise Price
    20136.76-9.7465 274 165 
    20148.94-16.05399 1,930 2399 
    201518.20-21.39211 1,645 3211 
    201615.93-16.86198 1,162 4198 
    201715.80-19.41236 1,387 5236 
    201822.49-32.71449 4,341 6330 
    201941.07-45.76590 9,275 7324 
    202044.84-59.49545 10,734 8197 
    202173.47-83.64567 18,597 9109 
    2022$79.79$94.88573 21,689 10— 
    TOTAL 3,833 $71,034  2,069 
    The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2022, 2021 and 2020 is as follows:
    December 31,
    Options202220212020
    Outstanding$183,593 $191,242 $182,552 
    Vested136,000 137,382 120,867 
    Expected to vest43,232 48,548 53,366 
    The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. The aggregate intrinsic value of options that vested during the year ended December 31, 2022, 2021 and 2020 was $27,955, $27,731, and $26,030, respectively. The total intrinsic value of options exercised during the year ended December 31, 2022, 2021 and 2020 was $47,441, $34,278, and $45,081, respectively.
    Restricted Stock Awards
    The Company granted 233, 222 and 281 restricted stock awards during the years ended December 31, 2022, 2021 and 2020, respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the years ended December 31, 2022, 2021 and 2020 ranged from $73.17 to $94.88, $72.84 to $93.31 and $35.47 to $58.06, respectively. The fair value per share includes quarterly stock awards to non-employee directors.

    A summary of the status of the Company's non-vested restricted stock awards as of December 31, 2022 and changes during the years ended December 31, 2022, 2021 and 2020 is presented below:
    Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
    Nonvested at January 1, 2020610 $31.35 
    Granted281 48.73 
    Vested(280)32.84 
    Forfeited(20)31.71 
    Nonvested at December 31, 2020591 $38.90 
    Granted222 81.65 
    Vested(244)47.45 
    Forfeited(20)45.64 
    Nonvested at December 31, 2021549 $52.16 
    Granted233 81.57 
    Vested(269)54.06 
    Forfeited(26)57.29 
    Nonvested at December 31, 2022487 $64.92 
    During the year ended December 31, 2022, the Company granted 18 automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors from the 2017 and 2022 Plan. The fair value per share of these stock awards ranged from $75.33 to $86.34 based on the market price on the grant date.
    Long-Term Incentive Plan
    On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off transaction in 2019 are granted shares of restricted stock upon successful completion. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested shall be entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $836, $854, and $881 for the years ended December 31, 2022, 2021 and 2020, respectively.
    Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December 31, 2022, 2021, and 2020 was as follows:

    Year Ended December 31,
     202220212020
    Stock-based compensation expense related to stock options$11,361 $8,459 $6,132 
    Stock-based compensation expense related to restricted stock awards9,920 8,385 7,373 
    Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors1,439 1,834 1,019 
    TOTAL$22,720 $18,678 $14,524 
    In future periods, the Company expects to recognize approximately $43,388 and $29,149 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of December 31, 2022. Future stock-based compensation expense will be recognized over 3.6 and 3.4 weighted average years for unvested options and restricted stock awards, respectively. There were 1,764 unvested and outstanding options as of December 31, 2022, of which 1,666 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of December 31, 2022 was 6.0 years.
    XML 46 R26.htm IDEA: XBRL DOCUMENT v3.22.4
    LEASES
    12 Months Ended
    Dec. 31, 2022
    Leases [Abstract]  
    LEASES LEASES
    The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 affiliated skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.
    The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
    The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations under the Master Leases was approximately $64,178, $59,571 and $52,838 for the years ended December 31, 2022, 2021 and 2020, respectively.
    Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December 31, 2022.
    In connection with the spin-off transaction in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.
    The Company leases certain affiliated operations and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $153,174, $139,458 and $129,990 for the year ended December 31, 2022, 2021 and 2020, respectively.
    Fifty-eight of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under ten separate master lease arrangements. During 2022, the Company amended two of its separate master leases to add operations and extend the initial terms, which increased the lease liabilities and right-of-use assets by $207,638 to reflect the new lease obligations. Additionally, during 2022, the Company added six new operations to two new master leases, which increased the lease liabilities and right-of-use assets by $54,755 to reflect the new lease obligations. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.
    During 2022, Standard Bearer acquired the real estate of three skilled nursing operations, which were previously under separate long-term lease arrangements. The aggregate reduction in the carrying value of the Company's lease liabilities and right-of-use assets related to this acquisition is $10,080.

    The components of operating lease expense are as follows:
    Year Ended December 31,
    202220212020
    Rent - cost of services(1)
    $153,049 $139,371 $129,926 
    General and administrative expense125 87 64 
    Depreciation and amortization(2)
    1,160 1,158 1,223 
    Variable lease costs(3)
    16,938 14,077 12,774 
    $171,272 $154,693 $143,987 
    (1)Rent- cost of services includes deferred rent expense adjustments of $493, $485 and $451 for the years ended December 31, 2022, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $5,878, $3,702, $2,394 for the years ended December 31, 2022, 2021, and 2020 respectively.
    (2)Depreciation and amortization is related to the amortization of favorable and direct lease costs.
    (3)Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.

    Future minimum lease payments for all leases as of December 31, 2022 are as follows:
    YearAmount
    2023$157,963 
    2024157,630 
    2025157,455 
    2026157,380 
    2027156,860 
    Thereafter1,456,411 
    TOTAL LEASE PAYMENTS2,243,699 
    Less: present value adjustment (822,790)
    PRESENT VALUE OF TOTAL LEASE LIABILITIES1,420,909 
    Less: current lease liabilities(65,796)
    LONG-TERM OPERATING LEASE LIABILITIES$1,355,113 
    Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of December 31, 2022 and 2021, the weighted average remaining lease term is 15.0 and 14.8, respectively, and the weighted average discount rate used to determine the operating lease liabilities is 6.7% and 7.6%, respectively.
    Subsequent to December 31, 2022, the Company expanded its operations through two separate master lease arrangements for 20 stand-alone skilled nursing operations, of which 17 will be operated by the Company's affiliated operating subsidiaries and the remaining three will be subleased to a third-party operator. The aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the two separate master lease agreements is estimated to be approximately $315,337.
    Lessor Activities

    In connection with the spin-off transaction in 2019, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. As of December 31, 2022, Ensign affiliates retained ownership of the real estate for these 29 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years.


    Total rental income from all third-party sources for the years ended December 31, 2022, 2021, and 2020 is as follows:

    Year Ended December 31,
    202220212020
    Pennant(1)
    $14,915 $14,073 $13,163 
    Other third-party1,842 1,912 1,994 
    $16,757 $15,985 $15,157 
    (1) Pennant rental income includes variable rent such as property taxes of $1,318, $1,199, and $1,224 during the year ended December 31, 2022, 2021, and 2020.

    Future annual rental income for all leases as of December 31, 2022 were as follows:
    Year
    Amount(1)
    2023$16,408 
    202415,826 
    202515,391 
    202615,166 
    202715,166 
    Thereafter79,171 
    TOTAL$157,128 
    (1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2022.
    LEASES LEASES
    The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 affiliated skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.
    The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
    The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations under the Master Leases was approximately $64,178, $59,571 and $52,838 for the years ended December 31, 2022, 2021 and 2020, respectively.
    Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December 31, 2022.
    In connection with the spin-off transaction in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.
    The Company leases certain affiliated operations and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $153,174, $139,458 and $129,990 for the year ended December 31, 2022, 2021 and 2020, respectively.
    Fifty-eight of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under ten separate master lease arrangements. During 2022, the Company amended two of its separate master leases to add operations and extend the initial terms, which increased the lease liabilities and right-of-use assets by $207,638 to reflect the new lease obligations. Additionally, during 2022, the Company added six new operations to two new master leases, which increased the lease liabilities and right-of-use assets by $54,755 to reflect the new lease obligations. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.
    During 2022, Standard Bearer acquired the real estate of three skilled nursing operations, which were previously under separate long-term lease arrangements. The aggregate reduction in the carrying value of the Company's lease liabilities and right-of-use assets related to this acquisition is $10,080.

    The components of operating lease expense are as follows:
    Year Ended December 31,
    202220212020
    Rent - cost of services(1)
    $153,049 $139,371 $129,926 
    General and administrative expense125 87 64 
    Depreciation and amortization(2)
    1,160 1,158 1,223 
    Variable lease costs(3)
    16,938 14,077 12,774 
    $171,272 $154,693 $143,987 
    (1)Rent- cost of services includes deferred rent expense adjustments of $493, $485 and $451 for the years ended December 31, 2022, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $5,878, $3,702, $2,394 for the years ended December 31, 2022, 2021, and 2020 respectively.
    (2)Depreciation and amortization is related to the amortization of favorable and direct lease costs.
    (3)Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.

    Future minimum lease payments for all leases as of December 31, 2022 are as follows:
    YearAmount
    2023$157,963 
    2024157,630 
    2025157,455 
    2026157,380 
    2027156,860 
    Thereafter1,456,411 
    TOTAL LEASE PAYMENTS2,243,699 
    Less: present value adjustment (822,790)
    PRESENT VALUE OF TOTAL LEASE LIABILITIES1,420,909 
    Less: current lease liabilities(65,796)
    LONG-TERM OPERATING LEASE LIABILITIES$1,355,113 
    Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of December 31, 2022 and 2021, the weighted average remaining lease term is 15.0 and 14.8, respectively, and the weighted average discount rate used to determine the operating lease liabilities is 6.7% and 7.6%, respectively.
    Subsequent to December 31, 2022, the Company expanded its operations through two separate master lease arrangements for 20 stand-alone skilled nursing operations, of which 17 will be operated by the Company's affiliated operating subsidiaries and the remaining three will be subleased to a third-party operator. The aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the two separate master lease agreements is estimated to be approximately $315,337.
    Lessor Activities

    In connection with the spin-off transaction in 2019, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. As of December 31, 2022, Ensign affiliates retained ownership of the real estate for these 29 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years.


    Total rental income from all third-party sources for the years ended December 31, 2022, 2021, and 2020 is as follows:

    Year Ended December 31,
    202220212020
    Pennant(1)
    $14,915 $14,073 $13,163 
    Other third-party1,842 1,912 1,994 
    $16,757 $15,985 $15,157 
    (1) Pennant rental income includes variable rent such as property taxes of $1,318, $1,199, and $1,224 during the year ended December 31, 2022, 2021, and 2020.

    Future annual rental income for all leases as of December 31, 2022 were as follows:
    Year
    Amount(1)
    2023$16,408 
    202415,826 
    202515,391 
    202615,166 
    202715,166 
    Thereafter79,171 
    TOTAL$157,128 
    (1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2022.
    XML 47 R27.htm IDEA: XBRL DOCUMENT v3.22.4
    SELF INSURANCE LIABILITIES
    12 Months Ended
    Dec. 31, 2022
    Insurance [Abstract]  
    SELF INSURANCE LIABILITIES SELF INSURANCE LIABILITIES
    The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2022 and 2021:
     
    Amount
    Balance January 1, 2021
     $96,798 
    Current year provisions 114,907 
    Claims paid and direct expenses (101,183)
    Change in long-term insurance losses recoverable (383)
    Balance December 31, 2021
    $110,139 
    Current year provisions115,793 
    Claims paid and direct expenses(98,007)
    Change in long-term insurance losses recoverable3,757 
    Balance December 31, 2022
    $131,682 
     
     
    Included in the table above are accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, of $87,000 and $69,748 as of December 31, 2022 and 2021, respectively. Included in long-term insurance losses recoverable as of December 31, 2022 and 2021 are anticipated insurance recoveries related to the Company's general and professional liability claims that are recorded on a gross rather than net basis in accordance with GAAP.
    XML 48 R28.htm IDEA: XBRL DOCUMENT v3.22.4
    DEFINED CONTRIBUTION PLANS
    12 Months Ended
    Dec. 31, 2022
    Retirement Benefits [Abstract]  
    DEFINED CONTRIBUTION PLANS DEFINED CONTRIBUTION PLANS
    The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 90% of their annual basic earnings, subject to applicable annual Internal Revenue Code limits. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company. The Company expensed matching contributions to the 401(k) Plan of $2,418, $2,121, and $1,889 during the years ended December 31, 2022, 2021 and 2020, respectively.


    During the year ended December 31, 2019, the Company implemented non-qualified deferred compensation plan (the DCP) that was effective in 2019 for certain executives. The plan was then offered to other highly compensated employees, which went into effect on January 1, 2020. These individuals are otherwise ineligible for participation in the Company's 401(k) plan. The DCP allows participating employees to defer the receipt of a portion of their base compensation and certain employees up to 100% of their eligible bonuses. Additionally, the plan allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to informally fund savings plans of this nature. The Company paid for related administrative costs, which were not significant during fiscal years 2022, 2021 and 2020.

    As of the years ended December 31, 2022, 2021, and 2020, the Company accrued $33,017, $26,832 and $14,232, respectively, as long term deferred compensation in other long term liabilities on the consolidated balance sheet. Cash surrender value of the contracts is based on investment funds that shadow the investment allocations specified by participants in the deferred compensation plan. Refer to Note 6, Fair Value Measurements for more information on the funds.

    For the year ended December 31, 2022, the Company recorded a loss on the investment acquired in connection with our deferred compensation plan of $4,188, which is included in other income (expense), net. During the same period, the Company recorded an offsetting reduction in expense of $4,051, which is allocated between cost of services and general and administrative expenses.
    For the years ended December 31, 2021 and 2020, the Company recorded net income on the investment acquired in connection with our deferred compensation plan of $1,612 and $1,396, respectively, which is included in other income (expense), net. During the same periods, the Company recorded an offsetting expense of $1,758, and $1,355, respectively, which is allocated between cost of services and general and administrative expenses.
    XML 49 R29.htm IDEA: XBRL DOCUMENT v3.22.4
    COMMITMENTS AND CONTINGENCIES
    12 Months Ended
    Dec. 31, 2022
    Commitments and Contingencies Disclosure [Abstract]  
    COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
    Regulatory Matters Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.
    Cost-Containment Measures Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.
    Indemnities From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities arising out of the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s consolidated balance sheets for any of the periods presented.

    In connection with the spin-off transaction in 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the transaction. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties.

    U.S. Department of Justice Civil Investigative DemandOn May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it was investigating whether there had been a violation of the False Claims Act and/or the Anti-Kickback Statute with respect to relationships between certain of the Company’s independently operated skilled nursing facilities and persons who serve or have served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of the Company’s Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, the Company’s independent operating entities have established and maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. The Company fully cooperated with the U.S. Department of Justice and promptly responded to its requests for information; in April 2020, the Company was advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.
    U.S. House of Representatives Select Subcommittee Request In 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee in connection with its investigation. The Company has cooperated in responding to this inquiry. In July 2022 and thereafter, the Company received follow up requests for additional documents and information. The Company has responded to these requests, and continued to cooperate with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act.
    Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. In addition, the Company, its independent operating subsidiaries, and others in the industry are subject to claims and lawsuits in connection with COVID-19 and a facility's preparation for and/or response to COVID-19. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.
    In addition to the potential lawsuits and claims described above, the Company and its independent operating subsidiaries are also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from Federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Under the qui tam or "whistleblower" provisions of the False Claims Act, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the Federal Government and receive a percentage of the Federal Government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the U.S. Department of Justice to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the involved qui tam relator has continued on with the lawsuit and is pursuing claims that the Company and certain of its independent operating subsidiaries have allegedly violated the False Claims Act and/or the Anti-Kickback Statute (AKS).
    In addition to the Federal False Claims Act, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company and its independent operating subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.
    In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a Federal False Claims Act violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.
    Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.
    Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent operating subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations.
    The Company and its independent operating subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including healthcare and non-healthcare services. These claims include, but are not limited to, potential claims filed by residents, customers, patients and responsible parties related to patient care and treatment (professional negligence claims); to non-care based activities of certain of the subsidiaries; and to employment related claims filed by current or former employees. A significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, these claims could impact the Company's ability to procure insurance to cover its exposure related to the various services provided by its independent operating subsidiaries to their residents, customers and patients.
    The Company and its independent subsidiaries are also subject to requests for information and investigations by other State and Federal governmental entities (e.g., offices of the attorney general and offices of the inspector general). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar state and federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent operating subsidiaries under a corporate integrity agreement and/or other such arrangement.
    Medicare Revenue Recoupments The Company's independent operating entities are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate Program. Beginning in August 2020, CMS resumed Targeted Probe and Educate Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of December 31, 2022 and since, 34 of the Company's independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process.
    Concentrations
    Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for 56.3% and 54.0% of its total accounts receivable as of December 31, 2022 and 2021, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 73.7%, 73.6% and 74.5% of the Company's revenue for the years ended December 31, 2022, 2021 and 2020, respectively.
    Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of January 30, 2023, the Company's uninsured cash deposits are not material. All uninsured bank deposits are held at high quality credit institutions.
    XML 50 R30.htm IDEA: XBRL DOCUMENT v3.22.4
    COMMON STOCK REPURCHASE PROGRAM
    12 Months Ended
    Dec. 31, 2022
    Equity [Abstract]  
    COMMON STOCK REPURCHASE PROGRAM COMMON STOCK REPURCHASE PROGRAM
    On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company did not purchase any shares pursuant to this stock repurchase program in the year ended December 31, 2022. The share repurchase program does not obligate the Company to acquire any specific number of shares.
    On February 9, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from February 10, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended June 30, 2022, the Company repurchased 271 shares of its common stock for $20,000. This repurchase program expired upon the repurchase of the fully authorized amount under the plan and is no longer in effect.
    On October 21, 2021, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months that started on October 29, 2021. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company repurchased 133 and 132 shares of its common stock for $9,882 and $10,118 during the years ended December 31, 2022 and 2021, respectively. This repurchase program expired upon the repurchase of the fully authorized amount under the plan and is no longer in effect.
    On March 4, 2020 and March 13, 2020, the Board of Directors approved two stock repurchase programs pursuant to which the Company was authorized to repurchase up to $20,000 and $5,000, respectively, of its common stock under the programs for a period of approximately 12 months. Under these programs, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the first quarter of 2020, the Company repurchased 503 and 189 shares of its common stock for $20,000 and $5,000, respectively. These repurchase programs expired upon the repurchase of the full authorized amount under the two plans and are no longer in effect.
    XML 51 R31.htm IDEA: XBRL DOCUMENT v3.22.4
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
    12 Months Ended
    Dec. 31, 2022
    Accounting Policies [Abstract]  
    Basis of Presentation Basis of Presentation The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its consolidated statements of income.The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest.
    Reclassifications ReclassificationsCertain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net income. Prior period results reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure as a result of the formation of Standard Bearer. Refer to Note 8, Business Segments. Reclassification adjustments have been made to reclassify investments associated with the Company's non-qualified deferred compensation plan with investments held by the Company's captive insurance subsidiary on the consolidated balance sheets.
    Estimates and Assumptions Estimates and Assumptions The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.
    Fair Value of Financial Instruments Fair Value of Financial InstrumentsThe Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations.
    Service and Rental Revenue Recognition Service Revenue RecognitionThe Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606).Rental Revenue Recognition The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842).
    Accounts Receivable and Allowance for Doubtful Accounts Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.
    Cash and Cash Equivalents Cash and Cash Equivalents Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.
    Insurance Subsidiary Deposits and Investments
    Insurance Subsidiary Deposits and Investments — The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution.
    The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. The fair value of the investment funds is derived using Level 2 inputs.
    When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.
    Property and Equipment Property and Equipment Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
    Leases and Leasehold Improvements
    Leases and Leasehold Improvements The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease at the inception of each lease. Leases commencing prior to the ASC 842 adoption date were classified as operating lease under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. For leases commencing subsequent to the ASC 842 adoption date, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December 31, 2022, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.
    The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.
    The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases.
    Impairment of Long-Lived Assets Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset.
    Intangible Assets and Goodwill
    Intangible Assets and Goodwill Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
    The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
    Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year.
    Self-Insurance
    Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,000 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
    The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider.
    The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.
    The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.
    In addition, the Company has recorded an asset and equal liability in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 13, Restricted and Other Assets.
    The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525, $500 and $300 for each covered person for fiscal years 2022, 2021 and 2020, respectively.
    The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.
    Income Taxes
    Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
    In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.
    Standard Bearer intends to qualify and elect to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer believes it has been organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions.
    Noncontrolling Interest Noncontrolling Interest The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
    Stock-Based Compensation Stock-Based CompensationThe Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.
    Comprehensive Income Comprehensive Income The Company does not have any components of other comprehensive income recorded within its consolidated Financial Statements and, therefore, does not separately present a statement of comprehensive income in its consolidated Financial Statements.
    Recent Accounting Pronouncements
    Recent Accounting Pronouncements Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.
    Recent Accounting Standards Adopted by the Company In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance,” which created FASB ASC Topic 832, Government Assistance (ASC 832). ASC 832 requires business entities to disclose information about certain government assistance they receive. The Company adopted this standard on January 1, 2022 and determined there was no material impact on the Company's Financial Statements.
    In February 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848)," which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace London Interbank Offered Rate (LIBOR) reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2024. During the year ended December 31, 2022, the Company and its subsidiaries including Standard Bearer, entered into the Second Amendment to Third Amended and Restated Credit Agreement (such agreement, the Amended Credit Agreement, and the revolving credit facility thereunder, the Revolving Credit Facility), which increased the Revolving Credit Facility by $250,000 to an aggregate principal amount of up to $600,000. Pursuant to the Amended Credit Agreement, the Company transitioned from LIBOR to the Secured Overnight Financing Rate (SOFR) as the applicable reference rate for borrowings under the Revolving Credit Facility and determined there was no resulting material impact on the Company's Financial Statements.
    XML 52 R32.htm IDEA: XBRL DOCUMENT v3.22.4
    REVENUE AND ACCOUNTS RECEIVABLE (Tables)
    12 Months Ended
    Dec. 31, 2022
    Revenue from Contract with Customer [Abstract]  
    Disaggregation of Revenue
    Service revenue for the years ended December 31, 2022, 2021, and 2020 is summarized in the following tables:
     Year Ended December 31,
    202220212020
    Revenue% of RevenueRevenue% of RevenueRevenue% of Revenue
    Medicaid(1)
    $1,183,156 39.3 %$1,022,460 39.2 %$900,249 37.7 %
    Medicare832,160 27.7 727,103 27.8 727,374 30.5 
    Medicaid — skilled200,878 6.7 172,770 6.6 149,846 6.3 
    Total Medicaid and Medicare2,216,194 73.7 1,922,333 73.6 1,777,469 74.5 
    Managed care525,710 17.5 456,728 17.5 367,095 15.4 
    Private and other(2)
    266,807 8.8 232,415 8.9 242,875 10.1 
    SERVICE REVENUE$3,008,711 100.0 %$2,611,476 100.0 %$2,387,439 100.0 %
    (1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP and other COVID-19 related state funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
    Schedule of Accounts Receivable
    Accounts receivable as of December 31, 2022 and 2021, is summarized in the following table:
    December 31,
    20222021
    Medicaid$157,878 $123,647 
    Managed care95,940 79,722 
    Medicare76,526 59,797 
    Private and other payors85,890 76,778 
     416,234 339,944 
    Less: allowance for doubtful accounts(7,802)(11,213)
    ACCOUNTS RECEIVABLE, NET$408,432 $328,731 
    XML 53 R33.htm IDEA: XBRL DOCUMENT v3.22.4
    COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)
    12 Months Ended
    Dec. 31, 2022
    Earnings Per Share [Abstract]  
    Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic Net Income Per Common Share
    A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:

    Year Ended December 31,
     202220212020
    NUMERATOR:
    Net income$224,652 $197,725 $171,364 
    Less: net (loss) income attributable to noncontrolling interests (29)3,073 886 
    Net income attributable to The Ensign Group, Inc. $224,681 $194,652 $170,478 
    DENOMINATOR:
    Weighted average shares outstanding for basic net income per share54,887 54,486 53,434 
    Basic net income per common share:$4.09 $3.57 $3.19 
    Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Diluted Net Income Per Common Share
    A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:

    Year Ended December 31,
     202220212020
    NUMERATOR:
    Net income $224,652 $197,725 $171,364 
    Less: net (loss) income attributable to noncontrolling interests(29)3,073 886 
    Net income attributable to The Ensign Group, Inc. $224,681 $194,652 $170,478 
    DENOMINATOR:
    Weighted average common shares outstanding54,887 54,486 53,434 
    Plus: incremental shares from assumed conversion (1)
    1,984 2,439 2,353 
    Adjusted weighted average common shares outstanding56,871 56,925 55,787 
    Diluted net income per common share:$3.95 $3.42 $3.06 
    (1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 780, 198 and 956 for the years ended December 31, 2022, 2021 and 2020, respectively.
    XML 54 R34.htm IDEA: XBRL DOCUMENT v3.22.4
    BUSINESS SEGMENTS (Tables)
    12 Months Ended
    Dec. 31, 2022
    Segment Reporting [Abstract]  
    Schedule of Segment Reporting Information
    The following tables set forth financial information for the segments:
     Year Ended December 31, 2022
     Skilled ServicesStandard Bearer
    All Other(1)
    Intercompany EliminationTotal
    Service revenue(2)
    $2,906,215 $— $115,214 $(12,718)$3,008,711 
    Rental revenue(3)
    — 72,937 7,396 (63,576)16,757 
    TOTAL REVENUE$2,906,215 $72,937 $122,610 $(76,294)$3,025,468 
    Segment income (loss)408,732 27,871 (150,781)— 285,822 
    Gain on sale of real estate assets and insurance recoveries, net3,267 
    Income before provision for income taxes$289,089 
    Depreciation and amortization33,224 21,613 7,518 — 62,355 
    Interest expense(4)
    $— $15,707 $1,870 $(8,646)$8,931 
    (1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
    (2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
    (3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
    (4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column.

     Year Ended December 31, 2021
     Skilled ServicesStandard Bearer
    All Other(1)
    Intercompany EliminationTotal
    Service revenue(2)
    $2,523,234 $— $95,276 $(7,034)$2,611,476 
    Rental revenue(3)
    — 58,127 7,409 (49,551)15,985 
    TOTAL REVENUE$2,523,234 $58,127 $102,685 $(56,585)$2,627,461 
    Segment income (loss)373,603 31,876 (147,915)— 257,564 
    Gain on real estate insurance recoveries440 
    Income before provision for income taxes$258,004 
    Depreciation and amortization30,681 17,558 7,746 — 55,985 
    Interest expense$— $6,842 $$— $6,849 
    (1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
    (2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
    (3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
     
    Year Ended December 31, 2020
     Skilled ServicesStandard Bearer
    All Other(1)
    Intercompany EliminationTotal
    Service revenue(2)
    $2,288,182 $— $105,548 $(6,291)$2,387,439 
    Rental revenue(3)
    — 54,104 7,171 (46,118)15,157 
    TOTAL REVENUE$2,288,182 $54,104 $112,719 $(52,409)$2,402,596 
    Segment income (loss)327,812 27,299 (134,752)— 220,359 
    Loss on sale of real estate and impairment charges(2,753)
    Income before provision for income taxes $217,606 
    Depreciation and amortization28,585 16,134 9,852 — 54,571 
    Interest expense$— $9,350 $12 $— $9,362 
    (1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
    (2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
    (3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
    Reconciliation of Revenue from Segments
    Service revenue by major payor source were as follows:
     Year Ended December 31, 2022
     Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
    Medicaid(1)
    $1,158,309 $24,847 $1,183,156 39.3 %
    Medicare832,160 — 832,160 27.7 
    Medicaid-skilled200,878 — 200,878 6.7 
    Subtotal2,191,347 24,847 2,216,194 73.7 
    Managed care525,710 — 525,710 17.5 
    Private and other(2)
    189,158 77,649 266,807 8.8 
    TOTAL SERVICE REVENUE$2,906,215 $102,496 $3,008,711 100.0 %
    (1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

     Year Ended December 31, 2021
     Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
    Medicaid(1)
    $1,007,061 $15,399 $1,022,460 39.2 %
    Medicare727,103 — 727,103 27.8 
    Medicaid-skilled172,770 — 172,770 6.6 
    Subtotal1,906,934 15,399 1,922,333 73.6 
    Managed care456,728 — 456,728 17.5 
    Private and other(2)
    159,572 72,843 232,415 8.9 
    TOTAL SERVICE REVENUE$2,523,234 $88,242 $2,611,476 100.0 %
    (1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
     
    Year Ended December 31, 2020
     Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
    Medicaid(1)
    $886,991 $13,258 $900,249 37.7 %
    Medicare727,374 — 727,374 30.5 
    Medicaid-skilled149,846 — 149,846 6.3 
    Subtotal1,764,211 13,258 1,777,469 74.5 
    Managed care367,095 — 367,095 15.4 
    Private and other(2)
    156,876 85,999 242,875 10.1 
    TOTAL SERVICE REVENUE$2,288,182 $99,257 $2,387,439 100.0 %
    (1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.
    (2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
    XML 55 R35.htm IDEA: XBRL DOCUMENT v3.22.4
    OPERATION EXPANSIONS (Tables)
    12 Months Ended
    Dec. 31, 2022
    Business Combination and Asset Acquisition [Abstract]  
    Schedule of Purchase Price Allocation
    The table below presents the allocation of the purchase price for the operations acquired during the years ended December 31, 2022, 2021, and 2020, excluding assets that were contributed to Pennant that occurred during the spin-off transaction in 2019.
    Year Ended December 31,
    202220212020
    Land$15,527 $19,928 $9,496 
    Building and improvements65,070 77,975 14,178 
    Equipment, furniture, and fixtures1,618 217 568 
    Assembled occupancy367 29 107 
    Goodwill16,400 6,000 — 
    Leased asset1,909 — — 
    Other indefinite-lived intangible assets245 75 648 
    TOTAL ACQUISITIONS$101,136 $104,224 $24,997 
    XML 56 R36.htm IDEA: XBRL DOCUMENT v3.22.4
    PROPERTY AND EQUIPMENT— NET (Tables)
    12 Months Ended
    Dec. 31, 2022
    Property, Plant and Equipment [Abstract]  
    Schedule of Property and Equipment Property and equipment, net consists of the following:
    December 31,
    20222021
    Land$134,864 $121,164 
    Buildings and improvements728,231 646,221 
    Leasehold improvements150,903 140,012 
    Equipment295,739 262,246 
    Furniture and fixtures4,544 4,305 
    Construction in progress17,521 10,253 
     1,331,802 1,184,201 
    Less: accumulated depreciation(339,792)(295,767)
    PROPERTY AND EQUIPMENT, NET$992,010 $888,434 
    XML 57 R37.htm IDEA: XBRL DOCUMENT v3.22.4
    INTANGIBLE ASSETS — NET (Tables)
    12 Months Ended
    Dec. 31, 2022
    Intangible Assets, Net (Excluding Goodwill) [Abstract]  
    Schedule of Finite-Lived Intangible Assets
    Weighted Average Life (Years)December 31,
    20222021
    Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
    Intangible AssetsNetNet
    Assembled occupancy0.3$435 $(388)$47 $68 $(68)$— 
    Facility trade name30.0733 (415)318 733 (391)342 
    Customer relationships18.44,582 (2,482)2,100 4,582 (2,272)2,310 
    TOTAL $5,750 $(3,285)$2,465 $5,383 $(2,731)$2,652 
    Schedule of Estimated Amortization Expense Estimated amortization expense for each of the years ending December 31 is as follows:
    YearAmount
    2023$281 
    2024234 
    2025234 
    2026234 
    2027234 
    Thereafter1,248 
     $2,465 
    XML 58 R38.htm IDEA: XBRL DOCUMENT v3.22.4
    GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS (Tables)
    12 Months Ended
    Dec. 31, 2022
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Schedule of Goodwill The following table represents activity in goodwill by skilled service segment and "all other" category as of and for the year ended December 31, 2022, 2021 and 2020:
    Goodwill
     Skilled ServicesAll OtherTotal
    January 1, 2020$45,486 $8,983 $54,469 
    December 31, 2020$45,486 $8,983 $54,469 
    Additions6,000 — 6,000 
    December 31, 2021$51,486 $8,983 $60,469 
    Additions16,400 — 16,400 
    December 31, 2022$67,886 $8,983 $76,869 
    Schedule of Other Indefinite-lived Intangible Assets
    Other indefinite-lived intangible assets consist of the following:
    December 31,
    20222021
    Trade name$889 $889 
    Medicare and Medicaid licenses3,083 2,838 
    TOTAL$3,972 $3,727 
    XML 59 R39.htm IDEA: XBRL DOCUMENT v3.22.4
    RESTRICTED AND OTHER ASSETS (Tables)
    12 Months Ended
    Dec. 31, 2022
    Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
    Schedule of Restricted and Other Assets Restricted and other assets consist of the following:
    December 31,
    20222021
    Debt issuance costs, net$3,753 $1,953 
    Long-term insurance losses recoverable asset10,512 6,755 
    Capital improvement reserves with landlords and lenders6,446 7,103 
    Deposits with landlords2,527 2,606 
    Other14,053 11,099 
    RESTRICTED AND OTHER ASSETS$37,291 $29,516 
    XML 60 R40.htm IDEA: XBRL DOCUMENT v3.22.4
    OTHER ACCRUED LIABILITIES (Tables)
    12 Months Ended
    Dec. 31, 2022
    Payables and Accruals [Abstract]  
    Schedule of Other Accrued Liabilities Other accrued liabilities consists of the following:
    December 31,
    20222021
    Quality assurance fee$7,701 $6,474 
    Refunds payable40,783 34,814 
    Resident advances9,698 9,337 
    Unapplied state relief funds1,001 1,781 
    Cash held in trust for patients6,400 6,430 
    Dividends payable3,201 3,035 
    Property taxes10,926 9,124 
    Legal finding accrued4,553 — 
    Other13,046 18,415 
    OTHER ACCRUED LIABILITIES$97,309 $89,410 
    XML 61 R41.htm IDEA: XBRL DOCUMENT v3.22.4
    INCOME TAXES (Tables)
    12 Months Ended
    Dec. 31, 2022
    Income Tax Disclosure [Abstract]  
    Schedule of Components of Income Tax Expense (Benefit)
    The provision for income taxes on continuing operations for the years ended December 31, 2022, 2021 and 2020 is summarized as follows:
     Year Ended December 31,
     2022 2021 2020
    Current:   
    Federal$56,717 $49,105 $60,591 
    State14,216 11,898 13,460 
     70,933 61,003 74,051 
    Deferred: 
    Federal(5,158)(716)(23,054)
    State(1,338)(8)(4,755)
    (6,496)(724)(27,809)
         TOTAL$64,437 $60,279 $46,242 
    Schedule of Effective Income Tax Rate Reconciliation
    A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2022, 2021 and 2020, respectively, is comprised as follows:

     
     December 31,
     202220212020
    Income tax expense at statutory rate21.0 %21.0 %21.0 %
    State income taxes - net of federal benefit3.5 3.7 3.2 
    Non-deductible expenses2.0 2.4 1.8 
    Equity compensation(3.6)(3.3)(4.3)
    Other adjustments(0.6)(0.4)(0.4)
    TOTAL INCOME TAX PROVISION22.3 %23.4 %21.3 %
    Schedule of Deferred Tax Assets and Liabilities
    The Company's deferred tax assets and liabilities as of December 31, 2022 and 2021 are summarized below.

     December 31,
     2022 2021
    Deferred tax assets (liabilities): 
    Accrued expenses$61,685 $58,640 
    Revenue related reserves18,046 13,171 
    Tax credits1,742 2,138 
    Insurance11,910 8,712 
    Lease liability 364,408 285,643 
    State taxes 28 (165)
    457,819 368,139 
    Valuation allowance(789)(789)
    TOTAL DEFERRED TAX ASSETS457,030 367,350 
    Depreciation and amortization(49,146)(45,827)
    Prepaid expenses(5,150)(4,265)
    Right of use asset (363,091)(284,111)
    TOTAL DEFERRED TAX LIABILITIES(417,387)(334,203)
    NET DEFERRED TAX ASSETS$39,643 $33,147 
    XML 62 R42.htm IDEA: XBRL DOCUMENT v3.22.4
    DEBT (Tables)
    12 Months Ended
    Dec. 31, 2022
    Debt Disclosure [Abstract]  
    Schedule of Long-term Debt
    Debt consists of the following:
    December 31,
    20222021
    Mortgage loans and promissory notes$156,271 $159,967 
    Less: current maturities(3,883)(3,760)
    Less: debt issuance costs, net(3,119)(3,324)
    LONG-TERM DEBT LESS CURRENT MATURITIES$149,269 $152,883 
    Schedule of Maturities of Long-term Debt
    Future principal payments due under the long-term debt arrangements discussed above are as follows:

    Years Ending December 31,Amount
    2023$3,883 
    20243,950 
    20254,086 
    20264,227 
    20273,897 
    Thereafter136,228 
     $156,271 
    XML 63 R43.htm IDEA: XBRL DOCUMENT v3.22.4
    OPTIONS AND AWARDS (Tables)
    12 Months Ended
    Dec. 31, 2022
    Share-Based Payment Arrangement [Abstract]  
    Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions :
    Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
    20225812.8%6.2 years42.1%0.3%
    20216211.0%6.2 years42.4%0.3%
    20206690.6%6.2 years39.4%0.4%
    Schedule of Weighted Average Grant Date Fair Value and Exercise Price of Options
    Grant YearGrantedWeighted Average Exercise PriceWeighted Average Fair Value of Options
    2022581$85.74 $37.83 
    2021621$80.19 $32.82 
    2020669$52.20 $19.52 
    Schedule of Employee Stock Option Roll Forward
    The following table represents the employee stock option activity during the year ended December 31, 2022, 2021 and 2020:
    Number of Options OutstandingWeighted Average
    Exercise Price
    Number of
    Options Vested
    Weighted Average Exercise Price of Options Vested
    January 1, 20204,428 $20.85 2,557 $12.82 
    Granted669 52.20 
    Forfeited(80)33.68 
    Exercised(979)12.93 
    December 31, 20204,038 $27.71 2,148 $16.66 
    Granted621 80.19 
    Forfeited(105)44.76 
    Exercised(516)17.80 
    December 31, 20214,038 $36.60 2,183 $21.02 
    Granted581 85.74 — — 
    Forfeited(98)59.52 — — 
    Exercised(688)18.43 — — 
    December 31, 20223,833 $46.72 2,069 $28.87 
    Share-based Payment Arrangement, Option, Exercise Price Range
    The following summary information reflects stock options outstanding, vested and related details as of December 31, 2022:
    Stock Options OutstandingStock Options Vested
     
    Number OutstandingBlack-Scholes Fair ValueRemaining Contractual Life (Years)Vested and Exercisable
    Year of GrantExercise Price
    20136.76-9.7465 274 165 
    20148.94-16.05399 1,930 2399 
    201518.20-21.39211 1,645 3211 
    201615.93-16.86198 1,162 4198 
    201715.80-19.41236 1,387 5236 
    201822.49-32.71449 4,341 6330 
    201941.07-45.76590 9,275 7324 
    202044.84-59.49545 10,734 8197 
    202173.47-83.64567 18,597 9109 
    2022$79.79$94.88573 21,689 10— 
    TOTAL 3,833 $71,034  2,069 
    Schedule of Aggregate Intrinsic Value of Options
    The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2022, 2021 and 2020 is as follows:
    December 31,
    Options202220212020
    Outstanding$183,593 $191,242 $182,552 
    Vested136,000 137,382 120,867 
    Expected to vest43,232 48,548 53,366 
    Schedule of Nonvested Restricted Stock Awards :
    Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
    Nonvested at January 1, 2020610 $31.35 
    Granted281 48.73 
    Vested(280)32.84 
    Forfeited(20)31.71 
    Nonvested at December 31, 2020591 $38.90 
    Granted222 81.65 
    Vested(244)47.45 
    Forfeited(20)45.64 
    Nonvested at December 31, 2021549 $52.16 
    Granted233 81.57 
    Vested(269)54.06 
    Forfeited(26)57.29 
    Nonvested at December 31, 2022487 $64.92 
    Schedule of Stock-Based Compensation Expense
    Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December 31, 2022, 2021, and 2020 was as follows:

    Year Ended December 31,
     202220212020
    Stock-based compensation expense related to stock options$11,361 $8,459 $6,132 
    Stock-based compensation expense related to restricted stock awards9,920 8,385 7,373 
    Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors1,439 1,834 1,019 
    TOTAL$22,720 $18,678 $14,524 
    XML 64 R44.htm IDEA: XBRL DOCUMENT v3.22.4
    LEASES (Tables)
    12 Months Ended
    Dec. 31, 2022
    Leases [Abstract]  
    Schedule of Operating Lease Expenses
    The components of operating lease expense are as follows:
    Year Ended December 31,
    202220212020
    Rent - cost of services(1)
    $153,049 $139,371 $129,926 
    General and administrative expense125 87 64 
    Depreciation and amortization(2)
    1,160 1,158 1,223 
    Variable lease costs(3)
    16,938 14,077 12,774 
    $171,272 $154,693 $143,987 
    (1)Rent- cost of services includes deferred rent expense adjustments of $493, $485 and $451 for the years ended December 31, 2022, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $5,878, $3,702, $2,394 for the years ended December 31, 2022, 2021, and 2020 respectively.
    (2)Depreciation and amortization is related to the amortization of favorable and direct lease costs.
    (3)Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.
    Schedule of Future Minimum Lease Payments
    Future minimum lease payments for all leases as of December 31, 2022 are as follows:
    YearAmount
    2023$157,963 
    2024157,630 
    2025157,455 
    2026157,380 
    2027156,860 
    Thereafter1,456,411 
    TOTAL LEASE PAYMENTS2,243,699 
    Less: present value adjustment (822,790)
    PRESENT VALUE OF TOTAL LEASE LIABILITIES1,420,909 
    Less: current lease liabilities(65,796)
    LONG-TERM OPERATING LEASE LIABILITIES$1,355,113 
    Schedule of Rental Income from Third-Party Sources
    Total rental income from all third-party sources for the years ended December 31, 2022, 2021, and 2020 is as follows:

    Year Ended December 31,
    202220212020
    Pennant(1)
    $14,915 $14,073 $13,163 
    Other third-party1,842 1,912 1,994 
    $16,757 $15,985 $15,157 
    (1) Pennant rental income includes variable rent such as property taxes of $1,318, $1,199, and $1,224 during the year ended December 31, 2022, 2021, and 2020.
    Schedule of Annual Rental Income
    Future annual rental income for all leases as of December 31, 2022 were as follows:
    Year
    Amount(1)
    2023$16,408 
    202415,826 
    202515,391 
    202615,166 
    202715,166 
    Thereafter79,171 
    TOTAL$157,128 
    (1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2022.
    XML 65 R45.htm IDEA: XBRL DOCUMENT v3.22.4
    SELF INSURANCE LIABILITIES (Tables)
    12 Months Ended
    Dec. 31, 2022
    Insurance [Abstract]  
    Schedule of Liability for Future Policy Benefits, by Product Segment
    The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2022 and 2021:
     
    Amount
    Balance January 1, 2021
     $96,798 
    Current year provisions 114,907 
    Claims paid and direct expenses (101,183)
    Change in long-term insurance losses recoverable (383)
    Balance December 31, 2021
    $110,139 
    Current year provisions115,793 
    Claims paid and direct expenses(98,007)
    Change in long-term insurance losses recoverable3,757 
    Balance December 31, 2022
    $131,682 
    XML 66 R46.htm IDEA: XBRL DOCUMENT v3.22.4
    DESCRIPTION OF BUSINESS (Details)
    Dec. 31, 2022
    operation
    facility
    senior_living_unit
    bed
    senior_living_community
    Dec. 31, 2021
    bed
    Dec. 31, 2020
    bed
    Mar. 31, 2020
    facility
    Oct. 31, 2019
    operation
    Restructuring Cost and Reserve [Line Items]          
    Health care facilities 271        
    Operational skilled nursing beds | bed 28,100        
    Operational senior living units | senior_living_unit 3,000        
    Number of real estate properties leased 192        
    Number of real estate properties leased with an option to purchase 11        
    Number of real estate properties 108        
    Standard Bearer          
    Restructuring Cost and Reserve [Line Items]          
    Number of real estate properties 103        
    Skilled Nursing Operations          
    Restructuring Cost and Reserve [Line Items]          
    Operational skilled nursing beds | bed 3,058 1,832 507    
    The Pennant Group, Inc. | Senior Living Facilities          
    Restructuring Cost and Reserve [Line Items]          
    Number of real estate properties       2  
    The Pennant Group, Inc. | Senior Living Facilities | Spinoff          
    Restructuring Cost and Reserve [Line Items]          
    Number of real estate properties 29       29
    Owned Properties          
    Restructuring Cost and Reserve [Line Items]          
    Number of real estate properties 79        
    Owned Properties | Standard Bearer          
    Restructuring Cost and Reserve [Line Items]          
    Number of real estate properties | operation 75        
    XML 67 R47.htm IDEA: XBRL DOCUMENT v3.22.4
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)
    12 Months Ended
    Dec. 31, 2022
    Minimum  
    Property, Plant and Equipment [Line Items]  
    Property, plant and equipment, useful life 3 years
    Maximum  
    Property, Plant and Equipment [Line Items]  
    Property, plant and equipment, useful life 59 years
    XML 68 R48.htm IDEA: XBRL DOCUMENT v3.22.4
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)
    12 Months Ended
    Dec. 31, 2022
    renewal_option
    Real Estate Properties [Line Items]  
    Lessee, operating lease, term of contract 10 years
    Lessee, operating lease, number of renewal options 1
    Minimum  
    Real Estate Properties [Line Items]  
    Lessee, operating lease, renewal term 10 years
    Maximum  
    Real Estate Properties [Line Items]  
    Lessee, operating lease, renewal term 15 years
    XML 69 R49.htm IDEA: XBRL DOCUMENT v3.22.4
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of Long-Lived Assets (Details) - USD ($)
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Accounting Policies [Abstract]      
    Impairment of long lived assets $ 0 $ 0 $ 2,681,000
    XML 70 R50.htm IDEA: XBRL DOCUMENT v3.22.4
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)
    12 Months Ended
    Dec. 31, 2022
    Facility trade name  
    Finite-Lived Intangible Assets [Line Items]  
    Finite-lived intangible asset, useful life 30 years
    Customer relationships  
    Finite-Lived Intangible Assets [Line Items]  
    Finite-lived intangible asset, useful life 20 years
    Minimum | Assembled occupancy  
    Finite-Lived Intangible Assets [Line Items]  
    Finite-lived intangible asset, useful life 4 months
    Maximum | Assembled occupancy  
    Finite-Lived Intangible Assets [Line Items]  
    Finite-lived intangible asset, useful life 8 months
    XML 71 R51.htm IDEA: XBRL DOCUMENT v3.22.4
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Workers' Compensation      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve $ 625    
    Workers' Compensation | TEXAS      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 750    
    Self-Insurance Retention Per Claim | General Liability      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 500    
    Loss-Sensitive Limit Per Claim | Workers' Compensation | Other States, Except California, Texas and Washington      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 350    
    Stop-Loss Insurance Limit Per Claim | Health Liability Insurance      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 525 $ 500 $ 300
    Parent Company | Self-Insurance Retention Per Claim | General Liability      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 500    
    Parent Company | Aggregate Deductible | General Liability | California      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 1,000    
    Parent Company | Aggregate Deductible | General Liability | Non-California      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 1,250    
    Third-Party Payor | Per Occurence | General Liability | All States Except Colorado      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 1,000    
    Third-Party Payor | Per Occurence | General Liability | Colorado      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 1,000    
    Third-Party Payor | Per Facility | General Liability | All States Except Colorado      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 3,000    
    Third-Party Payor | Per Facility | General Liability | Colorado      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve 3,000    
    Third-Party Payor | Blanket Aggregate | General Liability | All States Except Colorado      
    Liability for Claims and Claims Adjustment Expense [Line Items]      
    Self insurance reserve $ 5,000    
    XML 72 R52.htm IDEA: XBRL DOCUMENT v3.22.4
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recent Accounting Pronouncements (Details) - Revolving credit facility with Truist - Truist - USD ($)
    12 Months Ended
    Dec. 31, 2022
    Apr. 08, 2022
    Apr. 07, 2022
    Debt Instrument [Line Items]      
    Letter of credit increase $ 250,000,000    
    Line of credit facility, maximum borrowing capacity $ 600,000,000 $ 600,000,000 $ 350,000,000
    XML 73 R53.htm IDEA: XBRL DOCUMENT v3.22.4
    COVID-19 UPDATE (Details) - USD ($)
    1 Months Ended 12 Months Ended
    Mar. 31, 2021
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Unusual or Infrequent Items, or Both [Abstract]        
    Coronavirus Aid, Relief, and Economic Security (“CARES”) funds received and returned   $ 0 $ 11,637,000 $ 141,700,000
    Medicare accelerated and advance payment       105,255,000
    Repayment of medicare accelerated and advance payment program $ 102,023,000     3,232,000
    Unapplied state relief funds   1,001,000 1,781,000  
    FMAP payments received   81,057,000 70,484,000 51,927,000
    Revenue, FMAP payments received   $ 81,837,000 $ 75,231,000 45,407,000
    Total deferred payment of social security taxes       $ 48,309,000
    XML 74 R54.htm IDEA: XBRL DOCUMENT v3.22.4
    REVENUE AND ACCOUNTS RECEIVABLE - Revenue from Medicare and Medicaid Programs (Details) - Customer Concentration Risk - Revenue Benchmark
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Disaggregation of Revenue [Line Items]      
    Concentration risk 100.00% 100.00% 100.00%
    Total Medicare and Medicaid      
    Disaggregation of Revenue [Line Items]      
    Concentration risk 73.70% 73.60% 74.50%
    XML 75 R55.htm IDEA: XBRL DOCUMENT v3.22.4
    REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Disaggregation of Revenue [Line Items]      
    Revenue $ 3,008,711 $ 2,611,476 $ 2,387,439
    Rental revenue $ 16,757 $ 15,985 $ 15,157
    Customer Concentration Risk | Revenue Benchmark      
    Disaggregation of Revenue [Line Items]      
    Percentage of Revenue 100.00% 100.00% 100.00%
    Total Medicaid and Medicare      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 2,216,194 $ 1,922,333 $ 1,777,469
    Total Medicaid and Medicare | Customer Concentration Risk | Revenue Benchmark      
    Disaggregation of Revenue [Line Items]      
    Percentage of Revenue 73.70% 73.60% 74.50%
    Medicaid      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 1,183,156 $ 1,022,460 $ 900,249
    Medicaid | Customer Concentration Risk | Revenue Benchmark      
    Disaggregation of Revenue [Line Items]      
    Percentage of Revenue 39.30% 39.20% 37.70%
    Medicare      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 832,160 $ 727,103 $ 727,374
    Medicare | Customer Concentration Risk | Revenue Benchmark      
    Disaggregation of Revenue [Line Items]      
    Percentage of Revenue 27.70% 27.80% 30.50%
    Medicaid — skilled      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 200,878 $ 172,770 $ 149,846
    Medicaid — skilled | Customer Concentration Risk | Revenue Benchmark      
    Disaggregation of Revenue [Line Items]      
    Percentage of Revenue 6.70% 6.60% 6.30%
    Managed care      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 525,710 $ 456,728 $ 367,095
    Managed care | Customer Concentration Risk | Revenue Benchmark      
    Disaggregation of Revenue [Line Items]      
    Percentage of Revenue 17.50% 17.50% 15.40%
    Private and other      
    Disaggregation of Revenue [Line Items]      
    Revenue $ 266,807 $ 232,415 $ 242,875
    Private and other | Customer Concentration Risk | Revenue Benchmark      
    Disaggregation of Revenue [Line Items]      
    Percentage of Revenue 8.80% 8.90% 10.10%
    XML 76 R56.htm IDEA: XBRL DOCUMENT v3.22.4
    REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Accounts receivable, gross $ 416,234 $ 339,944
    Less: allowance for doubtful accounts (7,802) (11,213)
    ACCOUNTS RECEIVABLE, NET 408,432 328,731
    Medicaid    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Accounts receivable, gross 157,878 123,647
    Managed care    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Accounts receivable, gross 95,940 79,722
    Medicare    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Accounts receivable, gross 76,526 59,797
    Private and other payors    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Accounts receivable, gross $ 85,890 $ 76,778
    XML 77 R57.htm IDEA: XBRL DOCUMENT v3.22.4
    COMPUTATION OF NET INCOME PER COMMON SHARE (Details) - USD ($)
    $ / shares in Units, shares in Thousands, $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    NUMERATOR:      
    Net income $ 224,652 $ 197,725 $ 171,364
    Net (loss) income attributable to noncontrolling interests (29) 3,073 886
    Net income attributable to The Ensign Group, Inc. $ 224,681 $ 194,652 $ 170,478
    DENOMINATOR:      
    Weighted average shares outstanding for basic net income per share (in shares) 54,887 54,486 53,434
    Basic net income per common share (in dollars per share) $ 4.09 $ 3.57 $ 3.19
    Plus: incremental shares from assumed conversion (in shares) 1,984 2,439 2,353
    Adjusted weighted average common shares outstanding (in shares) 56,871 56,925 55,787
    Diluted net income per common share (in dollars per share) $ 3.95 $ 3.42 $ 3.06
    Antidilutive securities excluded from computation of earnings per share, amount (in shares) 780 198 956
    XML 78 R58.htm IDEA: XBRL DOCUMENT v3.22.4
    FAIR VALUE MEASUREMENTS (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Fair Value, Inputs, Level 1    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Cash and cash equivalents, fair value disclosure $ 316,270 $ 262,201
    Fair Value, Inputs, Level 2 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Deferred compensation plan investments 25,144 17,530
    Fair Value, Inputs, Level 2 [Member] | Captive Insurance Subsidiary    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Adjusted cost $ 69,290 $ 67,734
    XML 79 R59.htm IDEA: XBRL DOCUMENT v3.22.4
    STANDARD BEARER (Details)
    1 Months Ended 3 Months Ended 12 Months Ended
    Apr. 08, 2022
    Jan. 31, 2022
    lease
    renewal
    Dec. 31, 2022
    operation
    facility
    senior_living_community
    shares
    Dec. 31, 2022
    operation
    facility
    senior_living_community
    Dec. 31, 2022
    USD ($)
    operation
    facility
    senior_living_community
    Dec. 31, 2022
    operation
    facility
    senior_living_community
    Dec. 31, 2022
    operation
    facility
    skilled_nursing_property
    senior_living_community
    Dec. 31, 2022
    operation
    facility
    senior_living_community
    Dec. 31, 2022
    operation
    facility
    senior_living_community
    shares
    Dec. 31, 2022
    operation
    facility
    asset_acquisition
    senior_living_community
    Dec. 31, 2021
    USD ($)
    shares
    Dec. 31, 2020
    USD ($)
    shares
    Mar. 31, 2020
    facility
    Oct. 31, 2019
    operation
    Segment Reporting Information [Line Items]                            
    Number of real estate properties | facility     108 108 108 108 108 108 108 108        
    Number of master lease arrangements | lease   5                        
    Lessee, operating lease, term of contract     10 years 10 years 10 years 10 years 10 years 10 years 10 years 10 years        
    Rental revenue         $ 16,757,000           $ 15,985,000 $ 15,157,000    
    Options granted (in shares) | shares                 581,000   621,000 669,000    
    Non-controlling interest distribution         284,000           $ 2,908,000 $ 2,683,000    
    Standard Bearer                            
    Segment Reporting Information [Line Items]                            
    Rental revenue         57,967,000           $ 44,165,000 $ 40,946,000    
    Restricted Stock Awards                            
    Segment Reporting Information [Line Items]                            
    Award vesting period       5 years                    
    Granted restricted shares (in shares) | shares                 233,000   222,000 281,000    
    Standard Bearer Equity Plan                            
    Segment Reporting Information [Line Items]                            
    Award vesting period   5 years                        
    Proceeds from issuance of common stock         6,544,000                  
    Options granted (in shares) | shares     0           0          
    Proceeds from issuance of preferred shares         $ 149,000                  
    Standard Bearer Equity Plan | Restricted Stock Awards                            
    Segment Reporting Information [Line Items]                            
    Granted restricted shares (in shares) | shares     0           0          
    Minimum                            
    Segment Reporting Information [Line Items]                            
    Lessee, operating lease, renewal term     10 years 10 years 10 years 10 years 10 years 10 years 10 years 10 years        
    Minimum | Revolving credit facility with Truist | Truist | Base Rate                            
    Segment Reporting Information [Line Items]                            
    Interest rate margin 0.25%                          
    Minimum | Revolving credit facility with Truist | Truist | SOFR                            
    Segment Reporting Information [Line Items]                            
    Interest rate margin 1.25%                          
    Maximum                            
    Segment Reporting Information [Line Items]                            
    Lessee, operating lease, renewal term     15 years 15 years 15 years 15 years 15 years 15 years 15 years 15 years        
    Maximum | Revolving credit facility with Truist | Truist | Base Rate                            
    Segment Reporting Information [Line Items]                            
    Interest rate margin 1.25%                          
    Maximum | Revolving credit facility with Truist | Truist | SOFR                            
    Segment Reporting Information [Line Items]                            
    Interest rate margin 2.25%                          
    Standard Bearer Master Leases                            
    Segment Reporting Information [Line Items]                            
    Lessee leasing arrangements, operating leases, number of renewal terms | renewal   3                        
    Lessee, operating lease, renewal term   5 years                        
    Operating leases of lessee, contingent rentals, basis spread on variable rate   2.50%                        
    Rental revenue         $ 62,500,000                  
    Standard Bearer Master Leases | Base Management Fee                            
    Segment Reporting Information [Line Items]                            
    Management fees, as a percentage of total revenues   5.00%                        
    Management fees         $ 4,367,000           $ 0 $ 0    
    Standard Bearer Master Leases | Incentive Management Fee                            
    Segment Reporting Information [Line Items]                            
    Management fees, as a percentage of total revenues   1.00%                        
    Management fees, as a percentage of funds from operations   5.00%                        
    Standard Bearer Master Leases | Total Management Fee                            
    Segment Reporting Information [Line Items]                            
    Management fees, as a percentage of total revenues     6.00%         6.00%            
    Standard Bearer Master Leases | Minimum                            
    Segment Reporting Information [Line Items]                            
    Lessee, operating lease, term of contract   15 years                        
    Operating leases of lessee, contingent rentals, basis spread on variable rate   0.00%                        
    Standard Bearer Master Leases | Maximum                            
    Segment Reporting Information [Line Items]                            
    Lessee, operating lease, term of contract   19 years                        
    The Pennant Group, Inc. | Senior Living Facilities                            
    Segment Reporting Information [Line Items]                            
    Number of real estate properties | facility                         2  
    The Pennant Group, Inc. | Senior Living Facilities | Spinoff                            
    Segment Reporting Information [Line Items]                            
    Number of real estate properties     29 29 29 29 29 29 29 29       29
    Owned Properties                            
    Segment Reporting Information [Line Items]                            
    Number of real estate properties | facility     79 79 79 79 79 79 79 79        
    Standard Bearer                            
    Segment Reporting Information [Line Items]                            
    Number of real estate properties | facility     103 103 103 103 103 103 103 103        
    Cash dividends         $ 30,379,000                  
    Proceeds from Equity Method Investment, Distribution         30,095,000                  
    Non-controlling interest distribution         $ 284,000                  
    Standard Bearer | Third Parties                            
    Segment Reporting Information [Line Items]                            
    Number of real estate properties | operation     29 29 29 29 29 29 29 29        
    Standard Bearer | Owned Properties                            
    Segment Reporting Information [Line Items]                            
    Number of real estate properties | operation     75 75 75 75 75 75 75 75        
    Standard Bearer | Skilled Nursing Operations                            
    Segment Reporting Information [Line Items]                            
    Number of asset acquisitions           10       7        
    Purchase price         $ 84,656,000                  
    Number of real estate skilled nursing properties acquired | skilled_nursing_property             3              
    Standard Bearer | Skilled Nursing Operations | Spinoff | Remaining Company                            
    Segment Reporting Information [Line Items]                            
    Number of real estate properties | operation     1 1 1 1 1 1 1 1        
    XML 80 R60.htm IDEA: XBRL DOCUMENT v3.22.4
    BUSINESS SEGMENTS - Narrative (Details)
    $ in Thousands
    3 Months Ended 12 Months Ended
    Mar. 31, 2022
    segment
    Dec. 31, 2022
    USD ($)
    operation
    facility
    Dec. 31, 2021
    USD ($)
    Dec. 31, 2020
    USD ($)
    Segment Reporting Information [Line Items]        
    Number of reportable segments | segment 2      
    Transitional and skilled service facilities   234    
    Transitional and skilled services and senior living campuses   26    
    Number of real estate properties | facility   108    
    Senior living facilities | facility   11    
    Rental revenue | $   $ 16,757 $ 15,985 $ 15,157
    Owned Properties        
    Segment Reporting Information [Line Items]        
    Number of real estate properties | facility   79    
    Standard Bearer        
    Segment Reporting Information [Line Items]        
    Number of real estate properties | facility   103    
    Standard Bearer | Remaining Company | Spinoff | Skilled Nursing Operations        
    Segment Reporting Information [Line Items]        
    Number of real estate properties   1    
    Standard Bearer | Third Parties        
    Segment Reporting Information [Line Items]        
    Number of real estate properties   29    
    Standard Bearer | Owned Properties        
    Segment Reporting Information [Line Items]        
    Number of real estate properties   75    
    XML 81 R61.htm IDEA: XBRL DOCUMENT v3.22.4
    BUSINESS SEGMENTS - Schedule of Segment Reporting Information (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Segment Reporting Information [Line Items]      
    Service revenue $ 3,008,711 $ 2,611,476 $ 2,387,439
    Rental revenue 16,757 15,985 15,157
    TOTAL REVENUE 3,025,468 2,627,461 2,402,596
    Segment income (loss) 285,822 257,564 220,359
    Gain on sale of assets, net 3,267 440 (2,753)
    Income before provision for income taxes 289,089 258,004 217,606
    Depreciation and amortization 62,355 55,985 54,571
    Interest expense 8,931 6,849 9,362
    Standard Bearer      
    Segment Reporting Information [Line Items]      
    Rental revenue 57,967 44,165 40,946
    Operating Segments | Skilled Services      
    Segment Reporting Information [Line Items]      
    Service revenue 2,906,215 2,523,234 2,288,182
    Rental revenue 0 0 0
    TOTAL REVENUE 2,906,215 2,523,234 2,288,182
    Segment income (loss) 408,732 373,603 327,812
    Depreciation and amortization 33,224 30,681 28,585
    Interest expense 0 0 0
    Operating Segments | Standard Bearer      
    Segment Reporting Information [Line Items]      
    Service revenue 0 0 0
    Rental revenue 72,937 58,127 54,104
    TOTAL REVENUE 72,937 58,127 54,104
    Segment income (loss) 27,871 31,876 27,299
    Depreciation and amortization 21,613 17,558 16,134
    Interest expense 15,707 6,842 9,350
    Operating Segments | All Other      
    Segment Reporting Information [Line Items]      
    Service revenue 115,214 95,276 105,548
    Rental revenue 7,396 7,409 7,171
    TOTAL REVENUE 122,610 102,685 112,719
    Segment income (loss) (150,781) (147,915) (134,752)
    Depreciation and amortization 7,518 7,746 9,852
    Interest expense 1,870 7 12
    Intercompany Elimination      
    Segment Reporting Information [Line Items]      
    Service revenue (12,718) (7,034) (6,291)
    Rental revenue (63,576) (49,551) (46,118)
    TOTAL REVENUE (76,294) (56,585) (52,409)
    Segment income (loss) 0 0 0
    Depreciation and amortization 0 0 0
    Interest expense $ (8,646) $ 0 $ 0
    XML 82 R62.htm IDEA: XBRL DOCUMENT v3.22.4
    BUSINESS SEGMENTS - Revenue by Segment (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue $ 3,008,711 $ 2,611,476 $ 2,387,439
    Revenue Benchmark | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Concentration risk 100.00% 100.00% 100.00%
    Total Medicaid and Medicare      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue $ 2,216,194 $ 1,922,333 $ 1,777,469
    Total Medicaid and Medicare | Revenue Benchmark | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Concentration risk 73.70% 73.60% 74.50%
    Medicaid      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue $ 1,183,156 $ 1,022,460 $ 900,249
    Medicaid | Revenue Benchmark | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Concentration risk 39.30% 39.20% 37.70%
    Medicare      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue $ 832,160 $ 727,103 $ 727,374
    Medicare | Revenue Benchmark | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Concentration risk 27.70% 27.80% 30.50%
    Medicare      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue $ 200,878 $ 172,770 $ 149,846
    Medicare | Revenue Benchmark | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Concentration risk 6.70% 6.60% 6.30%
    Managed care      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue $ 525,710 $ 456,728 $ 367,095
    Managed care | Revenue Benchmark | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Concentration risk 17.50% 17.50% 15.40%
    Private and other      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue $ 266,807 $ 232,415 $ 242,875
    Private and other | Revenue Benchmark | Customer Concentration Risk      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Concentration risk 8.80% 8.90% 10.10%
    Operating Segments | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue $ 2,906,215 $ 2,523,234 $ 2,288,182
    Operating Segments | Total Medicaid and Medicare | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue 2,191,347 1,906,934 1,764,211
    Operating Segments | Medicaid | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue 1,158,309 1,007,061 886,991
    Operating Segments | Medicare | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue 832,160 727,103 727,374
    Operating Segments | Medicare | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue 200,878 172,770 149,846
    Operating Segments | Managed care | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue 525,710 456,728 367,095
    Operating Segments | Private and other | Skilled Services      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue 189,158 159,572 156,876
    Other Service Revenue      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue 102,496 88,242 99,257
    Other Service Revenue | Total Medicaid and Medicare      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue 24,847 15,399 13,258
    Other Service Revenue | Medicaid      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue 24,847 15,399 13,258
    Other Service Revenue | Medicare      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue 0 0 0
    Other Service Revenue | Medicare      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue 0 0 0
    Other Service Revenue | Managed care      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue 0 0 0
    Other Service Revenue | Private and other      
    Segment Reporting, Revenue Reconciling Item [Line Items]      
    Service revenue $ 77,649 $ 72,843 $ 85,999
    XML 83 R63.htm IDEA: XBRL DOCUMENT v3.22.4
    OPERATION EXPANSIONS (Details)
    $ in Thousands
    1 Months Ended 12 Months Ended
    Feb. 02, 2023
    bed
    operation
    Dec. 31, 2022
    facility
    senior_living_unit
    bed
    operation
    Dec. 31, 2022
    skilled_nursing_property
    facility
    senior_living_unit
    bed
    Dec. 31, 2022
    facility
    asset_acquisition
    senior_living_unit
    bed
    Dec. 31, 2022
    USD ($)
    facility
    senior_living_unit
    bed
    Dec. 31, 2021
    USD ($)
    business
    bed
    operation
    Dec. 31, 2020
    USD ($)
    operation
    facility
    bed
    Mar. 31, 2020
    facility
    Business Acquisition [Line Items]                
    Operational skilled nursing beds | bed   28,100 28,100 28,100 28,100      
    Operational senior living units | senior_living_unit   3,000 3,000 3,000 3,000      
    Aggregate purchase price of business and asset acquisitions         $ 101,136 $ 104,224    
    Goodwill         $ 16,400 6,000    
    Number of real estate properties | facility   108 108 108 108      
    The Pennant Group, Inc. | Senior Living Facilities                
    Business Acquisition [Line Items]                
    Number of real estate properties | facility               2
    Skilled Nursing Operations | Subsequent Event                
    Business Acquisition [Line Items]                
    Operational skilled nursing beds | bed 1,462              
    Series of Individually Immaterial Asset Acquisitions                
    Business Acquisition [Line Items]                
    Asset acquisition, purchase price         $ 84,736 $ 98,224    
    Real Estate Purchases                
    Business Acquisition [Line Items]                
    Number of asset acquisitions | business           5    
    Real Estate Purchases Of Previous Operations                
    Business Acquisition [Line Items]                
    Number of asset acquisitions | business           4    
    Asset Acquisition                
    Business Acquisition [Line Items]                
    Asset acquisition, purchase price             $ 24,997  
    Goodwill         $ 16,400 $ 6,000 $ 0  
    Standard Bearer                
    Business Acquisition [Line Items]                
    Number of real estate properties | facility   103 103 103 103      
    Standard Bearer | Skilled Nursing Operations                
    Business Acquisition [Line Items]                
    Number of asset acquisitions   10   7        
    Number of real estate skilled nursing properties acquired | skilled_nursing_property     3          
    Skilled Nursing Operations                
    Business Acquisition [Line Items]                
    Number of businesses acquired | operation   23       17 5  
    Number of real estate skilled nursing properties acquired | skilled_nursing_property     3          
    Operational skilled nursing beds | bed   3,058 3,058 3,058 3,058 1,832 507  
    Skilled Nursing Operations | Subsequent Event                
    Business Acquisition [Line Items]                
    Number of businesses acquired | operation 17              
    Campus Operation                
    Business Acquisition [Line Items]                
    Number of businesses acquired | operation   1            
    Senior Living Facilities                
    Business Acquisition [Line Items]                
    Number of businesses acquired | operation   5         1  
    Number of operations transferred from third parties | operation   3            
    Operational senior living units | senior_living_unit   674 674 674 674      
    Skilled nursing, assisted living and independent living facilities | facility             298  
    Series of Individually Immaterial Business Acquisitions                
    Business Acquisition [Line Items]                
    Goodwill         $ 16,400      
    Payments to acquire businesses, gross           $ 6,000    
    Owned Properties                
    Business Acquisition [Line Items]                
    Number of businesses acquired | facility             4  
    Transitional and Skilled Services and Senior Living Campuses                
    Business Acquisition [Line Items]                
    Number of businesses acquired | operation             1  
    XML 84 R64.htm IDEA: XBRL DOCUMENT v3.22.4
    OPERATION EXPANSIONS - Purchase Price Allocation (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Business Acquisition [Line Items]      
    Goodwill $ 16,400 $ 6,000  
    Asset Acquisition      
    Business Acquisition [Line Items]      
    Goodwill 16,400 6,000 $ 0
    Leased asset 1,909 0 0
    Other indefinite-lived intangible assets 245 75 648
    TOTAL ACQUISITIONS 101,136 104,224 24,997
    Land | Asset Acquisition      
    Business Acquisition [Line Items]      
    Property, plant and equipment 15,527 19,928 9,496
    Building and improvements | Asset Acquisition      
    Business Acquisition [Line Items]      
    Property, plant and equipment 65,070 77,975 14,178
    Equipment, furniture, and fixtures | Asset Acquisition      
    Business Acquisition [Line Items]      
    Property, plant and equipment 1,618 217 568
    Assembled occupancy | Asset Acquisition      
    Business Acquisition [Line Items]      
    Property, plant and equipment $ 367 $ 29 $ 107
    XML 85 R65.htm IDEA: XBRL DOCUMENT v3.22.4
    PROPERTY AND EQUIPMENT— NET - Summary (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Property, Plant and Equipment [Line Items]    
    Property and equipment $ 1,331,802 $ 1,184,201
    Less: accumulated depreciation (339,792) (295,767)
    PROPERTY AND EQUIPMENT, NET 992,010 888,434
    Land    
    Property, Plant and Equipment [Line Items]    
    Property and equipment 134,864 121,164
    Buildings and improvements    
    Property, Plant and Equipment [Line Items]    
    Property and equipment 728,231 646,221
    Leasehold improvements    
    Property, Plant and Equipment [Line Items]    
    Property and equipment 150,903 140,012
    Equipment    
    Property, Plant and Equipment [Line Items]    
    Property and equipment 295,739 262,246
    Furniture and fixtures    
    Property, Plant and Equipment [Line Items]    
    Property and equipment 4,544 4,305
    Construction in progress    
    Property, Plant and Equipment [Line Items]    
    Property and equipment $ 17,521 $ 10,253
    XML 86 R66.htm IDEA: XBRL DOCUMENT v3.22.4
    PROPERTY AND EQUIPMENT— NET - Narrative (Details) - USD ($)
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Property, Plant and Equipment [Line Items]      
    Impairment of long lived assets $ 0 $ 0 $ 2,681,000
    Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag     impairment charges
    Senior Living Operations | Disposal Group, Disposed of by Sale, Not Discontinued Operations      
    Property, Plant and Equipment [Line Items]      
    Proceeds from sale of real estate 8,607,000    
    Gains on sales property, plant and equipment $ 3,467,000    
    XML 87 R67.htm IDEA: XBRL DOCUMENT v3.22.4
    INTANGIBLE ASSETS — NET - Schedule of Finite Lived Intangible Assets (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Acquired Finite-Lived Intangible Assets [Line Items]    
    Gross Carrying Amount $ 5,750 $ 5,383
    Accumulated Amortization (3,285) (2,731)
    Net $ 2,465 2,652
    Assembled occupancy    
    Acquired Finite-Lived Intangible Assets [Line Items]    
    Weighted Average Life (Years) 3 months 18 days  
    Gross Carrying Amount $ 435 68
    Accumulated Amortization (388) (68)
    Net $ 47 0
    Facility trade name    
    Acquired Finite-Lived Intangible Assets [Line Items]    
    Weighted Average Life (Years) 30 years  
    Gross Carrying Amount $ 733 733
    Accumulated Amortization (415) (391)
    Net $ 318 342
    Customer relationships    
    Acquired Finite-Lived Intangible Assets [Line Items]    
    Weighted Average Life (Years) 18 years 4 months 24 days  
    Gross Carrying Amount $ 4,582 4,582
    Accumulated Amortization (2,482) (2,272)
    Net $ 2,100 $ 2,310
    XML 88 R68.htm IDEA: XBRL DOCUMENT v3.22.4
    INTANGIBLE ASSETS — NET - Narrative (Details) - USD ($)
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Finite-Lived Intangible Assets [Line Items]      
    Amortization of intangible assets $ 1,714,000 $ 1,435,000 $ 1,813,000
    Impairment of intangible assets (excluding goodwill) 0 0 0
    Depreciation and amortization      
    Finite-Lived Intangible Assets [Line Items]      
    Operating lease expense $ 1,160,000 $ 1,158,000 $ 1,223,000
    XML 89 R69.htm IDEA: XBRL DOCUMENT v3.22.4
    INTANGIBLE ASSETS — NET - Future Amortization (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]    
    2023 $ 281  
    2024 234  
    2025 234  
    2026 234  
    2027 234  
    Thereafter 1,248  
    Net $ 2,465 $ 2,652
    XML 90 R70.htm IDEA: XBRL DOCUMENT v3.22.4
    GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Narrative (Details) - USD ($)
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Indefinite-lived Intangible Assets [Line Items]      
    Goodwill impairment $ 0 $ 0 $ 0
    Goodwill, accumulated impairment loss 7,410,000    
    Medicare and Medicaid licenses      
    Indefinite-lived Intangible Assets [Line Items]      
    Indefinite-lived intangible assets $ 245,000 $ 181,000 $ 648,000
    XML 91 R71.htm IDEA: XBRL DOCUMENT v3.22.4
    GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Goodwill Rollforward (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Goodwill [Roll Forward]      
    Balance at beginning of period $ 60,469 $ 54,469 $ 54,469
    Additions 16,400 6,000  
    Balance at end of period 76,869 60,469 54,469
    Operating Segments | Skilled Services      
    Goodwill [Roll Forward]      
    Balance at beginning of period 51,486 45,486 45,486
    Additions 16,400 6,000  
    Balance at end of period 67,886 51,486 45,486
    Other Service Revenue      
    Goodwill [Roll Forward]      
    Balance at beginning of period 8,983 8,983 8,983
    Additions 0 0  
    Balance at end of period $ 8,983 $ 8,983 $ 8,983
    XML 92 R72.htm IDEA: XBRL DOCUMENT v3.22.4
    GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Indefinite-Lived Intangible Assets (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Indefinite-lived Intangible Assets [Line Items]    
    Other indefinite-lived intangibles $ 3,972 $ 3,727
    Trade name    
    Indefinite-lived Intangible Assets [Line Items]    
    Other indefinite-lived intangibles 889 889
    Medicare and Medicaid licenses    
    Indefinite-lived Intangible Assets [Line Items]    
    Other indefinite-lived intangibles $ 3,083 $ 2,838
    XML 93 R73.htm IDEA: XBRL DOCUMENT v3.22.4
    RESTRICTED AND OTHER ASSETS - Summary (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
    Debt issuance costs, net $ 3,753 $ 1,953
    Long-term insurance losses recoverable asset 10,512 6,755
    Capital improvement reserves with landlords and lenders 6,446 7,103
    Deposits with landlords 2,527 2,606
    Other 14,053 11,099
    RESTRICTED AND OTHER ASSETS $ 37,291 $ 29,516
    XML 94 R74.htm IDEA: XBRL DOCUMENT v3.22.4
    OTHER ACCRUED LIABILITIES (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Payables and Accruals [Abstract]      
    Quality assurance fee $ 7,701 $ 6,474  
    Refunds payable 40,783 34,814  
    Resident advances 9,698 9,337  
    Unapplied state relief funds 1,001 1,781  
    Cash held in trust for patients 6,400 6,430  
    Dividends payable 3,201 3,035 $ 2,868
    Property taxes 10,926 9,124  
    Legal finding accrued 4,553 0  
    Other 13,046 18,415  
    OTHER ACCRUED LIABILITIES $ 97,309 $ 89,410  
    XML 95 R75.htm IDEA: XBRL DOCUMENT v3.22.4
    INCOME TAXES - Expense (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Current:      
    Federal $ 56,717 $ 49,105 $ 60,591
    State 14,216 11,898 13,460
    Total current income tax expense (benefit) 70,933 61,003 74,051
    Deferred:      
    Federal (5,158) (716) (23,054)
    State (1,338) (8) (4,755)
    Total deferred income tax expense (benefit) (6,496) (724) (27,809)
    Provision for income taxes $ 64,437 $ 60,279 $ 46,242
    XML 96 R76.htm IDEA: XBRL DOCUMENT v3.22.4
    INCOME TAXES - Tax Rate (Details)
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Income Tax Disclosure [Abstract]      
    Income tax expense at statutory rate 21.00% 21.00% 21.00%
    State income taxes - net of federal benefit 3.50% 3.70% 3.20%
    Non-deductible expenses 2.00% 2.40% 1.80%
    Equity compensation (3.60%) (3.30%) (4.30%)
    Other adjustments (0.60%) (0.40%) (0.40%)
    TOTAL INCOME TAX PROVISION 22.30% 23.40% 21.30%
    XML 97 R77.htm IDEA: XBRL DOCUMENT v3.22.4
    INCOME TAXES - Narrative (YE) (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Income Tax Disclosure [Abstract]      
    Effective income tax rate 22.30% 23.40% 21.30%
    Tax credits $ 1,742 $ 2,138  
    Valuation allowance $ 789 $ 789  
    XML 98 R78.htm IDEA: XBRL DOCUMENT v3.22.4
    INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Income Tax Disclosure [Abstract]    
    Accrued expenses $ 61,685 $ 58,640
    Revenue related reserves 18,046 13,171
    Tax credits 1,742 2,138
    Insurance 11,910 8,712
    Lease liability 364,408 285,643
    State taxes 28 (165)
    Total deferred tax assets 457,819 368,139
    Valuation allowance (789) (789)
    TOTAL DEFERRED TAX ASSETS 457,030 367,350
    Depreciation and amortization (49,146) (45,827)
    Prepaid expenses (5,150) (4,265)
    Right of use asset (363,091) (284,111)
    TOTAL DEFERRED TAX LIABILITIES (417,387) (334,203)
    NET DEFERRED TAX ASSETS $ 39,643 $ 33,147
    XML 99 R79.htm IDEA: XBRL DOCUMENT v3.22.4
    DEBT - Schedule of Long-term Debt (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Debt Instrument [Line Items]    
    Less: current maturities $ (3,883) $ (3,760)
    Less: debt issuance costs, net (3,119) (3,324)
    Long-term debt—less current maturities 149,269 152,883
    Mortgage loans and promissory notes | Mortgage loans and promissory notes    
    Debt Instrument [Line Items]    
    Mortgage loans and promissory notes 156,271 $ 159,967
    Long-term debt—less current maturities $ 152,388  
    XML 100 R80.htm IDEA: XBRL DOCUMENT v3.22.4
    DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)
    12 Months Ended
    Apr. 08, 2022
    USD ($)
    Dec. 31, 2022
    USD ($)
    Dec. 31, 2021
    USD ($)
    Dec. 31, 2020
    USD ($)
    Jan. 30, 2023
    USD ($)
    Apr. 07, 2022
    USD ($)
    Debt Instrument [Line Items]            
    Write-off of deferred financing fees   $ 566,000 $ 0 $ 0    
    Payments of deferred financing costs   (3,197,000) $ (1,172,000) $ 0    
    Revolving credit facility with Truist | Truist            
    Debt Instrument [Line Items]            
    Line of credit facility, maximum borrowing capacity $ 600,000,000 600,000,000       $ 350,000,000
    Total net debt ratio, maximum 3.00          
    Long-term debt threshold for EBITDA ratio increase election period 6 months          
    Long-term debt, threshold for EBITDA ratio increase election $ 50,000,000          
    Total net debt ratio, maximum after increase election 3.50          
    Total net debt ratio, minimum 1.50          
    Long-term debt, gross   $ 0        
    Revolving credit facility with Truist | Truist | Subsequent Event            
    Debt Instrument [Line Items]            
    Long-term debt, gross         $ 0  
    Revolving credit facility with Truist | Truist | Minimum            
    Debt Instrument [Line Items]            
    Line of credit facility, unused capacity, commitment fee percentage 0.20%          
    Revolving credit facility with Truist | Truist | Minimum | Base Rate            
    Debt Instrument [Line Items]            
    Interest rate margin 0.25%          
    Revolving credit facility with Truist | Truist | Minimum | SOFR            
    Debt Instrument [Line Items]            
    Interest rate margin 1.25%          
    Revolving credit facility with Truist | Truist | Maximum            
    Debt Instrument [Line Items]            
    Line of credit facility, unused capacity, commitment fee percentage 0.40%          
    Revolving credit facility with Truist | Truist | Maximum | Base Rate            
    Debt Instrument [Line Items]            
    Interest rate margin 1.25%          
    Revolving credit facility with Truist | Truist | Maximum | SOFR            
    Debt Instrument [Line Items]            
    Interest rate margin 2.25%          
    XML 101 R81.htm IDEA: XBRL DOCUMENT v3.22.4
    DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    USD ($)
    subsidiary
    promissory_note
    Dec. 31, 2021
    USD ($)
    Debt Instrument [Line Items]    
    Amount outstanding, current $ 3,883 $ 3,760
    Long-term debt—less current maturities 149,269 152,883
    Letters of credit outstanding, pledged amount $ 6,710  
    Mortgage loans and promissory notes    
    Debt Instrument [Line Items]    
    Number of promissory notes | promissory_note 2  
    Mortgage loans and promissory notes | Notes Payable Other Payables    
    Debt Instrument [Line Items]    
    Long-term debt, gross $ 156,271 $ 159,967
    Long-term debt—less current maturities $ 152,388  
    Mortgage loans and promissory notes | Mortgages    
    Debt Instrument [Line Items]    
    Prepayment penalty reduced rate during period 3 years  
    Prepayment penalty reduced rate during first three years 10.00%  
    Prepayment penalty reduced rate during the fourth year 3.00%  
    Prepayment penalty reduced rate for the fifth through tenth years 1.00%  
    Mortgage loans and promissory notes | Mortgages | Twenty Three Subsidiaries    
    Debt Instrument [Line Items]    
    Number of operating subsidiaries | subsidiary 23  
    Notes payable $ 153,488  
    Mortgage loans and promissory notes | Mortgages | Minimum    
    Debt Instrument [Line Items]    
    Debt Instrument, pre-payment fee reduction, term 5 years  
    Debt instrument, term 25 years  
    Mortgage loans and promissory notes | Mortgages | Maximum    
    Debt Instrument [Line Items]    
    Debt Instrument, pre-payment fee reduction, term 10 years  
    Debt instrument, term 35 years  
    Mortgage loans and promissory notes | Notes Payable to Banks | Minimum    
    Debt Instrument [Line Items]    
    Debt instrument, interest rate, effective percentage 3.10%  
    Debt instrument, interest rate, stated percentage 2.40%  
    Mortgage loans and promissory notes | Notes Payable to Banks | Maximum    
    Debt Instrument [Line Items]    
    Debt instrument, interest rate, effective percentage 4.20%  
    Debt instrument, interest rate, stated percentage 3.30%  
    Mortgage loans and promissory notes | Promissory Note, 5.0%    
    Debt Instrument [Line Items]    
    Debt instrument, interest rate, stated percentage 6.30%  
    Debt instrument, term 10 months  
    Mortgage loans and promissory notes | Promissory Note, 5.3%    
    Debt Instrument [Line Items]    
    Debt instrument, interest rate, stated percentage 5.30%  
    Debt instrument, term 12 years  
    XML 102 R82.htm IDEA: XBRL DOCUMENT v3.22.4
    DEBT - Long-term Debt Arrangements (Details)
    $ in Thousands
    Dec. 31, 2022
    USD ($)
    Debt Disclosure [Abstract]  
    2023 $ 3,883
    2024 3,950
    2025 4,086
    2026 4,227
    2027 3,897
    Thereafter 136,228
    Long-term Debt $ 156,271
    XML 103 R83.htm IDEA: XBRL DOCUMENT v3.22.4
    OPTIONS AND AWARDS - Stock Options, Narrative (Details)
    shares in Thousands
    3 Months Ended 12 Months Ended
    Jun. 30, 2022
    installment
    shares
    Dec. 31, 2022
    repurchase_program
    installment
    $ / shares
    shares
    Dec. 31, 2021
    $ / shares
    shares
    Dec. 31, 2020
    $ / shares
    shares
    Oct. 31, 2019
    shares
    Dec. 31, 2017
    shares
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
    Number of option plans | repurchase_program   1        
    Options granted (in shares)   581 621 669    
    Forfeiture rate   7.84%        
    Grant date intrinsic value (in dollars per share) | $ / shares   $ 0 $ 0 $ 0    
    Restricted Stock Awards            
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
    Award vesting period   5 years        
    Granted restricted shares (in shares)   233 222 281    
    Non-employee directors | Restricted Stock Awards            
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
    Granted restricted shares (in shares)   18        
    2017 Plan            
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
    Number of shares authorized (in shares)           6,881
    Other than options, conversion to reduce shares availability   2.5        
    Award vesting period   5 years        
    Award vesting rights, percentage   20.00%        
    Expiration period   10 years        
    Conversion to reduce shares availability   1        
    Options granted (in shares)   165        
    2017 Plan | Restricted Stock Awards            
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
    Granted restricted shares (in shares)   116        
    2017 Plan | Spinoff            
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
    Number of shares authorized (in shares)         8,118  
    2017 Plan | Non-employee directors            
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
    Number of installments | installment   3        
    Award requisite service period   3 years        
    2022 Plan            
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
    Number of shares authorized (in shares) 3,452          
    Conversion to reduce shares availability 1          
    Other than options, conversion to reduce shares availability 2          
    Award vesting period 5 years          
    Award vesting rights, percentage 20.00%          
    Expiration period 10 years          
    Number of shares available for grant (in shares)   2,861        
    2022 Plan | Non-employee directors            
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
    Number of installments | installment 3          
    Award requisite service period 3 years          
    XML 104 R84.htm IDEA: XBRL DOCUMENT v3.22.4
    OPTIONS AND AWARDS - Valuation Assumptions (Details) - shares
    shares in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Share-Based Payment Arrangement [Abstract]      
    Options Granted (in shares) 581 621 669
    Weighted Average Risk-Free Rate 2.80% 1.00% 0.60%
    Expected Life 6 years 2 months 12 days 6 years 2 months 12 days 6 years 2 months 12 days
    Weighted Average Volatility 42.10% 42.40% 39.40%
    Weighted Average Dividend Yield 0.30% 0.30% 0.40%
    XML 105 R85.htm IDEA: XBRL DOCUMENT v3.22.4
    OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) - $ / shares
    shares in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Share-Based Payment Arrangement [Abstract]      
    Granted (in shares) 581 621 669
    Weighted Average Exercise Price (in dollars per share) $ 85.74 $ 80.19 $ 52.20
    Weighted Average Fair Value of Options (in dollars per share) $ 37.83 $ 32.82 $ 19.52
    XML 106 R86.htm IDEA: XBRL DOCUMENT v3.22.4
    OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) - $ / shares
    shares in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Number of Options Outstanding        
    Balance at beginning of period, (in shares) 4,038 4,038 4,428  
    Granted (in shares) 581 621 669  
    Forfeited (in shares) (98) (105) (80)  
    Exercised (in shares) (688) (516) (979)  
    Balance at end of period, (in shares) 3,833 4,038 4,038  
    Weighted Average Exercise Price        
    Balance at beginning of period (in dollars per share) $ 36.60 $ 27.71 $ 20.85  
    Granted (in dollars per share) 85.74 80.19 52.20  
    Forfeited (in dollars per share) 59.52 44.76 33.68  
    Exercised (in dollars per share) 18.43 17.80 12.93  
    Balance at end of period (in dollars per share) $ 46.72 $ 36.60 $ 27.71  
    Number of options vested (in shares) 2,069 2,183 2,148 2,557
    Weighted average exercise price of options vested (in dollars per share) $ 28.87 $ 21.02 $ 16.66 $ 12.82
    XML 107 R87.htm IDEA: XBRL DOCUMENT v3.22.4
    OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details)
    $ / shares in Units, shares in Thousands, $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    USD ($)
    $ / shares
    shares
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Number outstanding (in shares) 3,833
    Black-Scholes Fair Value | $ $ 71,034
    Stock options vested and exercisable (in shares) 2,069
    2013  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 6.76
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 9.74
    Number outstanding (in shares) 65
    Black-Scholes Fair Value | $ $ 274
    Remaining Contractual Life (Years) 1 year
    Stock options vested and exercisable (in shares) 65
    2014  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 8.94
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 16.05
    Number outstanding (in shares) 399
    Black-Scholes Fair Value | $ $ 1,930
    Remaining Contractual Life (Years) 2 years
    Stock options vested and exercisable (in shares) 399
    2015  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 18.20
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 21.39
    Number outstanding (in shares) 211
    Black-Scholes Fair Value | $ $ 1,645
    Remaining Contractual Life (Years) 3 years
    Stock options vested and exercisable (in shares) 211
    2016  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 15.93
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 16.86
    Number outstanding (in shares) 198
    Black-Scholes Fair Value | $ $ 1,162
    Remaining Contractual Life (Years) 4 years
    Stock options vested and exercisable (in shares) 198
    2017  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 15.80
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 19.41
    Number outstanding (in shares) 236
    Black-Scholes Fair Value | $ $ 1,387
    Remaining Contractual Life (Years) 5 years
    Stock options vested and exercisable (in shares) 236
    2018  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 22.49
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 32.71
    Number outstanding (in shares) 449
    Black-Scholes Fair Value | $ $ 4,341
    Remaining Contractual Life (Years) 6 years
    Stock options vested and exercisable (in shares) 330
    2019  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 41.07
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 45.76
    Number outstanding (in shares) 590
    Black-Scholes Fair Value | $ $ 9,275
    Remaining Contractual Life (Years) 7 years
    Stock options vested and exercisable (in shares) 324
    2020  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 44.84
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 59.49
    Number outstanding (in shares) 545
    Black-Scholes Fair Value | $ $ 10,734
    Remaining Contractual Life (Years) 8 years
    Stock options vested and exercisable (in shares) 197
    2021  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 73.47
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 83.64
    Number outstanding (in shares) 567
    Black-Scholes Fair Value | $ $ 18,597
    Remaining Contractual Life (Years) 9 years
    Stock options vested and exercisable (in shares) 109
    2022  
    Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
    Exercise price, lower range limit (in dollars per share) | $ / shares $ 79.79
    Exercise price, upper range limit (in dollars per share) | $ / shares $ 94.88
    Number outstanding (in shares) 573
    Black-Scholes Fair Value | $ $ 21,689
    Remaining Contractual Life (Years) 10 years
    Stock options vested and exercisable (in shares) 0
    XML 108 R88.htm IDEA: XBRL DOCUMENT v3.22.4
    OPTIONS AND AWARDS - Intrinsic Values (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Share-Based Payment Arrangement [Abstract]      
    Outstanding $ 183,593 $ 191,242 $ 182,552
    Vested 136,000 137,382 120,867
    Expected to vest 43,232 48,548 53,366
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Intrinsic value of options exercised in period 47,441 34,278 45,081
    Stock Options      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Aggregate intrinsic value of options that vested in period $ 27,955 $ 27,731 $ 26,030
    XML 109 R89.htm IDEA: XBRL DOCUMENT v3.22.4
    OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) - $ / shares
    shares in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Share-based compensation, restricted awards, exercise price (in dollars per share) $ 0    
    Restricted Stock Awards      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Granted (in shares) 233 222 281
    Award vesting period 5 years    
    Granted (in dollars per share) $ 81.57 $ 81.65 $ 48.73
    Restricted Stock Awards | Non-employee directors      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Granted (in shares) 18    
    Restricted Stock Awards | Minimum      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Granted (in dollars per share) $ 73.17 72.84 35.47
    Restricted Stock Awards | Minimum | Non-employee directors      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Granted (in dollars per share) 75.33    
    Restricted Stock Awards | Maximum      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Granted (in dollars per share) 94.88 $ 93.31 $ 58.06
    Restricted Stock Awards | Maximum | Non-employee directors      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Granted (in dollars per share) $ 86.34    
    XML 110 R90.htm IDEA: XBRL DOCUMENT v3.22.4
    OPTIONS AND AWARDS - Restricted Award Rollforward (Details) - Restricted Stock Awards - $ / shares
    shares in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Non-Vested Restricted Awards      
    Nonvested at beginning of period (in shares) 549 591 610
    Granted (in shares) 233 222 281
    Vested (in shares) (269) (244) (280)
    Forfeited (in shares) (26) (20) (20)
    Nonvested at end of period (in shares) 487 549 591
    Weighted Average Grant Date Fair Value      
    Nonvested at beginning of period (in dollars per share) $ 52.16 $ 38.90 $ 31.35
    Granted (in dollars per share) 81.57 81.65 48.73
    Vested (in dollars per share) 54.06 47.45 32.84
    Forfeited (in dollars per share) 57.29 45.64 31.71
    Nonvested at end of period (in dollars per share) $ 64.92 $ 52.16 $ 38.90
    XML 111 R91.htm IDEA: XBRL DOCUMENT v3.22.4
    OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Aug. 27, 2019
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Share-based compensation   $ 22,720 $ 18,678 $ 14,524
    Spinoff | 2019 LTI Plan        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Number of shares authorized (in shares) 500,000      
    Award vesting period 5 years      
    Award vesting rights, percentage 20.00%      
    Share-based compensation   $ 836 $ 854 $ 881
    XML 112 R92.htm IDEA: XBRL DOCUMENT v3.22.4
    OPTIONS AND AWARDS - Compensation Expense (Details) - USD ($)
    shares in Thousands, $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Stock-based compensation expense $ 22,720 $ 18,678 $ 14,524
    Share-based compensation, options outstanding, weighted average remaining contractual term 6 years    
    Stock-based compensation expense related to stock options      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Stock-based compensation expense $ 11,361 8,459 6,132
    Share-based compensation, nonvested awards, cost not yet recognized $ 43,388    
    Share-based compensation, nonvested awards, cost not yet recognized, period for recognition 3 years 7 months 6 days    
    Share-based compensation, nonvested awards (in shares) 1,764    
    Share-based compensation, options expected to vest, number (in shares) 1,666    
    Stock-based compensation expense related to restricted stock awards      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Stock-based compensation expense $ 9,920 8,385 7,373
    Share-based compensation, nonvested awards, cost not yet recognized $ 29,149    
    Share-based compensation, nonvested awards, cost not yet recognized, period for recognition 3 years 4 months 24 days    
    Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Stock-based compensation expense $ 1,439 $ 1,834 $ 1,019
    XML 113 R93.htm IDEA: XBRL DOCUMENT v3.22.4
    LEASES - Lessee Narrative (Details)
    $ in Thousands
    1 Months Ended 12 Months Ended
    Feb. 02, 2023
    USD ($)
    operation
    Dec. 31, 2022
    USD ($)
    skilled_nursing_property
    operation
    renewal
    agreement
    bed
    facility
    lease
    Dec. 31, 2021
    USD ($)
    bed
    operation
    Dec. 31, 2020
    USD ($)
    bed
    operation
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   10 years    
    Right-of-use assets obtained in exchange for new and modified operating lease obligations | $   $ 370,753 $ 198,593 $ 24,599
    Reduction of right-of-use asset operating lease liability due to acquiring leased assets | $   $ 10,080    
    Operating lease, weighted average remaining lease term   15 years 14 years 9 months 18 days  
    Operating lease, weighted average discount rate, percent   6.70% 7.60%  
    Operational skilled nursing beds | bed   28,100    
    Skilled Nursing Operations        
    Lessee, Lease, Description [Line Items]        
    Number of real estate skilled nursing properties acquired | skilled_nursing_property   3    
    Number of businesses acquired   23 17 5
    Operational skilled nursing beds | bed   3,058 1,832 507
    Skilled Nursing Operations | Subsequent Event        
    Lessee, Lease, Description [Line Items]        
    Number of businesses acquired 17      
    Cost of Sales and General and Administrative Expense        
    Lessee, Lease, Description [Line Items]        
    Rent expense | $   $ 153,174 $ 139,458 $ 129,990
    Minimum        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, renewal term   10 years    
    Maximum        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, renewal term   15 years    
    Amended Master Lease | Subsequent Event        
    Lessee, Lease, Description [Line Items]        
    Right-of-use assets obtained in exchange for new and modified operating lease obligations | $ $ 315,337      
    Number of lease agreement 2      
    Amended Master Lease | Skilled Nursing Operations | Subsequent Event        
    Lessee, Lease, Description [Line Items]        
    Number of businesses acquired 17      
    New Master Lease Agreement | Skilled Nursing Operations | Subsequent Event        
    Lessee, Lease, Description [Line Items]        
    Number of businesses acquired 20      
    Operational skilled nursing beds 2      
    Subleased To Third Party | Skilled Nursing Operations | Subsequent Event        
    Lessee, Lease, Description [Line Items]        
    Number of businesses acquired 3      
    Amended Master Lease Agreement        
    Lessee, Lease, Description [Line Items]        
    Amended of separate master leases   2    
    Right-of-use assets obtained in exchange for new and modified operating lease obligations | $   $ 207,638    
    New Master Lease Agreeement        
    Lessee, Lease, Description [Line Items]        
    Right-of-use assets obtained in exchange for new and modified operating lease obligations | $   $ 54,755    
    New operations under separate master leases   6    
    CareTrust REIT        
    Lessee, Lease, Description [Line Items]        
    Skilled nursing, assisted living and independent living facilities | facility   97    
    Master lease agreements | agreement   9    
    Lessee, operating lease, renewal term   5 years    
    Consumer price index   0    
    Operating leases of lessee, contingent rentals, basis spread on variable rate   2.50%    
    Number of stand-alone leases | lease   1    
    Rent expense | $   $ 64,178 $ 59,571 $ 52,838
    CareTrust REIT | Minimum        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   13 years    
    Lessee leasing arrangements, operating leases, number of renewal terms | renewal   2    
    CareTrust REIT | Maximum        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   20 years    
    Lessee leasing arrangements, operating leases, number of renewal terms | renewal   3    
    CareTrust REIT | Third Party Tenants Under Triple Net Lease Arrangements        
    Lessee, Lease, Description [Line Items]        
    Skilled nursing, assisted living and independent living facilities | facility   96    
    CareTrust REIT | Purchase Option        
    Lessee, Lease, Description [Line Items]        
    Skilled nursing, assisted living and independent living facilities | facility   4    
    Various Landlords        
    Lessee, Lease, Description [Line Items]        
    Master lease agreements | agreement   10    
    Facilities under master lease arrangement | facility   58    
    Various Landlords | Minimum        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   5 years    
    Various Landlords | Minimum | Equipment        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   3 years    
    Various Landlords | Maximum        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   20 years    
    Various Landlords | Maximum | Equipment        
    Lessee, Lease, Description [Line Items]        
    Lessee, operating lease, term of contract   5 years    
    Various Landlords | New Master Lease Agreeement        
    Lessee, Lease, Description [Line Items]        
    Additional master lease agreement | agreement   2    
    XML 114 R94.htm IDEA: XBRL DOCUMENT v3.22.4
    LEASES - Lessee Lease Cost (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Lessee, Lease, Description [Line Items]      
    Lease, Cost $ 171,272 $ 154,693 $ 143,987
    Amortization of deferred rent 493 485 451
    Cost of services      
    Lessee, Lease, Description [Line Items]      
    Operating lease expense 153,049 139,371 129,926
    Variable lease, cost 16,938 14,077 12,774
    CPI increases and short term-lease cost 5,878 3,702 2,394
    General and administrative expense      
    Lessee, Lease, Description [Line Items]      
    Operating lease expense 125 87 64
    Depreciation and amortization      
    Lessee, Lease, Description [Line Items]      
    Operating lease expense $ 1,160 $ 1,158 $ 1,223
    XML 115 R95.htm IDEA: XBRL DOCUMENT v3.22.4
    LEASES - Lessee Future Minimum Lease Payments (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2022
    Dec. 31, 2021
    Year    
    2023 $ 157,963  
    2024 157,630  
    2025 157,455  
    2026 157,380  
    2027 156,860  
    Thereafter 1,456,411  
    TOTAL LEASE PAYMENTS 2,243,699  
    Less: present value adjustment (822,790)  
    PRESENT VALUE OF TOTAL LEASE LIABILITIES 1,420,909  
    Less: current lease liabilities (65,796) $ (52,181)
    LONG-TERM OPERATING LEASE LIABILITIES $ 1,355,113 $ 1,056,515
    XML 116 R96.htm IDEA: XBRL DOCUMENT v3.22.4
    LEASES - Lessor Narrative (Details)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    USD ($)
    facility
    operation
    senior_living_community
    agreement
    Dec. 31, 2021
    USD ($)
    Dec. 31, 2020
    USD ($)
    Mar. 31, 2020
    facility
    Oct. 31, 2019
    operation
    Lessor, Lease, Description [Line Items]          
    Number of real estate properties | facility 108        
    Right-of-use assets obtained in exchange for new and modified operating lease obligations | $ $ 370,753 $ 198,593 $ 24,599    
    Amended Master Lease Agreement          
    Lessor, Lease, Description [Line Items]          
    Amended of separate master leases | operation 2        
    Right-of-use assets obtained in exchange for new and modified operating lease obligations | $ $ 207,638        
    New Master Lease Agreeement          
    Lessor, Lease, Description [Line Items]          
    Right-of-use assets obtained in exchange for new and modified operating lease obligations | $ $ 54,755        
    New operations under separate master leases | operation 6        
    Various Landlords          
    Lessor, Lease, Description [Line Items]          
    Facilities under master lease arrangement | facility 58        
    Master lease agreements | agreement 10        
    Various Landlords | New Master Lease Agreeement          
    Lessor, Lease, Description [Line Items]          
    Additional master lease agreement | agreement 2        
    Spinoff | Minimum          
    Lessor, Lease, Description [Line Items]          
    Lessor, operating lease, term of contract 14 years        
    Spinoff | Maximum          
    Lessor, Lease, Description [Line Items]          
    Lessor, operating lease, term of contract 16 years        
    The Pennant Group, Inc. | Senior Living Facilities          
    Lessor, Lease, Description [Line Items]          
    Number of real estate properties | facility       2  
    The Pennant Group, Inc. | Spinoff | Senior Living Facilities          
    Lessor, Lease, Description [Line Items]          
    Number of real estate properties 29       29
    XML 117 R97.htm IDEA: XBRL DOCUMENT v3.22.4
    LEASES - Lessor Rental Income (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Lessor, Lease, Description [Line Items]      
    Rental revenue $ 16,757 $ 15,985 $ 15,157
    Pennant      
    Lessor, Lease, Description [Line Items]      
    Operating lease, variable lease income 1,318 1,199 1,224
    Pennant      
    Lessor, Lease, Description [Line Items]      
    Rental revenue 14,915 14,073 13,163
    Other third-party      
    Lessor, Lease, Description [Line Items]      
    Rental revenue $ 1,842 $ 1,912 $ 1,994
    XML 118 R98.htm IDEA: XBRL DOCUMENT v3.22.4
    LEASES - Lessor Future Minimum Lease Payments Receivable (Details)
    $ in Thousands
    Dec. 31, 2022
    USD ($)
    Leases [Abstract]  
    2023 $ 16,408
    2024 15,826
    2025 15,391
    2026 15,166
    2027 15,166
    Thereafter 79,171
    TOTAL $ 157,128
    XML 119 R99.htm IDEA: XBRL DOCUMENT v3.22.4
    SELF INSURANCE LIABILITIES (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Movement in Liability for Future Policy Benefits [Roll Forward]    
    Beginning balance $ 110,139 $ 96,798
    Current year provisions 115,793 114,907
    Claims paid and direct expenses (98,007) (101,183)
    Change in long-term insurance losses recoverable 3,757 (383)
    Ending balance 131,682 110,139
    General and Professional Liability    
    Movement in Liability for Future Policy Benefits [Roll Forward]    
    Beginning balance 69,748  
    Ending balance $ 87,000 $ 69,748
    XML 120 R100.htm IDEA: XBRL DOCUMENT v3.22.4
    DEFINED CONTRIBUTION PLANS (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Defined Contribution Plan Disclosure [Line Items]      
    Employer discretionary contribution amount $ 2,418 $ 2,121 $ 1,889
    Deferred compensation liability, noncurrent 33,017 26,832 14,232
    Gain (loss) on deferral investment (4,188) 1,612 1,396
    Offsetting (reduction in expense) expense $ (4,051) $ 1,758 $ 1,355
    Qualified Plan      
    Defined Contribution Plan Disclosure [Line Items]      
    Maximum annual contributions per employee (as a percent) 90.00%    
    Nonqualified Plan      
    Defined Contribution Plan Disclosure [Line Items]      
    Maximum annual contributions per employee (as a percent) 100.00%    
    XML 121 R101.htm IDEA: XBRL DOCUMENT v3.22.4
    COMMITMENTS AND CONTINGENCIES (Details)
    $ in Thousands
    12 Months Ended
    May 31, 2018
    operating_entity
    Dec. 31, 2022
    facility
    Dec. 31, 2021
    Dec. 31, 2020
    Jan. 30, 2023
    USD ($)
    Concentration Risk [Line Items]          
    Operating facilities included in scope | operating_entity 10        
    Facilities under medicare probe reviews | facility   34      
    Subsequent Event          
    Concentration Risk [Line Items]          
    Cash, uninsured amount | $         $ 0
    Customer Concentration Risk | Revenue Benchmark          
    Concentration Risk [Line Items]          
    Concentration risk   100.00% 100.00% 100.00%  
    Customer Concentration Risk | Total Medicaid and Medicare | Accounts Receivable          
    Concentration Risk [Line Items]          
    Concentration risk   56.30% 54.00%    
    Customer Concentration Risk | Total Medicaid and Medicare | Revenue Benchmark          
    Concentration Risk [Line Items]          
    Concentration risk   73.70% 73.60% 74.50%  
    XML 122 R102.htm IDEA: XBRL DOCUMENT v3.22.4
    COMMON STOCK REPURCHASE PROGRAM (Details)
    shares in Thousands
    3 Months Ended 12 Months Ended
    Jul. 28, 2022
    USD ($)
    Feb. 09, 2022
    USD ($)
    Oct. 21, 2021
    USD ($)
    Mar. 04, 2020
    USD ($)
    Jun. 30, 2022
    USD ($)
    shares
    Mar. 31, 2020
    USD ($)
    shares
    Dec. 31, 2022
    USD ($)
    shares
    Dec. 31, 2021
    USD ($)
    shares
    Dec. 31, 2020
    USD ($)
    Mar. 13, 2020
    USD ($)
    repurchase_program
    Equity, Class of Treasury Stock [Line Items]                    
    Repurchase of common stock, value             $ 29,882,000 $ 10,118,000 $ 25,000,000  
    Number of stock repurchase programs | repurchase_program                   2
    July 2022 Repurchase Program                    
    Equity, Class of Treasury Stock [Line Items]                    
    Stock repurchase program, authorized amount $ 20,000,000                  
    Stock repurchase program, period in force 12 months                  
    February 9, 2022 Repurchase Program                    
    Equity, Class of Treasury Stock [Line Items]                    
    Stock repurchase program, authorized amount   $ 20,000,000                
    Stock repurchase program, period in force   12 months                
    Repurchase of common stock (in shares) | shares         271          
    Repurchase of common stock, value         $ 20,000,000          
    October 21, 2021 Repurchase Program                    
    Equity, Class of Treasury Stock [Line Items]                    
    Stock repurchase program, authorized amount     $ 20,000,000              
    Stock repurchase program, period in force     12 months              
    Repurchase of common stock (in shares) | shares             133 132    
    Repurchase of common stock, value             $ 9,882,000 $ 10,118,000    
    March 4, 2020 Repurchase Program                    
    Equity, Class of Treasury Stock [Line Items]                    
    Stock repurchase program, authorized amount       $ 20,000,000            
    Stock repurchase program, period in force       12 months            
    Repurchase of common stock (in shares) | shares           503        
    Repurchase of common stock, value           $ 20,000,000        
    March 13, 2020 Repurchase Program                    
    Equity, Class of Treasury Stock [Line Items]                    
    Stock repurchase program, authorized amount                   $ 5,000,000
    Repurchase of common stock (in shares) | shares           189        
    Repurchase of common stock, value           $ 5,000,000        
    XML 123 ensg-20221231_htm.xml IDEA: XBRL DOCUMENT 0001125376 2022-01-01 2022-12-31 0001125376 2022-06-30 0001125376 2023-01-30 0001125376 2022-12-31 0001125376 2021-12-31 0001125376 2021-01-01 2021-12-31 0001125376 2020-01-01 2020-12-31 0001125376 us-gaap:CommonStockMember 2019-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001125376 us-gaap:RetainedEarningsMember 2019-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2019-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2019-12-31 0001125376 2019-12-31 0001125376 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2020-01-01 2020-12-31 0001125376 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001125376 us-gaap:CommonStockMember 2020-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001125376 us-gaap:RetainedEarningsMember 2020-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2020-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2020-12-31 0001125376 2020-12-31 0001125376 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0001125376 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001125376 us-gaap:CommonStockMember 2021-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001125376 us-gaap:RetainedEarningsMember 2021-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2021-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2021-12-31 0001125376 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001125376 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001125376 us-gaap:CommonStockMember 2022-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001125376 us-gaap:RetainedEarningsMember 2022-12-31 0001125376 us-gaap:TreasuryStockCommonMember 2022-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2022-12-31 0001125376 us-gaap:WhollyOwnedPropertiesMember 2022-12-31 0001125376 ensg:SeniorLivingFacilitiesMember us-gaap:SpinoffMember ensg:ThePennantGroupInc.Member 2022-12-31 0001125376 ensg:RemainingCompanyMember ensg:SkilledNursingOperationsMember us-gaap:SpinoffMember ensg:StandardBearerHealthcareREITIncMember 2022-12-31 0001125376 srt:MinimumMember 2022-01-01 2022-12-31 0001125376 srt:MaximumMember 2022-01-01 2022-12-31 0001125376 srt:MinimumMember 2022-12-31 0001125376 srt:MaximumMember 2022-12-31 0001125376 srt:MinimumMember ensg:AssembledOccupancyAcquiredMember 2022-01-01 2022-12-31 0001125376 srt:MaximumMember ensg:AssembledOccupancyAcquiredMember 2022-01-01 2022-12-31 0001125376 us-gaap:TradeNamesMember 2022-01-01 2022-12-31 0001125376 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:SelfInsuranceRetentionPerClaimMember srt:ParentCompanyMember 2022-12-31 0001125376 us-gaap:GeneralLiabilityMember stpr:CA ensg:AggregateDeductibleMember srt:ParentCompanyMember 2022-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:NonCaliforniaMember ensg:AggregateDeductibleMember srt:ParentCompanyMember 2022-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:PerOccurenceMember naics:ZZ524292 2022-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:PerFacilityMember naics:ZZ524292 2022-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:BlanketAggregateMember naics:ZZ524292 2022-12-31 0001125376 us-gaap:GeneralLiabilityMember stpr:CO ensg:PerOccurenceMember naics:ZZ524292 2022-12-31 0001125376 us-gaap:GeneralLiabilityMember stpr:CO ensg:PerFacilityMember naics:ZZ524292 2022-12-31 0001125376 us-gaap:WorkersCompensationInsuranceMember 2022-12-31 0001125376 us-gaap:WorkersCompensationInsuranceMember stpr:TX 2022-12-31 0001125376 us-gaap:WorkersCompensationInsuranceMember ensg:OtherStatesExceptCaliforniaTexasAndWashingtonMember ensg:LossSensitivelimitperclaimMemberMember 2022-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:SelfInsuranceRetentionPerClaimMember 2022-12-31 0001125376 ensg:HealthLiabilityInsuranceMember ensg:StopLossInsuranceLimitPerClaimMember 2022-12-31 0001125376 ensg:HealthLiabilityInsuranceMember ensg:StopLossInsuranceLimitPerClaimMember 2021-12-31 0001125376 ensg:HealthLiabilityInsuranceMember ensg:StopLossInsuranceLimitPerClaimMember 2020-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-01-01 2022-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-12-31 0001125376 2021-03-01 2021-03-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001125376 ensg:MedicaidMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidMember 2021-01-01 2021-12-31 0001125376 ensg:MedicaidMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:MedicaidMember 2020-01-01 2020-12-31 0001125376 ensg:MedicaidMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001125376 ensg:MedicareMember 2022-01-01 2022-12-31 0001125376 ensg:MedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:MedicareMember 2021-01-01 2021-12-31 0001125376 ensg:MedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:MedicareMember 2020-01-01 2020-12-31 0001125376 ensg:MedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001125376 ensg:MedicaidSkilledMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidSkilledMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidSkilledMember 2021-01-01 2021-12-31 0001125376 ensg:MedicaidSkilledMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:MedicaidSkilledMember 2020-01-01 2020-12-31 0001125376 ensg:MedicaidSkilledMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001125376 ensg:MedicaidAndMedicareMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidAndMedicareMember 2021-01-01 2021-12-31 0001125376 ensg:MedicaidAndMedicareMember 2020-01-01 2020-12-31 0001125376 ensg:ManagedCareMember 2022-01-01 2022-12-31 0001125376 ensg:ManagedCareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:ManagedCareMember 2021-01-01 2021-12-31 0001125376 ensg:ManagedCareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:ManagedCareMember 2020-01-01 2020-12-31 0001125376 ensg:ManagedCareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001125376 ensg:PrivatePayAndOtherMember 2022-01-01 2022-12-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:PrivatePayAndOtherMember 2021-01-01 2021-12-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:PrivatePayAndOtherMember 2020-01-01 2020-12-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001125376 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001125376 ensg:MedicaidMember 2022-12-31 0001125376 ensg:MedicaidMember 2021-12-31 0001125376 ensg:ManagedCareMember 2022-12-31 0001125376 ensg:ManagedCareMember 2021-12-31 0001125376 ensg:MedicareMember 2022-12-31 0001125376 ensg:MedicareMember 2021-12-31 0001125376 ensg:PrivatePayAndOtherMember 2022-12-31 0001125376 ensg:PrivatePayAndOtherMember 2021-12-31 0001125376 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001125376 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001125376 srt:SubsidiariesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001125376 srt:SubsidiariesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001125376 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001125376 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001125376 ensg:StandardBearerHealthcareREITIncMember 2022-12-31 0001125376 us-gaap:WhollyOwnedPropertiesMember ensg:StandardBearerHealthcareREITIncMember 2022-12-31 0001125376 ensg:ThirdPartiesMember ensg:StandardBearerHealthcareREITIncMember 2022-12-31 0001125376 ensg:SkilledNursingOperationsMember ensg:StandardBearerHealthcareREITIncMember 2022-01-01 2022-12-31 0001125376 2022-01-01 2022-01-31 0001125376 srt:MinimumMember ensg:StandardBearerMasterLeasesMember 2022-01-31 0001125376 srt:MaximumMember ensg:StandardBearerMasterLeasesMember 2022-01-31 0001125376 ensg:StandardBearerMasterLeasesMember 2022-01-31 0001125376 ensg:StandardBearerSegmentMember 2022-01-01 2022-12-31 0001125376 ensg:StandardBearerSegmentMember 2021-01-01 2021-12-31 0001125376 ensg:StandardBearerSegmentMember 2020-01-01 2020-12-31 0001125376 ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-12-31 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-01-31 0001125376 us-gaap:ManagementServiceIncentiveMember ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-01-31 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-12-31 0001125376 ensg:ManagementServiceTotalMember ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-12-31 0001125376 ensg:ManagementServiceTotalMember ensg:StandardBearerMasterLeasesMember 2022-10-01 2022-12-31 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2021-01-01 2021-12-31 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2020-01-01 2020-12-31 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:BaseRateMember 2022-04-08 2022-04-08 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:BaseRateMember 2022-04-08 2022-04-08 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-04-08 2022-04-08 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-04-08 2022-04-08 0001125376 ensg:StandardBearerEquityPlanMember 2022-01-01 2022-01-31 0001125376 ensg:StandardBearerEquityPlanMember 2022-01-01 2022-12-31 0001125376 us-gaap:RestrictedStockMember ensg:StandardBearerEquityPlanMember 2022-01-01 2022-12-31 0001125376 us-gaap:RestrictedStockMember ensg:StandardBearerEquityPlanMember 2022-10-01 2022-12-31 0001125376 ensg:StandardBearerEquityPlanMember 2022-10-01 2022-12-31 0001125376 ensg:StandardBearerHealthcareREITIncMember 2022-01-01 2022-12-31 0001125376 2022-01-01 2022-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RealEstateSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2022-01-01 2022-12-31 0001125376 srt:ConsolidationEliminationsMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RealEstateSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2021-01-01 2021-12-31 0001125376 srt:ConsolidationEliminationsMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2020-01-01 2020-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RealEstateSegmentMember 2020-01-01 2020-12-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2020-01-01 2020-12-31 0001125376 srt:ConsolidationEliminationsMember 2020-01-01 2020-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember 2022-01-01 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember 2021-01-01 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember ensg:SkilledServicesSegmentMember 2020-01-01 2020-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember 2020-01-01 2020-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember ensg:SkilledServicesSegmentMember 2020-01-01 2020-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember 2020-01-01 2020-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember ensg:SkilledServicesSegmentMember 2020-01-01 2020-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember 2020-01-01 2020-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember ensg:SkilledServicesSegmentMember 2020-01-01 2020-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember 2020-01-01 2020-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember ensg:SkilledServicesSegmentMember 2020-01-01 2020-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember 2020-01-01 2020-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember ensg:SkilledServicesSegmentMember 2020-01-01 2020-12-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember 2020-01-01 2020-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-12-31 0001125376 ensg:SkilledNursingOperationsMember 2022-01-01 2022-12-31 0001125376 ensg:CampusOperationMember 2022-01-01 2022-12-31 0001125376 ensg:SeniorLivingFacilitiesMember 2022-01-01 2022-12-31 0001125376 ensg:SkilledNursingOperationsMember 2022-12-31 0001125376 ensg:SeniorLivingFacilitiesMember 2022-12-31 0001125376 us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember 2022-01-01 2022-12-31 0001125376 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-01-01 2022-12-31 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember 2023-01-01 2023-02-02 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember 2023-02-02 0001125376 ensg:SkilledNursingOperationsMember 2021-01-01 2021-12-31 0001125376 ensg:RealEstatePurchasesMember 2021-01-01 2021-12-31 0001125376 ensg:RealEstatePurchasesOfPreviousOperationsMember 2021-01-01 2021-12-31 0001125376 ensg:SkilledNursingOperationsMember 2021-12-31 0001125376 us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember 2021-01-01 2021-12-31 0001125376 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-01-01 2021-12-31 0001125376 ensg:SkilledNursingOperationsMember 2020-01-01 2020-12-31 0001125376 ensg:SeniorLivingFacilitiesMember 2020-01-01 2020-12-31 0001125376 ensg:SkilledServicesAndSeniorLivingCampusesMember 2020-01-01 2020-12-31 0001125376 ensg:OwnedPropertiesMember 2020-01-01 2020-12-31 0001125376 ensg:SkilledNursingOperationsMember 2020-12-31 0001125376 ensg:SeniorLivingFacilitiesMember 2020-12-31 0001125376 ensg:AssetAcquisitionMember 2020-01-01 2020-12-31 0001125376 ensg:SeniorLivingFacilitiesMember ensg:ThePennantGroupInc.Member 2020-03-31 0001125376 ensg:AssetAcquisitionMember us-gaap:LandMember 2022-01-01 2022-12-31 0001125376 ensg:AssetAcquisitionMember us-gaap:LandMember 2021-01-01 2021-12-31 0001125376 ensg:AssetAcquisitionMember us-gaap:LandMember 2020-01-01 2020-12-31 0001125376 ensg:AssetAcquisitionMember us-gaap:BuildingAndBuildingImprovementsMember 2022-01-01 2022-12-31 0001125376 ensg:AssetAcquisitionMember us-gaap:BuildingAndBuildingImprovementsMember 2021-01-01 2021-12-31 0001125376 ensg:AssetAcquisitionMember us-gaap:BuildingAndBuildingImprovementsMember 2020-01-01 2020-12-31 0001125376 ensg:AssetAcquisitionMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001125376 ensg:AssetAcquisitionMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0001125376 ensg:AssetAcquisitionMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0001125376 ensg:AssetAcquisitionMember ensg:AssembledOccupancyAcquiredMember 2022-01-01 2022-12-31 0001125376 ensg:AssetAcquisitionMember ensg:AssembledOccupancyAcquiredMember 2021-01-01 2021-12-31 0001125376 ensg:AssetAcquisitionMember ensg:AssembledOccupancyAcquiredMember 2020-01-01 2020-12-31 0001125376 ensg:AssetAcquisitionMember 2022-01-01 2022-12-31 0001125376 ensg:AssetAcquisitionMember 2021-01-01 2021-12-31 0001125376 us-gaap:LandMember 2022-12-31 0001125376 us-gaap:LandMember 2021-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2021-12-31 0001125376 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001125376 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001125376 us-gaap:EquipmentMember 2022-12-31 0001125376 us-gaap:EquipmentMember 2021-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001125376 us-gaap:ConstructionInProgressMember 2022-12-31 0001125376 us-gaap:ConstructionInProgressMember 2021-12-31 0001125376 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ensg:SeniorLivingOperationsMember 2022-01-01 2022-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2022-01-01 2022-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2022-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2021-12-31 0001125376 us-gaap:TradeNamesMember 2022-12-31 0001125376 us-gaap:TradeNamesMember 2021-12-31 0001125376 us-gaap:CustomerRelationshipsMember 2022-12-31 0001125376 us-gaap:CustomerRelationshipsMember 2021-12-31 0001125376 ensg:DepreciationAndAmortizationMember 2022-01-01 2022-12-31 0001125376 ensg:DepreciationAndAmortizationMember 2021-01-01 2021-12-31 0001125376 ensg:DepreciationAndAmortizationMember 2020-01-01 2020-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2019-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2019-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2020-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2020-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2021-12-31 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2022-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2022-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2022-01-01 2022-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2021-01-01 2021-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2020-01-01 2020-12-31 0001125376 us-gaap:TradeNamesMember 2022-12-31 0001125376 us-gaap:TradeNamesMember 2021-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2022-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2021-12-31 0001125376 us-gaap:NotesPayableOtherPayablesMember us-gaap:CollateralizedDebtObligationsMember 2022-12-31 0001125376 us-gaap:NotesPayableOtherPayablesMember us-gaap:CollateralizedDebtObligationsMember 2021-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-07 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-08 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-08 2022-04-08 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-08 2022-04-08 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:SubsequentEventMember 2023-01-30 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember ensg:TwentyThreeSubsidiariesMember 2022-12-31 0001125376 srt:MinimumMember us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2022-12-31 0001125376 srt:MaximumMember us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2022-12-31 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2022-12-31 0001125376 srt:MinimumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2022-01-01 2022-12-31 0001125376 srt:MaximumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2022-01-01 2022-12-31 0001125376 us-gaap:CollateralizedDebtObligationsMember 2022-01-01 2022-12-31 0001125376 ensg:PromissoryNote50Member us-gaap:CollateralizedDebtObligationsMember 2022-12-31 0001125376 ensg:PromissoryNote53Member us-gaap:CollateralizedDebtObligationsMember 2022-12-31 0001125376 ensg:PromissoryNote50Member us-gaap:CollateralizedDebtObligationsMember 2022-01-01 2022-12-31 0001125376 ensg:PromissoryNote53Member us-gaap:CollateralizedDebtObligationsMember 2022-01-01 2022-12-31 0001125376 ensg:A2022PlanMember 2022-06-30 0001125376 ensg:A2022PlanMember 2022-04-01 2022-06-30 0001125376 us-gaap:ShareBasedPaymentArrangementNonemployeeMember ensg:A2022PlanMember 2022-04-01 2022-06-30 0001125376 ensg:A2022PlanMember 2022-12-31 0001125376 ensg:A2017PlanMember 2017-12-31 0001125376 ensg:A2017PlanMember us-gaap:SpinoffMember 2019-10-31 0001125376 ensg:A2017PlanMember 2022-01-01 2022-12-31 0001125376 us-gaap:ShareBasedPaymentArrangementNonemployeeMember ensg:A2017PlanMember 2022-01-01 2022-12-31 0001125376 us-gaap:RestrictedStockMember ensg:A2017PlanMember 2022-01-01 2022-12-31 0001125376 ensg:ExercisePriceRangeOneMember 2022-01-01 2022-12-31 0001125376 ensg:ExercisePriceRangeOneMember 2022-12-31 0001125376 ensg:ExercisePriceRangeTwoMember 2022-01-01 2022-12-31 0001125376 ensg:ExercisePriceRangeTwoMember 2022-12-31 0001125376 ensg:ExercisePriceRangeThreeMember 2022-01-01 2022-12-31 0001125376 ensg:ExercisePriceRangeThreeMember 2022-12-31 0001125376 ensg:ExercisePriceRangeFourMember 2022-01-01 2022-12-31 0001125376 ensg:ExercisePriceRangeFourMember 2022-12-31 0001125376 ensg:ExercisePriceRangeFiveMember 2022-01-01 2022-12-31 0001125376 ensg:ExercisePriceRangeFiveMember 2022-12-31 0001125376 ensg:ExercisePriceRangeSixMember 2022-01-01 2022-12-31 0001125376 ensg:ExercisePriceRangeSixMember 2022-12-31 0001125376 ensg:ExercisePriceRangeSevenMember 2022-01-01 2022-12-31 0001125376 ensg:ExercisePriceRangeSevenMember 2022-12-31 0001125376 ensg:ExercisePriceRangeEightMember 2022-01-01 2022-12-31 0001125376 ensg:ExercisePriceRangeEightMember 2022-12-31 0001125376 ensg:ExercisePriceRangeNineMember 2022-01-01 2022-12-31 0001125376 ensg:ExercisePriceRangeNineMember 2022-12-31 0001125376 ensg:ExercisePriceRangeTenMember 2022-01-01 2022-12-31 0001125376 ensg:ExercisePriceRangeTenMember 2022-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001125376 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001125376 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001125376 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001125376 us-gaap:RestrictedStockMember 2019-12-31 0001125376 us-gaap:RestrictedStockMember 2020-12-31 0001125376 us-gaap:RestrictedStockMember 2021-12-31 0001125376 us-gaap:RestrictedStockMember 2022-12-31 0001125376 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-01-01 2022-12-31 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-01-01 2022-12-31 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-01-01 2022-12-31 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2019-08-27 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2019-08-27 2019-08-27 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2022-01-01 2022-12-31 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2021-01-01 2021-12-31 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2020-01-01 2020-12-31 0001125376 ensg:StockAwardsMember 2022-01-01 2022-12-31 0001125376 ensg:StockAwardsMember 2021-01-01 2021-12-31 0001125376 ensg:StockAwardsMember 2020-01-01 2020-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2022-12-31 0001125376 ensg:CareTrustREITMember 2022-12-31 0001125376 ensg:CareTrustREITMember ensg:ThirdPartyTenantsUnderTripleNetLeaseArrangementsMember 2022-12-31 0001125376 ensg:CareTrustREITMember srt:MinimumMember 2022-12-31 0001125376 ensg:CareTrustREITMember srt:MaximumMember 2022-12-31 0001125376 ensg:CareTrustREITMember ensg:PurchaseOptionMember 2022-12-31 0001125376 ensg:CareTrustREITMember 2022-01-01 2022-12-31 0001125376 ensg:CareTrustREITMember 2021-01-01 2021-12-31 0001125376 ensg:CareTrustREITMember 2020-01-01 2020-12-31 0001125376 ensg:VariousLandlordsMember srt:MinimumMember 2022-12-31 0001125376 ensg:VariousLandlordsMember srt:MaximumMember 2022-12-31 0001125376 ensg:VariousLandlordsMember srt:MinimumMember us-gaap:EquipmentMember 2022-12-31 0001125376 ensg:VariousLandlordsMember srt:MaximumMember us-gaap:EquipmentMember 2022-12-31 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2022-01-01 2022-12-31 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2021-01-01 2021-12-31 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2020-01-01 2020-12-31 0001125376 ensg:VariousLandlordsMember 2022-12-31 0001125376 ensg:AmendedMasterLeaseAgreementMember 2022-12-31 0001125376 ensg:AmendedMasterLeaseAgreementMember 2022-01-01 2022-12-31 0001125376 ensg:NewMasterLeaseAgreeementMember 2022-01-01 2022-12-31 0001125376 ensg:VariousLandlordsMember ensg:NewMasterLeaseAgreeementMember 2022-01-01 2022-12-31 0001125376 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001125376 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001125376 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember ensg:NewMasterLeaseAgreementMember 2023-02-02 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember ensg:NewMasterLeaseAgreementMember 2023-01-01 2023-02-02 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember ensg:AmendedMasterLeaseMember 2023-01-01 2023-02-02 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember ensg:SubleasedToThirdPartyMember 2023-01-01 2023-02-02 0001125376 us-gaap:SubsequentEventMember ensg:AmendedMasterLeaseMember 2023-02-02 0001125376 us-gaap:SubsequentEventMember ensg:AmendedMasterLeaseMember 2023-01-01 2023-02-02 0001125376 ensg:SeniorLivingFacilitiesMember us-gaap:SpinoffMember ensg:ThePennantGroupInc.Member 2019-10-31 0001125376 srt:MinimumMember us-gaap:SpinoffMember 2022-12-31 0001125376 srt:MaximumMember us-gaap:SpinoffMember 2022-12-31 0001125376 ensg:ThePennantGroupInc.Member 2022-01-01 2022-12-31 0001125376 ensg:ThePennantGroupInc.Member 2021-01-01 2021-12-31 0001125376 ensg:ThePennantGroupInc.Member 2020-01-01 2020-12-31 0001125376 ensg:ThirdPartyTenantsMember 2022-01-01 2022-12-31 0001125376 ensg:ThirdPartyTenantsMember 2021-01-01 2021-12-31 0001125376 ensg:ThirdPartyTenantsMember 2020-01-01 2020-12-31 0001125376 ensg:ThePennantGroupInc.Member 2022-01-01 2022-12-31 0001125376 ensg:ThePennantGroupInc.Member 2021-01-01 2021-12-31 0001125376 ensg:ThePennantGroupInc.Member 2020-01-01 2020-12-31 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2022-12-31 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2021-12-31 0001125376 us-gaap:QualifiedPlanMember 2022-01-01 2022-12-31 0001125376 us-gaap:NonqualifiedPlanMember 2022-01-01 2022-12-31 0001125376 2018-05-31 2018-05-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 us-gaap:SubsequentEventMember 2023-01-30 0001125376 ensg:July2022RepurchaseProgramMember 2022-07-28 0001125376 ensg:July2022RepurchaseProgramMember 2022-07-28 2022-07-28 0001125376 ensg:February92022RepurchaseProgramMember 2022-02-09 0001125376 ensg:February92022RepurchaseProgramMember 2022-02-09 2022-02-09 0001125376 ensg:February92022RepurchaseProgramMember 2022-04-01 2022-06-30 0001125376 ensg:October212021RepurchaseProgramMember 2021-10-21 0001125376 ensg:October212021RepurchaseProgramMember 2021-10-21 2021-10-21 0001125376 ensg:October212021RepurchaseProgramMember 2022-01-01 2022-12-31 0001125376 ensg:October212021RepurchaseProgramMember 2021-01-01 2021-12-31 0001125376 2020-03-13 0001125376 ensg:March42020RepurchaseProgramMember 2020-03-04 0001125376 ensg:March132020RepurchaseProgramMember 2020-03-13 0001125376 ensg:March42020RepurchaseProgramMember 2020-03-04 2020-03-04 0001125376 ensg:March42020RepurchaseProgramMember 2020-01-01 2020-03-31 0001125376 ensg:March132020RepurchaseProgramMember 2020-01-01 2020-03-31 iso4217:USD shares iso4217:USD shares ensg:facility ensg:bed ensg:senior_living_unit ensg:senior_living_community ensg:operation ensg:renewal_option pure ensg:skilled_nursing_property ensg:lease ensg:renewal ensg:segment ensg:asset_acquisition ensg:business ensg:subsidiary ensg:promissory_note ensg:repurchase_program ensg:installment ensg:agreement ensg:operating_entity 0001125376 2022 FY false P3Y0M0D P10Y P4M0D P5Y0M P10Y0M P10Y0M P5Y0M P3Y0M 10-K true 2022-12-31 --12-31 false 001-33757 ENSIGN GROUP, INC DE 33-0861263 29222 Rancho Viejo Road, Suite 127 San Juan Capistrano CA 92675 949 487-9500 Common Stock, par value $0.001 per share ENSG NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 2400450000 55732114 DELOITTE & TOUCHE LLP Costa Mesa, California 316270000 262201000 7802000 11213000 408432000 328731000 15441000 13763000 4643000 5452000 36339000 29562000 781125000 639709000 992010000 888434000 1450995000 1138872000 67652000 54097000 39643000 33147000 37291000 29516000 2465000 2652000 76869000 60469000 3972000 3727000 3452022000 2850623000 77087000 58116000 289810000 278770000 65796000 52181000 48187000 40831000 97309000 89410000 3883000 3760000 582072000 523068000 149269000 152883000 1355113000 1056515000 83495000 69308000 33273000 27135000 2203222000 1828909000 0.001 0.001 100000000 100000000 59029000 55661000 58134000 55190000 59000 58000 415560000 369760000 946339000 733992000 3368000 2944000 114626000 83042000 1247332000 1020768000 1468000 946000 1248800000 1021714000 3452022000 2850623000 3008711000 2611476000 2387439000 16757000 15985000 15157000 3025468000 2627461000 2402596000 2354434000 2019879000 1865201000 153049000 139371000 129926000 158805000 151761000 129743000 62355000 55985000 54571000 2728643000 2366996000 2179441000 296825000 260465000 223155000 8931000 6849000 9362000 1195000 4388000 3813000 -7736000 -2461000 -5549000 289089000 258004000 217606000 64437000 60279000 46242000 224652000 197725000 171364000 -29000 3073000 886000 224681000 194652000 170478000 4.09 3.57 3.19 3.95 3.42 3.06 54887000 54486000 53434000 56871000 56925000 55787000 53487000 56000 307914000 391523000 2079000 -45296000 1947000 656144000 979000 1000 12654000 12655000 872000 1000 3085000 3086000 20000 20000 917000 917000 0.2025 10946000 10946000 14524000 14524000 692000 692000 25000000 25000000 886000 886000 2683000 2683000 170478000 170478000 54626000 58000 338177000 551055000 2791000 -71213000 150000 818227000 516000 9180000 9180000 201000 3725000 3725000 21000 21000 1711000 1711000 0.2125 11715000 11715000 18678000 18678000 132000 132000 10118000 10118000 1369000 1369000 2000000 2000000 3073000 3073000 2908000 2908000 194652000 194652000 55190000 58000 369760000 733992000 2944000 -83042000 946000 1021714000 688000 1000 12676000 12677000 207000 5241000 5241000 20000 20000 1702000 1702000 0.2225 12334000 12334000 22720000 22720000 404000 404000 29882000 29882000 1539000 -835000 704000 6693000 6693000 -29000 -29000 -9000 284000 275000 224681000 224681000 55661000 59000 415560000 946339000 3368000 -114626000 1468000 1248800000 224652000 197725000 171364000 62355000 55985000 54571000 0 0 2681000 1036000 859000 840000 493000 485000 451000 566000 0 0 -6496000 -724000 -27809000 2390000 2609000 7058000 22720000 18678000 14524000 1282000 2382000 0 3467000 1371000 0 -3926000 977000 -625000 82426000 30771000 -2171000 -809000 4228000 485000 9141000 4898000 2897000 24155000 24154000 -48309000 7614000 10953000 6577000 7637000 11078000 6615000 345000 -5814000 -724000 17870000 7117000 6627000 38982000 47701000 68365000 3010000 1297000 17536000 17785000 13724000 10293000 -46000 -66000 -187000 272513000 275684000 373351000 87545000 69550000 50326000 16400000 6000000 0 84736000 98224000 24997000 0 -100000 100000 0 0 14050000 1339000 6899000 800000 8630000 1854000 412000 0 1984000 0 0 106000 0 21975000 32257000 21708000 14356000 27481000 24479000 -149000 2120000 1276000 -186182000 -173907000 -58666000 411000 45218000 417200000 4106000 3056000 629745000 12677000 9180000 12654000 1702000 1711000 917000 29882000 10118000 25000000 12168000 11548000 10830000 6693000 0 0 284000 2908000 2683000 704000 -2000000 0 3197000 1172000 0 0 11637000 246955000 0 113660000 144932000 -32262000 -76138000 -137298000 54069000 25639000 177387000 262201000 236562000 59175000 316270000 262201000 236562000 7604000 5690000 9920000 70055000 65547000 74365000 151870000 138795000 129569000 4800000 3700000 3400000 3201000 3035000 2868000 0 0 5500000 370753000 198593000 24599000 DESCRIPTION OF BUSINESS<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company's independent operating subsidiaries provide health care services across the post-acute care continuum, engaged in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of December 31, 2022, the Company's independent operating subsidiaries operated 271 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's independent operating subsidiaries have a collective capacity of approximately 28,100 operational skilled nursing beds and 3,000 senior living units. As of December 31, 2022, the Company's independent operating subsidiaries operated 192 facilities under long-term lease arrangements, and had options to purchase 11 of those 192 facilities. The Company's real estate portfolio includes 108 owned real estate properties, which included 79 facilities operated and managed by the Company's independent operating subsidiaries, 29 senior living operations leased to and operated by The Pennant Group, Inc. (Pennant) as part of the spin-off transaction in October 2019, and the Service Center location. Of those 29 senior living operations, one is located on the same real estate property as a skilled nursing facility that the Company owns and operates. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January of 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The Company expects the REIT structure will provide it with an efficient vehicle for future acquisitions of properties that could be operated by Ensign affiliates or other third parties. Refer to Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on Standard Bearer.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Annual Report is not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.</span></div> 271 28100 3000 192 11 192 108 79 29 29 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net income. Prior period results reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure as a result of the formation of Standard Bearer. Refer to Note 8, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segments.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Reclassification adjustments have been made to reclassify investments associated with the Company's non-qualified deferred compensation plan with investments held by the Company's captive insurance subsidiary on the consolidated balance sheets.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and Assumptions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. See Note 6,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Fair Value Measurements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue and Accounts Receivable.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 842). See Note 4,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue and Accounts Receivable.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Subsidiary Deposits and Investments — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. The fair value of the investment funds is derived using Level 2 inputs. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF82NC9mcmFnOjA0MDRhNjFkYjU5NDRmMjVhYjZmMTBhZmNhZGE0NWJiL3RleHRyZWdpb246MDQwNGE2MWRiNTk0NGYyNWFiNmYxMGFmY2FkYTQ1YmJfNDQ5Mw_a2fb2823-5a23-44d7-ae83-8bee2f92e20b">three</span> to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases and Leasehold Improvements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at the inception of each lease. Leases commencing prior to the ASC 842 adoption date were classified as operating lease under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. For leases commencing subsequent to the ASC 842 adoption date, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December 31, 2022, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF82NC9mcmFnOjA0MDRhNjFkYjU5NDRmMjVhYjZmMTBhZmNhZGE0NWJiL3RleHRyZWdpb246MDQwNGE2MWRiNTk0NGYyNWFiNmYxMGFmY2FkYTQ1YmJfNjc1OQ_a36720a4-7393-43eb-8eb2-b2ebdf933bb7">ten</span> to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the years ended December 31, 2022 and 2021. The Company recorded an impairment charge of $2,681 during the year ended December 31, 2020.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF82NC9mcmFnOjA0MDRhNjFkYjU5NDRmMjVhYjZmMTBhZmNhZGE0NWJiL3RleHRyZWdpb246MDQwNGE2MWRiNTk0NGYyNWFiNmYxMGFmY2FkYTQ1YmJfOTE0MQ_1b919c3c-1e8c-43a3-94a0-ea928f91c81f">four</span> to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any goodwill or intangible asset impairment during the years ended December 31, 2022, 2021, and 2020. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,000 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has recorded an asset and equal liability in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 13, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted and Other Assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525, $500 and $300 for each covered person for fiscal years 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer intends to qualify and elect to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer believes it has been organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company does not have any components of other comprehensive income recorded within its consolidated Financial Statements and, therefore, does not separately present a statement of comprehensive income in its consolidated Financial Statements. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Standards Adopted by the Company </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU 2021-10 “</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” which created FASB ASC Topic 832, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 832)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 832 requires business entities to disclose information about certain government assistance they receive.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard on January 1, 2022 and determined there was no material impact on the Company's Financial Statements. </span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the FASB issued ASU 2020-04</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Reference Rate Reform (Topic 848),"</span> which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace London Interbank Offered Rate (LIBOR) reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2024. During the year ended December 31, 2022, the Company and its subsidiaries including Standard Bearer, entered into the Second Amendment to Third Amended and Restated Credit Agreement (such agreement, the Amended Credit Agreement, and the revolving credit facility thereunder, the Revolving Credit Facility), which increased the Revolving Credit Facility by $250,000 to an aggregate principal amount of up to $600,000. Pursuant to the Amended Credit Agreement, the Company transitioned from LIBOR to the Secured Overnight Financing Rate (SOFR) as the applicable reference rate for borrowings under the Revolving Credit Facility and determined there was no resulting material impact on the Company's Financial Statements. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its consolidated statements of income.</span>The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net income. Prior period results reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure as a result of the formation of Standard Bearer. Refer to Note 8, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segments.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Reclassification adjustments have been made to reclassify investments associated with the Company's non-qualified deferred compensation plan with investments held by the Company's captive insurance subsidiary on the consolidated balance sheets.</span> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and Assumptions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.</span> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span>The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span>(ASC 606).<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span> (ASC 842). <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.</span> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.</span> <div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Subsidiary Deposits and Investments — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. The fair value of the investment funds is derived using Level 2 inputs. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.</span></div> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF82NC9mcmFnOjA0MDRhNjFkYjU5NDRmMjVhYjZmMTBhZmNhZGE0NWJiL3RleHRyZWdpb246MDQwNGE2MWRiNTk0NGYyNWFiNmYxMGFmY2FkYTQ1YmJfNDQ5Mw_a2fb2823-5a23-44d7-ae83-8bee2f92e20b">three</span> to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. P59Y <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases and Leasehold Improvements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at the inception of each lease. Leases commencing prior to the ASC 842 adoption date were classified as operating lease under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. For leases commencing subsequent to the ASC 842 adoption date, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December 31, 2022, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</span></div>The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF82NC9mcmFnOjA0MDRhNjFkYjU5NDRmMjVhYjZmMTBhZmNhZGE0NWJiL3RleHRyZWdpb246MDQwNGE2MWRiNTk0NGYyNWFiNmYxMGFmY2FkYTQ1YmJfNjc1OQ_a36720a4-7393-43eb-8eb2-b2ebdf933bb7">ten</span> to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. P10Y 1 P15Y <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span>The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. 0 0 2681000 <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF82NC9mcmFnOjA0MDRhNjFkYjU5NDRmMjVhYjZmMTBhZmNhZGE0NWJiL3RleHRyZWdpb246MDQwNGE2MWRiNTk0NGYyNWFiNmYxMGFmY2FkYTQ1YmJfOTE0MQ_1b919c3c-1e8c-43a3-94a0-ea928f91c81f">four</span> to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div>Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. P8M P30Y P20Y <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,000 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has recorded an asset and equal liability in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 13, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted and Other Assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525, $500 and $300 for each covered person for fiscal years 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.</span></div> 500000 1000000 1250000 1000000 3000000 5000000 1000000 3000000 625000 750000 350000 500000 525000 500000 300000 <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</span></div>Standard Bearer intends to qualify and elect to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer believes it has been organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span>The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.</span> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span> The Company does not have any components of other comprehensive income recorded within its consolidated Financial Statements and, therefore, does not separately present a statement of comprehensive income in its consolidated Financial Statements. <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Standards Adopted by the Company </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU 2021-10 “</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” which created FASB ASC Topic 832, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 832)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 832 requires business entities to disclose information about certain government assistance they receive.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard on January 1, 2022 and determined there was no material impact on the Company's Financial Statements. </span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the FASB issued ASU 2020-04</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Reference Rate Reform (Topic 848),"</span> which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace London Interbank Offered Rate (LIBOR) reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2024. During the year ended December 31, 2022, the Company and its subsidiaries including Standard Bearer, entered into the Second Amendment to Third Amended and Restated Credit Agreement (such agreement, the Amended Credit Agreement, and the revolving credit facility thereunder, the Revolving Credit Facility), which increased the Revolving Credit Facility by $250,000 to an aggregate principal amount of up to $600,000. Pursuant to the Amended Credit Agreement, the Company transitioned from LIBOR to the Secured Overnight Financing Rate (SOFR) as the applicable reference rate for borrowings under the Revolving Credit Facility and determined there was no resulting material impact on the Company's Financial Statements. 250000000 600000000 COVID-19 UPDATE<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has continued to impact the Company's affiliated operations. In prior years, as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act), the Company received cash distributions of relief fund payments (Provider Relief Funds) and funds authorized by </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Department of Health and Human Services (HHS)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be used to protect residents of nursing homes and long-term care (LTC) facilities from the impact of COVID-19</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company did not receive Provider Relief Funds. During the year ended December 31, 2021 and 2020, the Company received and returned $11,637 and $141,700, respectively, in Provider Relief Funds. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2020, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in 2020 and the remaining funds of $102,023 in March 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Families First Coronavirus Response Act was signed into law in 2020 to provide a temporary 6.2% increase to the Federal Medical Assistance Percentage (FMAP) effective January 1, 2020. The law permits states to retroactively change their state's Medicaid program rates effective as of January 1, 2020. The law provides discretion to each state and specifies the funds are to be used to reimburse the recipient for healthcare related expenses that are attributable to COVID-19 and associated with providing patient care. In addition, increases in Medicaid rates can come from other areas of the state's budget outside of FMAP funding. Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to COVID-19, the Company characterized such payments as variable revenue that required additional consideration and accordingly, the amount of state relief revenue recognized is limited to the actual COVID-19 related expenses incurred. As of December 31, 2022 and 2021, the Company had $1,001 and $1,781 in unapplied state relief funds, respectively. During the years ended December 31, 2022, 2021, and 2020, the Company received an additional $81,057, $70,484, and $51,927 in state relief funding and recognized $81,837, $75,231, and $45,407, respectively, as revenue. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with approximately 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020, and paid the first and second half of the payments in the fourth quarters of 2021 and 2022, respectively.</span></div> 0 11637000 141700000 105255000 3232000 102023000 1001000 1781000 81057000 70484000 51927000 81837000 75231000 45407000 48309000 REVENUE AND ACCOUNTS RECEIVABLE<div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known. </span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the Medicare and Medicaid programs accounted for 73.7%, 73.6% and 74.5% for the years ended December 31, 2022, 2021, and 2020, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the years ended December 31, 2022, 2021, and 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue is recognized on a straight-line basis over the lease term if it has been deemed probable of collection. The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Payor</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue for the years ended December 31, 2022, 2021, and 2020 is summarized in the following tables:</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,156 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,460 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,249 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.7 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,374 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid — skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,846 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,216,194</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,922,333</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,777,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,095 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,807 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,415 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,875 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SERVICE REVENUE</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008,711</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611,476</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,387,439</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to FMAP and other COVID-19 related state funding.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $16,757, $15,985 and $15,157 for the years ended December 31, 2022, 2021, and 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Impact</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Company’s consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of December 31, 2022 and 2021, or activity during the years ended December 31, 2022, 2021, and 2020.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of December 31, 2022 and 2021, is summarized in the following table:</span></div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,878 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,647 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,940 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,722 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,526 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,797 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,890 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,778 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">416,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">339,944</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,802)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,213)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ACCOUNTS RECEIVABLE, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408,432</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">328,731</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Practical Expedients and Exemptions</span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span>, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less. 0.737 0.736 0.745 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue for the years ended December 31, 2022, 2021, and 2020 is summarized in the following tables:</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,156 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,460 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,249 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.7 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,374 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid — skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,846 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,216,194</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,922,333</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,777,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,095 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,807 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,415 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,875 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SERVICE REVENUE</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008,711</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611,476</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,387,439</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to FMAP and other COVID-19 related state funding.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div> 1183156000 0.393 1022460000 0.392 900249000 0.377 832160000 0.277 727103000 0.278 727374000 0.305 200878000 0.067 172770000 0.066 149846000 0.063 2216194000 0.737 1922333000 0.736 1777469000 0.745 525710000 0.175 456728000 0.175 367095000 0.154 266807000 0.088 232415000 0.089 242875000 0.101 3008711000 1.000 2611476000 1.000 2387439000 1.000 16757000 15985000 15157000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of December 31, 2022 and 2021, is summarized in the following table:</span></div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,878 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,647 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,940 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,722 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,526 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,797 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,890 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,778 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">416,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">339,944</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,802)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,213)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ACCOUNTS RECEIVABLE, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408,432</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">328,731</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 157878000 123647000 95940000 79722000 76526000 59797000 85890000 76778000 416234000 339944000 7802000 11213000 408432000 328731000 COMPUTATION OF NET INCOME PER COMMON SHAREBasic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.133%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,364 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net (loss) income attributable to noncontrolling interests </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,681</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170,478</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,887 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,486 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,434 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per common share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.09</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.57</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.133%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,364 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net (loss) income attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,681</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170,478</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,887 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,486 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,434 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,871</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,925</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55,787</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per common share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.95</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.42</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.06</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">780, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">198 and 956</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for th</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">years ended December 31, 2022, 2021 and 2020, respectively.</span></div> <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.133%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,364 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net (loss) income attributable to noncontrolling interests </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,681</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170,478</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,887 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,486 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,434 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per common share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.09</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.57</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 224652000 197725000 171364000 -29000 3073000 886000 224681000 194652000 170478000 54887000 54486000 53434000 4.09 3.57 3.19 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.133%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,364 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net (loss) income attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,681</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170,478</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,887 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,486 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,434 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,871</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,925</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55,787</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per common share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.95</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.42</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.06</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">780, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">198 and 956</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for th</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">years ended December 31, 2022, 2021 and 2020, respectively.</span></div> 224652000 197725000 171364000 -29000 3073000 886000 224681000 194652000 170478000 54887000 54486000 53434000 1984000 2439000 2353000 56871000 56925000 55787000 3.95 3.42 3.06 780000 198000 956000 FAIR VALUE MEASUREMENTS<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents of $316,270 and $262,201 as of December 31, 2022 and 2021, respectively, is derived using Level 1 inputs. The Company's other financial assets include the captive insurance subsidiary's cash and cash equivalents, deposits and investments designated to support long-term insurance subsidiary liabilities and are carried at cost basis of $69,290 and $67,734 as of December 31, 2022 and 2021, respectively. Also included are contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans which are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. As of December 31, 2022, and 2021, the adjusted cost basis of the investment funds is $25,144 and $17,530, respectively. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the cost basis of the Company's financial assets included in the captive insurance subsidiary's investments and the deferred compensation plan investment funds are considered to approximate the fair value of these financial assets and are derived using Level 2 inputs.</span></div>The Company believes its investments that were in an unrealized loss position as of December 31, 2022 do not require an allowance for expected credit losses, nor has any event occurred subsequent to that date that would indicate so.The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value. 316270000 262201000 69290000 67734000 25144000 17530000 STANDARD BEARER<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Standard Bearer's real estate portfolio consists of 103 of the Company's 108 owned real estate properties, of which 75 are operated and managed by the Company and 29 are leased to and operated by Pennant. Of those 29 senior living operations, one is located on the same real estate property as a skilled nursing facility that the Company owns and operates. Standard Bearer intends to qualify and elect to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. During the year ended December 31, 2022, Standard Bearer acquired the real estate of ten</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">skilled nursing facilities for a purchase price of</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$84,656, three of which were previously operated and managed by Ensign's affiliated operations. Refer to Note 9, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operation Expansions </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the formation of Standard Bearer, certain of the Company's operating subsidiaries, Standard Bearer and Standard Bearer's subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As these intercompany arrangements were entered into when Standard Bearer was formed in January 2022, the transactions related to these agreements are reflected in Standard Bearer's segment income during year ended December 31, 2022. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany master lease agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's operating subsidiaries and the 75 Standard Bearer subsidiaries entered into five "triple-net" master lease agreements (collectively, the Standard Bearer Master Leases) in January 2022. The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the operating subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The ten real estate properties acquired during year ended December 31, 2022 were added to the Standard Bearer Master Leases. Rental revenue generated from Ensign affiliated operations was $57,967, $44,165 and $40,946 for the years ended December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022, total annual rental income under the Standard Bearer Master Lease is approximately $62.5 million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany management agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue. Management fee generated between Standard Bearer and the Service Center for the year ended December 31, 2022 was $4,367, which represents 6% of total Standard Bearer rental revenue. No management fees were recorded in 2021 and 2020, which was prior to the formation of Standard Bearer. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany debt arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Revolving Credit Facility to fund acquisitions and working capital needs. The interest rate under the Amended Credit Agreement is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory notes are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 16, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to these debts. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Instrument Denominated in the Shares of a Subsidiary</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's affiliated subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to Standard Bearer at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. During the year ended December 31, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the year ended December 31, 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders. The value of Standard Bearer common and preferred shares held by the Company are eliminated in consolidation and the value held by other shareholders are classified as noncontrolling interests on the Company's consolidated balance sheets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends on Shares of a Subsidiary</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, Standard Bearer met the requirement to distribute to its shareholders at least 90% of its annual taxable income through a declaration and payment of cash dividends totaling $30,379. Of that amount, $30,095 was paid in the form of a distribution to the Company and $284 was paid in the form of a distribution to noncontrolling interests.</span></div> 103 108 75 29 29 1 10 84656000 3 75 5 P15Y P19Y 3 P5Y 0 0.025 10 57967000 44165000 40946000 62500000 0.05 0.05 0.01 4367000 0.06 0.06 0 0 0.0025 0.0125 0.0125 0.0225 P5Y 6544000 0 0 0 0 149000 30379000 30095000 284000 BUSINESS SEGMENTS<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the formation of Standard Bearer in January 2022, the Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, began reviewing the results of Standard Bearer instead of all real estate properties. Accordingly, the Company revised its former real estate segment to include only real estate properties that are part of Standard Bearer. This change in organizational structure demonstrates that Standard Bearer's real estate is a core part of the Company's expansion of its real estate investment strategy. As of the first quarter of 2022, the Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. Segment information for prior periods has been recast to reflect the change of the Company’s segment structure.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the skilled services segment includes 234 skilled nursing operations and 26 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 103 owned real estate properties. These properties include 75 operations the Company operated and managed and 29 senior living operations that are leased to and operated by third parties. Of the 29 real estate operations leased to third parties, one senior living operation is located on the same real estate property as a skilled nursing facility that the Company owns and operates. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reports an “All Other” category that includes results from its senior living operations, which includes eleven stand-alone senior living operations and the senior living operations at 26 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accounting policies of the reportable segments are the same as those described in Note 2, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, real estate insurance recoveries and losses and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it is part of the CODM financial information. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth financial information for the segments:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906,215 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,214 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,718)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008,711 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,937 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,576)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,757 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,906,215</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,937</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122,610</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76,294)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,025,468</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,732 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,871 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,781)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,822 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of real estate assets and insurance recoveries, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,267 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289,089</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,224 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,613 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,518 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,355 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,707 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,646)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,931 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,523,234 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,276 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,034)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611,476 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,127 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,551)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,985 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,127</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,685</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,585)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,627,461</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,603 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,876 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,915)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,564 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on real estate insurance recoveries</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258,004</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,681 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,558 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,746 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,985 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,842 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,849 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288,182 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,548 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,291)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387,439 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,118)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,157 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,288,182</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,104</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,719</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52,409)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,402,596</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,812 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,299 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,752)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,359 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale of real estate and impairment charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,753)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">217,606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,585 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,134 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,852 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,571 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,362 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue by major payor source were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Service Revenue </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158,309 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,847 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,156 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,191,347</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,847</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,216,194</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,158 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,649 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,807 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,906,215</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,496</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008,711</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Service Revenue </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007,061 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,399 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,460 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,906,934</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,922,333</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,572 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,843 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,415 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,242</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611,476</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Service Revenue </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,991 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,258 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,249 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.7 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,374 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,374 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,846 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,846 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,764,211</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,258</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,777,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,095 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,095 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,876 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,999 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,875 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,288,182</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">99,257</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,387,439</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div> 2 234 26 103 75 29 29 1 11 26 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth financial information for the segments:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906,215 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,214 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,718)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008,711 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,937 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,576)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,757 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,906,215</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,937</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122,610</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76,294)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,025,468</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,732 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,871 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,781)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,822 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of real estate assets and insurance recoveries, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,267 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289,089</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,224 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,613 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,518 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,355 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,707 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,646)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,931 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,523,234 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,276 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,034)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611,476 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,127 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,551)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,985 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,127</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,685</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,585)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,627,461</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,603 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,876 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,915)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,564 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on real estate insurance recoveries</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258,004</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,681 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,558 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,746 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,985 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,842 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,849 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288,182 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,548 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,291)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387,439 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,118)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,157 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,288,182</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,104</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,719</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52,409)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,402,596</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,812 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,299 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,752)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,359 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale of real estate and impairment charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,753)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">217,606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,585 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,134 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,852 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,571 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,362 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div>(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. 2906215000 0 115214000 -12718000 3008711000 0 72937000 7396000 -63576000 16757000 2906215000 72937000 122610000 -76294000 3025468000 408732000 27871000 -150781000 0 285822000 3267000 289089000 33224000 21613000 7518000 0 62355000 0 15707000 1870000 -8646000 8931000 2523234000 0 95276000 -7034000 2611476000 0 58127000 7409000 -49551000 15985000 2523234000 58127000 102685000 -56585000 2627461000 373603000 31876000 -147915000 0 257564000 440000 258004000 30681000 17558000 7746000 0 55985000 0 6842000 7000 0 6849000 2288182000 0 105548000 -6291000 2387439000 0 54104000 7171000 -46118000 15157000 2288182000 54104000 112719000 -52409000 2402596000 327812000 27299000 -134752000 0 220359000 -2753000 217606000 28585000 16134000 9852000 0 54571000 0 9350000 12000 0 9362000 <div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue by major payor source were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Service Revenue </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158,309 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,847 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,156 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,191,347</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,847</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,216,194</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,158 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,649 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,807 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,906,215</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,496</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008,711</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Service Revenue </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007,061 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,399 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,460 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,906,934</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,922,333</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,572 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,843 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,415 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,242</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611,476</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Service Revenue </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,991 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,258 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,249 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.7 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,374 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,374 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,846 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,846 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,764,211</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,258</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,777,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,095 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,095 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,876 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,999 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,875 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,288,182</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">99,257</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,387,439</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP and other COVID-19 related state funding.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div> 1158309000 24847000 1183156000 0.393 832160000 0 832160000 0.277 200878000 0 200878000 0.067 2191347000 24847000 2216194000 0.737 525710000 0 525710000 0.175 189158000 77649000 266807000 0.088 2906215000 102496000 3008711000 1.000 1007061000 15399000 1022460000 0.392 727103000 0 727103000 0.278 172770000 0 172770000 0.066 1906934000 15399000 1922333000 0.736 456728000 0 456728000 0.175 159572000 72843000 232415000 0.089 2523234000 88242000 2611476000 1.000 886991000 13258000 900249000 0.377 727374000 0 727374000 0.305 149846000 0 149846000 0.063 1764211000 13258000 1777469000 0.745 367095000 0 367095000 0.154 156876000 85999000 242875000 0.101 2288182000 99257000 2387439000 1.000 OPERATION EXPANSIONS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's subsidiaries expansion focus is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business, or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, a real estate affiliated subsidiary will acquire the property of facilities that have previously been operated under third-party leases. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 805, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clarifying the Definition of a Business </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 805) defined the definition of a business to assist entities with evaluating when a set of transferred assets and activities is deemed to be a business. Determining whether a transferred set constitutes a business is important because the accounting for a business combination differs from that of an asset acquisition. The definition of a business also affects the accounting for dispositions. When substantially all of the fair value of assets acquired is concentrated in a single asset, or a group of similar assets, the assets acquired would not represent a business and business combination accounting would not be required. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Expansions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company expanded its operations through a combination of long-term leases and real estate purchases, with the addition of 23 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seven</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the stand-alone skilled nursing operations, which were leased back to Ensign affiliated entities. In addition, the Company purchased the real estate at three skilled nursing properties that the Company was already operating, further expanding the Company's real estate portfolio. Refer to Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on the purchase of real estate properties. In addition, the Company added five senior living operations that were transferred from Pennant, three of which are part of campuses operated by the Company's affiliated operating subsidiaries. These new operations added a total of 3,058 operational skilled nursing beds and 674 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate purchase price for these expansions during the year ended December 31, 2022 was </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$101,136</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aggregate </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase price for the transactions that were classified as asset acquisitions </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the year ended December 31, 2022 was $84,736, consisting of real estate properties and indefinite-lived intangible assets. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining aggregate purchase price for transactions during the year ended December 31, 2022 was concentrated in goodwill of $16,400 and accordingly, the transactions were classified as business combinations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2022, the Company expanded its operations through a combination of long-term leases, with the addition of seventeen stand-alone skilled nursing operations. These new operations added 1,462 operational skilled nursing beds. The Company also invested in new ancillary services that are complementary to its existing businesses.</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Expansions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company expanded its operations through a combination of long-term leases and a real estate purchase,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the addition of 17 stand-alone skilled nursing operations </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and five real estate purchases, four of which the Company previously operated and continues to operate. The remaining real estate purchase is operated by Pennant.</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These new operations added a total of 1,832 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate purchase price for these acquisitions during the year ended December 31, 2021 was $104,224. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate purchase price for the asset acquisitions during the year ended December 31, 2021 was $98,224, consisting of real estate properties. The fair value of assets for the remaining additions was concentrated in goodwill of $6,000 and as such, the transaction was classified as a business combination. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Acquisitions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company expanded its operations through a combination of long-term leases and real estate purchases,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the addition of five stand-alone skilled nursing operations, one stand-alone senior living operation and one campus operation. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of these additions, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">four</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are related to purchases of owned properties, further expanding the Company's real estate portfolio. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These new operations added a total of 507 operational skilled nursing beds and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 298 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operational senior living units to be operated by the Company's affiliated operating subsidiaries. The aggregate purchase price for these acquisitions during the year ended December 31, 2020 was $24,997. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of assets for the purchases of these properties was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the first quarter of 2020, the Company entered into a long-term lease agreement to transfer two senior living operations to Pennant. Ensign affiliates retained ownership of the real estate for these two senior living communities, which was subsequently sold in 2022. </span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the allocation of the purchase price for the operations acquired during the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December 31, 2022, 2021, and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, excluding assets that were contributed to Pennant that occurred during the spin-off transaction in 2019.</span></div><div style="margin-top:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,527 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,928 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,496 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,070 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,975 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture, and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL ACQUISITIONS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101,136</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104,224</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,997</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The assets added during the year ended December 31, 2022 and through the issuance of the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Statements</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the December 31, 2022 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> balance sheets of the Company, and the operating results have been included in the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> statements of operations of the Company since the date the Company gained effective control.</span> 23 1 7 3 5 3 3058 674 101136000 84736000 16400000 17 1462 17 5 4 1832 104224000 98224000 6000000 5 1 1 4 507 298 24997000 2 2 <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the allocation of the purchase price for the operations acquired during the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December 31, 2022, 2021, and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, excluding assets that were contributed to Pennant that occurred during the spin-off transaction in 2019.</span></div><div style="margin-top:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,527 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,928 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,496 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,070 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,975 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture, and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL ACQUISITIONS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101,136</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104,224</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,997</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15527000 19928000 9496000 65070000 77975000 14178000 1618000 217000 568000 367000 29000 107000 16400000 6000000 0 1909000 0 0 245000 75000 648000 101136000 104224000 24997000 PROPERTY AND EQUIPMENT - NET<div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,864 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,164 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,231 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,221 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,903 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,012 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,739 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,246 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,305 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,521 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,331,802</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,184,201</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,792)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295,767)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTY AND EQUIPMENT, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">992,010</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">888,434</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed the sale of assets for a sale price of $8,607 and recorded a gain of $3,467 within the Company's consolidated statement of income as cost of services during the year ended December 31, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company evaluated its long-lived assets and did not record an impairment charge for the fiscal years ended 2022 and 2021. The Company recorded impairment charges of $2,681 for the fiscal year ended 2020. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note 9, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operation Expansions </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for information on acquisitions during the year ended December 31, 2022.</span></div> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,864 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,164 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,231 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,221 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,903 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,012 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,739 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,246 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,305 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,521 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,331,802</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,184,201</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,792)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295,767)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTY AND EQUIPMENT, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">992,010</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">888,434</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 134864000 121164000 728231000 646221000 150903000 140012000 295739000 262246000 4544000 4305000 17521000 10253000 1331802000 1184201000 339792000 295767000 992010000 888434000 8607000 3467000 0 0 impairment charges 2681000 INTANGIBLE ASSETS - NET<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="5" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility trade name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,482)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,272)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,750</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,285)</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,465</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,383</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,731)</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022, 2021, and 2020, amortization expense was $1,714, $1,435 and $1,813, respectively, of which $1,160, $1,158, and $1,223 was related to the amortization of right-of-use assets, respectively.</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record any impairment charge to intangible assets during the years ended December 31, 2022, 2021, and 2020.</span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the years ending December 31 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,465</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="5" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility trade name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,482)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,272)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,750</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,285)</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,465</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,383</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,731)</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> P0Y3M18D 435000 388000 47000 68000 68000 0 P30Y 733000 415000 318000 733000 391000 342000 P18Y4M24D 4582000 2482000 2100000 4582000 2272000 2310000 5750000 3285000 2465000 5383000 2731000 2652000 1714000 1435000 1813000 1160000 1158000 1223000 0 0 0 <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the years ending December 31 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,465</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 281000 234000 234000 234000 234000 1248000 2465000 GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS<div style="margin-bottom:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles—Goodwill and Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value. </span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs its goodwill impairment test annually and evaluates goodwill when events or changes in circumstances indicate that its carrying value may not be recoverable. The Company performs the annual impairment testing of goodwill using October 1 as the measurement date. The Company completed its goodwill impairment test as of October 1, 2022 and did not record any impairment charge to goodwill or other intangible assets for the fiscal years 2022, 2021 or 2020. The Company has recognized cumulative goodwill impairment losses of $7,410.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that the majority of goodwill recognized will be fully deductible for tax purposes as of December 31, 2022. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's acquisitions during the year ended December 31, 2020 were classified as asset acquisitions and accordingly, no goodwill was recognized for these acquisitions. There were no other activities in goodwill during the year ended December 31, 2020. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of and for the year ended December 31, 2022, 2021 and 2020:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2020</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,886</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company acquired $245 in Medicare and Medicaid licenses compared to $181 and $648 in the fiscal years 2021 and 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,083 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,838 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,972</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,727 </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 0 7410000 The following table represents activity in goodwill by skilled service segment and "all other" category as of and for the year ended December 31, 2022, 2021 and 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2020</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,886</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 45486000 8983000 54469000 45486000 8983000 54469000 6000000 0 6000000 51486000 8983000 60469000 16400000 0 16400000 67886000 8983000 76869000 245000 181000 648000 <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,083 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,838 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,972</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,727 </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 889000 889000 3083000 2838000 3972000 3727000 RESTRICTED AND OTHER ASSETS<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted and other assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, net</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,753 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term insurance losses recoverable asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,755 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital improvement reserves with landlords and lenders</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,103 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits with landlords</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,606 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,099 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTED AND OTHER ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,291</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,516</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>Included in restricted and other assets as of December 31, 2022 and 2021 are anticipated insurance recoveries related to the Company's workers' compensation, general and professional liability claims that are recorded on a gross rather than net basis in accordance with an Accounting Standards Update issued by the FASB. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted and other assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, net</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,753 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term insurance losses recoverable asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,755 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital improvement reserves with landlords and lenders</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,103 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits with landlords</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,606 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,099 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTED AND OTHER ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,291</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,516</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3753000 1953000 10512000 6755000 6446000 7103000 2527000 2606000 14053000 11099000 37291000 29516000 OTHER ACCRUED LIABILITIES<div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance fee</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,701 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,474 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,783 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,814 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident advances</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,698 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,337 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unapplied state relief funds</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash held in trust for patients</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,926 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,124 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal finding accrued</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,046 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,415 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER ACCRUED LIABILITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97,309</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89,410</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the consolidated balance sheets.</span></div> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance fee</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,701 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,474 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,783 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,814 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident advances</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,698 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,337 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unapplied state relief funds</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash held in trust for patients</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,926 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,124 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal finding accrued</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,046 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,415 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER ACCRUED LIABILITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97,309</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89,410</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7701000 6474000 40783000 34814000 9698000 9337000 1001000 1781000 6400000 6430000 3201000 3035000 10926000 9124000 4553000 0 13046000 18415000 97309000 89410000 INCOME TAXES<div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on continuing operations for the years ended December 31, 2022, 2021 and 2020 is summarized as follows: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,717 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,105 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,591 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,216 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,898 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,460 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,933</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,003</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74,051</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,158)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(716)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,054)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,755)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,496)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(724)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,809)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">     TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,437</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,279</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,242</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2022, 2021 and 2020, respectively, is comprised as follows: </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at statutory rate</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes - net of federal benefit</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL INCOME TAX PROVISION</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's effective tax rate was 22.3% for the year ended December 31, 2022, compared to 23.4% for the same period in 2021 and 21.3% in 2020. The lower effective tax rate is due to higher tax benefits from stock compensation and lower tax expense from non-deductible expenses.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax assets and liabilities as of December 31, 2022 and 2021 are summarized below. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,685 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related reserves</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,046 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,171 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,910 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,712 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,408 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,643 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457,819</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">368,139</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX ASSETS</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457,030</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">367,350</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,146)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,827)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,150)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,265)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363,091)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(284,111)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX LIABILITIES</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(417,387)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(334,203)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET DEFERRED TAX ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,643</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,147</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had state credit carryforwards as of December 31, 2022 and 2021 of $1,742 and $2,138, respectively. These carryforwards almost entirely relate to state limitations on the application of Enterprise Zone employment-related tax credits. Unless the Company uses the Enterprise Zone credits beforehand, the carryforward will begin to expire in 2023. As of December 31, 2022 and 2021, the valuation allowance of $789, for both years, was primarily recorded against the Enterprise Zone credits as the Company believes it is more likely than not that some of the benefit of the credits will not be realized. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating loss carry forwards for states were not material during the years ended December 31, 2022 and 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, 2021 and 2020, the Company did not have any unrecognized tax benefits, net of its state benefits that would affect the Company's effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal statutes of limitations on the Company's 2018, 2017, and 2016 income tax years lapsed during the third quarter of 2022, 2021, and 2020, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses for the years ended December 31, 2022 and 2021 had no impact on the Company's unrecognized tax benefits. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the state of Wisconsin initiated and completed an examination of the Company's 2019, 2018, and 2017 state tax years with no adjustments. The Company is not under examination by any major income tax jurisdiction.</span></div> <div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on continuing operations for the years ended December 31, 2022, 2021 and 2020 is summarized as follows: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,717 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,105 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,591 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,216 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,898 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,460 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,933</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,003</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74,051</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,158)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(716)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,054)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,755)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,496)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(724)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,809)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">     TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,437</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,279</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,242</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 56717000 49105000 60591000 14216000 11898000 13460000 70933000 61003000 74051000 -5158000 -716000 -23054000 -1338000 -8000 -4755000 -6496000 -724000 -27809000 64437000 60279000 46242000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2022, 2021 and 2020, respectively, is comprised as follows: </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at statutory rate</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes - net of federal benefit</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL INCOME TAX PROVISION</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div> 0.210 0.210 0.210 0.035 0.037 0.032 0.020 0.024 0.018 -0.036 -0.033 -0.043 -0.006 -0.004 -0.004 0.223 0.234 0.213 0.223 0.234 0.213 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax assets and liabilities as of December 31, 2022 and 2021 are summarized below. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,685 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related reserves</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,046 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,171 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,910 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,712 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,408 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,643 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457,819</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">368,139</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX ASSETS</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457,030</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">367,350</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,146)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,827)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,150)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,265)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363,091)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(284,111)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX LIABILITIES</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(417,387)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(334,203)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET DEFERRED TAX ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,643</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,147</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 61685000 58640000 18046000 13171000 1742000 2138000 11910000 8712000 364408000 285643000 28000 -165000 457819000 368139000 789000 789000 457030000 367350000 49146000 45827000 5150000 4265000 363091000 284111000 417387000 334203000 39643000 33147000 1742000 2138000 789000 789000 DEBT<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans and promissory notes</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,271 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,967 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,883)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,760)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,119)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,324)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM DEBT LESS CURRENT MATURITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149,269</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,883</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility with a Lending Consortium Arranged by Truist </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a revolving credit facility between the Company and its subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Revolving Credit Facility). Borrowings are supported by a lending consortium arranged by Truist. On April 8, 2022, the Company and its subsidiaries, including Standard Bearer, entered into the Amended Credit Agreement, which amended the Revolving Credit Facility to increase the revolving line of credit from $350,000 to $600,000 in aggregate principal amount. The Amended Credit Agreement also extended the maturity date of the Revolving Credit Facility to April 8, 2027 and modified the reference rate from LIBOR to SOFR. The interest rates applicable to loans under the Amended Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company and its subsidiaries, including Standard Bearer, will pay a commitment fee on the unused portion of the commitments that will range from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. Except as set forth in the Amended Credit Facility, all other terms and conditions of the Credit Facility remained in full force and effect as described below. As part of the entry into the Amended Credit Agreement, deferred financing costs of $566 were written off and additional deferred financing costs of $3,197 were capitalized during the year ended December 31, 2022. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings made under the Revolving Credit Facility are guaranteed, jointly and severally, by certain of the Company’s wholly-owned subsidiaries, and are secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of their personal property. The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Amended Credit Agreement, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six months period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of December 31, 2022, and January 30, 2023, there was no outstanding debt under the Revolving Credit Facility. The Company was in compliance with all loan covenants as of December 31, 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mortgage Loans and Promissory Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company's operating subsidiaries had $156,271 outstanding under the mortgage loans and notes, of which $3,883 is classified as short-term and the remaining $152,388 is classified as long-term. The Company was in compliance with all loan covenants as of December 31, 2022. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, 23 of the Company's subsidiaries have mortgage loans insured with HUD in the aggregate amount of $153,488, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, we incur other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0%</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per year for years <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF8xNTcvZnJhZzpkYTZiY2ViODZjZjc0YzQzYWVmYjUwMWY3MzgyMDZhOC90ZXh0cmVnaW9uOmRhNmJjZWI4NmNmNzRjNDNhZWZiNTAxZjczODIwNmE4XzQyMjU_d43c6fa5-283e-408d-832d-1f5d6aede6ba">five</span> through <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF8xNTcvZnJhZzpkYTZiY2ViODZjZjc0YzQzYWVmYjUwMWY3MzgyMDZhOC90ZXh0cmVnaW9uOmRhNmJjZWI4NmNmNzRjNDNhZWZiNTAxZjczODIwNmE4XzQyMzY_8d28c61a-e83e-4f25-8f15-939eedf5b052">ten</span> of the loan. There is no prepayment penalty after year <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF8xNTcvZnJhZzpkYTZiY2ViODZjZjc0YzQzYWVmYjUwMWY3MzgyMDZhOC90ZXh0cmVnaW9uOmRhNmJjZWI4NmNmNzRjNDNhZWZiNTAxZjczODIwNmE4XzQyOTQ_439dbf43-2d8d-4a84-8fb6-9b27ca9ed1c1">ten</span>. The terms for all the mortgage loans are 25 to 35 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the HUD mortgage loans above, the Company has two promissory notes. The notes bear fixed interest rates of 6.3% and 5.3% per annum and the term of the notes are 10 months and 12 years, respectively. The 12 year note which was used for an acquisition is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments due under the long-term debt arrangements discussed above are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,883 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,228 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156,271</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had approximately $6,710 of borrowing capacity under the Revolving Credit Facility pledged as collateral to secure outstanding letters of credit, which remained consistent from 2021.</span></div> <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans and promissory notes</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,271 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,967 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,883)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,760)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,119)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,324)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM DEBT LESS CURRENT MATURITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149,269</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,883</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 156271000 159967000 3883000 3760000 3119000 3324000 149269000 152883000 350000000 600000000 0.0025 0.0125 0.0125 0.0225 0.0020 0.0040 566000 3197000 3.00 P6M 50000000 3.50 1.50 0 0 156271000 3883000 152388000 23 153488000 0.031 0.042 0.024 0.033 P3Y 0.100 0.030 0.010 P25Y P35Y 2 0.063 0.053 P10M P12Y P12Y <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments due under the long-term debt arrangements discussed above are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,883 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,228 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156,271</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3883000 3950000 4086000 4227000 3897000 136228000 156271000 6710000 OPTIONS AND AWARDS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s consolidated statements of income for the years ended December 31, 2022, 2021, and 2020 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one active stock incentive plan, the 2022 Omnibus Incentive Plan (the 2022 Plan), which was approved by the Company's stockholders on May 26, 2022, and replaced the Company's prior option plan, the 2017 Omnibus Incentive Plan (the 2017 Plan). </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Omnibus Incentive Plan (2022 Plan)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the second quarter of 2022, the Company's shareholders approved the 2022 Plan. Including the shares rolled over from the 2017 Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. At December 31, 2022, the total number of shares available for issuance under the 2022 Plan was 2,861.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Omnibus Incentive Plan (2017 Plan) —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Plan provided for the issuance of 6,881 shares of common stock which are to be proportionally adjusted in the event of any Equity Restructuring. The number of shares available to be issued under the 2017 Plan were adjusted to 8,118 shares of common stock in order to reflect the proportional adjustments as part of the spin-off transaction that occurred in October 2019. The number of shares available to be issued under the 2017 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) 2.5 shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Granted non-employee director options vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. The Company granted 165 stock options and 116 restricted stock awards from the 2017 Plan in the first half of 2022 prior to the retirement of the 2017 plan.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Black-Scholes model required the Company to make several key judgments including: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The expected option term is calculated by the average of the contractual term of the options and the weighted average vesting period for all options. The calculation of the expected option term is based on the Company's experience due to sufficient history.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The Company utilizes its own experience to calculate estimated volatility for options granted. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The dividend yield is based on the Company's historical pattern of dividends as well as expected dividend patterns.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The risk-free rate is based on the implied yield of U.S. Treasury notes as of the grant date with a remaining term approximately equal to the expected term.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Estimated forfeiture rate of approximately 7.84% per year is based on the Company's historical forfeiture activity of unvested stock options.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 581, 621 and 669 stock options from the available plans during the year ended December 31, 2022, 2021 and 2020, respectively. The Company used the following assumptions for stock options granted during the years ended December 31, 2022, 2021 and 2020: </span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021 and 2020, the following represents the exercise price and fair value displayed at grant date for stock option grants:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.687%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.74 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.83 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended December 31, 2022, 2021 and 2020 and therefore, the intrinsic value was $0 at the date of grant. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the year ended December 31, 2022, 2021 and 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Number of Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Number of<br/>Options Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Weighted Average Exercise Price of Options Vested</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2020</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,428 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.85 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,557 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.82 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.68 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(979)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.93 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.60 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.74 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.52 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.43 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,833 </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.72 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.87 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary information reflects stock options outstanding, vested and related details as of December 31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.892%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Vested</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Fair Value</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and Exercisable</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.76</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.74</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.05</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.39</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.93</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.86</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.41</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.49</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.71</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,341 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.07</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.76</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,275 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.84</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.49</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,734 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.47</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.64</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,597 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$79.79</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$94.88</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,689 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,833</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71,034</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,069</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,593 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,242 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,552 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,000 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,382 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,867 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,232 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The aggregate intrinsic value of options that vested </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the year ended December 31, 2022, 2021 and 2020 was</span><span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$27,955, $27,731, and $26,030, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the year ended December 31, 2022, 2021 and 2020 was $47,441, $34,278, and $45,081, respectively. </span><span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 233, 222</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 281 restricted stock awards during the years ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 and 2020, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the years ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ranged from</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $73.17 to $94.88,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $72.84 to $93.31 and $35.47 to $58.06, respectively. The fair value per share includes quarterly stock awards to non-employee directors. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's non-vested restricted stock awards as of December 31, 2022 and changes during the years ended December 31, 2022, 2021 and 2020 is presented below: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at January 1, 2020</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.35 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.73 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.84 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">591</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.90 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.65 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.64 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.57 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.06 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.29 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.92 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company granted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 18 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors from the 2017 and 2022 Plan. The fair value per share of these stock awards ranged from</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $75.33 to $86.34</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> based on the market price on the grant date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Incentive Plan</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off transaction in 2019 are granted shares of restricted stock upon successful completion. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested shall be entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $836, $854, and $881 for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December 31, 2022, 2021, and 2020 was as follows:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,361 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,459 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,132 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to restricted stock awards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,920 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,385 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,720</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,678</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,524</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In future periods, the Company expects to recognize approximately</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $43,388 and $29,149 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of December 31, 2022. Future stock-based compensation expense will be recognized over 3.6 and 3.4 weighted average years for unvested options and restricted stock awards, respectively. There were 1,764 unvested and outstanding options as of December 31, 2022, of which 1,666 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of December 31, 2022 was 6.0 years.</span> 1 3452000 1 2 3 P3Y P5Y 0.20 P10Y 2861000 6881000 8118000 1 2.5 3 P3Y P5Y 0.20 P10Y 165000 116000 0.0784 581000 621000 669000 : <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4%</span></td></tr></table> 581000 0.028 P6Y2M12D 0.421 0.003 621000 0.010 P6Y2M12D 0.424 0.003 669000 0.006 P6Y2M12D 0.394 0.004 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.687%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.74 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.83 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 581000 85.74 37.83 621000 80.19 32.82 669000 52.20 19.52 0 0 0 <div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the year ended December 31, 2022, 2021 and 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Number of Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Number of<br/>Options Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Weighted Average Exercise Price of Options Vested</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2020</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,428 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.85 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,557 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.82 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.68 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(979)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.93 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.60 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.74 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.52 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.43 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,833 </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.72 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.87 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4428000 20.85 2557000 12.82 669000 52.20 80000 33.68 979000 12.93 4038000 27.71 2148000 16.66 621000 80.19 105000 44.76 516000 17.80 4038000 36.60 2183000 21.02 581000 85.74 98000 59.52 688000 18.43 3833000 46.72 2069000 28.87 <div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary information reflects stock options outstanding, vested and related details as of December 31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.892%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Vested</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Fair Value</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and Exercisable</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.76</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.74</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.05</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.39</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.93</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.86</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.41</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.49</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.71</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,341 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.07</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.76</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,275 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.84</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.49</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,734 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.47</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.64</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,597 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$79.79</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$94.88</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,689 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,833</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71,034</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,069</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6.76 9.74 65000 274000 P1Y 65000 8.94 16.05 399000 1930000 P2Y 399000 18.20 21.39 211000 1645000 P3Y 211000 15.93 16.86 198000 1162000 P4Y 198000 15.80 19.41 236000 1387000 P5Y 236000 22.49 32.71 449000 4341000 P6Y 330000 41.07 45.76 590000 9275000 P7Y 324000 44.84 59.49 545000 10734000 P8Y 197000 73.47 83.64 567000 18597000 P9Y 109000 79.79 94.88 573000 21689000 P10Y 0 3833000 71034000 2069000 <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2022, 2021 and 2020 is as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,593 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,242 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,552 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,000 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,382 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,867 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,232 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 183593000 191242000 182552000 136000000 137382000 120867000 43232000 48548000 53366000 27955000 27731000 26030000 47441000 34278000 45081000 233000 222000 281000 0 P5Y 73.17 94.88 72.84 93.31 35.47 58.06 : <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at January 1, 2020</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.35 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.73 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.84 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">591</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.90 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.65 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.64 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.57 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.06 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.29 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.92 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 610000 31.35 281000 48.73 280000 32.84 20000 31.71 591000 38.90 222000 81.65 244000 47.45 20000 45.64 549000 52.16 233000 81.57 269000 54.06 26000 57.29 487000 64.92 18000 75.33 86.34 500000 P5Y 0.20 836000 854000 881000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December 31, 2022, 2021, and 2020 was as follows:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,361 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,459 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,132 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to restricted stock awards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,920 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,385 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,720</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,678</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,524</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11361000 8459000 6132000 9920000 8385000 7373000 1439000 1834000 1019000 22720000 18678000 14524000 43388000 29149000 P3Y7M6D P3Y4M24D 1764000 1666000 P6Y LEASES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 affiliated skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024. </span></div><div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Master Leases was approximately $64,178, $59,571 and $52,838 for the years ended December 31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December 31, 2022. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off transaction in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain affiliated operations and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF8xNzUvZnJhZzo4ZTlhZTA0MTkxMDM0NjMzOGRhMGRjM2RiMzVjZGJhOC90ZXh0cmVnaW9uOjhlOWFlMDQxOTEwMzQ2MzM4ZGEwZGMzZGIzNWNkYmE4XzQwNzg_0f0e4c41-252c-405b-a05d-bc8d79d59e68">five</span> to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF8xNzUvZnJhZzo4ZTlhZTA0MTkxMDM0NjMzOGRhMGRjM2RiMzVjZGJhOC90ZXh0cmVnaW9uOjhlOWFlMDQxOTEwMzQ2MzM4ZGEwZGMzZGIzNWNkYmE4XzQyMTU_d6c48001-055e-4521-bd3a-706269d23b97">three</span> to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $153,174, $139,458 and $129,990 for the year ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fifty-eight of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under ten separate master lease arrangements. During 2022, the Company amended two of its separate master leases to add operations and extend the initial terms, which increased the lease liabilities and right-of-use assets by $207,638 to reflect the new lease obligations. Additionally, during 2022, the Company added six new operations to two new master leases, which increased the lease liabilities and right-of-use assets by $54,755 to reflect the new lease obligations. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, Standard Bearer acquired the real estate of three skilled nursing operations, which were previously under separate long-term lease arrangements. The aggregate reduction in the carrying value of the Company's lease liabilities and right-of-use assets related to this acquisition is $10,080.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,049 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,926 </span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,938 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,077 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,774 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171,272</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,693</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143,987</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $493, $485 and $451 for the years ended December 31, 2022, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $5,878, $3,702, $2,394 for the years ended December 31, 2022, 2021, and 2020 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all leases as of December 31, 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,963 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,630 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,455 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,380 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,860 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,411 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,243,699</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(822,790)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,420,909</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,796)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,355,113</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of December 31, 2022 and 2021, the weighted average remaining lease term is 15.0 and 14.8, respectively, and the weighted average discount rate used to determine the operating lease liabilities is 6.7% and 7.6%, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2022, the Company expanded its operations through two separate master lease arrangements for 20 stand-alone skilled nursing operations, of which 17 will be operated by the Company's affiliated operating subsidiaries and the remaining three will be subleased to a third-party operator. The aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the two separate master lease agreements is estimated to be approximately $315,337. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off transaction in 2019, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. As of December 31, 2022, Ensign affiliates retained ownership of the real estate for these 29 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the years ended December 31, 2022, 2021, and 2020 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,915 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,073 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,163 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,757</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,985</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,157</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $1,318, $1,199, and $1,224 during the year ended December 31, 2022, 2021, and 2020.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all leases as of December 31, 2022 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,408 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,826 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,391 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,166 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,166 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,171 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,128</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2022. LEASES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 affiliated skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024. </span></div><div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Master Leases was approximately $64,178, $59,571 and $52,838 for the years ended December 31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December 31, 2022. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off transaction in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain affiliated operations and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF8xNzUvZnJhZzo4ZTlhZTA0MTkxMDM0NjMzOGRhMGRjM2RiMzVjZGJhOC90ZXh0cmVnaW9uOjhlOWFlMDQxOTEwMzQ2MzM4ZGEwZGMzZGIzNWNkYmE4XzQwNzg_0f0e4c41-252c-405b-a05d-bc8d79d59e68">five</span> to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlMmRmNDZiNTBjMTRmYTFiMTNiYjBiODJiYzUwOTRkL3NlYzpiZTJkZjQ2YjUwYzE0ZmExYjEzYmIwYjgyYmM1MDk0ZF8xNzUvZnJhZzo4ZTlhZTA0MTkxMDM0NjMzOGRhMGRjM2RiMzVjZGJhOC90ZXh0cmVnaW9uOjhlOWFlMDQxOTEwMzQ2MzM4ZGEwZGMzZGIzNWNkYmE4XzQyMTU_d6c48001-055e-4521-bd3a-706269d23b97">three</span> to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $153,174, $139,458 and $129,990 for the year ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fifty-eight of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under ten separate master lease arrangements. During 2022, the Company amended two of its separate master leases to add operations and extend the initial terms, which increased the lease liabilities and right-of-use assets by $207,638 to reflect the new lease obligations. Additionally, during 2022, the Company added six new operations to two new master leases, which increased the lease liabilities and right-of-use assets by $54,755 to reflect the new lease obligations. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, Standard Bearer acquired the real estate of three skilled nursing operations, which were previously under separate long-term lease arrangements. The aggregate reduction in the carrying value of the Company's lease liabilities and right-of-use assets related to this acquisition is $10,080.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,049 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,926 </span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,938 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,077 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,774 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171,272</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,693</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143,987</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $493, $485 and $451 for the years ended December 31, 2022, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $5,878, $3,702, $2,394 for the years ended December 31, 2022, 2021, and 2020 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all leases as of December 31, 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,963 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,630 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,455 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,380 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,860 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,411 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,243,699</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(822,790)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,420,909</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,796)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,355,113</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of December 31, 2022 and 2021, the weighted average remaining lease term is 15.0 and 14.8, respectively, and the weighted average discount rate used to determine the operating lease liabilities is 6.7% and 7.6%, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2022, the Company expanded its operations through two separate master lease arrangements for 20 stand-alone skilled nursing operations, of which 17 will be operated by the Company's affiliated operating subsidiaries and the remaining three will be subleased to a third-party operator. The aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the two separate master lease agreements is estimated to be approximately $315,337. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off transaction in 2019, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. As of December 31, 2022, Ensign affiliates retained ownership of the real estate for these 29 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the years ended December 31, 2022, 2021, and 2020 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,915 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,073 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,163 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,757</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,985</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,157</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $1,318, $1,199, and $1,224 during the year ended December 31, 2022, 2021, and 2020.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all leases as of December 31, 2022 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,408 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,826 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,391 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,166 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,166 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,171 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,128</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2022. 97 96 9 P13Y P20Y 2 3 P5Y 4 97 0 0.025 1 64178000 59571000 52838000 P20Y P5Y 153174000 139458000 129990000 58 10 2 207638000 6 2 54755000 3 10080000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,049 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,926 </span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,938 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,077 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,774 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171,272</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,693</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143,987</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $493, $485 and $451 for the years ended December 31, 2022, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $5,878, $3,702, $2,394 for the years ended December 31, 2022, 2021, and 2020 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.</span></div> 153049000 139371000 129926000 125000 87000 64000 1160000 1158000 1223000 16938000 14077000 12774000 171272000 154693000 143987000 493000 485000 451000 5878000 3702000 2394000 <div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all leases as of December 31, 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,963 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,630 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,455 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,380 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,860 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,411 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,243,699</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(822,790)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,420,909</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,796)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,355,113</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 157963000 157630000 157455000 157380000 156860000 1456411000 2243699000 822790000 1420909000 65796000 1355113000 P15Y P14Y9M18D 0.067 0.076 2 20 17 3 2 315337000 29 29 P14Y P16Y <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the years ended December 31, 2022, 2021, and 2020 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,915 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,073 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,163 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,757</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,985</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,157</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $1,318, $1,199, and $1,224 during the year ended December 31, 2022, 2021, and 2020.</span></div> 14915000 14073000 13163000 1842000 1912000 1994000 16757000 15985000 15157000 1318000 1199000 1224000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all leases as of December 31, 2022 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,408 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,826 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,391 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,166 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,166 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,171 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,128</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December 31, 2022. 16408000 15826000 15391000 15166000 15166000 79171000 157128000 SELF INSURANCE LIABILITIES<div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2022 and 2021: </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance January 1, 2021</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,798 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,907 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,183)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(383)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December 31, 2021</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,139 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,793 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,007)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,757 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December 31, 2022</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,682 </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div>Included in the table above are accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, of $87,000 and $69,748 as of December 31, 2022 and 2021, respectively. Included in long-term insurance losses recoverable as of December 31, 2022 and 2021 are anticipated insurance recoveries related to the Company's general and professional liability claims that are recorded on a gross rather than net basis in accordance with GAAP. <div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2022 and 2021: </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance January 1, 2021</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,798 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,907 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,183)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(383)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December 31, 2021</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,139 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,793 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,007)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,757 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December 31, 2022</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,682 </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 96798000 114907000 101183000 -383000 110139000 115793000 98007000 3757000 131682000 87000000 69748000 DEFINED CONTRIBUTION PLANS<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 90% of their annual basic earnings, subject to applicable annual Internal Revenue Code limits. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company. The Company expensed matching contributions to the 401(k) Plan of $2,418, $2,121, and $1,889 during the years ended December 31, 2022, 2021 and 2020, respectively. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company implemented non-qualified deferred compensation plan (the DCP) that was effective in 2019 for certain executives. The plan was then offered to other highly compensated employees, which went into effect on January 1, 2020. These individuals are otherwise ineligible for participation in the Company's 401(k) plan. The DCP allows participating employees to defer the receipt of a portion of their base compensation and certain employees up to 100% of their eligible bonuses. Additionally, the plan allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to informally fund savings plans of this nature. The Company paid for related administrative costs, which were not significant during fiscal years 2022, 2021 and 2020. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the years ended December 31, 2022, 2021, and 2020, the Company accrued $33,017, $26,832 and $14,232, respectively, as long term deferred compensation in other long term liabilities on the consolidated balance sheet. Cash surrender value of the contracts is based on investment funds that shadow the investment allocations specified by participants in the deferred compensation plan. Refer to Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information on the funds.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, the Company recorded a loss on the investment acquired in connection with our deferred compensation plan of $4,188, which is included in other income (expense), net. During the same period, the Company recorded an offsetting reduction in expense of $4,051, which is allocated between cost of services and general and administrative expenses.</span></div>For the years ended December 31, 2021 and 2020, the Company recorded net income on the investment acquired in connection with our deferred compensation plan of $1,612 and $1,396, respectively, which is included in other income (expense), net. During the same periods, the Company recorded an offsetting expense of $1,758, and $1,355, respectively, which is allocated between cost of services and general and administrative expenses. 0.90 2418000 2121000 1889000 1 33017000 26832000 14232000 -4188000 -4051000 1612000 1396000 1758000 1355000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost-Containment Measures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities arising out of the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s consolidated balance sheets for any of the periods presented.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off transaction in 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the transaction. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Department of Justice Civil Investigative Demand</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it was investigating whether there had been a violation of the False Claims Act and/or the Anti-Kickback Statute with respect to relationships between certain of the Company’s independently operated skilled nursing facilities and persons who serve or have served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of the Company’s Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, the Company’s independent operating entities have established and maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. The Company fully cooperated with the U.S. Department of Justice and promptly responded to its requests for information; in April 2020, the Company was advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. House of Representatives Select Subcommittee Request</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee in connection with its investigation. The Company has cooperated in responding to this inquiry. In July 2022 and thereafter, the Company received follow up requests for additional documents and information. The Company has responded to these requests, and continued to cooperate with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. In addition, the Company, its independent operating subsidiaries, and others in the industry are subject to claims and lawsuits in connection with COVID-19 and a facility's preparation for and/or response to COVID-19. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the potential lawsuits and claims described above, the Company and its independent operating subsidiaries are also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from Federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Under the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or "whistleblower" provisions of the False Claims Act, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the Federal Government and receive a percentage of the Federal Government's recovery. Due to these whistleblower incentives, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have become more frequent. For example, and despite the decision of the U.S. Department of Justice to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the involved </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relator has continued on with the lawsuit and is pursuing claims that the Company and certain of its independent operating subsidiaries have allegedly violated the False Claims Act and/or the Anti-Kickback Statute (AKS).</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Federal False Claims Act, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company and its independent operating subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a Federal False Claims Act violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent operating subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its independent operating subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including healthcare and non-healthcare services. These claims include, but are not limited to, potential claims filed by residents, customers, patients and responsible parties related to patient care and treatment (professional negligence claims); to non-care based activities of certain of the subsidiaries; and to employment related claims filed by current or former employees. A significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, these claims could impact the Company's ability to procure insurance to cover its exposure related to the various services provided by its independent operating subsidiaries to their residents, customers and patients.</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its independent subsidiaries are also subject to requests for information and investigations by other State and Federal governmental entities (e.g., offices of the attorney general and offices of the inspector general). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar state and federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiaries under a corporate integrity agreement and/or other such arrangement.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Revenue Recoupments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's independent operating entities are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate Program. Beginning in August 2020, CMS resumed Targeted Probe and Educate Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of December 31, 2022 and since, 34 of the Company's independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for 56.3% and 54.0% of its total accounts receivable as of December 31, 2022 and 2021, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 73.7%, 73.6% and 74.5% of the Company's revenue for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash in Excess of FDIC Limits</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of January 30, 2023, the Company's uninsured cash deposits are not material. All uninsured bank deposits are held at high quality credit institutions.</span></div> 10 34 0.563 0.540 0.737 0.736 0.745 0 COMMON STOCK REPURCHASE PROGRAM<div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company did not purchase any shares pursuant to this stock repurchase program in the year ended December 31, 2022. The share repurchase program does not obligate the Company to acquire any specific number of shares. </span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from February 10, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended June 30, 2022, the Company repurchased 271 shares of its common stock for $20,000. This repurchase program expired upon the repurchase of the fully authorized amount under the plan and is no longer in effect. </span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2021, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months that started on October 29, 2021. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company repurchased 133 and 132 shares of its common stock for $9,882 and $10,118 during the years ended December 31, 2022 and 2021, respectively. This repurchase program expired upon the repurchase of the fully authorized amount under the plan and is no longer in effect.</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2020 and March 13, 2020, the Board of Directors approved two stock repurchase programs pursuant to which the Company was authorized to repurchase up to $20,000 and $5,000, respectively, of its common stock under the programs for a period of approximately 12 months. Under these programs, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the first quarter of 2020, the Company repurchased 503 and 189 shares of its common stock for $20,000 and $5,000, respectively. These repurchase programs expired upon the repurchase of the full authorized amount under the two plans and are no longer in effect.</span></div> 20000000 P12M 20000000 P12M 271000 20000000 20000000 P12M 133000 132000 9882000 10118000 2 20000000 5000000 P12M 503000 189000 20000000 5000000 2 34 EXCEL 124 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ÿ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�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Ð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�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�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�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

    F3OVM/&%]C5 MCJQ-JB)7ER/N@]^ <88C'=4)I3D*,==P<592#N[-PF=363>X>23\8T M-,_Q_:S%SW2'G^](76-YG7C!NTOULL03\ .2""Z:Q.^!*<:>X*/UR!_1;EYA M>5IXS[;XXGF8&)Y05JB5XN"FI-%E3IF(FST_\315J![R;$N[^$ Y9R_OS,->M*-@FT*.WC1_P+G0S^[&DV_BMON& RX9CX2HCIEJYXN"\ ML "CCU8JX$?E1QLZ5,!)@;B:SNST9KM$/L&!PQ NFRUW9A.1$=B"2?VX.9U& M;_F/5?%9*[3;L+M[]Y]>9?SIL>8%^())//LK_#$(IPI+A2)/YG"0@5@^@5R_BG(ZQ3$"!POP5-P(E"VP!KM' RA(/]B:RC# MJQF'MI:&5LZ@"F\O^J%M^Y?5@_3O8^3[%W]O6E\K?%NL=J>N+='C5<=^Z: M:C0[]W[GW^< Q-5(7#M=D#/4"V4@F!".^X D&+N(.^YID\;1!\\9/%T6YNNS M:QA?.+!L:6)DOI(X8:0MJQ[G('[KQMPM, 31X8C&U"]E^(C"92)P9:O: PL)+;0:DR.\A3\&"FPM" "\1 E/ U8(OP!Y]V<39 MS0/)9D0V_;].^4.LW9&[ZZ_OA7FOV1JUHE\FFRY%[_KA35Q0 Z8T.B,#F M G?#*(D&D^@_IXW4QD6F1V+[9?UB? /\Z#WD=CQCKXXKO?4-OZ;S*H^>ZC\M M^"SR*VIW"2=*P) CE<$Q&Y'8NW[K)\1J",S@%S3&U@\%H3(&(%EXA^O!Z[>YP,&1U/"%FER&Q MHG7TG$9"O) PZ5O6R_NZ/:20%2_2N3(*"_/*"*!FA%DD<4?EQ1/?$5RIJJP3YE X.Z@^>%SIZ#:Q1YT MU$TJI,=!9JH7 VG[ND9GW.&"7^W@4UC+C+$^P=JPO8]12A=J3#H%NL YWLF' MZ"4.K!G1CC(%K4;V[;^&UKM@77 *A)!J( W3\[-%R OW67*O[KR+TS<%[R\_ M&"]E7U\C"O4)/LFM>='[<*I'$$GB(E+.*@%IU#K4V4951SNPJQ/)>)@<;<]= M)VJ*OWL3AWR ?\4WU4D8,8EM2&](L)7U7!_D.2L:R9,:4/X:7+%(1;P372;L M(A6Y^#M.07^=:E'!*!ER))P[L \#QNK@?#&6W4:!E_!,X13>P)#;4\_J/AAQ MV3_>JB<<2%]?^F4@!.H*OX%Z^/_B[BKIMK(RMV"^+.\*C^STUMS<0CF5B?G? M@Q?N]Q;([@W=>@3B,K@.NC]KB%65?03F I!=<+:?E2UF*QSGIK=N.KW3M9G7 M,V_6O]AP>R)/[]+]D%0&N#_\-Q3GK=>>',&U # 1C'Y^ J*7SQO=7;C8F%(P M*OO1Q%LPZU]U,1GFA.!K!JM; MD_9YQK6!B6'7X, UU'T %DP[B/43'*S3F(Z+VWI0@/!FOJ$&3/YANK- ^6E>8$_*B6;R2U:%R M2@[,[16)ZPE43F>#?Z!N_6=<9*%_Y<> MU#Z3"*',@.LDL#5?*C_AF%:0,3#E?./]IR[!]L/.1ZF3QC^I/(Q6V]Y-Q\VP MSIJ79\N@UZC4'Q$LSRMA:/O34VM'^TB;8$,%^2R*V":W#;6G:@5NN*!FV&3S M+N/@T.L1R$R@WOL G&!@W_#/']#0J7.'_K:GY@4QL-TZR6V=R/@ES0$H99UW$%FMI MZ^CG57-\8_9$CP8VUD6V]8]1:4O#FDO#5^HT-$VL45A3 UB3$67>\UA_N7/= MRM8^Q3\TCTJ 39KB)%$UZIUQI'HTM0Q0JV^'V;]M=;,>R]!.+T#4$EN'J['" M*71J!ATJ<)(,@*Z2!;E*5$GO8WL9R5V)-V'?A-S(FU)5O_O6\ZJ!I/:[X:^\SL)N?QMS\.+;S!-I55-5S6R)MA*3[2G <&8\4TKXX/Q: MW5UFR0N01I%X0U;XL<7XQ244EIO(#J,;;[M"^0GFQ60<:X_Z#1(:QI5#52%* M?DAZB:13D,?^6?C (NX^!P@F,SJU+('%N^$1'?#+@*]W*)N@%'ET>I>C4HZIH%@-(D[A+ /G(+^;8D"QO'@%50X23%_"UHC$O^* @8> ME_W>2DN$]@9'MGQZ2OX?YJ\VH%F M@7$/DP&%@&@M-EMW! C];&Y'SJO'VZMA@O3\SLC30H-^U]UH&=^;QP[OWR8\ MT_YF.3QT8,MG%N57=:UZLZEA1AX],7S/69W]=<&NC+I"SU^P)7R>FDH/DFNGV?S<@?JN[7LR0/V/W'.F^WA#RP"T2=J@A M*Z9,@!ORJC0SDUO,9R4BNHE8#8Y/0Z,SNC0#M7U136]?!GQ_>]90FB[NY!34 M"U?!([J]>*' 1M_"E;9)OUSSM4H5X0?OWQ%;D(DWR5K;07)5ZA'A(_0! MJ%A\WQ2::7IP$@GK(@; C(@OJI[B&HP;A_QOV;O?-GULQ2D(SN=:)/P,MARE M2.%%ZR+(116%]LP\;@HHV(G\'FF$9003:-K5>^4N4D>]/,\;@Y(#]H#OJ5,)O,OA#ZG+-;\OJ MKE*9(+C17]+0;,8 X<"DF;I>3)LSF)>?C!JS1=J=?W4QZ?:7+ZAUL=]VDQO] MST-I<"Z$V4EEJ,PMH(XMDU# DEW+H@'TD97M4SF\HTY!@5-C"Q?P\F'+NR+" MB*Z;M?SUOI7/&AM"!T);8_8X1%OAKZ;,<.@5IB0XIP=X-H]K@J47RSZ1,.,J M#\(.[E!^=HC4$3F8@)KW:R;7G\\>?=G]05@Y('I,0;6BF\.&2T=K94)&]R<0 M62=,5*(31DZ 7X'94Q//C3(.%D!26(+P",PP&N?;_7>OQ!*NM3YR)]( M-Y9V'SR<]"*I>ZQ 1#P(34_P=!TA&JH;0[DISA_ZN$4Y,WQ?[/D$"&YH4$DT M_57J_:]3R^QMN(H'N!82U\;C,0N.:]$)]..X$&AS"Q_Y(S*CQF>DS6 UZIH: M$R(KFUO$*N.)<#RX\!3DC@!$C['LQ"?P82U&OOIT5GXEM[EM^R[L1,BTIR6WGI)#:PD#FI M[HA =(@BGG$ 4GFY2VOD8KCPPO>R0%,?P*.;(CQ1.'XDIZ4J_8-K$,PA('U> M-J[#Q'!7+ U%I$=T7$4X) -7D&$J"'KX=P1[X:@SGF<'$D/2_@+]'E*RG?KQ MJ9"Q1D\L<^M [R<'<^R=M>F\<>T_ 81_[60(3*"67'F$ "206 ]\SO)(?!%N MH[-?]A3D9AHO<@WOLYVI10\$>%+2F<(/,_2?)3%[:=2)/+9PBD^H]?0I&$-@ MLJA%[Y'I'$>7);AJ+3E."PR3'&NCAX]9MEW&];UN$PF4N=L<<1\GUY8H8SW[ MHBDUP.;'&O^0\ZT@YQ.K9;31?WRO9IJ; "='MM L*]"11&LF_(R0 D#2OCV^ M(99D U]EV9O8@9;./OSTYW7!KV/!X.2L2/41(+\,X+R'7GA,#D9 M>:8-'/C:78LOTRRM/?M*S8K0#EFTTQ2!K%?-<5%.%*YZI\AV2R+OZDM7NIUL MR?S7+/^9$O'@U^$\OW$CM4;?8352UQ?Q*"O+NNO=)1@^]%]8.(8FVT[[_M>Q MYQ(3?C:;GA6>G]Q>O'@ASGS![(MX[GM<*4@LK9T6S8; U(!Q5KFFA-+)?80S M>J:AFWN6I/SU0U_9]N2> X)[J!CU3(XG.9WC;Z=:@Q M\&T]*+(?ES=968U@ M"VZ@&)61GP?-9#AIRWT:T;29"3@%AG5S@ ]4X&5SYB'*O,U ,Y91IB\^W M2]TE*QUH.*MQ)I=O3P0@PO_8%,L@G@C,)E01UT@8*(FX#%D MH&%0KL>^]LLCS9#*H-.^9N+&6$"?)?V(PY1-($0HZ0^@U'E:5GE9LGH0886Q7+O M7LWP+^!(MU&S!7OK+8+/XJ))E3:]I]C8MW8=LU33K[3H3Z$#+[&9F.2),3-[ MO3#X/)+K%%0#@SC@T":-W;/QK!6WI+9HU?J+R1OTIZ Y2/")3Y-I?!ZD"0QTX%E=5./H,>C1XF677\_"$[&?C'R"/"\&"A_ MT:<\03U<9L=K9I#P91Q^I5R+ U_6XX**G..)6(LC"D\1JX-1VA.A3/T\F\[9 M"XZ-#>D%*>>OW51E2>F_F!355O,&Z%)>DO6JZVIS]P$PA%2R^*S1AM^GN? ^ MBXZ'+7YVEM0"L<7+NP2MWM^]J_'R$A""9\%;6CUB?0K?H 4XEKP,$(<***@? M:J<\6FNP,5D^28U)IF>OJ>,PK7TAL$X.P0@8P9D MEFQ#JB#8F>7G@$^O+U,R3-M!3;!P\_?TW:[R,UW'"9#)Z[-:.EHN:ZWTJ3[& MO*134/;Z^_(5 5F=@+*95T;YT,EF9(9#55T5$&U1<&B7Z4C5-ZCX_']\-5&' MA^8(U04&1/EW _ (PNUDPA!.O@1#K& ,Y3MX6(\[F7C!6*'96ILJEG.9>".F MZL_[TI-O%\-^[:*8R%D0YU-0++*NH9?,BF'JE#%R\YN'N_$M&&UEJP=R79]] M+)X^854J+:IXR6 %Q'4+4@FN]MJ]@*XQQ1H0N8'H!VWG-A?$\%$%2ZV(D*>" M"P2CS9_?-GGEZ;DN$!*F&##(F5>(#@D5CMDI0F?+>%N/2*00X(7YE?2>H0XB M'9BG0=Z7&*E)J#X%C?Q3A=T#0,N&]PLPG;FEWB-[N3I:"<7)CW M(,K]W1+\81HR=8%L=W03R@0^14;0?B,6/HUB7N5@1TU#YXP(OKCB76\BG-*W2-MVR4!F MLVFD\U?CI(-!G&9/:T5+@X]VH_#@^ADVIS VNM0SHBJ+"R1AB5;X=&S"2GHHK=BO1:7[NN MND=1CUBF[_6Y6?AGJ7&5EMDMDGBX>Z#L;;7CS;T7\_3Q6UT.08&!TJGRQ@8%A0+?"$.IAN: M&2RZ%$R\0L^G7ZA/N/HGW4!"WNJ[W*N6]%Q",-QEPW(WC:CF"JG.[&-%1U N M (M+BS&JDY-\QW3=6@+IUK]K2QJ[_9M?[_QFU#@7.,R4/H7-*"$R4(8@W%1. MU&A_%3<2"^?N=ZJ^0PV,!6]/$BPGLARN;=Y_5R0E M21PSLVZ>V4&-&"'%S:!-T!K^=H[S,$<@H@0^LE@/)G$?$#QQD' _,-L/\>A( MV-7GR.Y9F]R\ATFCAD,&NL^<=739ZZIO,*V; A*F$:<@9XXW5.YCC$@"UYKV M<?&2LY(^V>R/DI8 M"JY/>#?GDU#PXFY.4_#LB$F;SJ#X!R>AX>\EF@\LUBR#O:8H-" >2 M \Y+F8"S M16D4&IF9S7QC4=F"UL/JZ'TWL#L\?; _N-AFIZV1L/WHKBVAQ M,^MX^F9LE!G6 >. 4NJ%?3T&1;:I #H4'GHAO-L%;C1_M*$0(3A3, MNL_"XA4?6Y^Q12KZWS7ZD!(MT"6-T@"""U]R\)1>*5^M=<>;U^V/MOX*\6N+ M\AEPNB!3_KG">3+Y86[;<6LS.*>6"DM;JT*G(!:X -"PHM;]@VY)X?7A@5\Y MD&;9,/ZJ7UUY7)_32&2 ^;LFB#XOG:P/'X;2P22(RB1F7'&[%UTO8\Z2)Y_0 M^:)IGM\W$[ZKTY!\].UUJ?3S!UR;VA_40ZKY21*G(*&Z4]#L<4^P/5FIXYQJ MUE)?BM9C%9N84U#P=C W;\TYO8HQSC&TAP?A+&B@#166H>JQ4))/U>H4I'8B MNM]HPX#].L(I7GYH'T]:7 UO\2*, YFGH#.(KMM+0JR)#6T7?5D]-2JJ,?V( M"Z4A45Z&!)-.._]85]1)9E0B::DP7N]^L]1&''K>]";94 MB[/5)D=W*149SU8@?#1W"8OSQ6FIFO=6>(]@HG$+U@CDT?K+AV8Z"#$PU_\! M3G;(CN1P+5E@=)D#NRNHQ)# !JE5N7'N/09ZF[RA^0Y^74!EZG6[@Y*&[=5& MJQN_TJJ-J*R-KCE8O.QGTZMMB^PWO'.2)!G 944A3DLZ6AOGU,SLX)3J,698 ME!]!J7K_BM GEB2SKW!V:^JO;H1+T7;34';BC]8F/N*E.! M)A3]*0_S)Y5BXVSI,0!Y\H;G!!W'I)T@&CBX'Z,)%.\]+&9:? ME/UJT,Q9LY@1GUP<.MIU#*U\G"G+KKJZ+X'VVAF2+/WK7U:TC?^NFE9B,R_V MH.5::\O DIAVW<^W@4X7PV]&3)9;;DI]KDPV5I[X286YWO\LX \\!>U.$)\" MW 1!*V3J3#GM@7CP!@[_L" H\=^%+LZ\Y,7/@4TLN;L77\RE']]1'0PX6K?^\XV M&507T*<95 F9'D,T%>OQB8-E]RB1W91U"&)V: M6GHF;>!>R_[7S'4=@9-K<,7\5K4/SO+OM@ZVKOUWK:7CCGSA\EV-?734PFS2=70QPA@-1&)SH*7.UTC#4EVE(&\20S MW.4=]E+7JWJ5FF\(2C4GB2*'=G.PSCUA :N@5*D%5!AD]S'56RZC$#=(-)19 M@R&?,O0W(**BC1?H(EKTF8ZJ>!VJ52?=)GA<_]G-]KQ*6E3?@*WCP^6]6?1Y M,R.B[[6_I5T'E3:2),76-&.968*Q6V4X9:PW!.STHZBBNC6MR;+N<#/T>QFB MPUW#\C,U:PQ>H+V2HZ%G,H;['N!6!?D:,+MZ5@?P.<<2D:.#R4MKZ"P>'YGG MGD6@2V$7EV$6U"@FP+\WJ<605%:@TWT$T*@6V.,OI%N(@\]=<+VH0I.4R67= MW%@=RY)<8].L]?B9$S3]Y>LOHBON4H.:0QL"4L9:;C<\SM?GS/?,XEOKZJ(. M-!S33"R;O9P*0F;FC$[ A7^92'P;A($,P]LF0(SA#;RDUI^1]RO&.>$/);/) M.IE0(?WJC/6]O5=1D[/TLG_ZAWC-;JVFZH,"KGQ$-:$QK\%4E%*VW/W$U)/, MM04/B*+P=XE4O72\5]B4QE6O&*I=-@S9F::;+);O>#A4]0OWZSBG(7^;8F3V M].IX[[.GNNK?3T%=Z%2((P*3=PJJKLPE"L#[V\X"G#R*"#>KK>6-[@#.)R=_ M/YR"6KYY=NV#=M=***NNZI:UHSH(W:5-\\Z?B8+NHW$&P7(,Q>0IZCJ"> M] 'V,.U65>.\PT>INF2WI6(Q@9P#&LAN;I X0@S([8;,M9A>?Q!0I/<[V7G\ M&#EL#2W5!UH6>8\^.!BY;J*AW=221<+^Z?R/3R!EIA N"C,1%D"%+S@.]C!U M!@A66VK#9G:+/-+DKT*T^U(1,N?*D"\6]C)0TM<$ZF-G$\JU?0JR$74_']R8 M'9>KXN\(HZ52=3U\P2/^M* ,:]Z6]RV_#/]LM'B[[*N5;+::/H$/XJ(C2#

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

    *N;I7CE^O$643/F]IGI.2^C(BADJ"72K8$G*XTX33XM2J,K"20/J'160, MA.)%[_U(4(X\K6RN :S00<<+J2F0A]"Y)AHG""G8SHKHU&SS(%^%C](4"<=) M$A#"XU;BR;%[M=>*+PV2CH+D%[^MY.DWZ:^\T1X@W+S*/$0'/8#,.F++*,+\ M-(Y#\B.@CD0'$843#Q60S]LU)(2 L!*??.F\/K.3XRJ'6O<"[L\:3+\(_?G& MCILW!V<8ZGG?B&V6#B*8(0 %V=U>S=6,8OT$&C/3HSOHC3?ZLS#G4]<\_ M-/;GU4BW&*7I_7^8@07AJ^QN N9$4XL?RMJ1@:70AIKI02#)VZW!Z\SC9UNQ M+R76Q%DR+C)1%7_J2!+HH*3Z+X=HSNW&J.Q7S0

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�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end

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 126 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 127 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 424 492 1 false 134 0 false 22 false false R1.htm 0000001 - Document - Cover Sheet http://www.ensigngroup.net/role/Cover Cover Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.ensigngroup.net/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME Sheet http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME CONSOLIDATED STATEMENTS OF INCOME Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 0000009 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS DESCRIPTION OF BUSINESS Notes 9 false false R10.htm 0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 0000011 - Disclosure - COVID-19 UPDATE Sheet http://www.ensigngroup.net/role/COVID19UPDATE COVID-19 UPDATE Notes 11 false false R12.htm 0000012 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE REVENUE AND ACCOUNTS RECEIVABLE Notes 12 false false R13.htm 0000013 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE Sheet http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE COMPUTATION OF NET INCOME PER COMMON SHARE Notes 13 false false R14.htm 0000014 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 14 false false R15.htm 0000015 - Disclosure - STANDARD BEARER Sheet http://www.ensigngroup.net/role/STANDARDBEARER STANDARD BEARER Notes 15 false false R16.htm 0000016 - Disclosure - BUSINESS SEGMENTS Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTS BUSINESS SEGMENTS Notes 16 false false R17.htm 0000017 - Disclosure - OPERATION EXPANSIONS Sheet http://www.ensigngroup.net/role/OPERATIONEXPANSIONS OPERATION EXPANSIONS Notes 17 false false R18.htm 0000018 - Disclosure - PROPERTY AND EQUIPMENT??? NET Sheet http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET PROPERTY AND EQUIPMENT??? NET Notes 18 false false R19.htm 0000019 - Disclosure - INTANGIBLE ASSETS ??? NET Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNET INTANGIBLE ASSETS ??? NET Notes 19 false false R20.htm 0000020 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS Sheet http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETS GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS Notes 20 false false R21.htm 0000021 - Disclosure - RESTRICTED AND OTHER ASSETS Sheet http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS RESTRICTED AND OTHER ASSETS Notes 21 false false R22.htm 0000022 - Disclosure - OTHER ACCRUED LIABILITIES Sheet http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES OTHER ACCRUED LIABILITIES Notes 22 false false R23.htm 0000023 - Disclosure - INCOME TAXES Sheet http://www.ensigngroup.net/role/INCOMETAXES INCOME TAXES Notes 23 false false R24.htm 0000024 - Disclosure - DEBT Sheet http://www.ensigngroup.net/role/DEBT DEBT Notes 24 false false R25.htm 0000025 - Disclosure - OPTIONS AND AWARDS Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDS OPTIONS AND AWARDS Notes 25 false false R26.htm 0000026 - Disclosure - LEASES Sheet http://www.ensigngroup.net/role/LEASES LEASES Notes 26 false false R27.htm 0000027 - Disclosure - SELF INSURANCE LIABILITIES Sheet http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES SELF INSURANCE LIABILITIES Notes 27 false false R28.htm 0000028 - Disclosure - DEFINED CONTRIBUTION PLANS Sheet http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS DEFINED CONTRIBUTION PLANS Notes 28 false false R29.htm 0000029 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 29 false false R30.htm 0000030 - Disclosure - COMMON STOCK REPURCHASE PROGRAM Sheet http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM COMMON STOCK REPURCHASE PROGRAM Notes 30 false false R31.htm 0000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 31 false false R32.htm 0000032 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables) Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables REVENUE AND ACCOUNTS RECEIVABLE (Tables) Tables http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE 32 false false R33.htm 0000033 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables) Sheet http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables COMPUTATION OF NET INCOME PER COMMON SHARE (Tables) Tables http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE 33 false false R34.htm 0000034 - Disclosure - BUSINESS SEGMENTS (Tables) Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables BUSINESS SEGMENTS (Tables) Tables http://www.ensigngroup.net/role/BUSINESSSEGMENTS 34 false false R35.htm 0000035 - Disclosure - OPERATION EXPANSIONS (Tables) Sheet http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables OPERATION EXPANSIONS (Tables) Tables http://www.ensigngroup.net/role/OPERATIONEXPANSIONS 35 false false R36.htm 0000036 - Disclosure - PROPERTY AND EQUIPMENT??? NET (Tables) Sheet http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables PROPERTY AND EQUIPMENT??? NET (Tables) Tables http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET 36 false false R37.htm 0000037 - Disclosure - INTANGIBLE ASSETS ??? NET (Tables) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables INTANGIBLE ASSETS ??? NET (Tables) Tables http://www.ensigngroup.net/role/INTANGIBLEASSETSNET 37 false false R38.htm 0000038 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS (Tables) Sheet http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSTables GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS (Tables) Tables http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETS 38 false false R39.htm 0000039 - Disclosure - RESTRICTED AND OTHER ASSETS (Tables) Sheet http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables RESTRICTED AND OTHER ASSETS (Tables) Tables http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS 39 false false R40.htm 0000040 - Disclosure - OTHER ACCRUED LIABILITIES (Tables) Sheet http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables OTHER ACCRUED LIABILITIES (Tables) Tables http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES 40 false false R41.htm 0000041 - Disclosure - INCOME TAXES (Tables) Sheet http://www.ensigngroup.net/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://www.ensigngroup.net/role/INCOMETAXES 41 false false R42.htm 0000042 - Disclosure - DEBT (Tables) Sheet http://www.ensigngroup.net/role/DEBTTables DEBT (Tables) Tables http://www.ensigngroup.net/role/DEBT 42 false false R43.htm 0000043 - Disclosure - OPTIONS AND AWARDS (Tables) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables OPTIONS AND AWARDS (Tables) Tables http://www.ensigngroup.net/role/OPTIONSANDAWARDS 43 false false R44.htm 0000044 - Disclosure - LEASES (Tables) Sheet http://www.ensigngroup.net/role/LEASESTables LEASES (Tables) Tables http://www.ensigngroup.net/role/LEASES 44 false false R45.htm 0000045 - Disclosure - SELF INSURANCE LIABILITIES (Tables) Sheet http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables SELF INSURANCE LIABILITIES (Tables) Tables http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES 45 false false R46.htm 0000046 - Disclosure - DESCRIPTION OF BUSINESS (Details) Sheet http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails DESCRIPTION OF BUSINESS (Details) Details http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS 46 false false R47.htm 0000047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Details 47 false false R48.htm 0000048 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details) Details 48 false false R49.htm 0000049 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of Long-Lived Assets (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESImpairmentofLongLivedAssetsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of Long-Lived Assets (Details) Details 49 false false R50.htm 0000050 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details) Details 50 false false R51.htm 0000051 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) Details 51 false false R52.htm 0000052 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recent Accounting Pronouncements (Details) Sheet http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecentAccountingPronouncementsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recent Accounting Pronouncements (Details) Details 52 false false R53.htm 0000053 - Disclosure - COVID-19 UPDATE (Details) Sheet http://www.ensigngroup.net/role/COVID19UPDATEDetails COVID-19 UPDATE (Details) Details http://www.ensigngroup.net/role/COVID19UPDATE 53 false false R54.htm 0000054 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Revenue from Medicare and Medicaid Programs (Details) Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails REVENUE AND ACCOUNTS RECEIVABLE - Revenue from Medicare and Medicaid Programs (Details) Details 54 false false R55.htm 0000055 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) Details 55 false false R56.htm 0000056 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) Sheet http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) Details 56 false false R57.htm 0000057 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Details) Sheet http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails COMPUTATION OF NET INCOME PER COMMON SHARE (Details) Details http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables 57 false false R58.htm 0000058 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails FAIR VALUE MEASUREMENTS (Details) Details http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS 58 false false R59.htm 0000059 - Disclosure - STANDARD BEARER (Details) Sheet http://www.ensigngroup.net/role/STANDARDBEARERDetails STANDARD BEARER (Details) Details http://www.ensigngroup.net/role/STANDARDBEARER 59 false false R60.htm 0000060 - Disclosure - BUSINESS SEGMENTS - Narrative (Details) Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails BUSINESS SEGMENTS - Narrative (Details) Details 60 false false R61.htm 0000061 - Disclosure - BUSINESS SEGMENTS - Schedule of Segment Reporting Information (Details) Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails BUSINESS SEGMENTS - Schedule of Segment Reporting Information (Details) Details 61 false false R62.htm 0000062 - Disclosure - BUSINESS SEGMENTS - Revenue by Segment (Details) Sheet http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails BUSINESS SEGMENTS - Revenue by Segment (Details) Details 62 false false R63.htm 0000063 - Disclosure - OPERATION EXPANSIONS (Details) Sheet http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails OPERATION EXPANSIONS (Details) Details http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables 63 false false R64.htm 0000064 - Disclosure - OPERATION EXPANSIONS - Purchase Price Allocation (Details) Sheet http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails OPERATION EXPANSIONS - Purchase Price Allocation (Details) Details 64 false false R65.htm 0000065 - Disclosure - PROPERTY AND EQUIPMENT??? NET - Summary (Details) Sheet http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails PROPERTY AND EQUIPMENT??? NET - Summary (Details) Details 65 false false R66.htm 0000066 - Disclosure - PROPERTY AND EQUIPMENT??? NET - Narrative (Details) Sheet http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails PROPERTY AND EQUIPMENT??? NET - Narrative (Details) Details 66 false false R67.htm 0000067 - Disclosure - INTANGIBLE ASSETS ??? NET - Schedule of Finite Lived Intangible Assets (Details) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails INTANGIBLE ASSETS ??? NET - Schedule of Finite Lived Intangible Assets (Details) Details 67 false false R68.htm 0000068 - Disclosure - INTANGIBLE ASSETS ??? NET - Narrative (Details) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails INTANGIBLE ASSETS ??? NET - Narrative (Details) Details 68 false false R69.htm 0000069 - Disclosure - INTANGIBLE ASSETS ??? NET - Future Amortization (Details) Sheet http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails INTANGIBLE ASSETS ??? NET - Future Amortization (Details) Details 69 false false R70.htm 0000070 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSNarrativeDetails GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Narrative (Details) Details http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSTables 70 false false R71.htm 0000071 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Goodwill Rollforward (Details) Sheet http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Goodwill Rollforward (Details) Details 71 false false R72.htm 0000072 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Indefinite-Lived Intangible Assets (Details) Sheet http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSIndefiniteLivedIntangibleAssetsDetails GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Indefinite-Lived Intangible Assets (Details) Details 72 false false R73.htm 0000073 - Disclosure - RESTRICTED AND OTHER ASSETS - Summary (Details) Sheet http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails RESTRICTED AND OTHER ASSETS - Summary (Details) Details 73 false false R74.htm 0000074 - Disclosure - OTHER ACCRUED LIABILITIES (Details) Sheet http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails OTHER ACCRUED LIABILITIES (Details) Details http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables 74 false false R75.htm 0000075 - Disclosure - INCOME TAXES - Expense (Details) Sheet http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails INCOME TAXES - Expense (Details) Details 75 false false R76.htm 0000076 - Disclosure - INCOME TAXES - Tax Rate (Details) Sheet http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails INCOME TAXES - Tax Rate (Details) Details 76 false false R77.htm 0000077 - Disclosure - INCOME TAXES - Narrative (YE) (Details) Sheet http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails INCOME TAXES - Narrative (YE) (Details) Details 77 false false R78.htm 0000078 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details) Sheet http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails INCOME TAXES - Deferred Tax Assets and Liabilities (Details) Details 78 false false R79.htm 0000079 - Disclosure - DEBT - Schedule of Long-term Debt (Details) Sheet http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails DEBT - Schedule of Long-term Debt (Details) Details 79 false false R80.htm 0000080 - Disclosure - DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details) Sheet http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details) Details 80 false false R81.htm 0000081 - Disclosure - DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) Notes http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) Details 81 false false R82.htm 0000082 - Disclosure - DEBT - Long-term Debt Arrangements (Details) Sheet http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails DEBT - Long-term Debt Arrangements (Details) Details 82 false false R83.htm 0000083 - Disclosure - OPTIONS AND AWARDS - Stock Options, Narrative (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails OPTIONS AND AWARDS - Stock Options, Narrative (Details) Details 83 false false R84.htm 0000084 - Disclosure - OPTIONS AND AWARDS - Valuation Assumptions (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails OPTIONS AND AWARDS - Valuation Assumptions (Details) Details 84 false false R85.htm 0000085 - Disclosure - OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) Details 85 false false R86.htm 0000086 - Disclosure - OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) Details 86 false false R87.htm 0000087 - Disclosure - OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details) Details 87 false false R88.htm 0000088 - Disclosure - OPTIONS AND AWARDS - Intrinsic Values (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails OPTIONS AND AWARDS - Intrinsic Values (Details) Details 88 false false R89.htm 0000089 - Disclosure - OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) Details 89 false false R90.htm 0000090 - Disclosure - OPTIONS AND AWARDS - Restricted Award Rollforward (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails OPTIONS AND AWARDS - Restricted Award Rollforward (Details) Details 90 false false R91.htm 0000091 - Disclosure - OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) Details 91 false false R92.htm 0000092 - Disclosure - OPTIONS AND AWARDS - Compensation Expense (Details) Sheet http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails OPTIONS AND AWARDS - Compensation Expense (Details) Details 92 false false R93.htm 0000093 - Disclosure - LEASES - Lessee Narrative (Details) Sheet http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails LEASES - Lessee Narrative (Details) Details 93 false false R94.htm 0000094 - Disclosure - LEASES - Lessee Lease Cost (Details) Sheet http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails LEASES - Lessee Lease Cost (Details) Details 94 false false R95.htm 0000095 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details) Sheet http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails LEASES - Lessee Future Minimum Lease Payments (Details) Details 95 false false R96.htm 0000096 - Disclosure - LEASES - Lessor Narrative (Details) Sheet http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails LEASES - Lessor Narrative (Details) Details 96 false false R97.htm 0000097 - Disclosure - LEASES - Lessor Rental Income (Details) Sheet http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails LEASES - Lessor Rental Income (Details) Details 97 false false R98.htm 0000098 - Disclosure - LEASES - Lessor Future Minimum Lease Payments Receivable (Details) Sheet http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails LEASES - Lessor Future Minimum Lease Payments Receivable (Details) Details 98 false false R99.htm 0000099 - Disclosure - SELF INSURANCE LIABILITIES (Details) Sheet http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails SELF INSURANCE LIABILITIES (Details) Details http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables 99 false false R100.htm 0000100 - Disclosure - DEFINED CONTRIBUTION PLANS (Details) Sheet http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails DEFINED CONTRIBUTION PLANS (Details) Details http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS 100 false false R101.htm 0000101 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES 101 false false R102.htm 0000102 - Disclosure - COMMON STOCK REPURCHASE PROGRAM (Details) Sheet http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails COMMON STOCK REPURCHASE PROGRAM (Details) Details http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM 102 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: ensg:DebtInstrumentPrePaymentFeeReductionTerm, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:PropertyPlantAndEquipmentUsefulLife - ensg-20221231.htm 4 [dqc-0015-Negative-Values] Fact us-gaap:DeferredTaxAssetsStateTaxes has a value of -165000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:DeferredTaxAssetsStateTaxes fact are: Context: i70d41dd9a07140c6b3c8a87b4a7465ad_I20211231, Unit: usd, Rule Element Id: 628. ensg-20221231.htm 4 ensg-20221231.htm ensg-20221231.xsd ensg-20221231_cal.xml ensg-20221231_def.xml ensg-20221231_lab.xml ensg-20221231_pre.xml ensg123122ex102.htm ensg123122ex103.htm ensg123122ex211.htm ensg123122ex231.htm ensgq42022ex311.htm ensgq42022ex312.htm ensgq42022ex321.htm ensgq42022ex322.htm ensg-20221231_g1.jpg ensg-20221231_g2.jpg ensg-20221231_g3.jpg ensg-20221231_g4.jpg ensg-20221231_g5.jpg ensg-20221231_g6.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 130 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ensg-20221231.htm": { "axisCustom": 4, "axisStandard": 38, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 1416, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 424, "dts": { "calculationLink": { "local": [ "ensg-20221231_cal.xml" ] }, "definitionLink": { "local": [ "ensg-20221231_def.xml" ] }, "inline": { "local": [ "ensg-20221231.htm" ] }, "labelLink": { "local": [ "ensg-20221231_lab.xml" ] }, "presentationLink": { "local": [ "ensg-20221231_pre.xml" ] }, "schema": { "local": [ "ensg-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 810, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 5, "http://www.ensigngroup.net/20221231": 3, "http://xbrl.sec.gov/dei/2022": 4, "total": 12 }, "keyCustom": 89, "keyStandard": 403, "memberCustom": 73, "memberStandard": 55, "nsprefix": "ensg", "nsuri": "http://www.ensigngroup.net/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.ensigngroup.net/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "10", "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000100 - Disclosure - DEFINED CONTRIBUTION PLANS (Details)", "menuCat": "Details", "order": "100", "role": "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails", "shortName": "DEFINED CONTRIBUTION PLANS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i7513cb0b514741858809122863c84d3f_D20180531-20180531", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:LossContingencyIndependentOperatingFacilitiesIncludedInScope", "reportCount": 1, "unique": true, "unitRef": "operating_entity", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000101 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "menuCat": "Details", "order": "101", "role": "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i7513cb0b514741858809122863c84d3f_D20180531-20180531", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:LossContingencyIndependentOperatingFacilitiesIncludedInScope", "reportCount": 1, "unique": true, "unitRef": "operating_entity", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000102 - Disclosure - COMMON STOCK REPURCHASE PROGRAM (Details)", "menuCat": "Details", "order": "102", "role": "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails", "shortName": "COMMON STOCK REPURCHASE PROGRAM (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "id1a8c7cbf9da41d0b12e386010cfa503_I20200313", "decimals": "INF", "lang": "en-US", "name": "ensg:NumberOfStockRepurchasePrograms", "reportCount": 1, "unique": true, "unitRef": "repurchase_program", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - COVID-19 UPDATE", "menuCat": "Notes", "order": "11", "role": "http://www.ensigngroup.net/role/COVID19UPDATE", "shortName": "COVID-19 UPDATE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE", "menuCat": "Notes", "order": "12", "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE", "menuCat": "Notes", "order": "13", "role": "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - FAIR VALUE MEASUREMENTS", "menuCat": "Notes", "order": "14", "role": "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ensg:StandardBearerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - STANDARD BEARER", "menuCat": "Notes", "order": "15", "role": "http://www.ensigngroup.net/role/STANDARDBEARER", "shortName": "STANDARD BEARER", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ensg:StandardBearerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - BUSINESS SEGMENTS", "menuCat": "Notes", "order": "16", "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTS", "shortName": "BUSINESS SEGMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - OPERATION EXPANSIONS", "menuCat": "Notes", "order": "17", "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONS", "shortName": "OPERATION EXPANSIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET", "menuCat": "Notes", "order": "18", "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET", "shortName": "PROPERTY AND EQUIPMENT\u2014 NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - INTANGIBLE ASSETS \u2014 NET", "menuCat": "Notes", "order": "19", "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNET", "shortName": "INTANGIBLE ASSETS \u2014 NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "menuCat": "Cover", "order": "2", "role": "http://www.ensigngroup.net/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS", "menuCat": "Notes", "order": "20", "role": "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETS", "shortName": "GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - RESTRICTED AND OTHER ASSETS", "menuCat": "Notes", "order": "21", "role": "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS", "shortName": "RESTRICTED AND OTHER ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - OTHER ACCRUED LIABILITIES", "menuCat": "Notes", "order": "22", "role": "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES", "shortName": "OTHER ACCRUED LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "23", "role": "http://www.ensigngroup.net/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - DEBT", "menuCat": "Notes", "order": "24", "role": "http://www.ensigngroup.net/role/DEBT", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - OPTIONS AND AWARDS", "menuCat": "Notes", "order": "25", "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDS", "shortName": "OPTIONS AND AWARDS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - LEASES", "menuCat": "Notes", "order": "26", "role": "http://www.ensigngroup.net/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - SELF INSURANCE LIABILITIES", "menuCat": "Notes", "order": "27", "role": "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES", "shortName": "SELF INSURANCE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - DEFINED CONTRIBUTION PLANS", "menuCat": "Notes", "order": "28", "role": "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS", "shortName": "DEFINED CONTRIBUTION PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "29", "role": "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "3", "role": "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - COMMON STOCK REPURCHASE PROGRAM", "menuCat": "Notes", "order": "30", "role": "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM", "shortName": "COMMON STOCK REPURCHASE PROGRAM", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "31", "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - BUSINESS SEGMENTS (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables", "shortName": "BUSINESS SEGMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - OPERATION EXPANSIONS (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables", "shortName": "OPERATION EXPANSIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables", "shortName": "PROPERTY AND EQUIPMENT\u2014 NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - INTANGIBLE ASSETS \u2014 NET (Tables)", "menuCat": "Tables", "order": "37", "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables", "shortName": "INTANGIBLE ASSETS \u2014 NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS (Tables)", "menuCat": "Tables", "order": "38", "role": "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSTables", "shortName": "GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - RESTRICTED AND OTHER ASSETS (Tables)", "menuCat": "Tables", "order": "39", "role": "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables", "shortName": "RESTRICTED AND OTHER ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "4", "role": "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - OTHER ACCRUED LIABILITIES (Tables)", "menuCat": "Tables", "order": "40", "role": "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables", "shortName": "OTHER ACCRUED LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "41", "role": "http://www.ensigngroup.net/role/INCOMETAXESTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - DEBT (Tables)", "menuCat": "Tables", "order": "42", "role": "http://www.ensigngroup.net/role/DEBTTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - OPTIONS AND AWARDS (Tables)", "menuCat": "Tables", "order": "43", "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables", "shortName": "OPTIONS AND AWARDS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - LEASES (Tables)", "menuCat": "Tables", "order": "44", "role": "http://www.ensigngroup.net/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - SELF INSURANCE LIABILITIES (Tables)", "menuCat": "Tables", "order": "45", "role": "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables", "shortName": "SELF INSURANCE LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ensg:NumberOfHealthCareFacilities", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - DESCRIPTION OF BUSINESS (Details)", "menuCat": "Details", "order": "46", "role": "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "shortName": "DESCRIPTION OF BUSINESS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ensg:NumberOfHealthCareFacilities", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "iecfc134d3908492b88310d1dd019292c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "menuCat": "Details", "order": "47", "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "iecfc134d3908492b88310d1dd019292c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)", "menuCat": "Details", "order": "48", "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "INF", "lang": "en-US", "name": "ensg:LesseeOperatingLeaseNumberOfRenewalOptions", "reportCount": 1, "unique": true, "unitRef": "renewal_option", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of Long-Lived Assets (Details)", "menuCat": "Details", "order": "49", "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESImpairmentofLongLivedAssetsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of Long-Lived Assets (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME", "menuCat": "Statements", "order": "5", "role": "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "shortName": "CONSOLIDATED STATEMENTS OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i6d9cbf56f8364a958e53808a311b21ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)", "menuCat": "Details", "order": "50", "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i6d9cbf56f8364a958e53808a311b21ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SelfInsuranceReservePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i77f6c717505d441b9663063ea83644ce_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details)", "menuCat": "Details", "order": "51", "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SelfInsuranceReservePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i77f6c717505d441b9663063ea83644ce_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "ie12d350a5340446ca242bc3d34f8199a_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recent Accounting Pronouncements (Details)", "menuCat": "Details", "order": "52", "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecentAccountingPronouncementsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recent Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "ie12d350a5340446ca242bc3d34f8199a_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - COVID-19 UPDATE (Details)", "menuCat": "Details", "order": "53", "role": "http://www.ensigngroup.net/role/COVID19UPDATEDetails", "shortName": "COVID-19 UPDATE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "ieca882f796024dcbba3c55f0e299fd9c_D20220101-20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Revenue from Medicare and Medicaid Programs (Details)", "menuCat": "Details", "order": "54", "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - Revenue from Medicare and Medicaid Programs (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)", "menuCat": "Details", "order": "55", "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details)", "menuCat": "Details", "order": "56", "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Details)", "menuCat": "Details", "order": "57", "role": "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i4661641089ff470e8768abfbf6b00069_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "menuCat": "Details", "order": "58", "role": "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i4661641089ff470e8768abfbf6b00069_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - STANDARD BEARER (Details)", "menuCat": "Details", "order": "59", "role": "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "shortName": "STANDARD BEARER (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i9a40dda2fe3c4b8f80ea67765e1a03d2_D20220101-20220131", "decimals": "INF", "lang": "en-US", "name": "ensg:NumberOfLeaseArrangements", "reportCount": 1, "unique": true, "unitRef": "lease", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i31f5544c26ec4ee4b058e3310f117922_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "menuCat": "Statements", "order": "6", "role": "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i31f5544c26ec4ee4b058e3310f117922_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "ic53fe94440064b2399e0712139547a84_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - BUSINESS SEGMENTS - Narrative (Details)", "menuCat": "Details", "order": "60", "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "shortName": "BUSINESS SEGMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "ic53fe94440064b2399e0712139547a84_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - BUSINESS SEGMENTS - Schedule of Segment Reporting Information (Details)", "menuCat": "Details", "order": "61", "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "shortName": "BUSINESS SEGMENTS - Schedule of Segment Reporting Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ensg:SegmentIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - BUSINESS SEGMENTS - Revenue by Segment (Details)", "menuCat": "Details", "order": "62", "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "shortName": "BUSINESS SEGMENTS - Revenue by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i0f0807fac5334932850ef19ce7487544_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-2", "first": true, "lang": "en-US", "name": "ensg:OperationalSkilledNursingBeds", "reportCount": 1, "unitRef": "bed", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - OPERATION EXPANSIONS (Details)", "menuCat": "Details", "order": "63", "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "shortName": "OPERATION EXPANSIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ensg:PaymentsToAcquireBusinessAndAssetAcquisitions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - OPERATION EXPANSIONS - Purchase Price Allocation (Details)", "menuCat": "Details", "order": "64", "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "shortName": "OPERATION EXPANSIONS - Purchase Price Allocation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i0e1453e4a91c4526b5a5bfa86eb09edf_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ensg:LeasedAssetsAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET - Summary (Details)", "menuCat": "Details", "order": "65", "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails", "shortName": "PROPERTY AND EQUIPMENT\u2014 NET - Summary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET - Narrative (Details)", "menuCat": "Details", "order": "66", "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails", "shortName": "PROPERTY AND EQUIPMENT\u2014 NET - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i03a3b518c030475ab3e2b4be0fbaa64e_D20200101-20201231", "decimals": null, "lang": "en-US", "name": "ensg:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Schedule of Finite Lived Intangible Assets (Details)", "menuCat": "Details", "order": "67", "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "shortName": "INTANGIBLE ASSETS \u2014 NET - Schedule of Finite Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Narrative (Details)", "menuCat": "Details", "order": "68", "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "shortName": "INTANGIBLE ASSETS \u2014 NET - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Future Amortization (Details)", "menuCat": "Details", "order": "69", "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails", "shortName": "INTANGIBLE ASSETS \u2014 NET - Future Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Narrative (Details)", "menuCat": "Details", "order": "70", "role": "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSNarrativeDetails", "shortName": "GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i70d41dd9a07140c6b3c8a87b4a7465ad_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Goodwill Rollforward (Details)", "menuCat": "Details", "order": "71", "role": "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails", "shortName": "GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Goodwill Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i73fb16855d5d43a49097547eb3b726a1_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Indefinite-Lived Intangible Assets (Details)", "menuCat": "Details", "order": "72", "role": "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSIndefiniteLivedIntangibleAssetsDetails", "shortName": "GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS - Indefinite-Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i7f69dbc1d3014d129181c3d7b57ca590_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - RESTRICTED AND OTHER ASSETS - Summary (Details)", "menuCat": "Details", "order": "73", "role": "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails", "shortName": "RESTRICTED AND OTHER ASSETS - Summary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ensg:QualityAssuranceFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - OTHER ACCRUED LIABILITIES (Details)", "menuCat": "Details", "order": "74", "role": "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails", "shortName": "OTHER ACCRUED LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ensg:QualityAssuranceFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - INCOME TAXES - Expense (Details)", "menuCat": "Details", "order": "75", "role": "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails", "shortName": "INCOME TAXES - Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - INCOME TAXES - Tax Rate (Details)", "menuCat": "Details", "order": "76", "role": "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails", "shortName": "INCOME TAXES - Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - INCOME TAXES - Narrative (YE) (Details)", "menuCat": "Details", "order": "77", "role": "http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails", "shortName": "INCOME TAXES - Narrative (YE) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details)", "menuCat": "Details", "order": "78", "role": "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails", "shortName": "INCOME TAXES - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - DEBT - Schedule of Long-term Debt (Details)", "menuCat": "Details", "order": "79", "role": "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails", "shortName": "DEBT - Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "8", "role": "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:WriteOffOfDeferredDebtIssuanceCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)", "menuCat": "Details", "order": "80", "role": "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "shortName": "DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "iaced0d2a1a7f4a18a389ef7b2fee385f_I20220408", "decimals": "INF", "lang": "en-US", "name": "ensg:TotalNetDebtRatioMaximum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)", "menuCat": "Details", "order": "81", "role": "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "shortName": "DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LettersOfCreditOutstandingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - DEBT - Long-term Debt Arrangements (Details)", "menuCat": "Details", "order": "82", "role": "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails", "shortName": "DEBT - Long-term Debt Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:NumberOfOptionPlans", "reportCount": 1, "unique": true, "unitRef": "repurchase_program", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - OPTIONS AND AWARDS - Stock Options, Narrative (Details)", "menuCat": "Details", "order": "83", "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "shortName": "OPTIONS AND AWARDS - Stock Options, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:NumberOfOptionPlans", "reportCount": 1, "unique": true, "unitRef": "repurchase_program", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000084 - Disclosure - OPTIONS AND AWARDS - Valuation Assumptions (Details)", "menuCat": "Details", "order": "84", "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails", "shortName": "OPTIONS AND AWARDS - Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000085 - Disclosure - OPTIONS AND AWARDS - Exercise Price and Fair Value (Details)", "menuCat": "Details", "order": "85", "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails", "shortName": "OPTIONS AND AWARDS - Exercise Price and Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "2", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i70d41dd9a07140c6b3c8a87b4a7465ad_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000086 - Disclosure - OPTIONS AND AWARDS - Options Outstanding Rollforward (Details)", "menuCat": "Details", "order": "86", "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails", "shortName": "OPTIONS AND AWARDS - Options Outstanding Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i73fb16855d5d43a49097547eb3b726a1_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000087 - Disclosure - OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details)", "menuCat": "Details", "order": "87", "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails", "shortName": "OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000088 - Disclosure - OPTIONS AND AWARDS - Intrinsic Values (Details)", "menuCat": "Details", "order": "88", "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails", "shortName": "OPTIONS AND AWARDS - Intrinsic Values (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ensg:SharebasedCompensationRestrictedAwardsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000089 - Disclosure - OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details)", "menuCat": "Details", "order": "89", "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "shortName": "OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ensg:SharebasedCompensationRestrictedAwardsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - DESCRIPTION OF BUSINESS", "menuCat": "Notes", "order": "9", "role": "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS", "shortName": "DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i55508559bf7a4476acafc73e0106bbc5_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000090 - Disclosure - OPTIONS AND AWARDS - Restricted Award Rollforward (Details)", "menuCat": "Details", "order": "90", "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "shortName": "OPTIONS AND AWARDS - Restricted Award Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i68f48cbef3a7428ca9f238ec83f3b917_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000091 - Disclosure - OPTIONS AND AWARDS - Long-Term Incentive Plan (Details)", "menuCat": "Details", "order": "91", "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "shortName": "OPTIONS AND AWARDS - Long-Term Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "ia3bf397768f84c43b8c3a0260cd66fa4_I20190827", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000092 - Disclosure - OPTIONS AND AWARDS - Compensation Expense (Details)", "menuCat": "Details", "order": "92", "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "shortName": "OPTIONS AND AWARDS - Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000093 - Disclosure - LEASES - Lessee Narrative (Details)", "menuCat": "Details", "order": "93", "role": "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "shortName": "LEASES - Lessee Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ensg:ReductionOfRightOfUseAssetOperatingLeaseLiabilityDueToAcquiringLeasedAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000094 - Disclosure - LEASES - Lessee Lease Cost (Details)", "menuCat": "Details", "order": "94", "role": "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "shortName": "LEASES - Lessee Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000095 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details)", "menuCat": "Details", "order": "95", "role": "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails", "shortName": "LEASES - Lessee Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000096 - Disclosure - LEASES - Lessor Narrative (Details)", "menuCat": "Details", "order": "96", "role": "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "shortName": "LEASES - Lessor Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i302630d1dfbb40e999d2644cffdb64a2_I20221231", "decimals": null, "lang": "en-US", "name": "us-gaap:LessorOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "idab46df91e74473ba0b934193314703d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000097 - Disclosure - LEASES - Lessor Rental Income (Details)", "menuCat": "Details", "order": "97", "role": "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "shortName": "LEASES - Lessor Rental Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i9d2761ab024c42b3844c847d18a2dc45_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OperatingLeaseVariableLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000098 - Disclosure - LEASES - Lessor Future Minimum Lease Payments Receivable (Details)", "menuCat": "Details", "order": "98", "role": "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails", "shortName": "LEASES - Lessor Future Minimum Lease Payments Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i24a0217957c04b1296cafb61b36352b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i70d41dd9a07140c6b3c8a87b4a7465ad_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000099 - Disclosure - SELF INSURANCE LIABILITIES (Details)", "menuCat": "Details", "order": "99", "role": "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails", "shortName": "SELF INSURANCE LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20221231.htm", "contextRef": "i0fc32122aa6c45bcadae57ee9978ce19_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 134, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "verboseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r690" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r691" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r692" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "ensg_A2017PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2017 Plan", "label": "2017 Plan [Member]", "terseLabel": "2017 Plan" } } }, "localname": "A2017PlanMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_A2019LTIPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 LTI Plan [Member]", "label": "2019 LTI Plan [Member]", "terseLabel": "2019 LTI Plan" } } }, "localname": "A2019LTIPlanMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "ensg_A2022PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Plan", "label": "2022 Plan [Member]", "terseLabel": "2022 Plan" } } }, "localname": "A2022PlanMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_AccruedLiabilitiesStateReliefContractLiabilities": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Liabilities, State Relief Contract Liabilities", "label": "Accrued Liabilities, State Relief Contract Liabilities", "terseLabel": "Unapplied state relief funds" } } }, "localname": "AccruedLiabilitiesStateReliefContractLiabilities", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails", "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "ensg_AdditionalMasterLeaserAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Master Leaser Agreements", "label": "Additional Master Leaser Agreements", "terseLabel": "Additional master lease agreement" } } }, "localname": "AdditionalMasterLeaserAgreements", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_AggregateDeductibleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate Deductible [Member]", "label": "Aggregate Deductible [Member]", "terseLabel": "Aggregate Deductible" } } }, "localname": "AggregateDeductibleMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_AllStatesExceptColoradoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All States Except Colorado [Domain]", "label": "All States Except Colorado [Member]", "terseLabel": "All States Except Colorado" } } }, "localname": "AllStatesExceptColoradoMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_AmendedMasterLeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended Master Lease Agreement", "label": "Amended Master Lease Agreement [Member]", "terseLabel": "Amended Master Lease Agreement" } } }, "localname": "AmendedMasterLeaseAgreementMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_AmendedMasterLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended Master Lease", "label": "Amended Master Lease [Member]", "terseLabel": "Amended Master Lease" } } }, "localname": "AmendedMasterLeaseMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_AmendedSeparateMasterLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended Separate Master Leases", "label": "Amended Separate Master Leases", "terseLabel": "Amended of separate master leases" } } }, "localname": "AmendedSeparateMasterLeases", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_AssembledOccupancyAcquiredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assembled occupancy acquired [Member]", "label": "Assembled Occupancy Acquired [Member]", "terseLabel": "Assembled occupancy", "verboseLabel": "Assembled occupancy" } } }, "localname": "AssembledOccupancyAcquiredMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "ensg_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Assets Acquired and Liabilities Assumed, Net", "label": "Asset Acquisition, Assets Acquired and Liabilities Assumed, Net", "totalLabel": "TOTAL ACQUISITIONS" } } }, "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "ensg_AssetAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "These acquisitions were classified as asset acquisitions in accordance with ASC 805.", "label": "Asset Acquisition [Member]", "terseLabel": "Asset Acquisition" } } }, "localname": "AssetAcquisitionMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "xbrltype": "domainItemType" }, "ensg_AssetsAdjustedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets, Adjusted Cost", "label": "Assets, Adjusted Cost", "terseLabel": "Adjusted cost" } } }, "localname": "AssetsAdjustedCost", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "xbrltype": "monetaryItemType" }, "ensg_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.ensigngroup.net/20221231", "xbrltype": "stringItemType" }, "ensg_BlanketAggregateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Blanket Aggregate [Member]", "label": "Blanket Aggregate [Member]", "terseLabel": "Blanket Aggregate" } } }, "localname": "BlanketAggregateMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_CampusOperationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Campus Operation", "label": "Campus Operation [Member]", "terseLabel": "Campus Operation" } } }, "localname": "CampusOperationMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "domainItemType" }, "ensg_CareTrustREITMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CareTrust REIT [Member]", "label": "CareTrust REIT [Member]", "terseLabel": "CareTrust REIT" } } }, "localname": "CareTrustREITMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_CashHeldInTrustForResidents": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "order": 9.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds.", "label": "Cash Held in Trust for Residents", "terseLabel": "Cash held in trust for patients" } } }, "localname": "CashHeldInTrustForResidents", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Received And Returned", "label": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Received And Returned", "terseLabel": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) funds received and returned" } } }, "localname": "CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds, Repayment", "label": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Repaid", "negatedTerseLabel": "Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)" } } }, "localname": "CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_CostofSalesandGeneralandAdministrativeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of services and general and administrative expense", "label": "Cost of Sales and General and Administrative Expense [Member]", "terseLabel": "Cost of Sales and General and Administrative Expense" } } }, "localname": "CostofSalesandGeneralandAdministrativeExpenseMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_DebtInstrumentPrePaymentFeeReductionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Pre-Payment Fee Reduction, Term", "label": "Debt Instrument, Pre-Payment Fee Reduction, Term", "terseLabel": "Debt Instrument, pre-payment fee reduction, term" } } }, "localname": "DebtInstrumentPrePaymentFeeReductionTerm", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "durationItemType" }, "ensg_DebtInstrumentsNumberOfInstruments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instruments, Number Of Instruments", "label": "Debt Instruments, Number Of Instruments", "terseLabel": "Number of promissory notes" } } }, "localname": "DebtInstrumentsNumberOfInstruments", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "integerItemType" }, "ensg_DeferredRentAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment to deferred rent arising from the difference between rent expense recognized and rental payments made in the current period.", "label": "Deferred Rent Adjustment", "terseLabel": "Amortization of deferred rent" } } }, "localname": "DeferredRentAdjustment", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "ensg_DeferredRentAndOtherLongTermLiabilities": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Rental expense in excess of actual rental payments and other long-term liabilities", "label": "Deferred rent and other long-term liabilities", "verboseLabel": "Other long-term liabilities" } } }, "localname": "DeferredRentAndOtherLongTermLiabilities", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability", "label": "Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_DeferredTaxLiabilitiesRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Right Of Use Asset", "label": "Deferred Tax Liabilities, Right Of Use Asset", "negatedLabel": "Right of use asset" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_DepreciationAndAmortizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Depreciation And Amortization [Member]", "label": "Depreciation And Amortization [Member]", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortizationMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "xbrltype": "domainItemType" }, "ensg_EmployeeServiceShareBasedCompensationNonvestedAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Service Share-based Compensation, Nonvested Awards", "label": "Employee Service Share-based Compensation, Nonvested Awards", "terseLabel": "Share-based compensation, nonvested awards (in shares)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwards", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "xbrltype": "sharesItemType" }, "ensg_ExercisePriceRangeEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Eight [Member]", "label": "Exercise Price Range Eight [Member]", "terseLabel": "2020" } } }, "localname": "ExercisePriceRangeEightMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Five [Member]", "label": "Exercise Price Range Five [Member]", "terseLabel": "2017" } } }, "localname": "ExercisePriceRangeFiveMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Four [Member]", "label": "Exercise Price Range Four [Member]", "terseLabel": "2016" } } }, "localname": "ExercisePriceRangeFourMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Nine [Member]", "label": "Exercise Price Range Nine [Member]", "terseLabel": "2021" } } }, "localname": "ExercisePriceRangeNineMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range One [Member]", "label": "Exercise Price Range One [Member]", "terseLabel": "2013" } } }, "localname": "ExercisePriceRangeOneMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Seven [Member]", "label": "Exercise Price Range Seven [Member]", "terseLabel": "2019" } } }, "localname": "ExercisePriceRangeSevenMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Six [Member]", "label": "Exercise Price Range Six [Member]", "terseLabel": "2018" } } }, "localname": "ExercisePriceRangeSixMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Ten [Member]", "label": "Exercise Price Range Ten [Member]", "terseLabel": "2022" } } }, "localname": "ExercisePriceRangeTenMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Three [Member]", "label": "Exercise Price Range Three [Member]", "terseLabel": "2015" } } }, "localname": "ExercisePriceRangeThreeMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Two [Member]", "label": "Exercise Price Range Two [Member]", "terseLabel": "2014" } } }, "localname": "ExercisePriceRangeTwoMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_FacilitiesUnderMasterLeaseArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk.", "label": "Facilities Under Master Lease Arrangement", "terseLabel": "Facilities under master lease arrangement" } } }, "localname": "FacilitiesUnderMasterLeaseArrangement", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_FacilitiesUnderMedicareProbeReviews": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments", "label": "Facilities Under Medicare Probe Reviews", "terseLabel": "Facilities under medicare probe reviews" } } }, "localname": "FacilitiesUnderMedicareProbeReviews", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "integerItemType" }, "ensg_FamilyFirstCoronavirusResponseActPaymentsReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Family First Coronavirus Response Act, Payments Received", "label": "Family First Coronavirus Response Act, Payments Received", "terseLabel": "FMAP payments received" } } }, "localname": "FamilyFirstCoronavirusResponseActPaymentsReceived", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_February92022RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "February 9, 2022 Repurchase Program", "label": "February 9, 2022 Repurchase Program [Member]", "terseLabel": "February 9, 2022 Repurchase Program" } } }, "localname": "February92022RepurchaseProgramMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "xbrltype": "domainItemType" }, "ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Insurance Claims And Disposal Of Assets", "label": "Gain (Loss) On Insurance Claims And Disposal Of Assets", "negatedLabel": "Loss (gain) on insurance claims, legal finding and asset disposals" } } }, "localname": "GainLossOnInsuranceClaimsAndDisposalOfAssets", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_HealthLiabilityInsuranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Liability Insurance [Member]", "label": "Health Liability Insurance [Member]", "terseLabel": "Health Liability Insurance" } } }, "localname": "HealthLiabilityInsuranceMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag", "label": "Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag", "terseLabel": "Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag" } } }, "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "xbrltype": "stringItemType" }, "ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) Due To Deferred Employer Taxes, CARES Act", "label": "Increase (Decrease) Due To Deferred Employer Taxes, CARES Act", "negatedTerseLabel": "Deferred employer portion of social security taxes" } } }, "localname": "IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_InsuranceCoverageLimitTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance Coverage Limit Type [Axis]", "label": "Insurance Coverage Limit Type [Axis]", "terseLabel": "Insurance Coverage Limit Type [Axis]" } } }, "localname": "InsuranceCoverageLimitTypeAxis", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "stringItemType" }, "ensg_InsuranceCoverageLimitTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance Coverage Limit Type [Domain]", "label": "Insurance Coverage Limit Type [Domain]", "terseLabel": "Insurance Coverage Limit Type [Domain]" } } }, "localname": "InsuranceCoverageLimitTypeDomain", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_InsuranceSubsidiaryDepositsAndInvestments": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Captive insurance subsidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity.", "label": "Insurance Subsidiary Deposits And Investments", "terseLabel": "Insurance subsidiary deposits and investments" } } }, "localname": "InsuranceSubsidiaryDepositsAndInvestments", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ensg_InvestmentExpenseIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment Expense (Income)", "label": "Investment Expense (Income)", "terseLabel": "Offsetting (reduction in expense) expense" } } }, "localname": "InvestmentExpenseIncome", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "xbrltype": "monetaryItemType" }, "ensg_July2022RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "July 2022 Repurchase Program", "label": "July 2022 Repurchase Program [Member]", "terseLabel": "July 2022 Repurchase Program" } } }, "localname": "July2022RepurchaseProgramMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "xbrltype": "domainItemType" }, "ensg_LeaseArrangementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by group of related lease arrangements.", "label": "Lease Arrangement [Axis]", "terseLabel": "Lease Arrangement [Axis]" } } }, "localname": "LeaseArrangementAxis", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "ensg_LeaseArrangementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangement", "label": "Lease Arrangement [Domain]", "terseLabel": "Lease Arrangement [Domain]" } } }, "localname": "LeaseArrangementDomain", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "ensg_LeasedAssetsAcquiredDuringPeriod": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": { "order": 4.0, "parentTag": "ensg_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Leased Assets, Acquired During Period", "label": "Leased Assets, Acquired During Period", "terseLabel": "Leased asset" } } }, "localname": "LeasedAssetsAcquiredDuringPeriod", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms", "label": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms", "terseLabel": "Lessee leasing arrangements, operating leases, number of renewal terms" } } }, "localname": "LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "integerItemType" }, "ensg_LesseeOperatingLeaseConsumerPriceIndex": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Consumer Price Index", "label": "Lessee, Operating Lease, Consumer Price Index", "terseLabel": "Consumer price index" } } }, "localname": "LesseeOperatingLeaseConsumerPriceIndex", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_LesseeOperatingLeaseNumberOfLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Leases", "label": "Lessee, Operating Lease, Number Of Leases", "terseLabel": "Number of stand-alone leases" } } }, "localname": "LesseeOperatingLeaseNumberOfLeases", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_LesseeOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "terseLabel": "Lessee, operating lease, number of renewal options" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "xbrltype": "integerItemType" }, "ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities, Deferred Tax Payments Under CARES Act", "label": "Liabilities, Deferred Tax Payments Under CARES Act", "terseLabel": "Total deferred payment of social security taxes" } } }, "localname": "LiabilitiesDeferredTaxPaymentsUnderCARESAct", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long Term Debt, net of Current Maturities and Debt Discount", "label": "Long Term Debt, net of Current Maturities and Debt Discount", "terseLabel": "Long-term debt\u2014less current maturities" } } }, "localname": "LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Threshold For EBITDA Ratio Increase Election", "label": "Long-Term Debt, Threshold For EBITDA Ratio Increase Election", "terseLabel": "Long-term debt, threshold for EBITDA ratio increase election" } } }, "localname": "LongTermDebtThresholdForEBITDARatioIncreaseElection", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Debt Threshold For EBITDA Ratio Increase Election Period", "label": "Long Term Debt Threshold For EBITDA Ratio Increase Election Period", "terseLabel": "Long-term debt threshold for EBITDA ratio increase election period" } } }, "localname": "LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "xbrltype": "durationItemType" }, "ensg_LossContingencyIndependentOperatingFacilitiesIncludedInScope": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Independent Operating Facilities Included In Scope", "label": "Loss Contingency, Independent Operating Facilities Included In Scope", "terseLabel": "Operating facilities included in scope" } } }, "localname": "LossContingencyIndependentOperatingFacilitiesIncludedInScope", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "integerItemType" }, "ensg_LossSensitivelimitperclaimMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss-Sensitive limit per claim", "label": "Loss-Sensitive limit per claim [Member] [Member]", "terseLabel": "Loss-Sensitive Limit Per Claim" } } }, "localname": "LossSensitivelimitperclaimMemberMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_ManagedCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from managed care payors [Member]", "label": "Managed Care [Member]", "netLabel": "Managed care", "terseLabel": "Managed care", "verboseLabel": "Managed care" } } }, "localname": "ManagedCareMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_ManagementServiceTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management Service, Total", "label": "Management Service, Total [Member]", "terseLabel": "Total Management Fee" } } }, "localname": "ManagementServiceTotalMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "ensg_March132020RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 13, 2020 Repurchase Program", "label": "March 13, 2020 Repurchase Program [Member]", "terseLabel": "March 13, 2020 Repurchase Program" } } }, "localname": "March132020RepurchaseProgramMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "xbrltype": "domainItemType" }, "ensg_March42020RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 4, 2020 Repurchase Program", "label": "March 4, 2020 Repurchase Program [Member]", "terseLabel": "March 4, 2020 Repurchase Program" } } }, "localname": "March42020RepurchaseProgramMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "xbrltype": "domainItemType" }, "ensg_MasterLeaseAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Master Lease agreements", "label": "Master Lease Agreements", "terseLabel": "Master lease agreements" } } }, "localname": "MasterLeaseAgreements", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_MedicaidAndMedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total revenue from Medicaid and Medicare [Member]", "label": "Medicaid and Medicare [Member]", "terseLabel": "Total Medicare and Medicaid", "verboseLabel": "Total Medicaid and Medicare" } } }, "localname": "MedicaidAndMedicareMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from Medicaid for custodial services [Member]", "label": "Medicaid [Member]", "terseLabel": "Medicaid" } } }, "localname": "MedicaidMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicaidSkilledMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from Medicaid for skilled services [Member]", "label": "Medicaid-skilled [Member]", "terseLabel": "Medicaid \u2014 skilled", "verboseLabel": "Medicare" } } }, "localname": "MedicaidSkilledMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicareAcceleratedAndAdvancePaymentCARESACT": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Medicare Accelerated And Advance Payment, CARES ACT", "label": "Medicare Accelerated And Advance Payment, CARES ACT", "terseLabel": "Medicare accelerated and advance payment" } } }, "localname": "MedicareAcceleratedAndAdvancePaymentCARESACT", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_MedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from Medicare [Member]", "label": "Medicare [Member]", "netLabel": "Medicare", "terseLabel": "Medicare", "verboseLabel": "Medicare" } } }, "localname": "MedicareMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicareandMedicaidLicensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare licenses for home health and hospice segment and all other segment.", "label": "Medicare and Medicaid Licenses [Member]", "terseLabel": "Medicare and Medicaid licenses" } } }, "localname": "MedicareandMedicaidLicensesMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSIndefiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_NewMasterLeaseAgreeementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Master Lease Agreeement", "label": "New Master Lease Agreeement [Member]", "terseLabel": "New Master Lease Agreeement" } } }, "localname": "NewMasterLeaseAgreeementMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_NewMasterLeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Master Lease Agreement", "label": "New Master Lease Agreement [Member]", "terseLabel": "New Master Lease Agreement" } } }, "localname": "NewMasterLeaseAgreementMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_NewOperationsUnderSeparateMasterLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Operations Under Separate Master Leases", "label": "New Operations Under Separate Master Leases", "terseLabel": "New operations under separate master leases" } } }, "localname": "NewOperationsUnderSeparateMasterLeases", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_NonCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-California [Domain]", "label": "Non-California [Member]", "terseLabel": "Non-California" } } }, "localname": "NonCaliforniaMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_NonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-Cash Lease Expense", "label": "Non-Cash Lease Expense", "terseLabel": "Non-cash leasing arrangement" } } }, "localname": "NonCashLeaseExpense", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_NoncontrollingInterestPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets.", "label": "Noncontrolling Interest [Policy Text Block]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestPolicyTextBlock", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "ensg_NumberOfAssetAcquisitions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Asset Acquisitions", "label": "Number of Asset Acquisitions", "terseLabel": "Number of asset acquisitions" } } }, "localname": "NumberOfAssetAcquisitions", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfHealthCareFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Health Care Facilities", "label": "Number Of Health Care Facilities", "terseLabel": "Health care facilities" } } }, "localname": "NumberOfHealthCareFacilities", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfLeaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Lease Agreement", "label": "Number of Lease Agreement", "terseLabel": "Number of lease agreement" } } }, "localname": "NumberOfLeaseAgreement", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfLeaseArrangements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Lease Arrangements", "label": "Number of Lease Arrangements", "terseLabel": "Number of master lease arrangements" } } }, "localname": "NumberOfLeaseArrangements", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfLivingOperationsTransferredFromThirdParties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Living Operations Transferred From Third-Parties", "label": "Number of Living Operations Transferred From Third-Parties", "terseLabel": "Number of operations transferred from third parties" } } }, "localname": "NumberOfLivingOperationsTransferredFromThirdParties", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfOperatingSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of operating subsidiaries entered into mortgage loans that are insured with HUD.", "label": "Number Of Operating Subsidiaries", "terseLabel": "Number of operating subsidiaries" } } }, "localname": "NumberOfOperatingSubsidiaries", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfOptionPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Option Plans", "label": "Number Of Option Plans", "terseLabel": "Number of option plans" } } }, "localname": "NumberOfOptionPlans", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfPropertiesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties Acquired", "label": "Number Of Properties Acquired", "terseLabel": "Number of real estate skilled nursing properties acquired" } } }, "localname": "NumberOfPropertiesAcquired", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfRealEstatePropertiesLeased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Real Estate Properties Leased", "label": "Number of Real Estate Properties Leased", "terseLabel": "Number of real estate properties leased" } } }, "localname": "NumberOfRealEstatePropertiesLeased", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Real Estate Properties Leased with an Option to Purchase", "label": "Number of Real Estate Properties Leased with an Option to Purchase", "terseLabel": "Number of real estate properties leased with an option to purchase" } } }, "localname": "NumberOfRealEstatePropertiesLeasedWithOptionToPurchase", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfStockRepurchasePrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Stock Repurchase Programs", "label": "Number Of Stock Repurchase Programs", "terseLabel": "Number of stock repurchase programs" } } }, "localname": "NumberOfStockRepurchasePrograms", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "xbrltype": "integerItemType" }, "ensg_October212021RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October 21, 2021 Repurchase Program", "label": "October 21, 2021 Repurchase Program [Member]", "terseLabel": "October 21, 2021 Repurchase Program" } } }, "localname": "October212021RepurchaseProgramMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "xbrltype": "domainItemType" }, "ensg_OperatingEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Entity [Axis]", "label": "Operating Entity [Axis]", "terseLabel": "Operating Entity [Axis]" } } }, "localname": "OperatingEntityAxis", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "ensg_OperatingEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Operating Entity [Axis]", "label": "Operating Entity [Domain]", "terseLabel": "Operating Entity [Domain]" } } }, "localname": "OperatingEntityDomain", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "ensg_OperationalSeniorLivingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operational Assisted Living and Independent Living Units", "label": "Operational Senior Living Units", "terseLabel": "Operational senior living units" } } }, "localname": "OperationalSeniorLivingUnits", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "integerItemType" }, "ensg_OperationalSkilledNursingBeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of skilled nursing beds available for use at a skilled nursing facility", "label": "Operational Skilled Nursing Beds", "terseLabel": "Operational skilled nursing beds" } } }, "localname": "OperationalSkilledNursingBeds", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "integerItemType" }, "ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other states, except California, Texas and Washington", "label": "Other states, except California, Texas and Washington [Member]", "terseLabel": "Other States, Except California, Texas and Washington" } } }, "localname": "OtherStatesExceptCaliforniaTexasAndWashingtonMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_OwnedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owned Properties", "label": "Owned Properties [Member]", "terseLabel": "Owned Properties" } } }, "localname": "OwnedPropertiesMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "domainItemType" }, "ensg_PaymentsForMedicareAndMedicaidLicenses": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Medicare and Medicaid Licenses", "label": "Payments For Medicare and Medicaid Licenses", "negatedTerseLabel": "Cash payments for Medicare and Medicaid licenses" } } }, "localname": "PaymentsForMedicareAndMedicaidLicenses", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_PaymentsToAcquireAssetAcquisitions": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid to acquire acquisitions.", "label": "Payments To Acquire Asset Acquisitions", "negatedTerseLabel": "Cash payments for asset acquisitions (Note 9)" } } }, "localname": "PaymentsToAcquireAssetAcquisitions", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_PaymentsToAcquireBusinessAndAssetAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid to acquire acquisitions.", "label": "Payments To Acquire Business And Asset Acquisitions", "terseLabel": "Aggregate purchase price of business and asset acquisitions" } } }, "localname": "PaymentsToAcquireBusinessAndAssetAcquisitions", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "monetaryItemType" }, "ensg_PaymentsToAcquirePropertyAndEquipment": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Property And Equipment", "label": "Payments To Acquire Property And Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyAndEquipment", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_PayorAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payor [Axis]", "label": "Payor [Axis]", "terseLabel": "Payor [Axis]" } } }, "localname": "PayorAxis", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "stringItemType" }, "ensg_PayorDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payor [Domain]", "label": "Payor [Domain]", "terseLabel": "Payor [Domain]" } } }, "localname": "PayorDomain", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_PerFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per Facility [Member]", "label": "Per Facility [Member]", "terseLabel": "Per Facility" } } }, "localname": "PerFacilityMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_PerOccurenceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per Occurence [Member]", "label": "Per Occurence [Member]", "terseLabel": "Per Occurence" } } }, "localname": "PerOccurenceMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_PrepaymentPenaltyReducedRateDuringFirstThreeYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced during the first three years.", "label": "Prepayment Penalty Reduced Rate During First Three Years", "terseLabel": "Prepayment penalty reduced rate during first three years" } } }, "localname": "PrepaymentPenaltyReducedRateDuringFirstThreeYears", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "ensg_PrepaymentPenaltyReducedRateDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment Penalty Reduced Rate During Period", "label": "Prepayment Penalty Reduced Rate During Period", "terseLabel": "Prepayment penalty reduced rate during period" } } }, "localname": "PrepaymentPenaltyReducedRateDuringPeriod", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "durationItemType" }, "ensg_PrepaymentPenaltyReducedRateDuringTheFourthYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced during the fourth year.", "label": "Prepayment Penalty Reduced Rate During The Fourth Year", "terseLabel": "Prepayment penalty reduced rate during the fourth year" } } }, "localname": "PrepaymentPenaltyReducedRateDuringTheFourthYear", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "ensg_PrepaymentPenaltyReducedRateForTheFifthThroughTenthYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced for the fifth through tenth years.", "label": "Prepayment Penalty Reduced Rate For The Fifth Through Tenth Years", "terseLabel": "Prepayment penalty reduced rate for the fifth through tenth years" } } }, "localname": "PrepaymentPenaltyReducedRateForTheFifthThroughTenthYears", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "ensg_PrivatePayAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from self-pay and Other payors [Member]", "label": "Private Pay and Other [Member]", "terseLabel": "Private and other payors", "verboseLabel": "Private and other" } } }, "localname": "PrivatePayAndOtherMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program", "label": "Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program", "terseLabel": "Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)" } } }, "localname": "ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans", "label": "Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans", "terseLabel": "Proceeds from sale of subsidiary shares (Note 7)" } } }, "localname": "ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_PromissoryNote50Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note, 5.0%", "label": "Promissory Note, 5.0% [Member]", "terseLabel": "Promissory Note, 5.0%" } } }, "localname": "PromissoryNote50Member", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "ensg_PromissoryNote53Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note, 5.3%", "label": "Promissory Note, 5.3% [Member]", "terseLabel": "Promissory Note, 5.3%" } } }, "localname": "PromissoryNote53Member", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "ensg_PropertyManagementFeePercentFeeOfFundsFromOperations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Management Fee, Percent Fee of Funds from Operations", "label": "Property Management Fee, Percent Fee of Funds from Operations", "terseLabel": "Management fees, as a percentage of funds from operations" } } }, "localname": "PropertyManagementFeePercentFeeOfFundsFromOperations", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "percentItemType" }, "ensg_PropertyManagementFeePercentFeeOfTotalRevenues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Management Fee, Percent Fee of Total Revenues", "label": "Property Management Fee, Percent Fee of Total Revenues", "terseLabel": "Management fees, as a percentage of total revenues" } } }, "localname": "PropertyManagementFeePercentFeeOfTotalRevenues", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "percentItemType" }, "ensg_PurchaseOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Option", "label": "Purchase Option [Member]", "terseLabel": "Purchase Option" } } }, "localname": "PurchaseOptionMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_PurchasesOfNonControllingInterest": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchases of Non-Controlling Interest", "label": "Purchases of Non-Controlling Interest", "negatedLabel": "Purchase of non-controlling interest" } } }, "localname": "PurchasesOfNonControllingInterest", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_QualityAssuranceFee": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days", "label": "Quality Assurance Fee", "terseLabel": "Quality assurance fee" } } }, "localname": "QualityAssuranceFee", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "ensg_RealEstatePurchasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real Estate Purchases", "label": "Real Estate Purchases [Member]", "terseLabel": "Real Estate Purchases" } } }, "localname": "RealEstatePurchasesMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "domainItemType" }, "ensg_RealEstatePurchasesOfPreviousOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real Estate Purchases Of Previous Operations", "label": "Real Estate Purchases Of Previous Operations [Member]", "terseLabel": "Real Estate Purchases Of Previous Operations" } } }, "localname": "RealEstatePurchasesOfPreviousOperationsMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "domainItemType" }, "ensg_RealEstateSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real Estate Segment", "label": "Real Estate Segment [Member]", "terseLabel": "Standard Bearer" } } }, "localname": "RealEstateSegmentMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "ensg_ReductionOfRightOfUseAssetOperatingLeaseLiabilityDueToAcquiringLeasedAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction Of Right-of-Use Asset Operating Lease Liability Due To Acquiring Leased Assets", "label": "Reduction Of Right-of-Use Asset Operating Lease Liability Due To Acquiring Leased Assets", "terseLabel": "Reduction of right-of-use asset operating lease liability due to acquiring leased assets" } } }, "localname": "ReductionOfRightOfUseAssetOperatingLeaseLiabilityDueToAcquiringLeasedAssets", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ensg_RemainingCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Ensign Group, Inc.", "label": "Remaining Company [Member]", "terseLabel": "Remaining Company" } } }, "localname": "RemainingCompanyMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "ensg_RentCostOfServices": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rent cost of services", "label": "Rent Cost Of Services", "terseLabel": "Rent\u2014cost of services" } } }, "localname": "RentCostOfServices", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act", "label": "Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act", "terseLabel": "Repayment of medicare accelerated and advance payment program" } } }, "localname": "RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_ResidentRefundsPayable": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "order": 5.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Resident refunds payable includes amounts due to residents for overpayments and duplicate payments", "label": "Resident Refunds Payable", "terseLabel": "Refunds payable" } } }, "localname": "ResidentRefundsPayable", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "ensg_RestrictedAndOtherAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restricted And Other Assets, Noncurrent", "label": "Restricted And Other Assets, Noncurrent", "terseLabel": "Restricted and other assets", "totalLabel": "RESTRICTED AND OTHER ASSETS" } } }, "localname": "RestrictedAndOtherAssetsNoncurrent", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails" ], "xbrltype": "monetaryItemType" }, "ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized", "label": "Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized", "terseLabel": "Revenue, FMAP payments received" } } }, "localname": "RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_SegmentIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Segment Income (Loss)", "label": "Segment Income (Loss)", "terseLabel": "Segment income (loss)" } } }, "localname": "SegmentIncomeLoss", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails" ], "xbrltype": "monetaryItemType" }, "ensg_SelfInsuranceRetentionPerClaimMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Self-insurance retention per claim [Member]", "label": "Self-insurance retention per claim [Member]", "terseLabel": "Self-Insurance Retention Per Claim" } } }, "localname": "SelfInsuranceRetentionPerClaimMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_SeniorLivingFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Assisted and Independent Living Facilities", "label": "Senior Living Facilities", "terseLabel": "Senior living facilities" } } }, "localname": "SeniorLivingFacilities", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_SeniorLivingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assisted Living Facilities [Member]", "label": "Senior Living Facilities [Member]", "terseLabel": "Senior Living Facilities" } } }, "localname": "SeniorLivingFacilitiesMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "ensg_SeniorLivingOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Living Operations", "label": "Senior Living Operations [Member]", "terseLabel": "Senior Living Operations" } } }, "localname": "SeniorLivingOperationsMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate", "label": "Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate", "terseLabel": "Forfeiture rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments", "terseLabel": "Number of installments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability", "terseLabel": "Conversion to reduce shares availability" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "pureItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number", "terseLabel": "Share-based compensation, options expected to vest, number (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "xbrltype": "sharesItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability", "terseLabel": "Other than options, conversion to reduce shares availability" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "pureItemType" }, "ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Fair Value", "terseLabel": "Black-Scholes Fair Value" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "monetaryItemType" }, "ensg_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversiontoReduceSharesAvailability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion to Reduce Shares Availability", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion to Reduce Shares Availability", "terseLabel": "Conversion to reduce shares availability" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversiontoReduceSharesAvailability", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "pureItemType" }, "ensg_SharebasedCompensationRestrictedAwardsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Restricted Awards, Exercise Price", "label": "Share-based Compensation, Restricted Awards, Exercise Price", "terseLabel": "Share-based compensation, restricted awards, exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationRestrictedAwardsExercisePrice", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "ensg_SkilledNursingOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing Operations", "label": "Skilled Nursing Operations [Member]", "terseLabel": "Skilled Nursing Operations" } } }, "localname": "SkilledNursingOperationsMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing, Senior Living and Independent Living Facilities", "label": "Skilled Nursing, Senior Living and Independent Living Facilities", "terseLabel": "Skilled nursing, assisted living and independent living facilities" } } }, "localname": "SkilledNursingSeniorLivingAndIndependentLivingFacilities", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "integerItemType" }, "ensg_SkilledServiceFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Service Facilities", "label": "Skilled Service Facilities", "terseLabel": "Transitional and skilled service facilities" } } }, "localname": "SkilledServiceFacilities", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_SkilledServicesAndSeniorLivingCampuses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transitional and Skilled Services and Assistant and Independent Living Campuses", "label": "Skilled Services And Senior Living Campuses", "terseLabel": "Transitional and skilled services and senior living campuses" } } }, "localname": "SkilledServicesAndSeniorLivingCampuses", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_SkilledServicesAndSeniorLivingCampusesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transitional and Skilled Services and Senior Living Campuses [Member]", "label": "Skilled Services and Senior Living Campuses [Member]", "terseLabel": "Transitional and Skilled Services and Senior Living Campuses" } } }, "localname": "SkilledServicesAndSeniorLivingCampusesMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "domainItemType" }, "ensg_SkilledServicesSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Services Segment", "label": "Skilled Services Segment [Member]", "terseLabel": "Skilled Services" } } }, "localname": "SkilledServicesSegmentMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "ensg_StandardBearerEquityPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Bearer Equity Plan", "label": "Standard Bearer Equity Plan [Member]", "terseLabel": "Standard Bearer Equity Plan" } } }, "localname": "StandardBearerEquityPlanMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "ensg_StandardBearerHealthcareREITIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Bearer Healthcare REIT, Inc.", "label": "Standard Bearer Healthcare REIT, Inc. [Member]", "terseLabel": "Standard Bearer" } } }, "localname": "StandardBearerHealthcareREITIncMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "ensg_StandardBearerMasterLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Bearer Master Leases", "label": "Standard Bearer Master Leases [Member]", "terseLabel": "Standard Bearer Master Leases" } } }, "localname": "StandardBearerMasterLeasesMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "ensg_StandardBearerSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Bearer Segment", "label": "Standard Bearer Segment [Member]", "terseLabel": "Standard Bearer" } } }, "localname": "StandardBearerSegmentMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "ensg_StandardBearerTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Bearer", "label": "Standard Bearer [Text Block]", "terseLabel": "STANDARD BEARER" } } }, "localname": "StandardBearerTextBlock", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARER" ], "xbrltype": "textBlockItemType" }, "ensg_StockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock awards [Member]", "label": "Stock awards [Member]", "terseLabel": "Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors" } } }, "localname": "StockAwardsMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "ensg_StopLossInsuranceLimitPerClaimMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stop-Loss Insurance limit per claim[Member]", "label": "Stop-Loss Insurance limit per claim [Member]", "terseLabel": "Stop-Loss Insurance Limit Per Claim" } } }, "localname": "StopLossInsuranceLimitPerClaimMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_SubleasedToThirdPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subleased To Third Party", "label": "Subleased To Third Party [Member]", "terseLabel": "Subleased To Third Party" } } }, "localname": "SubleasedToThirdPartyMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_ThePennantGroupInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Pennant Group, Inc.", "label": "The Pennant Group, Inc. [Member]", "terseLabel": "The Pennant Group, Inc.", "verboseLabel": "Pennant" } } }, "localname": "ThePennantGroupInc.Member", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "ensg_ThirdPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Parties", "label": "Third Parties [Member]", "terseLabel": "Third Parties" } } }, "localname": "ThirdPartiesMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "ensg_ThirdPartyTenantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Tenants [Member]", "label": "Third Party Tenants [Member]", "terseLabel": "Other third-party" } } }, "localname": "ThirdPartyTenantsMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "ensg_ThirdPartyTenantsUnderTripleNetLeaseArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Tenants Under Triple Net Lease Arrangements", "label": "Third Party Tenants Under Triple Net Lease Arrangements [Member]", "terseLabel": "Third Party Tenants Under Triple Net Lease Arrangements" } } }, "localname": "ThirdPartyTenantsUnderTripleNetLeaseArrangementsMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_TotalNetDebtRatioMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Net Debt Ratio, Maximum", "label": "Total Net Debt Ratio, Maximum", "terseLabel": "Total net debt ratio, maximum" } } }, "localname": "TotalNetDebtRatioMaximum", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "xbrltype": "pureItemType" }, "ensg_TotalNetDebtRatioMaximumAfterIncreaseElection": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Net Debt Ratio, Maximum After Increase Election", "label": "Total Net Debt Ratio, Maximum After Increase Election", "terseLabel": "Total net debt ratio, maximum after increase election" } } }, "localname": "TotalNetDebtRatioMaximumAfterIncreaseElection", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "xbrltype": "pureItemType" }, "ensg_TotalNetDebtRatioMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Net Debt Ratio, Minimum", "label": "Total Net Debt Ratio, Minimum", "terseLabel": "Total net debt ratio, minimum" } } }, "localname": "TotalNetDebtRatioMinimum", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "xbrltype": "pureItemType" }, "ensg_TruistBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Truist Bank [Member]", "label": "Truist Bank [Member]", "terseLabel": "Truist" } } }, "localname": "TruistBankMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "ensg_TwentyThreeSubsidiariesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty Three Subsidiaries", "label": "Twenty Three Subsidiaries [Member]", "terseLabel": "Twenty Three Subsidiaries" } } }, "localname": "TwentyThreeSubsidiariesMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "ensg_VariousLandlordsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Various Landlords[Member]", "label": "Various Landlords [Member]", "terseLabel": "Various Landlords" } } }, "localname": "VariousLandlordsMember", "nsuri": "http://www.ensigngroup.net/20221231", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "xbrltype": "domainItemType" }, "naics_ZZ524292": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "524292 Third Party Administration of Insurance and Pension Funds [Member]", "terseLabel": "Third-Party Payor" } } }, "localname": "ZZ524292", "nsuri": "http://xbrl.sec.gov/naics/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r265", "r546", "r547", "r550", "r551", "r591", "r636", "r733", "r736", "r737" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r265", "r546", "r547", "r550", "r551", "r591", "r636", "r733", "r736", "r737" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationEliminationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidation, Eliminations [Member]", "terseLabel": "Intercompany Elimination" } } }, "localname": "ConsolidationEliminationsMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r265", "r304", "r316", "r317", "r318", "r319", "r320", "r322", "r326", "r380", "r381", "r382", "r383", "r385", "r386", "r388", "r390", "r391", "r734", "r735" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r265", "r304", "r316", "r317", "r318", "r319", "r320", "r322", "r326", "r380", "r381", "r382", "r383", "r385", "r386", "r388", "r390", "r391", "r734", "r735" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r263", "r264", "r396", "r424", "r641", "r643" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r332", "r659", "r741", "r868" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r376", "r377", "r378", "r379", "r468", "r597", "r610", "r637", "r638", "r656", "r669", "r683", "r738", "r859", "r860", "r861", "r862", "r863", "r864" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r376", "r377", "r378", "r379", "r468", "r597", "r610", "r637", "r638", "r656", "r669", "r683", "r738", "r859", "r860", "r861", "r862", "r863", "r864" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r332", "r659", "r741", "r868" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "srt_ParentCompanyMember": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "label": "Parent Company [Member]", "terseLabel": "Parent Company" } } }, "localname": "ParentCompanyMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r328", "r598", "r657", "r679", "r730", "r731", "r741", "r866" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r328", "r598", "r657", "r679", "r730", "r731", "r741", "r866" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r376", "r377", "r378", "r379", "r460", "r468", "r499", "r500", "r501", "r596", "r597", "r610", "r637", "r638", "r656", "r669", "r683", "r729", "r738", "r860", "r861", "r862", "r863", "r864" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r376", "r377", "r378", "r379", "r460", "r468", "r499", "r500", "r501", "r596", "r597", "r610", "r637", "r638", "r656", "r669", "r683", "r729", "r738", "r860", "r861", "r862", "r863", "r864" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r263", "r264", "r396", "r424", "r642", "r643" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r329", "r330", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r658", "r680", "r741" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r329", "r330", "r619", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r658", "r680", "r741" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "stringItemType" }, "srt_SubsidiariesMember": { "auth_ref": [ "r789", "r854", "r855", "r856" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [Member]", "terseLabel": "Captive Insurance Subsidiary" } } }, "localname": "SubsidiariesMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "xbrltype": "domainItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CALIFORNIA", "terseLabel": "California" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "stpr_CO": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COLORADO", "terseLabel": "Colorado" } } }, "localname": "CO", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "stpr_TX": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TEXAS", "terseLabel": "TEXAS" } } }, "localname": "TX", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "OTHER ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r14", "r678" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGross": { "auth_ref": [ "r236", "r334" ], "calculation": { "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, before Allowance for Credit Loss", "terseLabel": "Accounts receivable, gross" } } }, "localname": "AccountsReceivableGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r334", "r335" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable\u2014less allowance for doubtful accounts of $7,802 and $11,213 at December\u00a031, 2022 and 2021, respectively", "totalLabel": "ACCOUNTS RECEIVABLE, NET" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent": { "auth_ref": [ "r146", "r193", "r213" ], "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "order": 7.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes.", "label": "Accrual for Taxes Other than Income Taxes", "terseLabel": "Property taxes" } } }, "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Legal finding accrued" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r105", "r231" ], "calculation": { "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted Average Life (Years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]", "terseLabel": "Cash paid during the period for:" } } }, "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r9" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r508", "r509", "r510", "r709", "r710", "r711", "r844" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares of common stock used to satisfy tax withholding obligations" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r143", "r144", "r470" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Employee stock award compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r300", "r316", "r317", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "All Other" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r503" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r237", "r338", "r343" ], "calculation": { "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "negatedTerseLabel": "Less: allowance for doubtful accounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r415", "r567", "r654", "r655", "r704" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred financing fees" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r56", "r88", "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r839" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r673", "r840", "r841", "r842" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Asset acquisition, purchase price" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r839" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r56", "r102" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment of long-lived assets" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r184", "r205", "r234", "r260", "r312", "r318", "r324", "r341", "r380", "r381", "r383", "r384", "r385", "r387", "r389", "r391", "r392", "r546", "r550", "r558", "r678", "r734", "r735", "r857" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r227", "r239", "r260", "r341", "r380", "r381", "r383", "r384", "r385", "r387", "r389", "r391", "r392", "r546", "r550", "r558", "r678", "r734", "r735", "r857" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r499", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings and improvements", "verboseLabel": "Building and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r542", "r667", "r668" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r153", "r154", "r542", "r667", "r668" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r158", "r543" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "OPERATION EXPANSIONS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r61", "r62", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accrued capital expenditures" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r58", "r229", "r639" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "verboseLabel": "Cash and cash equivalents, fair value disclosure" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r52", "r58", "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents end of period", "periodStartLabel": "Cash and cash equivalents beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r52", "r176" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashDivestedFromDeconsolidation": { "auth_ref": [ "r44" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.", "label": "Cash Divested from Deconsolidation", "negatedTerseLabel": "Deconsolidation of an ancillary business" } } }, "localname": "CashDivestedFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount", "terseLabel": "Cash, uninsured amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r122", "r123", "r124", "r125" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralizedDebtObligationsMember": { "auth_ref": [ "r85", "r765" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by a pool of assets.", "label": "Collateralized Debt Obligations [Member]", "terseLabel": "Mortgage loans and promissory notes" } } }, "localname": "CollateralizedDebtObligationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r24", "r194", "r212" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Notes 16, 18 and 21)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r111", "r374", "r375", "r623", "r732" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r709", "r710", "r844" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r115" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r8", "r678" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock: $0.001 par value; 100,000 shares authorized; 59,029 and 55,661 shares issued and outstanding at December\u00a031, 2022, respectively, and 58,134 and 55,190 shares issued and outstanding at December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r127", "r128", "r129", "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "terseLabel": "DEFINED CONTRIBUTION PLANS" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r71", "r72", "r173", "r174", "r332", "r622" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r71", "r72", "r173", "r174", "r332", "r618", "r622" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r71", "r72", "r173", "r174", "r332", "r622", "r871" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r71", "r72", "r173", "r174", "r332" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk", "verboseLabel": "Percentage of Revenue" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r69", "r71", "r72", "r73", "r173", "r175", "r622" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r71", "r72", "r173", "r174", "r332", "r622" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r437", "r438", "r457" ], "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "order": 6.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "verboseLabel": "Resident advances" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r82", "r317", "r318", "r319", "r320", "r326", "r715" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Other Service Revenue" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r34", "r598" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of services" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of services" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r33" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "TOTAL EXPENSES" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Expense:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r707", "r835", "r837" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r152", "r527", "r535", "r707" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current income tax expense (benefit)" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r707", "r835", "r837" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r70", "r332" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r114", "r258", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r409", "r416", "r417", "r419" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r185", "r188", "r203", "r265", "r393", "r394", "r395", "r396", "r397", "r399", "r405", "r406", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r568", "r651", "r652", "r653", "r654", "r655", "r705" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rate margin" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r3", "r188", "r203", "r420" ], "calculation": { "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Mortgage loans and promissory notes", "verboseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r21", "r178", "r422", "r568" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, interest rate, effective percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r21", "r394" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r22", "r265", "r393", "r394", "r395", "r396", "r397", "r399", "r405", "r406", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r568", "r651", "r652", "r653", "r654", "r655", "r705" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r22", "r116", "r117", "r118", "r119", "r177", "r178", "r180", "r200", "r265", "r393", "r394", "r395", "r396", "r397", "r399", "r405", "r406", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r418", "r568", "r651", "r652", "r653", "r654", "r655", "r705" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": { "auth_ref": [ "r181" ], "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails": { "order": 1.0, "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Net", "terseLabel": "Debt issuance costs, net" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "terseLabel": "Deferred compensation liability, noncurrent" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r695" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Deferred Compensation Plan Assets", "terseLabel": "Deferred compensation plan investments" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]", "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r707", "r836", "r837" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r831" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal, State and Local, Tax Expense (Benefit)", "totalLabel": "Total deferred income tax expense (benefit)" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r179", "r739" ], "calculation": { "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Less: debt issuance costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r56", "r152", "r528", "r534", "r535", "r707" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r5", "r6", "r186", "r202", "r522" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "TOTAL DEFERRED TAX LIABILITIES" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r707", "r836", "r837" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r523" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r833" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "NET DEFERRED TAX ASSETS" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r833" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "TOTAL DEFERRED TAX ASSETS" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsStateTaxes": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.", "label": "Deferred Tax Assets, State Taxes", "terseLabel": "State taxes" } } }, "localname": "DeferredTaxAssetsStateTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r149", "r150", "r834" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails", "http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r150", "r834" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r150", "r834" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Revenue related reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance": { "auth_ref": [ "r150", "r834" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated losses under self insurance.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance", "terseLabel": "Insurance" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r524" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "terseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails", "http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "Deferred Tax Liabilities, Prepaid Expenses", "negatedLabel": "Prepaid expenses" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r150", "r834" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Contribution Plan Disclosure [Line Items]", "terseLabel": "Defined Contribution Plan Disclosure [Line Items]" } } }, "localname": "DefinedContributionPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Employer discretionary contribution amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Maximum annual contributions per employee (as a percent)" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanTable": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan [Table]", "terseLabel": "Defined Contribution Plan [Table]" } } }, "localname": "DefinedContributionPlanTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r56", "r307" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "netLabel": "Depreciation and amortization", "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r456", "r657", "r658", "r659", "r660", "r661", "r662", "r663" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r741" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r473", "r504", "r505", "r507", "r512", "r670" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "OPTIONS AND AWARDS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r103", "r108" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r667", "r668" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r120", "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedTerseLabel": "Dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r120", "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "terseLabel": "Cash dividends" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r2", "r4", "r187", "r206" ], "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "order": 8.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "terseLabel": "Dividends payable", "verboseLabel": "Accrued dividends declared" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC." } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r248", "r271", "r272", "r273", "r274", "r275", "r279", "r281", "r286", "r287", "r288", "r292", "r554", "r555", "r602", "r606", "r646" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic net income per common share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r248", "r271", "r272", "r273", "r274", "r275", "r281", "r286", "r287", "r288", "r292", "r554", "r555", "r602", "r606", "r646" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted net income per common share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r289", "r290", "r291", "r293" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "COMPUTATION OF NET INCOME PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r518" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate", "totalLabel": "TOTAL INCOME TAX PROVISION" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails", "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r261", "r518", "r536" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Income tax expense at statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r832", "r838" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Non-deductible expenses" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r832", "r838" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r830", "r832" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "terseLabel": "Equity compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r832", "r838" ], "calculation": { "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income taxes\u00a0- net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued wages and related liabilities (Note 3)" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r506" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Share-based compensation, nonvested awards, cost not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Share-based compensation, nonvested awards, cost not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options", "verboseLabel": "Stock-based compensation expense related to stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r115", "r222", "r243", "r244", "r245", "r266", "r267", "r268", "r270", "r276", "r278", "r295", "r342", "r436", "r508", "r509", "r510", "r530", "r531", "r553", "r559", "r560", "r561", "r562", "r563", "r564", "r590", "r611", "r612", "r613" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r30", "r51", "r56", "r214" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Proceeds from Equity Method Investment, Distribution" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimatedInsuranceRecoveries": { "auth_ref": [ "r695" ], "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails": { "order": 2.0, "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.", "label": "Estimated Insurance Recoveries", "terseLabel": "Long-term insurance losses recoverable asset" } } }, "localname": "EstimatedInsuranceRecoveries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtraordinaryAndUnusualItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unusual or Infrequent Items, or Both [Abstract]" } } }, "localname": "ExtraordinaryAndUnusualItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r168", "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r407", "r461", "r462", "r463", "r464", "r465", "r466", "r556", "r593", "r594", "r595", "r652", "r653", "r664", "r665", "r666" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r407", "r461", "r466", "r556", "r593", "r664", "r665", "r666" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r407", "r461", "r466", "r556", "r594", "r652", "r653", "r664", "r665", "r666" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r407", "r461", "r462", "r463", "r464", "r465", "r466", "r593", "r594", "r595", "r652", "r653", "r664", "r665", "r666" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r233", "r361" ], "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r96" ], "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r96" ], "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r96" ], "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r96" ], "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r96" ], "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r358", "r360", "r361", "r363", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r94", "r600" ], "calculation": { "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r89", "r93" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r94", "r599" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures", "verboseLabel": "Equipment, furniture, and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r704" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Gain on sale of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r36", "r84", "r693" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "verboseLabel": "Gain (loss) on deferral investment" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "terseLabel": "Gains on sales property, plant and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r35" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of business insurance which provides insurance coverage for a wide variety of liability exposures including, but not limited to, contractual liability, product liability and personal injury liability.", "label": "General Liability [Member]", "terseLabel": "General Liability" } } }, "localname": "GeneralLiabilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r232", "r345", "r601", "r650", "r678", "r718", "r725" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r348", "r650" ], "calculation": { "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "ensg_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "netLabel": "Goodwill", "terseLabel": "Additions", "verboseLabel": "Goodwill" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r87", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r347", "r354", "r650" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Goodwill, accumulated impairment loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r56", "r346", "r351", "r357", "r650" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r469", "r471", "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r499", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]", "terseLabel": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [ "r469", "r471", "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r499", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]", "terseLabel": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r56", "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets (excluding goodwill)" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r56", "r102", "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairment of long lived assets" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESImpairmentofLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r101", "r109" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r29", "r183", "r195", "r216", "r312", "r317", "r323", "r326", "r603", "r648" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before provision for income taxes", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r667", "r668" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r365", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r261", "r519", "r520", "r526", "r532", "r537", "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r262", "r277", "r278", "r310", "r517", "r533", "r538", "r607" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes", "totalLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r242", "r513", "r514", "r520", "r521", "r525", "r529" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r53", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r55" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r55" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r55" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Deferred compensation liability" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r55" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued wages and related liabilities" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r703", "r849" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease obligations" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r55" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r55" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r55" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "auth_ref": [ "r55" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Taxes", "negatedTerseLabel": "Prepaid income taxes" } } }, "localname": "IncreaseDecreaseInPrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSelfInsuranceReserve": { "auth_ref": [ "r703" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount of accrued known and estimated losses incurred for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's' compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Increase (Decrease) in Self Insurance Reserve", "terseLabel": "Accrued self-insurance liabilities" } } }, "localname": "IncreaseDecreaseInSelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r282", "r283", "r284", "r288", "r472" ], "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Plus: incremental shares from assumed conversion (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r359", "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSIndefiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSIndefiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r97" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Other indefinite-lived intangibles" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r91", "r97" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSIndefiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": { "order": 3.0, "parentTag": "ensg_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.", "label": "Indefinite-Lived Intangible Assets Acquired", "terseLabel": "Indefinite-lived intangible assets", "verboseLabel": "Other indefinite-lived intangible assets" } } }, "localname": "IndefinitelivedIntangibleAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InsuranceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Insurance [Abstract]" } } }, "localname": "InsuranceAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS \u2014 NET" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNET" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r179", "r198", "r246", "r306", "r566" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r252", "r256", "r257" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r340", "r865" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Insurance Subsidiary Deposits and Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r742" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land", "verboseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r848" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r848" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r581", "r677" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Lease, Cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r850" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Operating Lease Expenses" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases and Leasehold Improvements" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r676" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Operating leases of lessee, contingent rentals, basis spread on variable rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r851" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r582" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "TOTAL LEASE PAYMENTS" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r582" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r582" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r582" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r582" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r582" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r582" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r582" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: present value adjustment" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r847" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lessee, operating lease, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r847" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, operating lease, term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessor, Lease, Description [Line Items]", "terseLabel": "Lessor, Lease, Description [Line Items]" } } }, "localname": "LessorLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorLeaseDescriptionTable": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessor's leases.", "label": "Lessor, Lease, Description [Table]", "terseLabel": "Lessor, Lease, Description [Table]" } } }, "localname": "LessorLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r585" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "TOTAL" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r585" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "terseLabel": "2027" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r585" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "terseLabel": "2026" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r852" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Annual Rental Income" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r585" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r585" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r585" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "terseLabel": "2025" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r585" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r853" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Lessor, operating lease, term of contract" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding, pledged amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r18", "r260", "r341", "r380", "r381", "r383", "r384", "r385", "r387", "r389", "r391", "r392", "r547", "r550", "r551", "r558", "r647", "r734", "r857", "r858" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r13", "r190", "r210", "r678", "r706", "r716", "r845" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r228", "r260", "r341", "r380", "r381", "r383", "r384", "r385", "r387", "r389", "r391", "r392", "r547", "r550", "r551", "r558", "r678", "r734", "r857", "r858" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Future Policy Benefit, by Product Segment [Line Items]", "terseLabel": "Liability for Future Policy Benefit, by Product Segment [Line Items]" } } }, "localname": "LiabilityForFuturePolicyBenefitByProductSegmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reflects the carrying amount of and other relevant, pertinent information about the liability as of the balance sheet date for future benefits to be paid to or on behalf of policyholders and related expenses less the present value of future net premiums by major product line segment.", "label": "Liability for Future Policy Benefit, by Product Segment [Table]", "terseLabel": "Liability for Future Policy Benefit, by Product Segment [Table]" } } }, "localname": "LiabilityForFuturePolicyBenefitByProductSegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefits": { "auth_ref": [ "r605", "r608", "r609", "r614", "r682" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.", "label": "Liability for Future Policy Benefit, before Reinsurance", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "LiabilityForFuturePolicyBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.", "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]", "terseLabel": "SELF INSURANCE LIABILITIES" } } }, "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease": { "auth_ref": [ "r217" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in accrued obligations to policyholders pertaining to insured events for the period.", "label": "Liability for Future Policy Benefits, Other Increase (Decrease)", "terseLabel": "Change in long-term insurance losses recoverable" } } }, "localname": "LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits": { "auth_ref": [ "r681", "r682", "r702", "r867", "r870" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to policyholder from benefit payment for expected future policy benefit and expense component of liability for future policy benefit.", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Benefit Payment", "negatedTerseLabel": "Claims paid and direct expenses" } } }, "localname": "LiabilityForFuturePolicyBenefitsPaymentForBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued obligations to policy and contract holders for long-duration insurance contracts.", "label": "Liability for Future Policy Benefits, Period Increase (Decrease)", "terseLabel": "Current year provisions" } } }, "localname": "LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The change in cash surrender or contract value during the period which adjusted the amount of premiums paid in determining the expense or income recognized under the contract for the period.", "label": "Life Insurance, Corporate or Bank Owned, Change in Value", "negatedTerseLabel": "Cash surrender value of life insurance policy premiums" } } }, "localname": "LifeInsuranceCorporateOrBankOwnedChangeInValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r16", "r705" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "auth_ref": [ "r705" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of the credit facility.", "label": "Line of Credit Facility, Increase (Decrease), Net", "terseLabel": "Letter of credit increase" } } }, "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecentAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r16", "r705" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r16" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecentAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r3", "r188", "r207", "r406", "r421", "r652", "r653" ], "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "negatedTerseLabel": "Less: current maturities", "terseLabel": "Current maturities of long-term debt", "verboseLabel": "Amount outstanding, current" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r112", "r265", "r740" ], "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r112", "r265", "r411" ], "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "order": 6.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r112", "r265", "r411" ], "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r112", "r265", "r411" ], "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r112", "r265", "r411" ], "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r112", "r265", "r411" ], "calculation": { "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r235" ], "calculation": { "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "totalLabel": "Long-term debt\u2014less current maturities", "verboseLabel": "Long-term debt\u2014less current maturities" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r22", "r113" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ManagementFeeExpense": { "auth_ref": [ "r182" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).", "label": "Management Fee Expense", "terseLabel": "Management fees" } } }, "localname": "ManagementFeeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManagementServiceBaseMember": { "auth_ref": [ "r742" ], "lang": { "en-us": { "role": { "documentation": "Contractually stipulated right to receive base compensation for operating and managing business.", "label": "Management Service, Base [Member]", "terseLabel": "Base Management Fee" } } }, "localname": "ManagementServiceBaseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ManagementServiceIncentiveMember": { "auth_ref": [ "r742" ], "lang": { "en-us": { "role": { "documentation": "Contractually stipulated right to receive incentive compensation for operating and managing business.", "label": "Management Service, Incentive [Member]", "terseLabel": "Incentive Management Fee" } } }, "localname": "ManagementServiceIncentiveMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r28", "r189", "r209", "r260", "r341", "r380", "r383", "r384", "r385", "r391", "r392", "r558" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r120" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distribution to noncontrolling interest holder and other changes" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r120", "r161", "r162" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedTerseLabel": "Acquisition of noncontrolling interest shares" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Less:" } } }, "localname": "MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgages" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Liability for Future Policy Benefits [Roll Forward]", "terseLabel": "Movement in Liability for Future Policy Benefits [Roll Forward]" } } }, "localname": "MovementInLiabilityForFuturePolicyBenefitsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r255" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH USED IN FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r255" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r52", "r54", "r57" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH PROVIDED BY OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r31", "r57", "r196", "r215", "r226", "r240", "r241", "r245", "r260", "r269", "r271", "r272", "r273", "r274", "r277", "r278", "r285", "r312", "r317", "r323", "r326", "r341", "r380", "r381", "r383", "r384", "r385", "r387", "r389", "r391", "r392", "r555", "r558", "r648", "r734" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to The Ensign Group, Inc.", "verboseLabel": "Net income attributable to the Ensign Group, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "NUMERATOR:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r163", "r166", "r240", "r241", "r277", "r278", "r698" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net (loss) income attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "auth_ref": [ "r61", "r62", "r63" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received", "terseLabel": "Note receivable from insurance settlement" } } }, "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "auth_ref": [ "r121", "r164" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.", "label": "Noncontrolling Interest, Decrease from Deconsolidation", "negatedTerseLabel": "Deconsolidation of an ancillary business" } } }, "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r121", "r161", "r164" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "verboseLabel": "Capital contribution from noncontrolling interest holder" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r159", "r436", "r709", "r710", "r711" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-Controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r37" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonqualifiedPlanMember": { "auth_ref": [ "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803" ], "lang": { "en-us": { "role": { "documentation": "Plan without tax-exempt status in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Nonqualified Plan [Member]", "terseLabel": "Nonqualified Plan" } } }, "localname": "NonqualifiedPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r3", "r188", "r207" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "verboseLabel": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Mortgage loans and promissory notes", "verboseLabel": "Notes Payable Other Payables" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes Payable to Banks" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfBusinessesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of businesses acquired by the entity during the period.", "label": "Number of Businesses Acquired", "terseLabel": "Number of businesses acquired" } } }, "localname": "NumberOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number of Real Estate Properties", "terseLabel": "Number of real estate properties" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r714" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r312", "r317", "r323", "r326", "r648" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r574", "r677" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease expense", "verboseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r846" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r294", "r584", "r588" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income", "terseLabel": "Rental revenue" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "auth_ref": [ "r294", "r588" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of income from operating lease.", "label": "Operating Lease, Lease Income [Table Text Block]", "terseLabel": "Schedule of Rental Income from Third-Party Sources" } } }, "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Year" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r570" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "PRESENT VALUE OF TOTAL LEASE LIABILITIES" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r570" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current lease liabilities", "terseLabel": "Lease liabilities\u2014current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r570" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term lease liabilities\u2014less current portion", "verboseLabel": "LONG-TERM OPERATING LEASE LIABILITIES" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r571", "r577" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r569" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseVariableLeaseIncome": { "auth_ref": [ "r294", "r587" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable.", "label": "Operating Lease, Variable Lease Income", "terseLabel": "Operating lease, variable lease income" } } }, "localname": "OperatingLeaseVariableLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r580", "r677" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating lease, weighted average discount rate, percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r579", "r677" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating lease, weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessor's operating leases.", "label": "Lessor, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "OperatingLeasesOfLessorDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r316", "r317", "r318", "r319", "r320", "r326" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r167" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "DESCRIPTION OF BUSINESS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities", "totalLabel": "OTHER ACCRUED LIABILITIES" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r238", "r678" ], "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails": { "order": 3.0, "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Other Assets Disclosure [Text Block]", "terseLabel": "RESTRICTED AND OTHER ASSETS" } } }, "localname": "OtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash financing and investing activity" } } }, "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (expense) income:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherRestrictedAssets": { "auth_ref": [ "r620", "r621", "r695" ], "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails": { "order": 4.0, "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year.", "label": "Other Restricted Assets", "terseLabel": "Capital improvement reserves with landlords and lenders" } } }, "localname": "OtherRestrictedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net cash outflow or inflow from the amount given in advance to show intention to complete the acquisition piece of land, anything permanently fixed to it, including buildings, structures on it, and so forth.", "label": "Payments for (Proceeds from) Deposits on Real Estate Acquisitions", "negatedLabel": "Escrow deposits" } } }, "localname": "PaymentsForProceedsFromDepositsOnRealEstateAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r700", "r701" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other restricted assets" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r47" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of shares of common stock (Note 22)" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r47" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedTerseLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r49" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedTerseLabel": "Payments of deferred financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r251" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Repurchase of shares of common stock to satisfy tax withholding obligations" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r43", "r544" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payments to acquire businesses, gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r43" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Cash payments for business acquisitions (Note 9)" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r44" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r250", "r840", "r841", "r842" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "Purchase price" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r49" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedTerseLabel": "Non-controlling interest distribution", "terseLabel": "Non-controlling interest distribution" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r697" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r640", "r649", "r717" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromDepositsOnRealEstateSales": { "auth_ref": [ "r699" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash inflow related to amounts received in advance from a potential buyer showing or confirming an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate.", "label": "Proceeds from Deposits on Real Estate Sales", "terseLabel": "Escrow deposits used to fund acquisitions" } } }, "localname": "ProceedsFromDepositsOnRealEstateSales", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": { "auth_ref": [ "r42", "r50" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities.", "label": "Proceeds from Insurance Settlement, Investing Activities", "terseLabel": "Cash from insurance proceeds" } } }, "localname": "ProceedsFromInsuranceSettlementInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": { "auth_ref": [ "r254", "r644" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.", "label": "Proceeds from Insurance Settlement, Operating Activities", "terseLabel": "Cash received from insurance proceeds" } } }, "localname": "ProceedsFromInsuranceSettlementOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of preferred shares" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r46" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from debt (Note 16)" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r42" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of real estate" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfAssetsInvestingActivities": { "auth_ref": [ "r700" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities.", "label": "Proceeds from Sales of Assets, Investing Activities", "terseLabel": "Cash proceeds from the sale of assets" } } }, "localname": "ProceedsFromSalesOfAssetsInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r45", "r141" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalMalpracticeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business insurance coverage for professionals, such as doctors, lawyers, insurance agents, accountants, real estate agents, veterinarians, and others. This liability coverage insures losses for claims arising from mistakes and errors or omissions in the course of professional activities.", "label": "Professional Malpractice Liability Insurance [Member]", "terseLabel": "General and Professional Liability" } } }, "localname": "ProfessionalMalpracticeLiabilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r226", "r240", "r241", "r253", "r260", "r269", "r277", "r278", "r312", "r317", "r323", "r326", "r341", "r380", "r381", "r383", "r384", "r385", "r387", "r389", "r391", "r392", "r545", "r548", "r549", "r555", "r558", "r603", "r648", "r674", "r675", "r698", "r734" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "NET INCOME" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLossFromRealEstateOperations": { "auth_ref": [ "r197" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cost of operation of other real estate (including provisions for real estate losses, rental income, and gains and losses on sales of real estate).", "label": "Profit (Loss) from Real Estate Operations", "terseLabel": "Gain on sale of assets, net" } } }, "localname": "ProfitLossFromRealEstateOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": { "order": 1.0, "parentTag": "ensg_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Additions", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentAdditions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r110", "r624", "r625", "r626" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT\u2014 NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r104", "r230" ], "calculation": { "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r106", "r211", "r604", "r678" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "PROPERTY AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r106", "r624", "r625" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, plant and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r249", "r344" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_QualifiedPlanMember": { "auth_ref": [ "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803" ], "lang": { "en-us": { "role": { "documentation": "Plan with tax-exempt status designed and operated in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Qualified Plan [Member]", "terseLabel": "Qualified Plan" } } }, "localname": "QualifiedPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealEstatePropertiesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by ownership of the property.", "label": "Real Estate Property Ownership [Axis]", "terseLabel": "Real Estate Property Ownership [Axis]" } } }, "localname": "RealEstatePropertiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePropertiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents categories of ownership of real estate properties.", "label": "Real Estate Properties [Domain]", "terseLabel": "Real Estate Properties [Domain]" } } }, "localname": "RealEstatePropertiesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealEstatePropertiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Real Estate Properties [Line Items]", "terseLabel": "Real Estate Properties [Line Items]" } } }, "localname": "RealEstatePropertiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r79", "r81" ], "lang": { "en-us": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r79", "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Revenue from Segments" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r48" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedTerseLabel": "Payments on debt (Note 16)" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards", "verboseLabel": "Stock-based compensation expense related to restricted stock awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r367", "r368", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r10", "r120", "r208", "r615", "r616", "r678" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r222", "r266", "r267", "r268", "r270", "r276", "r278", "r342", "r508", "r509", "r510", "r530", "r531", "r553", "r611", "r613" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTaxStatusAxis": { "auth_ref": [ "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803" ], "lang": { "en-us": { "role": { "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Tax Status [Axis]", "terseLabel": "Retirement Plan Tax Status [Axis]" } } }, "localname": "RetirementPlanTaxStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTaxStatusDomain": { "auth_ref": [ "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803" ], "lang": { "en-us": { "role": { "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Tax Status [Domain]", "terseLabel": "Retirement Plan Tax Status [Domain]" } } }, "localname": "RetirementPlanTaxStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r303", "r304", "r316", "r321", "r322", "r328", "r329", "r332", "r455", "r456", "r598" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "netLabel": "Revenue", "terseLabel": "Service revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r459", "r645" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Service and Rental Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE AND ACCOUNTS RECEIVABLE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r247", "r260", "r303", "r304", "r316", "r321", "r322", "r328", "r329", "r332", "r341", "r380", "r381", "r383", "r384", "r385", "r387", "r389", "r391", "r392", "r558", "r603", "r734" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "TOTAL REVENUE" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility with Truist" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r578", "r677" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new and modified operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r332", "r713" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLERevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts Receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Other Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.", "label": "Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Other Indefinite-lived Intangible Assets" } } }, "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r153", "r154", "r542" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "terseLabel": "Schedule of Employee Stock Option Roll Forward" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r22", "r116", "r117", "r118", "r119", "r177", "r178", "r180", "r200", "r652", "r654", "r708" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "auth_ref": [ "r66", "r68", "r712" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic Net Income Per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "auth_ref": [ "r66", "r68", "r712" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Diluted Net Income Per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r139", "r142" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r89", "r93", "r599" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r89", "r93" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r650" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r650", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r97", "r99" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSIndefiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the present values of future benefits to be paid to or on behalf of policyholders and related expenses less the present value of future net premiums using assumptions such as estimates of expected investment yields, mortality, morbidity, terminations and expenses, applicable at the time the insurance contracts are made and unpaid claim costs relating to insurance contracts including estimates of costs relating to incurred but not reported claims based on the estimated ultimate cost of settling the claims (including effects of inflation and other societal and economic factors), using past experience adjusted for current trends and any other factors that would modify past experience by element such as business segment, country and interest rate range.", "label": "Schedule of Liability for Future Policy Benefits, by Product Segment [Table Text Block]", "terseLabel": "Schedule of Liability for Future Policy Benefits, by Product Segment" } } }, "localname": "ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims.", "label": "Insurance Type and Tier Identifier [Axis]", "terseLabel": "Insurance Type and Tier Identifier [Axis]" } } }, "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Restricted Stock Awards" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Schedule of Other Assets [Table Text Block]", "terseLabel": "Schedule of Restricted and Other Assets" } } }, "localname": "ScheduleOfOtherAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]", "verboseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails", "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETSummaryDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property.", "label": "Schedule of Real Estate Properties [Table]", "terseLabel": "Schedule of Real Estate Properties [Table]" } } }, "localname": "ScheduleOfRealEstatePropertiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Purchase Price Allocation" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r367", "r368", "r369", "r370", "r371", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r77", "r78", "r80", "r87" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r77", "r78", "r80", "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r469", "r471", "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r499", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Estimated Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r843" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r695" ], "calculation": { "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails": { "order": 5.0, "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Deposits with landlords" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r300", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r332", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r370", "r373", "r650", "r866" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r300", "r301", "r302", "r312", "r315", "r320", "r324", "r325", "r326", "r327", "r328", "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "BUSINESS SEGMENTS" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingRevenueReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SelfInsuranceReserve": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Self Insurance Reserve", "terseLabel": "Self insurance reserve" } } }, "localname": "SelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReserveCurrent": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Current", "terseLabel": "Accrued self-insurance liabilities\u2014current" } } }, "localname": "SelfInsuranceReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReserveNoncurrent": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Noncurrent", "terseLabel": "Accrued self-insurance liabilities\u2014less current portion" } } }, "localname": "SelfInsuranceReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReservePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR).", "label": "Self Insurance Reserve [Policy Text Block]", "terseLabel": "Self-Insurance" } } }, "localname": "SelfInsuranceReservePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember": { "auth_ref": [ "r839" ], "lang": { "en-us": { "role": { "documentation": "Series of individually immaterial asset acquisitions.", "label": "Series of Individually Immaterial Asset Acquisitions [Member]", "terseLabel": "Series of Individually Immaterial Asset Acquisitions" } } }, "localname": "SeriesOfIndividuallyImmaterialAssetAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Series of Individually Immaterial Business Acquisitions" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r55" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r670" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Award requisite service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r670" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted restricted shares (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested at end of period (in shares)", "periodStartLabel": "Nonvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Non-Vested Restricted Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested at end of period (in dollars per share)", "periodStartLabel": "Nonvested at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Weighted Average Dividend Yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Weighted Average Risk-Free Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Weighted Average Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price of options vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r810" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r810" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value", "terseLabel": "Grant date intrinsic value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "netLabel": "Granted (in shares)", "terseLabel": "Options granted (in shares)", "verboseLabel": "Options Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Fair Value of Options (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Schedule of Weighted Average Grant Date Fair Value and Exercise Price of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r140" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r478", "r479" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Balance at end of period, (in shares)", "periodStartLabel": "Balance at beginning of period, (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r478", "r479" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Balance at end of period (in dollars per share)", "periodStartLabel": "Balance at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]", "terseLabel": "Schedule of Aggregate Intrinsic Value of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of options vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r499", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price (in dollars per share)", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r477", "r496", "r497", "r498", "r499", "r502", "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Exercise price, lower range limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Stock options vested and exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Number outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Exercise price, upper range limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "auth_ref": [ "r469", "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r499", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "terseLabel": "Non-employee directors" } } }, "localname": "ShareBasedPaymentArrangementNonemployeeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r804" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting rights, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Aggregate intrinsic value of options that vested in period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r671" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r140" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based compensation, options outstanding, weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Remaining Contractual Life (Years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares of common stock used to satisfy tax withholding obligations (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r191", "r192", "r204", "r696" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Investments\u2014current" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r575", "r677" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "CPI increases and short term-lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SpinoffMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Creation of an independent entity from an existing entity through divestiture, for example, but not limited to, sale or distribution of new shares.", "label": "Spinoff [Member]", "terseLabel": "Spinoff" } } }, "localname": "SpinoffMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r224", "r300", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r332", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r366", "r370", "r373", "r650", "r866" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentReportingInformationDetails", "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSGoodwillRollforwardDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r25", "r115", "r222", "r243", "r244", "r245", "r266", "r267", "r268", "r270", "r276", "r278", "r295", "r342", "r436", "r508", "r509", "r510", "r530", "r531", "r553", "r559", "r560", "r561", "r562", "r563", "r564", "r590", "r611", "r612", "r613" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r266", "r267", "r268", "r295", "r598" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r7", "r8", "r115", "r120" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r7", "r8", "r115", "r120" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r7", "r8", "r115", "r120" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock, net of forfeitures (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r7", "r8", "r115", "r120", "r483" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r7", "r8", "r115", "r120" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r115", "r120" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock, net of forfeitures" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Stock Repurchase Program, Period in Force", "terseLabel": "Stock repurchase program, period in force" } } }, "localname": "StockRepurchaseProgramPeriodInForce1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r8", "r11", "r12", "r83", "r678", "r706", "r716", "r845" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Ensign Group, Inc. stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Ensign Group, Inc. stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r159", "r160", "r165", "r222", "r223", "r244", "r266", "r267", "r268", "r270", "r276", "r342", "r436", "r508", "r509", "r510", "r530", "r531", "r553", "r559", "r560", "r564", "r590", "r612", "r613", "r706", "r716", "r845" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r126", "r259", "r423", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r552" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "COMMON STOCK REPURCHASE PROGRAM" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r565", "r592" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r565", "r592" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r565", "r592" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r219", "r220", "r221", "r336", "r337", "r339" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Facility trade name", "verboseLabel": "Trade name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GOODWILLANDOTHERINDEFINITELIVEDINTANGIBLEASSETSIndefiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "terseLabel": "Common stock in treasury, at cost" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r27", "r122", "r125" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "negatedTerseLabel": "Common stock in treasury, at cost, 3,368 and 2,944 shares at December\u00a031, 2022 and 2021, respectively (Note 22)" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r8", "r115", "r120" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Repurchase of common stock (in shares)", "verboseLabel": "Repurchase of common stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r115", "r120", "r122" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Repurchase of common stock", "verboseLabel": "Repurchase of common stock, value" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeAndTierIdentifierDomain": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims.", "label": "Type and Tier Identifier [Domain]", "terseLabel": "Type and Tier Identifier [Domain]" } } }, "localname": "TypeAndTierIdentifierDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r367", "r368", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Items, or Both, Disclosure [Text Block]", "terseLabel": "COVID-19 UPDATE" } } }, "localname": "UnusualOrInfrequentItemsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATE" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r74", "r75", "r76", "r296", "r297", "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Estimates and Assumptions" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r576", "r677" ], "calculation": { "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease, cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r280", "r288" ], "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Adjusted weighted average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING", "verboseLabel": "DENOMINATOR:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r279", "r288" ], "calculation": { "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding for basic net income per share (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails", "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "sharesItemType" }, "us-gaap_WhollyOwnedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real estate properties and units within those properties that are wholly owned.", "label": "Wholly Owned Properties [Member]", "terseLabel": "Owned Properties" } } }, "localname": "WhollyOwnedPropertiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails", "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails", "http://www.ensigngroup.net/role/STANDARDBEARERDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WorkersCompensationInsuranceMember": { "auth_ref": [ "r869" ], "lang": { "en-us": { "role": { "documentation": "Contract providing insurance coverage for employer's liability related to injury, disability, or death.", "label": "Workers' Compensation Insurance [Member]", "terseLabel": "Workers' Compensation" } } }, "localname": "WorkersCompensationInsuranceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r38" ], "calculation": { "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.", "label": "Write off of Deferred Debt Issuance Cost", "terseLabel": "Write-off of deferred financing fees" } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 22 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "https://asc.fasb.org/topic&trid=2127225", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org/topic&trid=2197446", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.14(d))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(13))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b),(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "21B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080549-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "220", "URI": "https://asc.fasb.org/subtopic&trid=114868817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "21B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080549-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919311-209978", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888252", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(13)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/subtopic&trid=2560295", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "13I", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783724-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "29E", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819541-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r684": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r685": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r686": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r687": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r688": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r689": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r691": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r692": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "325", "URI": "https://asc.fasb.org/extlink&oid=6384439&loc=d3e42048-111605", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "9C", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=122147696&loc=SL65671395-207642", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 131 0001125376-23-000018-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001125376-23-000018-xbrl.zip M4$L#!!0 ( "& 0E87/LS'!M<% *MI/ 1 96YS9RTR,#(R,3(S,2YH M=&WLO5MW$TFR-GR_?T5_??UZ.@^1IUXS\R[.FWFQH<'3#-STBLR(M$7+DD>2 M ?/KOTCY #9T8QK9525KSQ[&4I5*I7J>B'@B#Q%__[_O#\8_O.79?#2=_.-' M_3?UXP__]Y]___^VMOYS]_F3'^Y/R]$!3Q8_W)LQ+IA^>#=:[/_PDGC^^P]U M-CWXX>5T]OOH+6YM+3]S;WIX/!OM[2]^,,K82P=G/^<*:"N5K:)"WH)":@M5 MK%O(5 N20X[T?_9^+LE!M0:W2HQA"]#!5HJ9M]!II>02QOCT?^CGS(8J^.Q4 MT5!19VUS5CF:7)Q*0.UK]Q?RZ^073N8_O\^S\>@?/^XO%H<___33NW?O_M;> M^=MTMO>34S UP(2^0*VFVI MN&7UZ76^='LZI?33^_;\S^]H<3C[\F]N1R[<%_'HRV?*@8O/1N[Q]S_^^G;T M[-2C^=8>XN'G#^7TP(7K\F2^=^&R\L9H;[(WFQX=_FW")T]1F_,G($_RC]#7 M]I-'^_>/'!;]?_+2$\J=_ M_L___,_?%Z/%F/_9GM'6V7/X^T\G;_[]IY-+YRD=__/O-'K[PWQQ/.9__$BC M^>$8CW^>3"++\4X[OB,N9C5D02=K-01EZ;?[[5:45GKK(S83/&A?S:.?'TSD_H[OR<^9X?CQ MA/C]_^/C'W\84;NT_?4XWY^^?6*>OWUEMX_HS8.WKQ^E-T\/_C7>/GA^L'/_ M]6AG]^Z;[=WG!Z]V'XZV=W=&K][<'3V]_Z_1JP__?O=T]_GO3^S.^-6'P]'K MW7_]_OK-+^;5FW^_>_7A@7I]\.#]JS/SNU9N]XU<'VWK[_N_J]<-H MGYC7QZ]>%K]S_U_[K][<^;#]X?7O.^:7XYU'OXZW/^S!]OVB=\S.[SL??GFW M8UY]>+5[YRT]>CC*C_[M=QX]>/?ZX-"6?>?[[SLO'L'/_,;Q^ M^7S\ZLUC>/KR%R7_/?W,K_)=;O)Z=ZI>[=X]>/URV[U^].KX]9O'ZO6C7[3< MF]I^LS]^_>C7T?:;/??Z_B].[O'=D]T'B^T7ZKW\K]VY_T _O?,;^N0"A;25 MG1$O[I3?BL;C5K003#4.&.*/_U3BGK1Q-OB__W0!UNM$^2Q MRCOS#K,%Y.-6)%NVP*L8 ;7.J'_\9X.A,X2?R?6G MM,'X2A@??P%C:XU*.=>M$*O=@II@*V?66]JJ5#S95(QXZX>O;A#A.P(O+2$> MX]X&U:^A^N$+J)9,T2M1:!X*;D%*92NE"ELFI-P@B '4C_^L.)[SMP ;"%DR<=;=3HO4DIJ#\!]E1C_?QL-CWDV>+XF< MZ]'XR:ARMY";G7OIH!P\G#Q]_R.;=S7V!\\ZO0X/7!]N[= M_=<'._NO'SU0.R__-7IBGX_Y?Y\?OWY)A]F W[XO='CTP&R_?"[W^+O:$1AW M7CX<[1R\>K_]Z.'!*R/7W!5(#_Y5=P3&[7>_H:G91&.W',H_ !0D*XIV2_(> M-C49-BK_^,]G]I7:5O>_!;3B.;E$0=QWA%!3CJJ%Z.J (A8LOSW^(ZR>\'S. M_%3P$@$ZV7O"HB6?\X3?X7B79P>W#:T/AB%L!5L$IPLYZW(V6QE MPUE\GI44- A.6GV3R[3%^ Q(.1&!"L(!$5C&8C!!$F&&*UC6P]%DM. GH[=, MCR>2">Z-\ICO"(*WU[2>[CY0V[_\IG/2J8APT1Q%O5BT6PE0;3$F$R5,E:BK M0 ;?:%BZL("DO,)>S?@9 M'B_#'HN5T5%I25_W=O9^9[>\?3WYU_[K#X?R8%^/7IE?Y9JOW[Q^4]2K#[]\ M>/7RUX-VG>V7?WHOJ=?_V5?EX-<)ODQ'3P\$[(-_O7G=PM^! M_.?#\S<[]P7DE^V>[[R7:WUX>O_QNYV#!_"?#[\<;[_Y]V\$MOB*;LM$RUN@ M(DF"86A+5T<>F=AG%-2<.,1OBF%*5X#(7IL [&(*18GE1>N2@@I_)DXVJ'T% MM0^O?HMD8O$:MWB)FF2#6[%JMY5L8J;JLG+FQ#UN8.L);$]W?_D-;"+Q8G;+ MD-B9/%<0V++?2MF$@HE)%_U78"-?18F&0!(;@9%2\%9IJ-Z+DJPN?IOX: ] MK6V,:H9ET354'_Y]"M447N^.]U_O2E#;_?W]]OUMM?-F^\/31\_WMQ\]?[-M MGH^V/_SZYO6C?WT.E;JHJA@/#<&8EFRN4M5(ZV?V$LMXWS_CQ?S@((EC\L![U_7AP?"D;ST<'AN T M+]_;GS6H+PS;_NW]G.02/UV\QLGW?_S2TWN83X]FRU?+J92?3_ES"NY?2/K/ M+L3+L=FS5R-JK^N(9S\L;XB_.#MQ[_'_NSC&>/G#_SQ[Z^+5#YOY@N< M+>[C@I?#6%L-*WWVN8_'SF^3/IZJS9;5'[_BY,C9Z[,O^>G"@_KBL.K_0Z9&K/8$C2566 M/_]HR;Z3-P_$<1S-^)^G4V4___O%_;./GQTZ>]T^_\6G&5A#F_Q+3F>H\H=Q MI6;'S I1-,CR:4H$ZMO3M(UZW_TTY_LH1OK9 SVE\_+@-S]1(YF2H)&<""[( MVB1?4)2!SM9;9[+[)"[TZHE>LM!O>Z(7.:4(-%%"%32HXK,M$6,0]1G .Z3E M$]#]>P+Z>Y[ IQ;ZC&?;F_=Y,CT8 M3;YTV:M2^L(E?KIX]U]C?@*P#B*EPA8*2\K!3D=R6;/)29^,=NJSB-87 ER( M:/KJ$4VO+*(IBS;+DRK**A AF:T\+\BL:D;TP,OGILZ>F^KC"S"#I,J113ZIJL7_&M/\C$XW\;A.?S7OM0SYY"7)E[T_'(_*:+'- M!UF^@D8';4U$6S1TE@F\6,A/;Y]IH_J+XWO3@\/I1%[.[[P?25@Z.TW>/YA. M7BRFY?>3:_W]IR]^Q?E3.[^3;W* .JTL!$#*24FX@V@!$"HFP\)QDR1RUQ#4 MVD!SAVC4AD)P_ Q']'AR#P]'"QP/!*9:72FU.%T# ?F$&#U4"I+8NEA!KPU, MSWF!HPG3 YQ-).6>#P0?B9Z)J\I I,$*)D@NB: "4MZCA;7!9W>VU"+'2Q]W MXNX& I%82BF2>Z: "";IZ-F3TDBA2A3WZV-".]-)^^&SZ7@L%O18'H%(R<5 M4 JV9NVC<^0(+$)2*3@(G&T.QN,-HM35$[#%H:/L#1H IS56GRC96!,6R?Y# M!R)SR*JI>_5K)#] E:R6Z UL2K06ELLEHO(D M"4["7$FB/P>C;:[%K!^X-Z( N@=6&6037"YM4DK\,;H2E-<>8C! L8M95HE1+IJ'3%*IN=!$:(VAC$5CD'R/LUK ]'-CS*M$"551?4) M,HB^@&A\)&07F).DY(5UNCF4NGH"3B<32VF+X!!24%G%*C^^DJY9:!L[F (> MLFKJ?FX:# =YN) 5!]"HH\$017"YMJ-5^;I^@'8SRM0)N";5:+4D-C8D4(IR MT2%GDUARV0HYK1^X-S_*U FP1*[((XZY& -M?:01\R5O)2O*P5M)2I M$U2Q0"%V6N=2@$*.SF34.24HWEB[AN;:R2A3)]AR5L85)Q9*$21);B-,16OM MO I1*7]S:R:'K)=6M9CSHMF9$'S0"9Q!L&1S*@I5"IZ#8G95H>/8&*#1*Z8:X!@Q+_I&M$5 M:KM>2E%K@\]-CS*M#J)2P=J"*56;(8&.&55M=>523%I!71N(.AAE6AU*H9!6 MM82:C).\/$7VQBM1A"J(T96T(48,A[@ZP=V%1$GVA4/J1DJ2I80VN]^3&63H#5*!JS5,K) M(G V,42SS-XR5=(QK1^P-SS&T@VJ6K*%4*+VSH#W-EDKV1_%@( JXQJBVLD8 M2R?88BM=E$CK9J4.C"2%;=\]!@P5@]4WMS-WR'KI6K8,H^2 SI64*P!@RC$& MQRV#+X5]H;(VT'0QQK(ZF)(.C-9Z1A]!>8ER%MJ6I.JYFEK7QX)N=(QE=?A M:4-=K>"731 !42MEP(2 REB?PMK@<]-C+*N#2%E#+(F[T8DAJ9 0DTH%V29% M\70ESSI U,$8RW>A=%[ H6(9C>7K/BL+LJR+=G;T["I_5A?D_)*9/Z_:LKR: M'/BF"\UY,IK.?AN/WLHS_:V]_>7K?G[>5;[FXHR4*R7G4)QS%8S"6*,I(J&" M:MN$:0"^Y#GC^,&\L?6TB.Z(+W'TY;ZP\_CI._'T'T_I+T4O2B9Q&\[[MFT$ M044;C4F:K,\@F2D3#@&?5EZP+(YF0M)[TWDK;RSO\>PM7X3IQ>%H,JWU*\!\ M]7N7EG%>=NW!\F&.)?>LW#/W!'1>)P._0'GO,/3OYFQQ04@PT%;68%.?C$ MK;!LB=Z(-22N&^)?_M[Y;/%S/><#4;G+>S@XQ,GQJNB^+*)\ MIX@\F"^3G4^I_OMH/&;:.9K-Y7M/C7$Z^1K9O_K5K0[^$]X3AW_9K$6N3 AG M=)=QQK/_E9BPV"_RY_,'CW?%Q@=@9=.SI_1ENSH__,V6]%?*T_?,I!JUG^-D M[]1PVLMMH?3!T<$ZCF!QJ45;D.Q.14@FQVBU(DVD=#+)?+&"]@ P_=K!-BY MV,XW&_ WM"H8 VNRVZO17Z7JA.4H&MD#]YC5E"C0 0 M,5-6PWKTUV6!U_+H_TKOAYYA\/4>%/.[Q]OX9CJ[-\;Y_!,YTPX>R$GTM)0C M$6WE>"FT9DRK4(FW)Y2*SU36V9JL+Z#!YZ 5&I>P*"7>= B++OZR(?>1GH,D MD:=4WM?[2WOKL MBJAM;1,3ZE*2%JGMS6E5CS5&]][1?#$]X-ES'I\DZ?NCP[4$6JL28^88=7 0 M$T?R.?GJ8JHCLJE ML;)'DDK-&T'^T!B$:[21, MDK,%#!2)FM$3DXE(E%#\5UC*>2)4T'PNW"UD+)T88(DOVXA#I;2XP<"Z:J]'4AB1C<3%J6 =^;V3)7TZ4G_:>P$9#\HZB4PS M5+*RQMC6)1.CX]#CA5T;*FT$1AO*J[X$'9P2@0$Z)^^M\I:QS0Y!Z?'2_J_S M[.5T]CO/YFT@1#ZTG XX1W$@\+CLD"LR5Z- ZY2RY0K.FY0!2Y]'^:\5GI6X MA-W_]![^+( KC$(!RL I9 #11JQ+U:"@SWO7KB)=GR[V>79!O)Z/JNWR>YS? MF=!+G.^/)GN+KVZ56J$3?S*=SU^TCRU&;WG<3A#$RL<)H>L?U%P#Q\4HC#4U M))LS:*6RCZA 9%'4'ER?=^)L9@^OF1K:<.LDDR*+.S/"" 46V:?$0?G3/IO] MI,8?0[+DP\DZ_7,X5A;,OH&1B^EA&'S=12TQG"T5I:S,3!.L29.U3#C5I\(BFOWT%-ORXB7K^ MK U9I]!9:(JCH &3BR4+-4H&-815LN>KV69,H\79D,+E<@]OI^.V+?'B2=]+ MEO/MGZ,)/ZU?NH&3C:>SH]%\<1J06T:LQ,/AH0!D?';)B0!>\L:#]:0ES>UK"7-E>M$JY7![<7KD\ MN)RZFA6J7I7@G2A\9R!EERO65%-KP>$2.3$N[O*D[!_@[/=+>[!QS',Q MV!8[+SBB.Q,Z^7-V#6,4W>Z*G!RU&_]L-^3I->3/LPM<>1.DJ8Z+N!2ML*F4 MG$H)BJP!@L*^#JE%S<8V^F0;G32"L(XE0 :M#&?A-$ I0M""V;!/MG$VE9A,0/6N?AM5Y%0RI4O(_:*0/,F.4_SD=. M(6FM8AZ EN\#=ITH5VUKC"&+@(T6HI'_SQ[:FE2=10-A'0!V&_=SNRE,V5=4 MF$O%"!IS#HXM@06B)!RF 0CX*V"W-D.DERK+"'"2?[DHVE5%U7:<%O" VD5= M-LG76KF?]:1P8*]M3M%02$"<8_3RAT%-%H.U?@ "O@_8=:)MW4CC!Q0JP%@MW$_MYO"%(RO)L9,+@.S3\[ZF*OV&9/H M(#, 7^EQ/FTH/\Z"EB!+<=4P%;F-GL9K29EC3?0X@GIVP7AQN,-F,E&<9*( M:A*U598)(SNE$MI*A'1:R;3?$&V-.43+44N@14G@AK"QHF?K3#L1 MN I#/-F_6@B_D\$<=0ZY)A*!$).+0>LD<%(N MR@YA\7O/8.S$J>9J?2#BJ(J'$%+6B74MQ3([\&$(#9K^'$:C7AF 8HU:65^\=L$6*BD. +[;H;@V+/XS99>MH^)1NV*@-7A)8)P+M1 7 M:V'X8UXW!E\G4L K9= J7X@*!$JH=0E152,>21D[!$6W<4*WGL6E^NQ,2I@D ME'HV*3ME.)7*6@>P9?""]L;@ZV8=0JN/Y")K22U!2R;B8DW&UUA,#"6G <"W M<4*WGL68R)1"H*)E2$%A*Q&O*""J8C$./AU[-AN]E4?S#(\EKUX60EU'/6N, M+UK'5L;/0S4)D70H FR 4D76WCH4-ZYON&2FC#&XM-S3"3:%I,A5'TPE!&N4 M&X"Z[Y=+ZD3=LB"F0T4,.4&B()H(0VMEV=Q4+D/(T38NJ89[3%N:K8I%0I#4'R;]C56PV.64<4I1:+58!"KEJ@ M.O&;T6&KIS@ ];9A5V_EE,3=6FU(K6LL1.%7C)5H"$LY-NSJ;62T M+D#VT6BJ&3!"8D(@!YE5KDKUN*AX1]5(KJ=A(W/"XGRJFB$&"2$^:$_9!;;> ML^EW=Y%N45A=#X\ -HB7)?2Z0JB4528.U+;.6F]USQN;=3,IRD7RJQYV^ M.]HN?3W]J$WRVM5JF&"V*=J!6<<-X MK#!6>*\]:!53%?6D. 8?)5G-U6=Y?#[UUS[.TKV'.)K]BN,COGM\_N?_RA5Q M5O:/GT@:.+Z8'IZ?]'AR>+28+\_0 [&>#"IE2X40-1CQ:P5J&[X*KH)'B/VU MGN&@M<+8$TD7G96MCD$%$6'(7*(IVAM;:NRO;35?=V\ZF4_'(Q*W1@_:;8WX MU.,M&S(?Y?F(1CB3=UU*PC>PM%QP@02D:7 M%-M<#6D1MSU6M,-!:X4=?XLO45+SH"0M]Z[F8'T,H$PB%R1+[*]M$8]^?L)[ M.%XZW$_;8+Z0AT$XH[LL>?GLI/5O2]&?/WB\^WA2!F)'OEHRX'4KV"TYNHM6 M8F*K@ZC9,\+WG\N0?R.^7/' VE5_^,2J>G?%R?SH>'S]]-V'Z>,KWALAU M)T:IM8BI>NV4AI0QH4HA>J.Q>L[48V(L07@J/Q47H\G>9_#L[H]F] PW)+B* M=^!LG%'19'$)GEJ!$J]3;BU%:G5J2&N![LSGO+A3_GLTFH_:9/:G6)T4W-DY MFLV%,*?,$:V]1NSHMOWJ_.0!_S8Y><*_'9YXX>//&K(N'\X?G7WV+5?NT9H0 M%!&:RK9 CC4J1A^"=ZQ12=B[Q-ZF]/O6]_F;H))3OQNJL3Q<_C(NRT/?#$(V MBH))XCH4@;(>30C)5W81:C%PNFCB)I[]7XHC3]J/OC.;X62/V^?^T(BW<;[@ MV?+T[W8<+9U_WK[Q8W:_/9J,#HX.KCEN7�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�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